{"nersets":[[{"setid":"PMC2883751","drugname":"midazolam","startOffset":"92","endOffset":"101","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/div[1]/div[2]/span[1]","prefix":" fluconazole and itraconazole toward human liver microsomal ","suffix":" 1′-hydroxylation activities","exact":"midazolam"},{"setid":"PMC2883751","drugname":"midazolam","startOffset":"113","endOffset":"122","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/div[2]/span[1]","prefix":"conazole toward recombinant P450 3A4- and P450 3A5-mediated ","suffix":" 1′-hydroxylation activities","exact":"midazolam"},{"setid":"PMC2883751","drugname":"midazolam","startOffset":"283","endOffset":"292","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[2]","prefix":"ssed in bacterial membranes. Recombinant P450 3A5 catalyzed ","suffix":" 1′-hydroxylation more efficiently than did P450 3A4 (","exact":"midazolam"},{"setid":"PMC2883751","drugname":"midazolam","startOffset":"146","endOffset":"155","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/div[1]/div[2]/span[1]","prefix":"ology model of P450 3A5 (B) in comparison with the cases of ","suffix":" (C) and thalidomide (D). Voriconazole adopted an orientatio","exact":"midazolam"},{"setid":"PMC2883751","drugname":"cyclosporin a","startOffset":"27","endOffset":"40","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/div[1]/div[2]/span[1]","prefix":"Effects of voriconazole on ","suffix":" oxidation activities of recombinant P450 3A4 and P450 3A5 a","exact":"cyclosporin A"},{"setid":"PMC2883751","drugname":"thalidomide","startOffset":"56","endOffset":"67","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","prefix":"CYP3A5, CYP3A4, drug interaction, genetic polymorphism, ","suffix":", voriconazole","exact":"thalidomide"},{"setid":"PMC2883751","drugname":"thalidomide","startOffset":"164","endOffset":"175","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/div[1]/div[2]/span[1]","prefix":"0 3A5 (B) in comparison with the cases of midazolam (C) and ","suffix":" (D). Voriconazole adopted an orientation suitable for P450 ","exact":"thalidomide"},{"setid":"PMC2883751","drugname":"itraconazole","startOffset":"49","endOffset":"61","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/div[1]/div[2]/span[1]","prefix":"Reported inhibition constants of fluconazole and ","suffix":" toward human liver microsomal midazolam 1′-hydroxylation ac","exact":"itraconazole"},{"setid":"PMC2883751","drugname":"itraconazole","startOffset":"49","endOffset":"61","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/div[2]/span[1]","prefix":"Reported inhibition constants of fluconazole and ","suffix":" toward recombinant P450 3A4- and P450 3A5-mediated midazola","exact":"itraconazole"},{"setid":"PMC2883751","drugname":"fluconazole","startOffset":"33","endOffset":"44","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/div[1]/div[2]/span[1]","prefix":"Reported inhibition constants of ","suffix":" and itraconazole toward human liver microsomal midazolam 1′","exact":"fluconazole"},{"setid":"PMC2883751","drugname":"fluconazole","startOffset":"33","endOffset":"44","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/div[2]/span[1]","prefix":"Reported inhibition constants of ","suffix":" and itraconazole toward recombinant P450 3A4- and P450 3A5-","exact":"fluconazole"},{"setid":"PMC2883751","drugname":"voriconazole","startOffset":"69","endOffset":"81","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","prefix":"YP3A4, drug interaction, genetic polymorphism, thalidomide, ","suffix":"","exact":"voriconazole"},{"setid":"PMC2883751","drugname":"voriconazole","startOffset":"136","endOffset":"148","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","prefix":"ance and inhibition of triazole antifungal drugs, including ","suffix":", emphasising polymorphic P450 3A5 expression in genotyped l","exact":"voriconazole"},{"setid":"PMC2883751","drugname":"voriconazole","startOffset":"0","endOffset":"12","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","prefix":"","suffix":" is of particular interest because of different metabolic pa","exact":"Voriconazole"},{"setid":"PMC2883751","drugname":"voriconazole","startOffset":"11","endOffset":"23","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/div[1]/div[2]/span[1]","prefix":"Effects of ","suffix":" on cyclosporin A oxidation activities of recombinant P450 3","exact":"voriconazole"},{"setid":"PMC2883751","drugname":"voriconazole","startOffset":"22","endOffset":"34","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/div[1]/div[2]/span[1]","prefix":"Docking simulation of ","suffix":" into a reported structure of P450 3A4 (A) and a homology mo","exact":"voriconazole"},{"setid":"PMC2883751","drugname":"voriconazole","startOffset":"181","endOffset":"193","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/div[1]/div[2]/span[1]","prefix":"arison with the cases of midazolam (C) and thalidomide (D). ","suffix":" adopted an orientation suitable for P450 3A4 (corresponding","exact":"Voriconazole"}],[{"setid":"PMC3091944","drugname":"warfarin","startOffset":"0","endOffset":"8","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","prefix":"","suffix":", pharmacokinetics, drug transporters, drug interaction, hea","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":"40","endOffset":"48","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[3]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[3]/p[2]","prefix":"Pharmacokinetic parameters for R- and S-","suffix":" and their major metabolites were estimated from plasma conc","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":"0","endOffset":"8","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","prefix":"","suffix":", pharmacokinetics, drug transporters, drug interaction, hea","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":"0","endOffset":"8","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","prefix":"","suffix":" is a commonly prescribed anticoagulant for the prevention o","exact":"Warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":"169","endOffset":"177","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","prefix":"sm, and other thromboembolic events. But, successful use of ","suffix":" has been challenged by its large inter-individual variation","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":"250","endOffset":"258","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","prefix":"llenged by its large inter-individual variation in required ","suffix":" dose and narrow therapeutic index.(","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":"0","endOffset":"8","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","prefix":"","suffix":" is a racemic mixture of S- and R- enatiomers with S-warfari","exact":"Warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":"61","endOffset":"69","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","prefix":"arfarin is a racemic mixture of S- and R- enatiomers with S-","suffix":" being 2–5 times more potent and conferring the majority of ","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":"6","endOffset":"14","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[4]","prefix":"Since ","suffix":" is classified as a BDDCS Class 2 drug(","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":"63","endOffset":"71","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[1]","prefix":"the presence of 100 μM rifampin, the uptake of 1 μM racemic ","suffix":" was decreased by 23% in rat hepatocytes (p < 0.05; ","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":"0","endOffset":"8","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","prefix":"","suffix":", pharmacokinetics, drug transporters, drug interaction, hea","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":"28","endOffset":"36","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/div[1]/div[1]/div[2]/span[1]","prefix":"Inhibition of the uptake of ","suffix":" (1μM) by rifampin (100 μM) into (a) rat and (b) human hepat","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":"29","endOffset":"37","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/div[1]/h4[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/div[1]/h4[1]","prefix":"Pharmacokinetics of S- and R-","suffix":" ","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":"61","endOffset":"69","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","prefix":"arfarin is a racemic mixture of S- and R- enatiomers with S-","suffix":" being 2–5 times more potent and conferring the majority of ","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":"29","endOffset":"37","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/div[1]/h4[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/div[1]/h4[1]","prefix":"Pharmacokinetics of S- and R-","suffix":" ","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":"95","endOffset":"103","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/div[1]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/div[1]/div[1]/div[1]/div[2]/span[1]","prefix":"avenous rifampin on the mean plasma concentrations of (a) S-","suffix":" and (b) R-warfarin in 10 healthy volunteers after a single ","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":"40","endOffset":"48","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[3]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[3]/p[2]","prefix":"Pharmacokinetic parameters for R- and S-","suffix":" and their major metabolites were estimated from plasma conc","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":"31","endOffset":"39","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[6]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[6]/p[2]","prefix":"The concentrations of S- and R-","suffix":" and their main metabolites were measured using high pressur","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":"40","endOffset":"48","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[6]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[6]/p[5]","prefix":"Chromatographic conditions for S- and R-","suffix":" were as described by Naidong and colleagues(","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":"25","endOffset":"33","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[6]/p[7]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[6]/p[7]","prefix":"The methods for S- and R-","suffix":" were validated from 1.5 to 300 ng/ml. The 1 h and 2 h sampl","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":"111","endOffset":"119","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[10]/div[2]/div[36]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[10]/div[2]/div[36]/span[1]","prefix":" AE, Bertino JS., Jr. Effects of oral vitamin K on S- and R-","suffix":" pharmacokinetics and pharmacodynamics: enhanced safety of w","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":"29","endOffset":"37","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/div[1]/h4[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/div[1]/h4[1]","prefix":"Pharmacokinetics of S- and R-","suffix":" ","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":"114","endOffset":"122","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/div[1]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/div[1]/div[1]/div[1]/div[2]/span[1]","prefix":" the mean plasma concentrations of (a) S-warfarin and (b) R-","suffix":" in 10 healthy volunteers after a single oral dose of 7.5 mg","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":"191","endOffset":"199","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/div[1]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/div[1]/div[1]/div[1]/div[2]/span[1]","prefix":"althy volunteers after a single oral dose of 7.5 mg racemic ","suffix":". ","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":"206","endOffset":"214","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/div[2]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/div[2]/div[1]/div[1]/div[2]/span[1]","prefix":"althy volunteers after a single oral dose of 7.5 mg racemic ","suffix":". ","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":"96","endOffset":"104","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/div[4]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/div[4]/div[1]/div[1]/div[2]/span[1]","prefix":"0 healthy volunteers following a single oral dose of 7.5 mg ","suffix":" alone or in combination with a single dose of intravenous r","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":"29","endOffset":"37","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/div[1]/h4[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/div[1]/h4[1]","prefix":"Pharmacokinetics of S- and R-","suffix":" ","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":"29","endOffset":"37","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/div[1]/h4[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/div[1]/h4[1]","prefix":"Pharmacokinetics of S- and R-","suffix":" ","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":"29","endOffset":"37","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/div[1]/h4[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/div[1]/h4[1]","prefix":"Pharmacokinetics of S- and R-","suffix":" ","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":"20","endOffset":"28","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/div[2]/h4[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/div[2]/h4[1]","prefix":"Pharmacokinetics of ","suffix":" metabolites ","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":"29","endOffset":"37","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/div[1]/h4[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/div[1]/h4[1]","prefix":"Pharmacokinetics of S- and R-","suffix":" ","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":"56","endOffset":"64","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/div[2]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/div[2]/p[2]","prefix":"The concentration-time profiles of 7-hydroxywarfarin (S-","suffix":" metabolite) and 10-hydroxywarfarin (R-warfarin metabolite) ","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":"91","endOffset":"99","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/div[2]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/div[2]/p[2]","prefix":" of 7-hydroxywarfarin (S-warfarin metabolite) and 10-hydroxy","suffix":" (R-warfarin metabolite) after a single oral dose of 7.5 mg ","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":"103","endOffset":"111","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/div[2]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/div[2]/p[2]","prefix":"ywarfarin (S-warfarin metabolite) and 10-hydroxywarfarin (R-","suffix":" metabolite) after a single oral dose of 7.5 mg warfarin alo","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":"40","endOffset":"48","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[3]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[3]/p[2]","prefix":"Pharmacokinetic parameters for R- and S-","suffix":" and their major metabolites were estimated from plasma conc","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":"31","endOffset":"39","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[6]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[6]/p[2]","prefix":"The concentrations of S- and R-","suffix":" and their main metabolites were measured using high pressur","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":"29","endOffset":"37","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/div[1]/h4[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/div[1]/h4[1]","prefix":"Pharmacokinetics of S- and R-","suffix":" ","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":"103","endOffset":"111","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/div[2]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/div[2]/p[2]","prefix":"ywarfarin (S-warfarin metabolite) and 10-hydroxywarfarin (R-","suffix":" metabolite) after a single oral dose of 7.5 mg warfarin alo","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":"40","endOffset":"48","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[3]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[3]/p[2]","prefix":"Pharmacokinetic parameters for R- and S-","suffix":" and their major metabolites were estimated from plasma conc","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":"31","endOffset":"39","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[6]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[6]/p[2]","prefix":"The concentrations of S- and R-","suffix":" and their main metabolites were measured using high pressur","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":"159","endOffset":"167","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/div[2]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/div[2]/p[2]","prefix":" (R-warfarin metabolite) after a single oral dose of 7.5 mg ","suffix":" alone or with a single intravenous dose of rifampin are sho","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":"29","endOffset":"37","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/div[1]/h4[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/div[1]/h4[1]","prefix":"Pharmacokinetics of S- and R-","suffix":" ","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":"191","endOffset":"199","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/div[1]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/div[1]/div[1]/div[1]/div[2]/span[1]","prefix":"althy volunteers after a single oral dose of 7.5 mg racemic ","suffix":". ","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":"206","endOffset":"214","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/div[2]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/div[2]/div[1]/div[1]/div[2]/span[1]","prefix":"althy volunteers after a single oral dose of 7.5 mg racemic ","suffix":". ","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":"96","endOffset":"104","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/div[4]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/div[4]/div[1]/div[1]/div[2]/span[1]","prefix":"0 healthy volunteers following a single oral dose of 7.5 mg ","suffix":" alone or in combination with a single dose of intravenous r","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":"29","endOffset":"37","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/div[4]/p[2]","prefix":"A single 7.5 mg dose of oral ","suffix":" caused a small, transient increase in INR from baseline dur","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":"96","endOffset":"104","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/div[4]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/div[4]/div[1]/div[1]/div[2]/span[1]","prefix":"0 healthy volunteers following a single oral dose of 7.5 mg ","suffix":" alone or in combination with a single dose of intravenous r","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":"167","endOffset":"175","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","prefix":"of the widely-used, narrow therapeutic index, anticoagulant ","suffix":". The results of our clinical study demonstrated that co-adm","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":"0","endOffset":"8","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","prefix":"","suffix":", pharmacokinetics, drug transporters, drug interaction, hea","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":"0","endOffset":"8","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","prefix":"","suffix":", pharmacokinetics, drug transporters, drug interaction, hea","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":"187","endOffset":"195","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[5]","prefix":" polymorphisms in the human genome that may be important in ","suffix":" dose selection. In these GWAS studies, no common variants i","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":"364","endOffset":"372","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[5]","prefix":"ransporters were found to be significant in determining the ","suffix":" dose requirements of patients.(","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":"0","endOffset":"8","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","prefix":"","suffix":", pharmacokinetics, drug transporters, drug interaction, hea","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":"39","endOffset":"47","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[6]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[6]/p[3]","prefix":"The samples and standards for S- and R-","suffix":" (Sigma-Aldrich, St. Louis, MO) were prepared by liquid-liqu","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":"40","endOffset":"48","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[6]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[6]/p[5]","prefix":"Chromatographic conditions for S- and R-","suffix":" were as described by Naidong and colleagues(","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":"25","endOffset":"33","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[6]/p[7]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[6]/p[7]","prefix":"The methods for S- and R-","suffix":" were validated from 1.5 to 300 ng/ml. The 1 h and 2 h sampl","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":"0","endOffset":"8","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","prefix":"","suffix":", pharmacokinetics, drug transporters, drug interaction, hea","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":"110","endOffset":"118","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[7]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[7]","prefix":"eared to be delayed since early in the time course S- and R-","suffix":" concentration-time curves, AUC","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":"0","endOffset":"8","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","prefix":"","suffix":", pharmacokinetics, drug transporters, drug interaction, hea","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":"24","endOffset":"32","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[8]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[8]","prefix":"We purposely selected a ","suffix":" dose for this study (7.5mg) that would provide adequate dru","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":"328","endOffset":"336","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[8]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[8]","prefix":" volunteer study that also used a single 7.5mg dose of oral ","suffix":".(","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":"75","endOffset":"83","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[9]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[9]","prefix":"our single dose clinical study of the effect of rifampin on ","suffix":" pharmacokinetics in healthy volunteers suggeststhat hepatic","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":"226","endOffset":"234","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/div[1]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/div[1]/p[3]","prefix":"in was chosen to maximize OATP inhibition and any effect on ","suffix":" uptake Rifampin is a known inhibitor of the 3 major human O","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":"0","endOffset":"8","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","prefix":"","suffix":", pharmacokinetics, drug transporters, drug interaction, hea","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":"63","endOffset":"71","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[1]","prefix":"the presence of 100 μM rifampin, the uptake of 1 μM racemic ","suffix":" was decreased by 23% in rat hepatocytes (p < 0.05; ","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":"0","endOffset":"8","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","prefix":"","suffix":", pharmacokinetics, drug transporters, drug interaction, hea","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":"191","endOffset":"199","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/div[1]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/div[1]/div[1]/div[1]/div[2]/span[1]","prefix":"althy volunteers after a single oral dose of 7.5 mg racemic ","suffix":". ","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":"159","endOffset":"167","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/div[2]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/div[2]/p[2]","prefix":" (R-warfarin metabolite) after a single oral dose of 7.5 mg ","suffix":" alone or with a single intravenous dose of rifampin are sho","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":"206","endOffset":"214","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/div[2]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/div[2]/div[1]/div[1]/div[2]/span[1]","prefix":"althy volunteers after a single oral dose of 7.5 mg racemic ","suffix":". ","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":"29","endOffset":"37","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/div[4]/p[2]","prefix":"A single 7.5 mg dose of oral ","suffix":" caused a small, transient increase in INR from baseline dur","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":"96","endOffset":"104","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/div[4]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/div[4]/div[1]/div[1]/div[2]/span[1]","prefix":"0 healthy volunteers following a single oral dose of 7.5 mg ","suffix":" alone or in combination with a single dose of intravenous r","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":"105","endOffset":"113","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[2]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[2]/p[3]","prefix":"surements were collected at the following times relative to ","suffix":" dosing: predose, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 120 ","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":"412","endOffset":"420","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[2]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[2]/p[3]","prefix":"r INR determination at 0, 12, 24, 48, 72 and 96 hours after ","suffix":" dosing.","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":"40","endOffset":"48","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[3]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[3]/p[2]","prefix":"Pharmacokinetic parameters for R- and S-","suffix":" and their major metabolites were estimated from plasma conc","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":"26","endOffset":"34","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[5]/p[2]","prefix":"Using previously reported ","suffix":" pharmacokinetic data in healthy volunteers(","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":"29","endOffset":"37","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/div[1]/h4[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/div[1]/h4[1]","prefix":"Pharmacokinetics of S- and R-","suffix":" ","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":"159","endOffset":"167","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/div[2]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/div[2]/p[2]","prefix":" (R-warfarin metabolite) after a single oral dose of 7.5 mg ","suffix":" alone or with a single intravenous dose of rifampin are sho","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":"96","endOffset":"104","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/div[4]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/div[4]/div[1]/div[1]/div[2]/span[1]","prefix":"0 healthy volunteers following a single oral dose of 7.5 mg ","suffix":" alone or in combination with a single dose of intravenous r","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":"31","endOffset":"39","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[6]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[6]/p[2]","prefix":"The concentrations of S- and R-","suffix":" and their main metabolites were measured using high pressur","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":"0","endOffset":"8","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","prefix":"","suffix":", pharmacokinetics, drug transporters, drug interaction, hea","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":"0","endOffset":"8","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","prefix":"","suffix":", pharmacokinetics, drug transporters, drug interaction, hea","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":"0","endOffset":"8","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","prefix":"","suffix":", pharmacokinetics, drug transporters, drug interaction, hea","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":"0","endOffset":"8","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","prefix":"","suffix":", pharmacokinetics, drug transporters, drug interaction, hea","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":"39","endOffset":"47","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[6]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[6]/p[3]","prefix":"The samples and standards for S- and R-","suffix":" (Sigma-Aldrich, St. Louis, MO) were prepared by liquid-liqu","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":"30","endOffset":"38","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[6]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[6]/p[4]","prefix":"The samples and standards for ","suffix":" metabolites were prepared by liquid-liquid extraction of 10","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":"30","endOffset":"38","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[6]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[6]/p[4]","prefix":"The samples and standards for ","suffix":" metabolites were prepared by liquid-liquid extraction of 10","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":"40","endOffset":"48","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[6]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[6]/p[5]","prefix":"Chromatographic conditions for S- and R-","suffix":" were as described by Naidong and colleagues(","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":"0","endOffset":"8","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","prefix":"","suffix":", pharmacokinetics, drug transporters, drug interaction, hea","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":"19","endOffset":"27","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[6]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[6]/p[6]","prefix":"Chromatography for ","suffix":" metabolites was performed on an Agilent Eclipse XDB C18 col","exact":"warfarin"},{"setid":"PMC3091944","drugname":"warfarin","startOffset":"25","endOffset":"33","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[6]/p[7]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[6]/p[7]","prefix":"The methods for S- and R-","suffix":" were validated from 1.5 to 300 ng/ml. The 1 h and 2 h sampl","exact":"warfarin"},{"setid":"PMC3091944","drugname":"rifampin","startOffset":"26","endOffset":"34","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[1]","prefix":"In the presence of 100 μM ","suffix":", the uptake of 1 μM racemic warfarin was decreased by 23% i","exact":"rifampin"},{"setid":"PMC3091944","drugname":"rifampin","startOffset":"46","endOffset":"54","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/div[1]/div[1]/div[2]/span[1]","prefix":"Inhibition of the uptake of warfarin (1μM) by ","suffix":" (100 μM) into (a) rat and (b) human hepatocytes. Values are","exact":"rifampin"},{"setid":"PMC3091944","drugname":"rifampin","startOffset":"121","endOffset":"129","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[10]/div[2]/div[29]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[10]/div[2]/div[29]/span[1]","prefix":"uction of prehepatic and hepatic metabolism of verapamil by ","suffix":". ","exact":"rifampin"},{"setid":"PMC3091944","drugname":"rifampin","startOffset":"43","endOffset":"51","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/div[1]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/div[1]/div[1]/div[1]/div[2]/span[1]","prefix":"The effect of a single dose of intravenous ","suffix":" on the mean plasma concentrations of (a) S-warfarin and (b)","exact":"rifampin"},{"setid":"PMC3091944","drugname":"rifampin","startOffset":"43","endOffset":"51","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/div[2]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/div[2]/div[1]/div[1]/div[2]/span[1]","prefix":"The effect of a single dose of intravenous ","suffix":" on the mean plasma concentrations of (a) 7-hydroxywarfarin ","exact":"rifampin"},{"setid":"PMC3091944","drugname":"rifampin","startOffset":"163","endOffset":"171","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/div[4]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/div[4]/div[1]/div[1]/div[2]/span[1]","prefix":"n alone or in combination with a single dose of intravenous ","suffix":".","exact":"rifampin"},{"setid":"PMC3091944","drugname":"rifampin","startOffset":"47","endOffset":"55","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/div[1]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/div[1]/p[3]","prefix":"Analysis of all concentration-time data showed ","suffix":" significantly decreased the AUC","exact":"rifampin"},{"setid":"PMC3091944","drugname":"rifampin","startOffset":"211","endOffset":"219","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/div[2]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/div[2]/p[2]","prefix":" 7.5 mg warfarin alone or with a single intravenous dose of ","suffix":" are shown in ","exact":"rifampin"},{"setid":"PMC3091944","drugname":"rifampin","startOffset":"43","endOffset":"51","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/div[1]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/div[1]/div[1]/div[1]/div[2]/span[1]","prefix":"The effect of a single dose of intravenous ","suffix":" on the mean plasma concentrations of (a) S-warfarin and (b)","exact":"rifampin"},{"setid":"PMC3091944","drugname":"rifampin","startOffset":"43","endOffset":"51","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/div[2]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/div[2]/div[1]/div[1]/div[2]/span[1]","prefix":"The effect of a single dose of intravenous ","suffix":" on the mean plasma concentrations of (a) 7-hydroxywarfarin ","exact":"rifampin"},{"setid":"PMC3091944","drugname":"rifampin","startOffset":"163","endOffset":"171","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/div[4]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/div[4]/div[1]/div[1]/div[2]/span[1]","prefix":"n alone or in combination with a single dose of intravenous ","suffix":".","exact":"rifampin"},{"setid":"PMC3091944","drugname":"rifampin","startOffset":"163","endOffset":"171","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/div[4]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/div[4]/div[1]/div[1]/div[2]/span[1]","prefix":"n alone or in combination with a single dose of intravenous ","suffix":".","exact":"rifampin"},{"setid":"PMC3091944","drugname":"rifampin","startOffset":"276","endOffset":"284","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","prefix":"strated that co-administration of the potent OATP inhibitor ","suffix":", given as a single intravenous dose, had no effect on the A","exact":"rifampin"},{"setid":"PMC3091944","drugname":"rifampin","startOffset":"0","endOffset":"8","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[2]","prefix":"","suffix":" was chosen as a model OATP inhibitor to block the ","exact":"Rifampin"},{"setid":"PMC3091944","drugname":"rifampin","startOffset":"209","endOffset":"217","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","prefix":" atorvastatin and glyburide with hepatic OATP inhibition by ","suffix":"(","exact":"rifampin"},{"setid":"PMC3091944","drugname":"rifampin","startOffset":"30","endOffset":"38","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[6]","prefix":"Intravenous administration of ","suffix":" conceivably minimized any potential confounding interaction","exact":"rifampin"},{"setid":"PMC3091944","drugname":"rifampin","startOffset":"232","endOffset":"240","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[6]","prefix":"lack of an interaction cannot be fully confirmed. By giving ","suffix":" as a single dose, we attempted to avoid the well-described ","exact":"rifampin"},{"setid":"PMC3091944","drugname":"rifampin","startOffset":"163","endOffset":"171","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/div[4]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/div[4]/div[1]/div[1]/div[2]/span[1]","prefix":"n alone or in combination with a single dose of intravenous ","suffix":".","exact":"rifampin"},{"setid":"PMC3091944","drugname":"rifampin","startOffset":"63","endOffset":"71","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[9]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[9]","prefix":"conclusion, our single dose clinical study of the effect of ","suffix":" on warfarin pharmacokinetics in healthy volunteers suggests","exact":"rifampin"},{"setid":"PMC3091944","drugname":"rifampin","startOffset":"292","endOffset":"300","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[9]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[9]","prefix":"lized, narrow therapeutic index, anticoagulant. Single-dose ","suffix":" may induce metabolizing enzymes such as CYP2C9 and CYP3A4.","exact":"rifampin"},{"setid":"PMC3091944","drugname":"rifampin","startOffset":"122","endOffset":"130","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/div[1]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/div[1]/p[3]","prefix":"a 37°C water bath with either control (0.1% DMSO) or 100 μM ","suffix":". The 100 μM concentration of rifampin was chosen to maximiz","exact":"rifampin"},{"setid":"PMC3091944","drugname":"rifampin","startOffset":"160","endOffset":"168","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/div[1]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/div[1]/p[3]","prefix":"(0.1% DMSO) or 100 μM rifampin. The 100 μM concentration of ","suffix":" was chosen to maximize OATP inhibition and any effect on wa","exact":"rifampin"},{"setid":"PMC3091944","drugname":"rifampin","startOffset":"242","endOffset":"250","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/div[1]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/div[1]/p[3]","prefix":" maximize OATP inhibition and any effect on warfarin uptake ","suffix":" is a known inhibitor of the 3 major human OATPs, being a mo","exact":"Rifampin"},{"setid":"PMC3091944","drugname":"atorvastatin","startOffset":"150","endOffset":"162","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","prefix":"demonstrated significant changes in the pharmacokinetics of ","suffix":" and glyburide with hepatic OATP inhibition by rifampin(","exact":"atorvastatin"},{"setid":"PMC3091944","drugname":"atorvastatin","startOffset":"331","endOffset":"343","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[2]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[2]/p[2]","prefix":"mportance of OATP hepatic uptake in healthy voluneteers for ","suffix":"(","exact":"atorvastatin"},{"setid":"PMC3091944","drugname":"glyburide","startOffset":"167","endOffset":"176","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","prefix":"ificant changes in the pharmacokinetics of atorvastatin and ","suffix":" with hepatic OATP inhibition by rifampin(","exact":"glyburide"},{"setid":"PMC3091944","drugname":"glyburide","startOffset":"167","endOffset":"176","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","prefix":"ificant changes in the pharmacokinetics of atorvastatin and ","suffix":" with hepatic OATP inhibition by rifampin(","exact":"glyburide"},{"setid":"PMC3091944","drugname":"glyburide","startOffset":"101","endOffset":"110","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[10]/div[2]/div[12]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[10]/div[2]/div[12]/span[1]","prefix":". Elucidating rifampin's inducing and inhibiting effects on ","suffix":" pharmacokinetics and blood glucose in healthy volunteers: u","exact":"glyburide"},{"setid":"PMC3091944","drugname":"glyburide","startOffset":"58","endOffset":"67","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[2]/div[2]/ul[1]/li[3]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[2]/div[2]/ul[1]/li[3]/a[1]","prefix":"Elucidating rifampin's inducing and inhibiting effects on ","suffix":" pharmacokinetics and blood glucose in healthy volunteers: u","exact":"glyburide"},{"setid":"PMC3091944","drugname":"glyburide","startOffset":"58","endOffset":"67","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[7]/div[2]/ul[1]/li[2]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[7]/div[2]/ul[1]/li[2]/a[1]","prefix":"Elucidating rifampin's inducing and inhibiting effects on ","suffix":" pharmacokinetics and blood glucose in healthy volunteers: u","exact":"glyburide"},{"setid":"PMC3091944","drugname":"glyburide","startOffset":"58","endOffset":"67","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[15]/div[2]/ul[1]/li[2]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[15]/div[2]/ul[1]/li[2]/a[1]","prefix":"Elucidating rifampin's inducing and inhibiting effects on ","suffix":" pharmacokinetics and blood glucose in healthy volunteers: u","exact":"glyburide"},{"setid":"PMC3091944","drugname":"glyburide","startOffset":"58","endOffset":"67","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[8]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[8]","prefix":"Elucidating rifampin's inducing and inhibiting effects on ","suffix":" pharmacokinetics and blood glucose in healthy volunteers: u","exact":"glyburide"},{"setid":"PMC3091944","drugname":"nifedipine","startOffset":"110","endOffset":"120","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[10]/div[2]/div[30]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[10]/div[2]/div[30]/span[1]","prefix":"f single does of rifampicin on the pharmacokinetics of oral ","suffix":". ","exact":"nifedipine"},{"setid":"PMC3091944","drugname":"nifedipine","startOffset":"72","endOffset":"82","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[11]/div[2]/ul[1]/li[3]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[11]/div[2]/ul[1]/li[3]/a[1]","prefix":"f single does of rifampicin on the pharmacokinetics of oral ","suffix":".","exact":"nifedipine"},{"setid":"PMC3091944","drugname":"nifedipine","startOffset":"72","endOffset":"82","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[24]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[24]","prefix":"f single does of rifampicin on the pharmacokinetics of oral ","suffix":".","exact":"nifedipine"},{"setid":"PMC3091944","drugname":"dmso","startOffset":"106","endOffset":"110","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/div[1]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/div[1]/p[3]","prefix":"for 5 minute in a 37°C water bath with either control (0.1% ","suffix":") or 100 μM rifampin. The 100 μM concentration of rifampin w","exact":"DMSO"}],[{"setid":"PMC2527838","drugname":"tamoxifen","startOffset":"185","endOffset":"194","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"receptor-positive tumours. Cytochrome P-450 2D6 metabolises ","suffix":" to metabolites that more readily bind the oestrogen recepto","exact":"tamoxifen"},{"setid":"PMC2527838","drugname":"tamoxifen","startOffset":"400","endOffset":"409","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"se widely used drugs – when taken concurrently – may reduce ","suffix":"'s prevention of breast cancer recurrence. We studied citalo","exact":"tamoxifen"},{"setid":"PMC2527838","drugname":"tamoxifen","startOffset":"761","endOffset":"770","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"ogen-receptor-positive breast cancer 1985–2001 and who took ","suffix":" for 1, 2, or most often for 5 years. We ascertained prescri","exact":"tamoxifen"},{"setid":"PMC2527838","drugname":"tamoxifen","startOffset":"1080","endOffset":"1089","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"least one prescription for the SSRI citalopram while taking ","suffix":" (adjusted conditional odds ratio=0.85, 95% confidence inter","exact":"tamoxifen"},{"setid":"PMC2527838","drugname":"tamoxifen","startOffset":"1198","endOffset":"1207","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"dence interval=0.42, 1.7). We also observed no reduction of ","suffix":" effectiveness among regular citalopram users (⩾30% overlap ","exact":"tamoxifen"},{"setid":"PMC2527838","drugname":"tamoxifen","startOffset":"1272","endOffset":"1281","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"ctiveness among regular citalopram users (⩾30% overlap with ","suffix":" use). These results suggest that concurrent use of citalopr","exact":"tamoxifen"},{"setid":"PMC2527838","drugname":"tamoxifen","startOffset":"1360","endOffset":"1369","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"s suggest that concurrent use of citalopram does not reduce ","suffix":"'s prevention of breast cancer recurrence.","exact":"tamoxifen"},{"setid":"PMC2527838","drugname":"tamoxifen","startOffset":"52","endOffset":"61","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","prefix":"breast neoplasms, pharmacology and therapeutic use, ","suffix":", antagonists and inhibitors, serotonin reuptake inhibitors,","exact":"tamoxifen"},{"setid":"PMC2527838","drugname":"tamoxifen","startOffset":"0","endOffset":"9","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","prefix":"","suffix":" is a selective oestrogen receptor modulator (","exact":"Tamoxifen"},{"setid":"PMC2527838","drugname":"tamoxifen","startOffset":"36","endOffset":"45","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":"Breast cancer patients treated with ","suffix":" may also take other prescription medications that are metab","exact":"tamoxifen"},{"setid":"PMC2527838","drugname":"tamoxifen","startOffset":"154","endOffset":"163","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":"t are metabolised by some of the same enzymes that activate ","suffix":". For example, depression is a common comorbidity in breast ","exact":"tamoxifen"},{"setid":"PMC2527838","drugname":"tamoxifen","startOffset":"82","endOffset":"91","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","prefix":"o date of the potential for drug–drug interaction to reduce ","suffix":"'s protection against breast cancer recurrence, we examined ","exact":"tamoxifen"},{"setid":"PMC2527838","drugname":"tamoxifen","startOffset":"252","endOffset":"261","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","prefix":"h oestrogen-receptor-positive tumours who were treated with ","suffix":" for 1, 2, or most often for 5 years had a higher rate of re","exact":"tamoxifen"},{"setid":"PMC2527838","drugname":"tamoxifen","startOffset":"150","endOffset":"159","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[3]","prefix":"ed the oestrogen receptor protein and who were treated with ","suffix":" for at least 1 year; (b) group II women whose tumour did no","exact":"tamoxifen"},{"setid":"PMC2527838","drugname":"tamoxifen","startOffset":"283","endOffset":"292","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[3]","prefix":"press the oestrogen receptor protein, were not treated with ","suffix":", and who survived for at least one year; and (c) group III ","exact":"tamoxifen"},{"setid":"PMC2527838","drugname":"tamoxifen","startOffset":"451","endOffset":"460","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[3]","prefix":"excluded from this analysis. Group I women were assigned to ","suffix":" therapy protocols of 1, 2, or 5 years, depending on the gui","exact":"tamoxifen"},{"setid":"PMC2527838","drugname":"tamoxifen","startOffset":"317","endOffset":"326","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[3]","prefix":" radiation therapy, receipt of chemotherapy, and receipt of ","suffix":" therapy) from the DBCG database.","exact":"tamoxifen"},{"setid":"PMC2527838","drugname":"tamoxifen","startOffset":"98","endOffset":"107","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/div[2]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/div[2]/p[4]","prefix":"opram prescription, we calculated the percentage of time on ","suffix":" when they were simultaneously taking citalopram. We created","exact":"tamoxifen"},{"setid":"PMC2527838","drugname":"tamoxifen","startOffset":"253","endOffset":"262","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/div[2]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/div[2]/p[4]","prefix":"ttent citalopram use, defined as citalopram use overlapping ","suffix":" use for more than 0% but less than 30% of the time on tamox","exact":"tamoxifen"},{"setid":"PMC2527838","drugname":"tamoxifen","startOffset":"317","endOffset":"326","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/div[2]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/div[2]/p[4]","prefix":"xifen use for more than 0% but less than 30% of the time on ","suffix":" and (b) regular citalopram use, defined as citalopram use o","exact":"tamoxifen"},{"setid":"PMC2527838","drugname":"tamoxifen","startOffset":"397","endOffset":"406","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/div[2]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/div[2]/p[4]","prefix":"gular citalopram use, defined as citalopram use overlapping ","suffix":" use for 30% or more of the time on tamoxifen. We chose 30% ","exact":"tamoxifen"},{"setid":"PMC2527838","drugname":"tamoxifen","startOffset":"442","endOffset":"451","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/div[2]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/div[2]/p[4]","prefix":"se overlapping tamoxifen use for 30% or more of the time on ","suffix":". We chose 30% as the overlap boundary to allow sufficient s","exact":"tamoxifen"},{"setid":"PMC2527838","drugname":"tamoxifen","startOffset":"616","endOffset":"625","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/div[2]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/div[2]/p[4]","prefix":", while also investigating a substantial period of SSRI and ","suffix":" comedication.","exact":"tamoxifen"},{"setid":"PMC2527838","drugname":"tamoxifen","startOffset":"717","endOffset":"726","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/div[3]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/div[3]/p[2]","prefix":" inhibitor or substrate, including other SSRI, while taking ","suffix":".","exact":"tamoxifen"},{"setid":"PMC2527838","drugname":"tamoxifen","startOffset":"106","endOffset":"115","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[2]","prefix":"he two groups (oestrogen-receptor positive and treated with ","suffix":" or oestrogen-receptor negative and not treated with tamoxif","exact":"tamoxifen"},{"setid":"PMC2527838","drugname":"tamoxifen","startOffset":"168","endOffset":"177","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[2]","prefix":"moxifen or oestrogen-receptor negative and not treated with ","suffix":"). We computed the frequency and proportion of cases and con","exact":"tamoxifen"},{"setid":"PMC2527838","drugname":"tamoxifen","startOffset":"285","endOffset":"294","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[2]","prefix":"ases and controls within categories of assigned protocol of ","suffix":" duration, of citalopram use, of use of other CYP2D6 inhibit","exact":"tamoxifen"},{"setid":"PMC2527838","drugname":"tamoxifen","startOffset":"174","endOffset":"183","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/div[1]/div[2]/span[1]","prefix":"ing the oestrogen receptor and receiving at least 1 year of ","suffix":" therapy (ERP+/TAM+), or (II) not expressing the oestrogen","exact":"tamoxifen"},{"setid":"PMC2527838","drugname":"tamoxifen","startOffset":"210","endOffset":"219","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/div[2]/span[1]","prefix":"ing the oestrogen receptor and receiving at least 1 year of ","suffix":" therapy (ERP+/TAM+),","exact":"tamoxifen"},{"setid":"PMC2527838","drugname":"tamoxifen","startOffset":"174","endOffset":"183","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/div[1]/div[2]/span[1]","prefix":"ing the oestrogen receptor and receiving at least 1 year of ","suffix":" therapy (ERP+/TAM+), or (II) not expressing the oestrogen","exact":"tamoxifen"},{"setid":"PMC2527838","drugname":"tamoxifen","startOffset":"210","endOffset":"219","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/div[2]/span[1]","prefix":"ing the oestrogen receptor and receiving at least 1 year of ","suffix":" therapy (ERP+/TAM+),","exact":"tamoxifen"},{"setid":"PMC2527838","drugname":"tamoxifen","startOffset":"52","endOffset":"61","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","prefix":"Group I women who ever used citalopram while taking ","suffix":" did not have a higher rate of breast cancer recurrence than","exact":"tamoxifen"},{"setid":"PMC2527838","drugname":"tamoxifen","startOffset":"167","endOffset":"176","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","prefix":"ecurrence than women who never used citalopram while taking ","suffix":" (","exact":"tamoxifen"},{"setid":"PMC2527838","drugname":"tamoxifen","startOffset":"190","endOffset":"199","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/div[1]/div[2]/span[1]","prefix":" the oestrogen receptor and who received at least 1 year of ","suffix":" therapy (ERP+/TAM+) or (b) Group II,","exact":"tamoxifen"},{"setid":"PMC2527838","drugname":"tamoxifen","startOffset":"97","endOffset":"106","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"ort the hypothesis that citalopram, taken concurrently with ","suffix":", reduces tamoxifen's protective effect against breast cance","exact":"tamoxifen"},{"setid":"PMC2527838","drugname":"tamoxifen","startOffset":"116","endOffset":"125","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"that citalopram, taken concurrently with tamoxifen, reduces ","suffix":"'s protective effect against breast cancer recurrence in ear","exact":"tamoxifen"},{"setid":"PMC2527838","drugname":"tamoxifen","startOffset":"237","endOffset":"246","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":" centre, which also reported no substantial modification of ","suffix":" effectiveness by concomitant use of SSRI inhibitors of CYP2","exact":"tamoxifen"},{"setid":"PMC2527838","drugname":"tamoxifen","startOffset":"77","endOffset":"86","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"ic question may be whether reduced concentrations of active ","suffix":" metabolites result in substantially reduced occupancy of th","exact":"tamoxifen"},{"setid":"PMC2527838","drugname":"tamoxifen","startOffset":"92","endOffset":"101","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[9]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[9]","prefix":"udy yielded only 17 cases of breast cancer recurrence among ","suffix":"-treated women who had used citalopram while taking tamoxife","exact":"tamoxifen"},{"setid":"PMC2527838","drugname":"tamoxifen","startOffset":"153","endOffset":"162","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[9]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[9]","prefix":"amoxifen-treated women who had used citalopram while taking ","suffix":". The study was designed with 80% power to detect an OR of 1","exact":"tamoxifen"},{"setid":"PMC2527838","drugname":"tamoxifen","startOffset":"166","endOffset":"175","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[10]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[10]","prefix":"tration advisory committee recently recommended relabelling ","suffix":" with information on gene–drug and drug–drug interactions me","exact":"tamoxifen"},{"setid":"PMC2527838","drugname":"citalopram","startOffset":"463","endOffset":"473","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"oxifen's prevention of breast cancer recurrence. We studied ","suffix":" use in 184 cases of breast cancer recurrence and 184 matche","exact":"citalopram"},{"setid":"PMC2527838","drugname":"citalopram","startOffset":"1056","endOffset":"1066","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"trols (11%) received at least one prescription for the SSRI ","suffix":" while taking tamoxifen (adjusted conditional odds ratio=0.8","exact":"citalopram"},{"setid":"PMC2527838","drugname":"citalopram","startOffset":"1236","endOffset":"1246","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"erved no reduction of tamoxifen effectiveness among regular ","suffix":" users (⩾30% overlap with tamoxifen use). These results sugg","exact":"citalopram"},{"setid":"PMC2527838","drugname":"citalopram","startOffset":"1333","endOffset":"1343","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"amoxifen use). These results suggest that concurrent use of ","suffix":" does not reduce tamoxifen's prevention of breast cancer rec","exact":"citalopram"},{"setid":"PMC2527838","drugname":"citalopram","startOffset":"373","endOffset":"383","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","prefix":"te of recurrence if they were concomitantly taking the SSRI ","suffix":" or its S-stereoisomer (‘citalopram' from here onwards) than","exact":"citalopram"},{"setid":"PMC2527838","drugname":"citalopram","startOffset":"497","endOffset":"507","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","prefix":") than if they were not. As described in more detail below, ","suffix":" was the most frequently prescribed SSRI in the study popula","exact":"citalopram"},{"setid":"PMC2527838","drugname":"citalopram","startOffset":"642","endOffset":"652","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[3]","prefix":"cluded group II women to estimate the direct association of ","suffix":" prescription with recurrence rate, if any. We further restr","exact":"citalopram"},{"setid":"PMC2527838","drugname":"citalopram","startOffset":"1015","endOffset":"1025","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[3]","prefix":"sed to ascertain use of prescription medications, including ","suffix":". Follow-up time began 1 year after the date of breast cance","exact":"citalopram"},{"setid":"PMC2527838","drugname":"citalopram","startOffset":"32","endOffset":"42","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[4]","prefix":"We collected data on receipt of ","suffix":" prescription and other potential CYP2D6 inhibitors (includi","exact":"citalopram"},{"setid":"PMC2527838","drugname":"citalopram","startOffset":"497","endOffset":"507","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","prefix":") than if they were not. As described in more detail below, ","suffix":" was the most frequently prescribed SSRI in the study popula","exact":"citalopram"},{"setid":"PMC2527838","drugname":"citalopram","startOffset":"1015","endOffset":"1025","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[3]","prefix":"sed to ascertain use of prescription medications, including ","suffix":". Follow-up time began 1 year after the date of breast cance","exact":"citalopram"},{"setid":"PMC2527838","drugname":"citalopram","startOffset":"226","endOffset":"236","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/div[2]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/div[2]/p[4]","prefix":"d categories of (a) intermittent citalopram use, defined as ","suffix":" use overlapping tamoxifen use for more than 0% but less tha","exact":"citalopram"},{"setid":"PMC2527838","drugname":"citalopram","startOffset":"370","endOffset":"380","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/div[2]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/div[2]/p[4]","prefix":"ime on tamoxifen and (b) regular citalopram use, defined as ","suffix":" use overlapping tamoxifen use for 30% or more of the time o","exact":"citalopram"},{"setid":"PMC2527838","drugname":"citalopram","startOffset":"308","endOffset":"318","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[2]","prefix":"n categories of assigned protocol of tamoxifen duration, of ","suffix":" use, of use of other CYP2D6 inhibitors or substrates, and o","exact":"citalopram"},{"setid":"PMC2527838","drugname":"citalopram","startOffset":"508","endOffset":"518","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[2]","prefix":"receiving citalopram, the number of total prescriptions for ","suffix":" summed over all cases or controls, and the range of the num","exact":"citalopram"},{"setid":"PMC2527838","drugname":"citalopram","startOffset":"603","endOffset":"613","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[2]","prefix":" controls, and the range of the number of prescriptions for ","suffix":" received by each individual case or control.","exact":"citalopram"},{"setid":"PMC2527838","drugname":"citalopram","startOffset":"150","endOffset":"160","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","prefix":"t, the majority of SSRI prescriptions in our study were for ","suffix":" or its S-stereoisomer, both originally manufactured by Lund","exact":"citalopram"},{"setid":"PMC2527838","drugname":"citalopram","startOffset":"47","endOffset":"57","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","prefix":"Last, we do not know the indications for which ","suffix":" was prescribed to the study participants, although ordinari","exact":"citalopram"},{"setid":"PMC2527838","drugname":"citalopram","startOffset":"122","endOffset":"132","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[11]/div[2]/ul[1]/li[21]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[11]/div[2]/ul[1]/li[21]/span[1]","prefix":" Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by ","suffix":", fluoxetine, fluvoxamine and paroxetine. ","exact":"citalopram"},{"setid":"PMC2527838","drugname":"citalopram","startOffset":"62","endOffset":"72","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/div[2]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/div[2]/p[3]","prefix":" classified cases and controls as those with no record of a ","suffix":" prescription during their follow-up time (never citalopram)","exact":"citalopram"},{"setid":"PMC2527838","drugname":"citalopram","startOffset":"121","endOffset":"131","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/div[2]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/div[2]/p[3]","prefix":" citalopram prescription during their follow-up time (never ","suffix":") and those with any record of prescription for citalopram d","exact":"citalopram"},{"setid":"PMC2527838","drugname":"citalopram","startOffset":"143","endOffset":"153","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","prefix":" rate of breast cancer recurrence than women who never used ","suffix":" while taking tamoxifen (","exact":"citalopram"},{"setid":"PMC2527838","drugname":"citalopram","startOffset":"179","endOffset":"189","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/div[2]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/div[2]/p[3]","prefix":"r citalopram) and those with any record of prescription for ","suffix":" during their follow-up time (ever citalopram). We used a si","exact":"citalopram"},{"setid":"PMC2527838","drugname":"citalopram","startOffset":"121","endOffset":"131","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/div[2]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/div[2]/p[3]","prefix":" citalopram prescription during their follow-up time (never ","suffix":") and those with any record of prescription for citalopram d","exact":"citalopram"},{"setid":"PMC2527838","drugname":"citalopram","startOffset":"224","endOffset":"234","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/div[2]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/div[2]/p[3]","prefix":"escription for citalopram during their follow-up time (ever ","suffix":"). We used a similar procedure to classify cases and control","exact":"citalopram"},{"setid":"PMC2527838","drugname":"citalopram","startOffset":"33","endOffset":"43","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/div[2]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/div[2]/p[4]","prefix":"For group I women who ever had a ","suffix":" prescription, we calculated the percentage of time on tamox","exact":"citalopram"},{"setid":"PMC2527838","drugname":"citalopram","startOffset":"458","endOffset":"468","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[2]","prefix":" calculated the number of cases and controls ever receiving ","suffix":", the number of total prescriptions for citalopram summed ov","exact":"citalopram"},{"setid":"PMC2527838","drugname":"citalopram","startOffset":"28","endOffset":"38","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","prefix":"Group I women who ever used ","suffix":" while taking tamoxifen did not have a higher rate of breast","exact":"citalopram"},{"setid":"PMC2527838","drugname":"citalopram","startOffset":"143","endOffset":"153","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","prefix":" rate of breast cancer recurrence than women who never used ","suffix":" while taking tamoxifen (","exact":"citalopram"},{"setid":"PMC2527838","drugname":"citalopram","startOffset":"33","endOffset":"43","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/div[2]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/div[2]/p[4]","prefix":"For group I women who ever had a ","suffix":" prescription, we calculated the percentage of time on tamox","exact":"citalopram"},{"setid":"PMC2527838","drugname":"citalopram","startOffset":"145","endOffset":"155","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/div[2]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/div[2]/p[4]","prefix":"e of time on tamoxifen when they were simultaneously taking ","suffix":". We created categories of (a) intermittent citalopram use, ","exact":"citalopram"},{"setid":"PMC2527838","drugname":"citalopram","startOffset":"199","endOffset":"209","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/div[2]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/div[2]/p[4]","prefix":"aking citalopram. We created categories of (a) intermittent ","suffix":" use, defined as citalopram use overlapping tamoxifen use fo","exact":"citalopram"},{"setid":"PMC2527838","drugname":"citalopram","startOffset":"226","endOffset":"236","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/div[2]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/div[2]/p[4]","prefix":"d categories of (a) intermittent citalopram use, defined as ","suffix":" use overlapping tamoxifen use for more than 0% but less tha","exact":"citalopram"},{"setid":"PMC2527838","drugname":"citalopram","startOffset":"343","endOffset":"353","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/div[2]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/div[2]/p[4]","prefix":" but less than 30% of the time on tamoxifen and (b) regular ","suffix":" use, defined as citalopram use overlapping tamoxifen use fo","exact":"citalopram"},{"setid":"PMC2527838","drugname":"citalopram","startOffset":"370","endOffset":"380","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/div[2]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/div[2]/p[4]","prefix":"ime on tamoxifen and (b) regular citalopram use, defined as ","suffix":" use overlapping tamoxifen use for 30% or more of the time o","exact":"citalopram"},{"setid":"PMC2527838","drugname":"citalopram","startOffset":"537","endOffset":"547","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/div[2]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/div[2]/p[4]","prefix":"lap boundary to allow sufficient sample size in the regular ","suffix":" subgroup, while also investigating a substantial period of ","exact":"citalopram"},{"setid":"PMC2527838","drugname":"citalopram","startOffset":"308","endOffset":"318","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[2]","prefix":"n categories of assigned protocol of tamoxifen duration, of ","suffix":" use, of use of other CYP2D6 inhibitors or substrates, and o","exact":"citalopram"},{"setid":"PMC2527838","drugname":"citalopram","startOffset":"458","endOffset":"468","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[2]","prefix":" calculated the number of cases and controls ever receiving ","suffix":", the number of total prescriptions for citalopram summed ov","exact":"citalopram"},{"setid":"PMC2527838","drugname":"citalopram","startOffset":"508","endOffset":"518","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[2]","prefix":"receiving citalopram, the number of total prescriptions for ","suffix":" summed over all cases or controls, and the range of the num","exact":"citalopram"},{"setid":"PMC2527838","drugname":"citalopram","startOffset":"603","endOffset":"613","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[2]","prefix":" controls, and the range of the number of prescriptions for ","suffix":" received by each individual case or control.","exact":"citalopram"},{"setid":"PMC2527838","drugname":"citalopram","startOffset":"40","endOffset":"50","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[3]","prefix":"We estimated the rate ratio associating ","suffix":" prescription with breast cancer recurrence as the odds rati","exact":"citalopram"},{"setid":"PMC2527838","drugname":"citalopram","startOffset":"169","endOffset":"179","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[3]","prefix":"io (OR) in a conditional logistic regression including only ","suffix":" use as the exposure variable and conditioned on the matched","exact":"citalopram"},{"setid":"PMC2527838","drugname":"citalopram","startOffset":"28","endOffset":"38","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","prefix":"Group I women who ever used ","suffix":" while taking tamoxifen did not have a higher rate of breast","exact":"citalopram"},{"setid":"PMC2527838","drugname":"citalopram","startOffset":"143","endOffset":"153","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","prefix":" rate of breast cancer recurrence than women who never used ","suffix":" while taking tamoxifen (","exact":"citalopram"},{"setid":"PMC2527838","drugname":"citalopram","startOffset":"61","endOffset":"71","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"he results of this study do not support the hypothesis that ","suffix":", taken concurrently with tamoxifen, reduces tamoxifen's pro","exact":"citalopram"},{"setid":"PMC2527838","drugname":"citalopram","startOffset":"150","endOffset":"160","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","prefix":"t, the majority of SSRI prescriptions in our study were for ","suffix":" or its S-stereoisomer, both originally manufactured by Lund","exact":"citalopram"},{"setid":"PMC2527838","drugname":"citalopram","startOffset":"262","endOffset":"272","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","prefix":"nufactured by Lundbeck, a company headquartered in Denmark. ","suffix":" is a modest inhibitor of ","exact":"Citalopram"},{"setid":"PMC2527838","drugname":"citalopram","startOffset":"47","endOffset":"57","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","prefix":"Last, we do not know the indications for which ","suffix":" was prescribed to the study participants, although ordinari","exact":"citalopram"},{"setid":"PMC2527838","drugname":"citalopram","startOffset":"760","endOffset":"770","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[8]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[8]","prefix":" have high sensitivity and specificity for ascertainment of ","suffix":" prescriptions in the source population. Furthermore, becaus","exact":"citalopram"},{"setid":"PMC2527838","drugname":"citalopram","startOffset":"129","endOffset":"139","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[9]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[9]","prefix":"ancer recurrence among tamoxifen-treated women who had used ","suffix":" while taking tamoxifen. The study was designed with 80% pow","exact":"citalopram"},{"setid":"PMC2527838","drugname":"paroxetine","startOffset":"162","endOffset":"172","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[11]/div[2]/ul[1]/li[21]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[11]/div[2]/ul[1]/li[21]/span[1]","prefix":"P2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and ","suffix":". ","exact":"paroxetine"},{"setid":"PMC2527838","drugname":"paroxetine","startOffset":"60","endOffset":"70","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[11]/div[2]/ul[1]/li[44]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[11]/div[2]/ul[1]/li[44]/span[1]","prefix":"Zourková A, Cesková E, Hadasová E, Ravcuková B. Links among ","suffix":"-induced sexual dysfunctions, gender, and CYP2D6 activity. ","exact":"paroxetine"},{"setid":"PMC2527838","drugname":"fluoxetine","startOffset":"134","endOffset":"144","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[11]/div[2]/ul[1]/li[21]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[11]/div[2]/ul[1]/li[21]/span[1]","prefix":"ent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, ","suffix":", fluvoxamine and paroxetine. ","exact":"fluoxetine"},{"setid":"PMC2527838","drugname":"fluvoxamine","startOffset":"167","endOffset":"178","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[11]/div[2]/ul[1]/li[11]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[11]/div[2]/ul[1]/li[11]/span[1]","prefix":"himizu T, Otani K. Relationship between clinical effects of ","suffix":" and the steady-state plasma concentrations of fluvoxamine a","exact":"fluvoxamine"},{"setid":"PMC2527838","drugname":"fluvoxamine","startOffset":"146","endOffset":"157","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[11]/div[2]/ul[1]/li[21]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[11]/div[2]/ul[1]/li[21]/span[1]","prefix":"on of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, ","suffix":" and paroxetine. ","exact":"fluvoxamine"}],[{"setid":"PMC2764168","drugname":"tipranavir","startOffset":"0","endOffset":"10","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","prefix":"","suffix":" coadministered with low-dose ritonavir (TPV/r) is an effect","exact":"Tipranavir"},{"setid":"PMC2764168","drugname":"tipranavir","startOffset":"158","endOffset":"168","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[2]","prefix":"d a single 10-mg dose of rosuvastatin on day 1, followed by ","suffix":" 500 mg-ritonavir 200 mg twice daily for 11 days (days 3 to ","exact":"tipranavir"},{"setid":"PMC2764168","drugname":"tipranavir","startOffset":"653","endOffset":"663","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[2]","prefix":"/r at steady state) for rosuvastatin and days 12 and 13 for ","suffix":" and ritonavir. A standard 670-kcal (33% fat) breakfast was ","exact":"tipranavir"},{"setid":"PMC2764168","drugname":"tipranavir","startOffset":"1035","endOffset":"1045","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[2]","prefix":"nd 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, and 12 h postdose for ","suffix":" and ritonavir and 0 h predose and 0.5, 1, 1.5, 2, 3, 4, 5, ","exact":"tipranavir"},{"setid":"PMC2764168","drugname":"tipranavir","startOffset":"1376","endOffset":"1386","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[2]","prefix":"s undertaken. The short-term safety and steady-state PKs of ","suffix":" and ritonavir coadministered with single-dose rosuvastatin ","exact":"tipranavir"},{"setid":"PMC2764168","drugname":"tipranavir","startOffset":"547","endOffset":"557","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[2]","prefix":"0% adherence with study medication. The steady-state PKs of ","suffix":" were assessed on day 19 after ingestion of TPV/r alone and ","exact":"tipranavir"},{"setid":"PMC2764168","drugname":"tipranavir","startOffset":"30","endOffset":"40","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[3]","prefix":"Blood samples for analysis of ","suffix":" concentrations were collected in heparinized tubes on days ","exact":"tipranavir"},{"setid":"PMC2764168","drugname":"tipranavir","startOffset":"80","endOffset":"90","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[9]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[9]/p[2]","prefix":"MS method was used to measure plasma drug concentrations of ","suffix":" and ritonavir (","exact":"tipranavir"},{"setid":"PMC2764168","drugname":"tipranavir","startOffset":"324","endOffset":"334","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[2]","prefix":"orvastatin PK results from one subject and the steady-state ","suffix":" PK results from another subject were excluded from all stat","exact":"tipranavir"},{"setid":"PMC2764168","drugname":"tipranavir","startOffset":"64","endOffset":"74","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[3]","prefix":"le-dose atorvastatin did not affect the steady-state PKs of ","suffix":" (Table ","exact":"tipranavir"},{"setid":"PMC2764168","drugname":"ritonavir","startOffset":"75","endOffset":"84","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"rmacokinetic (PK) drug-drug interactions between tipranavir-","suffix":" (TPV/r) and rosuvastatin and atorvastatin, we conducted two","exact":"ritonavir"},{"setid":"PMC2764168","drugname":"ritonavir","startOffset":"40","endOffset":"49","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","prefix":"Tipranavir coadministered with low-dose ","suffix":" (TPV/r) is an effective treatment option in treatment-exper","exact":"ritonavir"},{"setid":"PMC2764168","drugname":"ritonavir","startOffset":"176","endOffset":"185","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[2]","prefix":"ose of rosuvastatin on day 1, followed by tipranavir 500 mg-","suffix":" 200 mg twice daily for 11 days (days 3 to 13), with a singl","exact":"ritonavir"},{"setid":"PMC2764168","drugname":"ritonavir","startOffset":"668","endOffset":"677","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[2]","prefix":"ate) for rosuvastatin and days 12 and 13 for tipranavir and ","suffix":". A standard 670-kcal (33% fat) breakfast was served to subj","exact":"ritonavir"},{"setid":"PMC2764168","drugname":"ritonavir","startOffset":"1050","endOffset":"1059","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[2]","prefix":" 2, 3, 4, 5, 6, 8, 10, and 12 h postdose for tipranavir and ","suffix":" and 0 h predose and 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, ","exact":"ritonavir"},{"setid":"PMC2764168","drugname":"ritonavir","startOffset":"1391","endOffset":"1400","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[2]","prefix":"he short-term safety and steady-state PKs of tipranavir and ","suffix":" coadministered with single-dose rosuvastatin (10 mg) were a","exact":"ritonavir"},{"setid":"PMC2764168","drugname":"ritonavir","startOffset":"276","endOffset":"285","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[3]","prefix":", 6, 8, 10, and 12 h after ingestion of TPV/r (12 samples). ","suffix":" plasma concentrations were not measured in this study.","exact":"Ritonavir"},{"setid":"PMC2764168","drugname":"ritonavir","startOffset":"95","endOffset":"104","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[9]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[9]/p[2]","prefix":"sed to measure plasma drug concentrations of tipranavir and ","suffix":" (","exact":"ritonavir"},{"setid":"PMC2764168","drugname":"ritonavir","startOffset":"116","endOffset":"125","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","prefix":"tion studies evaluating the effect of another PI, lopinavir-","suffix":" (LPV/r), when coadministered with rosuvastatin at steady st","exact":"ritonavir"},{"setid":"PMC2764168","drugname":"rosuvastatin","startOffset":"97","endOffset":"109","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"-drug interactions between tipranavir-ritonavir (TPV/r) and ","suffix":" and atorvastatin, we conducted two prospective, open-label,","exact":"rosuvastatin"},{"setid":"PMC2764168","drugname":"rosuvastatin","startOffset":"344","endOffset":"356","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":") for the area under the concentration-time curve (AUC) for ","suffix":" and 2.23 (90% CI, 1.83 to 2.72) for the maximum concentrati","exact":"rosuvastatin"},{"setid":"PMC2764168","drugname":"rosuvastatin","startOffset":"198","endOffset":"210","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[7]/p[3]","prefix":"e lower limit of quantitation was nominally 0.100 ng/ml for ","suffix":".","exact":"rosuvastatin"},{"setid":"PMC2764168","drugname":"rosuvastatin","startOffset":"9","endOffset":"21","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":"However, ","suffix":" is unlikely to interact with TPV/r since it is not a CYP3A4","exact":"rosuvastatin"},{"setid":"PMC2764168","drugname":"crestor","startOffset":"131","endOffset":"138","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":"t a CYP3A4 substrate and it is not extensively metabolized (","suffix":" package insert; AstraZeneca Pharmaceuticals, Wilmington, DE","exact":"Crestor"},{"setid":"PMC2764168","drugname":"rosuvastatin","startOffset":"379","endOffset":"391","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":"rug interactions between steady-state TPV/r and single-dose ","suffix":" (“rosuvastatin study”) and atorvastatin (“atorvastatin stud","exact":"rosuvastatin"},{"setid":"PMC2764168","drugname":"rosuvastatin","startOffset":"394","endOffset":"406","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":"s between steady-state TPV/r and single-dose rosuvastatin (“","suffix":" study”) and atorvastatin (“atorvastatin study”).","exact":"rosuvastatin"},{"setid":"PMC2764168","drugname":"rosuvastatin","startOffset":"123","endOffset":"135","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[2]","prefix":"dy-state PK study. Subjects received a single 10-mg dose of ","suffix":" on day 1, followed by tipranavir 500 mg-ritonavir 200 mg tw","exact":"rosuvastatin"},{"setid":"PMC2764168","drugname":"rosuvastatin","startOffset":"261","endOffset":"273","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[2]","prefix":"ily for 11 days (days 3 to 13), with a single 10-mg dose of ","suffix":" given on day 12. All study drug doses were given under dire","exact":"rosuvastatin"},{"setid":"PMC2764168","drugname":"rosuvastatin","startOffset":"617","endOffset":"629","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[2]","prefix":"f TPV/r) and days 12 to 14 (with TPV/r at steady state) for ","suffix":" and days 12 and 13 for tipranavir and ritonavir. A standard","exact":"rosuvastatin"},{"setid":"PMC2764168","drugname":"rosuvastatin","startOffset":"198","endOffset":"210","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[7]/p[3]","prefix":"e lower limit of quantitation was nominally 0.100 ng/ml for ","suffix":".","exact":"rosuvastatin"},{"setid":"PMC2764168","drugname":"rosuvastatin","startOffset":"1145","endOffset":"1157","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[2]","prefix":"1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, and 48 h postdose for ","suffix":". A pharmacokinetic comparison of single-dose rosuvastatin w","exact":"rosuvastatin"},{"setid":"PMC2764168","drugname":"rosuvastatin","startOffset":"1203","endOffset":"1215","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[2]","prefix":"r rosuvastatin. A pharmacokinetic comparison of single-dose ","suffix":" with single-dose rosuvastatin coadministered with TPV/r 500","exact":"rosuvastatin"},{"setid":"PMC2764168","drugname":"rosuvastatin","startOffset":"1233","endOffset":"1245","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[2]","prefix":"tic comparison of single-dose rosuvastatin with single-dose ","suffix":" coadministered with TPV/r 500 mg/200 mg twice daily at stea","exact":"rosuvastatin"},{"setid":"PMC2764168","drugname":"rosuvastatin","startOffset":"1433","endOffset":"1445","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[2]","prefix":"of tipranavir and ritonavir coadministered with single-dose ","suffix":" (10 mg) were also evaluated.","exact":"rosuvastatin"},{"setid":"PMC2764168","drugname":"rosuvastatin","startOffset":"96","endOffset":"108","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[7]/p[2]","prefix":"ped and validated by PPD (Richmond, VA) for the analysis of ","suffix":" in human plasma containing dipotassium EDTA. A 200-μl-sampl","exact":"rosuvastatin"},{"setid":"PMC2764168","drugname":"rosuvastatin","startOffset":"198","endOffset":"210","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[7]/p[3]","prefix":"e lower limit of quantitation was nominally 0.100 ng/ml for ","suffix":".","exact":"rosuvastatin"},{"setid":"PMC2764168","drugname":"rosuvastatin","startOffset":"144","endOffset":"156","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[11]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[11]/p[6]","prefix":" variation (CV) would range from 20% to 40% for the AUCs of ","suffix":" and atorvastatin. Therefore, a sample size of 20 would prov","exact":"rosuvastatin"},{"setid":"PMC2764168","drugname":"rosuvastatin","startOffset":"270","endOffset":"282","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[11]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[11]/p[6]","prefix":"d provide >90% power to detect a ≥25% change in the AUCs of ","suffix":" and atorvastatin.","exact":"rosuvastatin"},{"setid":"PMC2764168","drugname":"rosuvastatin","startOffset":"44","endOffset":"56","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[2]","prefix":"With TPV/r coadministration, the GM AUC for ","suffix":" was 38.6 ng·h/ml, a 37% increase compared with that of rosu","exact":"rosuvastatin"},{"setid":"PMC2764168","drugname":"rosuvastatin","startOffset":"112","endOffset":"124","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[2]","prefix":"atin was 38.6 ng·h/ml, a 37% increase compared with that of ","suffix":" alone (","exact":"rosuvastatin"},{"setid":"PMC2764168","drugname":"rosuvastatin","startOffset":"7","endOffset":"19","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/div[1]/div[2]/span[1]","prefix":"Plasma ","suffix":" concentration-time profile in the absence (open circles) an","exact":"rosuvastatin"},{"setid":"PMC2764168","drugname":"rosuvastatin","startOffset":"44","endOffset":"56","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[2]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[2]/div[1]/div[2]/span[1]","prefix":"Effect of steady-state TPV/r on single-dose ","suffix":" (ROS) ","exact":"rosuvastatin"},{"setid":"PMC2764168","drugname":"rosuvastatin","startOffset":"17","endOffset":"29","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[3]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[3]/div[1]/div[2]/span[1]","prefix":"PK parameters of ","suffix":" alone or rosuvastatin plus TPV/r","exact":"rosuvastatin"},{"setid":"PMC2764168","drugname":"rosuvastatin","startOffset":"17","endOffset":"29","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[3]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[3]/div[1]/div[2]/span[1]","prefix":"PK parameters of ","suffix":" alone or rosuvastatin plus TPV/r","exact":"rosuvastatin"},{"setid":"PMC2764168","drugname":"rosuvastatin","startOffset":"39","endOffset":"51","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[3]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[3]/div[1]/div[2]/span[1]","prefix":"PK parameters of rosuvastatin alone or ","suffix":" plus TPV/r","exact":"rosuvastatin"},{"setid":"PMC2764168","drugname":"rosuvastatin","startOffset":"68","endOffset":"80","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"g interaction was predicted to be unlikely to occur between ","suffix":" and TPV/r since rosuvastatin is not a known substrate, inhi","exact":"rosuvastatin"},{"setid":"PMC2764168","drugname":"rosuvastatin","startOffset":"97","endOffset":"109","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"o be unlikely to occur between rosuvastatin and TPV/r since ","suffix":" is not a known substrate, inhibitor, or inducer of CYP3A4. ","exact":"rosuvastatin"},{"setid":"PMC2764168","drugname":"rosuvastatin","startOffset":"182","endOffset":"194","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"wn substrate, inhibitor, or inducer of CYP3A4. Furthermore, ","suffix":" is not extensively metabolized, with approximately 10% of a","exact":"rosuvastatin"},{"setid":"PMC2764168","drugname":"crestor","startOffset":"131","endOffset":"138","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":"t a CYP3A4 substrate and it is not extensively metabolized (","suffix":" package insert; AstraZeneca Pharmaceuticals, Wilmington, DE","exact":"Crestor"},{"setid":"PMC2764168","drugname":"rosuvastatin","startOffset":"0","endOffset":"12","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"","suffix":" is not a P-glycoprotein (Pgp) substrate, but it is a substr","exact":"Rosuvastatin"},{"setid":"PMC2764168","drugname":"rosuvastatin","startOffset":"160","endOffset":"172","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","prefix":"r PI, lopinavir-ritonavir (LPV/r), when coadministered with ","suffix":" at steady state. A prospective study conducted with healthy","exact":"rosuvastatin"},{"setid":"PMC2764168","drugname":"rosuvastatin","startOffset":"255","endOffset":"267","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","prefix":"spective study conducted with healthy volunteers found that ","suffix":" AUC","exact":"rosuvastatin"},{"setid":"PMC2764168","drugname":"rosuvastatin","startOffset":"61","endOffset":"73","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","prefix":"n conclusion, we observed a clinically relevant increase in ","suffix":" and atorvastatin concentrations during coadministration of ","exact":"rosuvastatin"},{"setid":"PMC2764168","drugname":"rosuvastatin","startOffset":"212","endOffset":"224","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","prefix":" twice daily. Based on these results, a low initial dose of ","suffix":" (5 mg) and atorvastatin (10 mg) is recommended when combine","exact":"rosuvastatin"},{"setid":"PMC2764168","drugname":"rosuvastatin","startOffset":"334","endOffset":"346","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","prefix":"en combined with TPV/r, with careful clinical monitoring of ","suffix":"- or atorvastatin-related AEs, such as myopathy.","exact":"rosuvastatin"},{"setid":"PMC2764168","drugname":"rosuvastatin","startOffset":"368","endOffset":"380","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/div[2]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/div[2]/p[2]","prefix":"tawa Hospital and the Ottawa Health Research Institute. The ","suffix":" study is supported by a GCRC grant (RR-00052) and an invest","exact":"rosuvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":"114","endOffset":"126","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"s between tipranavir-ritonavir (TPV/r) and rosuvastatin and ","suffix":", we conducted two prospective, open-label, single-arm, two-","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":"114","endOffset":"126","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"s between tipranavir-ritonavir (TPV/r) and rosuvastatin and ","suffix":", we conducted two prospective, open-label, single-arm, two-","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":"419","endOffset":"431","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":"V/r and single-dose rosuvastatin (“rosuvastatin study”) and ","suffix":" (“atorvastatin study”).","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":"434","endOffset":"446","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":"dose rosuvastatin (“rosuvastatin study”) and atorvastatin (“","suffix":" study”).","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":"80","endOffset":"92","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[2]","prefix":"of atorvastatin, orthohydroxy atorvastatin, and parahydroxy ","suffix":" were assessed on day 1 after ingestion of 40 mg of atorvast","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":"1131","endOffset":"1143","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[2]","prefix":", 2, 3, 4, 5, 6, 8, 10, 12, 24, and 48 h after ingestion of ","suffix":" (14 samples).","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":"161","endOffset":"173","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[11]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[11]/p[6]","prefix":"ould range from 20% to 40% for the AUCs of rosuvastatin and ","suffix":". Therefore, a sample size of 20 would provide >90% power to","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":"262","endOffset":"274","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[2]","prefix":" kg, and a median height of 168 (range, 158 to 189) cm. The ","suffix":" PK results from one subject and the steady-state tipranavir","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":"114","endOffset":"126","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/div[1]/div[1]/div[2]/span[1]","prefix":"astatin (A), orthohydroxy atorvastatin (B), and parahydroxy ","suffix":" (C). Shown are 40 mg atorvastatin alone (open circles) (A t","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":"148","endOffset":"160","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/div[1]/div[1]/div[2]/span[1]","prefix":"atin (B), and parahydroxy atorvastatin (C). Shown are 40 mg ","suffix":" alone (open circles) (A to C), 10 mg atorvastatin plus stea","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":"86","endOffset":"98","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/div[3]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/div[3]/div[1]/div[2]/span[1]","prefix":"of atorvastatin, orthohydroxy atorvastatin, and parahydroxy ","suffix":" after administration of atorvastatin 40 mg alone and coadmi","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":"123","endOffset":"135","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/div[3]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/div[3]/div[1]/div[2]/span[1]","prefix":"tatin, and parahydroxy atorvastatin after administration of ","suffix":" 40 mg alone and coadministration of atorvastatin 10 mg and ","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":"172","endOffset":"184","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/div[3]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/div[3]/div[1]/div[2]/span[1]","prefix":"tration of atorvastatin 40 mg alone and coadministration of ","suffix":" 10 mg and steady-state TPV/r 500 mg/200 mg twice daily (","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":"100","endOffset":"112","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[7]/p[2]","prefix":"200 mg twice daily alone and in the presence of single-dose ","suffix":" was well tolerated in this study. There were no study disco","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":"78","endOffset":"90","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","prefix":"observed a clinically relevant increase in rosuvastatin and ","suffix":" concentrations during coadministration of TPV/r 500 mg/200 ","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":"236","endOffset":"248","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","prefix":"hese results, a low initial dose of rosuvastatin (5 mg) and ","suffix":" (10 mg) is recommended when combined with TPV/r, with caref","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":"124","endOffset":"136","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[10]/div[2]/div[8]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[10]/div[2]/div[8]/span[1]","prefix":" and J. L. Reubsaet. 2004. Substantially elevated levels of ","suffix":" and metabolites in cyclosporine-treated renal transplant re","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":"137","endOffset":"149","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[10]/div[2]/div[23]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[10]/div[2]/div[23]/span[1]","prefix":"Sedman. 1996. Tolerance and pharmacokinetics of single-dose ","suffix":", a potent inhibitor of HMG-CoA reductase, in healthy subjec","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":"46","endOffset":"58","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[5]/div[2]/ul[1]/li[2]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[5]/div[2]/ul[1]/li[2]/a[1]","prefix":"Tolerance and pharmacokinetics of single-dose ","suffix":", a potent inhibitor of HMG-CoA reductase, in healthy subjec","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":"46","endOffset":"58","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[20]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[20]","prefix":"Tolerance and pharmacokinetics of single-dose ","suffix":", a potent inhibitor of HMG-CoA reductase, in healthy subjec","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":"114","endOffset":"126","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"s between tipranavir-ritonavir (TPV/r) and rosuvastatin and ","suffix":", we conducted two prospective, open-label, single-arm, two-","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":"419","endOffset":"431","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":"V/r and single-dose rosuvastatin (“rosuvastatin study”) and ","suffix":" (“atorvastatin study”).","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":"434","endOffset":"446","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":"dose rosuvastatin (“rosuvastatin study”) and atorvastatin (“","suffix":" study”).","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":"80","endOffset":"92","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[2]","prefix":"of atorvastatin, orthohydroxy atorvastatin, and parahydroxy ","suffix":" were assessed on day 1 after ingestion of 40 mg of atorvast","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":"1131","endOffset":"1143","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[2]","prefix":", 2, 3, 4, 5, 6, 8, 10, 12, 24, and 48 h after ingestion of ","suffix":" (14 samples).","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":"161","endOffset":"173","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[11]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[11]/p[6]","prefix":"ould range from 20% to 40% for the AUCs of rosuvastatin and ","suffix":". Therefore, a sample size of 20 would provide >90% power to","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":"262","endOffset":"274","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[2]","prefix":" kg, and a median height of 168 (range, 158 to 189) cm. The ","suffix":" PK results from one subject and the steady-state tipranavir","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":"114","endOffset":"126","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/div[1]/div[1]/div[2]/span[1]","prefix":"astatin (A), orthohydroxy atorvastatin (B), and parahydroxy ","suffix":" (C). Shown are 40 mg atorvastatin alone (open circles) (A t","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":"148","endOffset":"160","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/div[1]/div[1]/div[2]/span[1]","prefix":"atin (B), and parahydroxy atorvastatin (C). Shown are 40 mg ","suffix":" alone (open circles) (A to C), 10 mg atorvastatin plus stea","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":"86","endOffset":"98","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/div[3]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/div[3]/div[1]/div[2]/span[1]","prefix":"of atorvastatin, orthohydroxy atorvastatin, and parahydroxy ","suffix":" after administration of atorvastatin 40 mg alone and coadmi","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":"123","endOffset":"135","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/div[3]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/div[3]/div[1]/div[2]/span[1]","prefix":"tatin, and parahydroxy atorvastatin after administration of ","suffix":" 40 mg alone and coadministration of atorvastatin 10 mg and ","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":"172","endOffset":"184","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/div[3]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/div[3]/div[1]/div[2]/span[1]","prefix":"tration of atorvastatin 40 mg alone and coadministration of ","suffix":" 10 mg and steady-state TPV/r 500 mg/200 mg twice daily (","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":"100","endOffset":"112","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[7]/p[2]","prefix":"200 mg twice daily alone and in the presence of single-dose ","suffix":" was well tolerated in this study. There were no study disco","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":"78","endOffset":"90","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","prefix":"observed a clinically relevant increase in rosuvastatin and ","suffix":" concentrations during coadministration of TPV/r 500 mg/200 ","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":"236","endOffset":"248","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","prefix":"hese results, a low initial dose of rosuvastatin (5 mg) and ","suffix":" (10 mg) is recommended when combined with TPV/r, with caref","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":"124","endOffset":"136","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[10]/div[2]/div[8]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[10]/div[2]/div[8]/span[1]","prefix":" and J. L. Reubsaet. 2004. Substantially elevated levels of ","suffix":" and metabolites in cyclosporine-treated renal transplant re","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":"137","endOffset":"149","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[10]/div[2]/div[23]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[10]/div[2]/div[23]/span[1]","prefix":"Sedman. 1996. Tolerance and pharmacokinetics of single-dose ","suffix":", a potent inhibitor of HMG-CoA reductase, in healthy subjec","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":"46","endOffset":"58","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[5]/div[2]/ul[1]/li[2]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[5]/div[2]/ul[1]/li[2]/a[1]","prefix":"Tolerance and pharmacokinetics of single-dose ","suffix":", a potent inhibitor of HMG-CoA reductase, in healthy subjec","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":"46","endOffset":"58","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[20]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[20]","prefix":"Tolerance and pharmacokinetics of single-dose ","suffix":", a potent inhibitor of HMG-CoA reductase, in healthy subjec","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":"104","endOffset":"116","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[3]/div[2]/div[1]/ul[1]/li[5]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[3]/div[2]/div[1]/ul[1]/li[5]/a[1]","prefix":"ibitor Telaprevir on the Pharmacokinetics of Amlodipine and ","suffix":"","exact":"Atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":"23","endOffset":"35","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[2]","prefix":"The single-dose PKs of ","suffix":", orthohydroxy atorvastatin, and parahydroxy atorvastatin we","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":"50","endOffset":"62","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[2]","prefix":"The single-dose PKs of atorvastatin, orthohydroxy ","suffix":", and parahydroxy atorvastatin were assessed on day 1 after ","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":"80","endOffset":"92","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[2]","prefix":"of atorvastatin, orthohydroxy atorvastatin, and parahydroxy ","suffix":" were assessed on day 1 after ingestion of 40 mg of atorvast","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":"144","endOffset":"156","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[2]","prefix":"vastatin were assessed on day 1 after ingestion of 40 mg of ","suffix":" alone. From days 14 to 21, subjects received TPV/r 500 mg/2","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":"705","endOffset":"717","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[2]","prefix":"on of TPV/r 500 mg/200 mg twice daily plus a single dose of ","suffix":" 10 mg, as an increase in atorvastatin concentrations was ex","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":"743","endOffset":"755","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[2]","prefix":"plus a single dose of atorvastatin 10 mg, as an increase in ","suffix":" concentrations was expected in combination with steady-stat","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":"883","endOffset":"895","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[2]","prefix":"at 500 mg/200 mg twice daily. Blood samples for analysis of ","suffix":" and hydroxy metabolites were collected on days 1 and 20 in ","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":"1131","endOffset":"1143","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[2]","prefix":", 2, 3, 4, 5, 6, 8, 10, 12, 24, and 48 h after ingestion of ","suffix":" (14 samples).","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":"21","endOffset":"33","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[4]","prefix":"On PK sampling days, ","suffix":" and TPV/r were administered orally at 8 a.m. with 240 ml of","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":"104","endOffset":"116","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[3]/div[2]/div[1]/ul[1]/li[5]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[3]/div[2]/div[1]/ul[1]/li[5]/a[1]","prefix":"ibitor Telaprevir on the Pharmacokinetics of Amlodipine and ","suffix":"","exact":"Atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":"25","endOffset":"37","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[8]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[8]/p[2]","prefix":"Plasma concentrations of ","suffix":" and its hydroxy metabolites were measured by validated liqu","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":"56","endOffset":"68","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[11]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[11]/p[3]","prefix":"Prior to statistical analysis of the effect of TPV/r on ","suffix":" (day 1 versus day 20), the atorvastatin AUC","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":"96","endOffset":"108","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[11]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[11]/p[3]","prefix":" effect of TPV/r on atorvastatin (day 1 versus day 20), the ","suffix":" AUC","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":"44","endOffset":"56","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/div[2]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/div[2]/div[1]/div[2]/span[1]","prefix":"Effect of steady-state TPV/r on single-dose ","suffix":" (ATO) ","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":"96","endOffset":"108","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[11]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[11]/p[3]","prefix":" effect of TPV/r on atorvastatin (day 1 versus day 20), the ","suffix":" AUC","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":"31","endOffset":"43","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[11]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[11]/p[4]","prefix":"In addition to the analysis of ","suffix":" and its hydroxy metabolites individually, the effect on tot","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":"277","endOffset":"289","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[11]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[11]/p[4]","prefix":"ted as the sum of the time-specific molar concentrations of ","suffix":" (normalized for a 40-mg dose), orthohydroxy atorvastatin, a","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":"334","endOffset":"346","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[11]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[11]/p[4]","prefix":"of atorvastatin (normalized for a 40-mg dose), orthohydroxy ","suffix":", and parahydroxy atorvastatin.","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":"364","endOffset":"376","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[11]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[11]/p[4]","prefix":"r a 40-mg dose), orthohydroxy atorvastatin, and parahydroxy ","suffix":".","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":"364","endOffset":"376","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[11]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[11]/p[4]","prefix":"r a 40-mg dose), orthohydroxy atorvastatin, and parahydroxy ","suffix":".","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":"161","endOffset":"173","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[11]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[11]/p[6]","prefix":"ould range from 20% to 40% for the AUCs of rosuvastatin and ","suffix":". Therefore, a sample size of 20 would provide >90% power to","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":"287","endOffset":"299","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[11]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[11]/p[6]","prefix":"wer to detect a ≥25% change in the AUCs of rosuvastatin and ","suffix":".","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":"114","endOffset":"126","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"s between tipranavir-ritonavir (TPV/r) and rosuvastatin and ","suffix":", we conducted two prospective, open-label, single-arm, two-","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":"419","endOffset":"431","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":"V/r and single-dose rosuvastatin (“rosuvastatin study”) and ","suffix":" (“atorvastatin study”).","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":"434","endOffset":"446","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":"dose rosuvastatin (“rosuvastatin study”) and atorvastatin (“","suffix":" study”).","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":"80","endOffset":"92","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[2]","prefix":"of atorvastatin, orthohydroxy atorvastatin, and parahydroxy ","suffix":" were assessed on day 1 after ingestion of 40 mg of atorvast","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":"1131","endOffset":"1143","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[2]","prefix":", 2, 3, 4, 5, 6, 8, 10, 12, 24, and 48 h after ingestion of ","suffix":" (14 samples).","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":"161","endOffset":"173","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[11]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[11]/p[6]","prefix":"ould range from 20% to 40% for the AUCs of rosuvastatin and ","suffix":". Therefore, a sample size of 20 would provide >90% power to","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":"262","endOffset":"274","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[2]","prefix":" kg, and a median height of 168 (range, 158 to 189) cm. The ","suffix":" PK results from one subject and the steady-state tipranavir","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":"114","endOffset":"126","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/div[1]/div[1]/div[2]/span[1]","prefix":"astatin (A), orthohydroxy atorvastatin (B), and parahydroxy ","suffix":" (C). Shown are 40 mg atorvastatin alone (open circles) (A t","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":"148","endOffset":"160","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/div[1]/div[1]/div[2]/span[1]","prefix":"atin (B), and parahydroxy atorvastatin (C). Shown are 40 mg ","suffix":" alone (open circles) (A to C), 10 mg atorvastatin plus stea","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":"86","endOffset":"98","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/div[3]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/div[3]/div[1]/div[2]/span[1]","prefix":"of atorvastatin, orthohydroxy atorvastatin, and parahydroxy ","suffix":" after administration of atorvastatin 40 mg alone and coadmi","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":"123","endOffset":"135","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/div[3]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/div[3]/div[1]/div[2]/span[1]","prefix":"tatin, and parahydroxy atorvastatin after administration of ","suffix":" 40 mg alone and coadministration of atorvastatin 10 mg and ","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":"172","endOffset":"184","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/div[3]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/div[3]/div[1]/div[2]/span[1]","prefix":"tration of atorvastatin 40 mg alone and coadministration of ","suffix":" 10 mg and steady-state TPV/r 500 mg/200 mg twice daily (","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":"100","endOffset":"112","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[7]/p[2]","prefix":"200 mg twice daily alone and in the presence of single-dose ","suffix":" was well tolerated in this study. There were no study disco","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":"78","endOffset":"90","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","prefix":"observed a clinically relevant increase in rosuvastatin and ","suffix":" concentrations during coadministration of TPV/r 500 mg/200 ","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":"236","endOffset":"248","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","prefix":"hese results, a low initial dose of rosuvastatin (5 mg) and ","suffix":" (10 mg) is recommended when combined with TPV/r, with caref","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":"124","endOffset":"136","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[10]/div[2]/div[8]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[10]/div[2]/div[8]/span[1]","prefix":" and J. L. Reubsaet. 2004. Substantially elevated levels of ","suffix":" and metabolites in cyclosporine-treated renal transplant re","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":"137","endOffset":"149","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[10]/div[2]/div[23]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[10]/div[2]/div[23]/span[1]","prefix":"Sedman. 1996. Tolerance and pharmacokinetics of single-dose ","suffix":", a potent inhibitor of HMG-CoA reductase, in healthy subjec","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":"46","endOffset":"58","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[5]/div[2]/ul[1]/li[2]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[5]/div[2]/ul[1]/li[2]/a[1]","prefix":"Tolerance and pharmacokinetics of single-dose ","suffix":", a potent inhibitor of HMG-CoA reductase, in healthy subjec","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":"46","endOffset":"58","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[20]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[20]","prefix":"Tolerance and pharmacokinetics of single-dose ","suffix":", a potent inhibitor of HMG-CoA reductase, in healthy subjec","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":"262","endOffset":"274","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[2]","prefix":" kg, and a median height of 168 (range, 158 to 189) cm. The ","suffix":" PK results from one subject and the steady-state tipranavir","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":"34","endOffset":"46","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[2]","prefix":"TPV/r increased the dose-adjusted ","suffix":" AUC","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":"49","endOffset":"61","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/div[1]/div[1]/div[2]/span[1]","prefix":"Plasma drug concentration (Cp)-time profiles for ","suffix":" (A), orthohydroxy atorvastatin (B), and parahydroxy atorvas","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":"80","endOffset":"92","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/div[1]/div[1]/div[2]/span[1]","prefix":"ation (Cp)-time profiles for atorvastatin (A), orthohydroxy ","suffix":" (B), and parahydroxy atorvastatin (C). Shown are 40 mg ator","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":"50","endOffset":"62","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[2]","prefix":"The single-dose PKs of atorvastatin, orthohydroxy ","suffix":", and parahydroxy atorvastatin were assessed on day 1 after ","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":"80","endOffset":"92","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[2]","prefix":"of atorvastatin, orthohydroxy atorvastatin, and parahydroxy ","suffix":" were assessed on day 1 after ingestion of 40 mg of atorvast","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":"334","endOffset":"346","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[11]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[11]/p[4]","prefix":"of atorvastatin (normalized for a 40-mg dose), orthohydroxy ","suffix":", and parahydroxy atorvastatin.","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":"80","endOffset":"92","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/div[1]/div[1]/div[2]/span[1]","prefix":"ation (Cp)-time profiles for atorvastatin (A), orthohydroxy ","suffix":" (B), and parahydroxy atorvastatin (C). Shown are 40 mg ator","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":"114","endOffset":"126","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/div[1]/div[1]/div[2]/span[1]","prefix":"astatin (A), orthohydroxy atorvastatin (B), and parahydroxy ","suffix":" (C). Shown are 40 mg atorvastatin alone (open circles) (A t","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":"56","endOffset":"68","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/div[3]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/div[3]/div[1]/div[2]/span[1]","prefix":"Single-dose PK parameters of atorvastatin, orthohydroxy ","suffix":", and parahydroxy atorvastatin after administration of atorv","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":"86","endOffset":"98","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/div[3]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/div[3]/div[1]/div[2]/span[1]","prefix":"of atorvastatin, orthohydroxy atorvastatin, and parahydroxy ","suffix":" after administration of atorvastatin 40 mg alone and coadmi","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":"80","endOffset":"92","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[2]","prefix":"of atorvastatin, orthohydroxy atorvastatin, and parahydroxy ","suffix":" were assessed on day 1 after ingestion of 40 mg of atorvast","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":"114","endOffset":"126","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/div[1]/div[1]/div[2]/span[1]","prefix":"astatin (A), orthohydroxy atorvastatin (B), and parahydroxy ","suffix":" (C). Shown are 40 mg atorvastatin alone (open circles) (A t","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":"148","endOffset":"160","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/div[1]/div[1]/div[2]/span[1]","prefix":"atin (B), and parahydroxy atorvastatin (C). Shown are 40 mg ","suffix":" alone (open circles) (A to C), 10 mg atorvastatin plus stea","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":"86","endOffset":"98","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/div[3]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/div[3]/div[1]/div[2]/span[1]","prefix":"of atorvastatin, orthohydroxy atorvastatin, and parahydroxy ","suffix":" after administration of atorvastatin 40 mg alone and coadmi","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":"123","endOffset":"135","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/div[3]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/div[3]/div[1]/div[2]/span[1]","prefix":"tatin, and parahydroxy atorvastatin after administration of ","suffix":" 40 mg alone and coadministration of atorvastatin 10 mg and ","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":"148","endOffset":"160","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/div[1]/div[1]/div[2]/span[1]","prefix":"atin (B), and parahydroxy atorvastatin (C). Shown are 40 mg ","suffix":" alone (open circles) (A to C), 10 mg atorvastatin plus stea","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":"198","endOffset":"210","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/div[1]/div[1]/div[2]/span[1]","prefix":"are 40 mg atorvastatin alone (open circles) (A to C), 10 mg ","suffix":" plus steady-state TPV/r (closed circles)","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":"44","endOffset":"56","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/div[2]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/div[2]/div[1]/div[2]/span[1]","prefix":"Effect of steady-state TPV/r on single-dose ","suffix":" (ATO) ","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":"29","endOffset":"41","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/div[3]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/div[3]/div[1]/div[2]/span[1]","prefix":"Single-dose PK parameters of ","suffix":", orthohydroxy atorvastatin, and parahydroxy atorvastatin af","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":"56","endOffset":"68","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/div[3]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/div[3]/div[1]/div[2]/span[1]","prefix":"Single-dose PK parameters of atorvastatin, orthohydroxy ","suffix":", and parahydroxy atorvastatin after administration of atorv","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":"86","endOffset":"98","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/div[3]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/div[3]/div[1]/div[2]/span[1]","prefix":"of atorvastatin, orthohydroxy atorvastatin, and parahydroxy ","suffix":" after administration of atorvastatin 40 mg alone and coadmi","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":"123","endOffset":"135","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/div[3]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/div[3]/div[1]/div[2]/span[1]","prefix":"tatin, and parahydroxy atorvastatin after administration of ","suffix":" 40 mg alone and coadministration of atorvastatin 10 mg and ","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":"172","endOffset":"184","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/div[3]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/div[3]/div[1]/div[2]/span[1]","prefix":"tration of atorvastatin 40 mg alone and coadministration of ","suffix":" 10 mg and steady-state TPV/r 500 mg/200 mg twice daily (","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":"12","endOffset":"24","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[3]","prefix":"Single-dose ","suffix":" did not affect the steady-state PKs of tipranavir (Table ","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":"100","endOffset":"112","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[7]/p[2]","prefix":"200 mg twice daily alone and in the presence of single-dose ","suffix":" was well tolerated in this study. There were no study disco","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":"96","endOffset":"108","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[11]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[11]/p[3]","prefix":" effect of TPV/r on atorvastatin (day 1 versus day 20), the ","suffix":" AUC","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":"287","endOffset":"299","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[11]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[11]/p[6]","prefix":"wer to detect a ≥25% change in the AUCs of rosuvastatin and ","suffix":".","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":"49","endOffset":"61","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[10]/div[2]/div[15]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[10]/div[2]/div[15]/span[1]","prefix":"Lennernäs, H. 2003. Clinical pharmacokinetics of ","suffix":". ","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":"105","endOffset":"117","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"ediated interaction, inhibition of first-pass metabolism of ","suffix":", rather than inhibition of its systemic metabolism, may exp","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":"207","endOffset":"219","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"s systemic metabolism, may explain the 8.6-fold increase in ","suffix":" ","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":"78","endOffset":"90","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","prefix":"observed a clinically relevant increase in rosuvastatin and ","suffix":" concentrations during coadministration of TPV/r 500 mg/200 ","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":"114","endOffset":"126","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"s between tipranavir-ritonavir (TPV/r) and rosuvastatin and ","suffix":", we conducted two prospective, open-label, single-arm, two-","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":"419","endOffset":"431","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":"V/r and single-dose rosuvastatin (“rosuvastatin study”) and ","suffix":" (“atorvastatin study”).","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":"434","endOffset":"446","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":"dose rosuvastatin (“rosuvastatin study”) and atorvastatin (“","suffix":" study”).","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":"80","endOffset":"92","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[2]","prefix":"of atorvastatin, orthohydroxy atorvastatin, and parahydroxy ","suffix":" were assessed on day 1 after ingestion of 40 mg of atorvast","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":"1131","endOffset":"1143","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[2]","prefix":", 2, 3, 4, 5, 6, 8, 10, 12, 24, and 48 h after ingestion of ","suffix":" (14 samples).","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":"161","endOffset":"173","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[11]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[11]/p[6]","prefix":"ould range from 20% to 40% for the AUCs of rosuvastatin and ","suffix":". Therefore, a sample size of 20 would provide >90% power to","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":"262","endOffset":"274","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[2]","prefix":" kg, and a median height of 168 (range, 158 to 189) cm. The ","suffix":" PK results from one subject and the steady-state tipranavir","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":"114","endOffset":"126","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/div[1]/div[1]/div[2]/span[1]","prefix":"astatin (A), orthohydroxy atorvastatin (B), and parahydroxy ","suffix":" (C). Shown are 40 mg atorvastatin alone (open circles) (A t","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":"148","endOffset":"160","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/div[1]/div[1]/div[2]/span[1]","prefix":"atin (B), and parahydroxy atorvastatin (C). Shown are 40 mg ","suffix":" alone (open circles) (A to C), 10 mg atorvastatin plus stea","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":"86","endOffset":"98","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/div[3]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/div[3]/div[1]/div[2]/span[1]","prefix":"of atorvastatin, orthohydroxy atorvastatin, and parahydroxy ","suffix":" after administration of atorvastatin 40 mg alone and coadmi","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":"123","endOffset":"135","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/div[3]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/div[3]/div[1]/div[2]/span[1]","prefix":"tatin, and parahydroxy atorvastatin after administration of ","suffix":" 40 mg alone and coadministration of atorvastatin 10 mg and ","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":"172","endOffset":"184","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/div[3]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/div[3]/div[1]/div[2]/span[1]","prefix":"tration of atorvastatin 40 mg alone and coadministration of ","suffix":" 10 mg and steady-state TPV/r 500 mg/200 mg twice daily (","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":"100","endOffset":"112","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[7]/p[2]","prefix":"200 mg twice daily alone and in the presence of single-dose ","suffix":" was well tolerated in this study. There were no study disco","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":"78","endOffset":"90","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","prefix":"observed a clinically relevant increase in rosuvastatin and ","suffix":" concentrations during coadministration of TPV/r 500 mg/200 ","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":"236","endOffset":"248","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","prefix":"hese results, a low initial dose of rosuvastatin (5 mg) and ","suffix":" (10 mg) is recommended when combined with TPV/r, with caref","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":"124","endOffset":"136","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[10]/div[2]/div[8]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[10]/div[2]/div[8]/span[1]","prefix":" and J. L. Reubsaet. 2004. Substantially elevated levels of ","suffix":" and metabolites in cyclosporine-treated renal transplant re","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":"137","endOffset":"149","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[10]/div[2]/div[23]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[10]/div[2]/div[23]/span[1]","prefix":"Sedman. 1996. Tolerance and pharmacokinetics of single-dose ","suffix":", a potent inhibitor of HMG-CoA reductase, in healthy subjec","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":"46","endOffset":"58","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[5]/div[2]/ul[1]/li[2]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[5]/div[2]/ul[1]/li[2]/a[1]","prefix":"Tolerance and pharmacokinetics of single-dose ","suffix":", a potent inhibitor of HMG-CoA reductase, in healthy subjec","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":"46","endOffset":"58","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[20]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[20]","prefix":"Tolerance and pharmacokinetics of single-dose ","suffix":", a potent inhibitor of HMG-CoA reductase, in healthy subjec","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"atorvastatin","startOffset":"351","endOffset":"363","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","prefix":"TPV/r, with careful clinical monitoring of rosuvastatin- or ","suffix":"-related AEs, such as myopathy.","exact":"atorvastatin"},{"setid":"PMC2764168","drugname":"caffeine","startOffset":"801","endOffset":"809","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[2]","prefix":" within 30 min before morning medication administration. No ","suffix":" or food was allowed until 5 h postdose. No grapefruit juice","exact":"caffeine"},{"setid":"PMC2764168","drugname":"edta","startOffset":"955","endOffset":"959","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[2]","prefix":" and hydroxy metabolites were collected on days 1 and 20 in ","suffix":"-containing tubes by an indwelling catheter or the venipunct","exact":"EDTA"},{"setid":"PMC2764168","drugname":"edta","startOffset":"302","endOffset":"306","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[8]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[8]/p[2]","prefix":"as ISs. Briefly, the analytes were extracted from 200 μl of ","suffix":" plasma by solid-phase extraction using C","exact":"EDTA"},{"setid":"PMC2764168","drugname":"dipotassium edta","startOffset":"136","endOffset":"152","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[7]/p[2]","prefix":"for the analysis of rosuvastatin in human plasma containing ","suffix":". A 200-μl-sample aliquot was fortified with 200 μl of inter","exact":"dipotassium EDTA"},{"setid":"PMC2764168","drugname":"acetonitrile","startOffset":"311","endOffset":"323","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[7]/p[2]","prefix":"lytes were isolated by protein precipitation with 400 μl of ","suffix":". Sample extraction steps were controlled and automated usin","exact":"acetonitrile"},{"setid":"PMC2764168","drugname":"acetonitrile","startOffset":"610","endOffset":"622","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[7]/p[2]","prefix":"emaining residue was reconstituted with 150 μl of 20:80:0.1 ","suffix":"-water-formic acid (vol/vol/vol). The final extract was anal","exact":"acetonitrile"},{"setid":"PMC2764168","drugname":"alanine","startOffset":"82","endOffset":"89","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[7]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[7]/p[4]","prefix":"one subject with an asymptomatic DAIDS grade 3 elevation in ","suffix":" aminotransferase, there were no clinically relevant changes","exact":"alanine"},{"setid":"PMC2764168","drugname":"alanine","startOffset":"286","endOffset":"293","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[7]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[7]/p[4]","prefix":"rom the median baseline were observed for triglycerides and ","suffix":" aminotransferase levels, which increased by 1.7-fold and 3.","exact":"alanine"},{"setid":"PMC2764168","drugname":"lopinavir","startOffset":"106","endOffset":"115","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","prefix":"ug interaction studies evaluating the effect of another PI, ","suffix":"-ritonavir (LPV/r), when coadministered with rosuvastatin at","exact":"lopinavir"}],[{"setid":"PMC1884432","drugname":"rifampicin","startOffset":"245","endOffset":"255","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[1]/p[1]","prefix":" 90%. This study was conducted to investigate the effect of ","suffix":" on the pharmacokinetics of pravastatin.","exact":"rifampicin"},{"setid":"PMC1884432","drugname":"rifampicin","startOffset":"128","endOffset":"138","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":"s, 10 healthy volunteers received a 5-day pretreatment with ","suffix":" (600 mg daily) or placebo. On day 6, a single 40 mg dose of","exact":"rifampicin"},{"setid":"PMC1884432","drugname":"rifampicin","startOffset":"11","endOffset":"21","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"During the ","suffix":" phase, the mean total area under the plasma concentration-t","exact":"rifampicin"},{"setid":"PMC1884432","drugname":"rifampicin","startOffset":"0","endOffset":"10","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","prefix":"","suffix":" caused a statistically significant decrease in the plasma c","exact":"Rifampicin"},{"setid":"PMC1884432","drugname":"rifampicin","startOffset":"170","endOffset":"180","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","prefix":"ingle oral dose to healthy subjects. However, the effect of ","suffix":" varied greatly between subjects. The mean rifampicin-induce","exact":"rifampicin"},{"setid":"PMC1884432","drugname":"rifampicin","startOffset":"223","endOffset":"233","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","prefix":"ect of rifampicin varied greatly between subjects. The mean ","suffix":"-induced decrease in pravastatin concentration was considera","exact":"rifampicin"},{"setid":"PMC1884432","drugname":"rifampicin","startOffset":"26","endOffset":"36","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","prefix":"interaction, pravastatin, ","suffix":"","exact":"rifampicin"},{"setid":"PMC1884432","drugname":"rifampicin","startOffset":"0","endOffset":"10","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","prefix":"","suffix":" is a potent inducer of several cytochrome P450 (CYP) enzyme","exact":"Rifampicin"},{"setid":"PMC1884432","drugname":"rifampicin","startOffset":"347","endOffset":"357","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","prefix":"n the phases was 4 weeks. Subjects were given either 600 mg ","suffix":" (Rifarm, Pharmacal, Helsinki, Finland) or matched placebo o","exact":"rifampicin"},{"setid":"PMC1884432","drugname":"rifampicin","startOffset":"635","endOffset":"645","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","prefix":"h 150 ml water at 9 AM, that is 17 h after the last dose of ","suffix":". The subjects had fasted overnight, and a standard meal was","exact":"rifampicin"},{"setid":"PMC1884432","drugname":"rifampicin","startOffset":"971","endOffset":"981","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","prefix":"s. The study design was otherwise identical to our previous ","suffix":"-simvastatin study [","exact":"rifampicin"},{"setid":"PMC1884432","drugname":"rifampicin","startOffset":"216","endOffset":"226","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[7]/p[1]","prefix":" calculated on the mean differences between the placebo and ","suffix":" phases for AUC(0–∞), ","exact":"rifampicin"},{"setid":"PMC1884432","drugname":"rifampicin","startOffset":"11","endOffset":"21","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","prefix":"During the ","suffix":" phase, the mean AUC(0–∞) of pravastatin was 69% (range 24–2","exact":"rifampicin"},{"setid":"PMC1884432","drugname":"rifampicin","startOffset":"141","endOffset":"151","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/div[1]/div[2]/span[1]","prefix":"estion of 40 mg pravastatin following treatment with 600 mg ","suffix":" or placebo twice daily for 5 days","exact":"rifampicin"},{"setid":"PMC1884432","drugname":"rifampicin","startOffset":"155","endOffset":"165","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/div[2]/span[1]","prefix":"ion of 40 mg pravastatin following pretreatment with 600 mg ","suffix":" (•) or placebo (○) once daily for five days.","exact":"rifampicin"},{"setid":"PMC1884432","drugname":"rifampicin","startOffset":"19","endOffset":"29","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[2]","prefix":"The mean effect of ","suffix":" on the AUC of pravastatin in the present study was consider","exact":"rifampicin"},{"setid":"PMC1884432","drugname":"rifampicin","startOffset":"48","endOffset":"58","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/div[1]/div[2]/span[1]","prefix":"Effect of an identical pretreatment with 600 mg ","suffix":" once daily for five days on the areas under the plasma conc","exact":"rifampicin"},{"setid":"PMC1884432","drugname":"rifampicin","startOffset":"102","endOffset":"112","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":" pravastatin were moderately decreased by pretreatment with ","suffix":". The mean AUC(0–∞) of pravastatin was decreased by 31%, but","exact":"rifampicin"},{"setid":"PMC1884432","drugname":"rifampicin","startOffset":"289","endOffset":"299","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"e of the 10 subjects the AUC(0–∞) of pravastatin during the ","suffix":" phase was 50% or less of that during the placebo phase. How","exact":"rifampicin"},{"setid":"PMC1884432","drugname":"rifampicin","startOffset":"445","endOffset":"455","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"e plasma concentrations of pravastatin increased during the ","suffix":" phase. The other pharmacokinetic variables studied were not","exact":"rifampicin"},{"setid":"PMC1884432","drugname":"rifampicin","startOffset":"586","endOffset":"596","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":" a statistically significant degree. Although the effect of ","suffix":" was statistically significant, the possibility of chance fi","exact":"rifampicin"},{"setid":"PMC1884432","drugname":"rifampicin","startOffset":"14","endOffset":"24","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"The effect of ","suffix":" on pravastatin pharmacokinetics is not likely to be caused ","exact":"rifampicin"},{"setid":"PMC1884432","drugname":"rifampicin","startOffset":"72","endOffset":"82","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","prefix":" showed that using an identical protocol, pretreatment with ","suffix":" greatly decreased the AUC(0–∞) of simvastatin and simvastat","exact":"rifampicin"},{"setid":"PMC1884432","drugname":"rifampicin","startOffset":"0","endOffset":"10","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"","suffix":" decreases the total AUC of fluvastatin, a CYP2C9 substrate ","exact":"Rifampicin"},{"setid":"PMC1884432","drugname":"rifampicin","startOffset":"15","endOffset":"25","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","prefix":"In conclusion, ","suffix":" had a relatively small but highly variable effect on the ph","exact":"rifampicin"},{"setid":"PMC1884432","drugname":"rifampicin","startOffset":"210","endOffset":"220","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","prefix":" adjustment in some individuals if long-term treatment with ","suffix":" is needed.","exact":"rifampicin"},{"setid":"PMC1884432","drugname":"pravastatin","startOffset":"283","endOffset":"294","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[1]/p[1]","prefix":"stigate the effect of rifampicin on the pharmacokinetics of ","suffix":".","exact":"pravastatin"},{"setid":"PMC1884432","drugname":"pravastatin","startOffset":"199","endOffset":"210","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":"(600 mg daily) or placebo. On day 6, a single 40 mg dose of ","suffix":" was administered orally. Plasma concentrations of pravastat","exact":"pravastatin"},{"setid":"PMC1884432","drugname":"pravastatin","startOffset":"261","endOffset":"272","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":"avastatin was administered orally. Plasma concentrations of ","suffix":" were measured up to 12 h by a sensitive LC-MS-MS method.","exact":"pravastatin"},{"setid":"PMC1884432","drugname":"pravastatin","startOffset":"94","endOffset":"105","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"ean total area under the plasma concentration-time curve of ","suffix":" [AUC(0–∞)] was 69% (range 24–220%) of the corresponding val","exact":"pravastatin"},{"setid":"PMC1884432","drugname":"pravastatin","startOffset":"266","endOffset":"277","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"idual variation. In five of the 10 subjects the AUC(0–∞) of ","suffix":" during the rifampicin phase was 50% or less of that during ","exact":"pravastatin"},{"setid":"PMC1884432","drugname":"pravastatin","startOffset":"86","endOffset":"97","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","prefix":"tically significant decrease in the plasma concentration of ","suffix":" given as a single oral dose to healthy subjects. However, t","exact":"pravastatin"},{"setid":"PMC1884432","drugname":"pravastatin","startOffset":"254","endOffset":"265","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","prefix":"y between subjects. The mean rifampicin-induced decrease in ","suffix":" concentration was considerably smaller than that observed p","exact":"pravastatin"},{"setid":"PMC1884432","drugname":"pravastatin","startOffset":"13","endOffset":"24","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","prefix":"interaction, ","suffix":", rifampicin","exact":"pravastatin"},{"setid":"PMC1884432","drugname":"pravastatin","startOffset":"38","endOffset":"49","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":"Unlike simvastatin, the metabolism of ","suffix":" is not significantly mediated by CYP enzymes [","exact":"pravastatin"},{"setid":"PMC1884432","drugname":"pravastatin","startOffset":"466","endOffset":"477","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","prefix":"d placebo orally once daily at 4 p.m. for 5 days. On day 6, ","suffix":" (a single Pravachol 40 mg tablet, Bristol-Myers Squibb, New","exact":"pravastatin"},{"setid":"PMC1884432","drugname":"pravachol","startOffset":"488","endOffset":"497","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","prefix":"daily at 4 p.m. for 5 days. On day 6, pravastatin (a single ","suffix":" 40 mg tablet, Bristol-Myers Squibb, New York, NY) was admin","exact":"Pravachol"},{"setid":"PMC1884432","drugname":"pravastatin","startOffset":"751","endOffset":"762","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","prefix":"ndard meal was served 3 and 7 h after the administration of ","suffix":". Alcohol or strenuous exercise was not allowed for two days","exact":"pravastatin"},{"setid":"PMC1884432","drugname":"pravastatin","startOffset":"96","endOffset":"107","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[1]","prefix":"n from a cannulated forearm vein prior to administration of ","suffix":" and 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, and 12 h later, an","exact":"pravastatin"},{"setid":"PMC1884432","drugname":"pravastatin","startOffset":"390","endOffset":"401","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[1]","prefix":"lected cumulatively from 0–12 h after the administration of ","suffix":".","exact":"pravastatin"},{"setid":"PMC1884432","drugname":"pravastatin","startOffset":"22","endOffset":"33","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[1]","prefix":"The concentrations of ","suffix":" in plasma and urine were measured by liquid chromatography-","exact":"pravastatin"},{"setid":"PMC1884432","drugname":"pravastatin","startOffset":"283","endOffset":"294","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[1]/p[1]","prefix":"stigate the effect of rifampicin on the pharmacokinetics of ","suffix":".","exact":"pravastatin"},{"setid":"PMC1884432","drugname":"pravastatin","startOffset":"390","endOffset":"401","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[1]","prefix":"lected cumulatively from 0–12 h after the administration of ","suffix":".","exact":"pravastatin"},{"setid":"PMC1884432","drugname":"pravastatin","startOffset":"121","endOffset":"132","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[9]/div[2]/div[27]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[9]/div[2]/div[27]/span[1]","prefix":"f St John's wort on the pharmacokinetics of simvastatin and ","suffix":". ","exact":"pravastatin"},{"setid":"PMC1884432","drugname":"pravastatin","startOffset":"94","endOffset":"105","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"ean total area under the plasma concentration-time curve of ","suffix":" [AUC(0–∞)] was 69% (range 24–220%) of the corresponding val","exact":"pravastatin"},{"setid":"PMC1884432","drugname":"pravastatin","startOffset":"50","endOffset":"61","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","prefix":"During the rifampicin phase, the mean AUC(0–∞) of ","suffix":" was 69% (range 24–220%, ","exact":"pravastatin"},{"setid":"PMC1884432","drugname":"pravastatin","startOffset":"283","endOffset":"294","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[1]/p[1]","prefix":"stigate the effect of rifampicin on the pharmacokinetics of ","suffix":".","exact":"pravastatin"},{"setid":"PMC1884432","drugname":"pravastatin","startOffset":"390","endOffset":"401","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[1]","prefix":"lected cumulatively from 0–12 h after the administration of ","suffix":".","exact":"pravastatin"},{"setid":"PMC1884432","drugname":"pravastatin","startOffset":"121","endOffset":"132","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[9]/div[2]/div[27]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[9]/div[2]/div[27]/span[1]","prefix":"f St John's wort on the pharmacokinetics of simvastatin and ","suffix":". ","exact":"pravastatin"},{"setid":"PMC1884432","drugname":"pravastatin","startOffset":"24","endOffset":"35","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[1]/h1[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[1]/h1[1]","prefix":"Effect of rifampicin on ","suffix":" pharmacokinetics in healthy subjects","exact":"pravastatin"},{"setid":"PMC1884432","drugname":"pravastatin","startOffset":"199","endOffset":"210","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":"(600 mg daily) or placebo. On day 6, a single 40 mg dose of ","suffix":" was administered orally. Plasma concentrations of pravastat","exact":"pravastatin"},{"setid":"PMC1884432","drugname":"pravastatin","startOffset":"261","endOffset":"272","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":"avastatin was administered orally. Plasma concentrations of ","suffix":" were measured up to 12 h by a sensitive LC-MS-MS method.","exact":"pravastatin"},{"setid":"PMC1884432","drugname":"pravastatin","startOffset":"94","endOffset":"105","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"ean total area under the plasma concentration-time curve of ","suffix":" [AUC(0–∞)] was 69% (range 24–220%) of the corresponding val","exact":"pravastatin"},{"setid":"PMC1884432","drugname":"pravastatin","startOffset":"86","endOffset":"97","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","prefix":"tically significant decrease in the plasma concentration of ","suffix":" given as a single oral dose to healthy subjects. However, t","exact":"pravastatin"},{"setid":"PMC1884432","drugname":"pravastatin","startOffset":"38","endOffset":"49","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":"Unlike simvastatin, the metabolism of ","suffix":" is not significantly mediated by CYP enzymes [","exact":"pravastatin"},{"setid":"PMC1884432","drugname":"pravastatin","startOffset":"751","endOffset":"762","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","prefix":"ndard meal was served 3 and 7 h after the administration of ","suffix":". Alcohol or strenuous exercise was not allowed for two days","exact":"pravastatin"},{"setid":"PMC1884432","drugname":"pravastatin","startOffset":"96","endOffset":"107","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[1]","prefix":"n from a cannulated forearm vein prior to administration of ","suffix":" and 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, and 12 h later, an","exact":"pravastatin"},{"setid":"PMC1884432","drugname":"pravastatin","startOffset":"22","endOffset":"33","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[1]","prefix":"The concentrations of ","suffix":" in plasma and urine were measured by liquid chromatography-","exact":"pravastatin"},{"setid":"PMC1884432","drugname":"pravastatin","startOffset":"50","endOffset":"61","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","prefix":"During the rifampicin phase, the mean AUC(0–∞) of ","suffix":" was 69% (range 24–220%, ","exact":"pravastatin"},{"setid":"PMC1884432","drugname":"pravastatin","startOffset":"33","endOffset":"44","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/div[1]/div[2]/span[1]","prefix":"The pharmacokinetic variables of ","suffix":" in 10 healthy subjects after the ingestion of 40 mg pravast","exact":"pravastatin"},{"setid":"PMC1884432","drugname":"pravastatin","startOffset":"97","endOffset":"108","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/div[1]/div[2]/span[1]","prefix":"astatin in 10 healthy subjects after the ingestion of 40 mg ","suffix":" following treatment with 600 mg rifampicin or placebo twice","exact":"pravastatin"},{"setid":"PMC1884432","drugname":"pravastatin","startOffset":"43","endOffset":"54","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/div[2]/span[1]","prefix":"Plasma concentrations (mean ± s.e.mean) of ","suffix":" in 10 healthy subjects after administration of 40 mg pravas","exact":"pravastatin"},{"setid":"PMC1884432","drugname":"pravastatin","startOffset":"108","endOffset":"119","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/div[2]/span[1]","prefix":"statin in 10 healthy subjects after administration of 40 mg ","suffix":" following pretreatment with 600 mg rifampicin (•) or placeb","exact":"pravastatin"},{"setid":"PMC1884432","drugname":"pravastatin","startOffset":"44","endOffset":"55","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[2]","prefix":"The mean effect of rifampicin on the AUC of ","suffix":" in the present study was considerably smaller and more vari","exact":"pravastatin"},{"setid":"PMC1884432","drugname":"pravastatin","startOffset":"174","endOffset":"185","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/div[1]/div[2]/span[1]","prefix":"concentration-time curve [AUC(0–∞)] of simvastatin acid and ","suffix":" as percent of control values. The simvastatin acid","exact":"pravastatin"},{"setid":"PMC1884432","drugname":"pravastatin","startOffset":"43","endOffset":"54","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"In this study the plasma concentrations of ","suffix":" were moderately decreased by pretreatment with rifampicin. ","exact":"pravastatin"},{"setid":"PMC1884432","drugname":"pravastatin","startOffset":"135","endOffset":"146","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"eased by pretreatment with rifampicin. The mean AUC(0–∞) of ","suffix":" was decreased by 31%, but there was considerable interindiv","exact":"pravastatin"},{"setid":"PMC1884432","drugname":"pravastatin","startOffset":"266","endOffset":"277","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"idual variation. In five of the 10 subjects the AUC(0–∞) of ","suffix":" during the rifampicin phase was 50% or less of that during ","exact":"pravastatin"},{"setid":"PMC1884432","drugname":"pravastatin","startOffset":"412","endOffset":"423","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"se. However, in three subjects the plasma concentrations of ","suffix":" increased during the rifampicin phase. The other pharmacoki","exact":"pravastatin"},{"setid":"PMC1884432","drugname":"pravastatin","startOffset":"28","endOffset":"39","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"The effect of rifampicin on ","suffix":" pharmacokinetics is not likely to be caused by induction of","exact":"pravastatin"},{"setid":"PMC1884432","drugname":"pravastatin","startOffset":"134","endOffset":"145","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"be caused by induction of CYP3A4 or P-glycoprotein, because ","suffix":" is not a substrate of P-glycoprotein, CYP3A4 or other CYP e","exact":"pravastatin"},{"setid":"PMC1884432","drugname":"pravastatin","startOffset":"65","endOffset":"76","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"ronidation appears to be one of the predominant pathways of ","suffix":" metabolism [","exact":"pravastatin"},{"setid":"PMC1884432","drugname":"pravastatin","startOffset":"103","endOffset":"114","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","prefix":"small but highly variable effect on the pharmacokinetics of ","suffix":". The dose of pravastatin might need adjustment in some indi","exact":"pravastatin"},{"setid":"PMC1884432","drugname":"pravastatin","startOffset":"128","endOffset":"139","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","prefix":" effect on the pharmacokinetics of pravastatin. The dose of ","suffix":" might need adjustment in some individuals if long-term trea","exact":"pravastatin"},{"setid":"PMC1884432","drugname":"pravastatin","startOffset":"91","endOffset":"102","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[9]/div[2]/div[12]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[9]/div[2]/div[12]/span[1]","prefix":" GC, Singhvi SM, Pan HY, Weinstein SH. Biotransformation of ","suffix":" sodium in humans. ","exact":"pravastatin"},{"setid":"PMC1884432","drugname":"pravastatin","startOffset":"81","endOffset":"92","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[9]/div[2]/div[13]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[9]/div[2]/div[13]/span[1]","prefix":". Ni'inuma K, Nishigaki R, Sugiyama Y. Biliary excretion of ","suffix":" in rats: contribution of the excretion pathway mediated by ","exact":"pravastatin"},{"setid":"PMC1884432","drugname":"pravastatin","startOffset":"61","endOffset":"72","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[9]/div[2]/div[18]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[9]/div[2]/div[18]/span[1]","prefix":"ulvana D, Jemal M, Pulver SC. Quantitative determination of ","suffix":" and its biotransformation products in human serum by turbo ","exact":"pravastatin"},{"setid":"PMC1884432","drugname":"pravastatin","startOffset":"121","endOffset":"132","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[9]/div[2]/div[27]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[9]/div[2]/div[27]/span[1]","prefix":"f St John's wort on the pharmacokinetics of simvastatin and ","suffix":". ","exact":"pravastatin"},{"setid":"PMC1884432","drugname":"pravastatin","startOffset":"33","endOffset":"44","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/div[1]/div[2]/span[1]","prefix":"The pharmacokinetic variables of ","suffix":" in 10 healthy subjects after the ingestion of 40 mg pravast","exact":"pravastatin"},{"setid":"PMC1884432","drugname":"pravastatin","startOffset":"97","endOffset":"108","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/div[1]/div[2]/span[1]","prefix":"astatin in 10 healthy subjects after the ingestion of 40 mg ","suffix":" following treatment with 600 mg rifampicin or placebo twice","exact":"pravastatin"},{"setid":"PMC1884432","drugname":"pravastatin","startOffset":"43","endOffset":"54","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/div[2]/span[1]","prefix":"Plasma concentrations (mean ± s.e.mean) of ","suffix":" in 10 healthy subjects after administration of 40 mg pravas","exact":"pravastatin"},{"setid":"PMC1884432","drugname":"pravastatin","startOffset":"108","endOffset":"119","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/div[2]/span[1]","prefix":"statin in 10 healthy subjects after administration of 40 mg ","suffix":" following pretreatment with 600 mg rifampicin (•) or placeb","exact":"pravastatin"},{"setid":"PMC1884432","drugname":"pravastatin","startOffset":"44","endOffset":"55","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[2]","prefix":"The mean effect of rifampicin on the AUC of ","suffix":" in the present study was considerably smaller and more vari","exact":"pravastatin"},{"setid":"PMC1884432","drugname":"pravastatin","startOffset":"174","endOffset":"185","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/div[1]/div[2]/span[1]","prefix":"concentration-time curve [AUC(0–∞)] of simvastatin acid and ","suffix":" as percent of control values. The simvastatin acid","exact":"pravastatin"},{"setid":"PMC1884432","drugname":"pravastatin","startOffset":"43","endOffset":"54","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"In this study the plasma concentrations of ","suffix":" were moderately decreased by pretreatment with rifampicin. ","exact":"pravastatin"},{"setid":"PMC1884432","drugname":"pravastatin","startOffset":"135","endOffset":"146","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"eased by pretreatment with rifampicin. The mean AUC(0–∞) of ","suffix":" was decreased by 31%, but there was considerable interindiv","exact":"pravastatin"},{"setid":"PMC1884432","drugname":"pravastatin","startOffset":"266","endOffset":"277","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"idual variation. In five of the 10 subjects the AUC(0–∞) of ","suffix":" during the rifampicin phase was 50% or less of that during ","exact":"pravastatin"},{"setid":"PMC1884432","drugname":"pravastatin","startOffset":"412","endOffset":"423","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"se. However, in three subjects the plasma concentrations of ","suffix":" increased during the rifampicin phase. The other pharmacoki","exact":"pravastatin"},{"setid":"PMC1884432","drugname":"pravastatin","startOffset":"28","endOffset":"39","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"The effect of rifampicin on ","suffix":" pharmacokinetics is not likely to be caused by induction of","exact":"pravastatin"},{"setid":"PMC1884432","drugname":"pravastatin","startOffset":"134","endOffset":"145","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"be caused by induction of CYP3A4 or P-glycoprotein, because ","suffix":" is not a substrate of P-glycoprotein, CYP3A4 or other CYP e","exact":"pravastatin"},{"setid":"PMC1884432","drugname":"pravastatin","startOffset":"65","endOffset":"76","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"ronidation appears to be one of the predominant pathways of ","suffix":" metabolism [","exact":"pravastatin"},{"setid":"PMC1884432","drugname":"pravastatin","startOffset":"103","endOffset":"114","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","prefix":"small but highly variable effect on the pharmacokinetics of ","suffix":". The dose of pravastatin might need adjustment in some indi","exact":"pravastatin"},{"setid":"PMC1884432","drugname":"pravastatin","startOffset":"128","endOffset":"139","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","prefix":" effect on the pharmacokinetics of pravastatin. The dose of ","suffix":" might need adjustment in some individuals if long-term trea","exact":"pravastatin"},{"setid":"PMC1884432","drugname":"simvastatin","startOffset":"339","endOffset":"350","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","prefix":" was considerably smaller than that observed previously for ","suffix":".","exact":"simvastatin"},{"setid":"PMC1884432","drugname":"simvastatin","startOffset":"7","endOffset":"18","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":"Unlike ","suffix":", the metabolism of pravastatin is not significantly mediate","exact":"simvastatin"},{"setid":"PMC1884432","drugname":"simvastatin","startOffset":"982","endOffset":"993","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","prefix":"y design was otherwise identical to our previous rifampicin-","suffix":" study [","exact":"simvastatin"},{"setid":"PMC1884432","drugname":"simvastatin","startOffset":"220","endOffset":"231","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/div[1]/div[2]/span[1]","prefix":"atin acid and pravastatin as percent of control values. The ","suffix":" acid","exact":"simvastatin"},{"setid":"PMC1884432","drugname":"simvastatin","startOffset":"117","endOffset":"128","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","prefix":"treatment with rifampicin greatly decreased the AUC(0–∞) of ","suffix":" and simvastatin acid in all of the 10 subjects studied [","exact":"simvastatin"},{"setid":"PMC1884432","drugname":"simvastatin","startOffset":"133","endOffset":"144","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","prefix":"ifampicin greatly decreased the AUC(0–∞) of simvastatin and ","suffix":" acid in all of the 10 subjects studied [","exact":"simvastatin"},{"setid":"PMC1884432","drugname":"fluvastatin","startOffset":"38","endOffset":"49","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"Rifampicin decreases the total AUC of ","suffix":", a CYP2C9 substrate [","exact":"fluvastatin"}],[{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":"92","endOffset":"103","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":"ubstrates or inhibitors of CYP3A4, P-gp and Bcrp (ABCG2) on ","suffix":" were studied in healthy volunteers.","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":"0","endOffset":"11","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"","suffix":" did not interact with midazolam (CYP3A4 probe substrate). E","exact":"Rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":"82","endOffset":"93","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"teract with midazolam (CYP3A4 probe substrate). Exposure to ","suffix":" when co-administered with midazolam was slightly decreased ","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":"214","endOffset":"225","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"y 11% (95% confidence interval [CI] −28%, 7%) compared with ","suffix":" alone. The following drugs moderately affected rivaroxaban ","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":"273","endOffset":"284","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":" rivaroxaban alone. The following drugs moderately affected ","suffix":" exposure, but not to a clinically relevant extent: erythrom","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":"628","endOffset":"639","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":" 42% increase [95% CI 29%, 56%]). A significant increase in ","suffix":" exposure was demonstrated with the strong CYP3A4, P-gp/Bcrp","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":"21","endOffset":"32","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","prefix":"Results suggest that ","suffix":" may be co-administered with CYP3A4 and/or P-gp substrates/m","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":"313","endOffset":"324","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","prefix":"protease inhibitors), which are multi-pathway inhibitors of ","suffix":" clearance and elimination.","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":"70","endOffset":"81","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","prefix":" P450, drug interactions, healthy subjects, P-glycoprotein, ","suffix":"","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":"0","endOffset":"11","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[1]/div[1]/div[1]/ul[1]/li[1]/div[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[1]/div[1]/div[1]/ul[1]/li[1]/div[1]","prefix":"","suffix":", an oral, direct Factor Xa inhibitor, is metabolized and ex","exact":"Rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":"224","endOffset":"235","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[1]/div[1]/div[1]/ul[1]/li[1]/div[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[1]/div[1]/div[1]/ul[1]/li[1]/div[1]","prefix":"inetic effects and implications of the co-administration of ","suffix":" and medications that interfere with these elimination pathw","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":"59","endOffset":"70","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/div[1]/ul[1]/li[1]/div[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/div[1]/ul[1]/li[1]/div[1]","prefix":"This paper reports on a series of interaction studies with ","suffix":" in healthy volunteers, the results of which suggest that ri","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":"128","endOffset":"139","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/div[1]/ul[1]/li[1]/div[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/div[1]/ul[1]/li[1]/div[1]","prefix":"an in healthy volunteers, the results of which suggest that ","suffix":" can be administered in conjunction with substrates or moder","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":"467","endOffset":"478","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/div[1]/ul[1]/li[1]/div[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/div[1]/ul[1]/li[1]/div[1]","prefix":"nd HIV protease inhibitors, cause a significant increase in ","suffix":" exposure that could increase the risk of bleeding. The exce","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":"23","endOffset":"34","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","prefix":"The oral anticoagulant ","suffix":" is a highly selective, direct Factor Xa inhibitor for the p","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":"0","endOffset":"11","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","prefix":"","suffix":" is approved for the prevention of venous thromboembolism (o","exact":"Rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":"0","endOffset":"11","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[3]","prefix":"","suffix":" has a dual mode of elimination. Approximately two-thirds of","exact":"Rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":"0","endOffset":"11","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[4]","prefix":"","suffix":" is metabolized via cytochrome P450 (CYP) 3A4/3A5, CYP2J2 an","exact":"Rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":"125","endOffset":"136","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","prefix":"e the extent of potential interactions with single doses of ","suffix":" (10 mg or 20 mg) and steady-state ketoconazole (200 mg once","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":"547","endOffset":"558","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","prefix":"the extent of the possible interaction between steady-state ","suffix":" (10 mg once daily) and high dose, steady-state ketoconazole","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":"146","endOffset":"157","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","prefix":". In the study investigating potential interactions between ","suffix":" and steady-state ketoconazole 200 mg, subjects received ket","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":"758","endOffset":"769","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","prefix":"e laboratory tests and to determine the pharmacokinetics of ","suffix":" and, where necessary, the pharmacokinetics of the potential","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":"67","endOffset":"78","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/div[1]/p[1]","prefix":" was undertaken to determine potential interactions between ","suffix":" and a sensitive probe substrate for CYP3A4 alone, midazolam","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":"98","endOffset":"109","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/div[1]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/div[1]/p[2]","prefix":"study, subjects were randomized to receive a single dose of ","suffix":" 20 mg alone, a single dose of midazolam 7.5 mg alone or the","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":"91","endOffset":"102","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","prefix":"o determine the extent of the potential interaction between ","suffix":" and strong inhibitors of CYP3A4/2J2, P-gp and Bcrp (ABCG2),","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":"107","endOffset":"118","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/p[1]","prefix":"stigated the potential interaction between a single dose of ","suffix":" and steady-state ketoconazole 200 mg once daily. In this op","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":"266","endOffset":"277","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/p[1]","prefix":"study, subjects were randomized to receive a single dose of ","suffix":" 10 mg, alone or with ketoconazole (4 days of oral ketoconaz","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":"364","endOffset":"375","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/p[1]","prefix":"onazole (4 days of oral ketoconazole 200 mg once daily with ","suffix":" given on day 4). Rivaroxaban was given under fasting condit","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":"393","endOffset":"404","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/p[1]","prefix":"onazole 200 mg once daily with rivaroxaban given on day 4). ","suffix":" was given under fasting conditions and ketoconazole was giv","exact":"Rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":"511","endOffset":"522","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/p[1]","prefix":"azole was given with food, except when co-administered with ","suffix":". After completion of this study, a publication suggested th","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":"51","endOffset":"62","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[2]/p[1]","prefix":"The potential interaction between a single dose of ","suffix":" and steady-state ritonavir was investigated in a non-random","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":"181","endOffset":"192","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[2]/p[1]","prefix":"mized, open label study. Subjects received a single dose of ","suffix":" 10 mg on day 1, ritonavir 600 mg twice daily on days 3–7, a","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":"306","endOffset":"317","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[2]/p[1]","prefix":"3–7, and ritonavir 600 mg twice daily plus a single dose of ","suffix":" on day 8. All study drugs were administered with food.","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":"416","endOffset":"427","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[2]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[2]/p[2]","prefix":"alid for the safety analysis. All received a single dose of ","suffix":" 10 mg on day 1 and at least one dose of ritonavir (600 mg).","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":"532","endOffset":"543","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[2]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[2]/p[2]","prefix":"navir (600 mg). Twelve subjects received the combination of ","suffix":" and ritonavir on day 8. However, none of the subjects recei","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":"62","endOffset":"73","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/div[1]/p[1]","prefix":"single study investigated the potential interaction between ","suffix":" and clarithromycin, classified as a strong inhibitor of CYP","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":"95","endOffset":"106","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/div[1]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/div[1]/p[2]","prefix":"study, subjects were randomized to receive a single dose of ","suffix":" 10 mg alone, or clarithromycin 500 mg twice daily for a per","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":"62","endOffset":"73","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/div[2]/p[1]","prefix":"single study investigated the potential interaction between ","suffix":" and erythromycin, classified as a moderate inhibitor of CYP","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":"96","endOffset":"107","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/div[2]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/div[2]/p[2]","prefix":"study, subjects were randomized to receive a single dose of ","suffix":" 10 mg alone, or erythromycin 500 mg three times daily given","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":"226","endOffset":"237","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/div[2]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/div[2]/p[2]","prefix":"n for 4 days, with a single 500 mg dose given on day 5 with ","suffix":" 10 mg. All study drugs were administered with food and ther","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":"62","endOffset":"73","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/div[3]/p[1]","prefix":"single study investigated the potential interaction between ","suffix":" and fluconazole, classified as a potent inhibitor of CYP2C9","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":"70","endOffset":"81","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","prefix":" P450, drug interactions, healthy subjects, P-glycoprotein, ","suffix":"","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":"135","endOffset":"146","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/div[3]/p[1]","prefix":"nd fluconazole, classified as a potent inhibitor of CYP2C9 (","suffix":" is not metabolized via CYP2C9), a moderate inhibitor of CYP","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":"96","endOffset":"107","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/div[3]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/div[3]/p[2]","prefix":"study, subjects were randomized to receive a single dose of ","suffix":" 20 mg alone, or fluconazole 400 mg once daily given for 6 d","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":"215","endOffset":"226","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/div[3]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/div[3]/p[2]","prefix":"iven for 6 days, with a concomitant administration of 20 mg ","suffix":" given on day 5. All study drugs were administered with food","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":"45","endOffset":"56","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/div[2]/p[1]","prefix":"Pharmacokinetic parameters were derived from ","suffix":" plasma concentration–time profiles obtained by serial blood","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":"304","endOffset":"315","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/div[2]/p[1]","prefix":"tervals after drug administration. Quantitative analysis of ","suffix":" concentrations (plasma and urine) was performed using a ful","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":"14","endOffset":"25","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/div[2]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/div[2]/p[2]","prefix":"The following ","suffix":" plasma pharmacokinetic parameters were assessed: area under","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":"194","endOffset":"205","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/div[2]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/div[2]/p[2]","prefix":"n the ketoconazole 400 mg study, in which multiple doses of ","suffix":" were given. Maximum drug concentration in plasma (","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":"24","endOffset":"35","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/div[1]/p[1]","prefix":"The pharmacokinetics of ","suffix":", midazolam and its CYP3A4-mediated metabolite, α-hydroxy-mi","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":"109","endOffset":"120","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/div[1]/p[1]","prefix":"d its CYP3A4-mediated metabolite, α-hydroxy-midazolam, when ","suffix":" 20 mg and midazolam 7.5 mg were administered alone and in c","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":"30","endOffset":"41","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/div[1]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/div[1]/div[1]/div[1]/div[2]/span[1]","prefix":"Pharmacokinetic parameters of ","suffix":" administered alone or in combination with midazolam 7.5 mg ","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":"34","endOffset":"45","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[1]/p[1]","prefix":"The pharmacokinetic parameters of ","suffix":" 10 mg administered alone or in combination with ketoconazol","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":"30","endOffset":"41","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/div[1]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/div[1]/div[1]/div[1]/div[2]/span[1]","prefix":"Pharmacokinetic parameters of ","suffix":" administered alone or in combination with midazolam 7.5 mg ","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":"30","endOffset":"41","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[1]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[1]/div[1]/div[1]/div[2]/span[1]","prefix":"Pharmacokinetic parameters of ","suffix":" (10 mg) administered alone or in combination with ketoconaz","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":"37","endOffset":"48","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[2]/p[1]","prefix":"The pharmacokinetics of steady-state ","suffix":" 10 mg (day 5) were compared with those of steady-state riva","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":"24","endOffset":"35","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[3]/p[1]","prefix":"The pharmacokinetics of ","suffix":" 10 mg were compared after a single dose (day 1) with those ","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":"24","endOffset":"35","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/div[1]/p[1]","prefix":"The pharmacokinetics of ","suffix":" were compared after a single dose of rivaroxaban 10 mg was ","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":"104","endOffset":"115","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[2]/p[1]","prefix":"aban 10 mg (day 5) were compared with those of steady-state ","suffix":" 10 mg in combination with steady-state ketoconazole 400 mg ","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":"263","endOffset":"274","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[2]/p[1]","prefix":"nistration with ketoconazole 400 mg significantly increased ","suffix":" plasma concentrations (","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":"37","endOffset":"48","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[2]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[2]/div[1]/div[1]/div[2]/span[1]","prefix":"Plasma concentration–time profile of ","suffix":" (20 mg [fluconazole study] or 10 mg [all other studies] onc","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":"24","endOffset":"35","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[3]/p[1]","prefix":"The pharmacokinetics of ","suffix":" 10 mg were compared after a single dose (day 1) with those ","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":"258","endOffset":"269","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[3]/p[1]","prefix":"s of ritonavir were compared in the absence and presence of ","suffix":" (days 7 and 8, respectively). Steady-state ritonavir signif","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":"24","endOffset":"35","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/div[1]/p[1]","prefix":"The pharmacokinetics of ","suffix":" were compared after a single dose of rivaroxaban 10 mg was ","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":"73","endOffset":"84","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/div[1]/p[1]","prefix":"inetics of rivaroxaban were compared after a single dose of ","suffix":" 10 mg was administered alone and co-administered with clari","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":"334","endOffset":"345","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/div[1]/p[1]","prefix":"icantly increased the primary pharmacokinetic parameters of ","suffix":" (","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":"324","endOffset":"335","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/div[3]/p[1]","prefix":"icantly increased the primary pharmacokinetic parameters of ","suffix":" (","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":"31","endOffset":"42","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/div[2]/p[1]","prefix":"The pharmacokinetic effects of ","suffix":" 10 mg administered alone (day 5) and in combination with st","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":"311","endOffset":"322","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/div[2]/p[1]","prefix":"rythromycin significantly increased the pharmacokinetics of ","suffix":" (","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":"24","endOffset":"35","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/div[3]/p[1]","prefix":"The pharmacokinetics of ","suffix":" were compared after a single dose of rivaroxaban 20 mg was ","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":"73","endOffset":"84","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/div[3]/p[1]","prefix":"inetics of rivaroxaban were compared after a single dose of ","suffix":" 20 mg was administered alone and co-administered with fluco","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":"334","endOffset":"345","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/div[1]/p[1]","prefix":"icantly increased the primary pharmacokinetic parameters of ","suffix":" (","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":"324","endOffset":"335","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/div[3]/p[1]","prefix":"icantly increased the primary pharmacokinetic parameters of ","suffix":" (","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":"211","endOffset":"222","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[5]/p[1]","prefix":"hich was serious, were considered to be possibly related to ","suffix":" alone or a combination involving rivaroxaban. Of these, hea","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":"256","endOffset":"267","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[5]/p[1]","prefix":"bly related to rivaroxaban alone or a combination involving ","suffix":". Of these, headache (32 events) and fatigue (13 events) wer","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":"87","endOffset":"98","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","prefix":"ic interaction studies in healthy subjects demonstrate that ","suffix":" does not interact with a probe substrate for CYP3A4 (midazo","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":"185","endOffset":"196","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","prefix":"robe substrate for CYP3A4 (midazolam). Co-administration of ","suffix":" with a moderate CYP3A4 and P-gp inhibitor (erythromycin), a","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":"458","endOffset":"469","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","prefix":"ithromycin), led to a statistically significant increase in ","suffix":" exposure. Of note, active renal secretion (CL","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":"25","endOffset":"36","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","prefix":"The co-administration of ","suffix":" with midazolam had no effect on the pharmacokinetics of riv","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":"93","endOffset":"104","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","prefix":"ban with midazolam had no effect on the pharmacokinetics of ","suffix":", or on the pharmacokinetics of midazolam or its CYP3A4-medi","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":"427","endOffset":"438","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","prefix":"d no effect on the pharmacokinetics and pharmacodynamics of ","suffix":", or on the pharmacokinetics of digoxin or atorvastatin [","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":"25","endOffset":"36","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","prefix":"The co-administration of ","suffix":" and the frequently used antibiotic erythromycin, a moderate","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":"48","endOffset":"59","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/div[2]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/div[2]/div[1]/div[2]/span[1]","prefix":"Metabolic clearance and elimination pathways of ","suffix":" based on ","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":"115","endOffset":"126","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[6]","prefix":"s P-gp and Bcrp (ABCG2), are involved in the elimination of ","suffix":". Therefore, it was important to determine the clinical exte","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":"226","endOffset":"237","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[6]","prefix":"ne the clinical extent of any potential interaction between ","suffix":" and drugs that are substrates for and/or inhibitors of thes","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":"388","endOffset":"399","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[6]","prefix":"e studies suggest that the oral, direct Factor Xa inhibitor ","suffix":" does not interact to a clinically relevant extent with subs","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":"730","endOffset":"741","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[6]","prefix":" HIV protease inhibitors. Therefore, the concomitant use of ","suffix":" with these agents should be avoided. The exception may be f","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"rivaroxaban","startOffset":"854","endOffset":"865","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[6]","prefix":"ay be fluconazole, which is expected to have less effect on ","suffix":" exposure and can be co-administered with caution [","exact":"rivaroxaban"},{"setid":"PMC3769672","drugname":"midazolam","startOffset":"34","endOffset":"43","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"Rivaroxaban did not interact with ","suffix":" (CYP3A4 probe substrate). Exposure to rivaroxaban when co-a","exact":"midazolam"},{"setid":"PMC3769672","drugname":"midazolam","startOffset":"120","endOffset":"129","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"bstrate). Exposure to rivaroxaban when co-administered with ","suffix":" was slightly decreased by 11% (95% confidence interval [CI]","exact":"midazolam"},{"setid":"PMC3769672","drugname":"midazolam","startOffset":"46","endOffset":"55","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/ul[1]/li[1]/div[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/ul[1]/li[1]/div[1]","prefix":"A sensitive probe substrate for CYP3A4 only – ","suffix":" [","exact":"midazolam"},{"setid":"PMC3769672","drugname":"midazolam","startOffset":"129","endOffset":"138","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/div[1]/p[1]","prefix":"varoxaban and a sensitive probe substrate for CYP3A4 alone, ","suffix":" [","exact":"midazolam"},{"setid":"PMC3769672","drugname":"midazolam","startOffset":"185","endOffset":"194","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/div[2]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/div[2]/p[4]","prefix":"ddition, as midazolam is metabolized by CYP3A4 to α-hydroxy-","suffix":" [","exact":"midazolam"},{"setid":"PMC3769672","drugname":"midazolam","startOffset":"419","endOffset":"428","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","prefix":"y-state fluconazole (400 mg once daily) or a single dose of ","suffix":" (7.5 mg). An additional study was undertaken to determine t","exact":"midazolam"},{"setid":"PMC3769672","drugname":"midazolam","startOffset":"129","endOffset":"138","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/div[1]/p[1]","prefix":"varoxaban and a sensitive probe substrate for CYP3A4 alone, ","suffix":" [","exact":"midazolam"},{"setid":"PMC3769672","drugname":"midazolam","startOffset":"140","endOffset":"149","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/div[1]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/div[1]/p[2]","prefix":" a single dose of rivaroxaban 20 mg alone, a single dose of ","suffix":" 7.5 mg alone or the combination. All study drugs were given","exact":"midazolam"},{"setid":"PMC3769672","drugname":"midazolam","startOffset":"137","endOffset":"146","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/div[2]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/div[2]/p[4]","prefix":"nation with the potential interacting drug. In addition, as ","suffix":" is metabolized by CYP3A4 to α-hydroxy-midazolam [","exact":"midazolam"},{"setid":"PMC3769672","drugname":"midazolam","startOffset":"185","endOffset":"194","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/div[2]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/div[2]/p[4]","prefix":"ddition, as midazolam is metabolized by CYP3A4 to α-hydroxy-","suffix":" [","exact":"midazolam"},{"setid":"PMC3769672","drugname":"midazolam","startOffset":"37","endOffset":"46","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/div[1]/p[1]","prefix":"The pharmacokinetics of rivaroxaban, ","suffix":" and its CYP3A4-mediated metabolite, α-hydroxy-midazolam, wh","exact":"midazolam"},{"setid":"PMC3769672","drugname":"midazolam","startOffset":"93","endOffset":"102","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/div[1]/p[1]","prefix":"an, midazolam and its CYP3A4-mediated metabolite, α-hydroxy-","suffix":", when rivaroxaban 20 mg and midazolam 7.5 mg were administe","exact":"midazolam"},{"setid":"PMC3769672","drugname":"midazolam","startOffset":"131","endOffset":"140","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/div[1]/p[1]","prefix":"metabolite, α-hydroxy-midazolam, when rivaroxaban 20 mg and ","suffix":" 7.5 mg were administered alone and in combination are summa","exact":"midazolam"},{"setid":"PMC3769672","drugname":"midazolam","startOffset":"84","endOffset":"93","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/div[1]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/div[1]/div[1]/div[1]/div[2]/span[1]","prefix":"rs of rivaroxaban administered alone or in combination with ","suffix":" 7.5 mg (mean/CV [range]) and comparison of pharmacokinetic ","exact":"midazolam"},{"setid":"PMC3769672","drugname":"midazolam","startOffset":"34","endOffset":"43","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"Rivaroxaban did not interact with ","suffix":" (CYP3A4 probe substrate). Exposure to rivaroxaban when co-a","exact":"midazolam"},{"setid":"PMC3769672","drugname":"midazolam","startOffset":"120","endOffset":"129","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"bstrate). Exposure to rivaroxaban when co-administered with ","suffix":" was slightly decreased by 11% (95% confidence interval [CI]","exact":"midazolam"},{"setid":"PMC3769672","drugname":"midazolam","startOffset":"46","endOffset":"55","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/ul[1]/li[1]/div[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/ul[1]/li[1]/div[1]","prefix":"A sensitive probe substrate for CYP3A4 only – ","suffix":" [","exact":"midazolam"},{"setid":"PMC3769672","drugname":"midazolam","startOffset":"419","endOffset":"428","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","prefix":"y-state fluconazole (400 mg once daily) or a single dose of ","suffix":" (7.5 mg). An additional study was undertaken to determine t","exact":"midazolam"},{"setid":"PMC3769672","drugname":"midazolam","startOffset":"129","endOffset":"138","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/div[1]/p[1]","prefix":"varoxaban and a sensitive probe substrate for CYP3A4 alone, ","suffix":" [","exact":"midazolam"},{"setid":"PMC3769672","drugname":"midazolam","startOffset":"140","endOffset":"149","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/div[1]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/div[1]/p[2]","prefix":" a single dose of rivaroxaban 20 mg alone, a single dose of ","suffix":" 7.5 mg alone or the combination. All study drugs were given","exact":"midazolam"},{"setid":"PMC3769672","drugname":"midazolam","startOffset":"137","endOffset":"146","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/div[2]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/div[2]/p[4]","prefix":"nation with the potential interacting drug. In addition, as ","suffix":" is metabolized by CYP3A4 to α-hydroxy-midazolam [","exact":"midazolam"},{"setid":"PMC3769672","drugname":"midazolam","startOffset":"185","endOffset":"194","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/div[2]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/div[2]/p[4]","prefix":"ddition, as midazolam is metabolized by CYP3A4 to α-hydroxy-","suffix":" [","exact":"midazolam"},{"setid":"PMC3769672","drugname":"midazolam","startOffset":"37","endOffset":"46","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/div[1]/p[1]","prefix":"The pharmacokinetics of rivaroxaban, ","suffix":" and its CYP3A4-mediated metabolite, α-hydroxy-midazolam, wh","exact":"midazolam"},{"setid":"PMC3769672","drugname":"midazolam","startOffset":"93","endOffset":"102","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/div[1]/p[1]","prefix":"an, midazolam and its CYP3A4-mediated metabolite, α-hydroxy-","suffix":", when rivaroxaban 20 mg and midazolam 7.5 mg were administe","exact":"midazolam"},{"setid":"PMC3769672","drugname":"midazolam","startOffset":"131","endOffset":"140","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/div[1]/p[1]","prefix":"metabolite, α-hydroxy-midazolam, when rivaroxaban 20 mg and ","suffix":" 7.5 mg were administered alone and in combination are summa","exact":"midazolam"},{"setid":"PMC3769672","drugname":"midazolam","startOffset":"84","endOffset":"93","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/div[1]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/div[1]/div[1]/div[1]/div[2]/span[1]","prefix":"rs of rivaroxaban administered alone or in combination with ","suffix":" 7.5 mg (mean/CV [range]) and comparison of pharmacokinetic ","exact":"midazolam"},{"setid":"PMC3769672","drugname":"midazolam","startOffset":"152","endOffset":"161","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","prefix":"oxaban does not interact with a probe substrate for CYP3A4 (","suffix":"). Co-administration of rivaroxaban with a moderate CYP3A4 a","exact":"midazolam"},{"setid":"PMC3769672","drugname":"midazolam","startOffset":"42","endOffset":"51","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","prefix":"The co-administration of rivaroxaban with ","suffix":" had no effect on the pharmacokinetics of rivaroxaban, or on","exact":"midazolam"},{"setid":"PMC3769672","drugname":"midazolam","startOffset":"136","endOffset":"145","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","prefix":"rmacokinetics of rivaroxaban, or on the pharmacokinetics of ","suffix":" or its CYP3A4-mediated metabolites. Previous interaction st","exact":"midazolam"},{"setid":"PMC3769672","drugname":"midazolam","startOffset":"67","endOffset":"76","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[13]/div[2]/div[28]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[13]/div[2]/div[28]/span[1]","prefix":"h T, Mathys D, Umeno M, Gonzalez FJ, Meyer UA. Oxidation of ","suffix":" and triazolam by human liver cytochrome P450IIIA4. ","exact":"midazolam"},{"setid":"PMC3769672","drugname":"midazolam","startOffset":"42","endOffset":"51","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","prefix":"The co-administration of rivaroxaban with ","suffix":" had no effect on the pharmacokinetics of rivaroxaban, or on","exact":"midazolam"},{"setid":"PMC3769672","drugname":"midazolam","startOffset":"136","endOffset":"145","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","prefix":"rmacokinetics of rivaroxaban, or on the pharmacokinetics of ","suffix":" or its CYP3A4-mediated metabolites. Previous interaction st","exact":"midazolam"},{"setid":"PMC3769672","drugname":"erythromycin","startOffset":"336","endOffset":"348","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"aroxaban exposure, but not to a clinically relevant extent: ","suffix":" (moderate CYP3A4/P-gp inhibitor; 34% increase [95% CI 23%, ","exact":"erythromycin"},{"setid":"PMC3769672","drugname":"erythromycin","startOffset":"42","endOffset":"54","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/ul[1]/li[4]/div[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/ul[1]/li[4]/div[1]","prefix":"A moderate inhibitor of CYP3A4 and P-gp – ","suffix":" [","exact":"erythromycin"},{"setid":"PMC3769672","drugname":"erythromycin","startOffset":"313","endOffset":"325","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","prefix":"ady-state clarithromycin (500 mg twice daily), steady-state ","suffix":" (500 mg three times daily), steady-state fluconazole (400 m","exact":"erythromycin"},{"setid":"PMC3769672","drugname":"erythromycin","startOffset":"429","endOffset":"441","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","prefix":"fter administration of the drug combinations, except in the ","suffix":" interaction study, in which subjects were discharged 72 h a","exact":"erythromycin"},{"setid":"PMC3769672","drugname":"erythromycin","startOffset":"78","endOffset":"90","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/div[2]/p[1]","prefix":"estigated the potential interaction between rivaroxaban and ","suffix":", classified as a moderate inhibitor of CYP3A4, and consider","exact":"erythromycin"},{"setid":"PMC3769672","drugname":"erythromycin","startOffset":"124","endOffset":"136","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/div[2]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/div[2]/p[2]","prefix":"zed to receive a single dose of rivaroxaban 10 mg alone, or ","suffix":" 500 mg three times daily given for 4 days, with a single 50","exact":"erythromycin"},{"setid":"PMC3769672","drugname":"erythromycin","startOffset":"120","endOffset":"132","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/div[2]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/div[2]/p[3]","prefix":"n findings (in the ketoconazole, ritonavir, clarithromycin, ","suffix":" and fluconazole studies), the fraction of free (unbound) dr","exact":"erythromycin"},{"setid":"PMC3769672","drugname":"erythromycin","startOffset":"210","endOffset":"222","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[1]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[1]/div[1]/div[1]/div[2]/span[1]","prefix":"avir 600 mg twice daily, clarithromycin 500 mg twice daily, ","suffix":" 500 mg three times daily or","exact":"erythromycin"},{"setid":"PMC3769672","drugname":"erythromycin","startOffset":"113","endOffset":"125","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/div[2]/p[1]","prefix":"nistered alone (day 5) and in combination with steady-state ","suffix":" (500 mg three times daily for 4 days with a single 500 mg d","exact":"erythromycin"},{"setid":"PMC3769672","drugname":"erythromycin","startOffset":"250","endOffset":"262","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/div[2]/p[1]","prefix":"n day 5) were analyzed. Co-administration with steady-state ","suffix":" significantly increased the pharmacokinetics of rivaroxaban","exact":"erythromycin"},{"setid":"PMC3769672","drugname":"erythromycin","startOffset":"336","endOffset":"348","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"aroxaban exposure, but not to a clinically relevant extent: ","suffix":" (moderate CYP3A4/P-gp inhibitor; 34% increase [95% CI 23%, ","exact":"erythromycin"},{"setid":"PMC3769672","drugname":"erythromycin","startOffset":"42","endOffset":"54","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/ul[1]/li[4]/div[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/ul[1]/li[4]/div[1]","prefix":"A moderate inhibitor of CYP3A4 and P-gp – ","suffix":" [","exact":"erythromycin"},{"setid":"PMC3769672","drugname":"erythromycin","startOffset":"313","endOffset":"325","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","prefix":"ady-state clarithromycin (500 mg twice daily), steady-state ","suffix":" (500 mg three times daily), steady-state fluconazole (400 m","exact":"erythromycin"},{"setid":"PMC3769672","drugname":"erythromycin","startOffset":"429","endOffset":"441","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","prefix":"fter administration of the drug combinations, except in the ","suffix":" interaction study, in which subjects were discharged 72 h a","exact":"erythromycin"},{"setid":"PMC3769672","drugname":"erythromycin","startOffset":"78","endOffset":"90","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/div[2]/p[1]","prefix":"estigated the potential interaction between rivaroxaban and ","suffix":", classified as a moderate inhibitor of CYP3A4, and consider","exact":"erythromycin"},{"setid":"PMC3769672","drugname":"erythromycin","startOffset":"124","endOffset":"136","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/div[2]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/div[2]/p[2]","prefix":"zed to receive a single dose of rivaroxaban 10 mg alone, or ","suffix":" 500 mg three times daily given for 4 days, with a single 50","exact":"erythromycin"},{"setid":"PMC3769672","drugname":"erythromycin","startOffset":"120","endOffset":"132","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/div[2]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/div[2]/p[3]","prefix":"n findings (in the ketoconazole, ritonavir, clarithromycin, ","suffix":" and fluconazole studies), the fraction of free (unbound) dr","exact":"erythromycin"},{"setid":"PMC3769672","drugname":"erythromycin","startOffset":"210","endOffset":"222","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[1]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[1]/div[1]/div[1]/div[2]/span[1]","prefix":"avir 600 mg twice daily, clarithromycin 500 mg twice daily, ","suffix":" 500 mg three times daily or","exact":"erythromycin"},{"setid":"PMC3769672","drugname":"erythromycin","startOffset":"113","endOffset":"125","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/div[2]/p[1]","prefix":"nistered alone (day 5) and in combination with steady-state ","suffix":" (500 mg three times daily for 4 days with a single 500 mg d","exact":"erythromycin"},{"setid":"PMC3769672","drugname":"erythromycin","startOffset":"250","endOffset":"262","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/div[2]/p[1]","prefix":"n day 5) were analyzed. Co-administration with steady-state ","suffix":" significantly increased the pharmacokinetics of rivaroxaban","exact":"erythromycin"},{"setid":"PMC3769672","drugname":"erythromycin","startOffset":"240","endOffset":"252","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","prefix":"n of rivaroxaban with a moderate CYP3A4 and P-gp inhibitor (","suffix":"), a moderate inhibitor of CYP3A4 and potentially Bcrp (ABCG","exact":"erythromycin"},{"setid":"PMC3769672","drugname":"erythromycin","startOffset":"72","endOffset":"84","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","prefix":"istration of rivaroxaban and the frequently used antibiotic ","suffix":", a moderate CYP inhibitor and weak to moderate P-gp inhibit","exact":"erythromycin"},{"setid":"PMC3769672","drugname":"erythromycin","startOffset":"77","endOffset":"89","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[13]/div[2]/div[38]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[13]/div[2]/div[38]/span[1]","prefix":" PD, Dane AL, Warwick MJ, Raza A, Schneck DW. The effect of ","suffix":" on the pharmacokinetics of rosuvastatin. ","exact":"erythromycin"},{"setid":"PMC3769672","drugname":"erythromycin","startOffset":"56","endOffset":"68","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[13]/div[2]/div[39]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[13]/div[2]/div[39]/span[1]","prefix":"Luurila H, Olkkola KT, Neuvonen PJ. Interaction between ","suffix":" and nitrazepam in healthy volunteers. ","exact":"erythromycin"},{"setid":"PMC3769672","drugname":"erythromycin","startOffset":"72","endOffset":"84","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","prefix":"istration of rivaroxaban and the frequently used antibiotic ","suffix":", a moderate CYP inhibitor and weak to moderate P-gp inhibit","exact":"erythromycin"},{"setid":"PMC3769672","drugname":"clarithromycin","startOffset":"415","endOffset":"429","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"ate CYP3A4/P-gp inhibitor; 34% increase [95% CI 23%, 46%]), ","suffix":" (strong CYP3A4/moderate P-gp inhibitor; 54% increase [95% C","exact":"clarithromycin"},{"setid":"PMC3769672","drugname":"clarithromycin","startOffset":"263","endOffset":"277","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","prefix":", steady-state ritonavir (600 mg twice daily), steady-state ","suffix":" (500 mg twice daily), steady-state erythromycin (500 mg thr","exact":"clarithromycin"},{"setid":"PMC3769672","drugname":"clarithromycin","startOffset":"123","endOffset":"137","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/div[1]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/div[1]/p[2]","prefix":"zed to receive a single dose of rivaroxaban 10 mg alone, or ","suffix":" 500 mg twice daily for a period of 4 days under steady-stat","exact":"clarithromycin"},{"setid":"PMC3769672","drugname":"clarithromycin","startOffset":"104","endOffset":"118","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/div[2]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/div[2]/p[3]","prefix":"pated interaction findings (in the ketoconazole, ritonavir, ","suffix":", erythromycin and fluconazole studies), the fraction of fre","exact":"clarithromycin"},{"setid":"PMC3769672","drugname":"clarithromycin","startOffset":"175","endOffset":"189","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[1]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[1]/div[1]/div[1]/div[2]/span[1]","prefix":"e daily or 400 mg once daily, ritonavir 600 mg twice daily, ","suffix":" 500 mg twice daily, erythromycin 500 mg three times daily o","exact":"clarithromycin"},{"setid":"PMC3769672","drugname":"clarithromycin","startOffset":"88","endOffset":"102","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[13]/div[2]/div[32]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[13]/div[2]/div[32]/span[1]","prefix":"ashida T, Futami T, Nohara R, Sasayama S, Inui K. Effect of ","suffix":" on renal excretion of digoxin: interaction with P-glycoprot","exact":"clarithromycin"},{"setid":"PMC3769672","drugname":"clarithromycin","startOffset":"62","endOffset":"76","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/ul[1]/li[3]/div[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/ul[1]/li[3]/div[1]","prefix":"strong inhibitor of CYP3A4 and moderate inhibitor of P-gp – ","suffix":" [","exact":"clarithromycin"},{"setid":"PMC3769672","drugname":"clarithromycin","startOffset":"263","endOffset":"277","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","prefix":", steady-state ritonavir (600 mg twice daily), steady-state ","suffix":" (500 mg twice daily), steady-state erythromycin (500 mg thr","exact":"clarithromycin"},{"setid":"PMC3769672","drugname":"clarithromycin","startOffset":"78","endOffset":"92","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/div[1]/p[1]","prefix":"estigated the potential interaction between rivaroxaban and ","suffix":", classified as a strong inhibitor of CYP3A4, and considered","exact":"clarithromycin"},{"setid":"PMC3769672","drugname":"clarithromycin","startOffset":"123","endOffset":"137","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/div[1]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/div[1]/p[2]","prefix":"zed to receive a single dose of rivaroxaban 10 mg alone, or ","suffix":" 500 mg twice daily for a period of 4 days under steady-stat","exact":"clarithromycin"},{"setid":"PMC3769672","drugname":"clarithromycin","startOffset":"104","endOffset":"118","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/div[2]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/div[2]/p[3]","prefix":"pated interaction findings (in the ketoconazole, ritonavir, ","suffix":", erythromycin and fluconazole studies), the fraction of fre","exact":"clarithromycin"},{"setid":"PMC3769672","drugname":"clarithromycin","startOffset":"175","endOffset":"189","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[1]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[1]/div[1]/div[1]/div[2]/span[1]","prefix":"e daily or 400 mg once daily, ritonavir 600 mg twice daily, ","suffix":" 500 mg twice daily, erythromycin 500 mg three times daily o","exact":"clarithromycin"},{"setid":"PMC3769672","drugname":"clarithromycin","startOffset":"139","endOffset":"153","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/div[1]/p[1]","prefix":"xaban 10 mg was administered alone and co-administered with ","suffix":" 500 mg after 4 days of pretreatment with clarithromycin 500","exact":"clarithromycin"},{"setid":"PMC3769672","drugname":"clarithromycin","startOffset":"195","endOffset":"209","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/div[1]/p[1]","prefix":"ith clarithromycin 500 mg after 4 days of pretreatment with ","suffix":" 500 mg twice daily. Co-administration with clarithromycin s","exact":"clarithromycin"},{"setid":"PMC3769672","drugname":"clarithromycin","startOffset":"253","endOffset":"267","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/div[1]/p[1]","prefix":"h clarithromycin 500 mg twice daily. Co-administration with ","suffix":" significantly increased the primary pharmacokinetic paramet","exact":"clarithromycin"},{"setid":"PMC3769672","drugname":"clarithromycin","startOffset":"415","endOffset":"429","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"ate CYP3A4/P-gp inhibitor; 34% increase [95% CI 23%, 46%]), ","suffix":" (strong CYP3A4/moderate P-gp inhibitor; 54% increase [95% C","exact":"clarithromycin"},{"setid":"PMC3769672","drugname":"clarithromycin","startOffset":"62","endOffset":"76","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/ul[1]/li[3]/div[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/ul[1]/li[3]/div[1]","prefix":"strong inhibitor of CYP3A4 and moderate inhibitor of P-gp – ","suffix":" [","exact":"clarithromycin"},{"setid":"PMC3769672","drugname":"clarithromycin","startOffset":"263","endOffset":"277","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","prefix":", steady-state ritonavir (600 mg twice daily), steady-state ","suffix":" (500 mg twice daily), steady-state erythromycin (500 mg thr","exact":"clarithromycin"},{"setid":"PMC3769672","drugname":"clarithromycin","startOffset":"78","endOffset":"92","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/div[1]/p[1]","prefix":"estigated the potential interaction between rivaroxaban and ","suffix":", classified as a strong inhibitor of CYP3A4, and considered","exact":"clarithromycin"},{"setid":"PMC3769672","drugname":"clarithromycin","startOffset":"123","endOffset":"137","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/div[1]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/div[1]/p[2]","prefix":"zed to receive a single dose of rivaroxaban 10 mg alone, or ","suffix":" 500 mg twice daily for a period of 4 days under steady-stat","exact":"clarithromycin"},{"setid":"PMC3769672","drugname":"clarithromycin","startOffset":"104","endOffset":"118","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/div[2]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/div[2]/p[3]","prefix":"pated interaction findings (in the ketoconazole, ritonavir, ","suffix":", erythromycin and fluconazole studies), the fraction of fre","exact":"clarithromycin"},{"setid":"PMC3769672","drugname":"clarithromycin","startOffset":"175","endOffset":"189","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[1]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[1]/div[1]/div[1]/div[2]/span[1]","prefix":"e daily or 400 mg once daily, ritonavir 600 mg twice daily, ","suffix":" 500 mg twice daily, erythromycin 500 mg three times daily o","exact":"clarithromycin"},{"setid":"PMC3769672","drugname":"clarithromycin","startOffset":"139","endOffset":"153","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/div[1]/p[1]","prefix":"xaban 10 mg was administered alone and co-administered with ","suffix":" 500 mg after 4 days of pretreatment with clarithromycin 500","exact":"clarithromycin"},{"setid":"PMC3769672","drugname":"clarithromycin","startOffset":"195","endOffset":"209","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/div[1]/p[1]","prefix":"ith clarithromycin 500 mg after 4 days of pretreatment with ","suffix":" 500 mg twice daily. Co-administration with clarithromycin s","exact":"clarithromycin"},{"setid":"PMC3769672","drugname":"clarithromycin","startOffset":"253","endOffset":"267","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/div[1]/p[1]","prefix":"h clarithromycin 500 mg twice daily. Co-administration with ","suffix":" significantly increased the primary pharmacokinetic paramet","exact":"clarithromycin"},{"setid":"PMC3769672","drugname":"clarithromycin","startOffset":"394","endOffset":"408","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","prefix":" strong inhibitor of CYP3A4 and moderate inhibitor of P-gp (","suffix":"), led to a statistically significant increase in rivaroxaba","exact":"clarithromycin"},{"setid":"PMC3769672","drugname":"clarithromycin","startOffset":"88","endOffset":"102","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[13]/div[2]/div[32]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[13]/div[2]/div[32]/span[1]","prefix":"ashida T, Futami T, Nohara R, Sasayama S, Inui K. Effect of ","suffix":" on renal excretion of digoxin: interaction with P-glycoprot","exact":"clarithromycin"},{"setid":"PMC3769672","drugname":"fluconazole","startOffset":"506","endOffset":"517","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"oderate P-gp inhibitor; 54% increase [95% CI 44%, 64%]) and ","suffix":" (moderate CYP3A4, possible Bcrp [ABCG2] inhibitor; 42% incr","exact":"fluconazole"},{"setid":"PMC3769672","drugname":"fluconazole","startOffset":"78","endOffset":"89","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/div[3]/p[1]","prefix":"estigated the potential interaction between rivaroxaban and ","suffix":", classified as a potent inhibitor of CYP2C9 (rivaroxaban is","exact":"fluconazole"},{"setid":"PMC3769672","drugname":"fluconazole","startOffset":"137","endOffset":"148","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/div[2]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/div[2]/p[3]","prefix":"e ketoconazole, ritonavir, clarithromycin, erythromycin and ","suffix":" studies), the fraction of free (unbound) drug in plasma (","exact":"fluconazole"},{"setid":"PMC3769672","drugname":"fluconazole","startOffset":"139","endOffset":"150","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/div[3]/p[1]","prefix":"xaban 20 mg was administered alone and co-administered with ","suffix":" 400 mg after 4 days of pretreatment with fluconazole 400 mg","exact":"fluconazole"},{"setid":"PMC3769672","drugname":"fluconazole","startOffset":"315","endOffset":"326","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","prefix":"a moderate inhibitor of CYP3A4 and potentially Bcrp (ABCG2, ","suffix":"), and a strong inhibitor of CYP3A4 and moderate inhibitor o","exact":"fluconazole"},{"setid":"PMC3769672","drugname":"fluconazole","startOffset":"232","endOffset":"243","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","prefix":"nhibitors (mainly comprising azole-antimycotics, apart from ","suffix":", and HIV protease inhibitors), which are multi-pathway inhi","exact":"fluconazole"},{"setid":"PMC3769672","drugname":"fluconazole","startOffset":"547","endOffset":"558","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/div[1]/ul[1]/li[1]/div[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/div[1]/ul[1]/li[1]/div[1]","prefix":" that could increase the risk of bleeding. The exception is ","suffix":", an azole-antimycotic, which interacted to a lesser degree ","exact":"fluconazole"},{"setid":"PMC3769672","drugname":"fluconazole","startOffset":"84","endOffset":"95","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/ul[1]/li[5]/div[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/ul[1]/li[5]/div[1]","prefix":"CYP3A4, also reported to potentially inhibit Bcrp (ABCG2) – ","suffix":" [","exact":"fluconazole"},{"setid":"PMC3769672","drugname":"fluconazole","startOffset":"367","endOffset":"378","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","prefix":"state erythromycin (500 mg three times daily), steady-state ","suffix":" (400 mg once daily) or a single dose of midazolam (7.5 mg).","exact":"fluconazole"},{"setid":"PMC3769672","drugname":"fluconazole","startOffset":"78","endOffset":"89","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/div[3]/p[1]","prefix":"estigated the potential interaction between rivaroxaban and ","suffix":", classified as a potent inhibitor of CYP2C9 (rivaroxaban is","exact":"fluconazole"},{"setid":"PMC3769672","drugname":"fluconazole","startOffset":"124","endOffset":"135","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/div[3]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/div[3]/p[2]","prefix":"zed to receive a single dose of rivaroxaban 20 mg alone, or ","suffix":" 400 mg once daily given for 6 days, with a concomitant admi","exact":"fluconazole"},{"setid":"PMC3769672","drugname":"fluconazole","startOffset":"137","endOffset":"148","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/div[2]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/div[2]/p[3]","prefix":"e ketoconazole, ritonavir, clarithromycin, erythromycin and ","suffix":" studies), the fraction of free (unbound) drug in plasma (","exact":"fluconazole"},{"setid":"PMC3769672","drugname":"fluconazole","startOffset":"57","endOffset":"68","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[2]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[2]/div[1]/div[1]/div[2]/span[1]","prefix":"Plasma concentration–time profile of rivaroxaban (20 mg [","suffix":" study] or 10 mg [all other studies] once daily) in the abse","exact":"fluconazole"},{"setid":"PMC3769672","drugname":"fluconazole","startOffset":"139","endOffset":"150","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/div[3]/p[1]","prefix":"xaban 20 mg was administered alone and co-administered with ","suffix":" 400 mg after 4 days of pretreatment with fluconazole 400 mg","exact":"fluconazole"},{"setid":"PMC3769672","drugname":"fluconazole","startOffset":"192","endOffset":"203","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/div[3]/p[1]","prefix":"d with fluconazole 400 mg after 4 days of pretreatment with ","suffix":" 400 mg once daily. Co-administration with fluconazole signi","exact":"fluconazole"},{"setid":"PMC3769672","drugname":"fluconazole","startOffset":"246","endOffset":"257","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/div[3]/p[1]","prefix":" with fluconazole 400 mg once daily. Co-administration with ","suffix":" significantly increased the primary pharmacokinetic paramet","exact":"fluconazole"},{"setid":"PMC3769672","drugname":"fluconazole","startOffset":"315","endOffset":"326","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","prefix":"a moderate inhibitor of CYP3A4 and potentially Bcrp (ABCG2, ","suffix":"), and a strong inhibitor of CYP3A4 and moderate inhibitor o","exact":"fluconazole"},{"setid":"PMC3769672","drugname":"fluconazole","startOffset":"800","endOffset":"811","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[6]","prefix":"n with these agents should be avoided. The exception may be ","suffix":", which is expected to have less effect on rivaroxaban expos","exact":"fluconazole"},{"setid":"PMC3769672","drugname":"ketoconazole","startOffset":"753","endOffset":"765","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"p/Bcrp (ABCG2) inhibitors (and potential CYP2J2 inhibitors) ","suffix":" (158% increase [95% CI 136%, 182%] for a 400 mg once daily ","exact":"ketoconazole"},{"setid":"PMC3769672","drugname":"ketoconazole","startOffset":"75","endOffset":"87","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/ul[1]/li[2]/div[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/ul[1]/li[2]/div[1]","prefix":"rs of CYP3A4 (and possibly CYP2J2), P-gp and Bcrp (ABCG2) – ","suffix":" [","exact":"ketoconazole"},{"setid":"PMC3769672","drugname":"ketoconazole","startOffset":"171","endOffset":"183","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","prefix":"ngle doses of rivaroxaban (10 mg or 20 mg) and steady-state ","suffix":" (200 mg once daily), steady-state ritonavir (600 mg twice d","exact":"ketoconazole"},{"setid":"PMC3769672","drugname":"ketoconazole","startOffset":"606","endOffset":"618","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","prefix":" rivaroxaban (10 mg once daily) and high dose, steady-state ","suffix":" (400 mg once daily).","exact":"ketoconazole"},{"setid":"PMC3769672","drugname":"ketoconazole","startOffset":"175","endOffset":"187","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","prefix":"potential interactions between rivaroxaban and steady-state ","suffix":" 200 mg, subjects received ketoconazole for 72 h as outpatie","exact":"ketoconazole"},{"setid":"PMC3769672","drugname":"ketoconazole","startOffset":"214","endOffset":"226","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","prefix":"ban and steady-state ketoconazole 200 mg, subjects received ","suffix":" for 72 h as outpatients. Subjects were kept in-house for 72","exact":"ketoconazole"},{"setid":"PMC3769672","drugname":"ketoconazole","startOffset":"163","endOffset":"175","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","prefix":"and strong inhibitors of CYP3A4/2J2, P-gp and Bcrp (ABCG2), ","suffix":" and ritonavir [","exact":"ketoconazole"},{"setid":"PMC3769672","drugname":"ketoconazole","startOffset":"12","endOffset":"24","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/p[1]","prefix":"The initial ","suffix":" interaction study investigated the potential interaction be","exact":"ketoconazole"},{"setid":"PMC3769672","drugname":"ketoconazole","startOffset":"136","endOffset":"148","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/p[1]","prefix":"ction between a single dose of rivaroxaban and steady-state ","suffix":" 200 mg once daily. In this open label, two way crossover st","exact":"ketoconazole"},{"setid":"PMC3769672","drugname":"ketoconazole","startOffset":"299","endOffset":"311","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/p[1]","prefix":"o receive a single dose of rivaroxaban 10 mg, alone or with ","suffix":" (4 days of oral ketoconazole 200 mg once daily with rivarox","exact":"ketoconazole"},{"setid":"PMC3769672","drugname":"ketoconazole","startOffset":"328","endOffset":"340","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/p[1]","prefix":"varoxaban 10 mg, alone or with ketoconazole (4 days of oral ","suffix":" 200 mg once daily with rivaroxaban given on day 4). Rivarox","exact":"ketoconazole"},{"setid":"PMC3769672","drugname":"ketoconazole","startOffset":"444","endOffset":"456","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/p[1]","prefix":" day 4). Rivaroxaban was given under fasting conditions and ","suffix":" was given with food, except when co-administered with rivar","exact":"ketoconazole"},{"setid":"PMC3769672","drugname":"ketoconazole","startOffset":"585","endOffset":"597","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/p[1]","prefix":"fter completion of this study, a publication suggested that ","suffix":" 400 mg may lead to higher inhibition of CYP ","exact":"ketoconazole"},{"setid":"PMC3769672","drugname":"ketoconazole","startOffset":"7","endOffset":"19","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/p[2]","prefix":"In the ","suffix":" 200 mg study, 12 subjects were enrolled. All completed the ","exact":"ketoconazole"},{"setid":"PMC3769672","drugname":"ketoconazole","startOffset":"243","endOffset":"255","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/p[2]","prefix":"4–41 years) and their mean weight was 86.4 ± 9.2 kg. In the ","suffix":" 400 mg study, a total of 20 subjects were enrolled. All com","exact":"ketoconazole"},{"setid":"PMC3769672","drugname":"ketoconazole","startOffset":"140","endOffset":"152","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/div[2]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/div[2]/p[2]","prefix":"under the plasma concentration–time curve (AUC(0,τ)) in the ","suffix":" 400 mg study, in which multiple doses of rivaroxaban were g","exact":"ketoconazole"},{"setid":"PMC3769672","drugname":"ketoconazole","startOffset":"79","endOffset":"91","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/div[2]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/div[2]/p[3]","prefix":"erpretation of the anticipated interaction findings (in the ","suffix":", ritonavir, clarithromycin, erythromycin and fluconazole st","exact":"ketoconazole"},{"setid":"PMC3769672","drugname":"ketoconazole","startOffset":"7","endOffset":"19","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/div[3]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/div[3]/p[2]","prefix":"In the ","suffix":" 400 mg once daily and ritonavir studies, both using sequent","exact":"ketoconazole"},{"setid":"PMC3769672","drugname":"ketoconazole","startOffset":"94","endOffset":"106","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[1]/p[1]","prefix":"rivaroxaban 10 mg administered alone or in combination with ","suffix":" 200 mg once daily are shown in ","exact":"ketoconazole"},{"setid":"PMC3769672","drugname":"ketoconazole","startOffset":"92","endOffset":"104","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[1]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[1]/div[1]/div[1]/div[2]/span[1]","prefix":"varoxaban (10 mg) administered alone or in combination with ","suffix":" 200 mg once daily or 400 mg once daily, ritonavir 600 mg tw","exact":"ketoconazole"},{"setid":"PMC3769672","drugname":"ketoconazole","startOffset":"155","endOffset":"167","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[2]/p[1]","prefix":"dy-state rivaroxaban 10 mg in combination with steady-state ","suffix":" 400 mg once daily (day 10). Co-administration with ketocona","exact":"ketoconazole"},{"setid":"PMC3769672","drugname":"ketoconazole","startOffset":"219","endOffset":"231","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[2]/p[1]","prefix":"conazole 400 mg once daily (day 10). Co-administration with ","suffix":" 400 mg significantly increased rivaroxaban plasma concentra","exact":"ketoconazole"},{"setid":"PMC3769672","drugname":"ketoconazole","startOffset":"165","endOffset":"177","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[2]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[2]/div[1]/div[1]/div[2]/span[1]","prefix":"once daily) in the absence and presence of (A) steady-state ","suffix":" (400 mg once daily given concomitantly for 5 days), ","exact":"ketoconazole"},{"setid":"PMC3769672","drugname":"ketoconazole","startOffset":"171","endOffset":"183","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[13]/div[2]/div[34]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[13]/div[2]/div[34]/span[1]","prefix":"uation of pharmacokinetic inhibition of CYP3A substrates by ","suffix":": a simulation study. ","exact":"ketoconazole"},{"setid":"PMC3769672","drugname":"ketoconazole","startOffset":"75","endOffset":"87","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/ul[1]/li[2]/div[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/ul[1]/li[2]/div[1]","prefix":"rs of CYP3A4 (and possibly CYP2J2), P-gp and Bcrp (ABCG2) – ","suffix":" [","exact":"ketoconazole"},{"setid":"PMC3769672","drugname":"ketoconazole","startOffset":"163","endOffset":"175","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","prefix":"and strong inhibitors of CYP3A4/2J2, P-gp and Bcrp (ABCG2), ","suffix":" and ritonavir [","exact":"ketoconazole"},{"setid":"PMC3769672","drugname":"ketoconazole","startOffset":"171","endOffset":"183","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","prefix":"ngle doses of rivaroxaban (10 mg or 20 mg) and steady-state ","suffix":" (200 mg once daily), steady-state ritonavir (600 mg twice d","exact":"ketoconazole"},{"setid":"PMC3769672","drugname":"ketoconazole","startOffset":"175","endOffset":"187","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","prefix":"potential interactions between rivaroxaban and steady-state ","suffix":" 200 mg, subjects received ketoconazole for 72 h as outpatie","exact":"ketoconazole"},{"setid":"PMC3769672","drugname":"ketoconazole","startOffset":"214","endOffset":"226","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","prefix":"ban and steady-state ketoconazole 200 mg, subjects received ","suffix":" for 72 h as outpatients. Subjects were kept in-house for 72","exact":"ketoconazole"},{"setid":"PMC3769672","drugname":"ketoconazole","startOffset":"136","endOffset":"148","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/p[1]","prefix":"ction between a single dose of rivaroxaban and steady-state ","suffix":" 200 mg once daily. In this open label, two way crossover st","exact":"ketoconazole"},{"setid":"PMC3769672","drugname":"ketoconazole","startOffset":"606","endOffset":"618","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","prefix":" rivaroxaban (10 mg once daily) and high dose, steady-state ","suffix":" (400 mg once daily).","exact":"ketoconazole"},{"setid":"PMC3769672","drugname":"ketoconazole","startOffset":"175","endOffset":"187","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","prefix":"potential interactions between rivaroxaban and steady-state ","suffix":" 200 mg, subjects received ketoconazole for 72 h as outpatie","exact":"ketoconazole"},{"setid":"PMC3769672","drugname":"ketoconazole","startOffset":"214","endOffset":"226","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","prefix":"ban and steady-state ketoconazole 200 mg, subjects received ","suffix":" for 72 h as outpatients. Subjects were kept in-house for 72","exact":"ketoconazole"},{"setid":"PMC3769672","drugname":"ketoconazole","startOffset":"75","endOffset":"87","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/ul[1]/li[2]/div[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/ul[1]/li[2]/div[1]","prefix":"rs of CYP3A4 (and possibly CYP2J2), P-gp and Bcrp (ABCG2) – ","suffix":" [","exact":"ketoconazole"},{"setid":"PMC3769672","drugname":"ketoconazole","startOffset":"163","endOffset":"175","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","prefix":"and strong inhibitors of CYP3A4/2J2, P-gp and Bcrp (ABCG2), ","suffix":" and ritonavir [","exact":"ketoconazole"},{"setid":"PMC3769672","drugname":"ketoconazole","startOffset":"12","endOffset":"24","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/p[1]","prefix":"The initial ","suffix":" interaction study investigated the potential interaction be","exact":"ketoconazole"},{"setid":"PMC3769672","drugname":"ketoconazole","startOffset":"136","endOffset":"148","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/p[1]","prefix":"ction between a single dose of rivaroxaban and steady-state ","suffix":" 200 mg once daily. In this open label, two way crossover st","exact":"ketoconazole"},{"setid":"PMC3769672","drugname":"ketoconazole","startOffset":"299","endOffset":"311","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/p[1]","prefix":"o receive a single dose of rivaroxaban 10 mg, alone or with ","suffix":" (4 days of oral ketoconazole 200 mg once daily with rivarox","exact":"ketoconazole"},{"setid":"PMC3769672","drugname":"ketoconazole","startOffset":"328","endOffset":"340","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/p[1]","prefix":"varoxaban 10 mg, alone or with ketoconazole (4 days of oral ","suffix":" 200 mg once daily with rivaroxaban given on day 4). Rivarox","exact":"ketoconazole"},{"setid":"PMC3769672","drugname":"ketoconazole","startOffset":"444","endOffset":"456","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/p[1]","prefix":" day 4). Rivaroxaban was given under fasting conditions and ","suffix":" was given with food, except when co-administered with rivar","exact":"ketoconazole"},{"setid":"PMC3769672","drugname":"ketoconazole","startOffset":"585","endOffset":"597","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/p[1]","prefix":"fter completion of this study, a publication suggested that ","suffix":" 400 mg may lead to higher inhibition of CYP ","exact":"ketoconazole"},{"setid":"PMC3769672","drugname":"ketoconazole","startOffset":"7","endOffset":"19","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/p[2]","prefix":"In the ","suffix":" 200 mg study, 12 subjects were enrolled. All completed the ","exact":"ketoconazole"},{"setid":"PMC3769672","drugname":"ketoconazole","startOffset":"243","endOffset":"255","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/p[2]","prefix":"4–41 years) and their mean weight was 86.4 ± 9.2 kg. In the ","suffix":" 400 mg study, a total of 20 subjects were enrolled. All com","exact":"ketoconazole"},{"setid":"PMC3769672","drugname":"ketoconazole","startOffset":"140","endOffset":"152","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/div[2]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/div[2]/p[2]","prefix":"under the plasma concentration–time curve (AUC(0,τ)) in the ","suffix":" 400 mg study, in which multiple doses of rivaroxaban were g","exact":"ketoconazole"},{"setid":"PMC3769672","drugname":"ketoconazole","startOffset":"79","endOffset":"91","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/div[2]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/div[2]/p[3]","prefix":"erpretation of the anticipated interaction findings (in the ","suffix":", ritonavir, clarithromycin, erythromycin and fluconazole st","exact":"ketoconazole"},{"setid":"PMC3769672","drugname":"ketoconazole","startOffset":"7","endOffset":"19","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/div[3]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/div[3]/p[2]","prefix":"In the ","suffix":" 400 mg once daily and ritonavir studies, both using sequent","exact":"ketoconazole"},{"setid":"PMC3769672","drugname":"ketoconazole","startOffset":"94","endOffset":"106","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[1]/p[1]","prefix":"rivaroxaban 10 mg administered alone or in combination with ","suffix":" 200 mg once daily are shown in ","exact":"ketoconazole"},{"setid":"PMC3769672","drugname":"ketoconazole","startOffset":"92","endOffset":"104","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[1]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[1]/div[1]/div[1]/div[2]/span[1]","prefix":"varoxaban (10 mg) administered alone or in combination with ","suffix":" 200 mg once daily or 400 mg once daily, ritonavir 600 mg tw","exact":"ketoconazole"},{"setid":"PMC3769672","drugname":"ketoconazole","startOffset":"155","endOffset":"167","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[2]/p[1]","prefix":"dy-state rivaroxaban 10 mg in combination with steady-state ","suffix":" 400 mg once daily (day 10). Co-administration with ketocona","exact":"ketoconazole"},{"setid":"PMC3769672","drugname":"ketoconazole","startOffset":"219","endOffset":"231","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[2]/p[1]","prefix":"conazole 400 mg once daily (day 10). Co-administration with ","suffix":" 400 mg significantly increased rivaroxaban plasma concentra","exact":"ketoconazole"},{"setid":"PMC3769672","drugname":"ketoconazole","startOffset":"171","endOffset":"183","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","prefix":"ngle doses of rivaroxaban (10 mg or 20 mg) and steady-state ","suffix":" (200 mg once daily), steady-state ritonavir (600 mg twice d","exact":"ketoconazole"},{"setid":"PMC3769672","drugname":"ketoconazole","startOffset":"606","endOffset":"618","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","prefix":" rivaroxaban (10 mg once daily) and high dose, steady-state ","suffix":" (400 mg once daily).","exact":"ketoconazole"},{"setid":"PMC3769672","drugname":"ketoconazole","startOffset":"175","endOffset":"187","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","prefix":"potential interactions between rivaroxaban and steady-state ","suffix":" 200 mg, subjects received ketoconazole for 72 h as outpatie","exact":"ketoconazole"},{"setid":"PMC3769672","drugname":"ketoconazole","startOffset":"214","endOffset":"226","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[3]","prefix":"ban and steady-state ketoconazole 200 mg, subjects received ","suffix":" for 72 h as outpatients. Subjects were kept in-house for 72","exact":"ketoconazole"},{"setid":"PMC3769672","drugname":"ketoconazole","startOffset":"136","endOffset":"148","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/p[1]","prefix":"ction between a single dose of rivaroxaban and steady-state ","suffix":" 200 mg once daily. In this open label, two way crossover st","exact":"ketoconazole"},{"setid":"PMC3769672","drugname":"ketoconazole","startOffset":"155","endOffset":"167","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[2]/p[1]","prefix":"dy-state rivaroxaban 10 mg in combination with steady-state ","suffix":" 400 mg once daily (day 10). Co-administration with ketocona","exact":"ketoconazole"},{"setid":"PMC3769672","drugname":"ketoconazole","startOffset":"165","endOffset":"177","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[2]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[2]/div[1]/div[1]/div[2]/span[1]","prefix":"once daily) in the absence and presence of (A) steady-state ","suffix":" (400 mg once daily given concomitantly for 5 days), ","exact":"ketoconazole"},{"setid":"PMC3769672","drugname":"ritonavir","startOffset":"835","endOffset":"844","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"rease [95% CI 136%, 182%] for a 400 mg once daily dose) and ","suffix":" (153% increase [95% CI 134%, 174%]).","exact":"ritonavir"},{"setid":"PMC3769672","drugname":"ritonavir","startOffset":"180","endOffset":"189","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","prefix":"tors of CYP3A4/2J2, P-gp and Bcrp (ABCG2), ketoconazole and ","suffix":" [","exact":"ritonavir"},{"setid":"PMC3769672","drugname":"ritonavir","startOffset":"80","endOffset":"89","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[2]/p[1]","prefix":"ction between a single dose of rivaroxaban and steady-state ","suffix":" was investigated in a non-randomized, open label study. Sub","exact":"ritonavir"},{"setid":"PMC3769672","drugname":"ritonavir","startOffset":"255","endOffset":"264","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[2]/p[1]","prefix":" mg on day 1, ritonavir 600 mg twice daily on days 3–7, and ","suffix":" 600 mg twice daily plus a single dose of rivaroxaban on day","exact":"ritonavir"},{"setid":"PMC3769672","drugname":"ritonavir","startOffset":"468","endOffset":"477","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[2]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[2]/p[2]","prefix":"dose of rivaroxaban 10 mg on day 1 and at least one dose of ","suffix":" (600 mg). Twelve subjects received the combination of rivar","exact":"ritonavir"},{"setid":"PMC3769672","drugname":"ritonavir","startOffset":"548","endOffset":"557","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[2]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[2]/p[2]","prefix":"Twelve subjects received the combination of rivaroxaban and ","suffix":" on day 8. However, none of the subjects received the second","exact":"ritonavir"},{"setid":"PMC3769672","drugname":"ritonavir","startOffset":"42","endOffset":"51","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/div[3]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/div[3]/p[2]","prefix":"In the ketoconazole 400 mg once daily and ","suffix":" studies, both using sequential designs, the pharmacokinetic","exact":"ritonavir"},{"setid":"PMC3769672","drugname":"ritonavir","startOffset":"313","endOffset":"322","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[3]/p[1]","prefix":"e of rivaroxaban (days 7 and 8, respectively). Steady-state ","suffix":" significantly increased the AUC and ","exact":"ritonavir"},{"setid":"PMC3769672","drugname":"ritonavir","startOffset":"218","endOffset":"227","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","prefix":"steady-state ketoconazole (200 mg once daily), steady-state ","suffix":" (600 mg twice daily), steady-state clarithromycin (500 mg t","exact":"ritonavir"},{"setid":"PMC3769672","drugname":"ritonavir","startOffset":"180","endOffset":"189","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","prefix":"tors of CYP3A4/2J2, P-gp and Bcrp (ABCG2), ketoconazole and ","suffix":" [","exact":"ritonavir"},{"setid":"PMC3769672","drugname":"ritonavir","startOffset":"80","endOffset":"89","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[2]/p[1]","prefix":"ction between a single dose of rivaroxaban and steady-state ","suffix":" was investigated in a non-randomized, open label study. Sub","exact":"ritonavir"},{"setid":"PMC3769672","drugname":"ritonavir","startOffset":"209","endOffset":"218","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[2]/p[1]","prefix":"jects received a single dose of rivaroxaban 10 mg on day 1, ","suffix":" 600 mg twice daily on days 3–7, and ritonavir 600 mg twice ","exact":"ritonavir"},{"setid":"PMC3769672","drugname":"ritonavir","startOffset":"255","endOffset":"264","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[2]/p[1]","prefix":" mg on day 1, ritonavir 600 mg twice daily on days 3–7, and ","suffix":" 600 mg twice daily plus a single dose of rivaroxaban on day","exact":"ritonavir"},{"setid":"PMC3769672","drugname":"ritonavir","startOffset":"468","endOffset":"477","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[2]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[2]/p[2]","prefix":"dose of rivaroxaban 10 mg on day 1 and at least one dose of ","suffix":" (600 mg). Twelve subjects received the combination of rivar","exact":"ritonavir"},{"setid":"PMC3769672","drugname":"ritonavir","startOffset":"548","endOffset":"557","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[2]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[2]/p[2]","prefix":"Twelve subjects received the combination of rivaroxaban and ","suffix":" on day 8. However, none of the subjects received the second","exact":"ritonavir"},{"setid":"PMC3769672","drugname":"ritonavir","startOffset":"626","endOffset":"635","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[2]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[2]/p[2]","prefix":". However, none of the subjects received the second dose of ","suffix":" on day 8 because of tolerability issues, which were conside","exact":"ritonavir"},{"setid":"PMC3769672","drugname":"ritonavir","startOffset":"716","endOffset":"725","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[2]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[2]/p[2]","prefix":"tolerability issues, which were considered to be related to ","suffix":". Four subjects withdrew from the study owing to adverse eve","exact":"ritonavir"},{"setid":"PMC3769672","drugname":"ritonavir","startOffset":"805","endOffset":"814","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[2]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[2]/p[2]","prefix":"drew from the study owing to adverse events while receiving ","suffix":" alone (see below). Therefore, 12 subjects were valid for th","exact":"ritonavir"},{"setid":"PMC3769672","drugname":"ritonavir","startOffset":"93","endOffset":"102","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/div[2]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/div[2]/p[3]","prefix":" the anticipated interaction findings (in the ketoconazole, ","suffix":", clarithromycin, erythromycin and fluconazole studies), the","exact":"ritonavir"},{"setid":"PMC3769672","drugname":"ritonavir","startOffset":"42","endOffset":"51","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/div[3]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/div[3]/p[2]","prefix":"In the ketoconazole 400 mg once daily and ","suffix":" studies, both using sequential designs, the pharmacokinetic","exact":"ritonavir"},{"setid":"PMC3769672","drugname":"ritonavir","startOffset":"145","endOffset":"154","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[1]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[1]/div[1]/div[1]/div[2]/span[1]","prefix":"n with ketoconazole 200 mg once daily or 400 mg once daily, ","suffix":" 600 mg twice daily, clarithromycin 500 mg twice daily, eryt","exact":"ritonavir"},{"setid":"PMC3769672","drugname":"ritonavir","startOffset":"128","endOffset":"137","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[3]/p[1]","prefix":"le dose (day 1) with those of a single dose of steady-state ","suffix":" 600 mg twice daily (day 8). In addition, the pharmacokineti","exact":"ritonavir"},{"setid":"PMC3769672","drugname":"ritonavir","startOffset":"203","endOffset":"212","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[3]/p[1]","prefix":"g twice daily (day 8). In addition, the pharmacokinetics of ","suffix":" were compared in the absence and presence of rivaroxaban (d","exact":"ritonavir"},{"setid":"PMC3769672","drugname":"ritonavir","startOffset":"313","endOffset":"322","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[3]/p[1]","prefix":"e of rivaroxaban (days 7 and 8, respectively). Steady-state ","suffix":" significantly increased the AUC and ","exact":"ritonavir"},{"setid":"PMC3769672","drugname":"ritonavir","startOffset":"430","endOffset":"439","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[5]/p[1]","prefix":"hanges in ECG or vital signs were observed. Subjects taking ","suffix":" exhibited adverse events consistent with its established sa","exact":"ritonavir"},{"setid":"PMC3769672","drugname":"digoxin","startOffset":"216","endOffset":"223","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","prefix":"3A4-mediated metabolites. Previous interaction studies with ","suffix":" (a pure P-gp substrate with a narrow therapeutic window) an","exact":"digoxin"},{"setid":"PMC3769672","drugname":"digoxin","startOffset":"470","endOffset":"477","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","prefix":"rmacodynamics of rivaroxaban, or on the pharmacokinetics of ","suffix":" or atorvastatin [","exact":"digoxin"},{"setid":"PMC3769672","drugname":"atorvastatin","startOffset":"285","endOffset":"297","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","prefix":"a pure P-gp substrate with a narrow therapeutic window) and ","suffix":" (a substrate of both CYP3A4 and P-gp) in healthy subjects d","exact":"atorvastatin"},{"setid":"PMC3769672","drugname":"atorvastatin","startOffset":"114","endOffset":"126","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[13]/div[2]/div[27]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[13]/div[2]/div[27]/span[1]","prefix":"varoxaban – a novel, oral, direct Factor Xa inhibitor – and ","suffix":". ","exact":"atorvastatin"},{"setid":"PMC3769672","drugname":"atorvastatin","startOffset":"481","endOffset":"493","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","prefix":"cs of rivaroxaban, or on the pharmacokinetics of digoxin or ","suffix":" [","exact":"atorvastatin"}],[{"setid":"PMC1874466","drugname":"rosuvastatin","startOffset":"98","endOffset":"110","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":"rial 24 healthy adult volunteers were randomized to receive ","suffix":" 10 mg orally each morning (07.00 h) or evening (18.00 h) fo","exact":"rosuvastatin"},{"setid":"PMC1874466","drugname":"rosuvastatin","startOffset":"269","endOffset":"281","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":"d, volunteers received the alternative regimen for 14 days. ","suffix":" was administered in the absence of food.","exact":"Rosuvastatin"},{"setid":"PMC1874466","drugname":"rosuvastatin","startOffset":"52","endOffset":"64","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","prefix":"The pharmacodynamic effects and pharmacokinetics of ","suffix":" are not dependent on time of dosing. Morning or evening adm","exact":"rosuvastatin"},{"setid":"PMC1874466","drugname":"rosuvastatin","startOffset":"50","endOffset":"62","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","prefix":"HMG-CoA reductase, LDL-C, morning/evening dosing, ","suffix":"","exact":"rosuvastatin"},{"setid":"PMC1874466","drugname":"rosuvastatin","startOffset":"0","endOffset":"12","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[1]/div[3]/div[1]/div[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[1]/div[3]/div[1]/div[4]","prefix":"","suffix":" is licensed from Shionogi and Co. Ltd, Osaka, Japan.","exact":"Rosuvastatin"},{"setid":"PMC1874466","drugname":"rosuvastatin","startOffset":"0","endOffset":"12","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","prefix":"","suffix":" (Crestor®) is a new and highly effective inhibitor of HMG-C","exact":"Rosuvastatin"},{"setid":"PMC1874466","drugname":"rosuvastatin","startOffset":"0","endOffset":"12","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/p[1]","prefix":"","suffix":" proved to be well tolerated over the two 14 day treatment p","exact":"Rosuvastatin"},{"setid":"PMC1874466","drugname":"rosuvastatin","startOffset":"0","endOffset":"12","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[2]/div[2]/div[1]/ul[1]/li[4]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[2]/div[2]/div[1]/ul[1]/li[4]/a[1]","prefix":"","suffix":": a highly effective new HMG-CoA reductase inhibitor.","exact":"Rosuvastatin"},{"setid":"PMC1874466","drugname":"crestor","startOffset":"14","endOffset":"21","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","prefix":"Rosuvastatin (","suffix":"®) is a new and highly effective inhibitor of HMG-CoA reduct","exact":"Crestor"},{"setid":"PMC1874466","drugname":"rosuvastatin","startOffset":"205","endOffset":"217","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","prefix":"eatment of patients with dyslipidaemia. In clinical trials, ","suffix":" (1–80 mg) produced reductions in LDL-C, total cholesterol (","exact":"rosuvastatin"},{"setid":"PMC1874466","drugname":"rosuvastatin","startOffset":"24","endOffset":"36","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[4]","prefix":"The pharmacokinetics of ","suffix":" following single- and multiple-dose administration of the d","exact":"rosuvastatin"},{"setid":"PMC1874466","drugname":"rosuvastatin","startOffset":"109","endOffset":"121","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[5]","prefix":" the pharmacodynamics and multiple-dose pharmacokinetics of ","suffix":" following morning and evening administration in healthy adu","exact":"rosuvastatin"},{"setid":"PMC1874466","drugname":"rosuvastatin","startOffset":"69","endOffset":"81","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[2]","prefix":"volunteers were randomized to receive a single oral dose of ","suffix":" (10 mg) each morning (approximately 07.00 h) or evening (ap","exact":"rosuvastatin"},{"setid":"PMC1874466","drugname":"rosuvastatin","startOffset":"434","endOffset":"446","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[2]","prefix":"required to fast for a minimum of 2 h before and after each ","suffix":" dose, and for at least 12 h (overnight) before collection o","exact":"rosuvastatin"},{"setid":"PMC1874466","drugname":"rosuvastatin","startOffset":"138","endOffset":"150","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","prefix":"concentrations before administration of the morning dose of ","suffix":" (morning dosing) or before the morning meal (evening dosing","exact":"rosuvastatin"},{"setid":"PMC1874466","drugname":"rosuvastatin","startOffset":"63","endOffset":"75","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","prefix":"ial venous blood samples (7 ml) for determination of plasma ","suffix":" concentrations were collected at 0.5 h predose and at fixed","exact":"rosuvastatin"},{"setid":"PMC1874466","drugname":"rosuvastatin","startOffset":"227","endOffset":"239","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","prefix":"6, 8, 10, 12, 18, 24, 48, and 72 h) after administration of ","suffix":" on treatment day 14. Blood samples were also collected at 0","exact":"rosuvastatin"},{"setid":"PMC1874466","drugname":"rosuvastatin","startOffset":"7","endOffset":"19","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[2]","prefix":"Plasma ","suffix":" concentration-time data were analysed by standard noncompar","exact":"rosuvastatin"},{"setid":"PMC1874466","drugname":"rosuvastatin","startOffset":"94","endOffset":"106","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[1]","prefix":" LDL-C were obtained following once daily administration of ","suffix":" 10 mg in the morning or evening. After 14 days of treatment","exact":"rosuvastatin"},{"setid":"PMC1874466","drugname":"rosuvastatin","startOffset":"98","endOffset":"110","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/div[1]/div[1]/div[2]/span[1]","prefix":" concentrations after morning and evening administration of ","suffix":".","exact":"rosuvastatin"},{"setid":"PMC1874466","drugname":"rosuvastatin","startOffset":"90","endOffset":"102","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[4]","prefix":"n LDL-C, TC, TG, and ApoB are consistent with the effect of ","suffix":". The small reductions in HDL-C and ApoA-I are atypical.","exact":"rosuvastatin"},{"setid":"PMC1874466","drugname":"rosuvastatin","startOffset":"98","endOffset":"110","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/div[2]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/div[2]/div[1]/div[2]/span[1]","prefix":"acid parameters after morning and evening administration of ","suffix":".","exact":"rosuvastatin"},{"setid":"PMC1874466","drugname":"rosuvastatin","startOffset":"117","endOffset":"129","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/div[3]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/div[3]/div[1]/div[2]/span[1]","prefix":"rofiles before, after morning and evening administration of ","suffix":". ▴ morning pre-dose, ▪ evening pre-dose, ▵ morning post-dos","exact":"rosuvastatin"},{"setid":"PMC1874466","drugname":"rosuvastatin","startOffset":"33","endOffset":"45","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[1]","prefix":"From inspection of trough plasma ","suffix":" concentration-time profiles, it was apparent that steady st","exact":"rosuvastatin"},{"setid":"PMC1874466","drugname":"rosuvastatin","startOffset":"161","endOffset":"173","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[1]","prefix":"y state was attained within 8 days of initiating once-daily ","suffix":" administration (with both morning and evening dosing regime","exact":"rosuvastatin"},{"setid":"PMC1874466","drugname":"rosuvastatin","startOffset":"292","endOffset":"304","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[1]","prefix":"ens). Under steady-state conditions, the mean trough plasma ","suffix":" concentration was approximately 0.6 ng ml","exact":"rosuvastatin"},{"setid":"PMC1874466","drugname":"rosuvastatin","startOffset":"22","endOffset":"34","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[1]/div[1]/div[2]/span[1]","prefix":"Geometric mean plasma ","suffix":" concentration-time profiles on day 14 after morning (♦) and","exact":"rosuvastatin"},{"setid":"PMC1874466","drugname":"rosuvastatin","startOffset":"98","endOffset":"110","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/div[1]/div[1]/div[2]/span[1]","prefix":" concentrations after morning and evening administration of ","suffix":".","exact":"rosuvastatin"},{"setid":"PMC1874466","drugname":"rosuvastatin","startOffset":"98","endOffset":"110","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/div[2]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/div[2]/div[1]/div[2]/span[1]","prefix":"acid parameters after morning and evening administration of ","suffix":".","exact":"rosuvastatin"},{"setid":"PMC1874466","drugname":"rosuvastatin","startOffset":"125","endOffset":"137","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[1]/div[1]/div[2]/span[1]","prefix":" day 14 after morning (♦) and evening (▪) administration of ","suffix":".","exact":"rosuvastatin"},{"setid":"PMC1874466","drugname":"rosuvastatin","startOffset":"99","endOffset":"111","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[2]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[2]/div[1]/div[2]/span[1]","prefix":"or rosuvastatin after morning and evening administration of ","suffix":".","exact":"rosuvastatin"},{"setid":"PMC1874466","drugname":"rosuvastatin","startOffset":"35","endOffset":"47","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[2]","prefix":"The apparent rate of absorption of ","suffix":" was essentially the same following morning and evening dosi","exact":"rosuvastatin"},{"setid":"PMC1874466","drugname":"rosuvastatin","startOffset":"42","endOffset":"54","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[2]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[2]/div[1]/div[2]/span[1]","prefix":"Summary of pharmacokinetic parameters for ","suffix":" after morning and evening administration of rosuvastatin.","exact":"rosuvastatin"},{"setid":"PMC1874466","drugname":"rosuvastatin","startOffset":"99","endOffset":"111","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[2]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[2]/div[1]/div[2]/span[1]","prefix":"or rosuvastatin after morning and evening administration of ","suffix":".","exact":"rosuvastatin"},{"setid":"PMC1874466","drugname":"rosuvastatin","startOffset":"0","endOffset":"12","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/p[1]","prefix":"","suffix":" proved to be well tolerated over the two 14 day treatment p","exact":"Rosuvastatin"},{"setid":"PMC1874466","drugname":"rosuvastatin","startOffset":"203","endOffset":"215","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/p[2]","prefix":"ateral leads), which occurred 3.5 h after the first dose of ","suffix":". The volunteer was asymptomatic and the T-wave abnormality ","exact":"rosuvastatin"},{"setid":"PMC1874466","drugname":"rosuvastatin","startOffset":"95","endOffset":"107","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","prefix":" the pharmacodynamics and multiple-dose pharmacokinetics of ","suffix":" following morning and evening administration in healthy vol","exact":"rosuvastatin"},{"setid":"PMC1874466","drugname":"rosuvastatin","startOffset":"198","endOffset":"210","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","prefix":"administration in healthy volunteers. The results show that ","suffix":" was equally effective in lowering serum LDL-C concentration","exact":"rosuvastatin"},{"setid":"PMC1874466","drugname":"rosuvastatin","startOffset":"380","endOffset":"392","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","prefix":"ing with this finding, the steady-state pharmacokinetics of ","suffix":" were very similar after morning and evening administration.","exact":"rosuvastatin"},{"setid":"PMC1874466","drugname":"rosuvastatin","startOffset":"561","endOffset":"573","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","prefix":"r both pharmacodynamics and pharmacokinetics differentiates ","suffix":" from other marketed statins.","exact":"rosuvastatin"},{"setid":"PMC1874466","drugname":"rosuvastatin","startOffset":"170","endOffset":"182","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","prefix":" in hypercholesterolaemic patients following treatment with ","suffix":" 10 mg once daily for 6 weeks (approximately −48%) [","exact":"rosuvastatin"},{"setid":"PMC1874466","drugname":"rosuvastatin","startOffset":"82","endOffset":"94","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","prefix":"ults of this trial indicate that the therapeutic benefit of ","suffix":" is not dose-time de-pendent, and that morning or evening ad","exact":"rosuvastatin"},{"setid":"PMC1874466","drugname":"rosuvastatin","startOffset":"253","endOffset":"265","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","prefix":"gulating lipid levels. In addition, the pharmacokinetics of ","suffix":" were independent of time of dosing.","exact":"rosuvastatin"},{"setid":"PMC1874466","drugname":"cholesterol","startOffset":"283","endOffset":"294","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[1]/p[1]","prefix":"on in volunteers with fasting serum low-density lipoprotein ","suffix":" (LDL-C) concentrations < 4.14 mmol l","exact":"cholesterol"},{"setid":"PMC1874466","drugname":"cholesterol","startOffset":"264","endOffset":"275","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","prefix":" rosuvastatin (1–80 mg) produced reductions in LDL-C, total ","suffix":" (TC), and triglycerides (TG), and increases in high-density","exact":"cholesterol"},{"setid":"PMC1874466","drugname":"cholesterol","startOffset":"185","endOffset":"196","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","prefix":"erapy, and are the most effective agents for reducing serum ","suffix":" concentrations and cardiovascular mortality [","exact":"cholesterol"},{"setid":"PMC1874466","drugname":"cholesterol","startOffset":"264","endOffset":"275","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","prefix":" rosuvastatin (1–80 mg) produced reductions in LDL-C, total ","suffix":" (TC), and triglycerides (TG), and increases in high-density","exact":"cholesterol"},{"setid":"PMC1874466","drugname":"cholesterol","startOffset":"348","endOffset":"359","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","prefix":"iglycerides (TG), and increases in high-density lipoprotein ","suffix":" (HDL-C) [","exact":"cholesterol"}],[{"setid":"PMC2598705","drugname":"simvastatin","startOffset":"249","endOffset":"260","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[1]","prefix":" this, we have seen a recent cluster of patients prescribed ","suffix":" whilst on PIs.","exact":"simvastatin"},{"setid":"PMC2598705","drugname":"simvastatin","startOffset":"193","endOffset":"204","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[2]","prefix":"the patient and his general practitioner (GP), stating that ","suffix":" is not recommended with his antiretroviral combination, but","exact":"simvastatin"},{"setid":"PMC2598705","drugname":"simvastatin","startOffset":"311","endOffset":"322","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[2]","prefix":"bination, but low dose atorvastatin or pravastatin is safe. ","suffix":" was prescribed by the GP.","exact":"Simvastatin"},{"setid":"PMC2598705","drugname":"simvastatin","startOffset":"257","endOffset":"268","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[3]","prefix":" and mentioned that her cholesterol was 8.5. Her GP started ","suffix":". The patient took the first dose but stopped after reading ","exact":"simvastatin"},{"setid":"PMC2598705","drugname":"simvastatin","startOffset":"212","endOffset":"223","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[4]","prefix":"is GP about current medications. Pravastatin was changed to ","suffix":" by his GP 6 years later.","exact":"simvastatin"},{"setid":"PMC2598705","drugname":"simvastatin","startOffset":"103","endOffset":"114","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[5]","prefix":"on protease inhibitors (PIs) have recently been switched to ","suffix":" by GPs. None have suffered adverse consequences, although s","exact":"simvastatin"},{"setid":"PMC2598705","drugname":"simvastatin","startOffset":"138","endOffset":"149","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[6]","prefix":"hibit cytochrome P450 (CYP) 3A4 activity, which metabolises ","suffix":" and atorvastatin. Simvastatin exposure is increased by up t","exact":"simvastatin"},{"setid":"PMC2598705","drugname":"simvastatin","startOffset":"168","endOffset":"179","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[6]","prefix":"4 activity, which metabolises simvastatin and atorvastatin. ","suffix":" exposure is increased by up to 3000% by PIs,","exact":"Simvastatin"},{"setid":"PMC2598705","drugname":"simvastatin","startOffset":"167","endOffset":"178","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[7]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[7]","prefix":"CYP3A4 metabolism, and reduces the concentrations of active ","suffix":", atorvastatin and pravastatin by 58%, 34% and 40%, respecti","exact":"simvastatin"},{"setid":"PMC2598705","drugname":"simvastatin","startOffset":"127","endOffset":"138","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[8]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[8]","prefix":"dications where possible, and this is driving the switch to ","suffix":". Simvastatin is also available without prescription in phar","exact":"simvastatin"},{"setid":"PMC2598705","drugname":"simvastatin","startOffset":"140","endOffset":"151","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[8]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[8]","prefix":"re possible, and this is driving the switch to simvastatin. ","suffix":" is also available without prescription in pharmacies. These","exact":"Simvastatin"},{"setid":"PMC2598705","drugname":"simvastatin","startOffset":"420","endOffset":"431","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[8]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[8]","prefix":"bout potential drug interactions. Where PIs are being used, ","suffix":" must be avoided.","exact":"simvastatin"},{"setid":"PMC2598705","drugname":"abacavir","startOffset":"29","endOffset":"37","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[2]","prefix":"A 58‐year‐old man was taking ","suffix":", lamivudine, atazanavir and ritonavir. His HIV physician no","exact":"abacavir"},{"setid":"PMC2598705","drugname":"lamivudine","startOffset":"39","endOffset":"49","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[2]","prefix":"A 58‐year‐old man was taking abacavir, ","suffix":", atazanavir and ritonavir. His HIV physician noted raised c","exact":"lamivudine"},{"setid":"PMC2598705","drugname":"lamivudine","startOffset":"40","endOffset":"50","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[4]","prefix":"A 53‐year‐old man was taking stavudine, ","suffix":" and nelfinavir. Pravastatin was started by his HIV physicia","exact":"lamivudine"},{"setid":"PMC2598705","drugname":"atazanavir","startOffset":"51","endOffset":"61","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[2]","prefix":"A 58‐year‐old man was taking abacavir, lamivudine, ","suffix":" and ritonavir. His HIV physician noted raised cholesterol a","exact":"atazanavir"},{"setid":"PMC2598705","drugname":"atazanavir","startOffset":"54","endOffset":"64","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[3]","prefix":"A 52‐year‐old woman was taking didanosine, efavirenz, ","suffix":" and ritonavir, as well as gliclazide, doxazosin and bendrof","exact":"atazanavir"},{"setid":"PMC2598705","drugname":"atazanavir","startOffset":"26","endOffset":"36","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[6]","prefix":"PIs, including ritonavir, ","suffix":", lopinavir, saquinavir and nelfinavir, inhibit cytochrome P","exact":"atazanavir"},{"setid":"PMC2598705","drugname":"ritonavir","startOffset":"66","endOffset":"75","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[2]","prefix":"ear‐old man was taking abacavir, lamivudine, atazanavir and ","suffix":". His HIV physician noted raised cholesterol and wrote to th","exact":"ritonavir"},{"setid":"PMC2598705","drugname":"ritonavir","startOffset":"69","endOffset":"78","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[3]","prefix":"‐old woman was taking didanosine, efavirenz, atazanavir and ","suffix":", as well as gliclazide, doxazosin and bendrofluazide. A let","exact":"ritonavir"},{"setid":"PMC2598705","drugname":"ritonavir","startOffset":"15","endOffset":"24","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[6]","prefix":"PIs, including ","suffix":", atazanavir, lopinavir, saquinavir and nelfinavir, inhibit ","exact":"ritonavir"},{"setid":"PMC2598705","drugname":"cholesterol","startOffset":"108","endOffset":"119","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[2]","prefix":"e, atazanavir and ritonavir. His HIV physician noted raised ","suffix":" and wrote to the patient and his general practitioner (GP),","exact":"cholesterol"},{"setid":"PMC2598705","drugname":"cholesterol","startOffset":"221","endOffset":"232","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[3]","prefix":"ian to her GP listed her medications and mentioned that her ","suffix":" was 8.5. Her GP started simvastatin. The patient took the f","exact":"cholesterol"},{"setid":"PMC2598705","drugname":"atorvastatin","startOffset":"274","endOffset":"286","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[2]","prefix":"commended with his antiretroviral combination, but low dose ","suffix":" or pravastatin is safe. Simvastatin was prescribed by the G","exact":"atorvastatin"},{"setid":"PMC2598705","drugname":"atorvastatin","startOffset":"154","endOffset":"166","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[6]","prefix":" P450 (CYP) 3A4 activity, which metabolises simvastatin and ","suffix":". Simvastatin exposure is increased by up to 3000% by PIs,","exact":"atorvastatin"},{"setid":"PMC2598705","drugname":"atorvastatin","startOffset":"180","endOffset":"192","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[7]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[7]","prefix":"lism, and reduces the concentrations of active simvastatin, ","suffix":" and pravastatin by 58%, 34% and 40%, respectively.","exact":"atorvastatin"},{"setid":"PMC2598705","drugname":"pravastatin","startOffset":"290","endOffset":"301","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[2]","prefix":"is antiretroviral combination, but low dose atorvastatin or ","suffix":" is safe. Simvastatin was prescribed by the GP.","exact":"pravastatin"},{"setid":"PMC2598705","drugname":"pravastatin","startOffset":"67","endOffset":"78","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[4]","prefix":"ar‐old man was taking stavudine, lamivudine and nelfinavir. ","suffix":" was started by his HIV physician, and letters were written ","exact":"Pravastatin"},{"setid":"PMC2598705","drugname":"pravastatin","startOffset":"185","endOffset":"196","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[4]","prefix":"were written regularly to his GP about current medications. ","suffix":" was changed to simvastatin by his GP 6 years later.","exact":"Pravastatin"},{"setid":"PMC2598705","drugname":"pravastatin","startOffset":"197","endOffset":"208","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[7]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[7]","prefix":" the concentrations of active simvastatin, atorvastatin and ","suffix":" by 58%, 34% and 40%, respectively.","exact":"pravastatin"},{"setid":"PMC2598705","drugname":"didanosine","startOffset":"31","endOffset":"41","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[3]","prefix":"A 52‐year‐old woman was taking ","suffix":", efavirenz, atazanavir and ritonavir, as well as gliclazide","exact":"didanosine"},{"setid":"PMC2598705","drugname":"efavirenz","startOffset":"43","endOffset":"52","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[3]","prefix":"A 52‐year‐old woman was taking didanosine, ","suffix":", atazanavir and ritonavir, as well as gliclazide, doxazosin","exact":"efavirenz"},{"setid":"PMC2598705","drugname":"efavirenz","startOffset":"29","endOffset":"38","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[7]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[7]","prefix":"It should also be noted that ","suffix":", a non‐nucleoside reverse transcriptase inhibitor, is an in","exact":"efavirenz"},{"setid":"PMC2598705","drugname":"gliclazide","startOffset":"91","endOffset":"101","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[3]","prefix":"didanosine, efavirenz, atazanavir and ritonavir, as well as ","suffix":", doxazosin and bendrofluazide. A letter from her HIV physic","exact":"gliclazide"},{"setid":"PMC2598705","drugname":"doxazosin","startOffset":"103","endOffset":"112","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[3]","prefix":"efavirenz, atazanavir and ritonavir, as well as gliclazide, ","suffix":" and bendrofluazide. A letter from her HIV physician to her ","exact":"doxazosin"},{"setid":"PMC2598705","drugname":"bendrofluazide","startOffset":"117","endOffset":"131","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[3]","prefix":"zanavir and ritonavir, as well as gliclazide, doxazosin and ","suffix":". A letter from her HIV physician to her GP listed her medic","exact":"bendrofluazide"},{"setid":"PMC2598705","drugname":"stavudine","startOffset":"29","endOffset":"38","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[4]","prefix":"A 53‐year‐old man was taking ","suffix":", lamivudine and nelfinavir. Pravastatin was started by his ","exact":"stavudine"},{"setid":"PMC2598705","drugname":"nelfinavir","startOffset":"55","endOffset":"65","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[4]","prefix":"A 53‐year‐old man was taking stavudine, lamivudine and ","suffix":". Pravastatin was started by his HIV physician, and letters ","exact":"nelfinavir"},{"setid":"PMC2598705","drugname":"nelfinavir","startOffset":"64","endOffset":"74","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[6]","prefix":" including ritonavir, atazanavir, lopinavir, saquinavir and ","suffix":", inhibit cytochrome P450 (CYP) 3A4 activity, which metaboli","exact":"nelfinavir"},{"setid":"PMC2598705","drugname":"lopinavir","startOffset":"38","endOffset":"47","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[6]","prefix":"PIs, including ritonavir, atazanavir, ","suffix":", saquinavir and nelfinavir, inhibit cytochrome P450 (CYP) 3","exact":"lopinavir"},{"setid":"PMC2598705","drugname":"saquinavir","startOffset":"49","endOffset":"59","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/p[6]","prefix":"PIs, including ritonavir, atazanavir, lopinavir, ","suffix":" and nelfinavir, inhibit cytochrome P450 (CYP) 3A4 activity,","exact":"saquinavir"}],[{"setid":"PMC1884190","drugname":"ketoconazole","startOffset":"32","endOffset":"44","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"Following coadministration with ","suffix":", rosuvastatin geometric least square mean AUC(0,","exact":"ketoconazole"},{"setid":"PMC1884190","drugname":"ketoconazole","startOffset":"0","endOffset":"12","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","prefix":"","suffix":" did not produce any change in rosuvastatin pharmacokinetics","exact":"Ketoconazole"},{"setid":"PMC1884190","drugname":"ketoconazole","startOffset":"8","endOffset":"20","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","prefix":"CYP3A4, ","suffix":", P-glycoprotein, rosuvastatin","exact":"ketoconazole"},{"setid":"PMC1884190","drugname":"ketoconazole","startOffset":"0","endOffset":"12","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[6]","prefix":"","suffix":" is also known to inhibit the activity of transport protein ","exact":"Ketoconazole"},{"setid":"PMC1884190","drugname":"ketoconazole","startOffset":"213","endOffset":"225","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","prefix":". Volunteers were randomized to receive daily oral doses of ","suffix":" 400 mg (1 × 200-mg tablet every 12 h) or matching placebo (","exact":"ketoconazole"},{"setid":"PMC1884190","drugname":"ketoconazole","startOffset":"525","endOffset":"537","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","prefix":"mg (1 × 80-mg encapsulated tablet) with the morning dose of ","suffix":" or placebo. Volunteers then remained in the Clinical Pharma","exact":"ketoconazole"},{"setid":"PMC1884190","drugname":"ketoconazole","startOffset":"278","endOffset":"290","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[1]","prefix":"mples were taken before administration of the first dose of ","suffix":" or placebo on day 1 of the second dosing period. Blood samp","exact":"ketoconazole"},{"setid":"PMC1884190","drugname":"ketoconazole","startOffset":"90","endOffset":"102","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[1]","prefix":"en before and 2 h after administration of the first dose of ","suffix":" or placebo on days 4, 5, 6 and 7 of each dosing period. Blo","exact":"ketoconazole"},{"setid":"PMC1884190","drugname":"ketoconazole","startOffset":"18","endOffset":"30","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[1]/h1[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[1]/h1[1]","prefix":"Lack of effect of ","suffix":" on the pharmacokinetics of rosuvastatin in healthy subjects","exact":"ketoconazole"},{"setid":"PMC1884190","drugname":"ketoconazole","startOffset":"32","endOffset":"44","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"Following coadministration with ","suffix":", rosuvastatin geometric least square mean AUC(0,","exact":"ketoconazole"},{"setid":"PMC1884190","drugname":"ketoconazole","startOffset":"8","endOffset":"20","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","prefix":"CYP3A4, ","suffix":", P-glycoprotein, rosuvastatin","exact":"ketoconazole"},{"setid":"PMC1884190","drugname":"ketoconazole","startOffset":"213","endOffset":"225","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","prefix":". Volunteers were randomized to receive daily oral doses of ","suffix":" 400 mg (1 × 200-mg tablet every 12 h) or matching placebo (","exact":"ketoconazole"},{"setid":"PMC1884190","drugname":"ketoconazole","startOffset":"525","endOffset":"537","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","prefix":"mg (1 × 80-mg encapsulated tablet) with the morning dose of ","suffix":" or placebo. Volunteers then remained in the Clinical Pharma","exact":"ketoconazole"},{"setid":"PMC1884190","drugname":"ketoconazole","startOffset":"278","endOffset":"290","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[1]","prefix":"mples were taken before administration of the first dose of ","suffix":" or placebo on day 1 of the second dosing period. Blood samp","exact":"ketoconazole"},{"setid":"PMC1884190","drugname":"ketoconazole","startOffset":"90","endOffset":"102","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[1]","prefix":"en before and 2 h after administration of the first dose of ","suffix":" or placebo on days 4, 5, 6 and 7 of each dosing period. Blo","exact":"ketoconazole"},{"setid":"PMC1884190","drugname":"ketoconazole","startOffset":"122","endOffset":"134","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[8]/p[1]","prefix":"dence interval (CI) for the treatment ratio (rosuvastatin + ","suffix":"/rosuvastatin + placebo) of the geometric least square means","exact":"ketoconazole"},{"setid":"PMC1884190","drugname":"ketoconazole","startOffset":"88","endOffset":"100","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/div[1]/div[2]/span[1]","prefix":"trations of rosuvastatin over time when coadministered with ","suffix":" or placebo. ○, Rosuvastatin + ketoconazole; ▪, rosuvastatin","exact":"ketoconazole"},{"setid":"PMC1884190","drugname":"ketoconazole","startOffset":"131","endOffset":"143","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/div[1]/div[2]/span[1]","prefix":"dministered with ketoconazole or placebo. ○, Rosuvastatin + ","suffix":"; ▪, rosuvastatin + placebo.","exact":"ketoconazole"},{"setid":"PMC1884190","drugname":"ketoconazole","startOffset":"155","endOffset":"167","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/div[1]/div[2]/span[1]","prefix":"astatin over time when rosuvastatin was coadministered with ","suffix":". A similar pattern was seen when rosuvastatin was coadminis","exact":"ketoconazole"},{"setid":"PMC1884190","drugname":"ketoconazole","startOffset":"17","endOffset":"29","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[4]","prefix":"Rosuvastatin and ","suffix":" were well tolerated when coadministered. There were no seri","exact":"ketoconazole"},{"setid":"PMC1884190","drugname":"ketoconazole","startOffset":"65","endOffset":"77","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"inistration of rosuvastatin and the potent CYP3A4 inhibitor ","suffix":" did not produce any change in pharmacokinetics of the forme","exact":"ketoconazole"},{"setid":"PMC1884190","drugname":"ketoconazole","startOffset":"178","endOffset":"190","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"netics of the former. Furthermore, the results suggest that ","suffix":" had no effect on the systemic clearance of rosuvastatin, as","exact":"ketoconazole"},{"setid":"PMC1884190","drugname":"ketoconazole","startOffset":"15","endOffset":"27","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","prefix":"In conclusion, ","suffix":" did not affect the pharmacokinetics of rosuvastatin in heal","exact":"ketoconazole"},{"setid":"PMC1884190","drugname":"ketoconazole","startOffset":"132","endOffset":"144","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","prefix":"astatin in healthy subjects. Therefore, coadministration of ","suffix":" and rosuvastatin is unlikely to increase the risk of toxici","exact":"ketoconazole"},{"setid":"PMC1884190","drugname":"ketoconazole","startOffset":"303","endOffset":"315","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/div[2]/p[1]","prefix":"Sciences Inc. (Montreal, Quebec, Canada) for performing the ","suffix":" assays, Olise M. Nwose MB BS for his support of this trial,","exact":"ketoconazole"},{"setid":"PMC1884190","drugname":"ketoconazole","startOffset":"18","endOffset":"30","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[5]/div[2]/div[1]/div[1]/ul[1]/li[1]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[5]/div[2]/div[1]/div[1]/ul[1]/li[1]/a[1]","prefix":"Lack of effect of ","suffix":" on the pharmacokinetics of rosuvastatin in health...","exact":"ketoconazole"},{"setid":"PMC1884190","drugname":"ketoconazole","startOffset":"18","endOffset":"30","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[5]/div[2]/div[1]/div[1]/ul[1]/li[1]/div[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[5]/div[2]/div[1]/div[1]/ul[1]/li[1]/div[1]","prefix":"Lack of effect of ","suffix":" on the pharmacokinetics of rosuvastatin in healthy subjects","exact":"ketoconazole"},{"setid":"PMC1884190","drugname":"ketoconazole","startOffset":"88","endOffset":"100","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/div[1]/div[2]/span[1]","prefix":"trations of rosuvastatin over time when coadministered with ","suffix":" or placebo. ○, Rosuvastatin + ketoconazole; ▪, rosuvastatin","exact":"ketoconazole"},{"setid":"PMC1884190","drugname":"ketoconazole","startOffset":"88","endOffset":"100","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/div[1]/div[2]/span[1]","prefix":"trations of rosuvastatin over time when coadministered with ","suffix":" or placebo. ○, Rosuvastatin + ketoconazole; ▪, rosuvastatin","exact":"ketoconazole"},{"setid":"PMC1884190","drugname":"ketoconazole","startOffset":"131","endOffset":"143","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/div[1]/div[2]/span[1]","prefix":"dministered with ketoconazole or placebo. ○, Rosuvastatin + ","suffix":"; ▪, rosuvastatin + placebo.","exact":"ketoconazole"},{"setid":"PMC1884190","drugname":"ketoconazole","startOffset":"155","endOffset":"167","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/div[1]/div[2]/span[1]","prefix":"astatin over time when rosuvastatin was coadministered with ","suffix":". A similar pattern was seen when rosuvastatin was coadminis","exact":"ketoconazole"},{"setid":"PMC1884190","drugname":"ketoconazole","startOffset":"17","endOffset":"29","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[4]","prefix":"Rosuvastatin and ","suffix":" were well tolerated when coadministered. There were no seri","exact":"ketoconazole"},{"setid":"PMC1884190","drugname":"ketoconazole","startOffset":"65","endOffset":"77","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"inistration of rosuvastatin and the potent CYP3A4 inhibitor ","suffix":" did not produce any change in pharmacokinetics of the forme","exact":"ketoconazole"},{"setid":"PMC1884190","drugname":"ketoconazole","startOffset":"178","endOffset":"190","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"netics of the former. Furthermore, the results suggest that ","suffix":" had no effect on the systemic clearance of rosuvastatin, as","exact":"ketoconazole"},{"setid":"PMC1884190","drugname":"ketoconazole","startOffset":"151","endOffset":"163","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"ion for, or induction or inhibition of, transport proteins. ","suffix":" is known to have inhibitory effects on the transport protei","exact":"Ketoconazole"},{"setid":"PMC1884190","drugname":"ketoconazole","startOffset":"15","endOffset":"27","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","prefix":"In conclusion, ","suffix":" did not affect the pharmacokinetics of rosuvastatin in heal","exact":"ketoconazole"},{"setid":"PMC1884190","drugname":"ketoconazole","startOffset":"132","endOffset":"144","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","prefix":"astatin in healthy subjects. Therefore, coadministration of ","suffix":" and rosuvastatin is unlikely to increase the risk of toxici","exact":"ketoconazole"},{"setid":"PMC1884190","drugname":"ketoconazole","startOffset":"303","endOffset":"315","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/div[2]/p[1]","prefix":"Sciences Inc. (Montreal, Quebec, Canada) for performing the ","suffix":" assays, Olise M. Nwose MB BS for his support of this trial,","exact":"ketoconazole"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"46","endOffset":"58","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"Following coadministration with ketoconazole, ","suffix":" geometric least square mean AUC(0,","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"43","endOffset":"55","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","prefix":"Ketoconazole did not produce any change in ","suffix":" pharmacokinetics in healthy subjects. The data suggest that","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"206","endOffset":"218","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","prefix":"r P-gp-mediated transport contributes to the elimination of ","suffix":".","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"357","endOffset":"369","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","prefix":"r P-gp-mediated transport contributes to the elimination of ","suffix":".","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"38","endOffset":"50","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","prefix":"CYP3A4, ketoconazole, P-glycoprotein, ","suffix":"","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"0","endOffset":"12","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","prefix":"","suffix":" (Crestor®) is an inhibitor of 3-hydroxy-3-methylglutaryl co","exact":"Rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"0","endOffset":"12","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[4]","prefix":"","suffix":" and ketoconazole were well tolerated when coadministered. T","exact":"Rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"0","endOffset":"12","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[2]/div[2]/div[1]/ul[1]/li[4]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[2]/div[2]/div[1]/ul[1]/li[4]/a[1]","prefix":"","suffix":": a highly efficacious statin for the treatment of dyslipida","exact":"Rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"0","endOffset":"12","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[2]/div[2]/div[1]/ul[1]/li[5]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[2]/div[2]/div[1]/ul[1]/li[5]/a[1]","prefix":"","suffix":": a new HMG-CoA reductase inhibitor for the treatment of hyp","exact":"Rosuvastatin"},{"setid":"PMC1884190","drugname":"crestor","startOffset":"14","endOffset":"21","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","prefix":"Rosuvastatin (","suffix":"®) is an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A ","exact":"Crestor"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"243","endOffset":"255","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","prefix":"eatment of patients with dyslipidaemia. In clinical trials, ","suffix":" (1-80 mg) produced highly significant dose-dependent reduct","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"24","endOffset":"36","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":"The pharmacokinetics of ","suffix":" following single- and multiple-dose administration of the d","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"15","endOffset":"27","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","prefix":"Elimination of ","suffix":" is primarily via the liver. In a clinical trial [","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"50","endOffset":"62","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[2]/div[2]/div[1]/ul[1]/li[1]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[2]/div[2]/div[1]/ul[1]/li[1]/a[1]","prefix":"Effect of itraconazole on the pharmacokinetics of ","suffix":".","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"53","endOffset":"65","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[2]/div[2]/div[1]/ul[1]/li[2]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[2]/div[2]/div[1]/ul[1]/li[2]/a[1]","prefix":"The effect of fluconazole on the pharmacokinetics of ","suffix":".","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"54","endOffset":"66","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[2]/div[2]/div[1]/ul[1]/li[3]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[2]/div[2]/div[1]/ul[1]/li[3]/a[1]","prefix":"The effect of erythromycin on the pharmacokinetics of ","suffix":".","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"58","endOffset":"70","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[1]/h1[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[1]/h1[1]","prefix":"Lack of effect of ketoconazole on the pharmacokinetics of ","suffix":" in healthy subjects","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"46","endOffset":"58","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"Following coadministration with ketoconazole, ","suffix":" geometric least square mean AUC(0,","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"43","endOffset":"55","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","prefix":"Ketoconazole did not produce any change in ","suffix":" pharmacokinetics in healthy subjects. The data suggest that","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"38","endOffset":"50","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","prefix":"CYP3A4, ketoconazole, P-glycoprotein, ","suffix":"","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"243","endOffset":"255","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","prefix":"eatment of patients with dyslipidaemia. In clinical trials, ","suffix":" (1-80 mg) produced highly significant dose-dependent reduct","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"24","endOffset":"36","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":"The pharmacokinetics of ","suffix":" following single- and multiple-dose administration of the d","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"15","endOffset":"27","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","prefix":"Elimination of ","suffix":" is primarily via the liver. In a clinical trial [","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"337","endOffset":"349","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[2]","prefix":"uring the washout period following the first dosing period (","suffix":" + placebo)]. This withdrawal was considered unlikely to hav","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"449","endOffset":"461","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","prefix":" dosing period, volunteers were given a single oral dose of ","suffix":" 80 mg (1 × 80-mg encapsulated tablet) with the morning dose","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"194","endOffset":"206","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[2]","prefix":" the first dose on day 1 until 96 h after administration of ","suffix":" in each dosing period), the consumption of caffeine-contain","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"372","endOffset":"384","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[2]","prefix":"om midnight before day 1 until 96 h after administration of ","suffix":" in each dosing period), and concomitant medications (none p","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"25","endOffset":"37","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[1]","prefix":"Blood samples (9 ml) for ","suffix":" assay were taken before administration of rosuvastatin on d","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"80","endOffset":"92","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[1]","prefix":" for rosuvastatin assay were taken before administration of ","suffix":" on day 4 of each dosing period and 0.5, 1, 2, 3, 4, 5, 6, 8","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"28","endOffset":"40","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[2]","prefix":"The blood samples taken for ","suffix":" assay were also used to obtain plasma for active and total ","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"107","endOffset":"119","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[8]/p[1]","prefix":"t the 90% confidence interval (CI) for the treatment ratio (","suffix":" + ketoconazole/rosuvastatin + placebo) of the geometric lea","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"135","endOffset":"147","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[8]/p[1]","prefix":"l (CI) for the treatment ratio (rosuvastatin + ketoconazole/","suffix":" + placebo) of the geometric least square means (gls","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"40","endOffset":"52","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/div[1]/div[2]/span[1]","prefix":"Geometric mean plasma concentrations of ","suffix":" over time when coadministered with ketoconazole or placebo.","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"148","endOffset":"160","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/div[1]/div[2]/span[1]","prefix":"ketoconazole or placebo. ○, Rosuvastatin + ketoconazole; ▪, ","suffix":" + placebo.","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"38","endOffset":"50","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/div[2]/span[1]","prefix":"Summary pharmacokinetic parameters of ","suffix":", and results of the statistical analysis of the plasma AUC(","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"94","endOffset":"106","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[2]","prefix":"ma concentration-time curves measured to a common point for ","suffix":" and active and total HMG-CoA reductase inhibitors indicated","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"230","endOffset":"242","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[2]","prefix":"t, within the accuracy and precision s of the methods used, ","suffix":" accounted for essentially all of the circulating active inh","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"90","endOffset":"102","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/div[1]/div[2]/span[1]","prefix":"ations of active and total HMG-CoA reductase inhibitors and ","suffix":" over time when rosuvastatin was coadministered with ketocon","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"118","endOffset":"130","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/div[1]/div[2]/span[1]","prefix":"MG-CoA reductase inhibitors and rosuvastatin over time when ","suffix":" was coadministered with ketoconazole. A similar pattern was","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"201","endOffset":"213","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/div[1]/div[2]/span[1]","prefix":"nistered with ketoconazole. A similar pattern was seen when ","suffix":" was coadministered with placebo. ○,","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"20","endOffset":"32","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"Coadministration of ","suffix":" and the potent CYP3A4 inhibitor ketoconazole did not produc","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"234","endOffset":"246","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"hat ketoconazole had no effect on the systemic clearance of ","suffix":", as individual plasma concentration profiles, including the","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"15","endOffset":"27","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"In contrast to ","suffix":", atorvastatin [","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"118","endOffset":"130","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"oncentrations were measured in this trial. The finding that ","suffix":" accounted for essentially all of the circulating active inh","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"327","endOffset":"339","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"e(s). The finding that the active inhibitors, and therefore ","suffix":", constituted the majority of the total inhibitors indicates","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"643","endOffset":"655","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":" support for previous data indicating limited metabolism of ","suffix":" [","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"67","endOffset":"79","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","prefix":"lusion, ketoconazole did not affect the pharmacokinetics of ","suffix":" in healthy subjects. Therefore, coadministration of ketocon","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"149","endOffset":"161","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","prefix":"y subjects. Therefore, coadministration of ketoconazole and ","suffix":" is unlikely to increase the risk of toxicity at therapeutic","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"231","endOffset":"243","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","prefix":"ly to increase the risk of toxicity at therapeutic doses of ","suffix":". The data suggest that neither cytochrome P450 3A4 nor P-gp","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"76","endOffset":"88","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/div[2]/p[1]","prefix":"k Quintiles Scotland Ltd (Edinburgh, UK) for performing the ","suffix":" assays, Medical Research Laboratories (Highland Heights, Ke","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"59","endOffset":"71","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[9]/div[2]/div[1]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[9]/div[2]/div[1]/span[1]","prefix":"Olsson AG, Pears J, McKellar J, Mizan J, Raza A. Effect of ","suffix":" on low-density lipoprotein cholesterol in patients with hyp","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"108","endOffset":"120","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[9]/div[2]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[9]/div[2]/div[2]/span[1]","prefix":"k MJ. No effect of age or gender on the pharmacokinetics of ","suffix":"—a new HMG-CoA reductase inhibitor. ","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"59","endOffset":"71","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[9]/div[2]/div[19]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[9]/div[2]/div[19]/span[1]","prefix":"Hull CK, Penman AD, Smith CK, Martin PD. Quantification of ","suffix":" in human plasma by automated solid-phase extraction using t","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"65","endOffset":"77","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[9]/div[2]/div[21]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[9]/div[2]/div[21]/span[1]","prefix":"n PD, Kemp J, Dane AL, Warwick MJ, Schneck DW. No effect of ","suffix":" on the pharmacokinetics of digoxin in healthy volunteers l.","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"37","endOffset":"49","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[3]/div[2]/div[1]/ul[1]/li[2]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[3]/div[2]/div[1]/ul[1]/li[2]/a[1]","prefix":"More potent lipid lowering effect by ","suffix":" compared to fluvastatin in everolimus treated renal transpl","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"51","endOffset":"63","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[3]/div[2]/div[1]/ul[1]/li[3]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[3]/div[2]/div[1]/ul[1]/li[3]/a[1]","prefix":"Pharmacokinetics and tolerability of multiple-dose ","suffix":": An open-label, randomized-sequence, three-way crossover tr","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"55","endOffset":"67","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[3]/div[2]/div[1]/ul[1]/li[5]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[3]/div[2]/div[1]/ul[1]/li[5]/a[1]","prefix":"Generation of polyclonal antibody with high avidity to ","suffix":" and its use in development of highly sensitive ELISA for de","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"142","endOffset":"154","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[3]/div[2]/div[1]/ul[1]/li[5]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[3]/div[2]/div[1]/ul[1]/li[5]/a[1]","prefix":" development of highly sensitive ELISA for determination of ","suffix":" in plasma","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"58","endOffset":"70","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[5]/div[2]/div[1]/div[1]/ul[1]/li[1]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[5]/div[2]/div[1]/div[1]/ul[1]/li[1]/a[1]","prefix":"Lack of effect of ketoconazole on the pharmacokinetics of ","suffix":" in health...","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"58","endOffset":"70","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[5]/div[2]/div[1]/div[1]/ul[1]/li[1]/div[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[5]/div[2]/div[1]/div[1]/ul[1]/li[1]/div[1]","prefix":"Lack of effect of ketoconazole on the pharmacokinetics of ","suffix":" in healthy subjects","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"83","endOffset":"95","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[5]/div[2]/div[1]/div[1]/ul[1]/li[3]/div[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[5]/div[2]/div[1]/div[1]/ul[1]/li[3]/div[1]","prefix":" and pharmacokinetics of a new HMG-CoA reductase inhibitor, ","suffix":", after morning or evening administration in healthy volunte","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"10","endOffset":"22","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[1]/div[2]/ul[1]/li[1]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[1]/div[2]/ul[1]/li[1]/a[1]","prefix":"Effect of ","suffix":" on low-density lipoprotein cholesterol in patients with hyp","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"54","endOffset":"66","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[2]/div[2]/ul[1]/li[1]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[2]/div[2]/ul[1]/li[1]/a[1]","prefix":"No effect of age or gender on the pharmacokinetics of ","suffix":": a new HMG-CoA reductase inhibitor.","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"18","endOffset":"30","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[6]/div[2]/ul[1]/li[1]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[6]/div[2]/ul[1]/li[1]/a[1]","prefix":"Quantification of ","suffix":" in human plasma by automated solid-phase extraction using t","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"13","endOffset":"25","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[10]/div[2]/ul[1]/li[2]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[10]/div[2]/ul[1]/li[2]/a[1]","prefix":"No effect of ","suffix":" on the pharmacokinetics of digoxin in healthy volunteers.","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"10","endOffset":"22","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[1]","prefix":"Effect of ","suffix":" on low-density lipoprotein cholesterol in patients with hyp","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"54","endOffset":"66","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[2]","prefix":"No effect of age or gender on the pharmacokinetics of ","suffix":": a new HMG-CoA reductase inhibitor.","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"18","endOffset":"30","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[18]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[18]","prefix":"Quantification of ","suffix":" in human plasma by automated solid-phase extraction using t","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"13","endOffset":"25","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[20]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[20]","prefix":"No effect of ","suffix":" on the pharmacokinetics of digoxin in healthy volunteers.","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"449","endOffset":"461","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","prefix":" dosing period, volunteers were given a single oral dose of ","suffix":" 80 mg (1 × 80-mg encapsulated tablet) with the morning dose","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"194","endOffset":"206","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[2]","prefix":" the first dose on day 1 until 96 h after administration of ","suffix":" in each dosing period), the consumption of caffeine-contain","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"372","endOffset":"384","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[2]","prefix":"om midnight before day 1 until 96 h after administration of ","suffix":" in each dosing period), and concomitant medications (none p","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"25","endOffset":"37","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[1]","prefix":"Blood samples (9 ml) for ","suffix":" assay were taken before administration of rosuvastatin on d","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"80","endOffset":"92","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[1]","prefix":" for rosuvastatin assay were taken before administration of ","suffix":" on day 4 of each dosing period and 0.5, 1, 2, 3, 4, 5, 6, 8","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"206","endOffset":"218","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","prefix":"r P-gp-mediated transport contributes to the elimination of ","suffix":".","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"357","endOffset":"369","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","prefix":"r P-gp-mediated transport contributes to the elimination of ","suffix":".","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"50","endOffset":"62","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[2]/div[2]/div[1]/ul[1]/li[1]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[2]/div[2]/div[1]/ul[1]/li[1]/a[1]","prefix":"Effect of itraconazole on the pharmacokinetics of ","suffix":".","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"53","endOffset":"65","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[2]/div[2]/div[1]/ul[1]/li[2]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[2]/div[2]/div[1]/ul[1]/li[2]/a[1]","prefix":"The effect of fluconazole on the pharmacokinetics of ","suffix":".","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"54","endOffset":"66","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[2]/div[2]/div[1]/ul[1]/li[3]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[2]/div[2]/div[1]/ul[1]/li[3]/a[1]","prefix":"The effect of erythromycin on the pharmacokinetics of ","suffix":".","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"28","endOffset":"40","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[2]","prefix":"The blood samples taken for ","suffix":" assay were also used to obtain plasma for active and total ","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"206","endOffset":"218","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","prefix":"r P-gp-mediated transport contributes to the elimination of ","suffix":".","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"357","endOffset":"369","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","prefix":"r P-gp-mediated transport contributes to the elimination of ","suffix":".","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"50","endOffset":"62","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[2]/div[2]/div[1]/ul[1]/li[1]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[2]/div[2]/div[1]/ul[1]/li[1]/a[1]","prefix":"Effect of itraconazole on the pharmacokinetics of ","suffix":".","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"53","endOffset":"65","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[2]/div[2]/div[1]/ul[1]/li[2]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[2]/div[2]/div[1]/ul[1]/li[2]/a[1]","prefix":"The effect of fluconazole on the pharmacokinetics of ","suffix":".","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"54","endOffset":"66","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[2]/div[2]/div[1]/ul[1]/li[3]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[2]/div[2]/div[1]/ul[1]/li[3]/a[1]","prefix":"The effect of erythromycin on the pharmacokinetics of ","suffix":".","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"58","endOffset":"70","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[1]/h1[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[1]/h1[1]","prefix":"Lack of effect of ketoconazole on the pharmacokinetics of ","suffix":" in healthy subjects","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"46","endOffset":"58","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"Following coadministration with ketoconazole, ","suffix":" geometric least square mean AUC(0,","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"43","endOffset":"55","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","prefix":"Ketoconazole did not produce any change in ","suffix":" pharmacokinetics in healthy subjects. The data suggest that","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"38","endOffset":"50","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","prefix":"CYP3A4, ketoconazole, P-glycoprotein, ","suffix":"","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"243","endOffset":"255","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","prefix":"eatment of patients with dyslipidaemia. In clinical trials, ","suffix":" (1-80 mg) produced highly significant dose-dependent reduct","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"24","endOffset":"36","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":"The pharmacokinetics of ","suffix":" following single- and multiple-dose administration of the d","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"15","endOffset":"27","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","prefix":"Elimination of ","suffix":" is primarily via the liver. In a clinical trial [","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"337","endOffset":"349","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[2]","prefix":"uring the washout period following the first dosing period (","suffix":" + placebo)]. This withdrawal was considered unlikely to hav","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"449","endOffset":"461","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","prefix":" dosing period, volunteers were given a single oral dose of ","suffix":" 80 mg (1 × 80-mg encapsulated tablet) with the morning dose","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"194","endOffset":"206","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[2]","prefix":" the first dose on day 1 until 96 h after administration of ","suffix":" in each dosing period), the consumption of caffeine-contain","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"372","endOffset":"384","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[2]","prefix":"om midnight before day 1 until 96 h after administration of ","suffix":" in each dosing period), and concomitant medications (none p","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"25","endOffset":"37","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[1]","prefix":"Blood samples (9 ml) for ","suffix":" assay were taken before administration of rosuvastatin on d","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"80","endOffset":"92","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[1]","prefix":" for rosuvastatin assay were taken before administration of ","suffix":" on day 4 of each dosing period and 0.5, 1, 2, 3, 4, 5, 6, 8","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"28","endOffset":"40","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[2]","prefix":"The blood samples taken for ","suffix":" assay were also used to obtain plasma for active and total ","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"107","endOffset":"119","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[8]/p[1]","prefix":"t the 90% confidence interval (CI) for the treatment ratio (","suffix":" + ketoconazole/rosuvastatin + placebo) of the geometric lea","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"135","endOffset":"147","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[8]/p[1]","prefix":"l (CI) for the treatment ratio (rosuvastatin + ketoconazole/","suffix":" + placebo) of the geometric least square means (gls","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"40","endOffset":"52","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/div[1]/div[2]/span[1]","prefix":"Geometric mean plasma concentrations of ","suffix":" over time when coadministered with ketoconazole or placebo.","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"148","endOffset":"160","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/div[1]/div[2]/span[1]","prefix":"ketoconazole or placebo. ○, Rosuvastatin + ketoconazole; ▪, ","suffix":" + placebo.","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"38","endOffset":"50","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/div[2]/span[1]","prefix":"Summary pharmacokinetic parameters of ","suffix":", and results of the statistical analysis of the plasma AUC(","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"94","endOffset":"106","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[2]","prefix":"ma concentration-time curves measured to a common point for ","suffix":" and active and total HMG-CoA reductase inhibitors indicated","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"230","endOffset":"242","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[2]","prefix":"t, within the accuracy and precision s of the methods used, ","suffix":" accounted for essentially all of the circulating active inh","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"90","endOffset":"102","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/div[1]/div[2]/span[1]","prefix":"ations of active and total HMG-CoA reductase inhibitors and ","suffix":" over time when rosuvastatin was coadministered with ketocon","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"118","endOffset":"130","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/div[1]/div[2]/span[1]","prefix":"MG-CoA reductase inhibitors and rosuvastatin over time when ","suffix":" was coadministered with ketoconazole. A similar pattern was","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"201","endOffset":"213","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/div[1]/div[2]/span[1]","prefix":"nistered with ketoconazole. A similar pattern was seen when ","suffix":" was coadministered with placebo. ○,","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"20","endOffset":"32","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"Coadministration of ","suffix":" and the potent CYP3A4 inhibitor ketoconazole did not produc","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"234","endOffset":"246","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"hat ketoconazole had no effect on the systemic clearance of ","suffix":", as individual plasma concentration profiles, including the","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"15","endOffset":"27","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"In contrast to ","suffix":", atorvastatin [","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"118","endOffset":"130","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"oncentrations were measured in this trial. The finding that ","suffix":" accounted for essentially all of the circulating active inh","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"327","endOffset":"339","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"e(s). The finding that the active inhibitors, and therefore ","suffix":", constituted the majority of the total inhibitors indicates","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"643","endOffset":"655","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":" support for previous data indicating limited metabolism of ","suffix":" [","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"67","endOffset":"79","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","prefix":"lusion, ketoconazole did not affect the pharmacokinetics of ","suffix":" in healthy subjects. Therefore, coadministration of ketocon","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"149","endOffset":"161","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","prefix":"y subjects. Therefore, coadministration of ketoconazole and ","suffix":" is unlikely to increase the risk of toxicity at therapeutic","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"231","endOffset":"243","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","prefix":"ly to increase the risk of toxicity at therapeutic doses of ","suffix":". The data suggest that neither cytochrome P450 3A4 nor P-gp","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"76","endOffset":"88","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/div[2]/p[1]","prefix":"k Quintiles Scotland Ltd (Edinburgh, UK) for performing the ","suffix":" assays, Medical Research Laboratories (Highland Heights, Ke","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"59","endOffset":"71","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[9]/div[2]/div[1]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[9]/div[2]/div[1]/span[1]","prefix":"Olsson AG, Pears J, McKellar J, Mizan J, Raza A. Effect of ","suffix":" on low-density lipoprotein cholesterol in patients with hyp","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"108","endOffset":"120","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[9]/div[2]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[9]/div[2]/div[2]/span[1]","prefix":"k MJ. No effect of age or gender on the pharmacokinetics of ","suffix":"—a new HMG-CoA reductase inhibitor. ","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"59","endOffset":"71","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[9]/div[2]/div[19]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[9]/div[2]/div[19]/span[1]","prefix":"Hull CK, Penman AD, Smith CK, Martin PD. Quantification of ","suffix":" in human plasma by automated solid-phase extraction using t","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"65","endOffset":"77","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[9]/div[2]/div[21]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[9]/div[2]/div[21]/span[1]","prefix":"n PD, Kemp J, Dane AL, Warwick MJ, Schneck DW. No effect of ","suffix":" on the pharmacokinetics of digoxin in healthy volunteers l.","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"37","endOffset":"49","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[3]/div[2]/div[1]/ul[1]/li[2]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[3]/div[2]/div[1]/ul[1]/li[2]/a[1]","prefix":"More potent lipid lowering effect by ","suffix":" compared to fluvastatin in everolimus treated renal transpl","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"51","endOffset":"63","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[3]/div[2]/div[1]/ul[1]/li[3]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[3]/div[2]/div[1]/ul[1]/li[3]/a[1]","prefix":"Pharmacokinetics and tolerability of multiple-dose ","suffix":": An open-label, randomized-sequence, three-way crossover tr","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"55","endOffset":"67","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[3]/div[2]/div[1]/ul[1]/li[5]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[3]/div[2]/div[1]/ul[1]/li[5]/a[1]","prefix":"Generation of polyclonal antibody with high avidity to ","suffix":" and its use in development of highly sensitive ELISA for de","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"142","endOffset":"154","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[3]/div[2]/div[1]/ul[1]/li[5]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[3]/div[2]/div[1]/ul[1]/li[5]/a[1]","prefix":" development of highly sensitive ELISA for determination of ","suffix":" in plasma","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"58","endOffset":"70","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[5]/div[2]/div[1]/div[1]/ul[1]/li[1]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[5]/div[2]/div[1]/div[1]/ul[1]/li[1]/a[1]","prefix":"Lack of effect of ketoconazole on the pharmacokinetics of ","suffix":" in health...","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"58","endOffset":"70","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[5]/div[2]/div[1]/div[1]/ul[1]/li[1]/div[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[5]/div[2]/div[1]/div[1]/ul[1]/li[1]/div[1]","prefix":"Lack of effect of ketoconazole on the pharmacokinetics of ","suffix":" in healthy subjects","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"83","endOffset":"95","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[5]/div[2]/div[1]/div[1]/ul[1]/li[3]/div[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[5]/div[2]/div[1]/div[1]/ul[1]/li[3]/div[1]","prefix":" and pharmacokinetics of a new HMG-CoA reductase inhibitor, ","suffix":", after morning or evening administration in healthy volunte","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"10","endOffset":"22","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[1]/div[2]/ul[1]/li[1]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[1]/div[2]/ul[1]/li[1]/a[1]","prefix":"Effect of ","suffix":" on low-density lipoprotein cholesterol in patients with hyp","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"54","endOffset":"66","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[2]/div[2]/ul[1]/li[1]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[2]/div[2]/ul[1]/li[1]/a[1]","prefix":"No effect of age or gender on the pharmacokinetics of ","suffix":": a new HMG-CoA reductase inhibitor.","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"18","endOffset":"30","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[6]/div[2]/ul[1]/li[1]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[6]/div[2]/ul[1]/li[1]/a[1]","prefix":"Quantification of ","suffix":" in human plasma by automated solid-phase extraction using t","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"13","endOffset":"25","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[10]/div[2]/ul[1]/li[2]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[10]/div[2]/ul[1]/li[2]/a[1]","prefix":"No effect of ","suffix":" on the pharmacokinetics of digoxin in healthy volunteers.","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"10","endOffset":"22","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[1]","prefix":"Effect of ","suffix":" on low-density lipoprotein cholesterol in patients with hyp","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"54","endOffset":"66","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[2]","prefix":"No effect of age or gender on the pharmacokinetics of ","suffix":": a new HMG-CoA reductase inhibitor.","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"18","endOffset":"30","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[18]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[18]","prefix":"Quantification of ","suffix":" in human plasma by automated solid-phase extraction using t","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"13","endOffset":"25","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[20]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[20]","prefix":"No effect of ","suffix":" on the pharmacokinetics of digoxin in healthy volunteers.","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"58","endOffset":"70","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[1]/h1[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[1]/h1[1]","prefix":"Lack of effect of ketoconazole on the pharmacokinetics of ","suffix":" in healthy subjects","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"46","endOffset":"58","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"Following coadministration with ketoconazole, ","suffix":" geometric least square mean AUC(0,","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"43","endOffset":"55","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","prefix":"Ketoconazole did not produce any change in ","suffix":" pharmacokinetics in healthy subjects. The data suggest that","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"38","endOffset":"50","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","prefix":"CYP3A4, ketoconazole, P-glycoprotein, ","suffix":"","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"243","endOffset":"255","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","prefix":"eatment of patients with dyslipidaemia. In clinical trials, ","suffix":" (1-80 mg) produced highly significant dose-dependent reduct","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"24","endOffset":"36","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":"The pharmacokinetics of ","suffix":" following single- and multiple-dose administration of the d","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"15","endOffset":"27","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","prefix":"Elimination of ","suffix":" is primarily via the liver. In a clinical trial [","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"337","endOffset":"349","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[2]","prefix":"uring the washout period following the first dosing period (","suffix":" + placebo)]. This withdrawal was considered unlikely to hav","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"449","endOffset":"461","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","prefix":" dosing period, volunteers were given a single oral dose of ","suffix":" 80 mg (1 × 80-mg encapsulated tablet) with the morning dose","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"194","endOffset":"206","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[2]","prefix":" the first dose on day 1 until 96 h after administration of ","suffix":" in each dosing period), the consumption of caffeine-contain","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"372","endOffset":"384","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[2]","prefix":"om midnight before day 1 until 96 h after administration of ","suffix":" in each dosing period), and concomitant medications (none p","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"25","endOffset":"37","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[1]","prefix":"Blood samples (9 ml) for ","suffix":" assay were taken before administration of rosuvastatin on d","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"80","endOffset":"92","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[1]","prefix":" for rosuvastatin assay were taken before administration of ","suffix":" on day 4 of each dosing period and 0.5, 1, 2, 3, 4, 5, 6, 8","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"28","endOffset":"40","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[2]","prefix":"The blood samples taken for ","suffix":" assay were also used to obtain plasma for active and total ","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"107","endOffset":"119","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[8]/p[1]","prefix":"t the 90% confidence interval (CI) for the treatment ratio (","suffix":" + ketoconazole/rosuvastatin + placebo) of the geometric lea","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"135","endOffset":"147","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[8]/p[1]","prefix":"l (CI) for the treatment ratio (rosuvastatin + ketoconazole/","suffix":" + placebo) of the geometric least square means (gls","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"40","endOffset":"52","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/div[1]/div[2]/span[1]","prefix":"Geometric mean plasma concentrations of ","suffix":" over time when coadministered with ketoconazole or placebo.","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"148","endOffset":"160","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/div[1]/div[2]/span[1]","prefix":"ketoconazole or placebo. ○, Rosuvastatin + ketoconazole; ▪, ","suffix":" + placebo.","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"38","endOffset":"50","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/div[2]/span[1]","prefix":"Summary pharmacokinetic parameters of ","suffix":", and results of the statistical analysis of the plasma AUC(","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"94","endOffset":"106","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[2]","prefix":"ma concentration-time curves measured to a common point for ","suffix":" and active and total HMG-CoA reductase inhibitors indicated","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"230","endOffset":"242","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[2]","prefix":"t, within the accuracy and precision s of the methods used, ","suffix":" accounted for essentially all of the circulating active inh","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"90","endOffset":"102","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/div[1]/div[2]/span[1]","prefix":"ations of active and total HMG-CoA reductase inhibitors and ","suffix":" over time when rosuvastatin was coadministered with ketocon","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"118","endOffset":"130","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/div[1]/div[2]/span[1]","prefix":"MG-CoA reductase inhibitors and rosuvastatin over time when ","suffix":" was coadministered with ketoconazole. A similar pattern was","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"201","endOffset":"213","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/div[1]/div[2]/span[1]","prefix":"nistered with ketoconazole. A similar pattern was seen when ","suffix":" was coadministered with placebo. ○,","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"20","endOffset":"32","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"Coadministration of ","suffix":" and the potent CYP3A4 inhibitor ketoconazole did not produc","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"234","endOffset":"246","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"hat ketoconazole had no effect on the systemic clearance of ","suffix":", as individual plasma concentration profiles, including the","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"15","endOffset":"27","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"In contrast to ","suffix":", atorvastatin [","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"118","endOffset":"130","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"oncentrations were measured in this trial. The finding that ","suffix":" accounted for essentially all of the circulating active inh","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"327","endOffset":"339","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"e(s). The finding that the active inhibitors, and therefore ","suffix":", constituted the majority of the total inhibitors indicates","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"643","endOffset":"655","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":" support for previous data indicating limited metabolism of ","suffix":" [","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"67","endOffset":"79","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","prefix":"lusion, ketoconazole did not affect the pharmacokinetics of ","suffix":" in healthy subjects. Therefore, coadministration of ketocon","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"149","endOffset":"161","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","prefix":"y subjects. Therefore, coadministration of ketoconazole and ","suffix":" is unlikely to increase the risk of toxicity at therapeutic","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"231","endOffset":"243","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","prefix":"ly to increase the risk of toxicity at therapeutic doses of ","suffix":". The data suggest that neither cytochrome P450 3A4 nor P-gp","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"76","endOffset":"88","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/div[2]/p[1]","prefix":"k Quintiles Scotland Ltd (Edinburgh, UK) for performing the ","suffix":" assays, Medical Research Laboratories (Highland Heights, Ke","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"59","endOffset":"71","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[9]/div[2]/div[1]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[9]/div[2]/div[1]/span[1]","prefix":"Olsson AG, Pears J, McKellar J, Mizan J, Raza A. Effect of ","suffix":" on low-density lipoprotein cholesterol in patients with hyp","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"108","endOffset":"120","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[9]/div[2]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[9]/div[2]/div[2]/span[1]","prefix":"k MJ. No effect of age or gender on the pharmacokinetics of ","suffix":"—a new HMG-CoA reductase inhibitor. ","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"59","endOffset":"71","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[9]/div[2]/div[19]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[9]/div[2]/div[19]/span[1]","prefix":"Hull CK, Penman AD, Smith CK, Martin PD. Quantification of ","suffix":" in human plasma by automated solid-phase extraction using t","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"65","endOffset":"77","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[9]/div[2]/div[21]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[9]/div[2]/div[21]/span[1]","prefix":"n PD, Kemp J, Dane AL, Warwick MJ, Schneck DW. No effect of ","suffix":" on the pharmacokinetics of digoxin in healthy volunteers l.","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"37","endOffset":"49","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[3]/div[2]/div[1]/ul[1]/li[2]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[3]/div[2]/div[1]/ul[1]/li[2]/a[1]","prefix":"More potent lipid lowering effect by ","suffix":" compared to fluvastatin in everolimus treated renal transpl","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"51","endOffset":"63","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[3]/div[2]/div[1]/ul[1]/li[3]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[3]/div[2]/div[1]/ul[1]/li[3]/a[1]","prefix":"Pharmacokinetics and tolerability of multiple-dose ","suffix":": An open-label, randomized-sequence, three-way crossover tr","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"55","endOffset":"67","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[3]/div[2]/div[1]/ul[1]/li[5]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[3]/div[2]/div[1]/ul[1]/li[5]/a[1]","prefix":"Generation of polyclonal antibody with high avidity to ","suffix":" and its use in development of highly sensitive ELISA for de","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"142","endOffset":"154","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[3]/div[2]/div[1]/ul[1]/li[5]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[3]/div[2]/div[1]/ul[1]/li[5]/a[1]","prefix":" development of highly sensitive ELISA for determination of ","suffix":" in plasma","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"58","endOffset":"70","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[5]/div[2]/div[1]/div[1]/ul[1]/li[1]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[5]/div[2]/div[1]/div[1]/ul[1]/li[1]/a[1]","prefix":"Lack of effect of ketoconazole on the pharmacokinetics of ","suffix":" in health...","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"58","endOffset":"70","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[5]/div[2]/div[1]/div[1]/ul[1]/li[1]/div[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[5]/div[2]/div[1]/div[1]/ul[1]/li[1]/div[1]","prefix":"Lack of effect of ketoconazole on the pharmacokinetics of ","suffix":" in healthy subjects","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"83","endOffset":"95","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[5]/div[2]/div[1]/div[1]/ul[1]/li[3]/div[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[5]/div[2]/div[1]/div[1]/ul[1]/li[3]/div[1]","prefix":" and pharmacokinetics of a new HMG-CoA reductase inhibitor, ","suffix":", after morning or evening administration in healthy volunte","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"10","endOffset":"22","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[1]/div[2]/ul[1]/li[1]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[1]/div[2]/ul[1]/li[1]/a[1]","prefix":"Effect of ","suffix":" on low-density lipoprotein cholesterol in patients with hyp","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"54","endOffset":"66","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[2]/div[2]/ul[1]/li[1]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[2]/div[2]/ul[1]/li[1]/a[1]","prefix":"No effect of age or gender on the pharmacokinetics of ","suffix":": a new HMG-CoA reductase inhibitor.","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"18","endOffset":"30","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[6]/div[2]/ul[1]/li[1]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[6]/div[2]/ul[1]/li[1]/a[1]","prefix":"Quantification of ","suffix":" in human plasma by automated solid-phase extraction using t","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"13","endOffset":"25","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[10]/div[2]/ul[1]/li[2]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[10]/div[2]/ul[1]/li[2]/a[1]","prefix":"No effect of ","suffix":" on the pharmacokinetics of digoxin in healthy volunteers.","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"10","endOffset":"22","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[1]","prefix":"Effect of ","suffix":" on low-density lipoprotein cholesterol in patients with hyp","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"54","endOffset":"66","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[2]","prefix":"No effect of age or gender on the pharmacokinetics of ","suffix":": a new HMG-CoA reductase inhibitor.","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"18","endOffset":"30","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[18]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[18]","prefix":"Quantification of ","suffix":" in human plasma by automated solid-phase extraction using t","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"13","endOffset":"25","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[20]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[20]","prefix":"No effect of ","suffix":" on the pharmacokinetics of digoxin in healthy volunteers.","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"643","endOffset":"655","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":" support for previous data indicating limited metabolism of ","suffix":" [","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"40","endOffset":"52","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/div[1]/div[2]/span[1]","prefix":"Geometric mean plasma concentrations of ","suffix":" over time when coadministered with ketoconazole or placebo.","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"0","endOffset":"12","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","prefix":"","suffix":" (Crestor®) is an inhibitor of 3-hydroxy-3-methylglutaryl co","exact":"Rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"116","endOffset":"128","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/div[1]/div[2]/span[1]","prefix":"r time when coadministered with ketoconazole or placebo. ○, ","suffix":" + ketoconazole; ▪, rosuvastatin + placebo.","exact":"Rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"0","endOffset":"12","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[4]","prefix":"","suffix":" and ketoconazole were well tolerated when coadministered. T","exact":"Rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"45","endOffset":"57","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[9]/div[2]/div[18]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[9]/div[2]/div[18]/span[1]","prefix":"Brown CDA, Windass A, Bleasby K, Lauffart B. ","suffix":" is a high affinity substrate of hepatic organic anion trans","exact":"Rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"0","endOffset":"12","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[2]/div[2]/div[1]/ul[1]/li[4]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[2]/div[2]/div[1]/ul[1]/li[4]/a[1]","prefix":"","suffix":": a highly efficacious statin for the treatment of dyslipida","exact":"Rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"0","endOffset":"12","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[2]/div[2]/div[1]/ul[1]/li[5]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[2]/div[2]/div[1]/ul[1]/li[5]/a[1]","prefix":"","suffix":": a new HMG-CoA reductase inhibitor for the treatment of hyp","exact":"Rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"33","endOffset":"45","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[3]/div[2]/div[1]/ul[1]/li[1]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[3]/div[2]/div[1]/ul[1]/li[1]/a[1]","prefix":"Optical Isomers of Atorvastatin, ","suffix":" and Fluvastatin Enantiospecifically Activate Pregnane X Rec","exact":"Rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"45","endOffset":"57","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[17]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[17]/span[1]","prefix":"Brown CDA, Windass A, Bleasby K, Lauffart B. ","suffix":" is a high affinity substrate of hepatic organic anion trans","exact":"Rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"46","endOffset":"58","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"Following coadministration with ketoconazole, ","suffix":" geometric least square mean AUC(0,","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"38","endOffset":"50","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","prefix":"CYP3A4, ketoconazole, P-glycoprotein, ","suffix":"","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"243","endOffset":"255","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","prefix":"eatment of patients with dyslipidaemia. In clinical trials, ","suffix":" (1-80 mg) produced highly significant dose-dependent reduct","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"449","endOffset":"461","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","prefix":" dosing period, volunteers were given a single oral dose of ","suffix":" 80 mg (1 × 80-mg encapsulated tablet) with the morning dose","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"148","endOffset":"160","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/div[1]/div[2]/span[1]","prefix":"ketoconazole or placebo. ○, Rosuvastatin + ketoconazole; ▪, ","suffix":" + placebo.","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"230","endOffset":"242","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[2]","prefix":"t, within the accuracy and precision s of the methods used, ","suffix":" accounted for essentially all of the circulating active inh","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"327","endOffset":"339","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"e(s). The finding that the active inhibitors, and therefore ","suffix":", constituted the majority of the total inhibitors indicates","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"67","endOffset":"79","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","prefix":"lusion, ketoconazole did not affect the pharmacokinetics of ","suffix":" in healthy subjects. Therefore, coadministration of ketocon","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"149","endOffset":"161","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","prefix":"y subjects. Therefore, coadministration of ketoconazole and ","suffix":" is unlikely to increase the risk of toxicity at therapeutic","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"76","endOffset":"88","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/div[2]/p[1]","prefix":"k Quintiles Scotland Ltd (Edinburgh, UK) for performing the ","suffix":" assays, Medical Research Laboratories (Highland Heights, Ke","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"59","endOffset":"71","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[9]/div[2]/div[1]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[9]/div[2]/div[1]/span[1]","prefix":"Olsson AG, Pears J, McKellar J, Mizan J, Raza A. Effect of ","suffix":" on low-density lipoprotein cholesterol in patients with hyp","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"59","endOffset":"71","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[9]/div[2]/div[19]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[9]/div[2]/div[19]/span[1]","prefix":"Hull CK, Penman AD, Smith CK, Martin PD. Quantification of ","suffix":" in human plasma by automated solid-phase extraction using t","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"65","endOffset":"77","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[9]/div[2]/div[21]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[9]/div[2]/div[21]/span[1]","prefix":"n PD, Kemp J, Dane AL, Warwick MJ, Schneck DW. No effect of ","suffix":" on the pharmacokinetics of digoxin in healthy volunteers l.","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"83","endOffset":"95","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[5]/div[2]/div[1]/div[1]/ul[1]/li[3]/div[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[5]/div[2]/div[1]/div[1]/ul[1]/li[3]/div[1]","prefix":" and pharmacokinetics of a new HMG-CoA reductase inhibitor, ","suffix":", after morning or evening administration in healthy volunte","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"38","endOffset":"50","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/div[2]/span[1]","prefix":"Summary pharmacokinetic parameters of ","suffix":", and results of the statistical analysis of the plasma AUC(","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"94","endOffset":"106","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[2]","prefix":"ma concentration-time curves measured to a common point for ","suffix":" and active and total HMG-CoA reductase inhibitors indicated","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"230","endOffset":"242","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[2]","prefix":"t, within the accuracy and precision s of the methods used, ","suffix":" accounted for essentially all of the circulating active inh","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"90","endOffset":"102","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/div[1]/div[2]/span[1]","prefix":"ations of active and total HMG-CoA reductase inhibitors and ","suffix":" over time when rosuvastatin was coadministered with ketocon","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"118","endOffset":"130","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/div[1]/div[2]/span[1]","prefix":"MG-CoA reductase inhibitors and rosuvastatin over time when ","suffix":" was coadministered with ketoconazole. A similar pattern was","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"201","endOffset":"213","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/div[1]/div[2]/span[1]","prefix":"nistered with ketoconazole. A similar pattern was seen when ","suffix":" was coadministered with placebo. ○,","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"0","endOffset":"12","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[4]","prefix":"","suffix":" and ketoconazole were well tolerated when coadministered. T","exact":"Rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"20","endOffset":"32","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"Coadministration of ","suffix":" and the potent CYP3A4 inhibitor ketoconazole did not produc","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"234","endOffset":"246","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"hat ketoconazole had no effect on the systemic clearance of ","suffix":", as individual plasma concentration profiles, including the","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"15","endOffset":"27","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"In contrast to ","suffix":", atorvastatin [","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"118","endOffset":"130","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"oncentrations were measured in this trial. The finding that ","suffix":" accounted for essentially all of the circulating active inh","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"327","endOffset":"339","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"e(s). The finding that the active inhibitors, and therefore ","suffix":", constituted the majority of the total inhibitors indicates","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"643","endOffset":"655","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":" support for previous data indicating limited metabolism of ","suffix":" [","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"67","endOffset":"79","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","prefix":"lusion, ketoconazole did not affect the pharmacokinetics of ","suffix":" in healthy subjects. Therefore, coadministration of ketocon","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"149","endOffset":"161","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","prefix":"y subjects. Therefore, coadministration of ketoconazole and ","suffix":" is unlikely to increase the risk of toxicity at therapeutic","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"231","endOffset":"243","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","prefix":"ly to increase the risk of toxicity at therapeutic doses of ","suffix":". The data suggest that neither cytochrome P450 3A4 nor P-gp","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"206","endOffset":"218","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","prefix":"r P-gp-mediated transport contributes to the elimination of ","suffix":".","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"357","endOffset":"369","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","prefix":"r P-gp-mediated transport contributes to the elimination of ","suffix":".","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"rosuvastatin","startOffset":"76","endOffset":"88","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/div[2]/p[1]","prefix":"k Quintiles Scotland Ltd (Edinburgh, UK) for performing the ","suffix":" assays, Medical Research Laboratories (Highland Heights, Ke","exact":"rosuvastatin"},{"setid":"PMC1884190","drugname":"cholesterol","startOffset":"130","endOffset":"141","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","prefix":"coenzyme A (HMG-CoA) reductase, the rate-limiting enzyme in ","suffix":" biosynthesis, and is effective for the treatment of patient","exact":"cholesterol"},{"setid":"PMC1884190","drugname":"cholesterol","startOffset":"347","endOffset":"358","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","prefix":"ficant dose-dependent reductions in low-density lipoprotein ","suffix":" (up to 65%) and was well-tolerated [","exact":"cholesterol"},{"setid":"PMC1884190","drugname":"atorvastatin","startOffset":"48","endOffset":"60","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[4]","prefix":"Some of the other HMG-CoA reductase inhibitors (","suffix":" [","exact":"atorvastatin"},{"setid":"PMC1884190","drugname":"atorvastatin","startOffset":"29","endOffset":"41","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"In contrast to rosuvastatin, ","suffix":" [","exact":"atorvastatin"},{"setid":"PMC1884190","drugname":"atorvastatin","startOffset":"29","endOffset":"41","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"In contrast to rosuvastatin, ","suffix":" [","exact":"atorvastatin"},{"setid":"PMC1884190","drugname":"atorvastatin","startOffset":"347","endOffset":"359","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","prefix":"ts metabolites may be affected. For example, in the case of ","suffix":", following coadministration with itraconazole, the mean AUC","exact":"atorvastatin"},{"setid":"PMC1884190","drugname":"atorvastatin","startOffset":"530","endOffset":"542","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","prefix":"ased 1.6- and 1.7-fold, respectively; the mean AUC(0,72) of ","suffix":" acid and lactone was increased 3.2- and 4.1-fold, respectiv","exact":"atorvastatin"},{"setid":"PMC1884190","drugname":"atorvastatin","startOffset":"50","endOffset":"62","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[3]/div[2]/ul[1]/li[4]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[3]/div[2]/ul[1]/li[4]/a[1]","prefix":"Effect of itraconazole on the pharmacokinetics of ","suffix":".","exact":"atorvastatin"},{"setid":"PMC1884190","drugname":"atorvastatin","startOffset":"50","endOffset":"62","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[9]/div[2]/ul[1]/li[1]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[9]/div[2]/ul[1]/li[1]/a[1]","prefix":"Effect of itraconazole on the pharmacokinetics of ","suffix":".","exact":"atorvastatin"},{"setid":"PMC1884190","drugname":"atorvastatin","startOffset":"50","endOffset":"62","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[9]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[9]","prefix":"Effect of itraconazole on the pharmacokinetics of ","suffix":".","exact":"atorvastatin"},{"setid":"PMC1884190","drugname":"itraconazole","startOffset":"393","endOffset":"405","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","prefix":"n the case of atorvastatin, following coadministration with ","suffix":", the mean AUC(0,72) of the active and total inhibitors was ","exact":"itraconazole"},{"setid":"PMC1884190","drugname":"alanine","startOffset":"356","endOffset":"363","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[1]","prefix":" haematology, or urinalysis results, or if total bilirubin, ","suffix":" aminotransferase, aspartate aminotransferase, alkaline phos","exact":"alanine"},{"setid":"PMC1884190","drugname":"caffeine","startOffset":"250","endOffset":"258","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[2]","prefix":" of rosuvastatin in each dosing period), the consumption of ","suffix":"-containing drinks/food and smoking (none permitted from mid","exact":"caffeine"},{"setid":"PMC1884190","drugname":"heparin","startOffset":"399","endOffset":"406","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[1]","prefix":" Blood samples were collected into tubes containing lithium ","suffix":" anticoagulant and centrifuged within 30 min. Plasma was the","exact":"heparin"},{"setid":"PMC1884190","drugname":"sodium acetate","startOffset":"511","endOffset":"525","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[1]","prefix":" Plasma was then harvested from the samples, mixed 1:1 with ","suffix":" buffer 0.1 ","exact":"sodium acetate"},{"setid":"PMC1884190","drugname":"acetonitrile","startOffset":"327","endOffset":"339","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[2]","prefix":" drug-related components were isolated from plasma by using ","suffix":" : acetone (95 : 5) to precipitate plasma proteins. The supe","exact":"acetonitrile"},{"setid":"PMC1884190","drugname":"acetone","startOffset":"342","endOffset":"349","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[2]","prefix":"omponents were isolated from plasma by using acetonitrile : ","suffix":" (95 : 5) to precipitate plasma proteins. The supernatant wa","exact":"acetone"},{"setid":"PMC1884190","drugname":"edta","startOffset":"210","endOffset":"214","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[1]","prefix":" period. Blood samples were collected into tubes containing ","suffix":" anticoagulant and centrifuged. Plasma was then harvested fr","exact":"EDTA"}],[{"setid":"PMC3922121","drugname":"atorvastatin","startOffset":"195","endOffset":"207","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":" incorporating genomic and clinical variables to avoid high ","suffix":" and rosuvastatin levels is described; further study will de","exact":"atorvastatin"},{"setid":"PMC3922121","drugname":"atorvastatin","startOffset":"106","endOffset":"118","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[1]","prefix":"London Health Sciences Center (LHSC, London, Canada) taking ","suffix":" or rosuvastatin daily to participate. Patients were exclude","exact":"atorvastatin"},{"setid":"PMC3922121","drugname":"atorvastatin","startOffset":"200","endOffset":"212","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[1]","prefix":" to participate. Patients were excluded if they were taking ","suffix":" or rosuvastatin in an alternate day dosing regimen, or if t","exact":"atorvastatin"},{"setid":"PMC3922121","drugname":"atorvastatin","startOffset":"301","endOffset":"313","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[1]","prefix":"ate day dosing regimen, or if they had not taken their last ","suffix":" or rosuvastatin dose within 24 hours of their clinic visit ","exact":"atorvastatin"},{"setid":"PMC3922121","drugname":"atorvastatin","startOffset":"418","endOffset":"430","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[1]","prefix":"r clinic visit and blood draw. All patients had been taking ","suffix":" or rosuvastatin at the same dose for at least six weeks pri","exact":"atorvastatin"},{"setid":"PMC3922121","drugname":"atorvastatin","startOffset":"205","endOffset":"217","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[1]","prefix":"ated in 300 μL acetonitrile containing internal standard d5-","suffix":" or d6-rosuvastatin, and centrifuged at 14,000 rpm for 20 mi","exact":"atorvastatin"},{"setid":"PMC3922121","drugname":"atorvastatin","startOffset":"556","endOffset":"568","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[1]","prefix":"dient to ratio of 10:90. Concentrations of rosuvastatin and ","suffix":" were measured by liquid chromatography-mass spectrometry (L","exact":"atorvastatin"},{"setid":"PMC3922121","drugname":"atorvastatin","startOffset":"52","endOffset":"64","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/div[1]/div[1]/div[2]/span[1]","prefix":"Population characteristics of prospective cohort of ","suffix":"- and rosuvastatin-treated patients","exact":"atorvastatin"},{"setid":"PMC3922121","drugname":"atorvastatin","startOffset":"24","endOffset":"36","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/div[1]/div[2]/span[1]","prefix":"Prospective analysis of ","suffix":" (A) plasma concentrations in patients taking 10, 20, 40, or","exact":"atorvastatin"},{"setid":"PMC3922121","drugname":"atorvastatin","startOffset":"102","endOffset":"114","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","prefix":"ld or higher variability between patients on the same daily ","suffix":" dose (","exact":"atorvastatin"},{"setid":"PMC3922121","drugname":"atorvastatin","startOffset":"58","endOffset":"70","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[2]","prefix":"Multiple linear regression analysis indicated that plasma ","suffix":" concentration was higher in individuals with the ","exact":"atorvastatin"},{"setid":"PMC3922121","drugname":"atorvastatin","startOffset":"54","endOffset":"66","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","prefix":"The mean lathosterol concentration in patients taking ","suffix":" was 3.9 μg/mL (SD 2.1) and rosuvastatin was 3.4 μg/mL (2.2)","exact":"atorvastatin"},{"setid":"PMC3922121","drugname":"atorvastatin","startOffset":"147","endOffset":"159","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","prefix":"1) and rosuvastatin was 3.4 μg/mL (2.2). In patients taking ","suffix":", lathosterol concentration was lower in patients taking a h","exact":"atorvastatin"},{"setid":"PMC3922121","drugname":"atorvastatin","startOffset":"233","endOffset":"245","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","prefix":"concentration was lower in patients taking a higher dose of ","suffix":" (p < 0.01), however, there was no significant association b","exact":"atorvastatin"},{"setid":"PMC3922121","drugname":"atorvastatin","startOffset":"328","endOffset":"340","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","prefix":"here was no significant association between rosuvastatin or ","suffix":" concentrations and lathosterol concentration detected in th","exact":"atorvastatin"},{"setid":"PMC3922121","drugname":"atorvastatin","startOffset":"17","endOffset":"29","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[7]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[7]/div[1]/div[1]/div[2]/span[1]","prefix":"Rosuvastatin and ","suffix":" dosing decision support algorithm. Doses are the maximum do","exact":"atorvastatin"},{"setid":"PMC3922121","drugname":"atorvastatin","startOffset":"136","endOffset":"148","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[7]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[7]/div[1]/div[1]/div[2]/span[1]","prefix":"he maximum doses that result in a predicted rosuvastatin or ","suffix":" concentration that is less than the 90th percentile. In pat","exact":"atorvastatin"},{"setid":"PMC3922121","drugname":"atorvastatin","startOffset":"221","endOffset":"233","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[7]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[7]/div[1]/div[1]/div[2]/span[1]","prefix":"n that is less than the 90th percentile. In patients taking ","suffix":", dose should be lowered","exact":"atorvastatin"},{"setid":"PMC3922121","drugname":"atorvastatin","startOffset":"185","endOffset":"197","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[8]/p[1]","prefix":"s (n = 579). The first cohort contained 224 patients taking ","suffix":" and 37 patients taking rosuvastatin in the context of routi","exact":"atorvastatin"},{"setid":"PMC3922121","drugname":"atorvastatin","startOffset":"362","endOffset":"374","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[8]/p[1]","prefix":"n the U.S.; the second cohort contained 121 patients taking ","suffix":" and 198 patients taking rosuvastatin treated in a lipid cli","exact":"atorvastatin"},{"setid":"PMC3922121","drugname":"atorvastatin","startOffset":"44","endOffset":"56","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[8]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[8]/div[1]/div[1]/div[2]/span[1]","prefix":"Population characteristics of retrospective ","suffix":" and rosuvastatin dosing cohort","exact":"atorvastatin"},{"setid":"PMC3922121","drugname":"atorvastatin","startOffset":"52","endOffset":"64","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[8]/div[2]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[8]/div[2]/div[1]/div[2]/span[1]","prefix":"Distribution of transporter genotypes and age among ","suffix":" (A) doses of 10, 20, 40, or 80 mg daily and rosuvastatin (B","exact":"atorvastatin"},{"setid":"PMC3922121","drugname":"atorvastatin","startOffset":"57","endOffset":"69","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[8]/div[3]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[8]/div[3]/div[1]/div[2]/span[1]","prefix":"Accuracy of dose prediction in retrospective analysis of ","suffix":" and rosuvastatin dosing","exact":"atorvastatin"},{"setid":"PMC3922121","drugname":"atorvastatin","startOffset":"301","endOffset":"313","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[1]","prefix":"ate day dosing regimen, or if they had not taken their last ","suffix":" or rosuvastatin dose within 24 hours of their clinic visit ","exact":"atorvastatin"},{"setid":"PMC3922121","drugname":"atorvastatin","startOffset":"102","endOffset":"114","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","prefix":"ld or higher variability between patients on the same daily ","suffix":" dose (","exact":"atorvastatin"},{"setid":"PMC3922121","drugname":"atorvastatin","startOffset":"328","endOffset":"340","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","prefix":"here was no significant association between rosuvastatin or ","suffix":" concentrations and lathosterol concentration detected in th","exact":"atorvastatin"},{"setid":"PMC3922121","drugname":"atorvastatin","startOffset":"136","endOffset":"148","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[7]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[7]/div[1]/div[1]/div[2]/span[1]","prefix":"he maximum doses that result in a predicted rosuvastatin or ","suffix":" concentration that is less than the 90th percentile. In pat","exact":"atorvastatin"},{"setid":"PMC3922121","drugname":"atorvastatin","startOffset":"55","endOffset":"67","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[8]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[8]/p[3]","prefix":"Among 67 patients on high-dose rosuvastatin (40 mg) or ","suffix":" (80 mg), nearly 50% exceeded the maximum dose recommended b","exact":"atorvastatin"},{"setid":"PMC3922121","drugname":"atorvastatin","startOffset":"237","endOffset":"249","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[8]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[8]/p[3]","prefix":"developing intolerance. Of the 16 patients taking high-dose ","suffix":" (80 mg) within our cohort derived from an EMR-linked bioban","exact":"atorvastatin"},{"setid":"PMC3922121","drugname":"atorvastatin","startOffset":"402","endOffset":"414","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[8]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[8]/p[3]","prefix":"nded dose, and only 7 of these patients were still on 80 mg ","suffix":" one year later. Conversely, all (7 of 7) subjects predicted","exact":"atorvastatin"},{"setid":"PMC3922121","drugname":"atorvastatin","startOffset":"534","endOffset":"546","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[8]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[8]/p[3]","prefix":" by our algorithm to tolerate 80 mg were still on high-dose ","suffix":" one year later, however, this result was not statistically ","exact":"atorvastatin"},{"setid":"PMC3922121","drugname":"atorvastatin","startOffset":"116","endOffset":"128","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"drug transporter polymorphisms and plasma concentrations of ","suffix":" and rosuvastatin in a real world population. We found a mar","exact":"atorvastatin"},{"setid":"PMC3922121","drugname":"atorvastatin","startOffset":"94","endOffset":"106","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","prefix":"as a significant factor in predicting the concentrations of ","suffix":" and rosuvastatin in patients. Age has been recognized as a ","exact":"atorvastatin"},{"setid":"PMC3922121","drugname":"atorvastatin","startOffset":"61","endOffset":"73","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[9]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[9]","prefix":"t the highest available dose, nearly 50% of patients taking ","suffix":" or rosuvastatin exceeded the maximum genotype-based dose re","exact":"atorvastatin"},{"setid":"PMC3922121","drugname":"atorvastatin","startOffset":"504","endOffset":"516","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[9]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[9]","prefix":" most useful when a patient is starting the highest dose of ","suffix":" or rosuvastatin, bearing in mind that ","exact":"atorvastatin"},{"setid":"PMC3922121","drugname":"atorvastatin","startOffset":"29","endOffset":"41","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[10]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[10]","prefix":"Here we present the range of ","suffix":" and rosuvastatin concentrations in a patient population, pr","exact":"atorvastatin"},{"setid":"PMC3922121","drugname":"rosuvastatin","startOffset":"46","endOffset":"58","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":"In total, 299 patients taking atorvastatin or ","suffix":" were prospectively recruited at an outpatient referral cent","exact":"rosuvastatin"},{"setid":"PMC3922121","drugname":"rosuvastatin","startOffset":"212","endOffset":"224","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"nomic and clinical variables to avoid high atorvastatin and ","suffix":" levels is described; further study will determine if this a","exact":"rosuvastatin"},{"setid":"PMC3922121","drugname":"rosuvastatin","startOffset":"122","endOffset":"134","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[1]","prefix":"iences Center (LHSC, London, Canada) taking atorvastatin or ","suffix":" daily to participate. Patients were excluded if they were t","exact":"rosuvastatin"},{"setid":"PMC3922121","drugname":"rosuvastatin","startOffset":"216","endOffset":"228","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[1]","prefix":" Patients were excluded if they were taking atorvastatin or ","suffix":" in an alternate day dosing regimen, or if they had not take","exact":"rosuvastatin"},{"setid":"PMC3922121","drugname":"rosuvastatin","startOffset":"317","endOffset":"329","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[1]","prefix":"egimen, or if they had not taken their last atorvastatin or ","suffix":" dose within 24 hours of their clinic visit and blood draw. ","exact":"rosuvastatin"},{"setid":"PMC3922121","drugname":"rosuvastatin","startOffset":"434","endOffset":"446","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[1]","prefix":"nd blood draw. All patients had been taking atorvastatin or ","suffix":" at the same dose for at least six weeks prior to participat","exact":"rosuvastatin"},{"setid":"PMC3922121","drugname":"rosuvastatin","startOffset":"224","endOffset":"236","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[1]","prefix":"onitrile containing internal standard d5-atorvastatin or d6-","suffix":", and centrifuged at 14,000 rpm for 20 minutes at 4 °C. The ","exact":"rosuvastatin"},{"setid":"PMC3922121","drugname":"rosuvastatin","startOffset":"539","endOffset":"551","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[1]","prefix":"70:30, with a gradient to ratio of 10:90. Concentrations of ","suffix":" and atorvastatin were measured by liquid chromatography-mas","exact":"rosuvastatin"},{"setid":"PMC3922121","drugname":"rosuvastatin","startOffset":"20","endOffset":"32","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[10]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[10]/p[2]","prefix":"For log-transformed ","suffix":" concentration, the effect sizes detectable with a power of ","exact":"rosuvastatin"},{"setid":"PMC3922121","drugname":"rosuvastatin","startOffset":"70","endOffset":"82","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/div[1]/div[1]/div[2]/span[1]","prefix":" characteristics of prospective cohort of atorvastatin- and ","suffix":"-treated patients","exact":"rosuvastatin"},{"setid":"PMC3922121","drugname":"rosuvastatin","startOffset":"48","endOffset":"60","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","prefix":"We observed up to 45-fold variability in plasma ","suffix":" concentration among individuals on the same dose (","exact":"rosuvastatin"},{"setid":"PMC3922121","drugname":"rosuvastatin","startOffset":"114","endOffset":"126","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/div[1]/div[2]/span[1]","prefix":"trations in patients taking 10, 20, 40, or 80 mg daily, and ","suffix":" (B) plasma concentrations in patients taking 5, 10, 20, or ","exact":"rosuvastatin"},{"setid":"PMC3922121","drugname":"rosuvastatin","startOffset":"199","endOffset":"211","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/div[1]/div[2]/span[1]","prefix":"oncentrations in patients taking 5, 10, 20, or 40 mg daily. ","suffix":" concentrations were collected within 0","exact":"Rosuvastatin"},{"setid":"PMC3922121","drugname":"rosuvastatin","startOffset":"86","endOffset":"98","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[2]","prefix":"ociation of clinical and pharmacogenetic variables with the ","suffix":" levels observed, we performed multiple linear regression an","exact":"rosuvastatin"},{"setid":"PMC3922121","drugname":"rosuvastatin","startOffset":"350","endOffset":"362","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[2]","prefix":". Multiple linear regression analysis indicated that plasma ","suffix":" concentration was higher in individuals with the reduced fu","exact":"rosuvastatin"},{"setid":"PMC3922121","drugname":"rosuvastatin","startOffset":"11","endOffset":"23","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","prefix":"Similar to ","suffix":", we observed 45-fold or higher variability between patients","exact":"rosuvastatin"},{"setid":"PMC3922121","drugname":"rosuvastatin","startOffset":"94","endOffset":"106","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","prefix":" in patients taking atorvastatin was 3.9 μg/mL (SD 2.1) and ","suffix":" was 3.4 μg/mL (2.2). In patients taking atorvastatin, latho","exact":"rosuvastatin"},{"setid":"PMC3922121","drugname":"rosuvastatin","startOffset":"312","endOffset":"324","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","prefix":".01), however, there was no significant association between ","suffix":" or atorvastatin concentrations and lathosterol concentratio","exact":"rosuvastatin"},{"setid":"PMC3922121","drugname":"rosuvastatin","startOffset":"226","endOffset":"238","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[1]","prefix":"n combination with plasma statin concentration. We examined ","suffix":" acid concentrations in patients taking 40 mg rosuvastatin d","exact":"rosuvastatin"},{"setid":"PMC3922121","drugname":"rosuvastatin","startOffset":"284","endOffset":"296","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[1]","prefix":"d rosuvastatin acid concentrations in patients taking 40 mg ","suffix":" daily, for whom no higher dose or more potent statin is ava","exact":"rosuvastatin"},{"setid":"PMC3922121","drugname":"rosuvastatin","startOffset":"620","endOffset":"632","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[1]","prefix":"nts who were not at target LDL-C (n = 12) had a mean plasma ","suffix":" concentration of 9.183 ng/mL (SD 1.6; 13.6 hours post dose)","exact":"rosuvastatin"},{"setid":"PMC3922121","drugname":"rosuvastatin","startOffset":"0","endOffset":"12","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[7]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[7]/div[1]/div[1]/div[2]/span[1]","prefix":"","suffix":" and atorvastatin dosing decision support algorithm. Doses a","exact":"Rosuvastatin"},{"setid":"PMC3922121","drugname":"rosuvastatin","startOffset":"120","endOffset":"132","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[7]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[7]/div[1]/div[1]/div[2]/span[1]","prefix":"thm. Doses are the maximum doses that result in a predicted ","suffix":" or atorvastatin concentration that is less than the 90th pe","exact":"rosuvastatin"},{"setid":"PMC3922121","drugname":"rosuvastatin","startOffset":"221","endOffset":"233","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[8]/p[1]","prefix":"ned 224 patients taking atorvastatin and 37 patients taking ","suffix":" in the context of routine clinical care at a large academic","exact":"rosuvastatin"},{"setid":"PMC3922121","drugname":"rosuvastatin","startOffset":"399","endOffset":"411","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[8]/p[1]","prefix":"ed 121 patients taking atorvastatin and 198 patients taking ","suffix":" treated in a lipid clinic at a large academic center in Can","exact":"rosuvastatin"},{"setid":"PMC3922121","drugname":"rosuvastatin","startOffset":"61","endOffset":"73","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[8]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[8]/div[1]/div[1]/div[2]/span[1]","prefix":"opulation characteristics of retrospective atorvastatin and ","suffix":" dosing cohort","exact":"rosuvastatin"},{"setid":"PMC3922121","drugname":"rosuvastatin","startOffset":"109","endOffset":"121","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[8]/div[2]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[8]/div[2]/div[1]/div[2]/span[1]","prefix":"ng atorvastatin (A) doses of 10, 20, 40, or 80 mg daily and ","suffix":" (B) doses of 5, 10, 20, or 40 mg daily in retrospective ana","exact":"rosuvastatin"},{"setid":"PMC3922121","drugname":"rosuvastatin","startOffset":"74","endOffset":"86","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[8]/div[3]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[8]/div[3]/div[1]/div[2]/span[1]","prefix":"se prediction in retrospective analysis of atorvastatin and ","suffix":" dosing","exact":"rosuvastatin"},{"setid":"PMC3922121","drugname":"rosuvastatin","startOffset":"31","endOffset":"43","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[8]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[8]/p[3]","prefix":"Among 67 patients on high-dose ","suffix":" (40 mg) or atorvastatin (80 mg), nearly 50% exceeded the ma","exact":"rosuvastatin"},{"setid":"PMC3922121","drugname":"rosuvastatin","startOffset":"133","endOffset":"145","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"polymorphisms and plasma concentrations of atorvastatin and ","suffix":" in a real world population. We found a marked, 45-fold inte","exact":"rosuvastatin"},{"setid":"PMC3922121","drugname":"rosuvastatin","startOffset":"501","endOffset":"513","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"level. Indeed, nearly 90% of the explainable variability in ","suffix":" concentration can be accounted for by two reduced function ","exact":"rosuvastatin"},{"setid":"PMC3922121","drugname":"rosuvastatin","startOffset":"111","endOffset":"123","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","prefix":"factor in predicting the concentrations of atorvastatin and ","suffix":" in patients. Age has been recognized as a clinical risk fac","exact":"rosuvastatin"},{"setid":"PMC3922121","drugname":"rosuvastatin","startOffset":"77","endOffset":"89","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[9]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[9]","prefix":"ailable dose, nearly 50% of patients taking atorvastatin or ","suffix":" exceeded the maximum genotype-based dose recommended by our","exact":"rosuvastatin"},{"setid":"PMC3922121","drugname":"rosuvastatin","startOffset":"520","endOffset":"532","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[9]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[9]","prefix":"n a patient is starting the highest dose of atorvastatin or ","suffix":", bearing in mind that ","exact":"rosuvastatin"},{"setid":"PMC3922121","drugname":"rosuvastatin","startOffset":"46","endOffset":"58","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[10]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[10]","prefix":"Here we present the range of atorvastatin and ","suffix":" concentrations in a patient population, providing a framewo","exact":"rosuvastatin"},{"setid":"PMC3922121","drugname":"rosuvastatin","startOffset":"309","endOffset":"321","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[10]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[10]","prefix":"statin transporter polymorphisms. In the clinical review of ","suffix":" originally submitted to the US FDA, all patients with serio","exact":"rosuvastatin"},{"setid":"PMC3922121","drugname":"rosuvastatin","startOffset":"452","endOffset":"464","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[10]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[10]","prefix":"events for whom drug levels were available (n = 6) had high ","suffix":" concentrations (> 50 ng/mL; ","exact":"rosuvastatin"},{"setid":"PMC3922121","drugname":"crestor","startOffset":"62","endOffset":"69","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[10]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[10]/a[1]","prefix":"tp://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-366_","suffix":"_Medr_P4.pdf","exact":"Crestor"},{"setid":"PMC3922121","drugname":"cholesterol","startOffset":"235","endOffset":"246","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","prefix":"by lowering plasma concentration of low-density lipoprotein ","suffix":" (LDL-C)","exact":"cholesterol"},{"setid":"PMC3922121","drugname":"cholesterol","startOffset":"406","endOffset":"417","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","prefix":"ss the efficacy of statin-mediated inhibition of endogenous ","suffix":" synthesis, as well as its relationship to statin concentrat","exact":"cholesterol"},{"setid":"PMC3922121","drugname":"cholesterol","startOffset":"638","endOffset":"649","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[1]","prefix":"to 80 mg one week prior to blood sampling to achieve better ","suffix":" lowering. The study was conducted between August 2009 and M","exact":"cholesterol"},{"setid":"PMC3922121","drugname":"cholesterol","startOffset":"6","endOffset":"17","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[8]/p[1]","prefix":"Total ","suffix":" was measured by the enzymatic colorimetric method, using th","exact":"cholesterol"},{"setid":"PMC3922121","drugname":"cholesterol","startOffset":"79","endOffset":"90","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[8]/p[1]","prefix":"as measured by the enzymatic colorimetric method, using the ","suffix":" E kit from Wako (Richmond, VA). Samples were measured in tr","exact":"Cholesterol"},{"setid":"PMC3922121","drugname":"cholesterol","startOffset":"469","endOffset":"480","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","prefix":"tion. In both groups, lathosterol was associated with total ","suffix":", and was higher in patients taking ezetimibe (","exact":"cholesterol"},{"setid":"PMC3922121","drugname":"cholesterol","startOffset":"225","endOffset":"236","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"ve. 4β-hydroxycholesterol is produced by CYP3A enzymes from ","suffix":", and has been proposed to be a marker of CYP3A activity in ","exact":"cholesterol"},{"setid":"PMC3922121","drugname":"cholesterol","startOffset":"38","endOffset":"49","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[7]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[7]","prefix":"Lathosterol is a late intermediate in ","suffix":" synthesis that can be used to measure the efficacy of stati","exact":"cholesterol"},{"setid":"PMC3922121","drugname":"edta","startOffset":"49","endOffset":"53","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","prefix":"A single venous 8 mL blood sample was drawn into ","suffix":"-containing tubes, and placed immediately on ice. Samples we","exact":"EDTA"},{"setid":"PMC3922121","drugname":"acetonitrile","startOffset":"160","endOffset":"172","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[1]","prefix":"ada). Plasma aliquots of 100 μL were precipitated in 300 μL ","suffix":" containing internal standard d5-atorvastatin or d6-rosuvast","exact":"acetonitrile"},{"setid":"PMC3922121","drugname":"acetonitrile","startOffset":"442","endOffset":"454","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[1]","prefix":" phases 0.05% formic acid in water and 0.05% formic acid in ","suffix":", starting at a ratio of 70:30, with a gradient to ratio of ","exact":"acetonitrile"},{"setid":"PMC3922121","drugname":"ezetimibe","startOffset":"516","endOffset":"525","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","prefix":"d with total cholesterol, and was higher in patients taking ","suffix":" (","exact":"ezetimibe"}],[{"setid":"PMC3571969","drugname":"cholesterol","startOffset":"23","endOffset":"34","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","prefix":"His values were: total ","suffix":" 277.7 mg/dL, triglycerides 448.2 mg/dL, HDL-C 36.7 mg/dl, f","exact":"cholesterol"},{"setid":"PMC3571969","drugname":"cholesterol","startOffset":"320","endOffset":"331","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[4]","prefix":"evel (349 mg/dL), CK was in the normal range (121 U/l), but ","suffix":" showed further increase (310.5 mg/dL). Taking the lipid lev","exact":"cholesterol"},{"setid":"PMC3571969","drugname":"cholesterol","startOffset":"104","endOffset":"115","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[5]","prefix":"ond control. This time both the values of triglycerides and ","suffix":" showed improvement, 154.1 and 249.8 mg/dL, respectively. Ho","exact":"cholesterol"},{"setid":"PMC3571969","drugname":"cholesterol","startOffset":"528","endOffset":"539","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[8]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[8]","prefix":"es (AST: 131.3; ALT: 95.5 U/l), and in LDH (386 U/l). Serum ","suffix":" level remained elevated (257.2 mg/dL), triglycerides reache","exact":"cholesterol"},{"setid":"PMC3571969","drugname":"cholesterol","startOffset":"312","endOffset":"323","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[9]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[9]","prefix":"transaminases were normal, dyslipidaemia was reduced (total ","suffix":" and triglycerides levels were 238.3 and 216.1 mg/dL, respec","exact":"cholesterol"},{"setid":"PMC3571969","drugname":"cholesterol","startOffset":"616","endOffset":"627","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[20]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[20]","prefix":"-fold higher triglyceride and the moderately elevated total ","suffix":" at the beginning. Third, unfortunately at the first blood t","exact":"cholesterol"},{"setid":"PMC3571969","drugname":"cholesterol","startOffset":"695","endOffset":"706","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[20]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[20]","prefix":"beginning. Third, unfortunately at the first blood test LDL-","suffix":" could not have been evaluated because of the disturbing eff","exact":"cholesterol"},{"setid":"PMC3571969","drugname":"cholesterol","startOffset":"838","endOffset":"849","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[20]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[20]","prefix":"d triglyceride. Later at the control blood tests only total ","suffix":" was measured. LDL-cholesterol is an essential parameter of ","exact":"cholesterol"},{"setid":"PMC3571969","drugname":"cholesterol","startOffset":"868","endOffset":"879","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[20]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[20]","prefix":"ontrol blood tests only total cholesterol was measured. LDL-","suffix":" is an essential parameter of cardiovascular risk stratifica","exact":"cholesterol"},{"setid":"PMC3571969","drugname":"cholesterol","startOffset":"76","endOffset":"87","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","prefix":"syndrome; TG: Triglyceride; HDL-C: High-density lipoprotein ","suffix":"; ESC/EAS: European Society of Cardiology and the European A","exact":"cholesterol"},{"setid":"PMC3571969","drugname":"fenofibrate","startOffset":"651","endOffset":"662","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[3]","prefix":"es and lack of lifestyle modification possibilities, 160 mg ","suffix":" per day was applied. The patient was also informed about th","exact":"fenofibrate"},{"setid":"PMC3571969","drugname":"fenofibrate","startOffset":"172","endOffset":"183","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[14]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[14]","prefix":"was probably the atrovastatin as compared with gemfibrozil, ","suffix":" were found to be less prone to make complications when used","exact":"fenofibrate"},{"setid":"PMC3571969","drugname":"fenofibrate","startOffset":"409","endOffset":"420","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[20]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[20]","prefix":"general practitioner sometimes limit our success. Secondly, ","suffix":" was administered first instead of atrovastatin. This choice","exact":"fenofibrate"},{"setid":"PMC3571969","drugname":"fenofibrate","startOffset":"24","endOffset":"35","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","prefix":"In conclusion, although ","suffix":" and statin combination therapy is supposed to be safe, myop","exact":"fenofibrate"},{"setid":"PMC3571969","drugname":"nebivolol","startOffset":"481","endOffset":"490","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","prefix":"h lipid lowering medications. The incidental interaction of ","suffix":" with statins or fibrates is also need to be clarified in th","exact":"nebivolol"},{"setid":"PMC3571969","drugname":"alanine","startOffset":"537","endOffset":"544","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","prefix":"s, like creatine kinase (CK), aspartate transaminase (AST), ","suffix":" transaminase (ALT) and gamma glutamyl transpeptidase (GGT) ","exact":"alanine"},{"setid":"PMC3571969","drugname":"alanine","startOffset":"226","endOffset":"233","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","prefix":"ety; CK: Creatine kinase; AST: Aspartate transaminase; ALT: ","suffix":" transaminases; GGT: Gamma glutamyl transpeptidase; LDH: Lac","exact":"Alanine"},{"setid":"PMC3571969","drugname":"urea","startOffset":"703","endOffset":"707","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","prefix":"/l, 23 U/l and 36 U/l, respectively). Renal function (blood ","suffix":" nitrogen: 7.6 mmol/l, serum creatinine: 97 μmol/L, glomerul","exact":"urea"},{"setid":"PMC3571969","drugname":"creatinine","startOffset":"736","endOffset":"746","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","prefix":"ly). Renal function (blood urea nitrogen: 7.6 mmol/l, serum ","suffix":": 97 μmol/L, glomerular filtration rate: >60 ml/min) was als","exact":"creatinine"},{"setid":"PMC3571969","drugname":"aspirin","startOffset":"151","endOffset":"158","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[3]","prefix":"ate regarding taking the prescribed medications (except for ","suffix":", because of bad family experience). About lifestyle modific","exact":"aspirin"},{"setid":"PMC3571969","drugname":"varenicline","startOffset":"797","endOffset":"808","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[3]","prefix":"-effects of the lipid-lowering therapy. Because of smoking, ","suffix":" therapy was prescribed as well, as the patient previously f","exact":"varenicline"},{"setid":"PMC3571969","drugname":"varenicline","startOffset":"100","endOffset":"111","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[4]","prefix":"ithout any symptoms, and mentioned that he had begun taking ","suffix":" only one week earlier. Laboratory parameters revealed the e","exact":"varenicline"},{"setid":"PMC3571969","drugname":"varenicline","startOffset":"22","endOffset":"33","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[6]","prefix":"He had stopped taking ","suffix":" after 2 weeks, and had taken the three types of medicines t","exact":"varenicline"},{"setid":"PMC3571969","drugname":"varenicline","startOffset":"122","endOffset":"133","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[6]","prefix":" the three types of medicines together (statin, fibrate and ","suffix":") only one week long. He did not smoke since then. The irreg","exact":"varenicline"},{"setid":"PMC3571969","drugname":"varenicline","startOffset":"565","endOffset":"576","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[9]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[9]","prefix":" takes 1 gram omega-3 fatty acid per day, and thanks to the ","suffix":" therapy he does not smoke.","exact":"varenicline"},{"setid":"PMC3571969","drugname":"varenicline","startOffset":"104","endOffset":"115","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[17]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[17]","prefix":"ibrate therapy-induced rhabdomyolysis could be connected to ","suffix":" intake. The theoretical background of this interaction is b","exact":"varenicline"},{"setid":"PMC3571969","drugname":"varenicline","startOffset":"263","endOffset":"274","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[17]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[17]","prefix":"brach et al., who found two metabolites in human excreta of ","suffix":": one of them is the N-carbamoylglucuronide, catalyzed by th","exact":"varenicline"},{"setid":"PMC3571969","drugname":"atorvastatin","startOffset":"481","endOffset":"493","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[4]","prefix":"r risk of the patient due to MetS into consideration, 20 mg ","suffix":" per day was added to the therapy. Similarly, a control labo","exact":"atorvastatin"},{"setid":"PMC3571969","drugname":"lactate","startOffset":"166","endOffset":"173","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[8]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[8]","prefix":"vated, while GGT remained in the normal range (38 U/l). The ","suffix":" dehydrogenase (LDH) level was also increased, 463 U/l. Stat","exact":"lactate"},{"setid":"PMC3571969","drugname":"lactate","startOffset":"290","endOffset":"297","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","prefix":"ine transaminases; GGT: Gamma glutamyl transpeptidase; LDH: ","suffix":" dehydrogenase; CYP: Cytochrome P enzyme; GFR: Glomerular fi","exact":"Lactate"},{"setid":"PMC3571969","drugname":"thyroid-stimulating hormone","startOffset":"739","endOffset":"766","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[8]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[8]","prefix":"normalities, and the thyroid function test was also normal (","suffix":" 1.42 μU/ml). As the patient remained asymptomatic, and the ","exact":"thyroid-stimulating hormone"},{"setid":"PMC3571969","drugname":"gemfibrozil","startOffset":"159","endOffset":"170","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[14]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[14]","prefix":" cause of it was probably the atrovastatin as compared with ","suffix":", fenofibrate were found to be less prone to make complicati","exact":"gemfibrozil"},{"setid":"PMC3571969","drugname":"ethanol","startOffset":"197","endOffset":"204","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[16]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[16]","prefix":"-induced statin-myopathy as in low amounts (12.7-38.1 ml of ","suffix":" per day in men) it was not found to be harmful [","exact":"ethanol"}],[{"setid":"PMC2602841","drugname":"sitagliptin","startOffset":"143","endOffset":"154","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":"ess, and tenderness after starting treatment with high dose ","suffix":" while on simvastatin. The patient had acute renal failure a","exact":"sitagliptin"},{"setid":"PMC2602841","drugname":"sitagliptin","startOffset":"265","endOffset":"276","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":"failure and rhabdomyolysis which resolved with cessation of ","suffix":", simvastatin, ezetimibe, diuretics and olmesartan. All drug","exact":"sitagliptin"},{"setid":"PMC2602841","drugname":"sitagliptin","startOffset":"345","endOffset":"356","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":"atin, ezetimibe, diuretics and olmesartan. All drugs except ","suffix":" and ezetimibe, simvastatin were resumed, and the patient wa","exact":"sitagliptin"},{"setid":"PMC2602841","drugname":"sitagliptin","startOffset":"14","endOffset":"25","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"High doses of ","suffix":" may have worsened this patient's renal failure and precipit","exact":"sitagliptin"},{"setid":"PMC2602841","drugname":"sitagliptin","startOffset":"185","endOffset":"196","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"ating levels of simvastatin. Given the high likelihood that ","suffix":" will be co-administered with statins and renally active med","exact":"sitagliptin"},{"setid":"PMC2602841","drugname":"sitagliptin","startOffset":"303","endOffset":"314","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"ly active medications, further study of long-term safety of ","suffix":" in renal sufficiency may be warranted.","exact":"sitagliptin"},{"setid":"PMC2602841","drugname":"sitagliptin","startOffset":"0","endOffset":"11","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","prefix":"","suffix":", a new oral glucose lowering medication, is already used wi","exact":"Sitagliptin"},{"setid":"PMC2602841","drugname":"sitagliptin","startOffset":"359","endOffset":"370","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","prefix":"reased glucagon production. The most common side effects of ","suffix":" include headache and pharyngitis, and few serious adverse e","exact":"sitagliptin"},{"setid":"PMC2602841","drugname":"sitagliptin","startOffset":"823","endOffset":"834","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","prefix":" in renal insufficiency. Single dose studies suggested that ","suffix":" may be used in the setting of renal insufficiency, but data","exact":"sitagliptin"},{"setid":"PMC2602841","drugname":"sitagliptin","startOffset":"1093","endOffset":"1104","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","prefix":"al failure and rhabdomyolysis after starting treatment with ","suffix":".","exact":"sitagliptin"},{"setid":"PMC2602841","drugname":"sitagliptin","startOffset":"612","endOffset":"623","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","prefix":"ibe 10 mg daily was added without incident. He began taking ","suffix":" 50 mg daily 6 weeks prior to presentation, increasing his d","exact":"sitagliptin"},{"setid":"PMC2602841","drugname":"sitagliptin","startOffset":"737","endOffset":"748","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","prefix":" his dose 3 weeks later to 100 mg daily. One week after the ","suffix":" dose was increased, he noted the onset of pain and tenderne","exact":"sitagliptin"},{"setid":"PMC2602841","drugname":"sitagliptin","startOffset":"1226","endOffset":"1237","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","prefix":"cute renal failure, and olmesartan, bumetanide, metolazone, ","suffix":", simvastatin, and ezetimibe were all stopped. His creatine ","exact":"sitagliptin"},{"setid":"PMC2602841","drugname":"sitagliptin","startOffset":"1461","endOffset":"1472","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","prefix":" resumed all medications except simvastatin, ezetimibe, and ","suffix":". He later started lovastatin which was increased to a dose ","exact":"sitagliptin"},{"setid":"PMC2602841","drugname":"sitagliptin","startOffset":"56","endOffset":"67","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","prefix":"Rhabdomyolysis was not reported in clinical trials with ","suffix":", although it is a well-documented side effect of statins. T","exact":"sitagliptin"},{"setid":"PMC2602841","drugname":"sitagliptin","startOffset":"345","endOffset":"356","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","prefix":"of myopathy. At presentation, the patient was taking 100 mg ","suffix":", double the recommended dose given his renal function. (","exact":"sitagliptin"},{"setid":"PMC2602841","drugname":"sitagliptin","startOffset":"19","endOffset":"30","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","prefix":"The association of ","suffix":" and renal insufficiency in this case is classified as “poss","exact":"sitagliptin"},{"setid":"PMC2602841","drugname":"sitagliptin","startOffset":"430","endOffset":"441","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[3]","prefix":"uggesting that this event was precipitated by initiation of ","suffix":" therapy.","exact":"sitagliptin"},{"setid":"PMC2602841","drugname":"sitagliptin","startOffset":"31","endOffset":"42","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","prefix":"Given the high likelihood that ","suffix":" will be co-administered with renally active drugs and stati","exact":"sitagliptin"},{"setid":"PMC2602841","drugname":"sitagliptin","startOffset":"211","endOffset":"222","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","prefix":"t that additional studies regarding the long-term safety of ","suffix":" in renal insufficiency may be warranted.","exact":"sitagliptin"},{"setid":"PMC2602841","drugname":"simvastatin","startOffset":"164","endOffset":"175","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":"fter starting treatment with high dose sitagliptin while on ","suffix":". The patient had acute renal failure and rhabdomyolysis whi","exact":"simvastatin"},{"setid":"PMC2602841","drugname":"simvastatin","startOffset":"278","endOffset":"289","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":"habdomyolysis which resolved with cessation of sitagliptin, ","suffix":", ezetimibe, diuretics and olmesartan. All drugs except sita","exact":"simvastatin"},{"setid":"PMC2602841","drugname":"simvastatin","startOffset":"372","endOffset":"383","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":"and olmesartan. All drugs except sitagliptin and ezetimibe, ","suffix":" were resumed, and the patient was subsequently started on l","exact":"simvastatin"},{"setid":"PMC2602841","drugname":"simvastatin","startOffset":"141","endOffset":"152","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"ipitated rhabdomyolysis by increasing circulating levels of ","suffix":". Given the high likelihood that sitagliptin will be co-admi","exact":"simvastatin"},{"setid":"PMC2602841","drugname":"simvastatin","startOffset":"416","endOffset":"427","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","prefix":"tolazone, amiodarone, bumetanide, glipizide, levothyroxine, ","suffix":", and ezetimibe. Four months prior to presentation, his simv","exact":"simvastatin"},{"setid":"PMC2602841","drugname":"simvastatin","startOffset":"483","endOffset":"494","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","prefix":"atin, and ezetimibe. Four months prior to presentation, his ","suffix":" dose had been increased from 40 to 80 mg daily and ezetimib","exact":"simvastatin"},{"setid":"PMC2602841","drugname":"simvastatin","startOffset":"1239","endOffset":"1250","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","prefix":"ilure, and olmesartan, bumetanide, metolazone, sitagliptin, ","suffix":", and ezetimibe were all stopped. His creatine kinase levels","exact":"simvastatin"},{"setid":"PMC2602841","drugname":"simvastatin","startOffset":"1433","endOffset":"1444","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","prefix":"o baseline within 7 days. He resumed all medications except ","suffix":", ezetimibe, and sitagliptin. He later started lovastatin wh","exact":"simvastatin"},{"setid":"PMC2602841","drugname":"simvastatin","startOffset":"254","endOffset":"265","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[3]","prefix":"s had been stable for months, and the patient had tolerated ","suffix":" and ezetemibe for at least 4 months prior to the onset of s","exact":"simvastatin"},{"setid":"PMC2602841","drugname":"ezetimibe","startOffset":"291","endOffset":"300","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":" which resolved with cessation of sitagliptin, simvastatin, ","suffix":", diuretics and olmesartan. All drugs except sitagliptin and","exact":"ezetimibe"},{"setid":"PMC2602841","drugname":"ezetimibe","startOffset":"361","endOffset":"370","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":" diuretics and olmesartan. All drugs except sitagliptin and ","suffix":", simvastatin were resumed, and the patient was subsequently","exact":"ezetimibe"},{"setid":"PMC2602841","drugname":"ezetimibe","startOffset":"433","endOffset":"442","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","prefix":"one, bumetanide, glipizide, levothyroxine, simvastatin, and ","suffix":". Four months prior to presentation, his simvastatin dose ha","exact":"ezetimibe"},{"setid":"PMC2602841","drugname":"ezetimibe","startOffset":"546","endOffset":"555","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","prefix":"vastatin dose had been increased from 40 to 80 mg daily and ","suffix":" 10 mg daily was added without incident. He began taking sit","exact":"ezetimibe"},{"setid":"PMC2602841","drugname":"ezetimibe","startOffset":"1256","endOffset":"1265","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","prefix":"rtan, bumetanide, metolazone, sitagliptin, simvastatin, and ","suffix":" were all stopped. His creatine kinase levels fell, his symp","exact":"ezetimibe"},{"setid":"PMC2602841","drugname":"ezetimibe","startOffset":"1446","endOffset":"1455","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","prefix":"thin 7 days. He resumed all medications except simvastatin, ","suffix":", and sitagliptin. He later started lovastatin which was inc","exact":"ezetimibe"},{"setid":"PMC2602841","drugname":"olmesartan","startOffset":"316","endOffset":"326","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":"ation of sitagliptin, simvastatin, ezetimibe, diuretics and ","suffix":". All drugs except sitagliptin and ezetimibe, simvastatin we","exact":"olmesartan"},{"setid":"PMC2602841","drugname":"olmesartan","startOffset":"321","endOffset":"331","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","prefix":" 204 μmol/L. His medications included aspirin, clopidogrel, ","suffix":", carvedilol, insulin, metolazone, amiodarone, bumetanide, g","exact":"olmesartan"},{"setid":"PMC2602841","drugname":"olmesartan","startOffset":"1190","endOffset":"1200","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","prefix":"o hospital with rhabdomyolysis and acute renal failure, and ","suffix":", bumetanide, metolazone, sitagliptin, simvastatin, and ezet","exact":"olmesartan"},{"setid":"PMC2602841","drugname":"lovastatin","startOffset":"442","endOffset":"452","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":"n were resumed, and the patient was subsequently started on ","suffix":" without recurrence of rhabdomyolysis.","exact":"lovastatin"},{"setid":"PMC2602841","drugname":"lovastatin","startOffset":"1491","endOffset":"1501","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","prefix":"t simvastatin, ezetimibe, and sitagliptin. He later started ","suffix":" which was increased to a dose of 10 mg daily without recurr","exact":"lovastatin"},{"setid":"PMC2602841","drugname":"glucagon","startOffset":"215","endOffset":"223","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","prefix":" IV enzyme thereby prolonging the post-prandial activity of ","suffix":"-like-peptide-1 (GLP-1). This results in increased insulin s","exact":"glucagon"},{"setid":"PMC2602841","drugname":"glucagon","startOffset":"306","endOffset":"314","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","prefix":". This results in increased insulin secretion and decreased ","suffix":" production. The most common side effects of sitagliptin inc","exact":"glucagon"},{"setid":"PMC2602841","drugname":"insulin","startOffset":"274","endOffset":"281","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","prefix":" glucagon-like-peptide-1 (GLP-1). This results in increased ","suffix":" secretion and decreased glucagon production. The most commo","exact":"insulin"},{"setid":"PMC2602841","drugname":"insulin","startOffset":"345","endOffset":"352","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","prefix":"ions included aspirin, clopidogrel, olmesartan, carvedilol, ","suffix":", metolazone, amiodarone, bumetanide, glipizide, levothyroxi","exact":"insulin"},{"setid":"PMC2602841","drugname":"vildagliptin","startOffset":"660","endOffset":"672","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","prefix":" organ of toxicity, and approval of its nearest competitor, ","suffix":", by the Federal Drug Administration (FDA) has been delayed ","exact":"vildagliptin"},{"setid":"PMC2602841","drugname":"creatinine","startOffset":"248","endOffset":"258","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","prefix":"al fibrillation, and chronic kidney disease with a baseline ","suffix":" of 204 μmol/L. His medications included aspirin, clopidogre","exact":"creatinine"},{"setid":"PMC2602841","drugname":"creatinine","startOffset":"1048","endOffset":"1058","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","prefix":"les in both legs. Laboratory tests revealed urea 43 mmol/L, ","suffix":" 398 μmol/L, and creatine kinase 22,000 IU/L. The patient wa","exact":"creatinine"},{"setid":"PMC2602841","drugname":"aspirin","startOffset":"299","endOffset":"306","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","prefix":"baseline creatinine of 204 μmol/L. His medications included ","suffix":", clopidogrel, olmesartan, carvedilol, insulin, metolazone, ","exact":"aspirin"},{"setid":"PMC2602841","drugname":"clopidogrel","startOffset":"308","endOffset":"319","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","prefix":"creatinine of 204 μmol/L. His medications included aspirin, ","suffix":", olmesartan, carvedilol, insulin, metolazone, amiodarone, b","exact":"clopidogrel"},{"setid":"PMC2602841","drugname":"carvedilol","startOffset":"333","endOffset":"343","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","prefix":" His medications included aspirin, clopidogrel, olmesartan, ","suffix":", insulin, metolazone, amiodarone, bumetanide, glipizide, le","exact":"carvedilol"},{"setid":"PMC2602841","drugname":"metolazone","startOffset":"354","endOffset":"364","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","prefix":"uded aspirin, clopidogrel, olmesartan, carvedilol, insulin, ","suffix":", amiodarone, bumetanide, glipizide, levothyroxine, simvasta","exact":"metolazone"},{"setid":"PMC2602841","drugname":"metolazone","startOffset":"1214","endOffset":"1224","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","prefix":"olysis and acute renal failure, and olmesartan, bumetanide, ","suffix":", sitagliptin, simvastatin, and ezetimibe were all stopped. ","exact":"metolazone"},{"setid":"PMC2602841","drugname":"amiodarone","startOffset":"366","endOffset":"376","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","prefix":", clopidogrel, olmesartan, carvedilol, insulin, metolazone, ","suffix":", bumetanide, glipizide, levothyroxine, simvastatin, and eze","exact":"amiodarone"},{"setid":"PMC2602841","drugname":"bumetanide","startOffset":"378","endOffset":"388","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","prefix":"l, olmesartan, carvedilol, insulin, metolazone, amiodarone, ","suffix":", glipizide, levothyroxine, simvastatin, and ezetimibe. Four","exact":"bumetanide"},{"setid":"PMC2602841","drugname":"bumetanide","startOffset":"1202","endOffset":"1212","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","prefix":"ith rhabdomyolysis and acute renal failure, and olmesartan, ","suffix":", metolazone, sitagliptin, simvastatin, and ezetimibe were a","exact":"bumetanide"},{"setid":"PMC2602841","drugname":"glipizide","startOffset":"390","endOffset":"399","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","prefix":"n, carvedilol, insulin, metolazone, amiodarone, bumetanide, ","suffix":", levothyroxine, simvastatin, and ezetimibe. Four months pri","exact":"glipizide"},{"setid":"PMC2602841","drugname":"levothyroxine","startOffset":"401","endOffset":"414","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","prefix":"ol, insulin, metolazone, amiodarone, bumetanide, glipizide, ","suffix":", simvastatin, and ezetimibe. Four months prior to presentat","exact":"levothyroxine"},{"setid":"PMC2602841","drugname":"urea","startOffset":"1032","endOffset":"1036","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/p[1]","prefix":"he proximal muscles in both legs. Laboratory tests revealed ","suffix":" 43 mmol/L, creatinine 398 μmol/L, and creatine kinase 22,00","exact":"urea"}],[{"setid":"PMC3477350","drugname":"rifampicin","startOffset":"154","endOffset":"164","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":"ived a single dose of dabigatran etexilate 150 mg on day 1, ","suffix":" 600 mg once daily on days 2–8, and single doses of dabigatr","exact":"rifampicin"},{"setid":"PMC3477350","drugname":"rifampicin","startOffset":"214","endOffset":"224","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":" administration of dabigatran etexilate following 7 days of ","suffix":" (treatment B) decreased the geometric mean (gMean) area und","exact":"rifampicin"},{"setid":"PMC3477350","drugname":"rifampicin","startOffset":"18","endOffset":"28","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","prefix":"Administration of ","suffix":" for 7 days resulted in a significant reduction in the bioav","exact":"rifampicin"},{"setid":"PMC3477350","drugname":"rifampicin","startOffset":"56","endOffset":"66","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","prefix":"dabigatran etexilate, drug interaction, P-glycoprotein, ","suffix":"","exact":"rifampicin"},{"setid":"PMC3477350","drugname":"rifampicin","startOffset":"18","endOffset":"28","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","prefix":"Administration of ","suffix":" for 7 days resulted in a significant reduction in the bioav","exact":"rifampicin"},{"setid":"PMC3477350","drugname":"rifampicin","startOffset":"18","endOffset":"28","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/div[1]/ul[1]/li[1]/div[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/div[1]/ul[1]/li[1]/div[1]","prefix":"Administration of ","suffix":" (a strong P-gp inducer) for 7 days before a single dose of ","exact":"rifampicin"},{"setid":"PMC3477350","drugname":"rifampicin","startOffset":"41","endOffset":"51","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/div[1]/ul[1]/li[2]/div[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/div[1]/ul[1]/li[2]/div[1]","prefix":"Within 7 days following the cessation of ","suffix":" administration, the bioavailability of dabigatran returned ","exact":"rifampicin"},{"setid":"PMC3477350","drugname":"rifampicin","startOffset":"0","endOffset":"10","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/div[1]/ul[1]/li[3]/div[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/div[1]/ul[1]/li[3]/div[1]","prefix":"","suffix":" is not recommended for use with dabigatran etexilate becaus","exact":"Rifampicin"},{"setid":"PMC3477350","drugname":"rifampicin","startOffset":"24","endOffset":"34","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[4]","prefix":"The antibacterial agent ","suffix":" (used primarily in the treatment of tuberculosis) is a stro","exact":"rifampicin"},{"setid":"PMC3477350","drugname":"rifampicin","startOffset":"99","endOffset":"109","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[5]","prefix":"to determine whether, and to what extent, the P-gp inducer, ","suffix":", affects the plasma exposure of dabigatran by investigating","exact":"rifampicin"},{"setid":"PMC3477350","drugname":"rifampicin","startOffset":"202","endOffset":"212","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[5]","prefix":"dabigatran by investigating the effect of multiple doses of ","suffix":" 600 mg once daily on the PK parameters of dabigatran follow","exact":"rifampicin"},{"setid":"PMC3477350","drugname":"rifampicin","startOffset":"493","endOffset":"503","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[5]","prefix":"preted as normal activity levels of P-gp after induction by ","suffix":". The doses selected for investigation reflect standard clin","exact":"rifampicin"},{"setid":"PMC3477350","drugname":"rifampicin","startOffset":"577","endOffset":"587","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[5]","prefix":"lected for investigation reflect standard clinical doses of ","suffix":" and dabigatran etexilate, and were expected to allow an ade","exact":"rifampicin"},{"setid":"PMC3477350","drugname":"rifampicin","startOffset":"741","endOffset":"751","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[5]","prefix":"meters of dabigatran after P-gp induction. The induction by ","suffix":" was to be confirmed further by measurement of a surrogate e","exact":"rifampicin"},{"setid":"PMC3477350","drugname":"rifampicin","startOffset":"89","endOffset":"99","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[6]","prefix":" to determine the safety and tolerability of dabigatran and ","suffix":" coadministration, and to determine the duration of the effe","exact":"rifampicin"},{"setid":"PMC3477350","drugname":"rifampicin","startOffset":"199","endOffset":"209","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[6]","prefix":"duration of the effect of P-gp induction after cessation of ","suffix":" treatment. If an interaction between rifampicin and dabigat","exact":"rifampicin"},{"setid":"PMC3477350","drugname":"rifampicin","startOffset":"247","endOffset":"257","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[6]","prefix":"essation of rifampicin treatment. If an interaction between ","suffix":" and dabigatran was observed, it was expected that this woul","exact":"rifampicin"},{"setid":"PMC3477350","drugname":"rifampicin","startOffset":"241","endOffset":"251","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","prefix":"en as single doses, either alone or after multiple doses of ","suffix":", or after cessation of rifampicin. Twenty-four subjects wer","exact":"rifampicin"},{"setid":"PMC3477350","drugname":"rifampicin","startOffset":"275","endOffset":"285","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","prefix":"r after multiple doses of rifampicin, or after cessation of ","suffix":". Twenty-four subjects were to be enrolled, with at least ei","exact":"rifampicin"},{"setid":"PMC3477350","drugname":"rifampicin","startOffset":"142","endOffset":"152","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[2]","prefix":"inistered as 150 mg hydroxypropyl methylcellulose capsules. ","suffix":" was administered as the commercially available Rifa® 600 mg","exact":"Rifampicin"},{"setid":"PMC3477350","drugname":"rifampicin","startOffset":"56","endOffset":"66","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","prefix":"dabigatran etexilate, drug interaction, P-glycoprotein, ","suffix":"","exact":"rifampicin"},{"setid":"PMC3477350","drugname":"rifampicin","startOffset":"117","endOffset":"127","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[2]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[2]/div[1]/div[2]/span[1]","prefix":"nistration of dabigatran etexilate 150 mg, with and without ","suffix":"","exact":"rifampicin"},{"setid":"PMC3477350","drugname":"rifampicin","startOffset":"191","endOffset":"201","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[5]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[5]/div[1]/div[2]/span[1]","prefix":"nistration of dabigatran etexilate 150 mg, with and without ","suffix":"","exact":"rifampicin"},{"setid":"PMC3477350","drugname":"rifampicin","startOffset":"213","endOffset":"223","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/div[1]/div[1]/div[2]/span[1]","prefix":"atran etexilate was always given in the morning at 08.00 h. ","suffix":" was always administered in","exact":"Rifampicin"},{"setid":"PMC3477350","drugname":"rifampicin","startOffset":"199","endOffset":"209","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[2]","prefix":"al or hormonal disorders, risk of bleeding, previous use of ","suffix":" or other P-gp or CYP450 inhibitors/inducers within 4 weeks ","exact":"rifampicin"},{"setid":"PMC3477350","drugname":"rifampicin","startOffset":"144","endOffset":"154","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[2]","prefix":"exilate 150 mg after 7 days of washout since last intake of ","suffix":" 600 mg) and reference treatment A, and between treatment D ","exact":"rifampicin"},{"setid":"PMC3477350","drugname":"rifampicin","startOffset":"305","endOffset":"315","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[2]","prefix":"ilate 150 mg after 14 days washout after the last intake of ","suffix":" 600 mg) and reference treatment A.","exact":"rifampicin"},{"setid":"PMC3477350","drugname":"rifampicin","startOffset":"389","endOffset":"399","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[6]","prefix":"n in the morning after subjects had received three doses of ","suffix":" during treatment B and before administration of dabigatran ","exact":"rifampicin"},{"setid":"PMC3477350","drugname":"rifampicin","startOffset":"117","endOffset":"127","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[2]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[2]/div[1]/div[2]/span[1]","prefix":"nistration of dabigatran etexilate 150 mg, with and without ","suffix":"","exact":"rifampicin"},{"setid":"PMC3477350","drugname":"rifampicin","startOffset":"191","endOffset":"201","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[5]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[5]/div[1]/div[2]/span[1]","prefix":"nistration of dabigatran etexilate 150 mg, with and without ","suffix":"","exact":"rifampicin"},{"setid":"PMC3477350","drugname":"rifampicin","startOffset":"117","endOffset":"127","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[2]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[2]/div[1]/div[2]/span[1]","prefix":"nistration of dabigatran etexilate 150 mg, with and without ","suffix":"","exact":"rifampicin"},{"setid":"PMC3477350","drugname":"rifampicin","startOffset":"191","endOffset":"201","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[5]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[5]/div[1]/div[2]/span[1]","prefix":"nistration of dabigatran etexilate 150 mg, with and without ","suffix":"","exact":"rifampicin"},{"setid":"PMC3477350","drugname":"rifampicin","startOffset":"117","endOffset":"127","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[2]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[2]/div[1]/div[2]/span[1]","prefix":"nistration of dabigatran etexilate 150 mg, with and without ","suffix":"","exact":"rifampicin"},{"setid":"PMC3477350","drugname":"rifampicin","startOffset":"191","endOffset":"201","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[5]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[5]/div[1]/div[2]/span[1]","prefix":"nistration of dabigatran etexilate 150 mg, with and without ","suffix":"","exact":"rifampicin"},{"setid":"PMC3477350","drugname":"rifampicin","startOffset":"117","endOffset":"127","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[2]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[2]/div[1]/div[2]/span[1]","prefix":"nistration of dabigatran etexilate 150 mg, with and without ","suffix":"","exact":"rifampicin"},{"setid":"PMC3477350","drugname":"rifampicin","startOffset":"191","endOffset":"201","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[5]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[5]/div[1]/div[2]/span[1]","prefix":"nistration of dabigatran etexilate 150 mg, with and without ","suffix":"","exact":"rifampicin"},{"setid":"PMC3477350","drugname":"rifampicin","startOffset":"106","endOffset":"116","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[2]","prefix":"n etexilate alone), the administration of the P-gp inducer, ","suffix":", over 7 days (treatment B) resulted in a significant reduct","exact":"rifampicin"},{"setid":"PMC3477350","drugname":"rifampicin","startOffset":"218","endOffset":"228","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[3]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[3]/div[1]/div[2]/span[1]","prefix":" treatment A) and after administration of multiple doses of ","suffix":" (test 1; treatment B)","exact":"rifampicin"},{"setid":"PMC3477350","drugname":"rifampicin","startOffset":"96","endOffset":"106","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[4]","prefix":"tran etexilate after a 7 day washout after the last dose of ","suffix":" (treatment C, day 16), AUC","exact":"rifampicin"},{"setid":"PMC3477350","drugname":"rifampicin","startOffset":"117","endOffset":"127","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[2]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[2]/div[1]/div[2]/span[1]","prefix":"nistration of dabigatran etexilate 150 mg, with and without ","suffix":"","exact":"rifampicin"},{"setid":"PMC3477350","drugname":"rifampicin","startOffset":"191","endOffset":"201","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[5]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[5]/div[1]/div[2]/span[1]","prefix":"nistration of dabigatran etexilate 150 mg, with and without ","suffix":"","exact":"rifampicin"},{"setid":"PMC3477350","drugname":"rifampicin","startOffset":"246","endOffset":"256","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/p[1]","prefix":" 22.0 (48.5), indicating CYP450 3A induction as a result of ","suffix":" administration. The urinary 6β-hydroxycortisol/cortisol rat","exact":"rifampicin"},{"setid":"PMC3477350","drugname":"rifampicin","startOffset":"450","endOffset":"460","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/p[1]","prefix":"baseline by day 23, 2 weeks after the end of treatment with ","suffix":".","exact":"rifampicin"},{"setid":"PMC3477350","drugname":"rifampicin","startOffset":"162","endOffset":"172","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[5]/p[2]","prefix":"%) subjects during treatment with dabigatran etexilate plus ","suffix":" and two (8.3%) subjects during treatment with rifampicin al","exact":"rifampicin"},{"setid":"PMC3477350","drugname":"rifampicin","startOffset":"219","endOffset":"229","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[5]/p[2]","prefix":"us rifampicin and two (8.3%) subjects during treatment with ","suffix":" alone (","exact":"rifampicin"},{"setid":"PMC3477350","drugname":"rifampicin","startOffset":"121","endOffset":"131","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[5]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[5]/p[3]","prefix":"s, with headache the most common (dabigatran, two subjects; ","suffix":", one subject; and dabigatran plus rifampicin, three subject","exact":"rifampicin"},{"setid":"PMC3477350","drugname":"rifampicin","startOffset":"166","endOffset":"176","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[5]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[5]/p[3]","prefix":" two subjects; rifampicin, one subject; and dabigatran plus ","suffix":", three subjects). No other AEs were reported during treatme","exact":"rifampicin"},{"setid":"PMC3477350","drugname":"rifampicin","startOffset":"358","endOffset":"368","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[5]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[5]/p[3]","prefix":"hyperhidrosis (one subject each) during the dabigatran plus ","suffix":" period; dizziness, nausea, oropharyngeal pain, vomiting and","exact":"rifampicin"},{"setid":"PMC3477350","drugname":"rifampicin","startOffset":"467","endOffset":"477","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[5]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[5]/p[3]","prefix":"al pain, vomiting and fatigue (one subject each) during the ","suffix":" alone period; and nausea (one subject) during the washout a","exact":"rifampicin"},{"setid":"PMC3477350","drugname":"rifampicin","startOffset":"37","endOffset":"47","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","prefix":"In this study, the administration of ","suffix":" for 7 days resulted in a significant and relevant reduction","exact":"rifampicin"},{"setid":"PMC3477350","drugname":"rifampicin","startOffset":"22","endOffset":"32","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","prefix":"In the present trial, ","suffix":" administration also induced CYP3A, as shown by an elevated ","exact":"rifampicin"},{"setid":"PMC3477350","drugname":"rifampicin","startOffset":"53","endOffset":"63","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","prefix":"The reduction of the total dabigatran exposure after ","suffix":" pretreatment seen in this trial was of similar magnitude or","exact":"rifampicin"},{"setid":"PMC3477350","drugname":"rifampicin","startOffset":"96","endOffset":"106","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[6]","prefix":"e absorbed mainly in the duodenum. The pronounced effect of ","suffix":" on dabigatran kinetics might, thus, be due to a remarkable ","exact":"rifampicin"},{"setid":"PMC3477350","drugname":"rifampicin","startOffset":"86","endOffset":"96","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[1]/h1[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[1]/h1[1]","prefix":"ailability of dabigatran etexilate after co-medication with ","suffix":"","exact":"rifampicin"},{"setid":"PMC3477350","drugname":"rifampicin","startOffset":"450","endOffset":"460","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/p[1]","prefix":"baseline by day 23, 2 weeks after the end of treatment with ","suffix":".","exact":"rifampicin"},{"setid":"PMC3477350","drugname":"rifampicin","startOffset":"238","endOffset":"248","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[6]","prefix":"duodenal P-gp expression (about a threefold increase) after ","suffix":", as reported ","exact":"rifampicin"},{"setid":"PMC3477350","drugname":"rifampicin","startOffset":"86","endOffset":"96","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[5]/div[2]/div[1]/div[1]/ul[1]/li[1]/div[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[5]/div[2]/div[1]/div[1]/ul[1]/li[1]/div[1]","prefix":"ailability of dabigatran etexilate after co-medication with ","suffix":"","exact":"rifampicin"},{"setid":"PMC3477350","drugname":"rifampicin","startOffset":"142","endOffset":"152","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[8]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[8]","prefix":"was well tolerated when given alone and in combination with ","suffix":". The results were in line with the known safety profile of ","exact":"rifampicin"},{"setid":"PMC3477350","drugname":"rifampicin","startOffset":"75","endOffset":"85","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[9]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[9]","prefix":"two-thirds in dabigatran exposure due to a 1 week course of ","suffix":" has clinically relevant consequences. Patients undergoing o","exact":"rifampicin"},{"setid":"PMC3477350","drugname":"rifampicin","startOffset":"321","endOffset":"331","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[9]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[9]","prefix":"rapeutic concentrations of dabigatran if they have received ","suffix":" immediately before surgery. Dabigatran etexilate is also in","exact":"rifampicin"},{"setid":"PMC3477350","drugname":"rifampicin","startOffset":"34","endOffset":"44","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[10]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[10]","prefix":"In summary, the administration of ","suffix":", a P-gp inducer, for 7 days resulted in a statistically sig","exact":"rifampicin"},{"setid":"PMC3477350","drugname":"rifampicin","startOffset":"292","endOffset":"302","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[10]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[10]","prefix":"ealthy volunteers. Within 7 days following the cessation of ","suffix":" administration, the bioavailability returned almost to base","exact":"rifampicin"},{"setid":"PMC3477350","drugname":"rifampicin","startOffset":"443","endOffset":"453","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[10]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[10]","prefix":" the potential for reduced systemic exposure to dabigatran, ","suffix":" and other P-gp inducers (e.g. carbamazepine and St John's w","exact":"rifampicin"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":"108","endOffset":"118","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[1]/p[1]","prefix":"lycoprotein inducer, rifampicin, on the pharmacokinetics of ","suffix":" following oral administration of the prodrug, dabigatran et","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":"102","endOffset":"112","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","prefix":"sulted in a significant reduction in the bioavailability of ","suffix":", which returned almost to baseline after 7 days washout.","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":"69","endOffset":"79","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[1]/div[1]/div[1]/ul[1]/li[1]/div[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[1]/div[1]/div[1]/ul[1]/li[1]/div[1]","prefix":"n etexilate is an oral prodrug that is rapidly converted to ","suffix":", a direct and reversible thrombin inhibitor.","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":"25","endOffset":"35","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[1]/div[1]/div[1]/ul[1]/li[2]/div[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[1]/div[1]/div[1]/ul[1]/li[2]/div[1]","prefix":"Dabigatran etexilate and ","suffix":" are not metabolized by the cytochrome P450 system, and dabi","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":"91","endOffset":"101","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[1]/div[1]/div[1]/ul[1]/li[2]/div[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[1]/div[1]/div[1]/ul[1]/li[2]/div[1]","prefix":"tran are not metabolized by the cytochrome P450 system, and ","suffix":" does not affect the metabolism of other drugs that utilize ","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":"30","endOffset":"40","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[1]/div[1]/div[1]/ul[1]/li[3]/div[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[1]/div[1]/div[1]/ul[1]/li[3]/div[1]","prefix":"Dabigatran etexilate, but not ","suffix":", is a P-glycoprotein (P-gp) substrate, and the bioavailabil","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":"107","endOffset":"117","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[1]/div[1]/div[1]/ul[1]/li[3]/div[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[1]/div[1]/div[1]/ul[1]/li[3]/div[1]","prefix":"P-glycoprotein (P-gp) substrate, and the bioavailability of ","suffix":" may be altered by P-gp inhibitors or inducers.","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":"171","endOffset":"181","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/div[1]/ul[1]/li[1]/div[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/div[1]/ul[1]/li[1]/div[1]","prefix":"sulted in a significant reduction in the bioavailability of ","suffix":" compared with administration of dabigatran etexilate alone.","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":"91","endOffset":"101","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/div[1]/ul[1]/li[2]/div[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/div[1]/ul[1]/li[2]/div[1]","prefix":"sation of rifampicin administration, the bioavailability of ","suffix":" returned almost to baseline values.","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":"122","endOffset":"132","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/div[1]/ul[1]/li[3]/div[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/div[1]/ul[1]/li[3]/div[1]","prefix":"e because of the potential for reduced systemic exposure to ","suffix":".","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":"141","endOffset":"151","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","prefix":"diates, BIBR 1087 SE and BIBR 951 BS, to the active moiety, ","suffix":", a direct and reversible thrombin inhibitor. Dabigatran is ","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":"197","endOffset":"207","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","prefix":"ty, dabigatran, a direct and reversible thrombin inhibitor. ","suffix":" is partly conjugated with activated glucuronic acid to form","exact":"Dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":"317","endOffset":"327","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","prefix":"id to form a pharmacologically equipotent glucuronide. Free ","suffix":" and total dabigatran (sum of free and glucuronidated dabiga","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":"0","endOffset":"10","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","prefix":"","suffix":" etexilate, drug interaction, P-glycoprotein, rifampicin","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":"338","endOffset":"348","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","prefix":"logically equipotent glucuronide. Free dabigatran and total ","suffix":" (sum of free and glucuronidated dabigatran) reach peak plas","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":"0","endOffset":"10","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","prefix":"","suffix":" etexilate, drug interaction, P-glycoprotein, rifampicin","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":"381","endOffset":"391","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","prefix":"gatran and total dabigatran (sum of free and glucuronidated ","suffix":") reach peak plasma concentrations after approximately 1.5 h","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":"25","endOffset":"35","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[1]/div[1]/div[1]/ul[1]/li[2]/div[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[1]/div[1]/div[1]/ul[1]/li[2]/div[1]","prefix":"Dabigatran etexilate and ","suffix":" are not metabolized by the cytochrome P450 system, and dabi","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":"25","endOffset":"35","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[3]","prefix":"Dabigatran etexilate and ","suffix":" are not metabolized by the cytochrome P450 (CYP) system, an","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":"91","endOffset":"101","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[1]/div[1]/div[1]/ul[1]/li[2]/div[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[1]/div[1]/div[1]/ul[1]/li[2]/div[1]","prefix":"tran are not metabolized by the cytochrome P450 system, and ","suffix":" does not affect the metabolism of other drugs that utilize ","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":"97","endOffset":"107","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[3]","prefix":"re not metabolized by the cytochrome P450 (CYP) system, and ","suffix":" does not affect the metabolism of other drugs that utilize ","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":"0","endOffset":"10","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","prefix":"","suffix":" etexilate, drug interaction, P-glycoprotein, rifampicin","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":"30","endOffset":"40","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[1]/div[1]/div[1]/ul[1]/li[3]/div[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[1]/div[1]/div[1]/ul[1]/li[3]/div[1]","prefix":"Dabigatran etexilate, but not ","suffix":", is a P-glycoprotein (P-gp) substrate, and the bioavailabil","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":"73","endOffset":"83","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","prefix":"nvestigations have shown that dabigatran etexilate (but not ","suffix":" or its intermediate metabolites) is a substrate for the eff","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":"142","endOffset":"152","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[5]","prefix":"he P-gp inducer, rifampicin, affects the plasma exposure of ","suffix":" by investigating the effect of multiple doses of rifampicin","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":"255","endOffset":"265","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[5]","prefix":"ses of rifampicin 600 mg once daily on the PK parameters of ","suffix":" following a single dose of 150 mg dabigatran etexilate. The","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":"401","endOffset":"411","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[5]","prefix":"uated the time course of a return to normal availability of ","suffix":", which could be interpreted as normal activity levels of P-","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":"691","endOffset":"701","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[5]","prefix":" to allow an adequate determination of the PK parameters of ","suffix":" after P-gp induction. The induction by rifampicin was to be","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":"74","endOffset":"84","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[6]","prefix":"objectives were to determine the safety and tolerability of ","suffix":" and rifampicin coadministration, and to determine the durat","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":"262","endOffset":"272","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[6]","prefix":"ampicin treatment. If an interaction between rifampicin and ","suffix":" was observed, it was expected that this would lead to decre","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":"337","endOffset":"347","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[6]","prefix":"observed, it was expected that this would lead to decreased ","suffix":" exposure.","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":"0","endOffset":"10","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","prefix":"","suffix":" etexilate, drug interaction, P-glycoprotein, rifampicin","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":"105","endOffset":"115","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[1]/div[1]/div[2]/span[1]","prefix":"ime profiles (semi-logarithmic scale) of total (a) and free ","suffix":" (b) after a single oral dose of 150 mg dabigatran etexilate","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":"36","endOffset":"46","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[2]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[2]/div[1]/div[2]/span[1]","prefix":"Pharmacokinetic parameters of total ","suffix":" after administration of dabigatran etexilate 150 mg, with a","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":"71","endOffset":"81","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[2]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[2]/div[1]/div[2]/span[1]","prefix":"etic parameters of total dabigatran after administration of ","suffix":" etexilate 150 mg, with and without rifampicin","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":"79","endOffset":"89","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[6]","prefix":"f free dabigatran followed the same trend as those of total ","suffix":" (","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":"140","endOffset":"150","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","prefix":"cant and relevant reduction in the bioavailability of total ","suffix":" (67 and 65.5% reduction in AUC","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":"18","endOffset":"28","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","prefix":"Blood samples for ","suffix":" PK measurements were collected before (−0.5 h) and at 0.5, ","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":"271","endOffset":"281","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","prefix":"atment period. Plasma concentrations of free, nonconjugated ","suffix":", total dabigatran [sum of free and conjugated dabigatran (m","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":"289","endOffset":"299","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","prefix":"sma concentrations of free, nonconjugated dabigatran, total ","suffix":" [sum of free and conjugated dabigatran (measured after alka","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":"0","endOffset":"10","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","prefix":"","suffix":" etexilate, drug interaction, P-glycoprotein, rifampicin","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":"328","endOffset":"338","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","prefix":"ed dabigatran, total dabigatran [sum of free and conjugated ","suffix":" (measured after alkaline cleavage of conjugates)], the prod","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":"108","endOffset":"118","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[2]","prefix":" 2000g–4000g for 10 minutes); for the determination of free ","suffix":", 50 µl of plasma was aliquoted, diluted with 50 µl 0.2 ","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":"0","endOffset":"10","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","prefix":"","suffix":" etexilate, drug interaction, P-glycoprotein, rifampicin","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":"52","endOffset":"62","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[4]","prefix":"The lowest limit of quantification of free or total ","suffix":" was 1 ng ml","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":"19","endOffset":"29","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[5]","prefix":"In addition, total ","suffix":" urine concentrations were measured. The calibration range w","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":"448","endOffset":"458","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[6]","prefix":" rifampicin during treatment B and before administration of ","suffix":" in each respective treatment period. Thus, morning spot uri","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":"71","endOffset":"81","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[1]","prefix":"of the plasma concentration–time profiles of free and total ","suffix":" were highly comparable, as shown in ","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":"0","endOffset":"10","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","prefix":"","suffix":" etexilate, drug interaction, P-glycoprotein, rifampicin","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":"105","endOffset":"115","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[1]/div[1]/div[2]/span[1]","prefix":"ime profiles (semi-logarithmic scale) of total (a) and free ","suffix":" (b) after a single oral dose of 150 mg dabigatran etexilate","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":"155","endOffset":"165","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[1]/div[1]/div[2]/span[1]","prefix":" and free dabigatran (b) after a single oral dose of 150 mg ","suffix":" etexilate on day 1 (reference; treatment A), on day 9 after","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":"36","endOffset":"46","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[2]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[2]/div[1]/div[2]/span[1]","prefix":"Pharmacokinetic parameters of total ","suffix":" after administration of dabigatran etexilate 150 mg, with a","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":"0","endOffset":"10","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","prefix":"","suffix":" etexilate, drug interaction, P-glycoprotein, rifampicin","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":"205","endOffset":"215","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[2]","prefix":"esulted in a significant reduction in the exposure to total ","suffix":" (67% reduction in AUC","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":"26","endOffset":"36","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[6]","prefix":"The PK parameters of free ","suffix":" followed the same trend as those of total dabigatran (","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":"0","endOffset":"10","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","prefix":"","suffix":" etexilate, drug interaction, P-glycoprotein, rifampicin","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":"79","endOffset":"89","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[6]","prefix":"f free dabigatran followed the same trend as those of total ","suffix":" (","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":"0","endOffset":"10","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","prefix":"","suffix":" etexilate, drug interaction, P-glycoprotein, rifampicin","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":"95","endOffset":"105","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[5]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[5]/p[3]","prefix":"re nervous system disorders, with headache the most common (","suffix":", two subjects; rifampicin, one subject; and dabigatran plus","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":"150","endOffset":"160","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[5]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[5]/p[3]","prefix":"mon (dabigatran, two subjects; rifampicin, one subject; and ","suffix":" plus rifampicin, three subjects). No other AEs were reporte","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":"244","endOffset":"254","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[5]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[5]/p[3]","prefix":"subjects). No other AEs were reported during treatment with ","suffix":" alone. Other AEs reported were vertigo and hyperhidrosis (o","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":"342","endOffset":"352","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[5]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[5]/p[3]","prefix":"ere vertigo and hyperhidrosis (one subject each) during the ","suffix":" plus rifampicin period; dizziness, nausea, oropharyngeal pa","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":"73","endOffset":"83","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","prefix":"nvestigations have shown that dabigatran etexilate (but not ","suffix":" or its intermediate metabolites) is a substrate for the eff","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":"233","endOffset":"243","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","prefix":"Previous investigations suggest that the bioavailability of ","suffix":" may be affected by P-gp inhibitors [","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":"0","endOffset":"10","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","prefix":"","suffix":" etexilate, drug interaction, P-glycoprotein, rifampicin","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":"140","endOffset":"150","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","prefix":"cant and relevant reduction in the bioavailability of total ","suffix":" (67 and 65.5% reduction in AUC","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":"27","endOffset":"37","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","prefix":"The reduction of the total ","suffix":" exposure after rifampicin pretreatment seen in this trial w","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":"110","endOffset":"120","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[6]","prefix":"nly in the duodenum. The pronounced effect of rifampicin on ","suffix":" kinetics might, thus, be due to a remarkable increase in du","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":"29","endOffset":"39","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[9]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[9]","prefix":"A reduction of two-thirds in ","suffix":" exposure due to a 1 week course of rifampicin has clinicall","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":"288","endOffset":"298","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[9]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[9]","prefix":"romboembolism may not achieve therapeutic concentrations of ","suffix":" if they have received rifampicin immediately before surgery","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran","startOffset":"431","endOffset":"441","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[10]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[10]","prefix":"es. Owing to the potential for reduced systemic exposure to ","suffix":", rifampicin and other P-gp inducers (e.g. carbamazepine and","exact":"dabigatran"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"165","endOffset":"185","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[1]/p[1]","prefix":"of dabigatran following oral administration of the prodrug, ","suffix":".","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"116","endOffset":"136","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":"y in healthy volunteers. Subjects received a single dose of ","suffix":" 150 mg on day 1, rifampicin 600 mg once daily on days 2–8, ","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"216","endOffset":"236","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":"fampicin 600 mg once daily on days 2–8, and single doses of ","suffix":" on days 9, 16 and 23.","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"113","endOffset":"133","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"d all treatments. Relative to the reference (single dose of ","suffix":" alone; treatment A), administration of dabigatran etexilate","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"173","endOffset":"193","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"dabigatran etexilate alone; treatment A), administration of ","suffix":" following 7 days of rifampicin (treatment B) decreased the ","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"0","endOffset":"20","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","prefix":"","suffix":", drug interaction, P-glycoprotein, rifampicin","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"0","endOffset":"20","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[1]/div[1]/div[1]/ul[1]/li[1]/div[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[1]/div[1]/div[1]/ul[1]/li[1]/div[1]","prefix":"","suffix":" is an oral prodrug that is rapidly converted to dabigatran,","exact":"Dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"0","endOffset":"20","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[1]/div[1]/div[1]/ul[1]/li[2]/div[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[1]/div[1]/div[1]/ul[1]/li[2]/div[1]","prefix":"","suffix":" and dabigatran are not metabolized by the cytochrome P450 s","exact":"Dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"0","endOffset":"20","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[1]/div[1]/div[1]/ul[1]/li[3]/div[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[1]/div[1]/div[1]/ul[1]/li[3]/div[1]","prefix":"","suffix":", but not dabigatran, is a P-glycoprotein (P-gp) substrate, ","exact":"Dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"88","endOffset":"108","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/div[1]/ul[1]/li[1]/div[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/div[1]/ul[1]/li[1]/div[1]","prefix":" (a strong P-gp inducer) for 7 days before a single dose of ","suffix":" resulted in a significant reduction in the bioavailability ","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"214","endOffset":"234","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/div[1]/ul[1]/li[1]/div[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/div[1]/ul[1]/li[1]/div[1]","prefix":"oavailability of dabigatran compared with administration of ","suffix":" alone.","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"43","endOffset":"63","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/div[1]/ul[1]/li[3]/div[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/div[1]/ul[1]/li[3]/div[1]","prefix":"Rifampicin is not recommended for use with ","suffix":" because of the potential for reduced systemic exposure to d","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"0","endOffset":"20","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","prefix":"","suffix":" is an oral prodrug that is rapidly converted via two interm","exact":"Dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"0","endOffset":"20","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","prefix":"","suffix":" is licensed for the prevention of venous thromboembolic eve","exact":"Dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"0","endOffset":"20","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[1]/div[1]/div[1]/ul[1]/li[2]/div[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[1]/div[1]/div[1]/ul[1]/li[2]/div[1]","prefix":"","suffix":" and dabigatran are not metabolized by the cytochrome P450 s","exact":"Dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"0","endOffset":"20","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[3]","prefix":"","suffix":" and dabigatran are not metabolized by the cytochrome P450 (","exact":"Dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"0","endOffset":"20","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","prefix":"","suffix":", drug interaction, P-glycoprotein, rifampicin","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"300","endOffset":"320","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[5]","prefix":" parameters of dabigatran following a single dose of 150 mg ","suffix":". The study also evaluated the time course of a return to no","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"592","endOffset":"612","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[5]","prefix":"stigation reflect standard clinical doses of rifampicin and ","suffix":", and were expected to allow an adequate determination of th","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"157","endOffset":"177","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","prefix":"ale subjects to investigate the relative bioavailability of ","suffix":" given as single doses, either alone or after multiple doses","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"0","endOffset":"20","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[1]/div[1]/div[1]/ul[1]/li[1]/div[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[1]/div[1]/div[1]/ul[1]/li[1]/div[1]","prefix":"","suffix":" is an oral prodrug that is rapidly converted to dabigatran,","exact":"Dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"0","endOffset":"20","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[1]/div[1]/div[1]/ul[1]/li[2]/div[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[1]/div[1]/div[1]/ul[1]/li[2]/div[1]","prefix":"","suffix":" and dabigatran are not metabolized by the cytochrome P450 s","exact":"Dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"0","endOffset":"20","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[1]/div[1]/div[1]/ul[1]/li[3]/div[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[1]/div[1]/div[1]/ul[1]/li[3]/div[1]","prefix":"","suffix":", but not dabigatran, is a P-glycoprotein (P-gp) substrate, ","exact":"Dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"0","endOffset":"20","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","prefix":"","suffix":" is an oral prodrug that is rapidly converted via two interm","exact":"Dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"0","endOffset":"20","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","prefix":"","suffix":" is licensed for the prevention of venous thromboembolic eve","exact":"Dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"0","endOffset":"20","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[3]","prefix":"","suffix":" and dabigatran are not metabolized by the cytochrome P450 (","exact":"Dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"0","endOffset":"20","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[2]","prefix":"","suffix":" (Pradaxa®; Boehringer Ingelheim Pharma GmbH & Co. KG) was a","exact":"Dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"0","endOffset":"20","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[6]","prefix":"","suffix":" is assumed to be absorbed mainly in the duodenum. The prono","exact":"Dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"0","endOffset":"20","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[2]/div[2]/div[1]/ul[1]/li[5]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[2]/div[2]/div[1]/ul[1]/li[5]/a[1]","prefix":"","suffix":" in venous thromboembolism.","exact":"Dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"0","endOffset":"20","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","prefix":"","suffix":", drug interaction, P-glycoprotein, rifampicin","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"43","endOffset":"63","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[3]","prefix":"The subjects received single oral doses of ","suffix":" (150 mg), always in the morning at 08.00 h, during the foll","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"148","endOffset":"168","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/div[1]/div[1]/div[2]/span[1]","prefix":"nt periods for safety analyses (lower half of the diagram). ","suffix":" was always given in the morning at 08.00 h. Rifampicin was ","exact":"Dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"108","endOffset":"128","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[4]","prefix":"between days −21 and −1. Washout periods between subsequent ","suffix":" doses were included between the study days (days 1, 9, 16 a","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"71","endOffset":"91","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[2]","prefix":"parisons were performed between treatment C (single dose of ","suffix":" 150 mg after 7 days of washout since last intake of rifampi","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"230","endOffset":"250","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[2]","prefix":"erence treatment A, and between treatment D (single dose of ","suffix":" 150 mg after 14 days washout after the last intake of rifam","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"179","endOffset":"199","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","prefix":"24 and 34 h after administration of a single dose of 150 mg ","suffix":" in each treatment period. Plasma concentrations of free, no","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"403","endOffset":"423","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","prefix":"sured after alkaline cleavage of conjugates)], the prodrug, ","suffix":", and the intermediate metabolites, BIBR 1087 SE and BIBR 95","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"40","endOffset":"60","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[1]/h1[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[1]/h1[1]","prefix":"Decrease in the oral bioavailability of ","suffix":" after co-medication with rifampicin","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"165","endOffset":"185","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[1]/p[1]","prefix":"of dabigatran following oral administration of the prodrug, ","suffix":".","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"116","endOffset":"136","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":"y in healthy volunteers. Subjects received a single dose of ","suffix":" 150 mg on day 1, rifampicin 600 mg once daily on days 2–8, ","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"216","endOffset":"236","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":"fampicin 600 mg once daily on days 2–8, and single doses of ","suffix":" on days 9, 16 and 23.","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"113","endOffset":"133","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"d all treatments. Relative to the reference (single dose of ","suffix":" alone; treatment A), administration of dabigatran etexilate","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"173","endOffset":"193","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"dabigatran etexilate alone; treatment A), administration of ","suffix":" following 7 days of rifampicin (treatment B) decreased the ","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"0","endOffset":"20","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","prefix":"","suffix":", drug interaction, P-glycoprotein, rifampicin","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"88","endOffset":"108","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/div[1]/ul[1]/li[1]/div[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/div[1]/ul[1]/li[1]/div[1]","prefix":" (a strong P-gp inducer) for 7 days before a single dose of ","suffix":" resulted in a significant reduction in the bioavailability ","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"214","endOffset":"234","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/div[1]/ul[1]/li[1]/div[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/div[1]/ul[1]/li[1]/div[1]","prefix":"oavailability of dabigatran compared with administration of ","suffix":" alone.","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"43","endOffset":"63","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/div[1]/ul[1]/li[3]/div[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/div[1]/ul[1]/li[3]/div[1]","prefix":"Rifampicin is not recommended for use with ","suffix":" because of the potential for reduced systemic exposure to d","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"300","endOffset":"320","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[5]","prefix":" parameters of dabigatran following a single dose of 150 mg ","suffix":". The study also evaluated the time course of a return to no","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"592","endOffset":"612","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[5]","prefix":"stigation reflect standard clinical doses of rifampicin and ","suffix":", and were expected to allow an adequate determination of th","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"157","endOffset":"177","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","prefix":"ale subjects to investigate the relative bioavailability of ","suffix":" given as single doses, either alone or after multiple doses","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"43","endOffset":"63","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[3]","prefix":"The subjects received single oral doses of ","suffix":" (150 mg), always in the morning at 08.00 h, during the foll","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"108","endOffset":"128","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[4]","prefix":"between days −21 and −1. Washout periods between subsequent ","suffix":" doses were included between the study days (days 1, 9, 16 a","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"71","endOffset":"91","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[2]","prefix":"parisons were performed between treatment C (single dose of ","suffix":" 150 mg after 7 days of washout since last intake of rifampi","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"230","endOffset":"250","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[2]","prefix":"erence treatment A, and between treatment D (single dose of ","suffix":" 150 mg after 14 days washout after the last intake of rifam","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"179","endOffset":"199","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","prefix":"24 and 34 h after administration of a single dose of 150 mg ","suffix":" in each treatment period. Plasma concentrations of free, no","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"403","endOffset":"423","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","prefix":"sured after alkaline cleavage of conjugates)], the prodrug, ","suffix":", and the intermediate metabolites, BIBR 1087 SE and BIBR 95","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"155","endOffset":"175","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[1]/div[1]/div[2]/span[1]","prefix":" and free dabigatran (b) after a single oral dose of 150 mg ","suffix":" on day 1 (reference; treatment A), on day 9 after administr","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"71","endOffset":"91","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[2]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[2]/div[1]/div[2]/span[1]","prefix":"etic parameters of total dabigatran after administration of ","suffix":" 150 mg, with and without rifampicin","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"37","endOffset":"57","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[2]","prefix":"Relative to the reference treatment (","suffix":" alone), the administration of the P-gp inducer, rifampicin,","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"107","endOffset":"127","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[3]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[3]/div[1]/div[2]/span[1]","prefix":"bility for intra-individual comparisons of a single dose of ","suffix":" 150 mg given alone (reference; treatment A) and after admin","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"30","endOffset":"50","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[4]","prefix":"For the single dose of 150 mg ","suffix":" after a 7 day washout after the last dose of rifampicin (tr","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"39","endOffset":"59","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[5]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[5]/div[1]/div[2]/span[1]","prefix":"Pharmacokinetic parameters of prodrug (","suffix":") and intermediate metabolites (BIBR 1087 SE and BIBR 951 BS","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"145","endOffset":"165","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[5]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[5]/div[1]/div[2]/span[1]","prefix":"ites (BIBR 1087 SE and BIBR 951 BS) after administration of ","suffix":" 150 mg, with and without rifampicin","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"64","endOffset":"84","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[5]/p[2]","prefix":" two (8.3%) subjects reported any AEs during treatment with ","suffix":" alone, four (16.7%) subjects during treatment with dabigatr","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"136","endOffset":"156","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[5]/p[2]","prefix":"texilate alone, four (16.7%) subjects during treatment with ","suffix":" plus rifampicin and two (8.3%) subjects during treatment wi","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"74","endOffset":"94","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[5]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[5]/div[1]/div[1]/div[2]/span[1]","prefix":"subjects with adverse events reported during treatment with ","suffix":" (excluding washout periods)","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"43","endOffset":"63","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","prefix":"Preclinical investigations have shown that ","suffix":" (but not dabigatran or its intermediate metabolites) is a s","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"13","endOffset":"33","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","prefix":"The approved ","suffix":" dose for stroke prevention in patients with atrial fibrilla","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"212","endOffset":"232","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[8]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[8]","prefix":". The results were in line with the known safety profile of ","suffix":".","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"176","endOffset":"196","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[9]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[9]","prefix":"uences. Patients undergoing orthopaedic surgery who receive ","suffix":" for the prevention of venous thromboembolism may not achiev","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"524","endOffset":"544","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[9]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[9]","prefix":"dose–response in stroke reduction has been demonstrated for ","suffix":" [","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"207","endOffset":"227","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[10]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[10]","prefix":"t reduction in the bioavailability of a single oral dose of ","suffix":" in healthy volunteers. Within 7 days following the cessatio","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"551","endOffset":"571","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[10]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[10]","prefix":"zepine and St John's wort) are not recommended for use with ","suffix":" [","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"97","endOffset":"117","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[11]/div[2]/div[4]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[11]/div[2]/div[4]/span[1]","prefix":" and pharmacodynamics of the oral direct thrombin inhibitor ","suffix":". ","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"125","endOffset":"145","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[11]/div[2]/div[6]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[11]/div[2]/div[6]/span[1]","prefix":"irment on the pharmacokinetics and pharmacodynamics of oral ","suffix":": an open-label, parallel-group, single-centre study. ","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"62","endOffset":"82","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[11]/div[2]/div[9]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[11]/div[2]/div[9]/span[1]","prefix":"otech Pharma News [Internet] Boehringer Ingelheim: PRAZAXA (","suffix":") approved in Japan for stroke prevention in atrial fibrilla","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"174","endOffset":"194","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[11]/div[2]/div[10]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[11]/div[2]/div[10]/span[1]","prefix":"rachchi R, Schnee J, Büller HR. (RE-MODEL Study Group) Oral ","suffix":" vs. subcutaneous enoxaparin for the prevention of venous th","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"111","endOffset":"131","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[11]/div[2]/div[14]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[11]/div[2]/div[14]/span[1]","prefix":"e T. Coadministration of the oral direct thrombin inhibitor ","suffix":" and diclofenac has little impact on the pharmacokinetics of","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"109","endOffset":"129","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[11]/div[2]/div[15]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[11]/div[2]/div[15]/span[1]","prefix":"cke T. No interaction of the oral direct thrombin inhibitor ","suffix":" and digoxin. ","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"84","endOffset":"104","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[11]/div[2]/div[16]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[11]/div[2]/div[16]/span[1]","prefix":"tähle H, Reseski K, Körnicke T, Roth W. Coadministration of ","suffix":" and atorvastatin: assessment of potential impact on pharmac","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"136","endOffset":"156","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[11]/div[2]/div[29]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[11]/div[2]/div[29]/span[1]","prefix":"ization of drug transporters involved in the disposition of ","suffix":" and its active form, dabigatran. 9th Int Mtg Int Soc Study ","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"29","endOffset":"49","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[2]/div[2]/div[1]/ul[1]/li[2]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[2]/div[2]/div[1]/ul[1]/li[2]/a[1]","prefix":"Switching from enoxaparin to ","suffix":": pharmacokinetics, pharmacodynamics, and safety profile.","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"62","endOffset":"82","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[2]/div[2]/div[1]/ul[1]/li[3]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[2]/div[2]/div[1]/ul[1]/li[3]/a[1]","prefix":"armacokinetic profile of the oral direct thrombin inhibitor ","suffix":" in healthy volunteers and patients undergoing total hip rep","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"85","endOffset":"105","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[2]/div[2]/div[1]/ul[1]/li[4]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[2]/div[2]/div[1]/ul[1]/li[4]/a[1]","prefix":" and pharmacodynamics of the oral direct thrombin inhibitor ","suffix":".","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"34","endOffset":"54","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[3]/div[2]/div[1]/ul[1]/li[4]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[3]/div[2]/div[1]/ul[1]/li[4]/a[1]","prefix":"A proposal for dose-adjustment of ","suffix":" in atrial fibrillation guided by thrombin time","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"40","endOffset":"60","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[5]/div[2]/div[1]/div[1]/ul[1]/li[1]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[5]/div[2]/div[1]/div[1]/ul[1]/li[1]/a[1]","prefix":"Decrease in the oral bioavailability of ","suffix":" after co-medication...","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"40","endOffset":"60","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[5]/div[2]/div[1]/div[1]/ul[1]/li[1]/div[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[5]/div[2]/div[1]/div[1]/ul[1]/li[1]/div[1]","prefix":"Decrease in the oral bioavailability of ","suffix":" after co-medication with rifampicin","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"62","endOffset":"82","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[1]/div[2]/ul[1]/li[1]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[1]/div[2]/ul[1]/li[1]/a[1]","prefix":"armacokinetic profile of the oral direct thrombin inhibitor ","suffix":" in healthy volunteers and patients undergoing total hip rep","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"83","endOffset":"103","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[1]/div[2]/ul[1]/li[2]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[1]/div[2]/ul[1]/li[2]/a[1]","prefix":"irment on the pharmacokinetics and pharmacodynamics of oral ","suffix":": an open-label, parallel-group, single-centre study.","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"59","endOffset":"79","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[2]/div[2]/ul[1]/li[2]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[2]/div[2]/ul[1]/li[2]/a[1]","prefix":"The pharmacokinetics, pharmacodynamics and tolerability of ","suffix":", a new oral direct thrombin inhibitor, in healthy male subj","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"5","endOffset":"25","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[2]/div[2]/ul[1]/li[3]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[2]/div[2]/ul[1]/li[3]/a[1]","prefix":"Oral ","suffix":" vs. subcutaneous enoxaparin for the prevention of venous th","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"20","endOffset":"40","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[3]/div[2]/ul[1]/li[2]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[3]/div[2]/ul[1]/li[2]/a[1]","prefix":"Coadministration of ","suffix":" and atorvastatin: assessment of potential impact on pharmac","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"62","endOffset":"82","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[1]","prefix":"armacokinetic profile of the oral direct thrombin inhibitor ","suffix":" in healthy volunteers and patients undergoing total hip rep","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"83","endOffset":"103","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[2]","prefix":"irment on the pharmacokinetics and pharmacodynamics of oral ","suffix":": an open-label, parallel-group, single-centre study.","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"62","endOffset":"82","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[4]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[4]/span[1]","prefix":"otech Pharma News [Internet] Boehringer Ingelheim: PRAZAXA (","suffix":") approved in Japan for stroke prevention in atrial fibrilla","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"59","endOffset":"79","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]","prefix":"The pharmacokinetics, pharmacodynamics and tolerability of ","suffix":", a new oral direct thrombin inhibitor, in healthy male subj","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"5","endOffset":"25","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[7]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[7]","prefix":"Oral ","suffix":" vs. subcutaneous enoxaparin for the prevention of venous th","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"111","endOffset":"131","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[9]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[9]/span[1]","prefix":"e T. Coadministration of the oral direct thrombin inhibitor ","suffix":" and diclofenac has little impact on the pharmacokinetics of","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"20","endOffset":"40","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[10]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[10]","prefix":"Coadministration of ","suffix":" and atorvastatin: assessment of potential impact on pharmac","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"136","endOffset":"156","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[24]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[24]/span[1]","prefix":"ization of drug transporters involved in the disposition of ","suffix":" and its active form, dabigatran. 9th Int Mtg Int Soc Study ","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"155","endOffset":"175","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[1]/div[1]/div[2]/span[1]","prefix":" and free dabigatran (b) after a single oral dose of 150 mg ","suffix":" on day 1 (reference; treatment A), on day 9 after administr","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"71","endOffset":"91","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[2]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[2]/div[1]/div[2]/span[1]","prefix":"etic parameters of total dabigatran after administration of ","suffix":" 150 mg, with and without rifampicin","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"113","endOffset":"133","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"d all treatments. Relative to the reference (single dose of ","suffix":" alone; treatment A), administration of dabigatran etexilate","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"214","endOffset":"234","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/div[1]/ul[1]/li[1]/div[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/div[1]/ul[1]/li[1]/div[1]","prefix":"oavailability of dabigatran compared with administration of ","suffix":" alone.","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"157","endOffset":"177","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","prefix":"ale subjects to investigate the relative bioavailability of ","suffix":" given as single doses, either alone or after multiple doses","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"37","endOffset":"57","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[2]","prefix":"Relative to the reference treatment (","suffix":" alone), the administration of the P-gp inducer, rifampicin,","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"107","endOffset":"127","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[3]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[3]/div[1]/div[2]/span[1]","prefix":"bility for intra-individual comparisons of a single dose of ","suffix":" 150 mg given alone (reference; treatment A) and after admin","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"64","endOffset":"84","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[5]/p[2]","prefix":" two (8.3%) subjects reported any AEs during treatment with ","suffix":" alone, four (16.7%) subjects during treatment with dabigatr","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"107","endOffset":"127","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[3]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[3]/div[1]/div[2]/span[1]","prefix":"bility for intra-individual comparisons of a single dose of ","suffix":" 150 mg given alone (reference; treatment A) and after admin","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"30","endOffset":"50","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[4]","prefix":"For the single dose of 150 mg ","suffix":" after a 7 day washout after the last dose of rifampicin (tr","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"40","endOffset":"60","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[1]/h1[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[1]/h1[1]","prefix":"Decrease in the oral bioavailability of ","suffix":" after co-medication with rifampicin","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"165","endOffset":"185","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[1]/p[1]","prefix":"of dabigatran following oral administration of the prodrug, ","suffix":".","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"116","endOffset":"136","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":"y in healthy volunteers. Subjects received a single dose of ","suffix":" 150 mg on day 1, rifampicin 600 mg once daily on days 2–8, ","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"216","endOffset":"236","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":"fampicin 600 mg once daily on days 2–8, and single doses of ","suffix":" on days 9, 16 and 23.","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"113","endOffset":"133","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"d all treatments. Relative to the reference (single dose of ","suffix":" alone; treatment A), administration of dabigatran etexilate","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"173","endOffset":"193","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"dabigatran etexilate alone; treatment A), administration of ","suffix":" following 7 days of rifampicin (treatment B) decreased the ","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"0","endOffset":"20","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","prefix":"","suffix":", drug interaction, P-glycoprotein, rifampicin","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"88","endOffset":"108","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/div[1]/ul[1]/li[1]/div[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/div[1]/ul[1]/li[1]/div[1]","prefix":" (a strong P-gp inducer) for 7 days before a single dose of ","suffix":" resulted in a significant reduction in the bioavailability ","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"214","endOffset":"234","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/div[1]/ul[1]/li[1]/div[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/div[1]/ul[1]/li[1]/div[1]","prefix":"oavailability of dabigatran compared with administration of ","suffix":" alone.","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"43","endOffset":"63","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/div[1]/ul[1]/li[3]/div[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/div[1]/ul[1]/li[3]/div[1]","prefix":"Rifampicin is not recommended for use with ","suffix":" because of the potential for reduced systemic exposure to d","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"300","endOffset":"320","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[5]","prefix":" parameters of dabigatran following a single dose of 150 mg ","suffix":". The study also evaluated the time course of a return to no","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"592","endOffset":"612","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[5]","prefix":"stigation reflect standard clinical doses of rifampicin and ","suffix":", and were expected to allow an adequate determination of th","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"157","endOffset":"177","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","prefix":"ale subjects to investigate the relative bioavailability of ","suffix":" given as single doses, either alone or after multiple doses","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"43","endOffset":"63","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[3]","prefix":"The subjects received single oral doses of ","suffix":" (150 mg), always in the morning at 08.00 h, during the foll","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"108","endOffset":"128","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[4]","prefix":"between days −21 and −1. Washout periods between subsequent ","suffix":" doses were included between the study days (days 1, 9, 16 a","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"71","endOffset":"91","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[2]","prefix":"parisons were performed between treatment C (single dose of ","suffix":" 150 mg after 7 days of washout since last intake of rifampi","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"230","endOffset":"250","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[2]","prefix":"erence treatment A, and between treatment D (single dose of ","suffix":" 150 mg after 14 days washout after the last intake of rifam","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"179","endOffset":"199","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","prefix":"24 and 34 h after administration of a single dose of 150 mg ","suffix":" in each treatment period. Plasma concentrations of free, no","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"403","endOffset":"423","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","prefix":"sured after alkaline cleavage of conjugates)], the prodrug, ","suffix":", and the intermediate metabolites, BIBR 1087 SE and BIBR 95","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"155","endOffset":"175","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[1]/div[1]/div[2]/span[1]","prefix":" and free dabigatran (b) after a single oral dose of 150 mg ","suffix":" on day 1 (reference; treatment A), on day 9 after administr","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"71","endOffset":"91","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[2]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[2]/div[1]/div[2]/span[1]","prefix":"etic parameters of total dabigatran after administration of ","suffix":" 150 mg, with and without rifampicin","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"37","endOffset":"57","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[2]","prefix":"Relative to the reference treatment (","suffix":" alone), the administration of the P-gp inducer, rifampicin,","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"107","endOffset":"127","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[3]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[3]/div[1]/div[2]/span[1]","prefix":"bility for intra-individual comparisons of a single dose of ","suffix":" 150 mg given alone (reference; treatment A) and after admin","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"30","endOffset":"50","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[4]","prefix":"For the single dose of 150 mg ","suffix":" after a 7 day washout after the last dose of rifampicin (tr","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"39","endOffset":"59","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[5]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[5]/div[1]/div[2]/span[1]","prefix":"Pharmacokinetic parameters of prodrug (","suffix":") and intermediate metabolites (BIBR 1087 SE and BIBR 951 BS","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"145","endOffset":"165","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[5]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[5]/div[1]/div[2]/span[1]","prefix":"ites (BIBR 1087 SE and BIBR 951 BS) after administration of ","suffix":" 150 mg, with and without rifampicin","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"64","endOffset":"84","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[5]/p[2]","prefix":" two (8.3%) subjects reported any AEs during treatment with ","suffix":" alone, four (16.7%) subjects during treatment with dabigatr","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"136","endOffset":"156","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[5]/p[2]","prefix":"texilate alone, four (16.7%) subjects during treatment with ","suffix":" plus rifampicin and two (8.3%) subjects during treatment wi","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"74","endOffset":"94","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[5]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[5]/div[1]/div[1]/div[2]/span[1]","prefix":"subjects with adverse events reported during treatment with ","suffix":" (excluding washout periods)","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"43","endOffset":"63","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","prefix":"Preclinical investigations have shown that ","suffix":" (but not dabigatran or its intermediate metabolites) is a s","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"13","endOffset":"33","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","prefix":"The approved ","suffix":" dose for stroke prevention in patients with atrial fibrilla","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"212","endOffset":"232","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[8]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[8]","prefix":". The results were in line with the known safety profile of ","suffix":".","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"176","endOffset":"196","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[9]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[9]","prefix":"uences. Patients undergoing orthopaedic surgery who receive ","suffix":" for the prevention of venous thromboembolism may not achiev","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"524","endOffset":"544","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[9]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[9]","prefix":"dose–response in stroke reduction has been demonstrated for ","suffix":" [","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"207","endOffset":"227","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[10]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[10]","prefix":"t reduction in the bioavailability of a single oral dose of ","suffix":" in healthy volunteers. Within 7 days following the cessatio","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"551","endOffset":"571","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[10]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[10]","prefix":"zepine and St John's wort) are not recommended for use with ","suffix":" [","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"97","endOffset":"117","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[11]/div[2]/div[4]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[11]/div[2]/div[4]/span[1]","prefix":" and pharmacodynamics of the oral direct thrombin inhibitor ","suffix":". ","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"125","endOffset":"145","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[11]/div[2]/div[6]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[11]/div[2]/div[6]/span[1]","prefix":"irment on the pharmacokinetics and pharmacodynamics of oral ","suffix":": an open-label, parallel-group, single-centre study. ","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"62","endOffset":"82","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[11]/div[2]/div[9]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[11]/div[2]/div[9]/span[1]","prefix":"otech Pharma News [Internet] Boehringer Ingelheim: PRAZAXA (","suffix":") approved in Japan for stroke prevention in atrial fibrilla","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"174","endOffset":"194","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[11]/div[2]/div[10]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[11]/div[2]/div[10]/span[1]","prefix":"rachchi R, Schnee J, Büller HR. (RE-MODEL Study Group) Oral ","suffix":" vs. subcutaneous enoxaparin for the prevention of venous th","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"111","endOffset":"131","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[11]/div[2]/div[14]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[11]/div[2]/div[14]/span[1]","prefix":"e T. Coadministration of the oral direct thrombin inhibitor ","suffix":" and diclofenac has little impact on the pharmacokinetics of","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"109","endOffset":"129","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[11]/div[2]/div[15]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[11]/div[2]/div[15]/span[1]","prefix":"cke T. No interaction of the oral direct thrombin inhibitor ","suffix":" and digoxin. ","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"84","endOffset":"104","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[11]/div[2]/div[16]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[11]/div[2]/div[16]/span[1]","prefix":"tähle H, Reseski K, Körnicke T, Roth W. Coadministration of ","suffix":" and atorvastatin: assessment of potential impact on pharmac","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"136","endOffset":"156","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[11]/div[2]/div[29]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[11]/div[2]/div[29]/span[1]","prefix":"ization of drug transporters involved in the disposition of ","suffix":" and its active form, dabigatran. 9th Int Mtg Int Soc Study ","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"29","endOffset":"49","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[2]/div[2]/div[1]/ul[1]/li[2]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[2]/div[2]/div[1]/ul[1]/li[2]/a[1]","prefix":"Switching from enoxaparin to ","suffix":": pharmacokinetics, pharmacodynamics, and safety profile.","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"62","endOffset":"82","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[2]/div[2]/div[1]/ul[1]/li[3]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[2]/div[2]/div[1]/ul[1]/li[3]/a[1]","prefix":"armacokinetic profile of the oral direct thrombin inhibitor ","suffix":" in healthy volunteers and patients undergoing total hip rep","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"85","endOffset":"105","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[2]/div[2]/div[1]/ul[1]/li[4]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[2]/div[2]/div[1]/ul[1]/li[4]/a[1]","prefix":" and pharmacodynamics of the oral direct thrombin inhibitor ","suffix":".","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"34","endOffset":"54","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[3]/div[2]/div[1]/ul[1]/li[4]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[3]/div[2]/div[1]/ul[1]/li[4]/a[1]","prefix":"A proposal for dose-adjustment of ","suffix":" in atrial fibrillation guided by thrombin time","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"40","endOffset":"60","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[5]/div[2]/div[1]/div[1]/ul[1]/li[1]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[5]/div[2]/div[1]/div[1]/ul[1]/li[1]/a[1]","prefix":"Decrease in the oral bioavailability of ","suffix":" after co-medication...","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"40","endOffset":"60","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[5]/div[2]/div[1]/div[1]/ul[1]/li[1]/div[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[5]/div[2]/div[1]/div[1]/ul[1]/li[1]/div[1]","prefix":"Decrease in the oral bioavailability of ","suffix":" after co-medication with rifampicin","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"62","endOffset":"82","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[1]/div[2]/ul[1]/li[1]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[1]/div[2]/ul[1]/li[1]/a[1]","prefix":"armacokinetic profile of the oral direct thrombin inhibitor ","suffix":" in healthy volunteers and patients undergoing total hip rep","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"83","endOffset":"103","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[1]/div[2]/ul[1]/li[2]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[1]/div[2]/ul[1]/li[2]/a[1]","prefix":"irment on the pharmacokinetics and pharmacodynamics of oral ","suffix":": an open-label, parallel-group, single-centre study.","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"59","endOffset":"79","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[2]/div[2]/ul[1]/li[2]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[2]/div[2]/ul[1]/li[2]/a[1]","prefix":"The pharmacokinetics, pharmacodynamics and tolerability of ","suffix":", a new oral direct thrombin inhibitor, in healthy male subj","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"5","endOffset":"25","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[2]/div[2]/ul[1]/li[3]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[2]/div[2]/ul[1]/li[3]/a[1]","prefix":"Oral ","suffix":" vs. subcutaneous enoxaparin for the prevention of venous th","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"20","endOffset":"40","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[3]/div[2]/ul[1]/li[2]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[3]/div[2]/ul[1]/li[2]/a[1]","prefix":"Coadministration of ","suffix":" and atorvastatin: assessment of potential impact on pharmac","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"62","endOffset":"82","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[1]","prefix":"armacokinetic profile of the oral direct thrombin inhibitor ","suffix":" in healthy volunteers and patients undergoing total hip rep","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"83","endOffset":"103","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[2]","prefix":"irment on the pharmacokinetics and pharmacodynamics of oral ","suffix":": an open-label, parallel-group, single-centre study.","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"62","endOffset":"82","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[4]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[4]/span[1]","prefix":"otech Pharma News [Internet] Boehringer Ingelheim: PRAZAXA (","suffix":") approved in Japan for stroke prevention in atrial fibrilla","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"59","endOffset":"79","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]","prefix":"The pharmacokinetics, pharmacodynamics and tolerability of ","suffix":", a new oral direct thrombin inhibitor, in healthy male subj","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"5","endOffset":"25","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[7]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[7]","prefix":"Oral ","suffix":" vs. subcutaneous enoxaparin for the prevention of venous th","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"111","endOffset":"131","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[9]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[9]/span[1]","prefix":"e T. Coadministration of the oral direct thrombin inhibitor ","suffix":" and diclofenac has little impact on the pharmacokinetics of","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"20","endOffset":"40","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[10]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[10]","prefix":"Coadministration of ","suffix":" and atorvastatin: assessment of potential impact on pharmac","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"136","endOffset":"156","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[24]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[24]/span[1]","prefix":"ization of drug transporters involved in the disposition of ","suffix":" and its active form, dabigatran. 9th Int Mtg Int Soc Study ","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"40","endOffset":"60","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[1]/h1[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[1]/h1[1]","prefix":"Decrease in the oral bioavailability of ","suffix":" after co-medication with rifampicin","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"165","endOffset":"185","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[1]/p[1]","prefix":"of dabigatran following oral administration of the prodrug, ","suffix":".","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"116","endOffset":"136","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":"y in healthy volunteers. Subjects received a single dose of ","suffix":" 150 mg on day 1, rifampicin 600 mg once daily on days 2–8, ","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"216","endOffset":"236","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":"fampicin 600 mg once daily on days 2–8, and single doses of ","suffix":" on days 9, 16 and 23.","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"113","endOffset":"133","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"d all treatments. Relative to the reference (single dose of ","suffix":" alone; treatment A), administration of dabigatran etexilate","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"173","endOffset":"193","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"dabigatran etexilate alone; treatment A), administration of ","suffix":" following 7 days of rifampicin (treatment B) decreased the ","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"0","endOffset":"20","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","prefix":"","suffix":", drug interaction, P-glycoprotein, rifampicin","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"88","endOffset":"108","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/div[1]/ul[1]/li[1]/div[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/div[1]/ul[1]/li[1]/div[1]","prefix":" (a strong P-gp inducer) for 7 days before a single dose of ","suffix":" resulted in a significant reduction in the bioavailability ","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"214","endOffset":"234","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/div[1]/ul[1]/li[1]/div[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/div[1]/ul[1]/li[1]/div[1]","prefix":"oavailability of dabigatran compared with administration of ","suffix":" alone.","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"43","endOffset":"63","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/div[1]/ul[1]/li[3]/div[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/div[1]/ul[1]/li[3]/div[1]","prefix":"Rifampicin is not recommended for use with ","suffix":" because of the potential for reduced systemic exposure to d","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"300","endOffset":"320","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[5]","prefix":" parameters of dabigatran following a single dose of 150 mg ","suffix":". The study also evaluated the time course of a return to no","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"592","endOffset":"612","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[5]","prefix":"stigation reflect standard clinical doses of rifampicin and ","suffix":", and were expected to allow an adequate determination of th","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"157","endOffset":"177","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","prefix":"ale subjects to investigate the relative bioavailability of ","suffix":" given as single doses, either alone or after multiple doses","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"43","endOffset":"63","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[3]","prefix":"The subjects received single oral doses of ","suffix":" (150 mg), always in the morning at 08.00 h, during the foll","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"108","endOffset":"128","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[4]","prefix":"between days −21 and −1. Washout periods between subsequent ","suffix":" doses were included between the study days (days 1, 9, 16 a","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"71","endOffset":"91","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[2]","prefix":"parisons were performed between treatment C (single dose of ","suffix":" 150 mg after 7 days of washout since last intake of rifampi","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"230","endOffset":"250","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[2]","prefix":"erence treatment A, and between treatment D (single dose of ","suffix":" 150 mg after 14 days washout after the last intake of rifam","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"179","endOffset":"199","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","prefix":"24 and 34 h after administration of a single dose of 150 mg ","suffix":" in each treatment period. Plasma concentrations of free, no","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"403","endOffset":"423","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","prefix":"sured after alkaline cleavage of conjugates)], the prodrug, ","suffix":", and the intermediate metabolites, BIBR 1087 SE and BIBR 95","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"155","endOffset":"175","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[1]/div[1]/div[2]/span[1]","prefix":" and free dabigatran (b) after a single oral dose of 150 mg ","suffix":" on day 1 (reference; treatment A), on day 9 after administr","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"71","endOffset":"91","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[2]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[2]/div[1]/div[2]/span[1]","prefix":"etic parameters of total dabigatran after administration of ","suffix":" 150 mg, with and without rifampicin","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"37","endOffset":"57","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[2]","prefix":"Relative to the reference treatment (","suffix":" alone), the administration of the P-gp inducer, rifampicin,","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"107","endOffset":"127","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[3]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[3]/div[1]/div[2]/span[1]","prefix":"bility for intra-individual comparisons of a single dose of ","suffix":" 150 mg given alone (reference; treatment A) and after admin","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"30","endOffset":"50","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[4]","prefix":"For the single dose of 150 mg ","suffix":" after a 7 day washout after the last dose of rifampicin (tr","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"39","endOffset":"59","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[5]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[5]/div[1]/div[2]/span[1]","prefix":"Pharmacokinetic parameters of prodrug (","suffix":") and intermediate metabolites (BIBR 1087 SE and BIBR 951 BS","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"145","endOffset":"165","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[5]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[5]/div[1]/div[2]/span[1]","prefix":"ites (BIBR 1087 SE and BIBR 951 BS) after administration of ","suffix":" 150 mg, with and without rifampicin","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"64","endOffset":"84","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[5]/p[2]","prefix":" two (8.3%) subjects reported any AEs during treatment with ","suffix":" alone, four (16.7%) subjects during treatment with dabigatr","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"136","endOffset":"156","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[5]/p[2]","prefix":"texilate alone, four (16.7%) subjects during treatment with ","suffix":" plus rifampicin and two (8.3%) subjects during treatment wi","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"74","endOffset":"94","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[5]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[5]/div[1]/div[1]/div[2]/span[1]","prefix":"subjects with adverse events reported during treatment with ","suffix":" (excluding washout periods)","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"43","endOffset":"63","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","prefix":"Preclinical investigations have shown that ","suffix":" (but not dabigatran or its intermediate metabolites) is a s","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"13","endOffset":"33","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","prefix":"The approved ","suffix":" dose for stroke prevention in patients with atrial fibrilla","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"212","endOffset":"232","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[8]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[8]","prefix":". The results were in line with the known safety profile of ","suffix":".","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"176","endOffset":"196","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[9]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[9]","prefix":"uences. Patients undergoing orthopaedic surgery who receive ","suffix":" for the prevention of venous thromboembolism may not achiev","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"524","endOffset":"544","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[9]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[9]","prefix":"dose–response in stroke reduction has been demonstrated for ","suffix":" [","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"207","endOffset":"227","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[10]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[10]","prefix":"t reduction in the bioavailability of a single oral dose of ","suffix":" in healthy volunteers. Within 7 days following the cessatio","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"551","endOffset":"571","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[10]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[10]","prefix":"zepine and St John's wort) are not recommended for use with ","suffix":" [","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"97","endOffset":"117","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[11]/div[2]/div[4]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[11]/div[2]/div[4]/span[1]","prefix":" and pharmacodynamics of the oral direct thrombin inhibitor ","suffix":". ","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"125","endOffset":"145","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[11]/div[2]/div[6]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[11]/div[2]/div[6]/span[1]","prefix":"irment on the pharmacokinetics and pharmacodynamics of oral ","suffix":": an open-label, parallel-group, single-centre study. ","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"62","endOffset":"82","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[11]/div[2]/div[9]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[11]/div[2]/div[9]/span[1]","prefix":"otech Pharma News [Internet] Boehringer Ingelheim: PRAZAXA (","suffix":") approved in Japan for stroke prevention in atrial fibrilla","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"174","endOffset":"194","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[11]/div[2]/div[10]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[11]/div[2]/div[10]/span[1]","prefix":"rachchi R, Schnee J, Büller HR. (RE-MODEL Study Group) Oral ","suffix":" vs. subcutaneous enoxaparin for the prevention of venous th","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"111","endOffset":"131","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[11]/div[2]/div[14]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[11]/div[2]/div[14]/span[1]","prefix":"e T. Coadministration of the oral direct thrombin inhibitor ","suffix":" and diclofenac has little impact on the pharmacokinetics of","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"109","endOffset":"129","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[11]/div[2]/div[15]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[11]/div[2]/div[15]/span[1]","prefix":"cke T. No interaction of the oral direct thrombin inhibitor ","suffix":" and digoxin. ","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"84","endOffset":"104","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[11]/div[2]/div[16]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[11]/div[2]/div[16]/span[1]","prefix":"tähle H, Reseski K, Körnicke T, Roth W. Coadministration of ","suffix":" and atorvastatin: assessment of potential impact on pharmac","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"136","endOffset":"156","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[11]/div[2]/div[29]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[11]/div[2]/div[29]/span[1]","prefix":"ization of drug transporters involved in the disposition of ","suffix":" and its active form, dabigatran. 9th Int Mtg Int Soc Study ","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"29","endOffset":"49","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[2]/div[2]/div[1]/ul[1]/li[2]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[2]/div[2]/div[1]/ul[1]/li[2]/a[1]","prefix":"Switching from enoxaparin to ","suffix":": pharmacokinetics, pharmacodynamics, and safety profile.","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"62","endOffset":"82","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[2]/div[2]/div[1]/ul[1]/li[3]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[2]/div[2]/div[1]/ul[1]/li[3]/a[1]","prefix":"armacokinetic profile of the oral direct thrombin inhibitor ","suffix":" in healthy volunteers and patients undergoing total hip rep","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"85","endOffset":"105","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[2]/div[2]/div[1]/ul[1]/li[4]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[2]/div[2]/div[1]/ul[1]/li[4]/a[1]","prefix":" and pharmacodynamics of the oral direct thrombin inhibitor ","suffix":".","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"34","endOffset":"54","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[3]/div[2]/div[1]/ul[1]/li[4]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[3]/div[2]/div[1]/ul[1]/li[4]/a[1]","prefix":"A proposal for dose-adjustment of ","suffix":" in atrial fibrillation guided by thrombin time","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"40","endOffset":"60","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[5]/div[2]/div[1]/div[1]/ul[1]/li[1]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[5]/div[2]/div[1]/div[1]/ul[1]/li[1]/a[1]","prefix":"Decrease in the oral bioavailability of ","suffix":" after co-medication...","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"40","endOffset":"60","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[5]/div[2]/div[1]/div[1]/ul[1]/li[1]/div[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[5]/div[2]/div[1]/div[1]/ul[1]/li[1]/div[1]","prefix":"Decrease in the oral bioavailability of ","suffix":" after co-medication with rifampicin","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"62","endOffset":"82","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[1]/div[2]/ul[1]/li[1]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[1]/div[2]/ul[1]/li[1]/a[1]","prefix":"armacokinetic profile of the oral direct thrombin inhibitor ","suffix":" in healthy volunteers and patients undergoing total hip rep","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"83","endOffset":"103","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[1]/div[2]/ul[1]/li[2]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[1]/div[2]/ul[1]/li[2]/a[1]","prefix":"irment on the pharmacokinetics and pharmacodynamics of oral ","suffix":": an open-label, parallel-group, single-centre study.","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"59","endOffset":"79","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[2]/div[2]/ul[1]/li[2]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[2]/div[2]/ul[1]/li[2]/a[1]","prefix":"The pharmacokinetics, pharmacodynamics and tolerability of ","suffix":", a new oral direct thrombin inhibitor, in healthy male subj","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"5","endOffset":"25","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[2]/div[2]/ul[1]/li[3]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[2]/div[2]/ul[1]/li[3]/a[1]","prefix":"Oral ","suffix":" vs. subcutaneous enoxaparin for the prevention of venous th","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"20","endOffset":"40","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[3]/div[2]/ul[1]/li[2]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[3]/div[2]/ul[1]/li[2]/a[1]","prefix":"Coadministration of ","suffix":" and atorvastatin: assessment of potential impact on pharmac","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"62","endOffset":"82","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[1]","prefix":"armacokinetic profile of the oral direct thrombin inhibitor ","suffix":" in healthy volunteers and patients undergoing total hip rep","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"83","endOffset":"103","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[2]","prefix":"irment on the pharmacokinetics and pharmacodynamics of oral ","suffix":": an open-label, parallel-group, single-centre study.","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"62","endOffset":"82","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[4]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[4]/span[1]","prefix":"otech Pharma News [Internet] Boehringer Ingelheim: PRAZAXA (","suffix":") approved in Japan for stroke prevention in atrial fibrilla","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"59","endOffset":"79","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]","prefix":"The pharmacokinetics, pharmacodynamics and tolerability of ","suffix":", a new oral direct thrombin inhibitor, in healthy male subj","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"5","endOffset":"25","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[7]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[7]","prefix":"Oral ","suffix":" vs. subcutaneous enoxaparin for the prevention of venous th","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"111","endOffset":"131","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[9]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[9]/span[1]","prefix":"e T. Coadministration of the oral direct thrombin inhibitor ","suffix":" and diclofenac has little impact on the pharmacokinetics of","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"20","endOffset":"40","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[10]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[10]","prefix":"Coadministration of ","suffix":" and atorvastatin: assessment of potential impact on pharmac","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"136","endOffset":"156","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[24]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[24]/span[1]","prefix":"ization of drug transporters involved in the disposition of ","suffix":" and its active form, dabigatran. 9th Int Mtg Int Soc Study ","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"71","endOffset":"91","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[2]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[2]/div[1]/div[2]/span[1]","prefix":"etic parameters of total dabigatran after administration of ","suffix":" 150 mg, with and without rifampicin","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"145","endOffset":"165","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[5]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[5]/div[1]/div[2]/span[1]","prefix":"ites (BIBR 1087 SE and BIBR 951 BS) after administration of ","suffix":" 150 mg, with and without rifampicin","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"64","endOffset":"84","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[5]/p[2]","prefix":" two (8.3%) subjects reported any AEs during treatment with ","suffix":" alone, four (16.7%) subjects during treatment with dabigatr","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"136","endOffset":"156","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[5]/p[2]","prefix":"texilate alone, four (16.7%) subjects during treatment with ","suffix":" plus rifampicin and two (8.3%) subjects during treatment wi","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"0","endOffset":"20","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","prefix":"","suffix":", drug interaction, P-glycoprotein, rifampicin","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"74","endOffset":"94","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[5]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[5]/div[1]/div[1]/div[2]/span[1]","prefix":"subjects with adverse events reported during treatment with ","suffix":" (excluding washout periods)","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"0","endOffset":"20","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","prefix":"","suffix":", drug interaction, P-glycoprotein, rifampicin","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"43","endOffset":"63","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","prefix":"Preclinical investigations have shown that ","suffix":" (but not dabigatran or its intermediate metabolites) is a s","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"13","endOffset":"33","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","prefix":"The approved ","suffix":" dose for stroke prevention in patients with atrial fibrilla","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"0","endOffset":"20","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","prefix":"","suffix":", drug interaction, P-glycoprotein, rifampicin","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"0","endOffset":"20","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[6]","prefix":"","suffix":" is assumed to be absorbed mainly in the duodenum. The prono","exact":"Dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"61","endOffset":"81","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[8]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[8]","prefix":"he overall safety profile of all treatments was favourable. ","suffix":" was well tolerated when given alone and in combination with","exact":"Dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"212","endOffset":"232","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[8]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[8]","prefix":". The results were in line with the known safety profile of ","suffix":".","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"176","endOffset":"196","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[9]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[9]","prefix":"uences. Patients undergoing orthopaedic surgery who receive ","suffix":" for the prevention of venous thromboembolism may not achiev","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"360","endOffset":"380","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[9]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[9]","prefix":"f they have received rifampicin immediately before surgery. ","suffix":" is also indicated for stroke prevention in patients with at","exact":"Dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"524","endOffset":"544","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[9]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[9]","prefix":"dose–response in stroke reduction has been demonstrated for ","suffix":" [","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"207","endOffset":"227","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[10]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[10]","prefix":"t reduction in the bioavailability of a single oral dose of ","suffix":" in healthy volunteers. Within 7 days following the cessatio","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"dabigatran etexilate","startOffset":"551","endOffset":"571","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[10]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[10]","prefix":"zepine and St John's wort) are not recommended for use with ","suffix":" [","exact":"dabigatran etexilate"},{"setid":"PMC3477350","drugname":"pradaxa","startOffset":"22","endOffset":"29","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[2]","prefix":"Dabigatran etexilate (","suffix":"®; Boehringer Ingelheim Pharma GmbH & Co. KG) was administer","exact":"Pradaxa"},{"setid":"PMC3477350","drugname":"pradaxa","startOffset":"15","endOffset":"22","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[11]/div[2]/div[8]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[11]/div[2]/div[8]/span[1]","prefix":"FDA [Internet] ","suffix":" label. 2010.  Available at  ","exact":"Pradaxa"},{"setid":"PMC3477350","drugname":"pradaxa","startOffset":"38","endOffset":"45","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[11]/div[2]/div[17]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[11]/div[2]/div[17]/span[1]","prefix":"Boehringer Ingelheim, Ridgefield, CT. ","suffix":"® US prescribing information [Internet] 2012.  Available at ","exact":"Pradaxa"},{"setid":"PMC3477350","drugname":"pradaxa","startOffset":"125","endOffset":"132","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[11]/div[2]/div[17]/span[1]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[11]/div[2]/div[17]/span[1]/a[1]","prefix":"r?docBase=renetnt&folderPath=/Prescribing%20Information/PIs/","suffix":"/Pradaxa.pdf","exact":"Pradaxa"},{"setid":"PMC3477350","drugname":"pradaxa","startOffset":"133","endOffset":"140","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[11]/div[2]/div[17]/span[1]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[11]/div[2]/div[17]/span[1]/a[1]","prefix":"e=renetnt&folderPath=/Prescribing%20Information/PIs/Pradaxa/","suffix":".pdf","exact":"Pradaxa"},{"setid":"PMC3477350","drugname":"pradaxa","startOffset":"33","endOffset":"40","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[11]/div[2]/div[32]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[11]/div[2]/div[32]/span[1]","prefix":"Boehringer Ingelheim, Ingelheim. ","suffix":"® summary of product characteristics [Internet] 2011.  Avail","exact":"Pradaxa"},{"setid":"PMC3477350","drugname":"pradaxa","startOffset":"51","endOffset":"58","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[11]/div[2]/div[32]/span[1]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[11]/div[2]/div[32]/span[1]/a[1]","prefix":"http://www.medicines.org.uk/emc/medicine/20760/SPC/","suffix":"+110+mg+hard+capsules","exact":"Pradaxa"},{"setid":"PMC3477350","drugname":"pradaxa","startOffset":"38","endOffset":"45","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[11]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[11]/span[1]","prefix":"Boehringer Ingelheim, Ridgefield, CT. ","suffix":"® US prescribing information [Internet] 2012.  Available at ","exact":"Pradaxa"},{"setid":"PMC3477350","drugname":"pradaxa","startOffset":"125","endOffset":"132","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[11]/span[1]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[11]/span[1]/a[1]","prefix":"r?docBase=renetnt&folderPath=/Prescribing%20Information/PIs/","suffix":"/Pradaxa.pdf","exact":"Pradaxa"},{"setid":"PMC3477350","drugname":"pradaxa","startOffset":"133","endOffset":"140","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[11]/span[1]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[11]/span[1]/a[1]","prefix":"e=renetnt&folderPath=/Prescribing%20Information/PIs/Pradaxa/","suffix":".pdf","exact":"Pradaxa"},{"setid":"PMC3477350","drugname":"pradaxa","startOffset":"15","endOffset":"22","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[18]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[18]/span[1]","prefix":"FDA [Internet] ","suffix":" label. 2010.  Available at  ","exact":"Pradaxa"},{"setid":"PMC3477350","drugname":"pradaxa","startOffset":"33","endOffset":"40","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[27]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[27]/span[1]","prefix":"Boehringer Ingelheim, Ingelheim. ","suffix":"® summary of product characteristics [Internet] 2011.  Avail","exact":"Pradaxa"},{"setid":"PMC3477350","drugname":"pradaxa","startOffset":"51","endOffset":"58","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[27]/span[1]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[27]/span[1]/a[1]","prefix":"http://www.medicines.org.uk/emc/medicine/20760/SPC/","suffix":"+110+mg+hard+capsules","exact":"Pradaxa"},{"setid":"PMC3477350","drugname":"thrombin","startOffset":"105","endOffset":"113","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[1]/div[1]/div[1]/ul[1]/li[1]/div[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[1]/div[1]/div[1]/ul[1]/li[1]/div[1]","prefix":"is rapidly converted to dabigatran, a direct and reversible ","suffix":" inhibitor.","exact":"thrombin"},{"setid":"PMC3477350","drugname":"thrombin","startOffset":"177","endOffset":"185","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","prefix":", to the active moiety, dabigatran, a direct and reversible ","suffix":" inhibitor. Dabigatran is partly conjugated with activated g","exact":"thrombin"},{"setid":"PMC3477350","drugname":"glucuronic acid","startOffset":"244","endOffset":"259","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","prefix":"n inhibitor. Dabigatran is partly conjugated with activated ","suffix":" to form a pharmacologically equipotent glucuronide. Free da","exact":"glucuronic acid"},{"setid":"PMC3477350","drugname":"cortisol","startOffset":"852","endOffset":"860","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[5]","prefix":"nt of a surrogate end-point, the urinary 6β-hydroxycortisol/","suffix":" ratio. This ratio is thought to reflect the CYP3A activity ","exact":"cortisol"},{"setid":"PMC3477350","drugname":"cortisol","startOffset":"23","endOffset":"31","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[6]","prefix":"The 6β-hydroxycortisol/","suffix":" ratio, an established marker of human hepatic CYP450 3A ind","exact":"cortisol"},{"setid":"PMC3477350","drugname":"cortisol","startOffset":"26","endOffset":"34","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[7]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[7]","prefix":"Urinary concentrations of ","suffix":" and 6β-hydroxycortisol were analysed by an HPLC-MS/MS metho","exact":"cortisol"},{"setid":"PMC3477350","drugname":"cortisol","startOffset":"187","endOffset":"195","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[7]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[7]","prefix":", France. The calibration curves for 6β-hydroxycortisol and ","suffix":" ranged between 1–1000 and 10–3000 ng ml","exact":"cortisol"},{"setid":"PMC3477350","drugname":"cortisol","startOffset":"843","endOffset":"851","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[5]","prefix":"measurement of a surrogate end-point, the urinary 6β-hydroxy","suffix":"/cortisol ratio. This ratio is thought to reflect the CYP3A ","exact":"cortisol"},{"setid":"PMC3477350","drugname":"cortisol","startOffset":"852","endOffset":"860","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[5]","prefix":"nt of a surrogate end-point, the urinary 6β-hydroxycortisol/","suffix":" ratio. This ratio is thought to reflect the CYP3A activity ","exact":"cortisol"},{"setid":"PMC3477350","drugname":"cortisol","startOffset":"14","endOffset":"22","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[6]","prefix":"The 6β-hydroxy","suffix":"/cortisol ratio, an established marker of human hepatic CYP4","exact":"cortisol"},{"setid":"PMC3477350","drugname":"cortisol","startOffset":"23","endOffset":"31","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[6]","prefix":"The 6β-hydroxycortisol/","suffix":" ratio, an established marker of human hepatic CYP450 3A ind","exact":"cortisol"},{"setid":"PMC3477350","drugname":"cortisol","startOffset":"26","endOffset":"34","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[7]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[7]","prefix":"Urinary concentrations of ","suffix":" and 6β-hydroxycortisol were analysed by an HPLC-MS/MS metho","exact":"cortisol"},{"setid":"PMC3477350","drugname":"cortisol","startOffset":"49","endOffset":"57","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[7]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[7]","prefix":"Urinary concentrations of cortisol and 6β-hydroxy","suffix":" were analysed by an HPLC-MS/MS method at SGS Cephac Europe,","exact":"cortisol"},{"setid":"PMC3477350","drugname":"cortisol","startOffset":"174","endOffset":"182","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[7]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[7]","prefix":"pe, St Benoît, France. The calibration curves for 6β-hydroxy","suffix":" and cortisol ranged between 1–1000 and 10–3000 ng ml","exact":"cortisol"},{"setid":"PMC3477350","drugname":"cortisol","startOffset":"187","endOffset":"195","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[7]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[7]","prefix":", France. The calibration curves for 6β-hydroxycortisol and ","suffix":" ranged between 1–1000 and 10–3000 ng ml","exact":"cortisol"},{"setid":"PMC3477350","drugname":"cortisol","startOffset":"43","endOffset":"51","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/p[1]","prefix":"Compared with day 1, the urinary 6β-hydroxy","suffix":"/cortisol ratio on day 9 was increased approximately 5.6-fol","exact":"cortisol"},{"setid":"PMC3477350","drugname":"cortisol","startOffset":"52","endOffset":"60","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/p[1]","prefix":"Compared with day 1, the urinary 6β-hydroxycortisol/","suffix":" ratio on day 9 was increased approximately 5.6-fold, from a","exact":"cortisol"},{"setid":"PMC3477350","drugname":"cortisol","startOffset":"145","endOffset":"153","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/p[1]","prefix":"ased approximately 5.6-fold, from a gMean (gCV %) 6β-hydroxy","suffix":"/cortisol ratio of 3.92 (65.3) to 22.0 (48.5), indicating CY","exact":"cortisol"},{"setid":"PMC3477350","drugname":"cortisol","startOffset":"154","endOffset":"162","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/p[1]","prefix":"oximately 5.6-fold, from a gMean (gCV %) 6β-hydroxycortisol/","suffix":" ratio of 3.92 (65.3) to 22.0 (48.5), indicating CYP450 3A i","exact":"cortisol"},{"setid":"PMC3477350","drugname":"cortisol","startOffset":"295","endOffset":"303","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/p[1]","prefix":" result of rifampicin administration. The urinary 6β-hydroxy","suffix":"/cortisol ratio was still slightly elevated on day 16 (∼1.2-","exact":"cortisol"},{"setid":"PMC3477350","drugname":"cortisol","startOffset":"304","endOffset":"312","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/p[1]","prefix":"f rifampicin administration. The urinary 6β-hydroxycortisol/","suffix":" ratio was still slightly elevated on day 16 (∼1.2-fold), bu","exact":"cortisol"},{"setid":"PMC3477350","drugname":"cortisol","startOffset":"110","endOffset":"118","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","prefix":"so induced CYP3A, as shown by an elevated urinary 6β-hydroxy","suffix":"/cortisol ratio [","exact":"cortisol"},{"setid":"PMC3477350","drugname":"cortisol","startOffset":"119","endOffset":"127","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","prefix":"d CYP3A, as shown by an elevated urinary 6β-hydroxycortisol/","suffix":" ratio [","exact":"cortisol"},{"setid":"PMC3477350","drugname":"cortisol","startOffset":"43","endOffset":"51","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[11]/div[2]/div[21]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[11]/div[2]/div[21]/span[1]","prefix":"Galteau MM, Shamsa F. Urinary 6beta-hydroxy","suffix":": a validated test for evaluating drug induction or drug inh","exact":"cortisol"},{"setid":"PMC3477350","drugname":"cortisol","startOffset":"101","endOffset":"109","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[11]/div[2]/div[24]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[11]/div[2]/div[24]/span[1]","prefix":", Martin DE. Morning spot and 24-hour urinary 6 beta-hydroxy","suffix":" to cortisol ratios: intraindividual variability and correla","exact":"cortisol"},{"setid":"PMC3477350","drugname":"cortisol","startOffset":"113","endOffset":"121","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[11]/div[2]/div[24]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[11]/div[2]/div[24]/span[1]","prefix":" Morning spot and 24-hour urinary 6 beta-hydroxycortisol to ","suffix":" ratios: intraindividual variability and correlation under b","exact":"cortisol"},{"setid":"PMC3477350","drugname":"cortisol","startOffset":"47","endOffset":"55","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[7]/div[2]/ul[1]/li[1]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[7]/div[2]/ul[1]/li[1]/a[1]","prefix":"Morning spot and 24-hour urinary 6 beta-hydroxy","suffix":" to cortisol ratios: intraindividual variability and correla","exact":"cortisol"},{"setid":"PMC3477350","drugname":"cortisol","startOffset":"59","endOffset":"67","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[7]/div[2]/ul[1]/li[1]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[7]/div[2]/ul[1]/li[1]/a[1]","prefix":"Morning spot and 24-hour urinary 6 beta-hydroxycortisol to ","suffix":" ratios: intraindividual variability and correlation under b","exact":"cortisol"},{"setid":"PMC3477350","drugname":"cortisol","startOffset":"47","endOffset":"55","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[19]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[19]","prefix":"Morning spot and 24-hour urinary 6 beta-hydroxy","suffix":" to cortisol ratios: intraindividual variability and correla","exact":"cortisol"},{"setid":"PMC3477350","drugname":"cortisol","startOffset":"59","endOffset":"67","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[19]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[19]","prefix":"Morning spot and 24-hour urinary 6 beta-hydroxycortisol to ","suffix":" ratios: intraindividual variability and correlation under b","exact":"cortisol"},{"setid":"PMC3477350","drugname":"cortisol","startOffset":"52","endOffset":"60","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/p[1]","prefix":"Compared with day 1, the urinary 6β-hydroxycortisol/","suffix":" ratio on day 9 was increased approximately 5.6-fold, from a","exact":"cortisol"},{"setid":"PMC3477350","drugname":"cortisol","startOffset":"145","endOffset":"153","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/p[1]","prefix":"ased approximately 5.6-fold, from a gMean (gCV %) 6β-hydroxy","suffix":"/cortisol ratio of 3.92 (65.3) to 22.0 (48.5), indicating CY","exact":"cortisol"},{"setid":"PMC3477350","drugname":"cortisol","startOffset":"154","endOffset":"162","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/p[1]","prefix":"oximately 5.6-fold, from a gMean (gCV %) 6β-hydroxycortisol/","suffix":" ratio of 3.92 (65.3) to 22.0 (48.5), indicating CYP450 3A i","exact":"cortisol"},{"setid":"PMC3477350","drugname":"cortisol","startOffset":"295","endOffset":"303","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/p[1]","prefix":" result of rifampicin administration. The urinary 6β-hydroxy","suffix":"/cortisol ratio was still slightly elevated on day 16 (∼1.2-","exact":"cortisol"},{"setid":"PMC3477350","drugname":"cortisol","startOffset":"304","endOffset":"312","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/p[1]","prefix":"f rifampicin administration. The urinary 6β-hydroxycortisol/","suffix":" ratio was still slightly elevated on day 16 (∼1.2-fold), bu","exact":"cortisol"},{"setid":"PMC3477350","drugname":"cortisol","startOffset":"119","endOffset":"127","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","prefix":"d CYP3A, as shown by an elevated urinary 6β-hydroxycortisol/","suffix":" ratio [","exact":"cortisol"},{"setid":"PMC3477350","drugname":"edta","startOffset":"34","endOffset":"38","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[2]","prefix":"Briefly, plasma was prepared from ","suffix":" blood (at 2000g–4000g for 10 minutes); for the determinatio","exact":"EDTA"},{"setid":"PMC3477350","drugname":"digoxin","startOffset":"172","endOffset":"179","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","prefix":"agnitude or only slightly exceeded the effects reported for ","suffix":" [","exact":"digoxin"},{"setid":"PMC3477350","drugname":"carbamazepine","startOffset":"484","endOffset":"497","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[10]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[10]","prefix":"ure to dabigatran, rifampicin and other P-gp inducers (e.g. ","suffix":" and St John's wort) are not recommended for use with dabiga","exact":"carbamazepine"}],[{"setid":"PMC3056523","drugname":"itraconazole","startOffset":"30","endOffset":"42","start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/div[1]/div[2]/span[1]","prefix":"Effect of escalating doses of ","suffix":" (ITZ) on disposition of oral midazolam (MDZ). Panel ","exact":"itraconazole"},{"setid":"PMC3056523","drugname":"itraconazole","startOffset":"10","endOffset":"22","start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[5]/div[2]/ul[1]/li[2]/a[1]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[5]/div[2]/ul[1]/li[2]/a[1]","prefix":"Effect of ","suffix":" and terbinafine on the pharmacokinetics and pharmacodynamic","exact":"itraconazole"},{"setid":"PMC3056523","drugname":"itraconazole","startOffset":"10","endOffset":"22","start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[4]/div[10]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[4]/div[10]","prefix":"Effect of ","suffix":" and terbinafine on the pharmacokinetics and pharmacodynamic","exact":"itraconazole"},{"setid":"PMC3056523","drugname":"itraconazole","startOffset":"44","endOffset":"56","start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[8]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[8]/div[1]/div[2]/span[1]","prefix":"Predicted vs. observed interactions between ","suffix":" (ITZ) and midazolam after escalating doses of ITZ. The circ","exact":"itraconazole"},{"setid":"PMC3056523","drugname":"midazolam","startOffset":"225","endOffset":"234","start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","prefix":"nal female subject was enrolled, but she withdrew after the ","suffix":" (MDZ) control session because of nausea and vomiting. No ot","exact":"midazolam"},{"setid":"PMC3056523","drugname":"midazolam","startOffset":"72","endOffset":"81","start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/div[1]/div[2]/span[1]","prefix":"calating doses of itraconazole (ITZ) on disposition of oral ","suffix":" (MDZ). Panel ","exact":"midazolam"},{"setid":"PMC3056523","drugname":"midazolam","startOffset":"67","endOffset":"76","start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[8]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[8]/div[1]/div[2]/span[1]","prefix":"ed vs. observed interactions between itraconazole (ITZ) and ","suffix":" after escalating doses of ITZ. The circles represent data f","exact":"midazolam"},{"setid":"PMC3056523","drugname":"midazolam","startOffset":"175","endOffset":"184","start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[11]/div[2]/div[9]/span[1]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[11]/div[2]/div[9]/span[1]","prefix":"armacokinetics and pharmacodynamics of intravenous and oral ","suffix":". ","exact":"midazolam"},{"setid":"PMC3056523","drugname":"midazolam","startOffset":"141","endOffset":"150","start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[5]/div[2]/ul[1]/li[1]/a[1]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[5]/div[2]/ul[1]/li[1]/a[1]","prefix":"armacokinetics and pharmacodynamics of intravenous and oral ","suffix":".","exact":"midazolam"},{"setid":"PMC3056523","drugname":"midazolam","startOffset":"141","endOffset":"150","start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[4]/div[9]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[4]/div[9]","prefix":"armacokinetics and pharmacodynamics of intravenous and oral ","suffix":".","exact":"midazolam"},{"setid":"PMC3056523","drugname":"caffeine","startOffset":"321","endOffset":"329","start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[2]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[2]","prefix":"ucts for the duration of the study and to avoid alcohol and ","suffix":" from 1 day before through the end of each urine-collection ","exact":"caffeine"},{"setid":"PMC3056523","drugname":"edta","startOffset":"995","endOffset":"999","start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[2]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[2]","prefix":"les were collected through indwelling venous catheters into ","suffix":"-containing tubes (BD Vacutainer; BD Biosciences, Franklin L","exact":"EDTA"}],[{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":"218","endOffset":"229","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[1]/p[1]","prefix":"on. The aim of this study was to evaluate the potential for ","suffix":" to affect warfarin pharmacokinetics and pharmacodynamics.","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":"132","endOffset":"143","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":"le dose of racemic warfarin 25 mg alone and after 8 days of ","suffix":" 10 mg once daily. Assessments included exposure (AUC","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":"0","endOffset":"11","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","prefix":"","suffix":", endothelin receptor antagonist, International Normalized R","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":"0","endOffset":"11","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"","suffix":" had no significant effects on the AUC","exact":"Ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":"18","endOffset":"29","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","prefix":"Multiple doses of ","suffix":" had no clinically relevant effects on the pharmacokinetics ","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":"18","endOffset":"29","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/ul[1]/li[2]/div[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/ul[1]/li[2]/div[1]","prefix":"Multiple doses of ","suffix":" had no clinically relevant effects on the pharmacokinetics ","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":"0","endOffset":"11","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","prefix":"","suffix":", endothelin receptor antagonist, International Normalized R","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":"0","endOffset":"11","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[1]/div[1]/ul[1]/li[2]/div[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[1]/div[1]/ul[1]/li[2]/div[1]","prefix":"","suffix":" is an orally active, propanoic acid-based endothelin recept","exact":"Ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":"98","endOffset":"109","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/ul[1]/li[1]/div[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/ul[1]/li[1]/div[1]","prefix":"ubjects to identify any potential drug interactions between ","suffix":" and warfarin.","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":"18","endOffset":"29","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","prefix":"Multiple doses of ","suffix":" had no clinically relevant effects on the pharmacokinetics ","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":"18","endOffset":"29","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/ul[1]/li[2]/div[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/ul[1]/li[2]/div[1]","prefix":"Multiple doses of ","suffix":" had no clinically relevant effects on the pharmacokinetics ","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":"235","endOffset":"246","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/ul[1]/li[2]/div[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/ul[1]/li[2]/div[1]","prefix":"ly relevant effects on the steady-state pharmacokinetics of ","suffix":".","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":"32","endOffset":"43","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/ul[1]/li[3]/div[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/ul[1]/li[3]/div[1]","prefix":"Therefore, co-administration of ","suffix":" with warfarin should not require adjustment of the therapeu","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":"133","endOffset":"144","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[2]","prefix":" dependence, bleeding disorders, sensitivity to warfarin or ","suffix":", or significant allergies. Subjects were also excluded if t","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":"192","endOffset":"203","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","prefix":"tic and/or pharmacodynamic interaction of multiple doses of ","suffix":" with a single dose of warfarin in healthy subjects (","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":"129","endOffset":"140","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/div[1]/div[2]/span[1]","prefix":"emic warfarin 25 mg were administered on days 1 and 13, and ","suffix":" 10 mg was administered once daily from day 5 to day 16. OD,","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":"273","endOffset":"284","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","prefix":"12, 18, 24, 36, 48, 72 and 96 h postdose. Blood samples for ","suffix":" pharmacokinetic assessments were collected relative to the ","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":"362","endOffset":"373","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","prefix":"ssessments were collected relative to the day 12 and day 13 ","suffix":" doses: predose (≤30 min prior), and 0.5, 1, 2, 3, 4, 6, 8, ","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":"476","endOffset":"487","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","prefix":", 2, 3, 4, 6, 8, 10, 12, 18 and 24 h postdose. Steady-state ","suffix":" concentrations were determined from samples collected at tr","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":"31","endOffset":"42","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","prefix":"The safety and tolerability of ","suffix":" and warfarin co-administration was assessed through adverse","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":"36","endOffset":"47","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[3]","prefix":"To assess the effect of concomitant ","suffix":" dosing on warfarin pharmacokinetics and pharmacodynamics, i","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":"74","endOffset":"85","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[1]/h1[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[1]/h1[1]","prefix":"netics and pharmacodynamics of warfarin in combination with ","suffix":" in healthy volunteers","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":"218","endOffset":"229","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[1]/p[1]","prefix":"on. The aim of this study was to evaluate the potential for ","suffix":" to affect warfarin pharmacokinetics and pharmacodynamics.","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":"132","endOffset":"143","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":"le dose of racemic warfarin 25 mg alone and after 8 days of ","suffix":" 10 mg once daily. Assessments included exposure (AUC","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":"18","endOffset":"29","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","prefix":"Multiple doses of ","suffix":" had no clinically relevant effects on the pharmacokinetics ","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":"0","endOffset":"11","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","prefix":"","suffix":", endothelin receptor antagonist, International Normalized R","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":"98","endOffset":"109","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/ul[1]/li[1]/div[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/ul[1]/li[1]/div[1]","prefix":"ubjects to identify any potential drug interactions between ","suffix":" and warfarin.","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":"18","endOffset":"29","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/ul[1]/li[2]/div[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/ul[1]/li[2]/div[1]","prefix":"Multiple doses of ","suffix":" had no clinically relevant effects on the pharmacokinetics ","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":"235","endOffset":"246","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/ul[1]/li[2]/div[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/ul[1]/li[2]/div[1]","prefix":"ly relevant effects on the steady-state pharmacokinetics of ","suffix":".","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":"32","endOffset":"43","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/ul[1]/li[3]/div[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/ul[1]/li[3]/div[1]","prefix":"Therefore, co-administration of ","suffix":" with warfarin should not require adjustment of the therapeu","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":"133","endOffset":"144","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[2]","prefix":" dependence, bleeding disorders, sensitivity to warfarin or ","suffix":", or significant allergies. Subjects were also excluded if t","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":"192","endOffset":"203","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","prefix":"tic and/or pharmacodynamic interaction of multiple doses of ","suffix":" with a single dose of warfarin in healthy subjects (","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":"129","endOffset":"140","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/div[1]/div[2]/span[1]","prefix":"emic warfarin 25 mg were administered on days 1 and 13, and ","suffix":" 10 mg was administered once daily from day 5 to day 16. OD,","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":"273","endOffset":"284","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","prefix":"12, 18, 24, 36, 48, 72 and 96 h postdose. Blood samples for ","suffix":" pharmacokinetic assessments were collected relative to the ","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":"362","endOffset":"373","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","prefix":"ssessments were collected relative to the day 12 and day 13 ","suffix":" doses: predose (≤30 min prior), and 0.5, 1, 2, 3, 4, 6, 8, ","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":"476","endOffset":"487","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","prefix":", 2, 3, 4, 6, 8, 10, 12, 18 and 24 h postdose. Steady-state ","suffix":" concentrations were determined from samples collected at tr","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":"31","endOffset":"42","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","prefix":"The safety and tolerability of ","suffix":" and warfarin co-administration was assessed through adverse","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":"36","endOffset":"47","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[3]","prefix":"To assess the effect of concomitant ","suffix":" dosing on warfarin pharmacokinetics and pharmacodynamics, i","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":"176","endOffset":"187","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[3]","prefix":" within-subject pair-wise differences of day 13 (warfarin + ","suffix":") ","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":"55","endOffset":"66","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[4]","prefix":"To assess the effect of concomitant warfarin dosing on ","suffix":" pharmacokinetics, individual within-subject pair-wise diffe","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":"155","endOffset":"166","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[4]","prefix":" within-subject pair-wise differences of day 13 (warfarin + ","suffix":") ","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":"189","endOffset":"200","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[5]","prefix":" to detect a 6% difference in INR between day 13 (warfarin +","suffix":") and day 1 (warfarin alone), and a >90% probability that th","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":"63","endOffset":"74","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[1]","prefix":"re were no clinically relevant effects of multiple doses of ","suffix":" on the concentration–time profiles of R-and S-warfarin (","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":"10","endOffset":"21","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/div[1]/div[1]/div[2]/span[1]","prefix":"Effect of ","suffix":" on R-and S-warfarin pharmacokinetics","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":"64","endOffset":"75","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[1]","prefix":"nistration of warfarin in the presence of multiple doses of ","suffix":" (","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":"10","endOffset":"21","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[1]/div[1]/div[2]/span[1]","prefix":"Effect of ","suffix":" on warfarin pharmacodynamics","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":"92","endOffset":"103","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/p[1]","prefix":"ct on the steady-state plasma concentration–time profile of ","suffix":" (","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":"31","endOffset":"42","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/div[1]/div[1]/div[2]/span[1]","prefix":"Effects of racemic warfarin on ","suffix":" steady-state pharmacokinetics","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":"43","endOffset":"54","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/div[2]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/div[2]/div[1]/div[2]/span[1]","prefix":"Mean plasma concentration–time profiles of ","suffix":" following multiple doses of ambrisentan alone (□) and in th","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":"83","endOffset":"94","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/div[2]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/div[2]/div[1]/div[2]/span[1]","prefix":"on–time profiles of ambrisentan following multiple doses of ","suffix":" alone (□) and in the presence of a single dose of warfarin ","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":"33","endOffset":"44","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","prefix":"In this study, multiple doses of ","suffix":" 10 mg once daily resulted in slight to modest changes in R-","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":"20","endOffset":"31","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","prefix":"In this study, both ","suffix":" and warfarin were administered at clinically effective dose","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":"457","endOffset":"468","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","prefix":"egarding the safety profile of chronic co-administration of ","suffix":" and warfarin. Of note, clinical studies in patients with PA","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":"614","endOffset":"625","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","prefix":" above, have demonstrated that chronic co-administration of ","suffix":" and warfarin does not appear to be associated with any spec","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":"29","endOffset":"40","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[10]/div[2]/div[12]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[10]/div[2]/div[12]/span[1]","prefix":"Gilead Sciences I. Letairis (","suffix":") tablets for oral use.  United States Food and Drug Adminis","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":"23","endOffset":"34","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[2]/div[2]/div[1]/ul[1]/li[2]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[2]/div[2]/div[1]/ul[1]/li[2]/a[1]","prefix":"Effect of steady-state ","suffix":" on the pharmacokinetics of a single dose of the oral contra","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":"30","endOffset":"41","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[2]/div[2]/div[1]/ul[1]/li[5]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[2]/div[2]/div[1]/ul[1]/li[5]/a[1]","prefix":"Pharmacokinetic evaluation of ","suffix":".","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":"74","endOffset":"85","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[5]/div[2]/div[1]/div[1]/ul[1]/li[1]/div[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[5]/div[2]/div[1]/div[1]/ul[1]/li[1]/div[1]","prefix":"netics and pharmacodynamics of warfarin in combination with ","suffix":" in healthy volunteers","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":"29","endOffset":"40","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[11]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[11]/span[1]","prefix":"Gilead Sciences I. Letairis (","suffix":") tablets for oral use.  United States Food and Drug Adminis","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":"55","endOffset":"66","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[4]","prefix":"To assess the effect of concomitant warfarin dosing on ","suffix":" pharmacokinetics, individual within-subject pair-wise diffe","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":"74","endOffset":"85","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[1]/h1[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[1]/h1[1]","prefix":"netics and pharmacodynamics of warfarin in combination with ","suffix":" in healthy volunteers","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":"218","endOffset":"229","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[1]/p[1]","prefix":"on. The aim of this study was to evaluate the potential for ","suffix":" to affect warfarin pharmacokinetics and pharmacodynamics.","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":"132","endOffset":"143","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":"le dose of racemic warfarin 25 mg alone and after 8 days of ","suffix":" 10 mg once daily. Assessments included exposure (AUC","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":"18","endOffset":"29","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","prefix":"Multiple doses of ","suffix":" had no clinically relevant effects on the pharmacokinetics ","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":"0","endOffset":"11","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","prefix":"","suffix":", endothelin receptor antagonist, International Normalized R","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":"98","endOffset":"109","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/ul[1]/li[1]/div[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/ul[1]/li[1]/div[1]","prefix":"ubjects to identify any potential drug interactions between ","suffix":" and warfarin.","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":"18","endOffset":"29","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/ul[1]/li[2]/div[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/ul[1]/li[2]/div[1]","prefix":"Multiple doses of ","suffix":" had no clinically relevant effects on the pharmacokinetics ","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":"235","endOffset":"246","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/ul[1]/li[2]/div[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/ul[1]/li[2]/div[1]","prefix":"ly relevant effects on the steady-state pharmacokinetics of ","suffix":".","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":"32","endOffset":"43","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/ul[1]/li[3]/div[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/ul[1]/li[3]/div[1]","prefix":"Therefore, co-administration of ","suffix":" with warfarin should not require adjustment of the therapeu","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":"133","endOffset":"144","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[2]","prefix":" dependence, bleeding disorders, sensitivity to warfarin or ","suffix":", or significant allergies. Subjects were also excluded if t","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":"192","endOffset":"203","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","prefix":"tic and/or pharmacodynamic interaction of multiple doses of ","suffix":" with a single dose of warfarin in healthy subjects (","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":"129","endOffset":"140","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/div[1]/div[2]/span[1]","prefix":"emic warfarin 25 mg were administered on days 1 and 13, and ","suffix":" 10 mg was administered once daily from day 5 to day 16. OD,","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":"273","endOffset":"284","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","prefix":"12, 18, 24, 36, 48, 72 and 96 h postdose. Blood samples for ","suffix":" pharmacokinetic assessments were collected relative to the ","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":"362","endOffset":"373","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","prefix":"ssessments were collected relative to the day 12 and day 13 ","suffix":" doses: predose (≤30 min prior), and 0.5, 1, 2, 3, 4, 6, 8, ","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":"476","endOffset":"487","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","prefix":", 2, 3, 4, 6, 8, 10, 12, 18 and 24 h postdose. Steady-state ","suffix":" concentrations were determined from samples collected at tr","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":"31","endOffset":"42","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","prefix":"The safety and tolerability of ","suffix":" and warfarin co-administration was assessed through adverse","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":"36","endOffset":"47","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[3]","prefix":"To assess the effect of concomitant ","suffix":" dosing on warfarin pharmacokinetics and pharmacodynamics, i","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":"176","endOffset":"187","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[3]","prefix":" within-subject pair-wise differences of day 13 (warfarin + ","suffix":") ","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":"55","endOffset":"66","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[4]","prefix":"To assess the effect of concomitant warfarin dosing on ","suffix":" pharmacokinetics, individual within-subject pair-wise diffe","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":"155","endOffset":"166","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[4]","prefix":" within-subject pair-wise differences of day 13 (warfarin + ","suffix":") ","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":"189","endOffset":"200","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[5]","prefix":" to detect a 6% difference in INR between day 13 (warfarin +","suffix":") and day 1 (warfarin alone), and a >90% probability that th","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":"63","endOffset":"74","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[1]","prefix":"re were no clinically relevant effects of multiple doses of ","suffix":" on the concentration–time profiles of R-and S-warfarin (","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":"10","endOffset":"21","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/div[1]/div[1]/div[2]/span[1]","prefix":"Effect of ","suffix":" on R-and S-warfarin pharmacokinetics","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":"64","endOffset":"75","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[1]","prefix":"nistration of warfarin in the presence of multiple doses of ","suffix":" (","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":"10","endOffset":"21","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[1]/div[1]/div[2]/span[1]","prefix":"Effect of ","suffix":" on warfarin pharmacodynamics","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":"92","endOffset":"103","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/p[1]","prefix":"ct on the steady-state plasma concentration–time profile of ","suffix":" (","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":"31","endOffset":"42","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/div[1]/div[1]/div[2]/span[1]","prefix":"Effects of racemic warfarin on ","suffix":" steady-state pharmacokinetics","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":"43","endOffset":"54","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/div[2]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/div[2]/div[1]/div[2]/span[1]","prefix":"Mean plasma concentration–time profiles of ","suffix":" following multiple doses of ambrisentan alone (□) and in th","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":"83","endOffset":"94","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/div[2]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/div[2]/div[1]/div[2]/span[1]","prefix":"on–time profiles of ambrisentan following multiple doses of ","suffix":" alone (□) and in the presence of a single dose of warfarin ","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":"33","endOffset":"44","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","prefix":"In this study, multiple doses of ","suffix":" 10 mg once daily resulted in slight to modest changes in R-","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":"20","endOffset":"31","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","prefix":"In this study, both ","suffix":" and warfarin were administered at clinically effective dose","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":"457","endOffset":"468","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","prefix":"egarding the safety profile of chronic co-administration of ","suffix":" and warfarin. Of note, clinical studies in patients with PA","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":"614","endOffset":"625","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","prefix":" above, have demonstrated that chronic co-administration of ","suffix":" and warfarin does not appear to be associated with any spec","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":"29","endOffset":"40","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[10]/div[2]/div[12]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[10]/div[2]/div[12]/span[1]","prefix":"Gilead Sciences I. Letairis (","suffix":") tablets for oral use.  United States Food and Drug Adminis","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":"23","endOffset":"34","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[2]/div[2]/div[1]/ul[1]/li[2]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[2]/div[2]/div[1]/ul[1]/li[2]/a[1]","prefix":"Effect of steady-state ","suffix":" on the pharmacokinetics of a single dose of the oral contra","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":"30","endOffset":"41","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[2]/div[2]/div[1]/ul[1]/li[5]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[2]/div[2]/div[1]/ul[1]/li[5]/a[1]","prefix":"Pharmacokinetic evaluation of ","suffix":".","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":"74","endOffset":"85","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[5]/div[2]/div[1]/div[1]/ul[1]/li[1]/div[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[5]/div[2]/div[1]/div[1]/ul[1]/li[1]/div[1]","prefix":"netics and pharmacodynamics of warfarin in combination with ","suffix":" in healthy volunteers","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":"29","endOffset":"40","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[11]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[11]/span[1]","prefix":"Gilead Sciences I. Letairis (","suffix":") tablets for oral use.  United States Food and Drug Adminis","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":"189","endOffset":"200","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[5]","prefix":" to detect a 6% difference in INR between day 13 (warfarin +","suffix":") and day 1 (warfarin alone), and a >90% probability that th","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":"43","endOffset":"54","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/div[2]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/div[2]/div[1]/div[2]/span[1]","prefix":"Mean plasma concentration–time profiles of ","suffix":" following multiple doses of ambrisentan alone (□) and in th","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":"83","endOffset":"94","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/div[2]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/div[2]/div[1]/div[2]/span[1]","prefix":"on–time profiles of ambrisentan following multiple doses of ","suffix":" alone (□) and in the presence of a single dose of warfarin ","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":"74","endOffset":"85","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[1]/h1[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[1]/h1[1]","prefix":"netics and pharmacodynamics of warfarin in combination with ","suffix":" in healthy volunteers","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":"218","endOffset":"229","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[1]/p[1]","prefix":"on. The aim of this study was to evaluate the potential for ","suffix":" to affect warfarin pharmacokinetics and pharmacodynamics.","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":"132","endOffset":"143","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":"le dose of racemic warfarin 25 mg alone and after 8 days of ","suffix":" 10 mg once daily. Assessments included exposure (AUC","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":"18","endOffset":"29","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","prefix":"Multiple doses of ","suffix":" had no clinically relevant effects on the pharmacokinetics ","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":"0","endOffset":"11","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","prefix":"","suffix":", endothelin receptor antagonist, International Normalized R","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":"98","endOffset":"109","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/ul[1]/li[1]/div[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/ul[1]/li[1]/div[1]","prefix":"ubjects to identify any potential drug interactions between ","suffix":" and warfarin.","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":"18","endOffset":"29","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/ul[1]/li[2]/div[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/ul[1]/li[2]/div[1]","prefix":"Multiple doses of ","suffix":" had no clinically relevant effects on the pharmacokinetics ","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":"235","endOffset":"246","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/ul[1]/li[2]/div[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/ul[1]/li[2]/div[1]","prefix":"ly relevant effects on the steady-state pharmacokinetics of ","suffix":".","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":"32","endOffset":"43","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/ul[1]/li[3]/div[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/ul[1]/li[3]/div[1]","prefix":"Therefore, co-administration of ","suffix":" with warfarin should not require adjustment of the therapeu","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":"133","endOffset":"144","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[2]","prefix":" dependence, bleeding disorders, sensitivity to warfarin or ","suffix":", or significant allergies. Subjects were also excluded if t","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":"192","endOffset":"203","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","prefix":"tic and/or pharmacodynamic interaction of multiple doses of ","suffix":" with a single dose of warfarin in healthy subjects (","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":"129","endOffset":"140","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/div[1]/div[2]/span[1]","prefix":"emic warfarin 25 mg were administered on days 1 and 13, and ","suffix":" 10 mg was administered once daily from day 5 to day 16. OD,","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":"273","endOffset":"284","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","prefix":"12, 18, 24, 36, 48, 72 and 96 h postdose. Blood samples for ","suffix":" pharmacokinetic assessments were collected relative to the ","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":"362","endOffset":"373","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","prefix":"ssessments were collected relative to the day 12 and day 13 ","suffix":" doses: predose (≤30 min prior), and 0.5, 1, 2, 3, 4, 6, 8, ","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":"476","endOffset":"487","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","prefix":", 2, 3, 4, 6, 8, 10, 12, 18 and 24 h postdose. Steady-state ","suffix":" concentrations were determined from samples collected at tr","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":"31","endOffset":"42","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","prefix":"The safety and tolerability of ","suffix":" and warfarin co-administration was assessed through adverse","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":"36","endOffset":"47","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[3]","prefix":"To assess the effect of concomitant ","suffix":" dosing on warfarin pharmacokinetics and pharmacodynamics, i","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":"176","endOffset":"187","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[3]","prefix":" within-subject pair-wise differences of day 13 (warfarin + ","suffix":") ","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":"55","endOffset":"66","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[4]","prefix":"To assess the effect of concomitant warfarin dosing on ","suffix":" pharmacokinetics, individual within-subject pair-wise diffe","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":"155","endOffset":"166","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[4]","prefix":" within-subject pair-wise differences of day 13 (warfarin + ","suffix":") ","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":"189","endOffset":"200","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[5]","prefix":" to detect a 6% difference in INR between day 13 (warfarin +","suffix":") and day 1 (warfarin alone), and a >90% probability that th","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":"63","endOffset":"74","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[1]","prefix":"re were no clinically relevant effects of multiple doses of ","suffix":" on the concentration–time profiles of R-and S-warfarin (","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":"10","endOffset":"21","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/div[1]/div[1]/div[2]/span[1]","prefix":"Effect of ","suffix":" on R-and S-warfarin pharmacokinetics","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":"64","endOffset":"75","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[1]","prefix":"nistration of warfarin in the presence of multiple doses of ","suffix":" (","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":"10","endOffset":"21","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[1]/div[1]/div[2]/span[1]","prefix":"Effect of ","suffix":" on warfarin pharmacodynamics","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":"92","endOffset":"103","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/p[1]","prefix":"ct on the steady-state plasma concentration–time profile of ","suffix":" (","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":"31","endOffset":"42","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/div[1]/div[1]/div[2]/span[1]","prefix":"Effects of racemic warfarin on ","suffix":" steady-state pharmacokinetics","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":"43","endOffset":"54","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/div[2]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/div[2]/div[1]/div[2]/span[1]","prefix":"Mean plasma concentration–time profiles of ","suffix":" following multiple doses of ambrisentan alone (□) and in th","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":"83","endOffset":"94","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/div[2]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/div[2]/div[1]/div[2]/span[1]","prefix":"on–time profiles of ambrisentan following multiple doses of ","suffix":" alone (□) and in the presence of a single dose of warfarin ","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":"33","endOffset":"44","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","prefix":"In this study, multiple doses of ","suffix":" 10 mg once daily resulted in slight to modest changes in R-","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":"20","endOffset":"31","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","prefix":"In this study, both ","suffix":" and warfarin were administered at clinically effective dose","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":"457","endOffset":"468","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","prefix":"egarding the safety profile of chronic co-administration of ","suffix":" and warfarin. Of note, clinical studies in patients with PA","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":"614","endOffset":"625","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","prefix":" above, have demonstrated that chronic co-administration of ","suffix":" and warfarin does not appear to be associated with any spec","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":"29","endOffset":"40","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[10]/div[2]/div[12]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[10]/div[2]/div[12]/span[1]","prefix":"Gilead Sciences I. Letairis (","suffix":") tablets for oral use.  United States Food and Drug Adminis","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":"23","endOffset":"34","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[2]/div[2]/div[1]/ul[1]/li[2]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[2]/div[2]/div[1]/ul[1]/li[2]/a[1]","prefix":"Effect of steady-state ","suffix":" on the pharmacokinetics of a single dose of the oral contra","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":"30","endOffset":"41","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[2]/div[2]/div[1]/ul[1]/li[5]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[2]/div[2]/div[1]/ul[1]/li[5]/a[1]","prefix":"Pharmacokinetic evaluation of ","suffix":".","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":"74","endOffset":"85","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[5]/div[2]/div[1]/div[1]/ul[1]/li[1]/div[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[5]/div[2]/div[1]/div[1]/ul[1]/li[1]/div[1]","prefix":"netics and pharmacodynamics of warfarin in combination with ","suffix":" in healthy volunteers","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":"29","endOffset":"40","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[11]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[11]/span[1]","prefix":"Gilead Sciences I. Letairis (","suffix":") tablets for oral use.  United States Food and Drug Adminis","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":"63","endOffset":"74","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[1]","prefix":"re were no clinically relevant effects of multiple doses of ","suffix":" on the concentration–time profiles of R-and S-warfarin (","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":"235","endOffset":"246","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/ul[1]/li[2]/div[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/ul[1]/li[2]/div[1]","prefix":"ly relevant effects on the steady-state pharmacokinetics of ","suffix":".","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":"30","endOffset":"41","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[2]/div[2]/div[1]/ul[1]/li[5]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[2]/div[2]/div[1]/ul[1]/li[5]/a[1]","prefix":"Pharmacokinetic evaluation of ","suffix":".","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":"10","endOffset":"21","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/div[1]/div[1]/div[2]/span[1]","prefix":"Effect of ","suffix":" on R-and S-warfarin pharmacokinetics","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":"0","endOffset":"11","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","prefix":"","suffix":", endothelin receptor antagonist, International Normalized R","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":"0","endOffset":"11","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","prefix":"","suffix":", endothelin receptor antagonist, International Normalized R","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":"64","endOffset":"75","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[1]","prefix":"nistration of warfarin in the presence of multiple doses of ","suffix":" (","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":"10","endOffset":"21","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[1]/div[1]/div[2]/span[1]","prefix":"Effect of ","suffix":" on warfarin pharmacodynamics","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":"0","endOffset":"11","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","prefix":"","suffix":", endothelin receptor antagonist, International Normalized R","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":"0","endOffset":"11","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","prefix":"","suffix":", endothelin receptor antagonist, International Normalized R","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":"92","endOffset":"103","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/p[1]","prefix":"ct on the steady-state plasma concentration–time profile of ","suffix":" (","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":"31","endOffset":"42","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/div[1]/div[1]/div[2]/span[1]","prefix":"Effects of racemic warfarin on ","suffix":" steady-state pharmacokinetics","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":"43","endOffset":"54","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/div[2]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/div[2]/div[1]/div[2]/span[1]","prefix":"Mean plasma concentration–time profiles of ","suffix":" following multiple doses of ambrisentan alone (□) and in th","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":"83","endOffset":"94","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/div[2]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/div[2]/div[1]/div[2]/span[1]","prefix":"on–time profiles of ambrisentan following multiple doses of ","suffix":" alone (□) and in the presence of a single dose of warfarin ","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":"33","endOffset":"44","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","prefix":"In this study, multiple doses of ","suffix":" 10 mg once daily resulted in slight to modest changes in R-","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":"0","endOffset":"11","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","prefix":"","suffix":" is primarily metabolized via hepatic glucuronidation [","exact":"Ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":"20","endOffset":"31","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","prefix":"In this study, both ","suffix":" and warfarin were administered at clinically effective dose","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":"457","endOffset":"468","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","prefix":"egarding the safety profile of chronic co-administration of ","suffix":" and warfarin. Of note, clinical studies in patients with PA","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"ambrisentan","startOffset":"614","endOffset":"625","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","prefix":" above, have demonstrated that chronic co-administration of ","suffix":" and warfarin does not appear to be associated with any spec","exact":"ambrisentan"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"103","endOffset":"111","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[1]/p[1]","prefix":"d endothelin receptor antagonist often co-administered with ","suffix":" to patients with pulmonary arterial hypertension. The aim o","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"240","endOffset":"248","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[1]/p[1]","prefix":"udy was to evaluate the potential for ambrisentan to affect ","suffix":" pharmacokinetics and pharmacodynamics.","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"91","endOffset":"99","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":"tudy, 22 healthy subjects received a single dose of racemic ","suffix":" 25 mg alone and after 8 days of ambrisentan 10 mg once dail","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"160","endOffset":"168","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","prefix":"acokinetics, pulmonary arterial hypertension, R-warfarin, S-","suffix":"","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"114","endOffset":"122","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/ul[1]/li[1]/div[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/ul[1]/li[1]/div[1]","prefix":"ify any potential drug interactions between ambrisentan and ","suffix":".","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"48","endOffset":"56","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[10]/div[2]/div[7]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[10]/div[2]/div[7]/span[1]","prefix":"Kaminsky LS, Zhang ZY. Human P450 metabolism of ","suffix":". ","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"144","endOffset":"152","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[10]/div[2]/div[14]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[10]/div[2]/div[14]/span[1]","prefix":"st bosentan on the pharmacokinetics and pharmacodynamics of ","suffix":". ","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"102","endOffset":"110","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[5]/div[2]/ul[1]/li[2]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[5]/div[2]/ul[1]/li[2]/a[1]","prefix":"st bosentan on the pharmacokinetics and pharmacodynamics of ","suffix":".","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"102","endOffset":"110","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[14]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[14]","prefix":"st bosentan on the pharmacokinetics and pharmacodynamics of ","suffix":".","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"130","endOffset":"138","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","prefix":"e pharmacokinetics and pharmacodynamics of a single dose of ","suffix":". Therefore, significant dose adjustments of either drug are","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"148","endOffset":"156","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","prefix":"amics, pharmacokinetics, pulmonary arterial hypertension, R-","suffix":", S-warfarin","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"160","endOffset":"168","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","prefix":"acokinetics, pulmonary arterial hypertension, R-warfarin, S-","suffix":"","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"0","endOffset":"8","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[1]/div[1]/ul[1]/li[1]/div[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[1]/div[1]/ul[1]/li[1]/div[1]","prefix":"","suffix":" anticoagulation therapy is commonly administered to patient","exact":"Warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"127","endOffset":"135","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[1]/div[1]/ul[1]/li[2]/div[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[1]/div[1]/ul[1]/li[2]/div[1]","prefix":"ceptor antagonist that is likely to be co-administered with ","suffix":" to PAH patients.","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"45","endOffset":"53","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[1]/div[1]/ul[1]/li[3]/div[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[1]/div[1]/ul[1]/li[3]/div[1]","prefix":"Concomitant therapies that induce or inhibit ","suffix":" metabolism may alter the systemic exposure of warfarin and ","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"100","endOffset":"108","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[1]/div[1]/ul[1]/li[3]/div[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[1]/div[1]/ul[1]/li[3]/div[1]","prefix":"ibit warfarin metabolism may alter the systemic exposure of ","suffix":" and significantly alter clotting time, as measured by proth","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"261","endOffset":"269","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[1]/div[1]/ul[1]/li[3]/div[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[1]/div[1]/ul[1]/li[3]/div[1]","prefix":"malized Ratio, thereby requiring substantial adjustments to ","suffix":" dose.","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"114","endOffset":"122","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/ul[1]/li[1]/div[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/ul[1]/li[1]/div[1]","prefix":"ify any potential drug interactions between ambrisentan and ","suffix":".","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"112","endOffset":"120","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/ul[1]/li[2]/div[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/ul[1]/li[2]/div[1]","prefix":"vant effects on the pharmacokinetics or pharmacodynamics of ","suffix":"; conversely, a single dose of warfarin had no clinically re","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"151","endOffset":"159","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/ul[1]/li[2]/div[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/ul[1]/li[2]/div[1]","prefix":" pharmacodynamics of warfarin; conversely, a single dose of ","suffix":" had no clinically relevant effects on the steady-state phar","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"49","endOffset":"57","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/ul[1]/li[3]/div[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/ul[1]/li[3]/div[1]","prefix":"Therefore, co-administration of ambrisentan with ","suffix":" should not require adjustment of the therapeutically effect","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"121","endOffset":"129","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[2]","prefix":"y of alcohol dependence, bleeding disorders, sensitivity to ","suffix":" or ambrisentan, or significant allergies. Subjects were als","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"226","endOffset":"234","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","prefix":"tion of multiple doses of ambrisentan with a single dose of ","suffix":" in healthy subjects (","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"74","endOffset":"82","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/div[1]/div[2]/span[1]","prefix":"egimen and blood sampling schedule. Single doses of racemic ","suffix":" 25 mg were administered on days 1 and 13, and ambrisentan 1","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"61","endOffset":"69","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","prefix":"lood samples for the pharmacokinetic assessments of R-and S-","suffix":" were collected at the following times relative to the day 1","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"141","endOffset":"149","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","prefix":"ted at the following times relative to the day 1 and day 13 ","suffix":" doses: predose (≤30 min prior), and 0.5, 1, 2, 3, 4, 6, 8, ","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"47","endOffset":"55","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","prefix":"The safety and tolerability of ambrisentan and ","suffix":" co-administration was assessed through adverse events (AEs)","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"58","endOffset":"66","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[3]","prefix":"To assess the effect of concomitant ambrisentan dosing on ","suffix":" pharmacokinetics and pharmacodynamics, individual within-su","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"45","endOffset":"53","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[1]/h1[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[1]/h1[1]","prefix":"The pharmacokinetics and pharmacodynamics of ","suffix":" in combination with ambrisentan in healthy volunteers","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"103","endOffset":"111","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[1]/p[1]","prefix":"d endothelin receptor antagonist often co-administered with ","suffix":" to patients with pulmonary arterial hypertension. The aim o","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"240","endOffset":"248","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[1]/p[1]","prefix":"udy was to evaluate the potential for ambrisentan to affect ","suffix":" pharmacokinetics and pharmacodynamics.","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"91","endOffset":"99","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":"tudy, 22 healthy subjects received a single dose of racemic ","suffix":" 25 mg alone and after 8 days of ambrisentan 10 mg once dail","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"130","endOffset":"138","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","prefix":"e pharmacokinetics and pharmacodynamics of a single dose of ","suffix":". Therefore, significant dose adjustments of either drug are","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"148","endOffset":"156","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","prefix":"amics, pharmacokinetics, pulmonary arterial hypertension, R-","suffix":", S-warfarin","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"160","endOffset":"168","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","prefix":"acokinetics, pulmonary arterial hypertension, R-warfarin, S-","suffix":"","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"127","endOffset":"135","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[1]/div[1]/ul[1]/li[2]/div[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[1]/div[1]/ul[1]/li[2]/div[1]","prefix":"ceptor antagonist that is likely to be co-administered with ","suffix":" to PAH patients.","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"45","endOffset":"53","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[1]/div[1]/ul[1]/li[3]/div[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[1]/div[1]/ul[1]/li[3]/div[1]","prefix":"Concomitant therapies that induce or inhibit ","suffix":" metabolism may alter the systemic exposure of warfarin and ","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"100","endOffset":"108","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[1]/div[1]/ul[1]/li[3]/div[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[1]/div[1]/ul[1]/li[3]/div[1]","prefix":"ibit warfarin metabolism may alter the systemic exposure of ","suffix":" and significantly alter clotting time, as measured by proth","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"261","endOffset":"269","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[1]/div[1]/ul[1]/li[3]/div[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[1]/div[1]/ul[1]/li[3]/div[1]","prefix":"malized Ratio, thereby requiring substantial adjustments to ","suffix":" dose.","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"112","endOffset":"120","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/ul[1]/li[2]/div[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/ul[1]/li[2]/div[1]","prefix":"vant effects on the pharmacokinetics or pharmacodynamics of ","suffix":"; conversely, a single dose of warfarin had no clinically re","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"151","endOffset":"159","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/ul[1]/li[2]/div[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/ul[1]/li[2]/div[1]","prefix":" pharmacodynamics of warfarin; conversely, a single dose of ","suffix":" had no clinically relevant effects on the steady-state phar","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"49","endOffset":"57","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/ul[1]/li[3]/div[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/ul[1]/li[3]/div[1]","prefix":"Therefore, co-administration of ambrisentan with ","suffix":" should not require adjustment of the therapeutically effect","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"121","endOffset":"129","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[2]","prefix":"y of alcohol dependence, bleeding disorders, sensitivity to ","suffix":" or ambrisentan, or significant allergies. Subjects were als","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"226","endOffset":"234","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","prefix":"tion of multiple doses of ambrisentan with a single dose of ","suffix":" in healthy subjects (","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"74","endOffset":"82","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/div[1]/div[2]/span[1]","prefix":"egimen and blood sampling schedule. Single doses of racemic ","suffix":" 25 mg were administered on days 1 and 13, and ambrisentan 1","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"61","endOffset":"69","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","prefix":"lood samples for the pharmacokinetic assessments of R-and S-","suffix":" were collected at the following times relative to the day 1","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"141","endOffset":"149","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","prefix":"ted at the following times relative to the day 1 and day 13 ","suffix":" doses: predose (≤30 min prior), and 0.5, 1, 2, 3, 4, 6, 8, ","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"47","endOffset":"55","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","prefix":"The safety and tolerability of ambrisentan and ","suffix":" co-administration was assessed through adverse events (AEs)","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"58","endOffset":"66","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[3]","prefix":"To assess the effect of concomitant ambrisentan dosing on ","suffix":" pharmacokinetics and pharmacodynamics, individual within-su","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"165","endOffset":"173","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[3]","prefix":" individual within-subject pair-wise differences of day 13 (","suffix":" + ambrisentan) ","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"36","endOffset":"44","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[4]","prefix":"To assess the effect of concomitant ","suffix":" dosing on ambrisentan pharmacokinetics, individual within-s","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"144","endOffset":"152","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[4]","prefix":" individual within-subject pair-wise differences of day 13 (","suffix":" + ambrisentan) ","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"179","endOffset":"187","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[5]","prefix":">80% power to detect a 6% difference in INR between day 13 (","suffix":" +ambrisentan) and day 1 (warfarin alone), and a >90% probab","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"213","endOffset":"221","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[5]","prefix":"ce in INR between day 13 (warfarin +ambrisentan) and day 1 (","suffix":" alone), and a >90% probability that the true 95% two-sided ","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"121","endOffset":"129","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[1]","prefix":"f ambrisentan on the concentration–time profiles of R-and S-","suffix":" (","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"33","endOffset":"41","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/div[1]/div[1]/div[2]/span[1]","prefix":"Effect of ambrisentan on R-and S-","suffix":" pharmacokinetics","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"18","endOffset":"26","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[1]","prefix":"Administration of ","suffix":" in the presence of multiple doses of ambrisentan (","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"25","endOffset":"33","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[1]/div[1]/div[2]/span[1]","prefix":"Effect of ambrisentan on ","suffix":" pharmacodynamics","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"8","endOffset":"16","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/p[1]","prefix":"Racemic ","suffix":" had little effect on the steady-state plasma concentration–","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"19","endOffset":"27","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/div[1]/div[1]/div[2]/span[1]","prefix":"Effects of racemic ","suffix":" on ambrisentan steady-state pharmacokinetics","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"145","endOffset":"153","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/div[2]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/div[2]/div[1]/div[2]/span[1]","prefix":"brisentan alone (□) and in the presence of a single dose of ","suffix":" (○) in 22 healthy subjects. Data are means ± standard devia","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"110","endOffset":"118","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","prefix":" once daily resulted in slight to modest changes in R-and S-","suffix":" pharmacokinetic (AUC","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"23","endOffset":"31","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","prefix":"Drug interactions with ","suffix":" have been previously demonstrated for the ERAs bosentan and","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"36","endOffset":"44","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","prefix":"In this study, both ambrisentan and ","suffix":" were administered at clinically effective doses, and no sig","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"168","endOffset":"176","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","prefix":"cant changes in the pharmacokinetics or pharmacodynamics of ","suffix":" were observed with co-administration. However, because of t","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"473","endOffset":"481","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","prefix":"ety profile of chronic co-administration of ambrisentan and ","suffix":". Of note, clinical studies in patients with PAH, such as th","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"630","endOffset":"638","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","prefix":"onstrated that chronic co-administration of ambrisentan and ","suffix":" does not appear to be associated with any specific safety c","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"44","endOffset":"52","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[10]/div[2]/div[5]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[10]/div[2]/div[5]/span[1]","prefix":"Takahashi H, Echizen H. Pharmacogenetics of ","suffix":" elimination and its clinical implications. ","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"70","endOffset":"78","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[10]/div[2]/div[6]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[10]/div[2]/div[6]/span[1]","prefix":"Lachlan A, O'Reilly R, Rowland M. Stereochemical aspects of ","suffix":" drug interactions: use of a combined pharmacokinetic–pharma","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"48","endOffset":"56","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[10]/div[2]/div[7]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[10]/div[2]/div[7]/span[1]","prefix":"Kaminsky LS, Zhang ZY. Human P450 metabolism of ","suffix":". ","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"122","endOffset":"130","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[10]/div[2]/div[13]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[10]/div[2]/div[13]/span[1]","prefix":"mance liquid chromatographic method for the quantitation of ","suffix":" enantiomers in human plasma. ","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"144","endOffset":"152","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[10]/div[2]/div[14]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[10]/div[2]/div[14]/span[1]","prefix":"st bosentan on the pharmacokinetics and pharmacodynamics of ","suffix":". ","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"95","endOffset":"103","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[2]/div[2]/div[1]/ul[1]/li[1]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[2]/div[2]/div[1]/ul[1]/li[1]/a[1]","prefix":"n the steady-state pharmacokinetics and pharmacodynamics of ","suffix":" in healthy subjects during a three-stage, open-label, multi","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"72","endOffset":"80","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[2]/div[2]/div[1]/ul[1]/li[3]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[2]/div[2]/div[1]/ul[1]/li[3]/a[1]","prefix":"esoterodine on the pharmacokinetics and pharmacodynamics of ","suffix":" in healthy volunteers.","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"45","endOffset":"53","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[5]/div[2]/div[1]/div[1]/ul[1]/li[1]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[5]/div[2]/div[1]/div[1]/ul[1]/li[1]/a[1]","prefix":"The pharmacokinetics and pharmacodynamics of ","suffix":" in combination with ambris...","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"45","endOffset":"53","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[5]/div[2]/div[1]/div[1]/ul[1]/li[1]/div[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[5]/div[2]/div[1]/div[1]/ul[1]/li[1]/div[1]","prefix":"The pharmacokinetics and pharmacodynamics of ","suffix":" in combination with ambrisentan in healthy volunteers","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"26","endOffset":"34","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[2]/div[2]/ul[1]/li[4]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[2]/div[2]/ul[1]/li[4]/a[1]","prefix":"Stereochemical aspects of ","suffix":" drug interactions: use of a combined pharmacokinetic-pharma","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"103","endOffset":"111","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[4]/div[2]/ul[1]/li[1]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[4]/div[2]/ul[1]/li[1]/a[1]","prefix":"mance liquid chromatographic method for the quantitation of ","suffix":" enantiomers in human plasma.","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"26","endOffset":"34","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]","prefix":"Stereochemical aspects of ","suffix":" drug interactions: use of a combined pharmacokinetic-pharma","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"103","endOffset":"111","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[13]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[13]","prefix":"mance liquid chromatographic method for the quantitation of ","suffix":" enantiomers in human plasma.","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"91","endOffset":"99","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":"tudy, 22 healthy subjects received a single dose of racemic ","suffix":" 25 mg alone and after 8 days of ambrisentan 10 mg once dail","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"160","endOffset":"168","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","prefix":"acokinetics, pulmonary arterial hypertension, R-warfarin, S-","suffix":"","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"179","endOffset":"187","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[5]","prefix":">80% power to detect a 6% difference in INR between day 13 (","suffix":" +ambrisentan) and day 1 (warfarin alone), and a >90% probab","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"213","endOffset":"221","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[5]","prefix":"ce in INR between day 13 (warfarin +ambrisentan) and day 1 (","suffix":" alone), and a >90% probability that the true 95% two-sided ","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"36","endOffset":"44","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[4]","prefix":"To assess the effect of concomitant ","suffix":" dosing on ambrisentan pharmacokinetics, individual within-s","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"45","endOffset":"53","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[1]/h1[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[1]/h1[1]","prefix":"The pharmacokinetics and pharmacodynamics of ","suffix":" in combination with ambrisentan in healthy volunteers","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"103","endOffset":"111","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[1]/p[1]","prefix":"d endothelin receptor antagonist often co-administered with ","suffix":" to patients with pulmonary arterial hypertension. The aim o","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"240","endOffset":"248","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[1]/p[1]","prefix":"udy was to evaluate the potential for ambrisentan to affect ","suffix":" pharmacokinetics and pharmacodynamics.","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"91","endOffset":"99","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":"tudy, 22 healthy subjects received a single dose of racemic ","suffix":" 25 mg alone and after 8 days of ambrisentan 10 mg once dail","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"130","endOffset":"138","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","prefix":"e pharmacokinetics and pharmacodynamics of a single dose of ","suffix":". Therefore, significant dose adjustments of either drug are","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"148","endOffset":"156","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","prefix":"amics, pharmacokinetics, pulmonary arterial hypertension, R-","suffix":", S-warfarin","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"160","endOffset":"168","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","prefix":"acokinetics, pulmonary arterial hypertension, R-warfarin, S-","suffix":"","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"127","endOffset":"135","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[1]/div[1]/ul[1]/li[2]/div[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[1]/div[1]/ul[1]/li[2]/div[1]","prefix":"ceptor antagonist that is likely to be co-administered with ","suffix":" to PAH patients.","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"45","endOffset":"53","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[1]/div[1]/ul[1]/li[3]/div[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[1]/div[1]/ul[1]/li[3]/div[1]","prefix":"Concomitant therapies that induce or inhibit ","suffix":" metabolism may alter the systemic exposure of warfarin and ","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"100","endOffset":"108","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[1]/div[1]/ul[1]/li[3]/div[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[1]/div[1]/ul[1]/li[3]/div[1]","prefix":"ibit warfarin metabolism may alter the systemic exposure of ","suffix":" and significantly alter clotting time, as measured by proth","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"261","endOffset":"269","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[1]/div[1]/ul[1]/li[3]/div[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[1]/div[1]/ul[1]/li[3]/div[1]","prefix":"malized Ratio, thereby requiring substantial adjustments to ","suffix":" dose.","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"112","endOffset":"120","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/ul[1]/li[2]/div[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/ul[1]/li[2]/div[1]","prefix":"vant effects on the pharmacokinetics or pharmacodynamics of ","suffix":"; conversely, a single dose of warfarin had no clinically re","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"151","endOffset":"159","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/ul[1]/li[2]/div[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/ul[1]/li[2]/div[1]","prefix":" pharmacodynamics of warfarin; conversely, a single dose of ","suffix":" had no clinically relevant effects on the steady-state phar","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"49","endOffset":"57","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/ul[1]/li[3]/div[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/ul[1]/li[3]/div[1]","prefix":"Therefore, co-administration of ambrisentan with ","suffix":" should not require adjustment of the therapeutically effect","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"121","endOffset":"129","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[2]","prefix":"y of alcohol dependence, bleeding disorders, sensitivity to ","suffix":" or ambrisentan, or significant allergies. Subjects were als","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"226","endOffset":"234","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","prefix":"tion of multiple doses of ambrisentan with a single dose of ","suffix":" in healthy subjects (","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"74","endOffset":"82","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/div[1]/div[2]/span[1]","prefix":"egimen and blood sampling schedule. Single doses of racemic ","suffix":" 25 mg were administered on days 1 and 13, and ambrisentan 1","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"61","endOffset":"69","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","prefix":"lood samples for the pharmacokinetic assessments of R-and S-","suffix":" were collected at the following times relative to the day 1","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"141","endOffset":"149","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","prefix":"ted at the following times relative to the day 1 and day 13 ","suffix":" doses: predose (≤30 min prior), and 0.5, 1, 2, 3, 4, 6, 8, ","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"47","endOffset":"55","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","prefix":"The safety and tolerability of ambrisentan and ","suffix":" co-administration was assessed through adverse events (AEs)","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"58","endOffset":"66","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[3]","prefix":"To assess the effect of concomitant ambrisentan dosing on ","suffix":" pharmacokinetics and pharmacodynamics, individual within-su","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"165","endOffset":"173","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[3]","prefix":" individual within-subject pair-wise differences of day 13 (","suffix":" + ambrisentan) ","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"36","endOffset":"44","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[4]","prefix":"To assess the effect of concomitant ","suffix":" dosing on ambrisentan pharmacokinetics, individual within-s","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"144","endOffset":"152","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[4]","prefix":" individual within-subject pair-wise differences of day 13 (","suffix":" + ambrisentan) ","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"179","endOffset":"187","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[5]","prefix":">80% power to detect a 6% difference in INR between day 13 (","suffix":" +ambrisentan) and day 1 (warfarin alone), and a >90% probab","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"213","endOffset":"221","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[5]","prefix":"ce in INR between day 13 (warfarin +ambrisentan) and day 1 (","suffix":" alone), and a >90% probability that the true 95% two-sided ","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"121","endOffset":"129","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[1]","prefix":"f ambrisentan on the concentration–time profiles of R-and S-","suffix":" (","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"33","endOffset":"41","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/div[1]/div[1]/div[2]/span[1]","prefix":"Effect of ambrisentan on R-and S-","suffix":" pharmacokinetics","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"18","endOffset":"26","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[1]","prefix":"Administration of ","suffix":" in the presence of multiple doses of ambrisentan (","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"25","endOffset":"33","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[1]/div[1]/div[2]/span[1]","prefix":"Effect of ambrisentan on ","suffix":" pharmacodynamics","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"8","endOffset":"16","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/p[1]","prefix":"Racemic ","suffix":" had little effect on the steady-state plasma concentration–","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"19","endOffset":"27","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/div[1]/div[1]/div[2]/span[1]","prefix":"Effects of racemic ","suffix":" on ambrisentan steady-state pharmacokinetics","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"145","endOffset":"153","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/div[2]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/div[2]/div[1]/div[2]/span[1]","prefix":"brisentan alone (□) and in the presence of a single dose of ","suffix":" (○) in 22 healthy subjects. Data are means ± standard devia","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"110","endOffset":"118","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","prefix":" once daily resulted in slight to modest changes in R-and S-","suffix":" pharmacokinetic (AUC","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"23","endOffset":"31","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","prefix":"Drug interactions with ","suffix":" have been previously demonstrated for the ERAs bosentan and","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"36","endOffset":"44","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","prefix":"In this study, both ambrisentan and ","suffix":" were administered at clinically effective doses, and no sig","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"168","endOffset":"176","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","prefix":"cant changes in the pharmacokinetics or pharmacodynamics of ","suffix":" were observed with co-administration. However, because of t","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"473","endOffset":"481","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","prefix":"ety profile of chronic co-administration of ambrisentan and ","suffix":". Of note, clinical studies in patients with PAH, such as th","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"630","endOffset":"638","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","prefix":"onstrated that chronic co-administration of ambrisentan and ","suffix":" does not appear to be associated with any specific safety c","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"44","endOffset":"52","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[10]/div[2]/div[5]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[10]/div[2]/div[5]/span[1]","prefix":"Takahashi H, Echizen H. Pharmacogenetics of ","suffix":" elimination and its clinical implications. ","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"70","endOffset":"78","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[10]/div[2]/div[6]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[10]/div[2]/div[6]/span[1]","prefix":"Lachlan A, O'Reilly R, Rowland M. Stereochemical aspects of ","suffix":" drug interactions: use of a combined pharmacokinetic–pharma","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"48","endOffset":"56","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[10]/div[2]/div[7]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[10]/div[2]/div[7]/span[1]","prefix":"Kaminsky LS, Zhang ZY. Human P450 metabolism of ","suffix":". ","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"122","endOffset":"130","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[10]/div[2]/div[13]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[10]/div[2]/div[13]/span[1]","prefix":"mance liquid chromatographic method for the quantitation of ","suffix":" enantiomers in human plasma. ","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"144","endOffset":"152","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[10]/div[2]/div[14]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[10]/div[2]/div[14]/span[1]","prefix":"st bosentan on the pharmacokinetics and pharmacodynamics of ","suffix":". ","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"95","endOffset":"103","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[2]/div[2]/div[1]/ul[1]/li[1]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[2]/div[2]/div[1]/ul[1]/li[1]/a[1]","prefix":"n the steady-state pharmacokinetics and pharmacodynamics of ","suffix":" in healthy subjects during a three-stage, open-label, multi","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"72","endOffset":"80","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[2]/div[2]/div[1]/ul[1]/li[3]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[2]/div[2]/div[1]/ul[1]/li[3]/a[1]","prefix":"esoterodine on the pharmacokinetics and pharmacodynamics of ","suffix":" in healthy volunteers.","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"45","endOffset":"53","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[5]/div[2]/div[1]/div[1]/ul[1]/li[1]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[5]/div[2]/div[1]/div[1]/ul[1]/li[1]/a[1]","prefix":"The pharmacokinetics and pharmacodynamics of ","suffix":" in combination with ambris...","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"45","endOffset":"53","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[5]/div[2]/div[1]/div[1]/ul[1]/li[1]/div[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[5]/div[2]/div[1]/div[1]/ul[1]/li[1]/div[1]","prefix":"The pharmacokinetics and pharmacodynamics of ","suffix":" in combination with ambrisentan in healthy volunteers","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"26","endOffset":"34","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[2]/div[2]/ul[1]/li[4]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[2]/div[2]/ul[1]/li[4]/a[1]","prefix":"Stereochemical aspects of ","suffix":" drug interactions: use of a combined pharmacokinetic-pharma","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"103","endOffset":"111","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[4]/div[2]/ul[1]/li[1]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[4]/div[2]/ul[1]/li[1]/a[1]","prefix":"mance liquid chromatographic method for the quantitation of ","suffix":" enantiomers in human plasma.","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"26","endOffset":"34","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]","prefix":"Stereochemical aspects of ","suffix":" drug interactions: use of a combined pharmacokinetic-pharma","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"103","endOffset":"111","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[13]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[13]","prefix":"mance liquid chromatographic method for the quantitation of ","suffix":" enantiomers in human plasma.","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"45","endOffset":"53","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[1]/h1[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[1]/h1[1]","prefix":"The pharmacokinetics and pharmacodynamics of ","suffix":" in combination with ambrisentan in healthy volunteers","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"103","endOffset":"111","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[1]/p[1]","prefix":"d endothelin receptor antagonist often co-administered with ","suffix":" to patients with pulmonary arterial hypertension. The aim o","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"240","endOffset":"248","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[1]/p[1]","prefix":"udy was to evaluate the potential for ambrisentan to affect ","suffix":" pharmacokinetics and pharmacodynamics.","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"91","endOffset":"99","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":"tudy, 22 healthy subjects received a single dose of racemic ","suffix":" 25 mg alone and after 8 days of ambrisentan 10 mg once dail","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"130","endOffset":"138","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","prefix":"e pharmacokinetics and pharmacodynamics of a single dose of ","suffix":". Therefore, significant dose adjustments of either drug are","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"148","endOffset":"156","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","prefix":"amics, pharmacokinetics, pulmonary arterial hypertension, R-","suffix":", S-warfarin","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"160","endOffset":"168","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","prefix":"acokinetics, pulmonary arterial hypertension, R-warfarin, S-","suffix":"","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"127","endOffset":"135","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[1]/div[1]/ul[1]/li[2]/div[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[1]/div[1]/ul[1]/li[2]/div[1]","prefix":"ceptor antagonist that is likely to be co-administered with ","suffix":" to PAH patients.","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"45","endOffset":"53","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[1]/div[1]/ul[1]/li[3]/div[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[1]/div[1]/ul[1]/li[3]/div[1]","prefix":"Concomitant therapies that induce or inhibit ","suffix":" metabolism may alter the systemic exposure of warfarin and ","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"100","endOffset":"108","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[1]/div[1]/ul[1]/li[3]/div[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[1]/div[1]/ul[1]/li[3]/div[1]","prefix":"ibit warfarin metabolism may alter the systemic exposure of ","suffix":" and significantly alter clotting time, as measured by proth","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"261","endOffset":"269","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[1]/div[1]/ul[1]/li[3]/div[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[1]/div[1]/ul[1]/li[3]/div[1]","prefix":"malized Ratio, thereby requiring substantial adjustments to ","suffix":" dose.","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"112","endOffset":"120","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/ul[1]/li[2]/div[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/ul[1]/li[2]/div[1]","prefix":"vant effects on the pharmacokinetics or pharmacodynamics of ","suffix":"; conversely, a single dose of warfarin had no clinically re","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"151","endOffset":"159","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/ul[1]/li[2]/div[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/ul[1]/li[2]/div[1]","prefix":" pharmacodynamics of warfarin; conversely, a single dose of ","suffix":" had no clinically relevant effects on the steady-state phar","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"49","endOffset":"57","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/ul[1]/li[3]/div[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/ul[1]/li[3]/div[1]","prefix":"Therefore, co-administration of ambrisentan with ","suffix":" should not require adjustment of the therapeutically effect","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"121","endOffset":"129","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[2]","prefix":"y of alcohol dependence, bleeding disorders, sensitivity to ","suffix":" or ambrisentan, or significant allergies. Subjects were als","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"226","endOffset":"234","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","prefix":"tion of multiple doses of ambrisentan with a single dose of ","suffix":" in healthy subjects (","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"74","endOffset":"82","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/div[1]/div[2]/span[1]","prefix":"egimen and blood sampling schedule. Single doses of racemic ","suffix":" 25 mg were administered on days 1 and 13, and ambrisentan 1","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"61","endOffset":"69","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","prefix":"lood samples for the pharmacokinetic assessments of R-and S-","suffix":" were collected at the following times relative to the day 1","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"141","endOffset":"149","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","prefix":"ted at the following times relative to the day 1 and day 13 ","suffix":" doses: predose (≤30 min prior), and 0.5, 1, 2, 3, 4, 6, 8, ","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"47","endOffset":"55","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","prefix":"The safety and tolerability of ambrisentan and ","suffix":" co-administration was assessed through adverse events (AEs)","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"58","endOffset":"66","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[3]","prefix":"To assess the effect of concomitant ambrisentan dosing on ","suffix":" pharmacokinetics and pharmacodynamics, individual within-su","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"165","endOffset":"173","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[3]","prefix":" individual within-subject pair-wise differences of day 13 (","suffix":" + ambrisentan) ","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"36","endOffset":"44","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[4]","prefix":"To assess the effect of concomitant ","suffix":" dosing on ambrisentan pharmacokinetics, individual within-s","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"144","endOffset":"152","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[4]","prefix":" individual within-subject pair-wise differences of day 13 (","suffix":" + ambrisentan) ","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"179","endOffset":"187","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[5]","prefix":">80% power to detect a 6% difference in INR between day 13 (","suffix":" +ambrisentan) and day 1 (warfarin alone), and a >90% probab","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"213","endOffset":"221","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[5]","prefix":"ce in INR between day 13 (warfarin +ambrisentan) and day 1 (","suffix":" alone), and a >90% probability that the true 95% two-sided ","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"121","endOffset":"129","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[1]","prefix":"f ambrisentan on the concentration–time profiles of R-and S-","suffix":" (","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"33","endOffset":"41","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/div[1]/div[1]/div[2]/span[1]","prefix":"Effect of ambrisentan on R-and S-","suffix":" pharmacokinetics","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"18","endOffset":"26","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[1]","prefix":"Administration of ","suffix":" in the presence of multiple doses of ambrisentan (","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"25","endOffset":"33","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[1]/div[1]/div[2]/span[1]","prefix":"Effect of ambrisentan on ","suffix":" pharmacodynamics","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"8","endOffset":"16","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/p[1]","prefix":"Racemic ","suffix":" had little effect on the steady-state plasma concentration–","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"19","endOffset":"27","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/div[1]/div[1]/div[2]/span[1]","prefix":"Effects of racemic ","suffix":" on ambrisentan steady-state pharmacokinetics","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"145","endOffset":"153","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/div[2]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/div[2]/div[1]/div[2]/span[1]","prefix":"brisentan alone (□) and in the presence of a single dose of ","suffix":" (○) in 22 healthy subjects. Data are means ± standard devia","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"110","endOffset":"118","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","prefix":" once daily resulted in slight to modest changes in R-and S-","suffix":" pharmacokinetic (AUC","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"23","endOffset":"31","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","prefix":"Drug interactions with ","suffix":" have been previously demonstrated for the ERAs bosentan and","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"36","endOffset":"44","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","prefix":"In this study, both ambrisentan and ","suffix":" were administered at clinically effective doses, and no sig","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"168","endOffset":"176","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","prefix":"cant changes in the pharmacokinetics or pharmacodynamics of ","suffix":" were observed with co-administration. However, because of t","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"473","endOffset":"481","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","prefix":"ety profile of chronic co-administration of ambrisentan and ","suffix":". Of note, clinical studies in patients with PAH, such as th","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"630","endOffset":"638","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","prefix":"onstrated that chronic co-administration of ambrisentan and ","suffix":" does not appear to be associated with any specific safety c","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"44","endOffset":"52","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[10]/div[2]/div[5]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[10]/div[2]/div[5]/span[1]","prefix":"Takahashi H, Echizen H. Pharmacogenetics of ","suffix":" elimination and its clinical implications. ","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"70","endOffset":"78","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[10]/div[2]/div[6]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[10]/div[2]/div[6]/span[1]","prefix":"Lachlan A, O'Reilly R, Rowland M. Stereochemical aspects of ","suffix":" drug interactions: use of a combined pharmacokinetic–pharma","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"48","endOffset":"56","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[10]/div[2]/div[7]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[10]/div[2]/div[7]/span[1]","prefix":"Kaminsky LS, Zhang ZY. Human P450 metabolism of ","suffix":". ","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"122","endOffset":"130","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[10]/div[2]/div[13]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[10]/div[2]/div[13]/span[1]","prefix":"mance liquid chromatographic method for the quantitation of ","suffix":" enantiomers in human plasma. ","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"144","endOffset":"152","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[10]/div[2]/div[14]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[10]/div[2]/div[14]/span[1]","prefix":"st bosentan on the pharmacokinetics and pharmacodynamics of ","suffix":". ","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"95","endOffset":"103","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[2]/div[2]/div[1]/ul[1]/li[1]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[2]/div[2]/div[1]/ul[1]/li[1]/a[1]","prefix":"n the steady-state pharmacokinetics and pharmacodynamics of ","suffix":" in healthy subjects during a three-stage, open-label, multi","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"72","endOffset":"80","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[2]/div[2]/div[1]/ul[1]/li[3]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[2]/div[2]/div[1]/ul[1]/li[3]/a[1]","prefix":"esoterodine on the pharmacokinetics and pharmacodynamics of ","suffix":" in healthy volunteers.","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"45","endOffset":"53","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[5]/div[2]/div[1]/div[1]/ul[1]/li[1]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[5]/div[2]/div[1]/div[1]/ul[1]/li[1]/a[1]","prefix":"The pharmacokinetics and pharmacodynamics of ","suffix":" in combination with ambris...","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"45","endOffset":"53","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[5]/div[2]/div[1]/div[1]/ul[1]/li[1]/div[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[5]/div[2]/div[1]/div[1]/ul[1]/li[1]/div[1]","prefix":"The pharmacokinetics and pharmacodynamics of ","suffix":" in combination with ambrisentan in healthy volunteers","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"26","endOffset":"34","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[2]/div[2]/ul[1]/li[4]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[2]/div[2]/ul[1]/li[4]/a[1]","prefix":"Stereochemical aspects of ","suffix":" drug interactions: use of a combined pharmacokinetic-pharma","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"103","endOffset":"111","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[4]/div[2]/ul[1]/li[1]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[4]/div[2]/ul[1]/li[1]/a[1]","prefix":"mance liquid chromatographic method for the quantitation of ","suffix":" enantiomers in human plasma.","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"26","endOffset":"34","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]","prefix":"Stereochemical aspects of ","suffix":" drug interactions: use of a combined pharmacokinetic-pharma","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"103","endOffset":"111","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[13]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[13]","prefix":"mance liquid chromatographic method for the quantitation of ","suffix":" enantiomers in human plasma.","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"91","endOffset":"99","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":"tudy, 22 healthy subjects received a single dose of racemic ","suffix":" 25 mg alone and after 8 days of ambrisentan 10 mg once dail","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"160","endOffset":"168","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","prefix":"acokinetics, pulmonary arterial hypertension, R-warfarin, S-","suffix":"","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"179","endOffset":"187","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[5]","prefix":">80% power to detect a 6% difference in INR between day 13 (","suffix":" +ambrisentan) and day 1 (warfarin alone), and a >90% probab","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"213","endOffset":"221","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[5]","prefix":"ce in INR between day 13 (warfarin +ambrisentan) and day 1 (","suffix":" alone), and a >90% probability that the true 95% two-sided ","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"121","endOffset":"129","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[1]","prefix":"f ambrisentan on the concentration–time profiles of R-and S-","suffix":" (","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"33","endOffset":"41","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/div[1]/div[1]/div[2]/span[1]","prefix":"Effect of ambrisentan on R-and S-","suffix":" pharmacokinetics","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"18","endOffset":"26","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[1]","prefix":"Administration of ","suffix":" in the presence of multiple doses of ambrisentan (","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"25","endOffset":"33","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[1]/div[1]/div[2]/span[1]","prefix":"Effect of ambrisentan on ","suffix":" pharmacodynamics","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"8","endOffset":"16","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/p[1]","prefix":"Racemic ","suffix":" had little effect on the steady-state plasma concentration–","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"19","endOffset":"27","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/div[1]/div[1]/div[2]/span[1]","prefix":"Effects of racemic ","suffix":" on ambrisentan steady-state pharmacokinetics","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"145","endOffset":"153","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/div[2]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/div[2]/div[1]/div[2]/span[1]","prefix":"brisentan alone (□) and in the presence of a single dose of ","suffix":" (○) in 22 healthy subjects. Data are means ± standard devia","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"110","endOffset":"118","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","prefix":" once daily resulted in slight to modest changes in R-and S-","suffix":" pharmacokinetic (AUC","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"23","endOffset":"31","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","prefix":"Drug interactions with ","suffix":" have been previously demonstrated for the ERAs bosentan and","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"36","endOffset":"44","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","prefix":"In this study, both ambrisentan and ","suffix":" were administered at clinically effective doses, and no sig","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"168","endOffset":"176","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","prefix":"cant changes in the pharmacokinetics or pharmacodynamics of ","suffix":" were observed with co-administration. However, because of t","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"473","endOffset":"481","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","prefix":"ety profile of chronic co-administration of ambrisentan and ","suffix":". Of note, clinical studies in patients with PAH, such as th","exact":"warfarin"},{"setid":"PMC2686069","drugname":"warfarin","startOffset":"630","endOffset":"638","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","prefix":"onstrated that chronic co-administration of ambrisentan and ","suffix":" does not appear to be associated with any specific safety c","exact":"warfarin"},{"setid":"PMC2686069","drugname":"prothrombin","startOffset":"163","endOffset":"174","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[1]/div[1]/ul[1]/li[3]/div[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[1]/div[1]/ul[1]/li[3]/div[1]","prefix":"farin and significantly alter clotting time, as measured by ","suffix":" time and International Normalized Ratio, thereby requiring ","exact":"prothrombin"},{"setid":"PMC2686069","drugname":"bosentan","startOffset":"79","endOffset":"87","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","prefix":"ith warfarin have been previously demonstrated for the ERAs ","suffix":" and sitaxsentan [","exact":"bosentan"},{"setid":"PMC2686069","drugname":"sitaxsentan","startOffset":"92","endOffset":"103","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","prefix":"have been previously demonstrated for the ERAs bosentan and ","suffix":" [","exact":"sitaxsentan"},{"setid":"PMC2686069","drugname":"caffeine","startOffset":"402","endOffset":"410","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","prefix":"e nontobacco users, and agreed to discontinue the intake of ","suffix":", alcohol, grapefruit products, liver, and leafy green veget","exact":"caffeine"},{"setid":"PMC2686069","drugname":"alanine","startOffset":"633","endOffset":"640","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","prefix":" within normal limits, serum aspartate aminotransferase and ","suffix":" aminotransferase concentrations <1x the upper limit of norm","exact":"alanine"}],[{"setid":"PMC3612775","drugname":"cholesterol","startOffset":"130","endOffset":"141","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","prefix":"pproach to lowering blood levels of low-density lipoprotein ","suffix":" (LDL-C) and the risk of vascular events.","exact":"cholesterol"},{"setid":"PMC3612775","drugname":"cholesterol","startOffset":"229","endOffset":"240","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","prefix":" eligible for inclusion if they had non-fasting blood total ","suffix":" concentrations of at least 3.5 mmol/L (135 mg/dL) and eithe","exact":"cholesterol"},{"setid":"PMC3612775","drugname":"cholesterol","startOffset":"117","endOffset":"128","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","prefix":"ndard spectrophotometric enzymatic methods to measure total ","suffix":" and lipid fractions (including LDL-C directly) and immunotu","exact":"cholesterol"},{"setid":"PMC3612775","drugname":"simvastatin","startOffset":"271","endOffset":"282","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[1]/p[1]","prefix":" identify genetic variants related to the lipid response to ","suffix":" and assess their impact on vascular risk response.","exact":"simvastatin"},{"setid":"PMC3612775","drugname":"simvastatin","startOffset":"79","endOffset":"90","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":" of the LDL-C and apolipoprotein B (ApoB) response to 40 mg ","suffix":" daily was performed in 3895 participants in the Heart Prote","exact":"simvastatin"},{"setid":"PMC3612775","drugname":"simvastatin","startOffset":"175","endOffset":"186","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"d there were similar large reductions in vascular risk with ","suffix":" irrespective of genotypes associated with the lipid respons","exact":"simvastatin"},{"setid":"PMC3612775","drugname":"simvastatin","startOffset":"251","endOffset":"262","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"spective of genotypes associated with the lipid response to ","suffix":". Consequently, their value for informing clinical decisions","exact":"simvastatin"},{"setid":"PMC3612775","drugname":"simvastatin","startOffset":"211","endOffset":"222","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[3]","prefix":"sociation analyses of the LDL-C and ApoB responses to 40 mg ","suffix":" daily in 3895 participants in the Heart Protection Study an","exact":"simvastatin"},{"setid":"PMC3612775","drugname":"simvastatin","startOffset":"664","endOffset":"675","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[3]","prefix":"assessed among 18 705 genotyped patients randomly allocated ","suffix":" vs. placebo for an average of 5 years.","exact":"simvastatin"},{"setid":"PMC3612775","drugname":"simvastatin","startOffset":"715","endOffset":"726","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","prefix":"involving 4 weeks of placebo followed by 4–6 weeks of 40 mg ","suffix":" daily, after which fully compliant individuals were randoml","exact":"simvastatin"},{"setid":"PMC3612775","drugname":"simvastatin","startOffset":"807","endOffset":"818","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","prefix":"ully compliant individuals were randomly allocated to 40 mg ","suffix":" daily or matching placebo for ∼5 years. A non-fasting blood","exact":"simvastatin"},{"setid":"PMC3612775","drugname":"simvastatin","startOffset":"997","endOffset":"1008","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","prefix":"atin therapy) and at the end of run-in (i.e. while on 40 mg ","suffix":" daily). The pre-specified primary outcome for assessing the","exact":"simvastatin"},{"setid":"PMC3612775","drugname":"simvastatin","startOffset":"167","endOffset":"178","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[5]/p[1]","prefix":"l/L reduction in LDL-C between participants allocated 40 mg ","suffix":" daily vs. placebo.","exact":"simvastatin"},{"setid":"PMC3612775","drugname":"simvastatin","startOffset":"11","endOffset":"22","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[5]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[5]/div[1]/div[1]/div[2]/span[1]","prefix":"Effects of ","suffix":" on major vascular events by genotype. Proportional and abso","exact":"simvastatin"},{"setid":"PMC3612775","drugname":"simvastatin","startOffset":"69","endOffset":"80","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","prefix":"nt study identified associations with the lipid response to ","suffix":" for SNPs in three genes—","exact":"simvastatin"},{"setid":"PMC3612775","drugname":"simvastatin","startOffset":"49","endOffset":"60","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/div[5]/p[1]","prefix":"The present large study of the lipid response to ","suffix":" therapy was undertaken in a fully compliant population with","exact":"simvastatin"},{"setid":"PMC3612775","drugname":"quad","startOffset":"159","endOffset":"163","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/div[1]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/div[1]/p[2]","prefix":"re selected, and genotypes measured using the Illumina 610K ","suffix":" panel. Genome-wide data were available for 3895 individuals","exact":"Quad"}],[{"setid":"PMC3703233","drugname":"dabigatran","startOffset":"331","endOffset":"341","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":"fourth day, or the same treatments in the reverse sequence. ","suffix":" plasma concentration and ecarin clotting time (ECT) were me","exact":"Dabigatran"},{"setid":"PMC3703233","drugname":"dabigatran","startOffset":"118","endOffset":"128","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"ion process with two compartments. The relationship between ","suffix":" concentration and ECT was implemented as a linear function.","exact":"dabigatran"},{"setid":"PMC3703233","drugname":"dabigatran","startOffset":"59","endOffset":"69","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","prefix":"The model proposed effectively describes the complex PK of ","suffix":" and takes into account drug–drug interactions with P-gp act","exact":"dabigatran"},{"setid":"PMC3703233","drugname":"dabigatran","startOffset":"33","endOffset":"43","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","prefix":"bioavailability, clarithromycin, ","suffix":", drug–drug interaction, P-glycoprotein inhibition, populati","exact":"dabigatran"},{"setid":"PMC3703233","drugname":"dabigatran","startOffset":"36","endOffset":"46","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[1]/div[1]/div[1]/ul[1]/li[3]/div[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[1]/div[1]/div[1]/ul[1]/li[3]/div[1]","prefix":"P-gp inhibitors increase the AUC of ","suffix":" from about 50% to over 200%.","exact":"dabigatran"},{"setid":"PMC3703233","drugname":"dabigatran","startOffset":"45","endOffset":"55","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/div[1]/ul[1]/li[1]/div[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/div[1]/ul[1]/li[1]/div[1]","prefix":"The pharmacokinetics and pharmacodynamics of ","suffix":" were described by a two compartment model with an absorptio","exact":"dabigatran"},{"setid":"PMC3703233","drugname":"dabigatran","startOffset":"12","endOffset":"22","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/div[1]/ul[1]/li[3]/div[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/div[1]/ul[1]/li[3]/div[1]","prefix":"Exposure to ","suffix":" is increased by 50% in the presence of clarithromycin and i","exact":"dabigatran"},{"setid":"PMC3703233","drugname":"dabigatran","startOffset":"72","endOffset":"82","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","prefix":"h other anticoagulant drugs, such as vitamin K antagonists, ","suffix":" has a low potential for drug–drug interactions. However, it","exact":"dabigatran"},{"setid":"PMC3703233","drugname":"dabigatran","startOffset":"320","endOffset":"330","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","prefix":"y, decrease or increase its bioavailability. An increase in ","suffix":" area under the concentration ","exact":"dabigatran"},{"setid":"PMC3703233","drugname":"dabigatran","startOffset":"92","endOffset":"102","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[3]","prefix":"elop a PK/PD model to assess drug–drug interactions between ","suffix":" and P-gp modulators, using clarithromycin, a strong inhibit","exact":"dabigatran"},{"setid":"PMC3703233","drugname":"dabigatran","startOffset":"215","endOffset":"225","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","prefix":" administration for measurement of plasma concentrations of ","suffix":". All analyses were performed on venous blood samples collec","exact":"dabigatran"},{"setid":"PMC3703233","drugname":"dabigatran","startOffset":"0","endOffset":"10","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[2]","prefix":"","suffix":" plasma concentrations were determined using the validated l","exact":"Dabigatran"},{"setid":"PMC3703233","drugname":"dabigatran","startOffset":"28","endOffset":"38","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[3]","prefix":"The anticoagulant effect of ","suffix":" was measured by an ecarin clotting time (ECT) assay, as des","exact":"dabigatran"},{"setid":"PMC3703233","drugname":"dabigatran","startOffset":"205","endOffset":"215","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[2]","prefix":"t step consisted in identifying the structural PK model for ","suffix":" without clarithromycin. The second step comprised the estim","exact":"dabigatran"},{"setid":"PMC3703233","drugname":"dabigatran","startOffset":"424","endOffset":"434","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/div[3]/p[1]","prefix":"del in order to test the presence of an interaction between ","suffix":" and clarithromycin:","exact":"dabigatran"},{"setid":"PMC3703233","drugname":"dabigatran","startOffset":"67","endOffset":"77","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[4]/p[1]","prefix":"t PK/PD model corresponded to a linear relationship between ","suffix":" concentration and its anticoagulant effect, based on the EC","exact":"dabigatran"},{"setid":"PMC3703233","drugname":"dabigatran","startOffset":"19","endOffset":"29","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[5]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[5]/div[1]/div[1]/div[2]/span[1]","prefix":"Absorption rate of ","suffix":" with and without clarithromycin. The solid black line repre","exact":"dabigatran"},{"setid":"PMC3703233","drugname":"dabigatran","startOffset":"125","endOffset":"135","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[5]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[5]/div[1]/div[1]/div[2]/span[1]","prefix":"e solid black line represents the median absorption rate of ","suffix":" without clarithromycin (A) and with clarithromycin (B). The","exact":"dabigatran"},{"setid":"PMC3703233","drugname":"dabigatran","startOffset":"94","endOffset":"104","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","prefix":"el to describe the pharmacokinetics and pharmacodynamics of ","suffix":" in healthy volunteers was a two compartment model with an a","exact":"dabigatran"},{"setid":"PMC3703233","drugname":"dabigatran","startOffset":"761","endOffset":"771","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","prefix":"llow relevant characterization of the complex absorption of ","suffix":" DE ","exact":"dabigatran"},{"setid":"PMC3703233","drugname":"dabigatran","startOffset":"51","endOffset":"61","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","prefix":"In our study, clarithromycin increased exposure to ","suffix":" (AUC) by more than 50%. This increase resulted in a proport","exact":"dabigatran"},{"setid":"PMC3703233","drugname":"dabigatran","startOffset":"53","endOffset":"63","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/div[2]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/div[2]/div[1]/div[2]/span[1]","prefix":"Pharmacokinetic profiles of three volunteers. Fit of ","suffix":" plasma concentration with (solid line) and without (dashed ","exact":"dabigatran"},{"setid":"PMC3703233","drugname":"dabigatran","startOffset":"88","endOffset":"98","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","prefix":"model effectively describes the complex pharmacokinetics of ","suffix":", allowing drug–drug interactions related to P-gp modulation","exact":"dabigatran"},{"setid":"PMC3703233","drugname":"dabigatran","startOffset":"230","endOffset":"240","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","prefix":" into account. Using this model, we showed that exposure to ","suffix":" is increased by 50% in the presence of clarithromycin and i","exact":"dabigatran"},{"setid":"PMC3703233","drugname":"dabigatran","startOffset":"490","endOffset":"500","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","prefix":"cient tool to investigate other drug–drug interactions with ","suffix":" concerning P-gp inhibitors, inductors or substrates.","exact":"dabigatran"},{"setid":"PMC3703233","drugname":"clarithromycin","startOffset":"145","endOffset":"159","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[1]/p[1]","prefix":"etween dabigatran and P-gp modulators, using the example of ","suffix":", a strong inhibitor of P-gp.","exact":"clarithromycin"},{"setid":"PMC3703233","drugname":"clarithromycin","startOffset":"177","endOffset":"191","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":"an etexilate (DE) and in the second treatment period 500 mg ","suffix":" twice daily during 3 days and then 300 mg DE plus 500 mg cl","exact":"clarithromycin"},{"setid":"PMC3703233","drugname":"clarithromycin","startOffset":"249","endOffset":"263","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":"in twice daily during 3 days and then 300 mg DE plus 500 mg ","suffix":" on the fourth day, or the same treatments in the reverse se","exact":"clarithromycin"},{"setid":"PMC3703233","drugname":"clarithromycin","startOffset":"317","endOffset":"331","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"n the objective function. The concomitant administration of ","suffix":" induced a significant change only in DE bioavailability, wh","exact":"clarithromycin"},{"setid":"PMC3703233","drugname":"clarithromycin","startOffset":"443","endOffset":"457","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"lity, which increased from 6.5% to 10.1% in the presence of ","suffix":". Clarithromycin increased peak concentration and AUC by 60.","exact":"clarithromycin"},{"setid":"PMC3703233","drugname":"clarithromycin","startOffset":"459","endOffset":"473","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"eased from 6.5% to 10.1% in the presence of clarithromycin. ","suffix":" increased peak concentration and AUC by 60.2% and 49.1% res","exact":"Clarithromycin"},{"setid":"PMC3703233","drugname":"clarithromycin","startOffset":"155","endOffset":"169","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","prefix":"ug–drug interactions with P-gp activity modulators, such as ","suffix":".","exact":"clarithromycin"},{"setid":"PMC3703233","drugname":"clarithromycin","startOffset":"17","endOffset":"31","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","prefix":"bioavailability, ","suffix":", dabigatran, drug–drug interaction, P-glycoprotein inhibiti","exact":"clarithromycin"},{"setid":"PMC3703233","drugname":"clarithromycin","startOffset":"62","endOffset":"76","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/div[1]/ul[1]/li[3]/div[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/div[1]/ul[1]/li[3]/div[1]","prefix":"posure to dabigatran is increased by 50% in the presence of ","suffix":" and is characterized by substantial variability.","exact":"clarithromycin"},{"setid":"PMC3703233","drugname":"clarithromycin","startOffset":"130","endOffset":"144","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[3]","prefix":" interactions between dabigatran and P-gp modulators, using ","suffix":", a strong inhibitor of P-gp, as an example.","exact":"clarithromycin"},{"setid":"PMC3703233","drugname":"clarithromycin","startOffset":"632","endOffset":"646","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","prefix":"ere excluded. Subjects with known hypersensitivity to DE or ","suffix":", or who had taken any medicine during the week before the s","exact":"clarithromycin"},{"setid":"PMC3703233","drugname":"clarithromycin","startOffset":"118","endOffset":"132","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[1]","prefix":"eive either first DE alone and then a combination of DE and ","suffix":", or first the combination treatment and then DE alone. The ","exact":"clarithromycin"},{"setid":"PMC3703233","drugname":"clarithromycin","startOffset":"204","endOffset":"218","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[6]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[6]/div[1]/div[1]/div[2]/span[1]","prefix":"rithromycin. The white circles represent data obtained with ","suffix":"","exact":"clarithromycin"},{"setid":"PMC3703233","drugname":"clarithromycin","startOffset":"224","endOffset":"238","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[2]","prefix":" identifying the structural PK model for dabigatran without ","suffix":". The second step comprised the estimation of PK/PD paramete","exact":"clarithromycin"},{"setid":"PMC3703233","drugname":"clarithromycin","startOffset":"440","endOffset":"454","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[2]","prefix":"al variability (IOV) on the full data set (with and without ","suffix":"). Finally, drug–drug interaction was investigated applying ","exact":"clarithromycin"},{"setid":"PMC3703233","drugname":"clarithromycin","startOffset":"47","endOffset":"61","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[5]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[5]/div[1]/div[1]/div[2]/span[1]","prefix":"Absorption rate of dabigatran with and without ","suffix":". The solid black line represents the median absorption rate","exact":"clarithromycin"},{"setid":"PMC3703233","drugname":"clarithromycin","startOffset":"288","endOffset":"302","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/div[3]/p[1]","prefix":"nd structural parameters. The concomitant administration of ","suffix":", was included as a categorical covariate in the absorption ","exact":"clarithromycin"},{"setid":"PMC3703233","drugname":"clarithromycin","startOffset":"439","endOffset":"453","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/div[3]/p[1]","prefix":" test the presence of an interaction between dabigatran and ","suffix":":","exact":"clarithromycin"},{"setid":"PMC3703233","drugname":"clarithromycin","startOffset":"22","endOffset":"36","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[5]/p[1]","prefix":"The administration of ","suffix":" induced a significant change only in the bioavailability of","exact":"clarithromycin"},{"setid":"PMC3703233","drugname":"clarithromycin","startOffset":"104","endOffset":"118","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[1]/h1[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[1]/h1[1]","prefix":"ate drug–drug interaction with dabigatran: application with ","suffix":"","exact":"clarithromycin"},{"setid":"PMC3703233","drugname":"clarithromycin","startOffset":"155","endOffset":"169","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","prefix":"ug–drug interactions with P-gp activity modulators, such as ","suffix":".","exact":"clarithromycin"},{"setid":"PMC3703233","drugname":"clarithromycin","startOffset":"204","endOffset":"218","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[6]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[6]/div[1]/div[1]/div[2]/span[1]","prefix":"rithromycin. The white circles represent data obtained with ","suffix":"","exact":"clarithromycin"},{"setid":"PMC3703233","drugname":"clarithromycin","startOffset":"249","endOffset":"263","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/div[2]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/div[2]/div[1]/div[2]/span[1]","prefix":" clarithromycin. White circles represent data obtained with ","suffix":"","exact":"clarithromycin"},{"setid":"PMC3703233","drugname":"clarithromycin","startOffset":"104","endOffset":"118","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[5]/div[2]/div[1]/div[1]/ul[1]/li[1]/div[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[5]/div[2]/div[1]/div[1]/ul[1]/li[1]/div[1]","prefix":"ate drug–drug interaction with dabigatran: application with ","suffix":"","exact":"clarithromycin"},{"setid":"PMC3703233","drugname":"clarithromycin","startOffset":"104","endOffset":"118","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[1]/h1[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[1]/h1[1]","prefix":"ate drug–drug interaction with dabigatran: application with ","suffix":"","exact":"clarithromycin"},{"setid":"PMC3703233","drugname":"clarithromycin","startOffset":"155","endOffset":"169","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","prefix":"ug–drug interactions with P-gp activity modulators, such as ","suffix":".","exact":"clarithromycin"},{"setid":"PMC3703233","drugname":"clarithromycin","startOffset":"204","endOffset":"218","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[6]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[6]/div[1]/div[1]/div[2]/span[1]","prefix":"rithromycin. The white circles represent data obtained with ","suffix":"","exact":"clarithromycin"},{"setid":"PMC3703233","drugname":"clarithromycin","startOffset":"249","endOffset":"263","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/div[2]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/div[2]/div[1]/div[2]/span[1]","prefix":" clarithromycin. White circles represent data obtained with ","suffix":"","exact":"clarithromycin"},{"setid":"PMC3703233","drugname":"clarithromycin","startOffset":"104","endOffset":"118","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[5]/div[2]/div[1]/div[1]/ul[1]/li[1]/div[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[5]/div[2]/div[1]/div[1]/ul[1]/li[1]/div[1]","prefix":"ate drug–drug interaction with dabigatran: application with ","suffix":"","exact":"clarithromycin"},{"setid":"PMC3703233","drugname":"clarithromycin","startOffset":"47","endOffset":"61","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[5]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[5]/div[1]/div[1]/div[2]/span[1]","prefix":"Absorption rate of dabigatran with and without ","suffix":". The solid black line represents the median absorption rate","exact":"clarithromycin"},{"setid":"PMC3703233","drugname":"clarithromycin","startOffset":"144","endOffset":"158","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[5]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[5]/div[1]/div[1]/div[2]/span[1]","prefix":"represents the median absorption rate of dabigatran without ","suffix":" (A) and with clarithromycin (B). The dashed lines indicate ","exact":"clarithromycin"},{"setid":"PMC3703233","drugname":"clarithromycin","startOffset":"172","endOffset":"186","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[5]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[5]/div[1]/div[1]/div[2]/span[1]","prefix":"tion rate of dabigatran without clarithromycin (A) and with ","suffix":" (B). The dashed lines indicate the 5% and 95% percentiles","exact":"clarithromycin"},{"setid":"PMC3703233","drugname":"clarithromycin","startOffset":"141","endOffset":"155","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[6]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[6]/div[1]/div[1]/div[2]/span[1]","prefix":"mulations. The grey circles represent data obtained without ","suffix":". The white circles represent data obtained with clarithromy","exact":"clarithromycin"},{"setid":"PMC3703233","drugname":"clarithromycin","startOffset":"204","endOffset":"218","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[6]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[6]/div[1]/div[1]/div[2]/span[1]","prefix":"rithromycin. The white circles represent data obtained with ","suffix":"","exact":"clarithromycin"},{"setid":"PMC3703233","drugname":"clarithromycin","startOffset":"14","endOffset":"28","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","prefix":"In our study, ","suffix":" increased exposure to dabigatran (AUC) by more than 50%. Th","exact":"clarithromycin"},{"setid":"PMC3703233","drugname":"clarithromycin","startOffset":"349","endOffset":"363","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","prefix":"rfectly the mechanism involved in the inhibition of P-gp by ","suffix":".","exact":"clarithromycin"},{"setid":"PMC3703233","drugname":"clarithromycin","startOffset":"104","endOffset":"118","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[1]/h1[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[1]/h1[1]","prefix":"ate drug–drug interaction with dabigatran: application with ","suffix":"","exact":"clarithromycin"},{"setid":"PMC3703233","drugname":"clarithromycin","startOffset":"155","endOffset":"169","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","prefix":"ug–drug interactions with P-gp activity modulators, such as ","suffix":".","exact":"clarithromycin"},{"setid":"PMC3703233","drugname":"clarithromycin","startOffset":"204","endOffset":"218","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[6]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[6]/div[1]/div[1]/div[2]/span[1]","prefix":"rithromycin. The white circles represent data obtained with ","suffix":"","exact":"clarithromycin"},{"setid":"PMC3703233","drugname":"clarithromycin","startOffset":"349","endOffset":"363","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","prefix":"rfectly the mechanism involved in the inhibition of P-gp by ","suffix":".","exact":"clarithromycin"},{"setid":"PMC3703233","drugname":"clarithromycin","startOffset":"129","endOffset":"143","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/div[2]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/div[2]/div[1]/div[2]/span[1]","prefix":"a concentration with (solid line) and without (dashed line) ","suffix":". Grey circles represent data obtained without clarithromyci","exact":"clarithromycin"},{"setid":"PMC3703233","drugname":"clarithromycin","startOffset":"249","endOffset":"263","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/div[2]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/div[2]/div[1]/div[2]/span[1]","prefix":" clarithromycin. White circles represent data obtained with ","suffix":"","exact":"clarithromycin"},{"setid":"PMC3703233","drugname":"clarithromycin","startOffset":"104","endOffset":"118","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[5]/div[2]/div[1]/div[1]/ul[1]/li[1]/div[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[5]/div[2]/div[1]/div[1]/ul[1]/li[1]/div[1]","prefix":"ate drug–drug interaction with dabigatran: application with ","suffix":"","exact":"clarithromycin"},{"setid":"PMC3703233","drugname":"clarithromycin","startOffset":"190","endOffset":"204","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/div[2]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/div[2]/div[1]/div[2]/span[1]","prefix":"larithromycin. Grey circles represent data obtained without ","suffix":". White circles represent data obtained with clarithromycin","exact":"clarithromycin"},{"setid":"PMC3703233","drugname":"clarithromycin","startOffset":"249","endOffset":"263","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/div[2]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/div[2]/div[1]/div[2]/span[1]","prefix":" clarithromycin. White circles represent data obtained with ","suffix":"","exact":"clarithromycin"},{"setid":"PMC3703233","drugname":"clarithromycin","startOffset":"62","endOffset":"76","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/div[1]/ul[1]/li[3]/div[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/div[1]/ul[1]/li[3]/div[1]","prefix":"posure to dabigatran is increased by 50% in the presence of ","suffix":" and is characterized by substantial variability.","exact":"clarithromycin"},{"setid":"PMC3703233","drugname":"clarithromycin","startOffset":"280","endOffset":"294","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","prefix":"posure to dabigatran is increased by 50% in the presence of ","suffix":" and is characterized by substantial variability. In contras","exact":"clarithromycin"},{"setid":"PMC3703233","drugname":"vitamin k","startOffset":"49","endOffset":"58","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","prefix":"Compared with other anticoagulant drugs, such as ","suffix":" antagonists, dabigatran has a low potential for drug–drug i","exact":"vitamin K"},{"setid":"PMC3703233","drugname":"fibrinogen","startOffset":"359","endOffset":"369","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","prefix":"zed ratio, activated partial thromboplastin time (aPPT) and ","suffix":" level. Volunteers with renal insufficiency, hepatic insuffi","exact":"fibrinogen"},{"setid":"PMC3703233","drugname":"fibrinogen","startOffset":"280","endOffset":"290","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[1]","prefix":"a, median aPPT (range) was 1.04 (0.9–1.15) s, median plasma ","suffix":" concentration 2.25 (1.6–3) g l","exact":"fibrinogen"},{"setid":"PMC3703233","drugname":"citrate","startOffset":"337","endOffset":"344","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","prefix":"s collected by venipuncture, using whole blood collected in ","suffix":" tubes for PD and heparinized tubes for PK analysis.","exact":"citrate"},{"setid":"PMC3703233","drugname":"creatinine","startOffset":"57","endOffset":"67","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/div[3]/p[1]","prefix":"Body mass index, weight, lean body weight, size, age and ","suffix":" clearance [calculated using the Modification of Diet in Ren","exact":"creatinine"},{"setid":"PMC3703233","drugname":"creatinine","startOffset":"86","endOffset":"96","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[3]","prefix":"ariates tested (weight, body mass index, body surface area, ","suffix":" clearance) was associated with a significant decrease in th","exact":"creatinine"}],[{"setid":"PMC3195022","drugname":"fluconazole","startOffset":"330","endOffset":"341","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"-way crossover study investigated the effect of concomitant ","suffix":" on voriconazole pharmacokinetics in 10 subjects: 8 extensiv","exact":"fluconazole"},{"setid":"PMC3195022","drugname":"fluconazole","startOffset":"527","endOffset":"538","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"sted of 4-day voriconazole-only and 5-day voriconazole-plus-","suffix":" treatments, separated by a 14-day washout. Voriconazole pha","exact":"fluconazole"},{"setid":"PMC3195022","drugname":"fluconazole","startOffset":"857","endOffset":"868","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"drug interaction should antifungal therapy be switched from ","suffix":" to voriconazole, following various simulated lag times for ","exact":"fluconazole"},{"setid":"PMC3195022","drugname":"fluconazole","startOffset":"975","endOffset":"986","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"ag times for the switch. In CYP2C19 extensive metabolizers, ","suffix":" increased the maximum plasma concentration and the area und","exact":"fluconazole"},{"setid":"PMC3195022","drugname":"fluconazole","startOffset":"1218","endOffset":"1229","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":", however, voriconazole pharmacokinetics were unaffected by ","suffix":". The simulations based on pharmacokinetic modeling predicte","exact":"fluconazole"},{"setid":"PMC3195022","drugname":"fluconazole","startOffset":"1366","endOffset":"1377","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"azole was started 6, 12, 24, or 36 h after the last dose of ","suffix":", the voriconazole AUC ratios (sequential therapy versus vor","exact":"fluconazole"},{"setid":"PMC3195022","drugname":"fluconazole","startOffset":"1567","endOffset":"1578","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"14, respectively. This suggests that the remaining systemic ","suffix":" would result in a marked drug interaction with voriconazole","exact":"fluconazole"},{"setid":"PMC3195022","drugname":"fluconazole","startOffset":"1734","endOffset":"1745","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"s were observed during coadministration, concomitant use of ","suffix":" and voriconazole is not recommended. Frequent monitoring fo","exact":"fluconazole"},{"setid":"PMC3195022","drugname":"fluconazole","startOffset":"1899","endOffset":"1910","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"nts is advisable if voriconazole is used sequentially after ","suffix":".","exact":"fluconazole"},{"setid":"PMC3195022","drugname":"fluconazole","startOffset":"17","endOffset":"28","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":"Voriconazole and ","suffix":" have similar mechanisms of action, and use of the combinati","exact":"fluconazole"},{"setid":"PMC3195022","drugname":"fluconazole","startOffset":"0","endOffset":"11","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","prefix":"","suffix":" is a potent CYP2C19 inhibitor (","exact":"Fluconazole"},{"setid":"PMC3195022","drugname":"fluconazole","startOffset":"98","endOffset":"109","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[4]","prefix":"e pharmacokinetics of voriconazole when coadministered with ","suffix":" to assess the maximal impact of fluconazole-mediated CYP2C1","exact":"fluconazole"},{"setid":"PMC3195022","drugname":"fluconazole","startOffset":"142","endOffset":"153","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[4]","prefix":"ministered with fluconazole to assess the maximal impact of ","suffix":"-mediated CYP2C19 inhibition on voriconazole levels. A physi","exact":"fluconazole"},{"setid":"PMC3195022","drugname":"fluconazole","startOffset":"433","endOffset":"444","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[4]","prefix":"zole therapy is initiated after various lag times following ","suffix":" discontinuation.","exact":"fluconazole"},{"setid":"PMC3195022","drugname":"fluconazole","startOffset":"129","endOffset":"140","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[3]","prefix":"zole-only treatment and a 5-day period of voriconazole-plus-","suffix":" combination treatment, separated by a 14-day washout phase.","exact":"fluconazole"},{"setid":"PMC3195022","drugname":"fluconazole","startOffset":"516","endOffset":"527","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[3]","prefix":"ery 12 h on days 2 and 3 and a single 200-mg dose on day 4. ","suffix":" was administered as a single loading dose of 400 mg orally ","exact":"Fluconazole"},{"setid":"PMC3195022","drugname":"fluconazole","startOffset":"762","endOffset":"773","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[3]","prefix":"ion of both agents. During the combination treatment phase, ","suffix":" was administered immediately after the voriconazole dose.","exact":"fluconazole"},{"setid":"PMC3195022","drugname":"fluconazole","startOffset":"4","endOffset":"15","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[3]","prefix":"For ","suffix":", standard inputs available within Simcyp were utilized. The","exact":"fluconazole"},{"setid":"PMC3195022","drugname":"fluconazole","startOffset":"256","endOffset":"267","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[4]","prefix":"e, dosing interval, and dosing duration of voriconazole and ","suffix":" in the simulation were identical to those used in the clini","exact":"fluconazole"},{"setid":"PMC3195022","drugname":"fluconazole","startOffset":"512","endOffset":"523","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[4]","prefix":"es of 200 mg each), or voriconazole was coadministered with ","suffix":" (first fluconazole dose of 400 mg and subsequent doses of 2","exact":"fluconazole"},{"setid":"PMC3195022","drugname":"fluconazole","startOffset":"531","endOffset":"542","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[4]","prefix":" or voriconazole was coadministered with fluconazole (first ","suffix":" dose of 400 mg and subsequent doses of 200 mg each every 24","exact":"fluconazole"},{"setid":"PMC3195022","drugname":"fluconazole","startOffset":"641","endOffset":"652","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[4]","prefix":" 200 mg each every 24 h). For simulating sequential dosing, ","suffix":" dosing remained the same, while voriconazole administration","exact":"fluconazole"},{"setid":"PMC3195022","drugname":"fluconazole","startOffset":"782","endOffset":"793","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[4]","prefix":"ated at times of 6, 12, and 24 h following the last dose of ","suffix":".","exact":"fluconazole"},{"setid":"PMC3195022","drugname":"fluconazole","startOffset":"120","endOffset":"131","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[2]","prefix":") received voriconazole alone followed by voriconazole plus ","suffix":", and five (mean age, 24 years; age range, 22 to 27 years) r","exact":"fluconazole"},{"setid":"PMC3195022","drugname":"fluconazole","startOffset":"217","endOffset":"228","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[2]","prefix":"ears; age range, 22 to 27 years) received voriconazole plus ","suffix":" followed by voriconazole alone. The mean weights in the two","exact":"fluconazole"},{"setid":"PMC3195022","drugname":"fluconazole","startOffset":"147","endOffset":"158","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/div[1]/div[2]/span[1]","prefix":" given voriconazole alone and voriconazole with concomitant ","suffix":".","exact":"fluconazole"},{"setid":"PMC3195022","drugname":"fluconazole","startOffset":"20","endOffset":"31","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[3]","prefix":"Coadministration of ","suffix":" had a different effect on voriconazole pharmacokinetics in ","exact":"fluconazole"},{"setid":"PMC3195022","drugname":"fluconazole","startOffset":"190","endOffset":"201","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[3]","prefix":"ons of voriconazole were increased when coadministered with ","suffix":" compared with voriconazole alone, while in PMs, the concent","exact":"fluconazole"},{"setid":"PMC3195022","drugname":"fluconazole","startOffset":"20","endOffset":"31","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[4]","prefix":"Coadministration of ","suffix":" reduced the intersubject variability of voriconazole ","exact":"fluconazole"},{"setid":"PMC3195022","drugname":"fluconazole","startOffset":"85","endOffset":"96","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/div[1]/div[1]/div[2]/span[1]","prefix":"centrations of voriconazole dosed alone or with concomitant ","suffix":" in extensive metabolizers (A) and poor metabolizers (B). Da","exact":"fluconazole"},{"setid":"PMC3195022","drugname":"fluconazole","startOffset":"122","endOffset":"133","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[3]","prefix":" sequential dosing of voriconazole following termination of ","suffix":" therapy. The doses of both drugs remained the same as in th","exact":"fluconazole"},{"setid":"PMC3195022","drugname":"fluconazole","startOffset":"346","endOffset":"357","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[3]","prefix":"time intervals (6, 12, 24, and 36 h) after the last dose of ","suffix":". Accordingly, fluconazole was given at a dose of 400 mg on ","exact":"fluconazole"},{"setid":"PMC3195022","drugname":"fluconazole","startOffset":"1182","endOffset":"1193","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"zole would persist for at least 24 h after the last dose of ","suffix":".","exact":"fluconazole"},{"setid":"PMC3195022","drugname":"fluconazole","startOffset":"372","endOffset":"383","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[3]","prefix":" and 36 h) after the last dose of fluconazole. Accordingly, ","suffix":" was given at a dose of 400 mg on day 1, followed by 200 mg ","exact":"fluconazole"},{"setid":"PMC3195022","drugname":"fluconazole","startOffset":"109","endOffset":"120","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/div[2]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/div[2]/div[1]/div[2]/span[1]","prefix":"e first dose of voriconazole, when given sequentially after ","suffix":" at various lag times after the last fluconazole dose","exact":"fluconazole"},{"setid":"PMC3195022","drugname":"fluconazole","startOffset":"157","endOffset":"168","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/div[2]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/div[2]/div[1]/div[2]/span[1]","prefix":"ially after fluconazole at various lag times after the last ","suffix":" dose","exact":"fluconazole"},{"setid":"PMC3195022","drugname":"fluconazole","startOffset":"78","endOffset":"89","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"s clinical study suggest that concomitant administration of ","suffix":" and voriconazole significantly increases plasma voriconazol","exact":"fluconazole"},{"setid":"PMC3195022","drugname":"fluconazole","startOffset":"292","endOffset":"303","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"armacokinetics of voriconazole appeared to be unaffected by ","suffix":" in that population. This observation is not surprising, sin","exact":"fluconazole"},{"setid":"PMC3195022","drugname":"fluconazole","startOffset":"1080","endOffset":"1091","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"mulations of sequential use suggested that the influence of ","suffix":" on systemic levels of voriconazole would persist for at lea","exact":"fluconazole"},{"setid":"PMC3195022","drugname":"fluconazole","startOffset":"1182","endOffset":"1193","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"zole would persist for at least 24 h after the last dose of ","suffix":".","exact":"fluconazole"},{"setid":"PMC3195022","drugname":"fluconazole","startOffset":"0","endOffset":"11","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"","suffix":" is categorized as a potent inhibitor of CYP2C9 and CPY2C19,","exact":"Fluconazole"},{"setid":"PMC3195022","drugname":"fluconazole","startOffset":"115","endOffset":"126","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"2C9 and CPY2C19, as well as a moderate inhibitor of CYP3A4. ","suffix":"'s effect on voriconazole pharmacokinetics is probably due t","exact":"Fluconazole"},{"setid":"PMC3195022","drugname":"fluconazole","startOffset":"192","endOffset":"203","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"etics was reduced when voriconazole was coadministered with ","suffix":" compared with the variability in pharmacokinetics when vori","exact":"fluconazole"},{"setid":"PMC3195022","drugname":"fluconazole","startOffset":"358","endOffset":"369","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"is presumably occurred because the inhibition of CYP2C19 by ","suffix":" caused EM subjects to behave in a similar fashion to PM sub","exact":"fluconazole"},{"setid":"PMC3195022","drugname":"fluconazole","startOffset":"526","endOffset":"537","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"the systemic exposure to voriconazole when given along with ","suffix":" observed in EMs did not exceed that observed in PMs. In cli","exact":"fluconazole"},{"setid":"PMC3195022","drugname":"fluconazole","startOffset":"757","endOffset":"768","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"of these results, it is tempting to deduce that concomitant ","suffix":" could be used as a booster to achieve therapeutic levels of","exact":"fluconazole"},{"setid":"PMC3195022","drugname":"fluconazole","startOffset":"1143","endOffset":"1154","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"equire additional consideration. First, the optimum dose of ","suffix":" needed to boost voriconazole levels is currently unknown. S","exact":"fluconazole"},{"setid":"PMC3195022","drugname":"fluconazole","startOffset":"1221","endOffset":"1232","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":" to boost voriconazole levels is currently unknown. Second, ","suffix":" alters the shape of the concentration-time curve and marked","exact":"fluconazole"},{"setid":"PMC3195022","drugname":"fluconazole","startOffset":"97","endOffset":"108","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","prefix":"erns were noted during coadministration of voriconazole and ","suffix":" in healthy volunteers in the present study. However, elevat","exact":"fluconazole"},{"setid":"PMC3195022","drugname":"fluconazole","startOffset":"78","endOffset":"89","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":" results of this study show that concomitantly administered ","suffix":" significantly increases plasma levels of voriconazole. Ther","exact":"fluconazole"},{"setid":"PMC3195022","drugname":"fluconazole","startOffset":"175","endOffset":"186","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"lasma levels of voriconazole. Therefore, concomitant use of ","suffix":" and voriconazole is not recommended until it has been furth","exact":"fluconazole"},{"setid":"PMC3195022","drugname":"fluconazole","startOffset":"395","endOffset":"406","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"nts is advisable if voriconazole is used sequentially after ","suffix":", especially when voriconazole is initiated within 24 h of t","exact":"fluconazole"},{"setid":"PMC3195022","drugname":"fluconazole","startOffset":"474","endOffset":"485","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"ally when voriconazole is initiated within 24 h of the last ","suffix":" dose.","exact":"fluconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":"77","endOffset":"89","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"ice, antifungal therapy may be switched from fluconazole to ","suffix":"; such sequential use poses the potential for drug interacti","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":"213","endOffset":"225","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"ue to cytochrome P450 2C19 (CYP2C19)-mediated inhibition of ","suffix":" metabolism. This open-label, randomized, two-way crossover ","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":"345","endOffset":"357","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"study investigated the effect of concomitant fluconazole on ","suffix":" pharmacokinetics in 10 subjects: 8 extensive metabolizers a","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":"481","endOffset":"493","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":" poor metabolizers of CYP2C19. The study consisted of 4-day ","suffix":"-only and 5-day voriconazole-plus-fluconazole treatments, se","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":"509","endOffset":"521","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"9. The study consisted of 4-day voriconazole-only and 5-day ","suffix":"-plus-fluconazole treatments, separated by a 14-day washout.","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":"582","endOffset":"594","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"plus-fluconazole treatments, separated by a 14-day washout. ","suffix":" pharmacokinetics were determined by noncompartmental analys","exact":"Voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":"872","endOffset":"884","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"n should antifungal therapy be switched from fluconazole to ","suffix":", following various simulated lag times for the switch. In C","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":"1094","endOffset":"1106","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"the area under the plasma concentration-time curve (AUC) of ","suffix":" by 57% and 178%, respectively. In poor metabolizers, howeve","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":"72","endOffset":"84","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[4]","prefix":"tion of fluconazole reduced the intersubject variability of ","suffix":" ","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":"77","endOffset":"89","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[10]/div[2]/div[3]/span[1]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[10]/div[2]/div[3]/span[1]/span[1]","prefix":" the cytochrome P450 enzymes involved in the N-oxidation of ","suffix":"","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":"43","endOffset":"55","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[10]/div[2]/div[25]/span[1]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[10]/div[2]/div[25]/span[1]/span[1]","prefix":"Pharmacokinetic/pharmacodynamic profile of ","suffix":"","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":"91","endOffset":"103","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[10]/div[2]/div[30]/span[1]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[10]/div[2]/div[30]/span[1]/span[1]","prefix":"tor contributing to the highly variable pharmacokinetics of ","suffix":"","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":"61","endOffset":"73","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[10]/div[2]/div[32]/span[1]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[10]/div[2]/div[32]/span[1]/span[1]","prefix":"ffect of omeprazole on the steady-state pharmacokinetics of ","suffix":"","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":"77","endOffset":"89","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[1]/div[2]/ul[1]/li[4]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[1]/div[2]/ul[1]/li[4]/a[1]","prefix":" the cytochrome P450 enzymes involved in the N-oxidation of ","suffix":".","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":"91","endOffset":"103","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[1]/div[2]/ul[1]/li[7]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[1]/div[2]/ul[1]/li[7]/a[1]","prefix":"tor contributing to the highly variable pharmacokinetics of ","suffix":".","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":"77","endOffset":"89","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[6]/div[2]/ul[1]/li[1]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[6]/div[2]/ul[1]/li[1]/a[1]","prefix":" the cytochrome P450 enzymes involved in the N-oxidation of ","suffix":".","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":"77","endOffset":"89","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[7]/div[2]/ul[1]/li[1]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[7]/div[2]/ul[1]/li[1]/a[1]","prefix":" the cytochrome P450 enzymes involved in the N-oxidation of ","suffix":".","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":"77","endOffset":"89","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[9]/div[2]/ul[1]/li[1]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[9]/div[2]/ul[1]/li[1]/a[1]","prefix":" the cytochrome P450 enzymes involved in the N-oxidation of ","suffix":".","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":"61","endOffset":"73","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[9]/div[2]/ul[1]/li[4]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[9]/div[2]/ul[1]/li[4]/a[1]","prefix":"ffect of omeprazole on the steady-state pharmacokinetics of ","suffix":".","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":"77","endOffset":"89","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[4]","prefix":" the cytochrome P450 enzymes involved in the N-oxidation of ","suffix":".","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":"91","endOffset":"103","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[7]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[7]","prefix":"tor contributing to the highly variable pharmacokinetics of ","suffix":".","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":"61","endOffset":"73","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[30]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[30]","prefix":"ffect of omeprazole on the steady-state pharmacokinetics of ","suffix":".","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":"1169","endOffset":"1181","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":" 57% and 178%, respectively. In poor metabolizers, however, ","suffix":" pharmacokinetics were unaffected by fluconazole. The simula","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":"1299","endOffset":"1311","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"lations based on pharmacokinetic modeling predicted that if ","suffix":" was started 6, 12, 24, or 36 h after the last dose of fluco","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":"1383","endOffset":"1395","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":" 6, 12, 24, or 36 h after the last dose of fluconazole, the ","suffix":" AUC ratios (sequential therapy versus voriconazole only) af","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":"1434","endOffset":"1446","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"ole, the voriconazole AUC ratios (sequential therapy versus ","suffix":" only) after the first dose would be 1.51, 1.41, 1.28, and 1","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":"1626","endOffset":"1638","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":" fluconazole would result in a marked drug interaction with ","suffix":" for ≥24 h. Although no safety issues were observed during c","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":"1750","endOffset":"1762","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"during coadministration, concomitant use of fluconazole and ","suffix":" is not recommended. Frequent monitoring for voriconazole-re","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":"1807","endOffset":"1819","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"nd voriconazole is not recommended. Frequent monitoring for ","suffix":"-related adverse events is advisable if voriconazole is used","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":"1859","endOffset":"1871","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"ing for voriconazole-related adverse events is advisable if ","suffix":" is used sequentially after fluconazole.","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":"48","endOffset":"60","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","prefix":"The pharmacokinetics of the triazole antifungal ","suffix":" have been widely studied (","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":"0","endOffset":"12","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":"","suffix":" and fluconazole have similar mechanisms of action, and use ","exact":"Voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":"60","endOffset":"72","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[4]","prefix":"To examine these issues, we studied the pharmacokinetics of ","suffix":" when coadministered with fluconazole to assess the maximal ","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":"185","endOffset":"197","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[4]","prefix":"aximal impact of fluconazole-mediated CYP2C19 inhibition on ","suffix":" levels. A physiologically based pharmacokinetic (PBPK) mode","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":"365","endOffset":"377","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[4]","prefix":"xtent/magnitude of the drug interaction in situations where ","suffix":" therapy is initiated after various lag times following fluc","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":"61","endOffset":"73","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[3]","prefix":"he study was divided into two treatments, a 4-day period of ","suffix":"-only treatment and a 5-day period of voriconazole-plus-fluc","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":"111","endOffset":"123","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[3]","prefix":"period of voriconazole-only treatment and a 5-day period of ","suffix":"-plus-fluconazole combination treatment, separated by a 14-d","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":"342","endOffset":"354","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[3]","prefix":" All treatments were administered orally in a fasted state. ","suffix":" was given as a loading dose of 400 mg orally twice daily (e","exact":"Voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":"813","endOffset":"825","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[3]","prefix":"t phase, fluconazole was administered immediately after the ","suffix":" dose.","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":"26","endOffset":"38","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[2]","prefix":"Serial plasma samples for ","suffix":" pharmacokinetics were collected predosing and at 1, 2, 3, 4","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":"190","endOffset":"202","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[2]","prefix":"48 h after dosing on day 4. Plasma samples were assayed for ","suffix":" by a previously validated method using automated solid-phas","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":"0","endOffset":"12","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[3]","prefix":"","suffix":" pharmacokinetic parameters were determined by noncompartmen","exact":"Voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":"31","endOffset":"43","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[2]","prefix":"Pharmacokinetic parameters for ","suffix":" calculated on day 4 of each treatment period were used as e","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":"31","endOffset":"43","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[2]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[2]/div[1]/div[2]/span[1]","prefix":"Pharmacokinetic parameters for ","suffix":"","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":"72","endOffset":"84","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[4]","prefix":"tion of fluconazole reduced the intersubject variability of ","suffix":" ","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":"77","endOffset":"89","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[10]/div[2]/div[3]/span[1]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[10]/div[2]/div[3]/span[1]/span[1]","prefix":" the cytochrome P450 enzymes involved in the N-oxidation of ","suffix":"","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":"43","endOffset":"55","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[10]/div[2]/div[25]/span[1]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[10]/div[2]/div[25]/span[1]/span[1]","prefix":"Pharmacokinetic/pharmacodynamic profile of ","suffix":"","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":"91","endOffset":"103","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[10]/div[2]/div[30]/span[1]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[10]/div[2]/div[30]/span[1]/span[1]","prefix":"tor contributing to the highly variable pharmacokinetics of ","suffix":"","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":"61","endOffset":"73","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[10]/div[2]/div[32]/span[1]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[10]/div[2]/div[32]/span[1]/span[1]","prefix":"ffect of omeprazole on the steady-state pharmacokinetics of ","suffix":"","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":"249","endOffset":"261","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[2]","prefix":"Simcyp Ltd., Sheffield, United Kingdom). A Simcyp model for ","suffix":" was developed using the physicochemical properties, ","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":"32","endOffset":"44","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/div[1]/div[1]/div[2]/span[1]","prefix":"Summary of input parameters for ","suffix":" used in the Simcyp model","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":"239","endOffset":"251","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[4]","prefix":"th sexes. The dose, dosing interval, and dosing duration of ","suffix":" and fluconazole in the simulation were identical to those u","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":"351","endOffset":"363","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[4]","prefix":"identical to those used in the clinical study. Accordingly, ","suffix":" alone was dosed every 12 h for 4 days (first two doses of 4","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":"475","endOffset":"487","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[4]","prefix":"ses of 400 mg and subsequent five doses of 200 mg each), or ","suffix":" was coadministered with fluconazole (first fluconazole dose","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":"685","endOffset":"697","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[4]","prefix":"uential dosing, fluconazole dosing remained the same, while ","suffix":" administration was initiated at times of 6, 12, and 24 h fo","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":"71","endOffset":"83","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[2]","prefix":"ts (mean age, 29 years; age range, 24 to 43 years) received ","suffix":" alone followed by voriconazole plus fluconazole, and five (","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":"102","endOffset":"114","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[2]","prefix":"ge, 24 to 43 years) received voriconazole alone followed by ","suffix":" plus fluconazole, and five (mean age, 24 years; age range, ","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":"199","endOffset":"211","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[2]","prefix":"ve (mean age, 24 years; age range, 22 to 27 years) received ","suffix":" plus fluconazole followed by voriconazole alone. The mean w","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":"241","endOffset":"253","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[2]","prefix":"7 years) received voriconazole plus fluconazole followed by ","suffix":" alone. The mean weights in the two groups were 70 kg (range","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":"30","endOffset":"42","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/div[1]/div[2]/span[1]","prefix":"Mean plasma concentrations of ","suffix":" over time in extensive and poor metabolizers given voricona","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":"94","endOffset":"106","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/div[1]/div[2]/span[1]","prefix":"conazole over time in extensive and poor metabolizers given ","suffix":" alone and voriconazole with concomitant fluconazole.","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":"117","endOffset":"129","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/div[1]/div[2]/span[1]","prefix":"xtensive and poor metabolizers given voriconazole alone and ","suffix":" with concomitant fluconazole.","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":"31","endOffset":"43","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[2]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[2]/div[1]/div[2]/span[1]","prefix":"Pharmacokinetic parameters for ","suffix":"","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":"58","endOffset":"70","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[3]","prefix":"Coadministration of fluconazole had a different effect on ","suffix":" pharmacokinetics in EMs and PMs. In EMs, plasma concentrati","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":"137","endOffset":"149","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[3]","prefix":"cokinetics in EMs and PMs. In EMs, plasma concentrations of ","suffix":" were increased when coadministered with fluconazole compare","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":"216","endOffset":"228","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[3]","prefix":"ncreased when coadministered with fluconazole compared with ","suffix":" alone, while in PMs, the concentration-time profiles were s","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":"72","endOffset":"84","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[4]","prefix":"tion of fluconazole reduced the intersubject variability of ","suffix":" ","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":"31","endOffset":"43","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[2]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[2]/div[1]/div[2]/span[1]","prefix":"Pharmacokinetic parameters for ","suffix":"","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":"72","endOffset":"84","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[4]","prefix":"tion of fluconazole reduced the intersubject variability of ","suffix":" ","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":"77","endOffset":"89","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[10]/div[2]/div[3]/span[1]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[10]/div[2]/div[3]/span[1]/span[1]","prefix":" the cytochrome P450 enzymes involved in the N-oxidation of ","suffix":"","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":"43","endOffset":"55","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[10]/div[2]/div[25]/span[1]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[10]/div[2]/div[25]/span[1]/span[1]","prefix":"Pharmacokinetic/pharmacodynamic profile of ","suffix":"","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":"91","endOffset":"103","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[10]/div[2]/div[30]/span[1]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[10]/div[2]/div[30]/span[1]/span[1]","prefix":"tor contributing to the highly variable pharmacokinetics of ","suffix":"","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":"61","endOffset":"73","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[10]/div[2]/div[32]/span[1]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[10]/div[2]/div[32]/span[1]/span[1]","prefix":"ffect of omeprazole on the steady-state pharmacokinetics of ","suffix":"","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":"31","endOffset":"43","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[2]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[2]/div[1]/div[2]/span[1]","prefix":"Pharmacokinetic parameters for ","suffix":"","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":"40","endOffset":"52","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/div[1]/div[1]/div[2]/span[1]","prefix":"Simulated mean plasma concentrations of ","suffix":" dosed alone or with concomitant fluconazole in extensive me","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":"84","endOffset":"96","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[3]","prefix":" carried out to evaluate the effect of sequential dosing of ","suffix":" following termination of fluconazole therapy. The doses of ","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":"235","endOffset":"247","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[3]","prefix":" the same as in the clinical study, with the exception that ","suffix":" was initiated sequentially at various time intervals (6, 12","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":"474","endOffset":"486","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[3]","prefix":"on day 1, followed by 200 mg every 24 h on days 2 to 5, and ","suffix":" was initiated sequentially at doses of 400 mg every 12 h on","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":"31","endOffset":"43","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[2]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[2]/div[1]/div[2]/span[1]","prefix":"Pharmacokinetic parameters for ","suffix":"","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":"72","endOffset":"84","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[4]","prefix":"tion of fluconazole reduced the intersubject variability of ","suffix":" ","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":"77","endOffset":"89","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[10]/div[2]/div[3]/span[1]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[10]/div[2]/div[3]/span[1]/span[1]","prefix":" the cytochrome P450 enzymes involved in the N-oxidation of ","suffix":"","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":"43","endOffset":"55","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[10]/div[2]/div[25]/span[1]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[10]/div[2]/div[25]/span[1]/span[1]","prefix":"Pharmacokinetic/pharmacodynamic profile of ","suffix":"","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":"91","endOffset":"103","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[10]/div[2]/div[30]/span[1]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[10]/div[2]/div[30]/span[1]/span[1]","prefix":"tor contributing to the highly variable pharmacokinetics of ","suffix":"","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":"61","endOffset":"73","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[10]/div[2]/div[32]/span[1]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[10]/div[2]/div[32]/span[1]/span[1]","prefix":"ffect of omeprazole on the steady-state pharmacokinetics of ","suffix":"","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":"65","endOffset":"77","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/div[2]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/div[2]/div[1]/div[2]/span[1]","prefix":"-predicted pharmacokinetic parameters for the first dose of ","suffix":", when given sequentially after fluconazole at various lag t","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":"94","endOffset":"106","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":" suggest that concomitant administration of fluconazole and ","suffix":" significantly increases plasma voriconazole concentrations ","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":"138","endOffset":"150","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"fluconazole and voriconazole significantly increases plasma ","suffix":" concentrations in CYP2C19 EMs. Although the sample size was","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":"250","endOffset":"262","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":" the sample size was small for PMs, the pharmacokinetics of ","suffix":" appeared to be unaffected by fluconazole in that population","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":"1114","endOffset":"1126","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"ted that the influence of fluconazole on systemic levels of ","suffix":" would persist for at least 24 h after the last dose of fluc","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":"139","endOffset":"151","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":" as a moderate inhibitor of CYP3A4. Fluconazole's effect on ","suffix":" pharmacokinetics is probably due to its inhibition of CPY2C","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":"221","endOffset":"233","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"inetics is probably due to its inhibition of CPY2C19, since ","suffix":" metabolism is mainly mediated by CYP2C19, followed by CYP3A","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":"108","endOffset":"120","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"an volunteers, the considerable intersubject variability in ","suffix":" pharmacokinetics was reduced when voriconazole was coadmini","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":"155","endOffset":"167","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"riability in voriconazole pharmacokinetics was reduced when ","suffix":" was coadministered with fluconazole compared with the varia","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":"259","endOffset":"271","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"zole compared with the variability in pharmacokinetics when ","suffix":" was administered alone. This presumably occurred because th","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":"491","endOffset":"503","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"cts in this respect. Nevertheless, the systemic exposure to ","suffix":" when given along with fluconazole observed in EMs did not e","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":"613","endOffset":"625","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":" did not exceed that observed in PMs. In clinical practice, ","suffix":" is administered to both EMs and PMs at an identical dose. O","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":"829","endOffset":"841","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"could be used as a booster to achieve therapeutic levels of ","suffix":" with doses lower than those currently recommended, to allow","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":"913","endOffset":"925","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"lower than those currently recommended, to allow once-daily ","suffix":" dosing, or to reduce the intersubject variability in vorico","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":"979","endOffset":"991","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"nazole dosing, or to reduce the intersubject variability in ","suffix":" pharmacokinetics. Although this approach seems attractive, ","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":"1171","endOffset":"1183","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"ion. First, the optimum dose of fluconazole needed to boost ","suffix":" levels is currently unknown. Second, fluconazole alters the","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":"1305","endOffset":"1317","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"hape of the concentration-time curve and markedly increases ","suffix":" trough concentrations, which have been linked to a higher i","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":"1389","endOffset":"1401","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"entrations, which have been linked to a higher incidence of ","suffix":"-associated toxicity (","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":"80","endOffset":"92","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","prefix":"icant safety concerns were noted during coadministration of ","suffix":" and fluconazole in healthy volunteers in the present study.","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":"171","endOffset":"183","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","prefix":" healthy volunteers in the present study. However, elevated ","suffix":" plasma levels are associated with an increased likelihood o","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":"131","endOffset":"143","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"stered fluconazole significantly increases plasma levels of ","suffix":". Therefore, concomitant use of fluconazole and voriconazole","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":"191","endOffset":"203","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"voriconazole. Therefore, concomitant use of fluconazole and ","suffix":" is not recommended until it has been further evaluated in c","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":"303","endOffset":"315","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"rther evaluated in clinical trials. Frequent monitoring for ","suffix":"-related adverse events is advisable if voriconazole is used","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":"355","endOffset":"367","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"ing for voriconazole-related adverse events is advisable if ","suffix":" is used sequentially after fluconazole, especially when vor","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"voriconazole","startOffset":"424","endOffset":"436","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"ole is used sequentially after fluconazole, especially when ","suffix":" is initiated within 24 h of the last fluconazole dose.","exact":"voriconazole"},{"setid":"PMC3195022","drugname":"advantage","startOffset":"133","endOffset":"142","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":"f the combination of both drugs does not appear to offer an ","suffix":" over use of the single agents (","exact":"advantage"}],[{"setid":"PMC3900249","drugname":"amiodarone","startOffset":"237","endOffset":"247","start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"ange in warfarin dose requirement. To evaluate the roles of ","suffix":" and its circulating metabolites in this highly variable inh","exact":"amiodarone"},{"setid":"PMC3900249","drugname":"amiodarone","startOffset":"0","endOffset":"10","start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","prefix":"","suffix":" (AMIO) was originally introduced as an anti-anginal drug ov","exact":"Amiodarone"},{"setid":"PMC3900249","drugname":"amiodarone","startOffset":"0","endOffset":"10","start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/div[2]/span[1]","prefix":"","suffix":" metabolites in human plasma.","exact":"Amiodarone"},{"setid":"PMC3900249","drugname":"amiodarone","startOffset":"0","endOffset":"10","start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[11]/div[2]/div[25]/span[1]/span[1]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[11]/div[2]/div[25]/span[1]/span[1]","prefix":"","suffix":": pharmacology, pharmacokinetics, toxicology, clinical effec","exact":"Amiodarone"},{"setid":"PMC3900249","drugname":"amiodarone","startOffset":"0","endOffset":"10","start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/div[2]/span[1]","prefix":"","suffix":" metabolites in human plasma.","exact":"Amiodarone"},{"setid":"PMC3900249","drugname":"amiodarone","startOffset":"186","endOffset":"196","start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[5]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[5]","prefix":" dose change required to maintain an INR of 2.0 – 3.0 after ","suffix":" was added or discontinued in a cohort of patients undergoin","exact":"amiodarone"},{"setid":"PMC3900249","drugname":"amiodarone","startOffset":"141","endOffset":"151","start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/div[1]/div[1]/div[2]/span[1]","prefix":"maintain INR 2.0 – 3.0 after addition or discontinuation of ","suffix":".","exact":"amiodarone"},{"setid":"PMC3900249","drugname":"amiodarone","startOffset":"277","endOffset":"287","start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[1]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[1]","prefix":"in which an out-of-range INR was attributed to the warfarin-","suffix":" drug interaction were identified. These incidents were asso","exact":"amiodarone"},{"setid":"PMC3900249","drugname":"amiodarone","startOffset":"381","endOffset":"391","start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[1]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[1]","prefix":" These incidents were associated with 163 episodes in which ","suffix":" was added or discontinued in patients taking warfarin, or i","exact":"amiodarone"},{"setid":"PMC3900249","drugname":"amiodarone","startOffset":"463","endOffset":"473","start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[1]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[1]","prefix":"r discontinued in patients taking warfarin, or in which the ","suffix":" dose was changed. Of these 163 episodes, 90 were excluded f","exact":"amiodarone"},{"setid":"PMC3900249","drugname":"amiodarone","startOffset":"607","endOffset":"617","start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[1]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[1]","prefix":"ue to either unstable warfarin therapy prior to addition of ","suffix":" (n=40), an interaction due to change in amiodarone dose (n=","exact":"amiodarone"},{"setid":"PMC3900249","drugname":"amiodarone","startOffset":"658","endOffset":"668","start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[1]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[1]","prefix":"ition of amiodarone (n=40), an interaction due to change in ","suffix":" dose (n=27); warfarin and amiodarone having been initiated ","exact":"amiodarone"},{"setid":"PMC3900249","drugname":"amiodarone","startOffset":"695","endOffset":"705","start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[1]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[1]","prefix":"ction due to change in amiodarone dose (n=27); warfarin and ","suffix":" having been initiated concurrently (n=14), the duration of ","exact":"amiodarone"},{"setid":"PMC3900249","drugname":"amiodarone","startOffset":"785","endOffset":"795","start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[1]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[1]","prefix":"ed concurrently (n=14), the duration of concurrent warfarin/","suffix":" therapy being less than 1 month (n=6) or no records availab","exact":"amiodarone"},{"setid":"PMC3900249","drugname":"amiodarone","startOffset":"141","endOffset":"151","start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/div[1]/div[1]/div[2]/span[1]","prefix":"maintain INR 2.0 – 3.0 after addition or discontinuation of ","suffix":".","exact":"amiodarone"},{"setid":"PMC3900249","drugname":"amiodarone","startOffset":"284","endOffset":"294","start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[9]/div[2]/p[1]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[9]/div[2]/p[1]","prefix":"ing us with blood samples from patients undergoing warfarin/","suffix":" therapy. This work was supported by the National Institutes","exact":"amiodarone"},{"setid":"PMC3900249","drugname":"amiodarone","startOffset":"276","endOffset":"286","start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[11]/div[2]/div[9]/span[1]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[11]/div[2]/div[9]/span[1]","prefix":"tic factors, dose-dependent clearance, and interaction with ","suffix":". ","exact":"amiodarone"},{"setid":"PMC3900249","drugname":"amiodarone","startOffset":"77","endOffset":"87","start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[11]/div[2]/div[30]/span[1]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[11]/div[2]/div[30]/span[1]","prefix":"esse M. Synthesis of two metabolites of the antiarrythmicum ","suffix":". ","exact":"amiodarone"},{"setid":"PMC3900249","drugname":"warfarin","startOffset":"185","endOffset":"193","start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"ion/elimination of amiodarone resulted in a 6–65% change in ","suffix":" dose requirement. To evaluate the roles of amiodarone and i","exact":"warfarin"},{"setid":"PMC3900249","drugname":"warfarin","startOffset":"69","endOffset":"77","start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","prefix":" interactions, plasma, in vitro, in vivo, pharmacokinetics, ","suffix":", inhibition, adverse drug reactions, metabolites","exact":"warfarin"},{"setid":"PMC3900249","drugname":"warfarin","startOffset":"142","endOffset":"150","start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":"F). Stroke is a major concern in patients with AF and since ","suffix":" is the preferred treatment for stroke prevention, AMIO is t","exact":"warfarin"},{"setid":"PMC3900249","drugname":"warfarin","startOffset":"246","endOffset":"254","start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":"ke prevention, AMIO is therefore often co-administered with ","suffix":" (","exact":"warfarin"},{"setid":"PMC3900249","drugname":"warfarin","startOffset":"246","endOffset":"254","start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":"ke prevention, AMIO is therefore often co-administered with ","suffix":" (","exact":"warfarin"},{"setid":"PMC3900249","drugname":"warfarin","startOffset":"116","endOffset":"124","start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","prefix":"rated that AMIO inhibits the clearance of both (S)- and (R)-","suffix":" (","exact":"warfarin"},{"setid":"PMC3900249","drugname":"warfarin","startOffset":"85","endOffset":"93","start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/div[1]/div[1]/div[2]/span[1]","prefix":"ciprocal plots of the velocity of formation of (S)-7-hydroxy","suffix":" vs. (S)-warfarin concentration (1, 4 and 16 μM) in the pres","exact":"warfarin"},{"setid":"PMC3900249","drugname":"warfarin","startOffset":"102","endOffset":"110","start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/div[1]/div[1]/div[2]/span[1]","prefix":" the velocity of formation of (S)-7-hydroxywarfarin vs. (S)-","suffix":" concentration (1, 4 and 16 μM) in the presence of fixed con","exact":"warfarin"},{"setid":"PMC3900249","drugname":"warfarin","startOffset":"108","endOffset":"116","start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[2]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[2]","prefix":"mpounds were carried out in the presence of either 4 μM (S)-","suffix":", for studies in HLM, or 2 μg/mL rac-warfarin (approximate p","exact":"warfarin"},{"setid":"PMC3900249","drugname":"warfarin","startOffset":"153","endOffset":"161","start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[2]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[2]","prefix":"ither 4 μM (S)-warfarin, for studies in HLM, or 2 μg/mL rac-","suffix":" (approximate physiological concentration), for studies in h","exact":"warfarin"},{"setid":"PMC3900249","drugname":"warfarin","startOffset":"49","endOffset":"57","start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[6]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[6]","prefix":"The overall change in intrinsic clearance of (S)-","suffix":" caused by the drug interaction with AMIO can be predicted a","exact":"warfarin"},{"setid":"PMC3900249","drugname":"warfarin","startOffset":"108","endOffset":"116","start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[7]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[7]","prefix":"ntration vs time curve (AUC) is therefore predicted for (S)-","suffix":" clearance based on the sum of the [I]/K","exact":"warfarin"},{"setid":"PMC3900249","drugname":"warfarin","startOffset":"44","endOffset":"52","start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[8]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[8]","prefix":"The actual increase in the mean AUC for (S)-","suffix":" caused by the drug interaction with AMIO has been reported ","exact":"warfarin"},{"setid":"PMC3900249","drugname":"warfarin","startOffset":"268","endOffset":"276","start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[1]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[1]","prefix":"ncidents in which an out-of-range INR was attributed to the ","suffix":"-amiodarone drug interaction were identified. These incident","exact":"warfarin"},{"setid":"PMC3900249","drugname":"warfarin","startOffset":"32","endOffset":"40","start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[5]/p[2]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[5]/p[2]","prefix":"HLMs were preincubated with (S)-","suffix":", inhibitor and buffer at 37°C and 70 rpm in a water bath fo","exact":"warfarin"},{"setid":"PMC3900249","drugname":"warfarin","startOffset":"467","endOffset":"475","start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[5]/p[2]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[5]/p[2]","prefix":"rpm for 5 min. Supernatants were then analyzed for 7-hydroxy","suffix":" content by HPLC using fluorescence detection. A time course","exact":"warfarin"},{"setid":"PMC3900249","drugname":"warfarin","startOffset":"601","endOffset":"609","start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[5]/p[2]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[5]/p[2]","prefix":" revealed that, under the experimental conditions, 7-hydroxy","suffix":" production was essentially linear out to 30 minutes.","exact":"warfarin"},{"setid":"PMC3900249","drugname":"warfarin","startOffset":"116","endOffset":"124","start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[11]/div[2]/div[15]/span[1]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[11]/div[2]/div[15]/span[1]","prefix":"The incidence, magnitude, and time course of the amiodarone-","suffix":" interaction. ","exact":"warfarin"},{"setid":"PMC3900249","drugname":"warfarin","startOffset":"185","endOffset":"193","start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[11]/div[2]/div[21]/span[1]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[11]/div[2]/div[21]/span[1]","prefix":"ytochrome P-450: a role for P-4502C9 in the etiology of (S)-","suffix":"-drug interactions. ","exact":"warfarin"},{"setid":"PMC3900249","drugname":"warfarin","startOffset":"118","endOffset":"126","start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[5]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[5]","prefix":"spective study was performed to determine mean and range of ","suffix":" dose change required to maintain an INR of 2.0 – 3.0 after ","exact":"warfarin"},{"setid":"PMC3900249","drugname":"warfarin","startOffset":"265","endOffset":"273","start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[5]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[5]","prefix":"d or discontinued in a cohort of patients undergoing stable ","suffix":" therapy. Next, stabilized plasma concentrations, [I], of AM","exact":"warfarin"},{"setid":"PMC3900249","drugname":"warfarin","startOffset":"403","endOffset":"411","start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[5]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[5]","prefix":"e of its circulating metabolites were determined in several ","suffix":" patients undergoing combination therapy. In order to measur","exact":"warfarin"},{"setid":"PMC3900249","drugname":"warfarin","startOffset":"178","endOffset":"186","start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[1]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[1]","prefix":"ers of our analysis for an out of range INR attributed to a ","suffix":"-AMIO drug interaction which occurred upon either addition o","exact":"warfarin"},{"setid":"PMC3900249","drugname":"warfarin","startOffset":"306","endOffset":"314","start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[1]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[1]","prefix":"r elimination of AMIO therapy to patients undergoing stable ","suffix":" treatment. Results of the analysis are described in ","exact":"warfarin"},{"setid":"PMC3900249","drugname":"warfarin","startOffset":"55","endOffset":"63","start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/div[1]/div[1]/div[2]/span[1]","prefix":"Demographic characteristics of patients, and change in ","suffix":" dose required to maintain INR 2.0 – 3.0 after addition or d","exact":"warfarin"},{"setid":"PMC3900249","drugname":"warfarin","startOffset":"125","endOffset":"133","start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/div[2]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/div[2]/div[1]/div[2]/span[1]","prefix":"ulating metabolites in patients (n = 3), already undergoing ","suffix":" treatment, who were started on AMIO therapy. Error bars den","exact":"warfarin"},{"setid":"PMC3900249","drugname":"warfarin","startOffset":"85","endOffset":"93","start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/div[1]/div[1]/div[2]/span[1]","prefix":"ciprocal plots of the velocity of formation of (S)-7-hydroxy","suffix":" vs. (S)-warfarin concentration (1, 4 and 16 μM) in the pres","exact":"warfarin"},{"setid":"PMC3900249","drugname":"warfarin","startOffset":"102","endOffset":"110","start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/div[1]/div[1]/div[2]/span[1]","prefix":" the velocity of formation of (S)-7-hydroxywarfarin vs. (S)-","suffix":" concentration (1, 4 and 16 μM) in the presence of fixed con","exact":"warfarin"},{"setid":"PMC3900249","drugname":"warfarin","startOffset":"108","endOffset":"116","start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[2]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[2]","prefix":"mpounds were carried out in the presence of either 4 μM (S)-","suffix":", for studies in HLM, or 2 μg/mL rac-warfarin (approximate p","exact":"warfarin"},{"setid":"PMC3900249","drugname":"warfarin","startOffset":"153","endOffset":"161","start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[2]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[2]","prefix":"ither 4 μM (S)-warfarin, for studies in HLM, or 2 μg/mL rac-","suffix":" (approximate physiological concentration), for studies in h","exact":"warfarin"},{"setid":"PMC3900249","drugname":"warfarin","startOffset":"234","endOffset":"242","start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[2]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[2]","prefix":" physiological concentration), for studies in human plasma. ","suffix":" was found not to affect metabolite protein binding in eithe","exact":"Warfarin"},{"setid":"PMC3900249","drugname":"warfarin","startOffset":"4","endOffset":"12","start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","prefix":"The ","suffix":"-AMIO interaction is known to be due to metabolic inhibition","exact":"warfarin"},{"setid":"PMC3900249","drugname":"warfarin","startOffset":"126","endOffset":"134","start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","prefix":"bition of the P450 enzymes responsible for the clearance of ","suffix":", mainly CYP2C9 (","exact":"warfarin"},{"setid":"PMC3900249","drugname":"warfarin","startOffset":"49","endOffset":"57","start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[6]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[6]","prefix":"The overall change in intrinsic clearance of (S)-","suffix":" caused by the drug interaction with AMIO can be predicted a","exact":"warfarin"},{"setid":"PMC3900249","drugname":"warfarin","startOffset":"108","endOffset":"116","start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[7]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[7]","prefix":"ntration vs time curve (AUC) is therefore predicted for (S)-","suffix":" clearance based on the sum of the [I]/K","exact":"warfarin"},{"setid":"PMC3900249","drugname":"warfarin","startOffset":"44","endOffset":"52","start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[8]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[8]","prefix":"The actual increase in the mean AUC for (S)-","suffix":" caused by the drug interaction with AMIO has been reported ","exact":"warfarin"},{"setid":"PMC3900249","drugname":"warfarin","startOffset":"147","endOffset":"155","start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[8]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[8]","prefix":"h AMIO has been reported to range from 27 to 110% in single ","suffix":" dose studies carried out in small groups (n = 5 or 6) of he","exact":"warfarin"},{"setid":"PMC3900249","drugname":"warfarin","startOffset":"155","endOffset":"163","start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[1]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[1]","prefix":"patient anticoagulation management for 3129 patients taking ","suffix":". During this 6 year period, a total of 230 incidents in whi","exact":"warfarin"},{"setid":"PMC3900249","drugname":"warfarin","startOffset":"268","endOffset":"276","start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[1]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[1]","prefix":"ncidents in which an out-of-range INR was attributed to the ","suffix":"-amiodarone drug interaction were identified. These incident","exact":"warfarin"},{"setid":"PMC3900249","drugname":"warfarin","startOffset":"437","endOffset":"445","start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[1]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[1]","prefix":"ich amiodarone was added or discontinued in patients taking ","suffix":", or in which the amiodarone dose was changed. Of these 163 ","exact":"warfarin"},{"setid":"PMC3900249","drugname":"warfarin","startOffset":"569","endOffset":"577","start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[1]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[1]","prefix":"odes, 90 were excluded from analysis due to either unstable ","suffix":" therapy prior to addition of amiodarone (n=40), an interact","exact":"warfarin"},{"setid":"PMC3900249","drugname":"warfarin","startOffset":"682","endOffset":"690","start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[1]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[1]","prefix":"0), an interaction due to change in amiodarone dose (n=27); ","suffix":" and amiodarone having been initiated concurrently (n=14), t","exact":"warfarin"},{"setid":"PMC3900249","drugname":"warfarin","startOffset":"776","endOffset":"784","start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[1]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/p[1]","prefix":"n initiated concurrently (n=14), the duration of concurrent ","suffix":"/amiodarone therapy being less than 1 month (n=6) or no reco","exact":"warfarin"},{"setid":"PMC3900249","drugname":"warfarin","startOffset":"29","endOffset":"37","start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[1]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[1]","prefix":"Three patients stabilized on ","suffix":" who were to be initiated on concomitant AMIO therapy were r","exact":"warfarin"},{"setid":"PMC3900249","drugname":"warfarin","startOffset":"468","endOffset":"476","start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[1]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[1]","prefix":" patients resulted in a 33, 40 or 71% reduction in required ","suffix":" dose. All patients gave informed consent for the study whic","exact":"warfarin"},{"setid":"PMC3900249","drugname":"warfarin","startOffset":"32","endOffset":"40","start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[5]/p[2]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[5]/p[2]","prefix":"HLMs were preincubated with (S)-","suffix":", inhibitor and buffer at 37°C and 70 rpm in a water bath fo","exact":"warfarin"},{"setid":"PMC3900249","drugname":"warfarin","startOffset":"275","endOffset":"283","start":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[9]/div[2]/p[1]","end":"/html[1]/body[1]/div[3]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[9]/div[2]/p[1]","prefix":"in providing us with blood samples from patients undergoing ","suffix":"/amiodarone therapy. This work was supported by the National","exact":"warfarin"}],[{"setid":"PMC1459289","drugname":"nelfinavir","startOffset":"37","endOffset":"47","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","prefix":"HIV infection, statins, pravastatin, ","suffix":", drug interactions","exact":"nelfinavir"},{"setid":"PMC1459289","drugname":"nelfinavir","startOffset":"0","endOffset":"10","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","prefix":"","suffix":" (NFV) is an HIV protease inhibitor (PI) that has demonstrat","exact":"Nelfinavir"},{"setid":"PMC1459289","drugname":"nelfinavir","startOffset":"0","endOffset":"10","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[2]/div[2]/div[1]/ul[1]/li[5]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[2]/div[2]/div[1]/ul[1]/li[5]/a[1]","prefix":"","suffix":": an update on its use in HIV infection.","exact":"Nelfinavir"},{"setid":"PMC1459289","drugname":"nelfinavir","startOffset":"174","endOffset":"184","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/div[1]/div[2]/span[1]/strong[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/div[1]/div[2]/span[1]/strong[1]","prefix":"hout (day 3; —) and with (day 16; - - -) coadminstration of ","suffix":".","exact":"nelfinavir"},{"setid":"PMC1459289","drugname":"nelfinavir","startOffset":"47","endOffset":"57","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/div[2]/span[1]","prefix":"Pravastatin pharmacokinetics parameters in the ","suffix":" arm (","exact":"nelfinavir"},{"setid":"PMC1459289","drugname":"pravastatin","startOffset":"24","endOffset":"35","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","prefix":"HIV infection, statins, ","suffix":", nelfinavir, drug interactions","exact":"pravastatin"},{"setid":"PMC1459289","drugname":"pravastatin","startOffset":"61","endOffset":"72","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":"he mechanism by which these drugs reduce plasma exposure to ","suffix":" is unknown, but this drug–drug interaction is of concern be","exact":"pravastatin"},{"setid":"PMC1459289","drugname":"pravastatin","startOffset":"153","endOffset":"164","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":" drug–drug interaction is of concern because a reduction in ","suffix":" plasma concentration may adversely affect the drug's abilit","exact":"pravastatin"},{"setid":"PMC1459289","drugname":"pravastatin","startOffset":"494","endOffset":"505","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":"n inhibitor of CYP3A4 but an inducer of other CYP isoforms. ","suffix":" metabolism is complex, utilizing both oxidative and conjuga","exact":"Pravastatin"},{"setid":"PMC1459289","drugname":"pravastatin","startOffset":"728","endOffset":"739","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":"ines the hypothesis that NFV would have a similar effect on ","suffix":" pharmacokinetics as ritonavir/saquinavir.","exact":"pravastatin"},{"setid":"PMC1459289","drugname":"pravastatin","startOffset":"222","endOffset":"233","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","prefix":" examine the effect of efavirenz on the pharmacokinetics of ","suffix":", atorvastatin, and simvastatin and the effect of NFV on the","exact":"pravastatin"},{"setid":"PMC1459289","drugname":"pravastatin","startOffset":"314","endOffset":"325","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","prefix":"imvastatin and the effect of NFV on the pharmacokinetics of ","suffix":". The efavirenz–statin interactions were recently published ","exact":"pravastatin"},{"setid":"PMC1459289","drugname":"pravastatin","startOffset":"27","endOffset":"38","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","prefix":"Subjects self-administered ","suffix":" 40 mg daily in the morning for the first 3 days and on the ","exact":"pravastatin"},{"setid":"PMC1459289","drugname":"pravastatin","startOffset":"109","endOffset":"120","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","prefix":"y in the morning for the first 3 days and on the fourth day ","suffix":" was administered under observation. Blood samples were obta","exact":"pravastatin"},{"setid":"PMC1459289","drugname":"pravastatin","startOffset":"285","endOffset":"296","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","prefix":"5, 1, 2, 3, 4, 6, 8, 12, and 24 h after administration, for ","suffix":" pharmacokinetics. On days 4 through 12, subjects took NFV 1","exact":"pravastatin"},{"setid":"PMC1459289","drugname":"pravastatin","startOffset":"447","endOffset":"458","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","prefix":"On days 13 through 15, subjects continued NFV and restarted ","suffix":" with the morning dose of NFV. On day 16, pravastatin and NF","exact":"pravastatin"},{"setid":"PMC1459289","drugname":"pravastatin","startOffset":"500","endOffset":"511","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","prefix":"tarted pravastatin with the morning dose of NFV. On day 16, ","suffix":" and NFV doses were administered under observation and sampl","exact":"pravastatin"},{"setid":"PMC1459289","drugname":"pravastatin","startOffset":"603","endOffset":"614","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","prefix":" under observation and samples were collected over 24 h for ","suffix":" pharmacokinetics. Fasting serum total cholesterol, triglyce","exact":"pravastatin"},{"setid":"PMC1459289","drugname":"pravastatin","startOffset":"12","endOffset":"23","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[1]","prefix":"Samples for ","suffix":" plasma concentrations were analyzed by Advion Biosciences I","exact":"pravastatin"},{"setid":"PMC1459289","drugname":"pravastatin","startOffset":"29","endOffset":"40","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[1]","prefix":"The primary endpoint was the ","suffix":" AUC from 0 to 24 h before and after coadministration of NFV","exact":"pravastatin"},{"setid":"PMC1459289","drugname":"pravastatin","startOffset":"56","endOffset":"67","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[2]","prefix":"Plots of time-specific geometric mean concentrations of ","suffix":" with and without NFV are shown in ","exact":"pravastatin"},{"setid":"PMC1459289","drugname":"pravastatin","startOffset":"32","endOffset":"43","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/div[1]/div[2]/span[1]/strong[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/div[1]/div[2]/span[1]/strong[1]","prefix":"Geometric mean concentration of ","suffix":" at each scheduled sample time and under the two dosing cond","exact":"pravastatin"},{"setid":"PMC1459289","drugname":"pravastatin","startOffset":"0","endOffset":"11","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/div[2]/span[1]","prefix":"","suffix":" pharmacokinetics parameters in the nelfinavir arm (","exact":"Pravastatin"},{"setid":"PMC1459289","drugname":"pravastatin","startOffset":"0","endOffset":"11","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"","suffix":" has become the preferred statin because of its lack of sign","exact":"Pravastatin"},{"setid":"PMC1459289","drugname":"pravastatin","startOffset":"142","endOffset":"153","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"abolism by P4503A4 and results from studies suggesting that ","suffix":" is safe and tolerable in patients taking potent antiretrovi","exact":"pravastatin"},{"setid":"PMC1459289","drugname":"pravastatin","startOffset":"23","endOffset":"34","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"The mechanism by which ","suffix":" concentrations are reduced is not known. The metabolism of ","exact":"pravastatin"},{"setid":"PMC1459289","drugname":"pravastatin","startOffset":"94","endOffset":"105","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":" concentrations are reduced is not known. The metabolism of ","suffix":" is complex. Induction of non-CYP3A4 oxidation or glucuronid","exact":"pravastatin"},{"setid":"PMC1459289","drugname":"pravastatin","startOffset":"209","endOffset":"220","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"on or glucuronidation may result in more rapid clearance of ","suffix":". In addition, hepatic transporter OATP1B1 may participate i","exact":"pravastatin"},{"setid":"PMC1459289","drugname":"pravastatin","startOffset":"20","endOffset":"31","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","prefix":"Clinical studies of ","suffix":" for the treatment of HIV-associated dyslipidemia have shown","exact":"pravastatin"},{"setid":"PMC1459289","drugname":"pravastatin","startOffset":"145","endOffset":"156","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","prefix":" shown mixed results. For example, in a randomized trial of ","suffix":" versus fenofibrate for combined HIV-associated dyslipidemia","exact":"pravastatin"},{"setid":"PMC1459289","drugname":"pravastatin","startOffset":"255","endOffset":"266","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","prefix":"sociated dyslipidemia, only 36% of subjects receiving 40 mg ","suffix":" daily met the LDL goal (median 20% decrease) and 18% met th","exact":"pravastatin"},{"setid":"PMC1459289","drugname":"pravastatin","startOffset":"12","endOffset":"23","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"In summary, ","suffix":" remains the statin of choice in HIV-infected persons taking","exact":"pravastatin"},{"setid":"PMC1459289","drugname":"pravastatin","startOffset":"216","endOffset":"227","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"in and atorvastatin. The observed near 50% reduction in the ","suffix":" median AUC and a trend toward less reduction in LDL when co","exact":"pravastatin"},{"setid":"PMC1459289","drugname":"pravastatin","startOffset":"338","endOffset":"349","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"L when coadministered with NFV suggest that higher doses of ","suffix":" may need to be prescribed to achieve optimal lipid-lowering","exact":"pravastatin"},{"setid":"PMC1459289","drugname":"pravastatin","startOffset":"464","endOffset":"475","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"ering activity. It remains unclear what the optimal dose of ","suffix":" is to achieve maximal lipid-lowering activity safely in HIV","exact":"pravastatin"},{"setid":"PMC1459289","drugname":"pravastatin","startOffset":"669","endOffset":"680","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"hat greater improvements in lipid levels may be observed if ","suffix":" doses are adjusted in the setting of agents that are known ","exact":"pravastatin"},{"setid":"PMC1459289","drugname":"pravastatin","startOffset":"864","endOffset":"875","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"g the safety, tolerability, and efficacy of higher doses of ","suffix":" are warranted.","exact":"pravastatin"},{"setid":"PMC1459289","drugname":"simvastatin","startOffset":"253","endOffset":"264","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","prefix":"z on the pharmacokinetics of pravastatin, atorvastatin, and ","suffix":" and the effect of NFV on the pharmacokinetics of pravastati","exact":"simvastatin"},{"setid":"PMC1459289","drugname":"simvastatin","startOffset":"147","endOffset":"158","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"iretroviral therapy, given its safety profile compared with ","suffix":" and atorvastatin. The observed near 50% reduction in the pr","exact":"simvastatin"},{"setid":"PMC1459289","drugname":"ritonavir","startOffset":"347","endOffset":"356","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":" PI drugs in clinical use that is not usually combined with ","suffix":", but NFV has a similar effect on the CYP enzymes as ritonav","exact":"ritonavir"},{"setid":"PMC1459289","drugname":"ritonavir","startOffset":"409","endOffset":"418","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":"tonavir, but NFV has a similar effect on the CYP enzymes as ","suffix":" in that it is an inhibitor of CYP3A4 but an inducer of othe","exact":"ritonavir"},{"setid":"PMC1459289","drugname":"ritonavir","startOffset":"760","endOffset":"769","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":"ld have a similar effect on pravastatin pharmacokinetics as ","suffix":"/saquinavir.","exact":"ritonavir"},{"setid":"PMC1459289","drugname":"saquinavir","startOffset":"770","endOffset":"780","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":"similar effect on pravastatin pharmacokinetics as ritonavir/","suffix":".","exact":"saquinavir"},{"setid":"PMC1459289","drugname":"saquinavir","startOffset":"770","endOffset":"780","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":"similar effect on pravastatin pharmacokinetics as ritonavir/","suffix":".","exact":"saquinavir"},{"setid":"PMC1459289","drugname":"atorvastatin","startOffset":"235","endOffset":"247","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","prefix":"effect of efavirenz on the pharmacokinetics of pravastatin, ","suffix":", and simvastatin and the effect of NFV on the pharmacokinet","exact":"atorvastatin"},{"setid":"PMC1459289","drugname":"atorvastatin","startOffset":"163","endOffset":"175","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"apy, given its safety profile compared with simvastatin and ","suffix":". The observed near 50% reduction in the pravastatin median ","exact":"atorvastatin"},{"setid":"PMC1459289","drugname":"efavirenz","startOffset":"185","endOffset":"194","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","prefix":"study. The primary objectives were to examine the effect of ","suffix":" on the pharmacokinetics of pravastatin, atorvastatin, and s","exact":"efavirenz"},{"setid":"PMC1459289","drugname":"cholesterol","startOffset":"241","endOffset":"252","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":"tion may adversely affect the drug's ability to lower serum ","suffix":" effectively. NFV is one of the few PI drugs in clinical use","exact":"cholesterol"},{"setid":"PMC1459289","drugname":"cholesterol","startOffset":"653","endOffset":"664","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[1]","prefix":" 24 h for pravastatin pharmacokinetics. Fasting serum total ","suffix":", triglycerides, and high density lipoprotein concentrations","exact":"cholesterol"},{"setid":"PMC1459289","drugname":"alanine","startOffset":"485","endOffset":"492","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/p[1]","prefix":"wo had grade 2 gastrointestinal complaints, one had grade 3 ","suffix":" aminotransferase and grade 2 aspartate aminotransferase on ","exact":"alanine"},{"setid":"PMC1459289","drugname":"fenofibrate","startOffset":"164","endOffset":"175","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","prefix":"s. For example, in a randomized trial of pravastatin versus ","suffix":" for combined HIV-associated dyslipidemia, only 36% of subje","exact":"fenofibrate"}],[{"setid":"PMC3681953","drugname":"simvastatin","startOffset":"704","endOffset":"715","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"0.166, 0.036 to 0.185, and 0.014 to 0.044 for atorvastatin, ","suffix":", and the combined statin analysis, respectively.","exact":"simvastatin"},{"setid":"PMC3681953","drugname":"simvastatin","startOffset":"153","endOffset":"164","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[7]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[7]","prefix":"ys only a secondary role in the metabolism of atorvastatin, ","suffix":", and lovastatin. Nonetheless, our current investigation int","exact":"simvastatin"},{"setid":"PMC3681953","drugname":"simvastatin","startOffset":"309","endOffset":"320","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","prefix":"Median, first quartile, and third quartile of atorvastatin, ","suffix":", and lovastatin dose were determined for each combined geno","exact":"simvastatin"},{"setid":"PMC3681953","drugname":"simvastatin","startOffset":"599","endOffset":"610","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","prefix":". Potency differences were accounted for by normalizing the ","suffix":" and lovastatin doses to atorvastatin-equivalent doses (i.e.","exact":"simvastatin"},{"setid":"PMC3681953","drugname":"simvastatin","startOffset":"672","endOffset":"683","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","prefix":"nd lovastatin doses to atorvastatin-equivalent doses (i.e., ","suffix":" and lovastatin have 83% and 58% the potency, respectively, ","exact":"simvastatin"},{"setid":"PMC3681953","drugname":"lovastatin","startOffset":"170","endOffset":"180","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[7]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[7]","prefix":"ry role in the metabolism of atorvastatin, simvastatin, and ","suffix":". Nonetheless, our current investigation intends to use the ","exact":"lovastatin"},{"setid":"PMC3681953","drugname":"lovastatin","startOffset":"326","endOffset":"336","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","prefix":"rtile, and third quartile of atorvastatin, simvastatin, and ","suffix":" dose were determined for each combined genotype group. As u","exact":"lovastatin"},{"setid":"PMC3681953","drugname":"lovastatin","startOffset":"615","endOffset":"625","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","prefix":"ences were accounted for by normalizing the simvastatin and ","suffix":" doses to atorvastatin-equivalent doses (i.e., simvastatin a","exact":"lovastatin"},{"setid":"PMC3681953","drugname":"lovastatin","startOffset":"688","endOffset":"698","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","prefix":"ses to atorvastatin-equivalent doses (i.e., simvastatin and ","suffix":" have 83% and 58% the potency, respectively, of atorvastatin","exact":"lovastatin"},{"setid":"PMC3681953","drugname":"atorvastatin","startOffset":"690","endOffset":"702","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"from 0.129 to 0.166, 0.036 to 0.185, and 0.014 to 0.044 for ","suffix":", simvastatin, and the combined statin analysis, respectivel","exact":"atorvastatin"},{"setid":"PMC3681953","drugname":"atorvastatin","startOffset":"254","endOffset":"266","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":"CYP3A5 were determined to be responsible for 85% and 15% of ","suffix":" metabolism, respectively, in a reported ","exact":"atorvastatin"},{"setid":"PMC3681953","drugname":"atorvastatin","startOffset":"139","endOffset":"151","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[7]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[7]","prefix":"3A5 likely plays only a secondary role in the metabolism of ","suffix":", simvastatin, and lovastatin. Nonetheless, our current inve","exact":"atorvastatin"},{"setid":"PMC3681953","drugname":"atorvastatin","startOffset":"295","endOffset":"307","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","prefix":"notype group. Median, first quartile, and third quartile of ","suffix":", simvastatin, and lovastatin dose were determined for each ","exact":"atorvastatin"},{"setid":"PMC3681953","drugname":"atorvastatin","startOffset":"635","endOffset":"647","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","prefix":" for by normalizing the simvastatin and lovastatin doses to ","suffix":"-equivalent doses (i.e., simvastatin and lovastatin have 83%","exact":"atorvastatin"},{"setid":"PMC3681953","drugname":"atorvastatin","startOffset":"746","endOffset":"758","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","prefix":"d lovastatin have 83% and 58% the potency, respectively, of ","suffix":" [","exact":"atorvastatin"}],[{"setid":"PMC2722908","drugname":"warfarin","startOffset":"331","endOffset":"339","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[1]/p[1]","prefix":"eloped and used an algorithm for estimating the appropriate ","suffix":" dose that is based on both clinical and genetic data from a","exact":"warfarin"},{"setid":"PMC2722908","drugname":"warfarin","startOffset":"374","endOffset":"382","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":"culating the percentage of patients whose predicted dose of ","suffix":" was within 20% of the actual stable therapeutic dose; we al","exact":"warfarin"},{"setid":"PMC2722908","drugname":"warfarin","startOffset":"131","endOffset":"139","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"tified larger proportions of patients who required 21 mg of ","suffix":" or less per week and of those who required 49 mg or more pe","exact":"warfarin"},{"setid":"PMC2722908","drugname":"warfarin","startOffset":"86","endOffset":"94","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","prefix":"ic algorithm for estimating the appropriate initial dose of ","suffix":" produces recommendations that are significantly closer to t","exact":"warfarin"},{"setid":"PMC2722908","drugname":"warfarin","startOffset":"359","endOffset":"367","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","prefix":" the 46.2% of the population that required 21 mg or less of ","suffix":" per week or 49 mg or more per week for therapeutic anticoag","exact":"warfarin"},{"setid":"PMC2722908","drugname":"warfarin","startOffset":"0","endOffset":"8","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","prefix":"","suffix":" is the most widely used oral anticoagulant agent worldwide;","exact":"Warfarin"},{"setid":"PMC2722908","drugname":"warfarin","startOffset":"18","endOffset":"26","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[1]/div[2]/div[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[1]/div[2]/div[1]","prefix":"The International ","suffix":" Pharmacogenetics Consortium","exact":"Warfarin"},{"setid":"PMC2722908","drugname":"warfarin","startOffset":"18","endOffset":"26","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[1]","prefix":"The International ","suffix":" Pharmacogenetics Consortium comprises 21 research groups fr","exact":"Warfarin"},{"setid":"PMC2722908","drugname":"warfarin","startOffset":"228","endOffset":"236","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[1]","prefix":"tic data for a total of 5700 patients who were treated with ","suffix":". These data were curated (i.e., collected, formatted, and s","exact":"warfarin"},{"setid":"PMC2722908","drugname":"warfarin","startOffset":"80","endOffset":"88","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[2]","prefix":" clinical factors that have previously been associated with ","suffix":" therapy and that were available from the information receiv","exact":"warfarin"},{"setid":"PMC2722908","drugname":"warfarin","startOffset":"266","endOffset":"274","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[2]","prefix":" on demographic characteristics, the primary indication for ","suffix":" treatment, the stable therapeutic dose of warfarin, the tre","exact":"warfarin"},{"setid":"PMC2722908","drugname":"warfarin","startOffset":"317","endOffset":"325","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[2]","prefix":"tion for warfarin treatment, the stable therapeutic dose of ","suffix":", the treatment INR (the INR achieved with a stable warfarin","exact":"warfarin"},{"setid":"PMC2722908","drugname":"warfarin","startOffset":"377","endOffset":"385","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[2]","prefix":"warfarin, the treatment INR (the INR achieved with a stable ","suffix":" dose), the target INR (the desired INR), the use of concomi","exact":"warfarin"},{"setid":"PMC2722908","drugname":"warfarin","startOffset":"133","endOffset":"141","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[1]","prefix":"site, for a total of 4043 patients who had a stable dose of ","suffix":" and a target INR of 2 to 3) as the “derivation cohort” for ","exact":"warfarin"},{"setid":"PMC2722908","drugname":"warfarin","startOffset":"15","endOffset":"23","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/div[1]/div[1]/div[2]/span[1]/strong[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/div[1]/div[1]/div[2]/span[1]/strong[1]","prefix":"Comparisons of ","suffix":" Doses Predicted According to the Clinical Algorithm and the","exact":"Warfarin"},{"setid":"PMC2722908","drugname":"warfarin","startOffset":"10","endOffset":"18","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/div[2]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/div[2]/div[1]/div[2]/span[1]","prefix":"Predicted ","suffix":" Doses with the Pharmacogenetic Algorithm, Clinical Algorith","exact":"Warfarin"},{"setid":"PMC2722908","drugname":"warfarin","startOffset":"149","endOffset":"157","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/div[2]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/div[2]/div[1]/div[2]/span[1]","prefix":"ort with an Ideal, Underestimated, or Overestimated Dose of ","suffix":", as Estimated with the Pharmacogenetic Algorithm, Clinical ","exact":"Warfarin"},{"setid":"PMC2722908","drugname":"warfarin","startOffset":"117","endOffset":"125","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/div[3]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/div[3]/div[1]/div[2]/span[1]","prefix":" Correctly Identify Patients Requiring Low or High Doses of ","suffix":".","exact":"Warfarin"},{"setid":"PMC2722908","drugname":"warfarin","startOffset":"112","endOffset":"120","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"significantly better predictions of the appropriate dose of ","suffix":" than either the clinical algorithm or a fixed-dose approach","exact":"warfarin"},{"setid":"PMC2722908","drugname":"warfarin","startOffset":"295","endOffset":"303","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"proaches were noted among patients whose stable therapeutic ","suffix":" doses were 21 mg or less per week and among those whose sta","exact":"warfarin"},{"setid":"PMC2722908","drugname":"warfarin","startOffset":"77","endOffset":"85","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":" not address the issue of whether a precise initial dose of ","suffix":" translates into improved clinical end points, such as a red","exact":"warfarin"},{"setid":"PMC2722908","drugname":"warfarin","startOffset":"90","endOffset":"98","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":" of pharmacogenetic dose prediction as compared with actual ","suffix":" dose (Section 8 in ","exact":"warfarin"},{"setid":"PMC2722908","drugname":"warfarin","startOffset":"121","endOffset":"129","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"patients, we developed a pharmacogenetic dose algorithm for ","suffix":" that uses genotypes from two genes (","exact":"warfarin"},{"setid":"PMC2722908","drugname":"warfarin","startOffset":"634","endOffset":"642","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[9]/div[2]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[9]/div[2]/p[2]","prefix":"polymorphisms in CYP4F2 with the stable therapeutic dose of ","suffix":" (a patent that has been licensed by the Marshfield Clinic t","exact":"warfarin"},{"setid":"PMC2722908","drugname":"vitamin k","startOffset":"167","endOffset":"176","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","prefix":"clude potentially important factors such as smoking status, ","suffix":" intake, or alcohol consumption, as well as other genetic fa","exact":"vitamin K"},{"setid":"PMC2722908","drugname":"lasso","startOffset":"797","endOffset":"802","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[1]","prefix":"te adaptive regression splines, least-angle regression, and ","suffix":", in addition to ordinary linear regression. Logarithmic and","exact":"Lasso"}],[{"setid":"PMC1156914","drugname":"olanzapine","startOffset":"348","endOffset":"358","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":" polypharmacy, and 13.9 days without antipsychotic therapy. ","suffix":"-initiated patients were significantly more likely to be on ","exact":"Olanzapine"},{"setid":"PMC1156914","drugname":"olanzapine","startOffset":"620","endOffset":"630","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"he number of monotherapy days was significantly greater for ","suffix":" than quetiapine (p < .001), but not for olanzapine versus r","exact":"olanzapine"},{"setid":"PMC1156914","drugname":"olanzapine","startOffset":"671","endOffset":"681","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"ater for olanzapine than quetiapine (p < .001), but not for ","suffix":" versus risperidone, or for risperidone versus quetiapine-in","exact":"olanzapine"},{"setid":"PMC1156914","drugname":"olanzapine","startOffset":"391","endOffset":"401","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[8]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[8]","prefix":"tients initiated on commonly used atypical antipsychotics – ","suffix":", quetiapine, or risperidone – and compared their rates and ","exact":"olanzapine"},{"setid":"PMC1156914","drugname":"olanzapine","startOffset":"131","endOffset":"141","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[5]","prefix":"ted on one of three commonly used atypical antipsychotics – ","suffix":", quetiapine, or risperidone, in regular oral formulation. P","exact":"olanzapine"},{"setid":"PMC1156914","drugname":"olanzapine","startOffset":"97","endOffset":"107","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[2]/div[2]/div[1]/ul[1]/li[5]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[2]/div[2]/div[1]/ul[1]/li[5]/a[1]","prefix":"study of outcome in schizophrenic outpatients, treated with ","suffix":".","exact":"olanzapine"},{"setid":"PMC1156914","drugname":"olanzapine","startOffset":"391","endOffset":"401","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[8]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[8]","prefix":"tients initiated on commonly used atypical antipsychotics – ","suffix":", quetiapine, or risperidone – and compared their rates and ","exact":"olanzapine"},{"setid":"PMC1156914","drugname":"olanzapine","startOffset":"131","endOffset":"141","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[5]","prefix":"ted on one of three commonly used atypical antipsychotics – ","suffix":", quetiapine, or risperidone, in regular oral formulation. P","exact":"olanzapine"},{"setid":"PMC1156914","drugname":"olanzapine","startOffset":"122","endOffset":"132","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[3]","prefix":"utcome measures for initiating treatment group comparisons (","suffix":", quetiapine, or risperidone): (a) the percentage of patient","exact":"olanzapine"},{"setid":"PMC1156914","drugname":"olanzapine","startOffset":"50","endOffset":"60","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/div[1]/div[1]/div[2]/span[1]","prefix":"Baseline characteristics of patients initiated on ","suffix":", risperidone, and quetiapine","exact":"olanzapine"},{"setid":"PMC1156914","drugname":"olanzapine","startOffset":"38","endOffset":"48","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","prefix":"A significantly greater percentage of ","suffix":"-treated patients were on antipsychotic monotherapy during t","exact":"olanzapine"},{"setid":"PMC1156914","drugname":"olanzapine","startOffset":"168","endOffset":"178","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","prefix":"he 1-year period compared to risperidone and to quetiapine. ","suffix":"-treated patients were 2.08 times more likely to be on monot","exact":"Olanzapine"},{"setid":"PMC1156914","drugname":"olanzapine","startOffset":"132","endOffset":"142","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/div[2]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/div[2]/div[1]/div[2]/span[1]","prefix":"ypharmacy or antipsychotic monotherapy. Abbreviations: OLZ, ","suffix":"; Poly, polypharmacy at initiation; QUE, quetiapine; RIS, ri","exact":"olanzapine"},{"setid":"PMC1156914","drugname":"olanzapine","startOffset":"81","endOffset":"91","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[3]","prefix":"ber of monotherapy days on the initiating antipsychotic for ","suffix":", quetiapine, and risperidone are presented in Table ","exact":"olanzapine"},{"setid":"PMC1156914","drugname":"olanzapine","startOffset":"81","endOffset":"91","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[3]","prefix":"ber of monotherapy days on the initiating antipsychotic for ","suffix":", quetiapine, and risperidone are presented in Table ","exact":"olanzapine"},{"setid":"PMC1156914","drugname":"olanzapine","startOffset":"134","endOffset":"144","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"the time of initiation on the studied atypical medications (","suffix":", quetiapine, and risperidone). These monotherapy-initiated ","exact":"olanzapine"},{"setid":"PMC1156914","drugname":"olanzapine","startOffset":"173","endOffset":"183","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"d atypical antipsychotic medications. Patients initiated on ","suffix":" were significantly more likely to be on monotherapy compare","exact":"olanzapine"},{"setid":"PMC1156914","drugname":"olanzapine","startOffset":"448","endOffset":"458","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"gs appear consistent with several previous studies in which ","suffix":"-treated patients were found to have significantly higher ra","exact":"olanzapine"},{"setid":"PMC1156914","drugname":"olanzapine","startOffset":"221","endOffset":"231","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[9]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[9]","prefix":"or of the sponsor's antipsychotic medication (in this case, ","suffix":"). Although we cannot completely rule out this possibility, ","exact":"olanzapine"},{"setid":"PMC1156914","drugname":"quetiapine","startOffset":"243","endOffset":"253","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":"ho were initiated during the study on olanzapine (N = 405), ","suffix":" (N = 115), or risperidone (N = 276). The percentage of pati","exact":"quetiapine"},{"setid":"PMC1156914","drugname":"quetiapine","startOffset":"728","endOffset":"738","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"or olanzapine versus risperidone, or for risperidone versus ","suffix":"-initiated patients.","exact":"quetiapine"},{"setid":"PMC1156914","drugname":"quetiapine","startOffset":"403","endOffset":"413","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[8]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[8]","prefix":"ated on commonly used atypical antipsychotics – olanzapine, ","suffix":", or risperidone – and compared their rates and duration of ","exact":"quetiapine"},{"setid":"PMC1156914","drugname":"quetiapine","startOffset":"143","endOffset":"153","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[5]","prefix":"f three commonly used atypical antipsychotics – olanzapine, ","suffix":", or risperidone, in regular oral formulation. Participants ","exact":"quetiapine"},{"setid":"PMC1156914","drugname":"quetiapine","startOffset":"134","endOffset":"144","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[3]","prefix":"res for initiating treatment group comparisons (olanzapine, ","suffix":", or risperidone): (a) the percentage of patients on antipsy","exact":"quetiapine"},{"setid":"PMC1156914","drugname":"quetiapine","startOffset":"79","endOffset":"89","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/div[1]/div[1]/div[2]/span[1]","prefix":"stics of patients initiated on olanzapine, risperidone, and ","suffix":"","exact":"quetiapine"},{"setid":"PMC1156914","drugname":"quetiapine","startOffset":"480","endOffset":"490","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","prefix":", 1.01–1.84, p = .043). Differences between risperidone and ","suffix":" initiators showed a trend toward significance (OR = 1.53, 9","exact":"quetiapine"},{"setid":"PMC1156914","drugname":"quetiapine","startOffset":"183","endOffset":"193","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/div[2]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/div[2]/div[1]/div[2]/span[1]","prefix":"ns: OLZ, olanzapine; Poly, polypharmacy at initiation; QUE, ","suffix":"; RIS, risperidone; Mono, monotherapy at initiation","exact":"quetiapine"},{"setid":"PMC1156914","drugname":"quetiapine","startOffset":"93","endOffset":"103","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[3]","prefix":"herapy days on the initiating antipsychotic for olanzapine, ","suffix":", and risperidone are presented in Table ","exact":"quetiapine"},{"setid":"PMC1156914","drugname":"quetiapine","startOffset":"146","endOffset":"156","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"initiation on the studied atypical medications (olanzapine, ","suffix":", and risperidone). These monotherapy-initiated patients con","exact":"quetiapine"},{"setid":"PMC1156914","drugname":"quetiapine","startOffset":"424","endOffset":"434","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[8]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[8]","prefix":"is also important because some antipsychotics, particularly ","suffix":" in low doses, may have been used to treat insomnia rather t","exact":"quetiapine"},{"setid":"PMC1156914","drugname":"quetiapine","startOffset":"49","endOffset":"59","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[12]/div[2]/ul[1]/li[30]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[12]/div[2]/ul[1]/li[30]/span[1]","prefix":"Wang PF, Zhao Z. Comparison of olanzapine versus ","suffix":" in the treatment of hospitalized patients with schizophreni","exact":"quetiapine"},{"setid":"PMC1156914","drugname":"quetiapine","startOffset":"49","endOffset":"59","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[21]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[21]/span[1]","prefix":"Wang PF, Zhao Z. Comparison of olanzapine versus ","suffix":" in the treatment of hospitalized patients with schizophreni","exact":"quetiapine"},{"setid":"PMC1156914","drugname":"quetiapine","startOffset":"536","endOffset":"546","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"-year post initiation compared to risperidone (p = .043) or ","suffix":" (p = .002). The number of monotherapy days was significantl","exact":"quetiapine"},{"setid":"PMC1156914","drugname":"quetiapine","startOffset":"728","endOffset":"738","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"or olanzapine versus risperidone, or for risperidone versus ","suffix":"-initiated patients.","exact":"quetiapine"},{"setid":"PMC1156914","drugname":"quetiapine","startOffset":"636","endOffset":"646","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"otherapy days was significantly greater for olanzapine than ","suffix":" (p < .001), but not for olanzapine versus risperidone, or f","exact":"quetiapine"},{"setid":"PMC1156914","drugname":"quetiapine","startOffset":"728","endOffset":"738","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"or olanzapine versus risperidone, or for risperidone versus ","suffix":"-initiated patients.","exact":"quetiapine"},{"setid":"PMC1156914","drugname":"quetiapine","startOffset":"403","endOffset":"413","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[8]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[8]","prefix":"ated on commonly used atypical antipsychotics – olanzapine, ","suffix":", or risperidone – and compared their rates and duration of ","exact":"quetiapine"},{"setid":"PMC1156914","drugname":"quetiapine","startOffset":"79","endOffset":"89","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/div[1]/div[1]/div[2]/span[1]","prefix":"stics of patients initiated on olanzapine, risperidone, and ","suffix":"","exact":"quetiapine"},{"setid":"PMC1156914","drugname":"quetiapine","startOffset":"143","endOffset":"153","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[5]","prefix":"f three commonly used atypical antipsychotics – olanzapine, ","suffix":", or risperidone, in regular oral formulation. Participants ","exact":"quetiapine"},{"setid":"PMC1156914","drugname":"quetiapine","startOffset":"79","endOffset":"89","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/div[1]/div[1]/div[2]/span[1]","prefix":"stics of patients initiated on olanzapine, risperidone, and ","suffix":"","exact":"quetiapine"},{"setid":"PMC1156914","drugname":"quetiapine","startOffset":"403","endOffset":"413","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[8]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[8]","prefix":"ated on commonly used atypical antipsychotics – olanzapine, ","suffix":", or risperidone – and compared their rates and duration of ","exact":"quetiapine"},{"setid":"PMC1156914","drugname":"quetiapine","startOffset":"143","endOffset":"153","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[5]","prefix":"f three commonly used atypical antipsychotics – olanzapine, ","suffix":", or risperidone, in regular oral formulation. Participants ","exact":"quetiapine"},{"setid":"PMC1156914","drugname":"quetiapine","startOffset":"134","endOffset":"144","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[3]","prefix":"res for initiating treatment group comparisons (olanzapine, ","suffix":", or risperidone): (a) the percentage of patients on antipsy","exact":"quetiapine"},{"setid":"PMC1156914","drugname":"quetiapine","startOffset":"79","endOffset":"89","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/div[1]/div[1]/div[2]/span[1]","prefix":"stics of patients initiated on olanzapine, risperidone, and ","suffix":"","exact":"quetiapine"},{"setid":"PMC1156914","drugname":"quetiapine","startOffset":"243","endOffset":"253","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":"ho were initiated during the study on olanzapine (N = 405), ","suffix":" (N = 115), or risperidone (N = 276). The percentage of pati","exact":"quetiapine"},{"setid":"PMC1156914","drugname":"quetiapine","startOffset":"728","endOffset":"738","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"or olanzapine versus risperidone, or for risperidone versus ","suffix":"-initiated patients.","exact":"quetiapine"},{"setid":"PMC1156914","drugname":"quetiapine","startOffset":"403","endOffset":"413","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[8]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[8]","prefix":"ated on commonly used atypical antipsychotics – olanzapine, ","suffix":", or risperidone – and compared their rates and duration of ","exact":"quetiapine"},{"setid":"PMC1156914","drugname":"quetiapine","startOffset":"143","endOffset":"153","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[5]","prefix":"f three commonly used atypical antipsychotics – olanzapine, ","suffix":", or risperidone, in regular oral formulation. Participants ","exact":"quetiapine"},{"setid":"PMC1156914","drugname":"quetiapine","startOffset":"134","endOffset":"144","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[3]","prefix":"res for initiating treatment group comparisons (olanzapine, ","suffix":", or risperidone): (a) the percentage of patients on antipsy","exact":"quetiapine"},{"setid":"PMC1156914","drugname":"quetiapine","startOffset":"79","endOffset":"89","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/div[1]/div[1]/div[2]/span[1]","prefix":"stics of patients initiated on olanzapine, risperidone, and ","suffix":"","exact":"quetiapine"},{"setid":"PMC1156914","drugname":"quetiapine","startOffset":"480","endOffset":"490","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","prefix":", 1.01–1.84, p = .043). Differences between risperidone and ","suffix":" initiators showed a trend toward significance (OR = 1.53, 9","exact":"quetiapine"},{"setid":"PMC1156914","drugname":"quetiapine","startOffset":"183","endOffset":"193","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/div[2]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/div[2]/div[1]/div[2]/span[1]","prefix":"ns: OLZ, olanzapine; Poly, polypharmacy at initiation; QUE, ","suffix":"; RIS, risperidone; Mono, monotherapy at initiation","exact":"quetiapine"},{"setid":"PMC1156914","drugname":"quetiapine","startOffset":"93","endOffset":"103","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[3]","prefix":"herapy days on the initiating antipsychotic for olanzapine, ","suffix":", and risperidone are presented in Table ","exact":"quetiapine"},{"setid":"PMC1156914","drugname":"quetiapine","startOffset":"146","endOffset":"156","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"initiation on the studied atypical medications (olanzapine, ","suffix":", and risperidone). These monotherapy-initiated patients con","exact":"quetiapine"},{"setid":"PMC1156914","drugname":"quetiapine","startOffset":"424","endOffset":"434","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[8]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[8]","prefix":"is also important because some antipsychotics, particularly ","suffix":" in low doses, may have been used to treat insomnia rather t","exact":"quetiapine"},{"setid":"PMC1156914","drugname":"quetiapine","startOffset":"49","endOffset":"59","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[12]/div[2]/ul[1]/li[30]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[12]/div[2]/ul[1]/li[30]/span[1]","prefix":"Wang PF, Zhao Z. Comparison of olanzapine versus ","suffix":" in the treatment of hospitalized patients with schizophreni","exact":"quetiapine"},{"setid":"PMC1156914","drugname":"quetiapine","startOffset":"49","endOffset":"59","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[21]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[21]/span[1]","prefix":"Wang PF, Zhao Z. Comparison of olanzapine versus ","suffix":" in the treatment of hospitalized patients with schizophreni","exact":"quetiapine"},{"setid":"PMC1156914","drugname":"quetiapine","startOffset":"79","endOffset":"89","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/div[1]/div[1]/div[2]/span[1]","prefix":"stics of patients initiated on olanzapine, risperidone, and ","suffix":"","exact":"quetiapine"},{"setid":"PMC1156914","drugname":"quetiapine","startOffset":"156","endOffset":"166","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","prefix":"apy during the 1-year period compared to risperidone and to ","suffix":". Olanzapine-treated patients were 2.08 times more likely to","exact":"quetiapine"},{"setid":"PMC1156914","drugname":"quetiapine","startOffset":"250","endOffset":"260","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","prefix":"ients were 2.08 times more likely to be on monotherapy than ","suffix":" (Odds Ratio (OR) = 2.08, 95% Confidence Interval (CI), 1.30","exact":"quetiapine"},{"setid":"PMC1156914","drugname":"quetiapine","startOffset":"480","endOffset":"490","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","prefix":", 1.01–1.84, p = .043). Differences between risperidone and ","suffix":" initiators showed a trend toward significance (OR = 1.53, 9","exact":"quetiapine"},{"setid":"PMC1156914","drugname":"quetiapine","startOffset":"183","endOffset":"193","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/div[2]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/div[2]/div[1]/div[2]/span[1]","prefix":"ns: OLZ, olanzapine; Poly, polypharmacy at initiation; QUE, ","suffix":"; RIS, risperidone; Mono, monotherapy at initiation","exact":"quetiapine"},{"setid":"PMC1156914","drugname":"quetiapine","startOffset":"93","endOffset":"103","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[3]","prefix":"herapy days on the initiating antipsychotic for olanzapine, ","suffix":", and risperidone are presented in Table ","exact":"quetiapine"},{"setid":"PMC1156914","drugname":"quetiapine","startOffset":"79","endOffset":"89","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/div[1]/div[1]/div[2]/span[1]","prefix":"stics of patients initiated on olanzapine, risperidone, and ","suffix":"","exact":"quetiapine"},{"setid":"PMC1156914","drugname":"quetiapine","startOffset":"93","endOffset":"103","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[3]","prefix":"herapy days on the initiating antipsychotic for olanzapine, ","suffix":", and risperidone are presented in Table ","exact":"quetiapine"},{"setid":"PMC1156914","drugname":"quetiapine","startOffset":"146","endOffset":"156","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"initiation on the studied atypical medications (olanzapine, ","suffix":", and risperidone). These monotherapy-initiated patients con","exact":"quetiapine"},{"setid":"PMC1156914","drugname":"quetiapine","startOffset":"248","endOffset":"258","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":" significantly more likely to be on monotherapy compared to ","suffix":" (rate and duration) or risperidone-initiated patients (rate","exact":"quetiapine"},{"setid":"PMC1156914","drugname":"quetiapine","startOffset":"424","endOffset":"434","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[8]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[8]","prefix":"is also important because some antipsychotics, particularly ","suffix":" in low doses, may have been used to treat insomnia rather t","exact":"quetiapine"},{"setid":"PMC1156914","drugname":"quetiapine","startOffset":"581","endOffset":"591","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[8]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[8]","prefix":"phrenia. Although some have speculated that higher doses of ","suffix":" produce better outcome, the available data [","exact":"quetiapine"},{"setid":"PMC1156914","drugname":"quetiapine","startOffset":"79","endOffset":"89","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/div[1]/div[1]/div[2]/span[1]","prefix":"stics of patients initiated on olanzapine, risperidone, and ","suffix":"","exact":"quetiapine"},{"setid":"PMC1156914","drugname":"quetiapine","startOffset":"171","endOffset":"181","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[12]/div[2]/ul[1]/li[36]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[12]/div[2]/ul[1]/li[36]/span[1]","prefix":"ata from a randomized double-blind study of risperidone and ","suffix":". ","exact":"quetiapine"},{"setid":"PMC1156914","drugname":"risperidone","startOffset":"268","endOffset":"279","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":"the study on olanzapine (N = 405), quetiapine (N = 115), or ","suffix":" (N = 276). The percentage of patients with monotherapy on t","exact":"risperidone"},{"setid":"PMC1156914","drugname":"risperidone","startOffset":"709","endOffset":"720","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":" < .001), but not for olanzapine versus risperidone, or for ","suffix":" versus quetiapine-initiated patients.","exact":"risperidone"},{"setid":"PMC1156914","drugname":"risperidone","startOffset":"418","endOffset":"429","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[8]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[8]","prefix":"y used atypical antipsychotics – olanzapine, quetiapine, or ","suffix":" – and compared their rates and duration of monotherapy duri","exact":"risperidone"},{"setid":"PMC1156914","drugname":"risperidone","startOffset":"158","endOffset":"169","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[5]","prefix":"y used atypical antipsychotics – olanzapine, quetiapine, or ","suffix":", in regular oral formulation. Participants were defined as ","exact":"risperidone"},{"setid":"PMC1156914","drugname":"risperidone","startOffset":"149","endOffset":"160","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[3]","prefix":"ing treatment group comparisons (olanzapine, quetiapine, or ","suffix":"): (a) the percentage of patients on antipsychotic monothera","exact":"risperidone"},{"setid":"PMC1156914","drugname":"risperidone","startOffset":"510","endOffset":"521","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"antipsychotic during the 1-year post initiation compared to ","suffix":" (p = .043) or quetiapine (p = .002). The number of monother","exact":"risperidone"},{"setid":"PMC1156914","drugname":"risperidone","startOffset":"689","endOffset":"700","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"e than quetiapine (p < .001), but not for olanzapine versus ","suffix":", or for risperidone versus quetiapine-initiated patients.","exact":"risperidone"},{"setid":"PMC1156914","drugname":"risperidone","startOffset":"709","endOffset":"720","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":" < .001), but not for olanzapine versus risperidone, or for ","suffix":" versus quetiapine-initiated patients.","exact":"risperidone"},{"setid":"PMC1156914","drugname":"risperidone","startOffset":"709","endOffset":"720","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":" < .001), but not for olanzapine versus risperidone, or for ","suffix":" versus quetiapine-initiated patients.","exact":"risperidone"},{"setid":"PMC1156914","drugname":"risperidone","startOffset":"418","endOffset":"429","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[8]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[8]","prefix":"y used atypical antipsychotics – olanzapine, quetiapine, or ","suffix":" – and compared their rates and duration of monotherapy duri","exact":"risperidone"},{"setid":"PMC1156914","drugname":"risperidone","startOffset":"158","endOffset":"169","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[5]","prefix":"y used atypical antipsychotics – olanzapine, quetiapine, or ","suffix":", in regular oral formulation. Participants were defined as ","exact":"risperidone"},{"setid":"PMC1156914","drugname":"risperidone","startOffset":"158","endOffset":"169","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[5]","prefix":"y used atypical antipsychotics – olanzapine, quetiapine, or ","suffix":", in regular oral formulation. Participants were defined as ","exact":"risperidone"},{"setid":"PMC1156914","drugname":"risperidone","startOffset":"418","endOffset":"429","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[8]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[8]","prefix":"y used atypical antipsychotics – olanzapine, quetiapine, or ","suffix":" – and compared their rates and duration of monotherapy duri","exact":"risperidone"},{"setid":"PMC1156914","drugname":"risperidone","startOffset":"158","endOffset":"169","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[5]","prefix":"y used atypical antipsychotics – olanzapine, quetiapine, or ","suffix":", in regular oral formulation. Participants were defined as ","exact":"risperidone"},{"setid":"PMC1156914","drugname":"risperidone","startOffset":"149","endOffset":"160","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[3]","prefix":"ing treatment group comparisons (olanzapine, quetiapine, or ","suffix":"): (a) the percentage of patients on antipsychotic monothera","exact":"risperidone"},{"setid":"PMC1156914","drugname":"risperidone","startOffset":"268","endOffset":"279","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":"the study on olanzapine (N = 405), quetiapine (N = 115), or ","suffix":" (N = 276). The percentage of patients with monotherapy on t","exact":"risperidone"},{"setid":"PMC1156914","drugname":"risperidone","startOffset":"709","endOffset":"720","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":" < .001), but not for olanzapine versus risperidone, or for ","suffix":" versus quetiapine-initiated patients.","exact":"risperidone"},{"setid":"PMC1156914","drugname":"risperidone","startOffset":"418","endOffset":"429","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[8]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[8]","prefix":"y used atypical antipsychotics – olanzapine, quetiapine, or ","suffix":" – and compared their rates and duration of monotherapy duri","exact":"risperidone"},{"setid":"PMC1156914","drugname":"risperidone","startOffset":"158","endOffset":"169","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[5]","prefix":"y used atypical antipsychotics – olanzapine, quetiapine, or ","suffix":", in regular oral formulation. Participants were defined as ","exact":"risperidone"},{"setid":"PMC1156914","drugname":"risperidone","startOffset":"149","endOffset":"160","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[3]","prefix":"ing treatment group comparisons (olanzapine, quetiapine, or ","suffix":"): (a) the percentage of patients on antipsychotic monothera","exact":"risperidone"},{"setid":"PMC1156914","drugname":"risperidone","startOffset":"62","endOffset":"73","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/div[1]/div[1]/div[2]/span[1]","prefix":"seline characteristics of patients initiated on olanzapine, ","suffix":", and quetiapine","exact":"risperidone"},{"setid":"PMC1156914","drugname":"risperidone","startOffset":"137","endOffset":"148","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","prefix":"ipsychotic monotherapy during the 1-year period compared to ","suffix":" and to quetiapine. Olanzapine-treated patients were 2.08 ti","exact":"risperidone"},{"setid":"PMC1156914","drugname":"risperidone","startOffset":"391","endOffset":"402","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","prefix":".002), and 1.36 times more likely to be on monotherapy than ","suffix":" (OR = 1.36, 95%CI, 1.01–1.84, p = .043). Differences betwee","exact":"risperidone"},{"setid":"PMC1156914","drugname":"risperidone","startOffset":"464","endOffset":"475","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","prefix":"OR = 1.36, 95%CI, 1.01–1.84, p = .043). Differences between ","suffix":" and quetiapine initiators showed a trend toward significanc","exact":"risperidone"},{"setid":"PMC1156914","drugname":"risperidone","startOffset":"200","endOffset":"211","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/div[2]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/div[2]/div[1]/div[2]/span[1]","prefix":"ne; Poly, polypharmacy at initiation; QUE, quetiapine; RIS, ","suffix":"; Mono, monotherapy at initiation","exact":"risperidone"},{"setid":"PMC1156914","drugname":"risperidone","startOffset":"109","endOffset":"120","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[3]","prefix":"he initiating antipsychotic for olanzapine, quetiapine, and ","suffix":" are presented in Table ","exact":"risperidone"},{"setid":"PMC1156914","drugname":"risperidone","startOffset":"109","endOffset":"120","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[3]","prefix":"he initiating antipsychotic for olanzapine, quetiapine, and ","suffix":" are presented in Table ","exact":"risperidone"},{"setid":"PMC1156914","drugname":"risperidone","startOffset":"162","endOffset":"173","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"e studied atypical medications (olanzapine, quetiapine, and ","suffix":"). These monotherapy-initiated patients continued on monothe","exact":"risperidone"},{"setid":"PMC1156914","drugname":"risperidone","startOffset":"282","endOffset":"293","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"n monotherapy compared to quetiapine (rate and duration) or ","suffix":"-initiated patients (rate only) during the 1-year post treat","exact":"risperidone"},{"setid":"PMC1156914","drugname":"risperidone","startOffset":"548","endOffset":"559","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"o have significantly higher rate of monotherapy compared to ","suffix":" [","exact":"risperidone"}],[{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"35","endOffset":"46","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":"Subjects received rosuvastatin and ","suffix":" orally: day 1, rosuvastatin 10 mg single dose; days 6 to 9,","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"107","endOffset":"118","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":"orally: day 1, rosuvastatin 10 mg single dose; days 6 to 9, ","suffix":" 75 mg once daily; day 10, eltrombopag 75 mg once daily and ","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"145","endOffset":"156","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":"le dose; days 6 to 9, eltrombopag 75 mg once daily; day 10, ","suffix":" 75 mg once daily and rosuvastatin 10 mg single dose. Advers","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"21","endOffset":"32","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"Co-administration of ","suffix":" with rosuvastatin increased geometric mean (90% confidence ","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"30","endOffset":"41","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","prefix":"Concomitant administration of ","suffix":" with rosuvastatin was associated with increased rosuvastati","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"30","endOffset":"41","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/ul[1]/li[1]/div[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/ul[1]/li[1]/div[1]","prefix":"Concomitant administration of ","suffix":" with rosuvastatin was associated with increased rosuvastati","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"209","endOffset":"220","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","prefix":"ductase inhibitors may be reduced by the concomitant use of ","suffix":". In subjects taking eltrombopag, a reduced dose of HMG Co-A","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"245","endOffset":"256","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/ul[1]/li[1]/div[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/ul[1]/li[1]/div[1]","prefix":"ductase inhibitors may be reduced by the concomitant use of ","suffix":". In subjects taking eltrombopag, a reduced dose of HMG Co-A","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"224","endOffset":"235","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[10]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[10]","prefix":"ductase inhibitors may be reduced by the concomitant use of ","suffix":". In subjects taking eltrombopag, a reduced dose of HMG Co-A","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"241","endOffset":"252","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","prefix":"d by the concomitant use of eltrombopag. In subjects taking ","suffix":", a reduced dose of HMG Co-A reductase inhibitors may be nee","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"277","endOffset":"288","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/ul[1]/li[1]/div[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/ul[1]/li[1]/div[1]","prefix":"d by the concomitant use of eltrombopag. In subjects taking ","suffix":", a reduced dose of HMG Co-A reductase inhibitors may be nee","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"256","endOffset":"267","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[10]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[10]","prefix":"d by the concomitant use of eltrombopag. In subjects taking ","suffix":", a reduced dose of HMG Co-A reductase inhibitors may be nee","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"24","endOffset":"35","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","prefix":"BCRP, drug interaction, ","suffix":", OATP1B1, rosuvastatin","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"123","endOffset":"134","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[1]/div[1]/ul[1]/li[1]/div[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[1]/div[1]/ul[1]/li[1]/div[1]","prefix":"P is important for rosuvastatin absorption and elimination. ","suffix":" inhibits OATP1B1 and BCRP ","exact":"Eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"30","endOffset":"41","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","prefix":"Concomitant administration of ","suffix":" with rosuvastatin was associated with increased rosuvastati","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"30","endOffset":"41","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/ul[1]/li[1]/div[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/ul[1]/li[1]/div[1]","prefix":"Concomitant administration of ","suffix":" with rosuvastatin was associated with increased rosuvastati","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"209","endOffset":"220","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","prefix":"ductase inhibitors may be reduced by the concomitant use of ","suffix":". In subjects taking eltrombopag, a reduced dose of HMG Co-A","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"245","endOffset":"256","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/ul[1]/li[1]/div[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/ul[1]/li[1]/div[1]","prefix":"ductase inhibitors may be reduced by the concomitant use of ","suffix":". In subjects taking eltrombopag, a reduced dose of HMG Co-A","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"224","endOffset":"235","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[10]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[10]","prefix":"ductase inhibitors may be reduced by the concomitant use of ","suffix":". In subjects taking eltrombopag, a reduced dose of HMG Co-A","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"241","endOffset":"252","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","prefix":"d by the concomitant use of eltrombopag. In subjects taking ","suffix":", a reduced dose of HMG Co-A reductase inhibitors may be nee","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"277","endOffset":"288","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/ul[1]/li[1]/div[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/ul[1]/li[1]/div[1]","prefix":"d by the concomitant use of eltrombopag. In subjects taking ","suffix":", a reduced dose of HMG Co-A reductase inhibitors may be nee","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"256","endOffset":"267","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[10]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[10]","prefix":"d by the concomitant use of eltrombopag. In subjects taking ","suffix":", a reduced dose of HMG Co-A reductase inhibitors may be nee","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"0","endOffset":"11","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[1]/h1[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[1]/h1[1]","prefix":"","suffix":" increases plasma rosuvastatin exposure in healthy volunteer","exact":"Eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"0","endOffset":"11","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[1]/p[1]","prefix":"","suffix":", an oral, nonpeptide thrombopoietin receptor agonist, inhib","exact":"Eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"0","endOffset":"11","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","prefix":"","suffix":" (GlaxoSmithKline) is an oral, nonpeptide thrombopoietin rec","exact":"Eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"0","endOffset":"11","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[5]/div[2]/div[1]/div[1]/ul[1]/li[1]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[5]/div[2]/div[1]/div[1]/ul[1]/li[1]/a[1]","prefix":"","suffix":" increases plasma rosuvastatin exposure in healthy volunteer","exact":"Eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"0","endOffset":"11","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[5]/div[2]/div[1]/div[1]/ul[1]/li[1]/div[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[5]/div[2]/div[1]/div[1]/ul[1]/li[1]/div[1]","prefix":"","suffix":" increases plasma rosuvastatin exposure in healthy volunteer","exact":"Eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"0","endOffset":"11","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[1]/div[2]/ul[1]/li[2]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[1]/div[2]/ul[1]/li[2]/a[1]","prefix":"","suffix":" for thrombocytopenia in patients with cirrhosis associated ","exact":"Eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"0","endOffset":"11","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[2]","prefix":"","suffix":" for thrombocytopenia in patients with cirrhosis associated ","exact":"Eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"24","endOffset":"35","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","prefix":"In preclinical studies, ","suffix":" inhibited the organic anion transporting polypeptide 1B1 (O","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"148","endOffset":"159","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","prefix":" 1B1 (OATP1B1) and breast cancer resistance protein (BCRP). ","suffix":" was also identified as a BCRP substrate ","exact":"Eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"232","endOffset":"243","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","prefix":"itten, informed consent. Subjects received rosuvastatin and ","suffix":" orally in the following sequence: day 1, rosuvastatin 10 mg","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"338","endOffset":"349","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","prefix":"day 1, rosuvastatin 10 mg single dose; day 6 through day 9, ","suffix":" 75 mg once daily; day 10, eltrombopag 75 mg once daily and ","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"376","endOffset":"387","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","prefix":" day 6 through day 9, eltrombopag 75 mg once daily; day 10, ","suffix":" 75 mg once daily and rosuvastatin 10 mg single dose. This s","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"20","endOffset":"31","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[6]","prefix":"Steady-state plasma ","suffix":" ","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"25","endOffset":"36","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[7]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[7]","prefix":"To assess the effects of ","suffix":" on rosuvastatin PK, log transformed plasma rosuvastatin AUC","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"21","endOffset":"32","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[2]","prefix":"Co-administration of ","suffix":" with rosuvastatin increased plasma rosuvastatin AUC(0,∞) by","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"35","endOffset":"46","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":"Subjects received rosuvastatin and ","suffix":" orally: day 1, rosuvastatin 10 mg single dose; days 6 to 9,","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"107","endOffset":"118","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":"orally: day 1, rosuvastatin 10 mg single dose; days 6 to 9, ","suffix":" 75 mg once daily; day 10, eltrombopag 75 mg once daily and ","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"145","endOffset":"156","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":"le dose; days 6 to 9, eltrombopag 75 mg once daily; day 10, ","suffix":" 75 mg once daily and rosuvastatin 10 mg single dose. Advers","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"21","endOffset":"32","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"Co-administration of ","suffix":" with rosuvastatin increased geometric mean (90% confidence ","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"30","endOffset":"41","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","prefix":"Concomitant administration of ","suffix":" with rosuvastatin was associated with increased rosuvastati","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"209","endOffset":"220","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","prefix":"ductase inhibitors may be reduced by the concomitant use of ","suffix":". In subjects taking eltrombopag, a reduced dose of HMG Co-A","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"241","endOffset":"252","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","prefix":"d by the concomitant use of eltrombopag. In subjects taking ","suffix":", a reduced dose of HMG Co-A reductase inhibitors may be nee","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"24","endOffset":"35","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","prefix":"BCRP, drug interaction, ","suffix":", OATP1B1, rosuvastatin","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"30","endOffset":"41","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/ul[1]/li[1]/div[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/ul[1]/li[1]/div[1]","prefix":"Concomitant administration of ","suffix":" with rosuvastatin was associated with increased rosuvastati","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"245","endOffset":"256","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/ul[1]/li[1]/div[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/ul[1]/li[1]/div[1]","prefix":"ductase inhibitors may be reduced by the concomitant use of ","suffix":". In subjects taking eltrombopag, a reduced dose of HMG Co-A","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"277","endOffset":"288","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/ul[1]/li[1]/div[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/ul[1]/li[1]/div[1]","prefix":"d by the concomitant use of eltrombopag. In subjects taking ","suffix":", a reduced dose of HMG Co-A reductase inhibitors may be nee","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"24","endOffset":"35","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","prefix":"In preclinical studies, ","suffix":" inhibited the organic anion transporting polypeptide 1B1 (O","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"232","endOffset":"243","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","prefix":"itten, informed consent. Subjects received rosuvastatin and ","suffix":" orally in the following sequence: day 1, rosuvastatin 10 mg","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"338","endOffset":"349","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","prefix":"day 1, rosuvastatin 10 mg single dose; day 6 through day 9, ","suffix":" 75 mg once daily; day 10, eltrombopag 75 mg once daily and ","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"376","endOffset":"387","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","prefix":" day 6 through day 9, eltrombopag 75 mg once daily; day 10, ","suffix":" 75 mg once daily and rosuvastatin 10 mg single dose. This s","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"20","endOffset":"31","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[6]","prefix":"Steady-state plasma ","suffix":" ","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"25","endOffset":"36","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[7]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[7]","prefix":"To assess the effects of ","suffix":" on rosuvastatin PK, log transformed plasma rosuvastatin AUC","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"21","endOffset":"32","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[2]","prefix":"Co-administration of ","suffix":" with rosuvastatin increased plasma rosuvastatin AUC(0,∞) by","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"101","endOffset":"112","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[2]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[2]/div[1]/div[2]/span[1]","prefix":"time profiles. rosuvastain alone (no symbol = rosuvastain + ","suffix":") (▴); overall population (","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"57","endOffset":"68","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[4]","prefix":"For the overall population, the geometric mean of plasma ","suffix":" ","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"18","endOffset":"29","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[4]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[4]/div[1]/div[2]/span[1]","prefix":"Summary of plasma ","suffix":" pharmacokinetics","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"37","endOffset":"48","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[8]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[8]","prefix":"The impact of rosuvastatin on plasma ","suffix":" PK was not formally assessed. However, eltrombopag trough c","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"88","endOffset":"99","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[8]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[8]","prefix":"n plasma eltrombopag PK was not formally assessed. However, ","suffix":" trough concentrations collected prior to co-administration ","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"306","endOffset":"317","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[8]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[8]","prefix":"ation of a single dose of rosuvastatin. In addition, plasma ","suffix":" exposure for the 75 mg once daily regimen (in combination w","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"454","endOffset":"465","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[8]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[8]","prefix":" of rosuvastatin) was generally as expected based on plasma ","suffix":" exposures observed in other eltrombopag studies [","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"494","endOffset":"505","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[8]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[8]","prefix":"ted based on plasma eltrombopag exposures observed in other ","suffix":" studies [","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"7","endOffset":"18","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[9]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[9]","prefix":"Plasma ","suffix":" exposures collected in the presence of rosuvastatin were si","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"218","endOffset":"229","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[9]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[9]","prefix":"tudies that have shown approximately two-fold higher plasma ","suffix":" exposures in Asian ","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"45","endOffset":"56","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[10]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[10]","prefix":"In conclusion, concomitant administration of ","suffix":" with rosuvastatin was associated with increased rosuvastati","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"224","endOffset":"235","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[10]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[10]","prefix":"ductase inhibitors may be reduced by the concomitant use of ","suffix":". In subjects taking eltrombopag, a reduced dose of HMG Co-A","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"256","endOffset":"267","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[10]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[10]","prefix":"d by the concomitant use of eltrombopag. In subjects taking ","suffix":", a reduced dose of HMG Co-A reductase inhibitors may be nee","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"138","endOffset":"149","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[11]/div[2]/div[1]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[11]/div[2]/div[1]/span[1]","prefix":"s JM, Roychowdhury D, Mayer B, Stone N, Arning M. Effect of ","suffix":" on platelet counts and bleeding during treatment of chronic","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"163","endOffset":"174","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[11]/div[2]/div[4]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[11]/div[2]/div[4]/span[1]","prefix":"G, Luengo JI, Duffy KJ, Jenkins JM. Preclinical activity of ","suffix":" (SB-497115), an oral, nonpeptide thrombopoietin receptor ag","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"107","endOffset":"118","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[11]/div[2]/div[20]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[11]/div[2]/div[20]/span[1]","prefix":"V, Collins D, Erickson-Miller CL. Phase 1 clinical study of ","suffix":", an oral, nonpeptide thrombopoietin receptor agonist. ","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"84","endOffset":"95","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[11]/div[2]/div[22]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[11]/div[2]/div[22]/span[1]","prefix":"lliams D, Wang Z, Ouellet D. Population pharmacokinetics of ","suffix":" in healthy subjects and patients with chronic idiopathic th","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"47","endOffset":"58","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[2]/div[2]/div[1]/ul[1]/li[1]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[2]/div[2]/div[1]/ul[1]/li[1]/a[1]","prefix":"Interaction of novel platelet-increasing agent ","suffix":" with rosuvastatin via breast cancer resistance protein in h","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"10","endOffset":"21","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[1]/div[2]/ul[1]/li[1]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[1]/div[2]/ul[1]/li[1]/a[1]","prefix":"Effect of ","suffix":" on platelet counts and bleeding during treatment of chronic","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"24","endOffset":"35","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[1]/div[2]/ul[1]/li[3]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[1]/div[2]/ul[1]/li[3]/a[1]","prefix":"Preclinical activity of ","suffix":" (SB-497115), an oral, nonpeptide thrombopoietin receptor ag","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"26","endOffset":"37","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[11]/div[2]/ul[1]/li[1]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[11]/div[2]/ul[1]/li[1]/a[1]","prefix":"Phase 1 clinical study of ","suffix":", an oral, nonpeptide thrombopoietin receptor agonist.","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"31","endOffset":"42","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[11]/div[2]/ul[1]/li[2]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[11]/div[2]/ul[1]/li[2]/a[1]","prefix":"Population pharmacokinetics of ","suffix":" in healthy subjects and patients with chronic idiopathic th","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"31","endOffset":"42","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[12]/div[2]/ul[1]/li[1]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[12]/div[2]/ul[1]/li[1]/a[1]","prefix":"Population pharmacokinetics of ","suffix":" in healthy subjects and patients with chronic idiopathic th","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"10","endOffset":"21","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[1]","prefix":"Effect of ","suffix":" on platelet counts and bleeding during treatment of chronic","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"24","endOffset":"35","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[3]","prefix":"Preclinical activity of ","suffix":" (SB-497115), an oral, nonpeptide thrombopoietin receptor ag","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"26","endOffset":"37","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[19]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[19]","prefix":"Phase 1 clinical study of ","suffix":", an oral, nonpeptide thrombopoietin receptor agonist.","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"31","endOffset":"42","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[20]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[20]","prefix":"Population pharmacokinetics of ","suffix":" in healthy subjects and patients with chronic idiopathic th","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"57","endOffset":"68","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[4]","prefix":"For the overall population, the geometric mean of plasma ","suffix":" ","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"20","endOffset":"31","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[6]","prefix":"Steady-state plasma ","suffix":" ","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"57","endOffset":"68","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[4]","prefix":"For the overall population, the geometric mean of plasma ","suffix":" ","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"18","endOffset":"29","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[4]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[4]/div[1]/div[2]/span[1]","prefix":"Summary of plasma ","suffix":" pharmacokinetics","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"37","endOffset":"48","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[8]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[8]","prefix":"The impact of rosuvastatin on plasma ","suffix":" PK was not formally assessed. However, eltrombopag trough c","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"88","endOffset":"99","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[8]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[8]","prefix":"n plasma eltrombopag PK was not formally assessed. However, ","suffix":" trough concentrations collected prior to co-administration ","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"306","endOffset":"317","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[8]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[8]","prefix":"ation of a single dose of rosuvastatin. In addition, plasma ","suffix":" exposure for the 75 mg once daily regimen (in combination w","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"454","endOffset":"465","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[8]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[8]","prefix":" of rosuvastatin) was generally as expected based on plasma ","suffix":" exposures observed in other eltrombopag studies [","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"494","endOffset":"505","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[8]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[8]","prefix":"ted based on plasma eltrombopag exposures observed in other ","suffix":" studies [","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"7","endOffset":"18","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[9]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[9]","prefix":"Plasma ","suffix":" exposures collected in the presence of rosuvastatin were si","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"218","endOffset":"229","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[9]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[9]","prefix":"tudies that have shown approximately two-fold higher plasma ","suffix":" exposures in Asian ","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"45","endOffset":"56","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[10]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[10]","prefix":"In conclusion, concomitant administration of ","suffix":" with rosuvastatin was associated with increased rosuvastati","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"209","endOffset":"220","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","prefix":"ductase inhibitors may be reduced by the concomitant use of ","suffix":". In subjects taking eltrombopag, a reduced dose of HMG Co-A","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"245","endOffset":"256","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/ul[1]/li[1]/div[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/ul[1]/li[1]/div[1]","prefix":"ductase inhibitors may be reduced by the concomitant use of ","suffix":". In subjects taking eltrombopag, a reduced dose of HMG Co-A","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"224","endOffset":"235","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[10]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[10]","prefix":"ductase inhibitors may be reduced by the concomitant use of ","suffix":". In subjects taking eltrombopag, a reduced dose of HMG Co-A","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"241","endOffset":"252","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","prefix":"d by the concomitant use of eltrombopag. In subjects taking ","suffix":", a reduced dose of HMG Co-A reductase inhibitors may be nee","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"277","endOffset":"288","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/ul[1]/li[1]/div[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/ul[1]/li[1]/div[1]","prefix":"d by the concomitant use of eltrombopag. In subjects taking ","suffix":", a reduced dose of HMG Co-A reductase inhibitors may be nee","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"eltrombopag","startOffset":"256","endOffset":"267","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[10]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[10]","prefix":"d by the concomitant use of eltrombopag. In subjects taking ","suffix":", a reduced dose of HMG Co-A reductase inhibitors may be nee","exact":"eltrombopag"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":"18","endOffset":"30","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":"Subjects received ","suffix":" and eltrombopag orally: day 1, rosuvastatin 10 mg single do","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":"62","endOffset":"74","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":"bjects received rosuvastatin and eltrombopag orally: day 1, ","suffix":" 10 mg single dose; days 6 to 9, eltrombopag 75 mg once dail","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":"178","endOffset":"190","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":" 75 mg once daily; day 10, eltrombopag 75 mg once daily and ","suffix":" 10 mg single dose. Adverse event assessments were performed","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":"38","endOffset":"50","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"Co-administration of eltrombopag with ","suffix":" increased geometric mean (90% confidence interval) plasma r","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":"109","endOffset":"121","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"n increased geometric mean (90% confidence interval) plasma ","suffix":" AUC(0,∞) by 55% (42%, 69%) and ","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":"80","endOffset":"92","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[7]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[7]","prefix":"s of eltrombopag on rosuvastatin PK, log transformed plasma ","suffix":" AUC(0,∞) and ","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":"63","endOffset":"75","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[8]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[8]","prefix":"tivariate analyses of the relationship between day 1 plasma ","suffix":" AUC(0,∞) and ","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":"68","endOffset":"80","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[2]","prefix":"istration of eltrombopag with rosuvastatin increased plasma ","suffix":" AUC(0,∞) by 55% and ","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":"377","endOffset":"389","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[3]","prefix":"ions regarding the relationship between genotype and plasma ","suffix":" exposure. Plasma rosuvastatin AUC(0,∞) ","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":"407","endOffset":"419","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[3]","prefix":"p between genotype and plasma rosuvastatin exposure. Plasma ","suffix":" AUC(0,∞) ","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":"47","endOffset":"59","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","prefix":"Concomitant administration of eltrombopag with ","suffix":" was associated with increased rosuvastatin exposure. The th","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":"90","endOffset":"102","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","prefix":"eltrombopag with rosuvastatin was associated with increased ","suffix":" exposure. The therapeutic index of HMG Co-A reductase inhib","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":"105","endOffset":"117","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[10]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[10]","prefix":"eltrombopag with rosuvastatin was associated with increased ","suffix":" exposure. The therapeutic index of HMG Co-A reductase inhib","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":"46","endOffset":"58","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","prefix":"BCRP, drug interaction, eltrombopag, OATP1B1, ","suffix":"","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":"43","endOffset":"55","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[1]/div[1]/ul[1]/li[1]/div[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[1]/div[1]/ul[1]/li[1]/div[1]","prefix":"OATP1B1 is important for hepatic uptake of ","suffix":" and BCRP is important for rosuvastatin absorption and elimi","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":"82","endOffset":"94","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[1]/div[1]/ul[1]/li[1]/div[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[1]/div[1]/ul[1]/li[1]/div[1]","prefix":"or hepatic uptake of rosuvastatin and BCRP is important for ","suffix":" absorption and elimination. Eltrombopag inhibits OATP1B1 an","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":"47","endOffset":"59","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/ul[1]/li[1]/div[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/ul[1]/li[1]/div[1]","prefix":"Concomitant administration of eltrombopag with ","suffix":" was associated with increased rosuvastatin exposure via inh","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":"90","endOffset":"102","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/ul[1]/li[1]/div[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/ul[1]/li[1]/div[1]","prefix":"eltrombopag with rosuvastatin was associated with increased ","suffix":" exposure via inhibition of drug transporters. The therapeut","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":"0","endOffset":"12","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[3]","prefix":"","suffix":" has known transporter-mediated drug interactions, such as i","exact":"Rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":"215","endOffset":"227","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","prefix":"jects provided written, informed consent. Subjects received ","suffix":" and eltrombopag orally in the following sequence: day 1, ro","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":"285","endOffset":"297","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","prefix":"in and eltrombopag orally in the following sequence: day 1, ","suffix":" 10 mg single dose; day 6 through day 9, eltrombopag 75 mg o","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":"409","endOffset":"421","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[1]","prefix":" 75 mg once daily; day 10, eltrombopag 75 mg once daily and ","suffix":" 10 mg single dose. This study was designed and monitored in","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":"438","endOffset":"450","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[4]","prefix":"6, 8, 12, 24, 36, 48, 60, 72, 84 and 96 h after single dose ","suffix":" administration on days 1 and 10. A blood sample was obtaine","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":"62","endOffset":"74","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[4]","prefix":"asma PK samples collected on days 1 and 10 were assayed for ","suffix":" using a validated analytical method based on solid phase ex","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":"330","endOffset":"342","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[4]","prefix":"liquot of plasma, the lower limit of quantification for the ","suffix":" assay was 0.2 ng ml","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":"40","endOffset":"52","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[7]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[7]","prefix":"To assess the effects of eltrombopag on ","suffix":" PK, log transformed plasma rosuvastatin AUC(0,∞) and ","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":"80","endOffset":"92","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[7]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[7]","prefix":"s of eltrombopag on rosuvastatin PK, log transformed plasma ","suffix":" AUC(0,∞) and ","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":"7","endOffset":"19","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[3]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[3]/div[1]/div[2]/span[1]","prefix":"Plasma ","suffix":" AUC(0,∞) by OATP1B1 (","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":"63","endOffset":"75","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[8]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[8]","prefix":"tivariate analyses of the relationship between day 1 plasma ","suffix":" AUC(0,∞) and ","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":"18","endOffset":"30","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[1]/div[1]/div[2]/span[1]","prefix":"Summary of plasma ","suffix":" pharmacokinetics and treatment comparisons","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":"38","endOffset":"50","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[2]","prefix":"Co-administration of eltrombopag with ","suffix":" increased plasma rosuvastatin AUC(0,∞) by 55% and ","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":"68","endOffset":"80","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[2]","prefix":"istration of eltrombopag with rosuvastatin increased plasma ","suffix":" AUC(0,∞) by 55% and ","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":"7","endOffset":"19","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[3]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[3]/div[1]/div[2]/span[1]","prefix":"Plasma ","suffix":" AUC(0,∞) by OATP1B1 (","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":"14","endOffset":"26","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[2]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[2]/div[1]/div[2]/span[1]","prefix":"Median plasma ","suffix":" concentration–time profiles. rosuvastain alone (no symbol =","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":"14","endOffset":"26","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[2]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[2]/div[1]/div[2]/span[1]","prefix":"Median plasma ","suffix":" concentration–time profiles. rosuvastain alone (no symbol =","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":"77","endOffset":"89","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[3]","prefix":"bined genotype scores (approach 3) of 2–3 had higher plasma ","suffix":" exposures than subjects with scores of 0–1, and there was a","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":"179","endOffset":"191","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[3]","prefix":"scores of 0–1, and there was also a trend for higher plasma ","suffix":" exposures for subjects in category 4 (approach 2). However,","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":"377","endOffset":"389","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[3]","prefix":"ions regarding the relationship between genotype and plasma ","suffix":" exposure. Plasma rosuvastatin AUC(0,∞) ","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":"407","endOffset":"419","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/p[3]","prefix":"p between genotype and plasma rosuvastatin exposure. Plasma ","suffix":" AUC(0,∞) ","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":"7","endOffset":"19","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[3]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[3]/div[1]/div[2]/span[1]","prefix":"Plasma ","suffix":" AUC(0,∞) by OATP1B1 (","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":"7","endOffset":"19","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[3]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[3]/div[1]/div[2]/span[1]","prefix":"Plasma ","suffix":" AUC(0,∞) by OATP1B1 (","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":"53","endOffset":"65","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","prefix":"Because it was known that Asian subjects have higher ","suffix":" exposures than non-Asian subjects [","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":"55","endOffset":"67","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","prefix":"The finding of statistically significant higher plasma ","suffix":" exposures in female subjects has not been reported in the l","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":"14","endOffset":"26","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[8]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[8]","prefix":"The impact of ","suffix":" on plasma eltrombopag PK was not formally assessed. However","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":"162","endOffset":"174","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[8]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[8]","prefix":"ough concentrations collected prior to co-administration of ","suffix":" were similar to trough concentrations collected 24 h after ","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":"272","endOffset":"284","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[8]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[8]","prefix":" collected 24 h after co-administration of a single dose of ","suffix":". In addition, plasma eltrombopag exposure for the 75 mg onc","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":"398","endOffset":"410","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[8]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[8]","prefix":"mg once daily regimen (in combination with a single dose of ","suffix":") was generally as expected based on plasma eltrombopag expo","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":"58","endOffset":"70","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[9]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[9]","prefix":"Plasma eltrombopag exposures collected in the presence of ","suffix":" were similar between Asian and non-Asian subjects. This is ","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":"62","endOffset":"74","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[10]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[10]","prefix":" conclusion, concomitant administration of eltrombopag with ","suffix":" was associated with increased rosuvastatin exposure. The th","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":"90","endOffset":"102","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","prefix":"eltrombopag with rosuvastatin was associated with increased ","suffix":" exposure. The therapeutic index of HMG Co-A reductase inhib","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"rosuvastatin","startOffset":"105","endOffset":"117","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[10]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[10]","prefix":"eltrombopag with rosuvastatin was associated with increased ","suffix":" exposure. The therapeutic index of HMG Co-A reductase inhib","exact":"rosuvastatin"},{"setid":"PMC3162661","drugname":"gemfibrozil","startOffset":"92","endOffset":"103","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[3]","prefix":"er-mediated drug interactions, such as its interaction with ","suffix":" and cyclosporin [","exact":"gemfibrozil"},{"setid":"PMC3162661","drugname":"cyclosporin","startOffset":"108","endOffset":"119","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[3]","prefix":" interactions, such as its interaction with gemfibrozil and ","suffix":" [","exact":"cyclosporin"}],[{"setid":"PMC1490169","drugname":"warfarin","startOffset":"45","endOffset":"53","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"Retrospective cohort study of patients using ","suffix":" who initiated an antibiotic (azithromycin, levofloxacin, or","exact":"warfarin"},{"setid":"PMC1490169","drugname":"warfarin","startOffset":"0","endOffset":"8","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","prefix":"","suffix":", overanticoagulation, drug interaction, azithromycin, levof","exact":"warfarin"},{"setid":"PMC1490169","drugname":"warfarin","startOffset":"16","endOffset":"24","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","prefix":"The benefits of ","suffix":" are well established but offset by the risk of major hemorr","exact":"warfarin"},{"setid":"PMC1490169","drugname":"warfarin","startOffset":"66","endOffset":"74","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","prefix":"ducted a retrospective cohort study of patients with stable ","suffix":" doses and INRs who received a prescription for terazosin, a","exact":"warfarin"},{"setid":"PMC1490169","drugname":"warfarin","startOffset":"373","endOffset":"381","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","prefix":"osen as our control because of its lack of interaction with ","suffix":".","exact":"warfarin"},{"setid":"PMC1490169","drugname":"warfarin","startOffset":"378","endOffset":"386","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"years old. There were no differences in the indications for ","suffix":" use (","exact":"warfarin"},{"setid":"PMC1490169","drugname":"warfarin","startOffset":"54","endOffset":"62","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"A graded increase in both the incidence and degree of ","suffix":" interaction from terazosin to azithromycin to levofloxacin ","exact":"warfarin"},{"setid":"PMC1490169","drugname":"warfarin","startOffset":"142","endOffset":"150","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","prefix":"azithromycin, levofloxacin, or TMP/SMX was added to chronic ","suffix":" therapy in patients who were acutely ill. Prior studies are","exact":"warfarin"},{"setid":"PMC1490169","drugname":"warfarin","startOffset":"60","endOffset":"68","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","prefix":"It is well known that sulfa-based antibiotics interact with ","suffix":", but the incidence has not been adequately studied.","exact":"warfarin"},{"setid":"PMC1490169","drugname":"warfarin","startOffset":"87","endOffset":"95","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","prefix":"gths. We eliminated patients who did not have both a stable ","suffix":" dose and a stable level of anticoagulant intensity and limi","exact":"warfarin"},{"setid":"PMC1490169","drugname":"warfarin","startOffset":"957","endOffset":"965","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","prefix":"ty to our findings. Terazosin is known not to interact with ","suffix":", while TMP/SMX has a well-described interaction.","exact":"warfarin"},{"setid":"PMC1490169","drugname":"azithromycin","startOffset":"83","endOffset":"95","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"udy of patients using warfarin who initiated an antibiotic (","suffix":", levofloxacin, or trimethoprim/sulfamethoxazole (TMP/SMX)) ","exact":"azithromycin"},{"setid":"PMC1490169","drugname":"azithromycin","startOffset":"57","endOffset":"69","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[5]/p[1]","prefix":"The mean change in INR was −0.15 for terazosin, 0.51 for ","suffix":", 0.85 for levofloxacin, and 1.76 for TMP/SMX. These mean IN","exact":"azithromycin"},{"setid":"PMC1490169","drugname":"azithromycin","startOffset":"291","endOffset":"303","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[5]/p[1]","prefix":"dence of supratherapeutic INR was 5% for terazosin, 31% for ","suffix":", 33% for levofloxacin, and 69% for TMP/SMX. The incidence o","exact":"azithromycin"},{"setid":"PMC1490169","drugname":"azithromycin","startOffset":"413","endOffset":"425","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[5]/p[1]","prefix":"ncidence of absolute INR >4.0 was 0% for terazosin, 16% for ","suffix":", 19% for levofloxacin, and 44% for TMP/SMX.","exact":"azithromycin"},{"setid":"PMC1490169","drugname":"azithromycin","startOffset":"49","endOffset":"61","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[6]/p[1]","prefix":"Among acutely ill outpatients, oral antibiotics (","suffix":", levofloxacin, and TMP/SMX) increase the incidence and degr","exact":"azithromycin"},{"setid":"PMC1490169","drugname":"azithromycin","startOffset":"258","endOffset":"270","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"MX in 120 patients. Initially 43, 35, 41, and 24 terazosin, ","suffix":", levofloxacin, and TMP/SMX patients, respectively, were inc","exact":"azithromycin"},{"setid":"PMC1490169","drugname":"azithromycin","startOffset":"63","endOffset":"75","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[9]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[9]/p[1]","prefix":"ng acutely ill outpatients, the use of the oral antibiotics ","suffix":", levofloxacin, and TMP/SMX increases both the incidence and","exact":"azithromycin"},{"setid":"PMC1490169","drugname":"azithromycin","startOffset":"49","endOffset":"61","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","prefix":"warfarin, overanticoagulation, drug interaction, ","suffix":", levofloxacin, trimethoprim/sulfamethoxazole","exact":"azithromycin"},{"setid":"PMC1490169","drugname":"azithromycin","startOffset":"133","endOffset":"145","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","prefix":"n doses and INRs who received a prescription for terazosin, ","suffix":", levofloxacin, or TMP/SMX for clinical indications between ","exact":"azithromycin"},{"setid":"PMC1490169","drugname":"azithromycin","startOffset":"85","endOffset":"97","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"ptions for terazosin in 333 patients, 273 prescriptions for ","suffix":" in 158 patients, 370 prescriptions for levofloxacin in 258 ","exact":"azithromycin"},{"setid":"PMC1490169","drugname":"azithromycin","startOffset":"258","endOffset":"270","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"MX in 120 patients. Initially 43, 35, 41, and 24 terazosin, ","suffix":", levofloxacin, and TMP/SMX patients, respectively, were inc","exact":"azithromycin"},{"setid":"PMC1490169","drugname":"azithromycin","startOffset":"665","endOffset":"677","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":" patients had INRs drawn between days 15 and 30. Thirty-two ","suffix":", 27 levofloxacin, and 16 TMP/SMX patients were included in ","exact":"azithromycin"},{"setid":"PMC1490169","drugname":"azithromycin","startOffset":"83","endOffset":"95","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"udy of patients using warfarin who initiated an antibiotic (","suffix":", levofloxacin, or trimethoprim/sulfamethoxazole (TMP/SMX)) ","exact":"azithromycin"},{"setid":"PMC1490169","drugname":"azithromycin","startOffset":"57","endOffset":"69","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[5]/p[1]","prefix":"The mean change in INR was −0.15 for terazosin, 0.51 for ","suffix":", 0.85 for levofloxacin, and 1.76 for TMP/SMX. These mean IN","exact":"azithromycin"},{"setid":"PMC1490169","drugname":"azithromycin","startOffset":"291","endOffset":"303","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[5]/p[1]","prefix":"dence of supratherapeutic INR was 5% for terazosin, 31% for ","suffix":", 33% for levofloxacin, and 69% for TMP/SMX. The incidence o","exact":"azithromycin"},{"setid":"PMC1490169","drugname":"azithromycin","startOffset":"413","endOffset":"425","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[5]/p[1]","prefix":"ncidence of absolute INR >4.0 was 0% for terazosin, 16% for ","suffix":", 19% for levofloxacin, and 44% for TMP/SMX.","exact":"azithromycin"},{"setid":"PMC1490169","drugname":"azithromycin","startOffset":"49","endOffset":"61","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[6]/p[1]","prefix":"Among acutely ill outpatients, oral antibiotics (","suffix":", levofloxacin, and TMP/SMX) increase the incidence and degr","exact":"azithromycin"},{"setid":"PMC1490169","drugname":"azithromycin","startOffset":"49","endOffset":"61","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","prefix":"warfarin, overanticoagulation, drug interaction, ","suffix":", levofloxacin, trimethoprim/sulfamethoxazole","exact":"azithromycin"},{"setid":"PMC1490169","drugname":"azithromycin","startOffset":"133","endOffset":"145","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","prefix":"n doses and INRs who received a prescription for terazosin, ","suffix":", levofloxacin, or TMP/SMX for clinical indications between ","exact":"azithromycin"},{"setid":"PMC1490169","drugname":"azithromycin","startOffset":"85","endOffset":"97","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"ptions for terazosin in 333 patients, 273 prescriptions for ","suffix":" in 158 patients, 370 prescriptions for levofloxacin in 258 ","exact":"azithromycin"},{"setid":"PMC1490169","drugname":"azithromycin","startOffset":"258","endOffset":"270","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"MX in 120 patients. Initially 43, 35, 41, and 24 terazosin, ","suffix":", levofloxacin, and TMP/SMX patients, respectively, were inc","exact":"azithromycin"},{"setid":"PMC1490169","drugname":"azithromycin","startOffset":"665","endOffset":"677","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":" patients had INRs drawn between days 15 and 30. Thirty-two ","suffix":", 27 levofloxacin, and 16 TMP/SMX patients were included in ","exact":"azithromycin"},{"setid":"PMC1490169","drugname":"azithromycin","startOffset":"188","endOffset":"200","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"ysis. The median time to follow-up was 17.5 (terazosin), 7 (","suffix":"), 6 (levofloxacin), and 6 (TMP/SMX) days. Men constituted 9","exact":"azithromycin"},{"setid":"PMC1490169","drugname":"azithromycin","startOffset":"93","endOffset":"105","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"idence and degree of warfarin interaction from terazosin to ","suffix":" to levofloxacin to TMP/SMX was found (","exact":"azithromycin"},{"setid":"PMC1490169","drugname":"azithromycin","startOffset":"82","endOffset":"94","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","prefix":"icant increase in the incidence of overanticoagulation when ","suffix":", levofloxacin, or TMP/SMX was added to chronic warfarin the","exact":"azithromycin"},{"setid":"PMC1490169","drugname":"azithromycin","startOffset":"100","endOffset":"112","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","prefix":"d no significant differences in INR after the initiation of ","suffix":" for clinical indications compared with terazosin","exact":"azithromycin"},{"setid":"PMC1490169","drugname":"azithromycin","startOffset":"656","endOffset":"668","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","prefix":"ease. Chronic renal disease was seen more frequently in the ","suffix":" and levofloxacin groups than the TMP/SMX and terazosin grou","exact":"azithromycin"},{"setid":"PMC1490169","drugname":"azithromycin","startOffset":"63","endOffset":"75","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[9]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[9]/p[1]","prefix":"ng acutely ill outpatients, the use of the oral antibiotics ","suffix":", levofloxacin, and TMP/SMX increases both the incidence and","exact":"azithromycin"},{"setid":"PMC1490169","drugname":"azithromycin","startOffset":"89","endOffset":"101","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[11]/div[2]/div[9]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[11]/div[2]/div[9]/span[1]","prefix":"Retrospective evaluation of a potential interaction between ","suffix":" and warfarin in patients stabilized on warfarin. ","exact":"azithromycin"},{"setid":"PMC1490169","drugname":"azithromycin","startOffset":"90","endOffset":"102","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[11]/div[2]/div[11]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[11]/div[2]/div[11]/span[1]","prefix":"AD. Determination of the lack of a drug interaction between ","suffix":" and warfarin. ","exact":"azithromycin"},{"setid":"PMC1490169","drugname":"azithromycin","startOffset":"60","endOffset":"72","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[2]/div[2]/div[1]/ul[1]/li[2]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[2]/div[2]/div[1]/ul[1]/li[2]/a[1]","prefix":"Retrospective evaluation of a potential interaction between ","suffix":"e and warfarin in patients stabilized on warfarin.","exact":"azithromycin"},{"setid":"PMC1490169","drugname":"azithromycin","startOffset":"10","endOffset":"22","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[2]/div[2]/div[1]/ul[1]/li[4]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[2]/div[2]/div[1]/ul[1]/li[4]/a[1]","prefix":"Effect of ","suffix":" on anticoagulation-related outcomes in geriatric patients r","exact":"azithromycin"},{"setid":"PMC1490169","drugname":"azithromycin","startOffset":"60","endOffset":"72","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[2]/div[2]/ul[1]/li[1]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[2]/div[2]/ul[1]/li[1]/a[1]","prefix":"Retrospective evaluation of a potential interaction between ","suffix":"e and warfarin in patients stabilized on warfarin.","exact":"azithromycin"},{"setid":"PMC1490169","drugname":"azithromycin","startOffset":"60","endOffset":"72","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[3]/div[2]/ul[1]/li[1]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[3]/div[2]/ul[1]/li[1]/a[1]","prefix":"Retrospective evaluation of a potential interaction between ","suffix":"e and warfarin in patients stabilized on warfarin.","exact":"azithromycin"},{"setid":"PMC1490169","drugname":"azithromycin","startOffset":"56","endOffset":"68","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[3]/div[2]/ul[1]/li[2]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[3]/div[2]/ul[1]/li[2]/a[1]","prefix":"Determination of the lack of a drug interaction between ","suffix":" and warfarin.","exact":"azithromycin"},{"setid":"PMC1490169","drugname":"azithromycin","startOffset":"60","endOffset":"72","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[6]/div[2]/ul[1]/li[2]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[6]/div[2]/ul[1]/li[2]/a[1]","prefix":"Retrospective evaluation of a potential interaction between ","suffix":"e and warfarin in patients stabilized on warfarin.","exact":"azithromycin"},{"setid":"PMC1490169","drugname":"azithromycin","startOffset":"60","endOffset":"72","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]","prefix":"Retrospective evaluation of a potential interaction between ","suffix":"e and warfarin in patients stabilized on warfarin.","exact":"azithromycin"},{"setid":"PMC1490169","drugname":"azithromycin","startOffset":"56","endOffset":"68","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[8]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[8]","prefix":"Determination of the lack of a drug interaction between ","suffix":" and warfarin.","exact":"azithromycin"},{"setid":"PMC1490169","drugname":"azithromycin","startOffset":"93","endOffset":"105","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"idence and degree of warfarin interaction from terazosin to ","suffix":" to levofloxacin to TMP/SMX was found (","exact":"azithromycin"},{"setid":"PMC1490169","drugname":"azithromycin","startOffset":"83","endOffset":"95","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"udy of patients using warfarin who initiated an antibiotic (","suffix":", levofloxacin, or trimethoprim/sulfamethoxazole (TMP/SMX)) ","exact":"azithromycin"},{"setid":"PMC1490169","drugname":"azithromycin","startOffset":"57","endOffset":"69","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[5]/p[1]","prefix":"The mean change in INR was −0.15 for terazosin, 0.51 for ","suffix":", 0.85 for levofloxacin, and 1.76 for TMP/SMX. These mean IN","exact":"azithromycin"},{"setid":"PMC1490169","drugname":"azithromycin","startOffset":"291","endOffset":"303","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[5]/p[1]","prefix":"dence of supratherapeutic INR was 5% for terazosin, 31% for ","suffix":", 33% for levofloxacin, and 69% for TMP/SMX. The incidence o","exact":"azithromycin"},{"setid":"PMC1490169","drugname":"azithromycin","startOffset":"413","endOffset":"425","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[5]/p[1]","prefix":"ncidence of absolute INR >4.0 was 0% for terazosin, 16% for ","suffix":", 19% for levofloxacin, and 44% for TMP/SMX.","exact":"azithromycin"},{"setid":"PMC1490169","drugname":"azithromycin","startOffset":"49","endOffset":"61","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[6]/p[1]","prefix":"Among acutely ill outpatients, oral antibiotics (","suffix":", levofloxacin, and TMP/SMX) increase the incidence and degr","exact":"azithromycin"},{"setid":"PMC1490169","drugname":"azithromycin","startOffset":"49","endOffset":"61","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","prefix":"warfarin, overanticoagulation, drug interaction, ","suffix":", levofloxacin, trimethoprim/sulfamethoxazole","exact":"azithromycin"},{"setid":"PMC1490169","drugname":"azithromycin","startOffset":"133","endOffset":"145","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","prefix":"n doses and INRs who received a prescription for terazosin, ","suffix":", levofloxacin, or TMP/SMX for clinical indications between ","exact":"azithromycin"},{"setid":"PMC1490169","drugname":"azithromycin","startOffset":"85","endOffset":"97","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"ptions for terazosin in 333 patients, 273 prescriptions for ","suffix":" in 158 patients, 370 prescriptions for levofloxacin in 258 ","exact":"azithromycin"},{"setid":"PMC1490169","drugname":"azithromycin","startOffset":"258","endOffset":"270","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"MX in 120 patients. Initially 43, 35, 41, and 24 terazosin, ","suffix":", levofloxacin, and TMP/SMX patients, respectively, were inc","exact":"azithromycin"},{"setid":"PMC1490169","drugname":"azithromycin","startOffset":"665","endOffset":"677","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":" patients had INRs drawn between days 15 and 30. Thirty-two ","suffix":", 27 levofloxacin, and 16 TMP/SMX patients were included in ","exact":"azithromycin"},{"setid":"PMC1490169","drugname":"azithromycin","startOffset":"188","endOffset":"200","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"ysis. The median time to follow-up was 17.5 (terazosin), 7 (","suffix":"), 6 (levofloxacin), and 6 (TMP/SMX) days. Men constituted 9","exact":"azithromycin"},{"setid":"PMC1490169","drugname":"azithromycin","startOffset":"93","endOffset":"105","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"idence and degree of warfarin interaction from terazosin to ","suffix":" to levofloxacin to TMP/SMX was found (","exact":"azithromycin"},{"setid":"PMC1490169","drugname":"azithromycin","startOffset":"82","endOffset":"94","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","prefix":"icant increase in the incidence of overanticoagulation when ","suffix":", levofloxacin, or TMP/SMX was added to chronic warfarin the","exact":"azithromycin"},{"setid":"PMC1490169","drugname":"azithromycin","startOffset":"100","endOffset":"112","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","prefix":"d no significant differences in INR after the initiation of ","suffix":" for clinical indications compared with terazosin","exact":"azithromycin"},{"setid":"PMC1490169","drugname":"azithromycin","startOffset":"656","endOffset":"668","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","prefix":"ease. Chronic renal disease was seen more frequently in the ","suffix":" and levofloxacin groups than the TMP/SMX and terazosin grou","exact":"azithromycin"},{"setid":"PMC1490169","drugname":"azithromycin","startOffset":"63","endOffset":"75","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[9]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[9]/p[1]","prefix":"ng acutely ill outpatients, the use of the oral antibiotics ","suffix":", levofloxacin, and TMP/SMX increases both the incidence and","exact":"azithromycin"},{"setid":"PMC1490169","drugname":"azithromycin","startOffset":"89","endOffset":"101","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[11]/div[2]/div[9]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[11]/div[2]/div[9]/span[1]","prefix":"Retrospective evaluation of a potential interaction between ","suffix":" and warfarin in patients stabilized on warfarin. ","exact":"azithromycin"},{"setid":"PMC1490169","drugname":"azithromycin","startOffset":"90","endOffset":"102","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[11]/div[2]/div[11]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[11]/div[2]/div[11]/span[1]","prefix":"AD. Determination of the lack of a drug interaction between ","suffix":" and warfarin. ","exact":"azithromycin"},{"setid":"PMC1490169","drugname":"azithromycin","startOffset":"60","endOffset":"72","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[2]/div[2]/div[1]/ul[1]/li[2]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[2]/div[2]/div[1]/ul[1]/li[2]/a[1]","prefix":"Retrospective evaluation of a potential interaction between ","suffix":"e and warfarin in patients stabilized on warfarin.","exact":"azithromycin"},{"setid":"PMC1490169","drugname":"azithromycin","startOffset":"10","endOffset":"22","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[2]/div[2]/div[1]/ul[1]/li[4]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[2]/div[2]/div[1]/ul[1]/li[4]/a[1]","prefix":"Effect of ","suffix":" on anticoagulation-related outcomes in geriatric patients r","exact":"azithromycin"},{"setid":"PMC1490169","drugname":"azithromycin","startOffset":"60","endOffset":"72","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[2]/div[2]/ul[1]/li[1]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[2]/div[2]/ul[1]/li[1]/a[1]","prefix":"Retrospective evaluation of a potential interaction between ","suffix":"e and warfarin in patients stabilized on warfarin.","exact":"azithromycin"},{"setid":"PMC1490169","drugname":"azithromycin","startOffset":"60","endOffset":"72","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[3]/div[2]/ul[1]/li[1]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[3]/div[2]/ul[1]/li[1]/a[1]","prefix":"Retrospective evaluation of a potential interaction between ","suffix":"e and warfarin in patients stabilized on warfarin.","exact":"azithromycin"},{"setid":"PMC1490169","drugname":"azithromycin","startOffset":"56","endOffset":"68","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[3]/div[2]/ul[1]/li[2]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[3]/div[2]/ul[1]/li[2]/a[1]","prefix":"Determination of the lack of a drug interaction between ","suffix":" and warfarin.","exact":"azithromycin"},{"setid":"PMC1490169","drugname":"azithromycin","startOffset":"60","endOffset":"72","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[6]/div[2]/ul[1]/li[2]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[6]/div[2]/ul[1]/li[2]/a[1]","prefix":"Retrospective evaluation of a potential interaction between ","suffix":"e and warfarin in patients stabilized on warfarin.","exact":"azithromycin"},{"setid":"PMC1490169","drugname":"azithromycin","startOffset":"60","endOffset":"72","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]","prefix":"Retrospective evaluation of a potential interaction between ","suffix":"e and warfarin in patients stabilized on warfarin.","exact":"azithromycin"},{"setid":"PMC1490169","drugname":"azithromycin","startOffset":"56","endOffset":"68","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[8]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[8]","prefix":"Determination of the lack of a drug interaction between ","suffix":" and warfarin.","exact":"azithromycin"},{"setid":"PMC1490169","drugname":"azithromycin","startOffset":"83","endOffset":"95","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"udy of patients using warfarin who initiated an antibiotic (","suffix":", levofloxacin, or trimethoprim/sulfamethoxazole (TMP/SMX)) ","exact":"azithromycin"},{"setid":"PMC1490169","drugname":"azithromycin","startOffset":"57","endOffset":"69","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[5]/p[1]","prefix":"The mean change in INR was −0.15 for terazosin, 0.51 for ","suffix":", 0.85 for levofloxacin, and 1.76 for TMP/SMX. These mean IN","exact":"azithromycin"},{"setid":"PMC1490169","drugname":"azithromycin","startOffset":"291","endOffset":"303","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[5]/p[1]","prefix":"dence of supratherapeutic INR was 5% for terazosin, 31% for ","suffix":", 33% for levofloxacin, and 69% for TMP/SMX. The incidence o","exact":"azithromycin"},{"setid":"PMC1490169","drugname":"azithromycin","startOffset":"413","endOffset":"425","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[5]/p[1]","prefix":"ncidence of absolute INR >4.0 was 0% for terazosin, 16% for ","suffix":", 19% for levofloxacin, and 44% for TMP/SMX.","exact":"azithromycin"},{"setid":"PMC1490169","drugname":"azithromycin","startOffset":"49","endOffset":"61","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[6]/p[1]","prefix":"Among acutely ill outpatients, oral antibiotics (","suffix":", levofloxacin, and TMP/SMX) increase the incidence and degr","exact":"azithromycin"},{"setid":"PMC1490169","drugname":"azithromycin","startOffset":"49","endOffset":"61","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","prefix":"warfarin, overanticoagulation, drug interaction, ","suffix":", levofloxacin, trimethoprim/sulfamethoxazole","exact":"azithromycin"},{"setid":"PMC1490169","drugname":"azithromycin","startOffset":"133","endOffset":"145","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","prefix":"n doses and INRs who received a prescription for terazosin, ","suffix":", levofloxacin, or TMP/SMX for clinical indications between ","exact":"azithromycin"},{"setid":"PMC1490169","drugname":"azithromycin","startOffset":"85","endOffset":"97","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"ptions for terazosin in 333 patients, 273 prescriptions for ","suffix":" in 158 patients, 370 prescriptions for levofloxacin in 258 ","exact":"azithromycin"},{"setid":"PMC1490169","drugname":"azithromycin","startOffset":"258","endOffset":"270","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"MX in 120 patients. Initially 43, 35, 41, and 24 terazosin, ","suffix":", levofloxacin, and TMP/SMX patients, respectively, were inc","exact":"azithromycin"},{"setid":"PMC1490169","drugname":"azithromycin","startOffset":"665","endOffset":"677","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":" patients had INRs drawn between days 15 and 30. Thirty-two ","suffix":", 27 levofloxacin, and 16 TMP/SMX patients were included in ","exact":"azithromycin"},{"setid":"PMC1490169","drugname":"azithromycin","startOffset":"188","endOffset":"200","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"ysis. The median time to follow-up was 17.5 (terazosin), 7 (","suffix":"), 6 (levofloxacin), and 6 (TMP/SMX) days. Men constituted 9","exact":"azithromycin"},{"setid":"PMC1490169","drugname":"azithromycin","startOffset":"93","endOffset":"105","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"idence and degree of warfarin interaction from terazosin to ","suffix":" to levofloxacin to TMP/SMX was found (","exact":"azithromycin"},{"setid":"PMC1490169","drugname":"azithromycin","startOffset":"82","endOffset":"94","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","prefix":"icant increase in the incidence of overanticoagulation when ","suffix":", levofloxacin, or TMP/SMX was added to chronic warfarin the","exact":"azithromycin"},{"setid":"PMC1490169","drugname":"azithromycin","startOffset":"100","endOffset":"112","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","prefix":"d no significant differences in INR after the initiation of ","suffix":" for clinical indications compared with terazosin","exact":"azithromycin"},{"setid":"PMC1490169","drugname":"azithromycin","startOffset":"656","endOffset":"668","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","prefix":"ease. Chronic renal disease was seen more frequently in the ","suffix":" and levofloxacin groups than the TMP/SMX and terazosin grou","exact":"azithromycin"},{"setid":"PMC1490169","drugname":"azithromycin","startOffset":"63","endOffset":"75","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[9]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[9]/p[1]","prefix":"ng acutely ill outpatients, the use of the oral antibiotics ","suffix":", levofloxacin, and TMP/SMX increases both the incidence and","exact":"azithromycin"},{"setid":"PMC1490169","drugname":"azithromycin","startOffset":"89","endOffset":"101","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[11]/div[2]/div[9]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[11]/div[2]/div[9]/span[1]","prefix":"Retrospective evaluation of a potential interaction between ","suffix":" and warfarin in patients stabilized on warfarin. ","exact":"azithromycin"},{"setid":"PMC1490169","drugname":"azithromycin","startOffset":"90","endOffset":"102","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[11]/div[2]/div[11]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[11]/div[2]/div[11]/span[1]","prefix":"AD. Determination of the lack of a drug interaction between ","suffix":" and warfarin. ","exact":"azithromycin"},{"setid":"PMC1490169","drugname":"azithromycin","startOffset":"60","endOffset":"72","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[2]/div[2]/div[1]/ul[1]/li[2]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[2]/div[2]/div[1]/ul[1]/li[2]/a[1]","prefix":"Retrospective evaluation of a potential interaction between ","suffix":"e and warfarin in patients stabilized on warfarin.","exact":"azithromycin"},{"setid":"PMC1490169","drugname":"azithromycin","startOffset":"10","endOffset":"22","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[2]/div[2]/div[1]/ul[1]/li[4]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[2]/div[2]/div[1]/ul[1]/li[4]/a[1]","prefix":"Effect of ","suffix":" on anticoagulation-related outcomes in geriatric patients r","exact":"azithromycin"},{"setid":"PMC1490169","drugname":"azithromycin","startOffset":"60","endOffset":"72","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[2]/div[2]/ul[1]/li[1]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[2]/div[2]/ul[1]/li[1]/a[1]","prefix":"Retrospective evaluation of a potential interaction between ","suffix":"e and warfarin in patients stabilized on warfarin.","exact":"azithromycin"},{"setid":"PMC1490169","drugname":"azithromycin","startOffset":"60","endOffset":"72","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[3]/div[2]/ul[1]/li[1]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[3]/div[2]/ul[1]/li[1]/a[1]","prefix":"Retrospective evaluation of a potential interaction between ","suffix":"e and warfarin in patients stabilized on warfarin.","exact":"azithromycin"},{"setid":"PMC1490169","drugname":"azithromycin","startOffset":"56","endOffset":"68","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[3]/div[2]/ul[1]/li[2]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[3]/div[2]/ul[1]/li[2]/a[1]","prefix":"Determination of the lack of a drug interaction between ","suffix":" and warfarin.","exact":"azithromycin"},{"setid":"PMC1490169","drugname":"azithromycin","startOffset":"60","endOffset":"72","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[6]/div[2]/ul[1]/li[2]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[6]/div[2]/ul[1]/li[2]/a[1]","prefix":"Retrospective evaluation of a potential interaction between ","suffix":"e and warfarin in patients stabilized on warfarin.","exact":"azithromycin"},{"setid":"PMC1490169","drugname":"azithromycin","startOffset":"60","endOffset":"72","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]","prefix":"Retrospective evaluation of a potential interaction between ","suffix":"e and warfarin in patients stabilized on warfarin.","exact":"azithromycin"},{"setid":"PMC1490169","drugname":"azithromycin","startOffset":"56","endOffset":"68","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[8]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[8]","prefix":"Determination of the lack of a drug interaction between ","suffix":" and warfarin.","exact":"azithromycin"},{"setid":"PMC1490169","drugname":"azithromycin","startOffset":"82","endOffset":"94","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","prefix":"icant increase in the incidence of overanticoagulation when ","suffix":", levofloxacin, or TMP/SMX was added to chronic warfarin the","exact":"azithromycin"},{"setid":"PMC1490169","drugname":"azithromycin","startOffset":"100","endOffset":"112","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","prefix":"d no significant differences in INR after the initiation of ","suffix":" for clinical indications compared with terazosin","exact":"azithromycin"},{"setid":"PMC1490169","drugname":"azithromycin","startOffset":"656","endOffset":"668","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","prefix":"ease. Chronic renal disease was seen more frequently in the ","suffix":" and levofloxacin groups than the TMP/SMX and terazosin grou","exact":"azithromycin"},{"setid":"PMC1490169","drugname":"azithromycin","startOffset":"63","endOffset":"75","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[9]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[9]/p[1]","prefix":"ng acutely ill outpatients, the use of the oral antibiotics ","suffix":", levofloxacin, and TMP/SMX increases both the incidence and","exact":"azithromycin"},{"setid":"PMC1490169","drugname":"levofloxacin","startOffset":"97","endOffset":"109","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"s using warfarin who initiated an antibiotic (azithromycin, ","suffix":", or trimethoprim/sulfamethoxazole (TMP/SMX)) or terazosin f","exact":"levofloxacin"},{"setid":"PMC1490169","drugname":"levofloxacin","startOffset":"80","endOffset":"92","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[5]/p[1]","prefix":"NR was −0.15 for terazosin, 0.51 for azithromycin, 0.85 for ","suffix":", and 1.76 for TMP/SMX. These mean INR changes in the antibi","exact":"levofloxacin"},{"setid":"PMC1490169","drugname":"levofloxacin","startOffset":"313","endOffset":"325","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[5]/p[1]","prefix":"tic INR was 5% for terazosin, 31% for azithromycin, 33% for ","suffix":", and 69% for TMP/SMX. The incidence of absolute INR >4.0 wa","exact":"levofloxacin"},{"setid":"PMC1490169","drugname":"levofloxacin","startOffset":"435","endOffset":"447","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[5]/p[1]","prefix":"NR >4.0 was 0% for terazosin, 16% for azithromycin, 19% for ","suffix":", and 44% for TMP/SMX.","exact":"levofloxacin"},{"setid":"PMC1490169","drugname":"levofloxacin","startOffset":"63","endOffset":"75","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[6]/p[1]","prefix":"ng acutely ill outpatients, oral antibiotics (azithromycin, ","suffix":", and TMP/SMX) increase the incidence and degree of overanti","exact":"levofloxacin"},{"setid":"PMC1490169","drugname":"levofloxacin","startOffset":"272","endOffset":"284","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"ents. Initially 43, 35, 41, and 24 terazosin, azithromycin, ","suffix":", and TMP/SMX patients, respectively, were included and brou","exact":"levofloxacin"},{"setid":"PMC1490169","drugname":"levofloxacin","startOffset":"77","endOffset":"89","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[9]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[9]/p[1]","prefix":" outpatients, the use of the oral antibiotics azithromycin, ","suffix":", and TMP/SMX increases both the incidence and degree of ove","exact":"levofloxacin"},{"setid":"PMC1490169","drugname":"levofloxacin","startOffset":"63","endOffset":"75","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","prefix":"farin, overanticoagulation, drug interaction, azithromycin, ","suffix":", trimethoprim/sulfamethoxazole","exact":"levofloxacin"},{"setid":"PMC1490169","drugname":"levofloxacin","startOffset":"147","endOffset":"159","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","prefix":"Rs who received a prescription for terazosin, azithromycin, ","suffix":", or TMP/SMX for clinical indications between January 1998 a","exact":"levofloxacin"},{"setid":"PMC1490169","drugname":"levofloxacin","startOffset":"137","endOffset":"149","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"ons for azithromycin in 158 patients, 370 prescriptions for ","suffix":" in 258 patients, and 151 prescriptions for TMP/SMX in 120 p","exact":"levofloxacin"},{"setid":"PMC1490169","drugname":"levofloxacin","startOffset":"272","endOffset":"284","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"ents. Initially 43, 35, 41, and 24 terazosin, azithromycin, ","suffix":", and TMP/SMX patients, respectively, were included and brou","exact":"levofloxacin"},{"setid":"PMC1490169","drugname":"levofloxacin","startOffset":"682","endOffset":"694","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"s drawn between days 15 and 30. Thirty-two azithromycin, 27 ","suffix":", and 16 TMP/SMX patients were included in the trial (","exact":"levofloxacin"},{"setid":"PMC1490169","drugname":"levofloxacin","startOffset":"97","endOffset":"109","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"s using warfarin who initiated an antibiotic (azithromycin, ","suffix":", or trimethoprim/sulfamethoxazole (TMP/SMX)) or terazosin f","exact":"levofloxacin"},{"setid":"PMC1490169","drugname":"levofloxacin","startOffset":"80","endOffset":"92","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[5]/p[1]","prefix":"NR was −0.15 for terazosin, 0.51 for azithromycin, 0.85 for ","suffix":", and 1.76 for TMP/SMX. These mean INR changes in the antibi","exact":"levofloxacin"},{"setid":"PMC1490169","drugname":"levofloxacin","startOffset":"313","endOffset":"325","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[5]/p[1]","prefix":"tic INR was 5% for terazosin, 31% for azithromycin, 33% for ","suffix":", and 69% for TMP/SMX. The incidence of absolute INR >4.0 wa","exact":"levofloxacin"},{"setid":"PMC1490169","drugname":"levofloxacin","startOffset":"435","endOffset":"447","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[5]/p[1]","prefix":"NR >4.0 was 0% for terazosin, 16% for azithromycin, 19% for ","suffix":", and 44% for TMP/SMX.","exact":"levofloxacin"},{"setid":"PMC1490169","drugname":"levofloxacin","startOffset":"63","endOffset":"75","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[6]/p[1]","prefix":"ng acutely ill outpatients, oral antibiotics (azithromycin, ","suffix":", and TMP/SMX) increase the incidence and degree of overanti","exact":"levofloxacin"},{"setid":"PMC1490169","drugname":"levofloxacin","startOffset":"63","endOffset":"75","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","prefix":"farin, overanticoagulation, drug interaction, azithromycin, ","suffix":", trimethoprim/sulfamethoxazole","exact":"levofloxacin"},{"setid":"PMC1490169","drugname":"levofloxacin","startOffset":"147","endOffset":"159","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","prefix":"Rs who received a prescription for terazosin, azithromycin, ","suffix":", or TMP/SMX for clinical indications between January 1998 a","exact":"levofloxacin"},{"setid":"PMC1490169","drugname":"levofloxacin","startOffset":"137","endOffset":"149","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"ons for azithromycin in 158 patients, 370 prescriptions for ","suffix":" in 258 patients, and 151 prescriptions for TMP/SMX in 120 p","exact":"levofloxacin"},{"setid":"PMC1490169","drugname":"levofloxacin","startOffset":"272","endOffset":"284","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"ents. Initially 43, 35, 41, and 24 terazosin, azithromycin, ","suffix":", and TMP/SMX patients, respectively, were included and brou","exact":"levofloxacin"},{"setid":"PMC1490169","drugname":"levofloxacin","startOffset":"682","endOffset":"694","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"s drawn between days 15 and 30. Thirty-two azithromycin, 27 ","suffix":", and 16 TMP/SMX patients were included in the trial (","exact":"levofloxacin"},{"setid":"PMC1490169","drugname":"levofloxacin","startOffset":"206","endOffset":"218","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"ime to follow-up was 17.5 (terazosin), 7 (azithromycin), 6 (","suffix":"), and 6 (TMP/SMX) days. Men constituted 97% of all patients","exact":"levofloxacin"},{"setid":"PMC1490169","drugname":"levofloxacin","startOffset":"109","endOffset":"121","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"e of warfarin interaction from terazosin to azithromycin to ","suffix":" to TMP/SMX was found (","exact":"levofloxacin"},{"setid":"PMC1490169","drugname":"levofloxacin","startOffset":"96","endOffset":"108","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","prefix":" in the incidence of overanticoagulation when azithromycin, ","suffix":", or TMP/SMX was added to chronic warfarin therapy in patien","exact":"levofloxacin"},{"setid":"PMC1490169","drugname":"levofloxacin","startOffset":"673","endOffset":"685","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","prefix":"al disease was seen more frequently in the azithromycin and ","suffix":" groups than the TMP/SMX and terazosin groups; however, the ","exact":"levofloxacin"},{"setid":"PMC1490169","drugname":"levofloxacin","startOffset":"77","endOffset":"89","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[9]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[9]/p[1]","prefix":" outpatients, the use of the oral antibiotics azithromycin, ","suffix":", and TMP/SMX increases both the incidence and degree of ove","exact":"levofloxacin"},{"setid":"PMC1490169","drugname":"levofloxacin","startOffset":"62","endOffset":"74","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[11]/div[2]/div[15]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[11]/div[2]/div[15]/span[1]","prefix":"ao S, Palmer M, Fowler C, Nayak RK. Absence of an effect of ","suffix":" on warfarin pharmacokinetics and anticoagulation in male vo","exact":"levofloxacin"},{"setid":"PMC1490169","drugname":"levofloxacin","startOffset":"87","endOffset":"99","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[11]/div[2]/div[16]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[11]/div[2]/div[16]/span[1]","prefix":"Kipatrick DM, Enlow AM, Burrows MM, Greenwood MC. Effect of ","suffix":" coadministration on the international normalized ratios dur","exact":"levofloxacin"},{"setid":"PMC1490169","drugname":"levofloxacin","startOffset":"47","endOffset":"59","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[11]/div[2]/div[17]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[11]/div[2]/div[17]/span[1]","prefix":"Glasheen JJ, Fugit RV, Prochazka AV. Effect of ","suffix":" coadministration on the international normalized ratios dur","exact":"levofloxacin"},{"setid":"PMC1490169","drugname":"levofloxacin","startOffset":"117","endOffset":"129","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[2]/div[2]/div[1]/ul[1]/li[1]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[2]/div[2]/div[1]/ul[1]/li[1]/a[1]","prefix":"lation after initiation of trimethoprim-sulfamethoxazole or ","suffix":".","exact":"levofloxacin"},{"setid":"PMC1490169","drugname":"levofloxacin","startOffset":"24","endOffset":"36","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[4]/div[2]/ul[1]/li[2]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[4]/div[2]/ul[1]/li[2]/a[1]","prefix":"Absence of an effect of ","suffix":" on warfarin pharmacokinetics and anticoagulation in male vo","exact":"levofloxacin"},{"setid":"PMC1490169","drugname":"levofloxacin","startOffset":"10","endOffset":"22","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[4]/div[2]/ul[1]/li[3]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[4]/div[2]/ul[1]/li[3]/a[1]","prefix":"Effect of ","suffix":" coadministration on the international normalized ratios dur","exact":"levofloxacin"},{"setid":"PMC1490169","drugname":"levofloxacin","startOffset":"10","endOffset":"22","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[4]/div[2]/ul[1]/li[4]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[4]/div[2]/ul[1]/li[4]/a[1]","prefix":"Effect of ","suffix":" coadministration on the international normalized ratios dur","exact":"levofloxacin"},{"setid":"PMC1490169","drugname":"levofloxacin","startOffset":"24","endOffset":"36","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[10]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[10]","prefix":"Absence of an effect of ","suffix":" on warfarin pharmacokinetics and anticoagulation in male vo","exact":"levofloxacin"},{"setid":"PMC1490169","drugname":"levofloxacin","startOffset":"10","endOffset":"22","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[11]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[11]","prefix":"Effect of ","suffix":" coadministration on the international normalized ratios dur","exact":"levofloxacin"},{"setid":"PMC1490169","drugname":"levofloxacin","startOffset":"10","endOffset":"22","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[12]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[12]","prefix":"Effect of ","suffix":" coadministration on the international normalized ratios dur","exact":"levofloxacin"},{"setid":"PMC1490169","drugname":"levofloxacin","startOffset":"109","endOffset":"121","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"e of warfarin interaction from terazosin to azithromycin to ","suffix":" to TMP/SMX was found (","exact":"levofloxacin"},{"setid":"PMC1490169","drugname":"levofloxacin","startOffset":"97","endOffset":"109","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"s using warfarin who initiated an antibiotic (azithromycin, ","suffix":", or trimethoprim/sulfamethoxazole (TMP/SMX)) or terazosin f","exact":"levofloxacin"},{"setid":"PMC1490169","drugname":"levofloxacin","startOffset":"80","endOffset":"92","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[5]/p[1]","prefix":"NR was −0.15 for terazosin, 0.51 for azithromycin, 0.85 for ","suffix":", and 1.76 for TMP/SMX. These mean INR changes in the antibi","exact":"levofloxacin"},{"setid":"PMC1490169","drugname":"levofloxacin","startOffset":"313","endOffset":"325","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[5]/p[1]","prefix":"tic INR was 5% for terazosin, 31% for azithromycin, 33% for ","suffix":", and 69% for TMP/SMX. The incidence of absolute INR >4.0 wa","exact":"levofloxacin"},{"setid":"PMC1490169","drugname":"levofloxacin","startOffset":"435","endOffset":"447","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[5]/p[1]","prefix":"NR >4.0 was 0% for terazosin, 16% for azithromycin, 19% for ","suffix":", and 44% for TMP/SMX.","exact":"levofloxacin"},{"setid":"PMC1490169","drugname":"levofloxacin","startOffset":"63","endOffset":"75","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[6]/p[1]","prefix":"ng acutely ill outpatients, oral antibiotics (azithromycin, ","suffix":", and TMP/SMX) increase the incidence and degree of overanti","exact":"levofloxacin"},{"setid":"PMC1490169","drugname":"levofloxacin","startOffset":"63","endOffset":"75","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","prefix":"farin, overanticoagulation, drug interaction, azithromycin, ","suffix":", trimethoprim/sulfamethoxazole","exact":"levofloxacin"},{"setid":"PMC1490169","drugname":"levofloxacin","startOffset":"147","endOffset":"159","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","prefix":"Rs who received a prescription for terazosin, azithromycin, ","suffix":", or TMP/SMX for clinical indications between January 1998 a","exact":"levofloxacin"},{"setid":"PMC1490169","drugname":"levofloxacin","startOffset":"137","endOffset":"149","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"ons for azithromycin in 158 patients, 370 prescriptions for ","suffix":" in 258 patients, and 151 prescriptions for TMP/SMX in 120 p","exact":"levofloxacin"},{"setid":"PMC1490169","drugname":"levofloxacin","startOffset":"272","endOffset":"284","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"ents. Initially 43, 35, 41, and 24 terazosin, azithromycin, ","suffix":", and TMP/SMX patients, respectively, were included and brou","exact":"levofloxacin"},{"setid":"PMC1490169","drugname":"levofloxacin","startOffset":"682","endOffset":"694","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"s drawn between days 15 and 30. Thirty-two azithromycin, 27 ","suffix":", and 16 TMP/SMX patients were included in the trial (","exact":"levofloxacin"},{"setid":"PMC1490169","drugname":"levofloxacin","startOffset":"206","endOffset":"218","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"ime to follow-up was 17.5 (terazosin), 7 (azithromycin), 6 (","suffix":"), and 6 (TMP/SMX) days. Men constituted 97% of all patients","exact":"levofloxacin"},{"setid":"PMC1490169","drugname":"levofloxacin","startOffset":"109","endOffset":"121","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"e of warfarin interaction from terazosin to azithromycin to ","suffix":" to TMP/SMX was found (","exact":"levofloxacin"},{"setid":"PMC1490169","drugname":"levofloxacin","startOffset":"96","endOffset":"108","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","prefix":" in the incidence of overanticoagulation when azithromycin, ","suffix":", or TMP/SMX was added to chronic warfarin therapy in patien","exact":"levofloxacin"},{"setid":"PMC1490169","drugname":"levofloxacin","startOffset":"673","endOffset":"685","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","prefix":"al disease was seen more frequently in the azithromycin and ","suffix":" groups than the TMP/SMX and terazosin groups; however, the ","exact":"levofloxacin"},{"setid":"PMC1490169","drugname":"levofloxacin","startOffset":"77","endOffset":"89","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[9]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[9]/p[1]","prefix":" outpatients, the use of the oral antibiotics azithromycin, ","suffix":", and TMP/SMX increases both the incidence and degree of ove","exact":"levofloxacin"},{"setid":"PMC1490169","drugname":"levofloxacin","startOffset":"62","endOffset":"74","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[11]/div[2]/div[15]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[11]/div[2]/div[15]/span[1]","prefix":"ao S, Palmer M, Fowler C, Nayak RK. Absence of an effect of ","suffix":" on warfarin pharmacokinetics and anticoagulation in male vo","exact":"levofloxacin"},{"setid":"PMC1490169","drugname":"levofloxacin","startOffset":"87","endOffset":"99","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[11]/div[2]/div[16]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[11]/div[2]/div[16]/span[1]","prefix":"Kipatrick DM, Enlow AM, Burrows MM, Greenwood MC. Effect of ","suffix":" coadministration on the international normalized ratios dur","exact":"levofloxacin"},{"setid":"PMC1490169","drugname":"levofloxacin","startOffset":"47","endOffset":"59","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[11]/div[2]/div[17]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[11]/div[2]/div[17]/span[1]","prefix":"Glasheen JJ, Fugit RV, Prochazka AV. Effect of ","suffix":" coadministration on the international normalized ratios dur","exact":"levofloxacin"},{"setid":"PMC1490169","drugname":"levofloxacin","startOffset":"117","endOffset":"129","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[2]/div[2]/div[1]/ul[1]/li[1]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[2]/div[2]/div[1]/ul[1]/li[1]/a[1]","prefix":"lation after initiation of trimethoprim-sulfamethoxazole or ","suffix":".","exact":"levofloxacin"},{"setid":"PMC1490169","drugname":"levofloxacin","startOffset":"24","endOffset":"36","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[4]/div[2]/ul[1]/li[2]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[4]/div[2]/ul[1]/li[2]/a[1]","prefix":"Absence of an effect of ","suffix":" on warfarin pharmacokinetics and anticoagulation in male vo","exact":"levofloxacin"},{"setid":"PMC1490169","drugname":"levofloxacin","startOffset":"10","endOffset":"22","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[4]/div[2]/ul[1]/li[3]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[4]/div[2]/ul[1]/li[3]/a[1]","prefix":"Effect of ","suffix":" coadministration on the international normalized ratios dur","exact":"levofloxacin"},{"setid":"PMC1490169","drugname":"levofloxacin","startOffset":"10","endOffset":"22","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[4]/div[2]/ul[1]/li[4]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[4]/div[2]/ul[1]/li[4]/a[1]","prefix":"Effect of ","suffix":" coadministration on the international normalized ratios dur","exact":"levofloxacin"},{"setid":"PMC1490169","drugname":"levofloxacin","startOffset":"24","endOffset":"36","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[10]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[10]","prefix":"Absence of an effect of ","suffix":" on warfarin pharmacokinetics and anticoagulation in male vo","exact":"levofloxacin"},{"setid":"PMC1490169","drugname":"levofloxacin","startOffset":"10","endOffset":"22","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[11]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[11]","prefix":"Effect of ","suffix":" coadministration on the international normalized ratios dur","exact":"levofloxacin"},{"setid":"PMC1490169","drugname":"levofloxacin","startOffset":"10","endOffset":"22","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[12]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[12]","prefix":"Effect of ","suffix":" coadministration on the international normalized ratios dur","exact":"levofloxacin"},{"setid":"PMC1490169","drugname":"levofloxacin","startOffset":"97","endOffset":"109","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"s using warfarin who initiated an antibiotic (azithromycin, ","suffix":", or trimethoprim/sulfamethoxazole (TMP/SMX)) or terazosin f","exact":"levofloxacin"},{"setid":"PMC1490169","drugname":"levofloxacin","startOffset":"80","endOffset":"92","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[5]/p[1]","prefix":"NR was −0.15 for terazosin, 0.51 for azithromycin, 0.85 for ","suffix":", and 1.76 for TMP/SMX. These mean INR changes in the antibi","exact":"levofloxacin"},{"setid":"PMC1490169","drugname":"levofloxacin","startOffset":"313","endOffset":"325","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[5]/p[1]","prefix":"tic INR was 5% for terazosin, 31% for azithromycin, 33% for ","suffix":", and 69% for TMP/SMX. The incidence of absolute INR >4.0 wa","exact":"levofloxacin"},{"setid":"PMC1490169","drugname":"levofloxacin","startOffset":"435","endOffset":"447","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[5]/p[1]","prefix":"NR >4.0 was 0% for terazosin, 16% for azithromycin, 19% for ","suffix":", and 44% for TMP/SMX.","exact":"levofloxacin"},{"setid":"PMC1490169","drugname":"levofloxacin","startOffset":"63","endOffset":"75","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[6]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[6]/p[1]","prefix":"ng acutely ill outpatients, oral antibiotics (azithromycin, ","suffix":", and TMP/SMX) increase the incidence and degree of overanti","exact":"levofloxacin"},{"setid":"PMC1490169","drugname":"levofloxacin","startOffset":"63","endOffset":"75","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","prefix":"farin, overanticoagulation, drug interaction, azithromycin, ","suffix":", trimethoprim/sulfamethoxazole","exact":"levofloxacin"},{"setid":"PMC1490169","drugname":"levofloxacin","startOffset":"147","endOffset":"159","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","prefix":"Rs who received a prescription for terazosin, azithromycin, ","suffix":", or TMP/SMX for clinical indications between January 1998 a","exact":"levofloxacin"},{"setid":"PMC1490169","drugname":"levofloxacin","startOffset":"137","endOffset":"149","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"ons for azithromycin in 158 patients, 370 prescriptions for ","suffix":" in 258 patients, and 151 prescriptions for TMP/SMX in 120 p","exact":"levofloxacin"},{"setid":"PMC1490169","drugname":"levofloxacin","startOffset":"272","endOffset":"284","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"ents. Initially 43, 35, 41, and 24 terazosin, azithromycin, ","suffix":", and TMP/SMX patients, respectively, were included and brou","exact":"levofloxacin"},{"setid":"PMC1490169","drugname":"levofloxacin","startOffset":"682","endOffset":"694","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"s drawn between days 15 and 30. Thirty-two azithromycin, 27 ","suffix":", and 16 TMP/SMX patients were included in the trial (","exact":"levofloxacin"},{"setid":"PMC1490169","drugname":"levofloxacin","startOffset":"206","endOffset":"218","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"ime to follow-up was 17.5 (terazosin), 7 (azithromycin), 6 (","suffix":"), and 6 (TMP/SMX) days. Men constituted 97% of all patients","exact":"levofloxacin"},{"setid":"PMC1490169","drugname":"levofloxacin","startOffset":"109","endOffset":"121","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"e of warfarin interaction from terazosin to azithromycin to ","suffix":" to TMP/SMX was found (","exact":"levofloxacin"},{"setid":"PMC1490169","drugname":"levofloxacin","startOffset":"96","endOffset":"108","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","prefix":" in the incidence of overanticoagulation when azithromycin, ","suffix":", or TMP/SMX was added to chronic warfarin therapy in patien","exact":"levofloxacin"},{"setid":"PMC1490169","drugname":"levofloxacin","startOffset":"673","endOffset":"685","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","prefix":"al disease was seen more frequently in the azithromycin and ","suffix":" groups than the TMP/SMX and terazosin groups; however, the ","exact":"levofloxacin"},{"setid":"PMC1490169","drugname":"levofloxacin","startOffset":"77","endOffset":"89","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[9]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[9]/p[1]","prefix":" outpatients, the use of the oral antibiotics azithromycin, ","suffix":", and TMP/SMX increases both the incidence and degree of ove","exact":"levofloxacin"},{"setid":"PMC1490169","drugname":"levofloxacin","startOffset":"62","endOffset":"74","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[11]/div[2]/div[15]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[11]/div[2]/div[15]/span[1]","prefix":"ao S, Palmer M, Fowler C, Nayak RK. Absence of an effect of ","suffix":" on warfarin pharmacokinetics and anticoagulation in male vo","exact":"levofloxacin"},{"setid":"PMC1490169","drugname":"levofloxacin","startOffset":"87","endOffset":"99","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[11]/div[2]/div[16]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[11]/div[2]/div[16]/span[1]","prefix":"Kipatrick DM, Enlow AM, Burrows MM, Greenwood MC. Effect of ","suffix":" coadministration on the international normalized ratios dur","exact":"levofloxacin"},{"setid":"PMC1490169","drugname":"levofloxacin","startOffset":"47","endOffset":"59","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[11]/div[2]/div[17]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[11]/div[2]/div[17]/span[1]","prefix":"Glasheen JJ, Fugit RV, Prochazka AV. Effect of ","suffix":" coadministration on the international normalized ratios dur","exact":"levofloxacin"},{"setid":"PMC1490169","drugname":"levofloxacin","startOffset":"117","endOffset":"129","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[2]/div[2]/div[1]/ul[1]/li[1]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[2]/div[2]/div[1]/ul[1]/li[1]/a[1]","prefix":"lation after initiation of trimethoprim-sulfamethoxazole or ","suffix":".","exact":"levofloxacin"},{"setid":"PMC1490169","drugname":"levofloxacin","startOffset":"24","endOffset":"36","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[4]/div[2]/ul[1]/li[2]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[4]/div[2]/ul[1]/li[2]/a[1]","prefix":"Absence of an effect of ","suffix":" on warfarin pharmacokinetics and anticoagulation in male vo","exact":"levofloxacin"},{"setid":"PMC1490169","drugname":"levofloxacin","startOffset":"10","endOffset":"22","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[4]/div[2]/ul[1]/li[3]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[4]/div[2]/ul[1]/li[3]/a[1]","prefix":"Effect of ","suffix":" coadministration on the international normalized ratios dur","exact":"levofloxacin"},{"setid":"PMC1490169","drugname":"levofloxacin","startOffset":"10","endOffset":"22","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[4]/div[2]/ul[1]/li[4]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[4]/div[2]/ul[1]/li[4]/a[1]","prefix":"Effect of ","suffix":" coadministration on the international normalized ratios dur","exact":"levofloxacin"},{"setid":"PMC1490169","drugname":"levofloxacin","startOffset":"24","endOffset":"36","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[10]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[10]","prefix":"Absence of an effect of ","suffix":" on warfarin pharmacokinetics and anticoagulation in male vo","exact":"levofloxacin"},{"setid":"PMC1490169","drugname":"levofloxacin","startOffset":"10","endOffset":"22","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[11]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[11]","prefix":"Effect of ","suffix":" coadministration on the international normalized ratios dur","exact":"levofloxacin"},{"setid":"PMC1490169","drugname":"levofloxacin","startOffset":"10","endOffset":"22","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[12]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[12]","prefix":"Effect of ","suffix":" coadministration on the international normalized ratios dur","exact":"levofloxacin"},{"setid":"PMC1490169","drugname":"levofloxacin","startOffset":"96","endOffset":"108","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","prefix":" in the incidence of overanticoagulation when azithromycin, ","suffix":", or TMP/SMX was added to chronic warfarin therapy in patien","exact":"levofloxacin"},{"setid":"PMC1490169","drugname":"levofloxacin","startOffset":"673","endOffset":"685","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","prefix":"al disease was seen more frequently in the azithromycin and ","suffix":" groups than the TMP/SMX and terazosin groups; however, the ","exact":"levofloxacin"},{"setid":"PMC1490169","drugname":"levofloxacin","startOffset":"77","endOffset":"89","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[9]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[9]/p[1]","prefix":" outpatients, the use of the oral antibiotics azithromycin, ","suffix":", and TMP/SMX increases both the incidence and degree of ove","exact":"levofloxacin"},{"setid":"PMC1490169","drugname":"trimethoprim","startOffset":"114","endOffset":"126","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"who initiated an antibiotic (azithromycin, levofloxacin, or ","suffix":"/sulfamethoxazole (TMP/SMX)) or terazosin for clinical indic","exact":"trimethoprim"},{"setid":"PMC1490169","drugname":"trimethoprim","startOffset":"77","endOffset":"89","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","prefix":"icoagulation, drug interaction, azithromycin, levofloxacin, ","suffix":"/sulfamethoxazole","exact":"trimethoprim"},{"setid":"PMC1490169","drugname":"sulfamethoxazole","startOffset":"127","endOffset":"143","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":" an antibiotic (azithromycin, levofloxacin, or trimethoprim/","suffix":" (TMP/SMX)) or terazosin for clinical indications between Ja","exact":"sulfamethoxazole"},{"setid":"PMC1490169","drugname":"sulfamethoxazole","startOffset":"90","endOffset":"106","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","prefix":" drug interaction, azithromycin, levofloxacin, trimethoprim/","suffix":"","exact":"sulfamethoxazole"},{"setid":"PMC1490169","drugname":"sulfamethoxazole","startOffset":"97","endOffset":"113","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[2]/div[2]/div[1]/ul[1]/li[1]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[2]/div[2]/div[1]/ul[1]/li[1]/a[1]","prefix":"duction on anticoagulation after initiation of trimethoprim-","suffix":" or levofloxacin.","exact":"sulfamethoxazole"},{"setid":"PMC1490169","drugname":"sulfamethoxazole","startOffset":"54","endOffset":"70","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[2]/div[2]/div[1]/ul[1]/li[5]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[2]/div[2]/div[1]/ul[1]/li[5]/a[1]","prefix":"Interaction of vitamin K antagonists and trimethoprim-","suffix":": ignore at your patient's risk.","exact":"sulfamethoxazole"},{"setid":"PMC1490169","drugname":"sulfamethoxazole","startOffset":"34","endOffset":"50","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[5]/div[2]/ul[1]/li[3]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[5]/div[2]/ul[1]/li[3]/a[1]","prefix":"Racemic warfarin and trimethoprim-","suffix":" interaction in humans.","exact":"sulfamethoxazole"},{"setid":"PMC1490169","drugname":"sulfamethoxazole","startOffset":"34","endOffset":"50","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[15]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[15]","prefix":"Racemic warfarin and trimethoprim-","suffix":" interaction in humans.","exact":"sulfamethoxazole"},{"setid":"PMC1490169","drugname":"sulfamethoxazole","startOffset":"90","endOffset":"106","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","prefix":" drug interaction, azithromycin, levofloxacin, trimethoprim/","suffix":"","exact":"sulfamethoxazole"},{"setid":"PMC1490169","drugname":"sulfamethoxazole","startOffset":"127","endOffset":"143","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":" an antibiotic (azithromycin, levofloxacin, or trimethoprim/","suffix":" (TMP/SMX)) or terazosin for clinical indications between Ja","exact":"sulfamethoxazole"},{"setid":"PMC1490169","drugname":"sulfamethoxazole","startOffset":"90","endOffset":"106","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","prefix":" drug interaction, azithromycin, levofloxacin, trimethoprim/","suffix":"","exact":"sulfamethoxazole"},{"setid":"PMC1490169","drugname":"sulfamethoxazole","startOffset":"97","endOffset":"113","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[2]/div[2]/div[1]/ul[1]/li[1]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[2]/div[2]/div[1]/ul[1]/li[1]/a[1]","prefix":"duction on anticoagulation after initiation of trimethoprim-","suffix":" or levofloxacin.","exact":"sulfamethoxazole"},{"setid":"PMC1490169","drugname":"sulfamethoxazole","startOffset":"54","endOffset":"70","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[2]/div[2]/div[1]/ul[1]/li[5]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[2]/div[2]/div[1]/ul[1]/li[5]/a[1]","prefix":"Interaction of vitamin K antagonists and trimethoprim-","suffix":": ignore at your patient's risk.","exact":"sulfamethoxazole"},{"setid":"PMC1490169","drugname":"sulfamethoxazole","startOffset":"34","endOffset":"50","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[5]/div[2]/ul[1]/li[3]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[5]/div[2]/ul[1]/li[3]/a[1]","prefix":"Racemic warfarin and trimethoprim-","suffix":" interaction in humans.","exact":"sulfamethoxazole"},{"setid":"PMC1490169","drugname":"sulfamethoxazole","startOffset":"34","endOffset":"50","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[15]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[15]","prefix":"Racemic warfarin and trimethoprim-","suffix":" interaction in humans.","exact":"sulfamethoxazole"},{"setid":"PMC1490169","drugname":"terazosin","startOffset":"158","endOffset":"167","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"evofloxacin, or trimethoprim/sulfamethoxazole (TMP/SMX)) or ","suffix":" for clinical indications between January 1998 and December ","exact":"terazosin"},{"setid":"PMC1490169","drugname":"terazosin","startOffset":"37","endOffset":"46","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[5]/p[1]","prefix":"The mean change in INR was −0.15 for ","suffix":", 0.51 for azithromycin, 0.85 for levofloxacin, and 1.76 for","exact":"terazosin"},{"setid":"PMC1490169","drugname":"terazosin","startOffset":"206","endOffset":"215","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[5]/p[1]","prefix":"antibiotic groups were all statistically different from the ","suffix":" group. The incidence of supratherapeutic INR was 5% for ter","exact":"terazosin"},{"setid":"PMC1490169","drugname":"terazosin","startOffset":"272","endOffset":"281","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[5]/p[1]","prefix":"sin group. The incidence of supratherapeutic INR was 5% for ","suffix":", 31% for azithromycin, 33% for levofloxacin, and 69% for TM","exact":"terazosin"},{"setid":"PMC1490169","drugname":"terazosin","startOffset":"394","endOffset":"403","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[5]/p[1]","prefix":" for TMP/SMX. The incidence of absolute INR >4.0 was 0% for ","suffix":", 16% for azithromycin, 19% for levofloxacin, and 44% for TM","exact":"terazosin"},{"setid":"PMC1490169","drugname":"terazosin","startOffset":"122","endOffset":"131","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","prefix":"ble warfarin doses and INRs who received a prescription for ","suffix":", azithromycin, levofloxacin, or TMP/SMX for clinical indica","exact":"terazosin"},{"setid":"PMC1490169","drugname":"terazosin","startOffset":"297","endOffset":"306","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","prefix":"t a university-affiliated Veteran's Affairs Medical Center. ","suffix":" was chosen as our control because of its lack of interactio","exact":"Terazosin"},{"setid":"PMC1490169","drugname":"terazosin","startOffset":"158","endOffset":"167","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"evofloxacin, or trimethoprim/sulfamethoxazole (TMP/SMX)) or ","suffix":" for clinical indications between January 1998 and December ","exact":"terazosin"},{"setid":"PMC1490169","drugname":"terazosin","startOffset":"37","endOffset":"46","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[5]/p[1]","prefix":"The mean change in INR was −0.15 for ","suffix":", 0.51 for azithromycin, 0.85 for levofloxacin, and 1.76 for","exact":"terazosin"},{"setid":"PMC1490169","drugname":"terazosin","startOffset":"206","endOffset":"215","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[5]/p[1]","prefix":"antibiotic groups were all statistically different from the ","suffix":" group. The incidence of supratherapeutic INR was 5% for ter","exact":"terazosin"},{"setid":"PMC1490169","drugname":"terazosin","startOffset":"272","endOffset":"281","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[5]/p[1]","prefix":"sin group. The incidence of supratherapeutic INR was 5% for ","suffix":", 31% for azithromycin, 33% for levofloxacin, and 69% for TM","exact":"terazosin"},{"setid":"PMC1490169","drugname":"terazosin","startOffset":"394","endOffset":"403","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[5]/p[1]","prefix":" for TMP/SMX. The incidence of absolute INR >4.0 was 0% for ","suffix":", 16% for azithromycin, 19% for levofloxacin, and 44% for TM","exact":"terazosin"},{"setid":"PMC1490169","drugname":"terazosin","startOffset":"122","endOffset":"131","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","prefix":"ble warfarin doses and INRs who received a prescription for ","suffix":", azithromycin, levofloxacin, or TMP/SMX for clinical indica","exact":"terazosin"},{"setid":"PMC1490169","drugname":"terazosin","startOffset":"36","endOffset":"45","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"We identified 333 prescriptions for ","suffix":" in 333 patients, 273 prescriptions for azithromycin in 158 ","exact":"terazosin"},{"setid":"PMC1490169","drugname":"terazosin","startOffset":"247","endOffset":"256","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"s for TMP/SMX in 120 patients. Initially 43, 35, 41, and 24 ","suffix":", azithromycin, levofloxacin, and TMP/SMX patients, respecti","exact":"terazosin"},{"setid":"PMC1490169","drugname":"terazosin","startOffset":"530","endOffset":"539","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"all exclusions were made as indicated. Nine patients in the ","suffix":" group had follow-up INRs on or before day 15 and an additio","exact":"terazosin"},{"setid":"PMC1490169","drugname":"terazosin","startOffset":"45","endOffset":"54","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"There were no differences in outcomes in the ","suffix":" data analyzed at day 15 or 30, so the latter was used in al","exact":"terazosin"},{"setid":"PMC1490169","drugname":"terazosin","startOffset":"173","endOffset":"182","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"ll further analysis. The median time to follow-up was 17.5 (","suffix":"), 7 (azithromycin), 6 (levofloxacin), and 6 (TMP/SMX) days.","exact":"terazosin"},{"setid":"PMC1490169","drugname":"terazosin","startOffset":"80","endOffset":"89","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":" both the incidence and degree of warfarin interaction from ","suffix":" to azithromycin to levofloxacin to TMP/SMX was found (","exact":"terazosin"},{"setid":"PMC1490169","drugname":"terazosin","startOffset":"152","endOffset":"161","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","prefix":"tion of azithromycin for clinical indications compared with ","suffix":"","exact":"terazosin"},{"setid":"PMC1490169","drugname":"terazosin","startOffset":"714","endOffset":"723","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","prefix":"e azithromycin and levofloxacin groups than the TMP/SMX and ","suffix":" groups; however, the significance of this is unknown but is","exact":"terazosin"},{"setid":"PMC1490169","drugname":"terazosin","startOffset":"839","endOffset":"848","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","prefix":"t is likely to be minimal. Finally, we utilized a negative (","suffix":") and positive (TMP/SMX) control to confer validity to our f","exact":"terazosin"},{"setid":"PMC1490169","drugname":"terazosin","startOffset":"36","endOffset":"45","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"We identified 333 prescriptions for ","suffix":" in 333 patients, 273 prescriptions for azithromycin in 158 ","exact":"terazosin"},{"setid":"PMC1490169","drugname":"terazosin","startOffset":"247","endOffset":"256","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"s for TMP/SMX in 120 patients. Initially 43, 35, 41, and 24 ","suffix":", azithromycin, levofloxacin, and TMP/SMX patients, respecti","exact":"terazosin"},{"setid":"PMC1490169","drugname":"terazosin","startOffset":"530","endOffset":"539","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"all exclusions were made as indicated. Nine patients in the ","suffix":" group had follow-up INRs on or before day 15 and an additio","exact":"terazosin"},{"setid":"PMC1490169","drugname":"terazosin","startOffset":"45","endOffset":"54","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"There were no differences in outcomes in the ","suffix":" data analyzed at day 15 or 30, so the latter was used in al","exact":"terazosin"},{"setid":"PMC1490169","drugname":"terazosin","startOffset":"158","endOffset":"167","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"evofloxacin, or trimethoprim/sulfamethoxazole (TMP/SMX)) or ","suffix":" for clinical indications between January 1998 and December ","exact":"terazosin"},{"setid":"PMC1490169","drugname":"terazosin","startOffset":"37","endOffset":"46","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[5]/p[1]","prefix":"The mean change in INR was −0.15 for ","suffix":", 0.51 for azithromycin, 0.85 for levofloxacin, and 1.76 for","exact":"terazosin"},{"setid":"PMC1490169","drugname":"terazosin","startOffset":"206","endOffset":"215","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[5]/p[1]","prefix":"antibiotic groups were all statistically different from the ","suffix":" group. The incidence of supratherapeutic INR was 5% for ter","exact":"terazosin"},{"setid":"PMC1490169","drugname":"terazosin","startOffset":"272","endOffset":"281","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[5]/p[1]","prefix":"sin group. The incidence of supratherapeutic INR was 5% for ","suffix":", 31% for azithromycin, 33% for levofloxacin, and 69% for TM","exact":"terazosin"},{"setid":"PMC1490169","drugname":"terazosin","startOffset":"394","endOffset":"403","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[5]/p[1]","prefix":" for TMP/SMX. The incidence of absolute INR >4.0 was 0% for ","suffix":", 16% for azithromycin, 19% for levofloxacin, and 44% for TM","exact":"terazosin"},{"setid":"PMC1490169","drugname":"terazosin","startOffset":"122","endOffset":"131","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","prefix":"ble warfarin doses and INRs who received a prescription for ","suffix":", azithromycin, levofloxacin, or TMP/SMX for clinical indica","exact":"terazosin"},{"setid":"PMC1490169","drugname":"terazosin","startOffset":"36","endOffset":"45","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"We identified 333 prescriptions for ","suffix":" in 333 patients, 273 prescriptions for azithromycin in 158 ","exact":"terazosin"},{"setid":"PMC1490169","drugname":"terazosin","startOffset":"247","endOffset":"256","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"s for TMP/SMX in 120 patients. Initially 43, 35, 41, and 24 ","suffix":", azithromycin, levofloxacin, and TMP/SMX patients, respecti","exact":"terazosin"},{"setid":"PMC1490169","drugname":"terazosin","startOffset":"530","endOffset":"539","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"all exclusions were made as indicated. Nine patients in the ","suffix":" group had follow-up INRs on or before day 15 and an additio","exact":"terazosin"},{"setid":"PMC1490169","drugname":"terazosin","startOffset":"45","endOffset":"54","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"There were no differences in outcomes in the ","suffix":" data analyzed at day 15 or 30, so the latter was used in al","exact":"terazosin"},{"setid":"PMC1490169","drugname":"terazosin","startOffset":"173","endOffset":"182","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"ll further analysis. The median time to follow-up was 17.5 (","suffix":"), 7 (azithromycin), 6 (levofloxacin), and 6 (TMP/SMX) days.","exact":"terazosin"},{"setid":"PMC1490169","drugname":"terazosin","startOffset":"80","endOffset":"89","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":" both the incidence and degree of warfarin interaction from ","suffix":" to azithromycin to levofloxacin to TMP/SMX was found (","exact":"terazosin"},{"setid":"PMC1490169","drugname":"terazosin","startOffset":"152","endOffset":"161","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","prefix":"tion of azithromycin for clinical indications compared with ","suffix":"","exact":"terazosin"},{"setid":"PMC1490169","drugname":"terazosin","startOffset":"714","endOffset":"723","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","prefix":"e azithromycin and levofloxacin groups than the TMP/SMX and ","suffix":" groups; however, the significance of this is unknown but is","exact":"terazosin"},{"setid":"PMC1490169","drugname":"terazosin","startOffset":"839","endOffset":"848","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","prefix":"t is likely to be minimal. Finally, we utilized a negative (","suffix":") and positive (TMP/SMX) control to confer validity to our f","exact":"terazosin"},{"setid":"PMC1490169","drugname":"terazosin","startOffset":"80","endOffset":"89","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":" both the incidence and degree of warfarin interaction from ","suffix":" to azithromycin to levofloxacin to TMP/SMX was found (","exact":"terazosin"},{"setid":"PMC1490169","drugname":"terazosin","startOffset":"158","endOffset":"167","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"evofloxacin, or trimethoprim/sulfamethoxazole (TMP/SMX)) or ","suffix":" for clinical indications between January 1998 and December ","exact":"terazosin"},{"setid":"PMC1490169","drugname":"terazosin","startOffset":"37","endOffset":"46","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[5]/p[1]","prefix":"The mean change in INR was −0.15 for ","suffix":", 0.51 for azithromycin, 0.85 for levofloxacin, and 1.76 for","exact":"terazosin"},{"setid":"PMC1490169","drugname":"terazosin","startOffset":"206","endOffset":"215","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[5]/p[1]","prefix":"antibiotic groups were all statistically different from the ","suffix":" group. The incidence of supratherapeutic INR was 5% for ter","exact":"terazosin"},{"setid":"PMC1490169","drugname":"terazosin","startOffset":"272","endOffset":"281","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[5]/p[1]","prefix":"sin group. The incidence of supratherapeutic INR was 5% for ","suffix":", 31% for azithromycin, 33% for levofloxacin, and 69% for TM","exact":"terazosin"},{"setid":"PMC1490169","drugname":"terazosin","startOffset":"394","endOffset":"403","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[5]/p[1]","prefix":" for TMP/SMX. The incidence of absolute INR >4.0 was 0% for ","suffix":", 16% for azithromycin, 19% for levofloxacin, and 44% for TM","exact":"terazosin"},{"setid":"PMC1490169","drugname":"terazosin","startOffset":"122","endOffset":"131","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","prefix":"ble warfarin doses and INRs who received a prescription for ","suffix":", azithromycin, levofloxacin, or TMP/SMX for clinical indica","exact":"terazosin"},{"setid":"PMC1490169","drugname":"terazosin","startOffset":"36","endOffset":"45","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"We identified 333 prescriptions for ","suffix":" in 333 patients, 273 prescriptions for azithromycin in 158 ","exact":"terazosin"},{"setid":"PMC1490169","drugname":"terazosin","startOffset":"247","endOffset":"256","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"s for TMP/SMX in 120 patients. Initially 43, 35, 41, and 24 ","suffix":", azithromycin, levofloxacin, and TMP/SMX patients, respecti","exact":"terazosin"},{"setid":"PMC1490169","drugname":"terazosin","startOffset":"530","endOffset":"539","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"all exclusions were made as indicated. Nine patients in the ","suffix":" group had follow-up INRs on or before day 15 and an additio","exact":"terazosin"},{"setid":"PMC1490169","drugname":"terazosin","startOffset":"45","endOffset":"54","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"There were no differences in outcomes in the ","suffix":" data analyzed at day 15 or 30, so the latter was used in al","exact":"terazosin"},{"setid":"PMC1490169","drugname":"terazosin","startOffset":"173","endOffset":"182","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"ll further analysis. The median time to follow-up was 17.5 (","suffix":"), 7 (azithromycin), 6 (levofloxacin), and 6 (TMP/SMX) days.","exact":"terazosin"},{"setid":"PMC1490169","drugname":"terazosin","startOffset":"80","endOffset":"89","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":" both the incidence and degree of warfarin interaction from ","suffix":" to azithromycin to levofloxacin to TMP/SMX was found (","exact":"terazosin"},{"setid":"PMC1490169","drugname":"terazosin","startOffset":"152","endOffset":"161","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","prefix":"tion of azithromycin for clinical indications compared with ","suffix":"","exact":"terazosin"},{"setid":"PMC1490169","drugname":"terazosin","startOffset":"714","endOffset":"723","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","prefix":"e azithromycin and levofloxacin groups than the TMP/SMX and ","suffix":" groups; however, the significance of this is unknown but is","exact":"terazosin"},{"setid":"PMC1490169","drugname":"terazosin","startOffset":"839","endOffset":"848","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","prefix":"t is likely to be minimal. Finally, we utilized a negative (","suffix":") and positive (TMP/SMX) control to confer validity to our f","exact":"terazosin"},{"setid":"PMC1490169","drugname":"terazosin","startOffset":"158","endOffset":"167","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"evofloxacin, or trimethoprim/sulfamethoxazole (TMP/SMX)) or ","suffix":" for clinical indications between January 1998 and December ","exact":"terazosin"},{"setid":"PMC1490169","drugname":"terazosin","startOffset":"37","endOffset":"46","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[5]/p[1]","prefix":"The mean change in INR was −0.15 for ","suffix":", 0.51 for azithromycin, 0.85 for levofloxacin, and 1.76 for","exact":"terazosin"},{"setid":"PMC1490169","drugname":"terazosin","startOffset":"206","endOffset":"215","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[5]/p[1]","prefix":"antibiotic groups were all statistically different from the ","suffix":" group. The incidence of supratherapeutic INR was 5% for ter","exact":"terazosin"},{"setid":"PMC1490169","drugname":"terazosin","startOffset":"272","endOffset":"281","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[5]/p[1]","prefix":"sin group. The incidence of supratherapeutic INR was 5% for ","suffix":", 31% for azithromycin, 33% for levofloxacin, and 69% for TM","exact":"terazosin"},{"setid":"PMC1490169","drugname":"terazosin","startOffset":"394","endOffset":"403","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[5]/p[1]","prefix":" for TMP/SMX. The incidence of absolute INR >4.0 was 0% for ","suffix":", 16% for azithromycin, 19% for levofloxacin, and 44% for TM","exact":"terazosin"},{"setid":"PMC1490169","drugname":"terazosin","startOffset":"122","endOffset":"131","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","prefix":"ble warfarin doses and INRs who received a prescription for ","suffix":", azithromycin, levofloxacin, or TMP/SMX for clinical indica","exact":"terazosin"},{"setid":"PMC1490169","drugname":"terazosin","startOffset":"36","endOffset":"45","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"We identified 333 prescriptions for ","suffix":" in 333 patients, 273 prescriptions for azithromycin in 158 ","exact":"terazosin"},{"setid":"PMC1490169","drugname":"terazosin","startOffset":"247","endOffset":"256","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"s for TMP/SMX in 120 patients. Initially 43, 35, 41, and 24 ","suffix":", azithromycin, levofloxacin, and TMP/SMX patients, respecti","exact":"terazosin"},{"setid":"PMC1490169","drugname":"terazosin","startOffset":"530","endOffset":"539","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"all exclusions were made as indicated. Nine patients in the ","suffix":" group had follow-up INRs on or before day 15 and an additio","exact":"terazosin"},{"setid":"PMC1490169","drugname":"terazosin","startOffset":"45","endOffset":"54","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"There were no differences in outcomes in the ","suffix":" data analyzed at day 15 or 30, so the latter was used in al","exact":"terazosin"},{"setid":"PMC1490169","drugname":"terazosin","startOffset":"173","endOffset":"182","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"ll further analysis. The median time to follow-up was 17.5 (","suffix":"), 7 (azithromycin), 6 (levofloxacin), and 6 (TMP/SMX) days.","exact":"terazosin"},{"setid":"PMC1490169","drugname":"terazosin","startOffset":"80","endOffset":"89","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":" both the incidence and degree of warfarin interaction from ","suffix":" to azithromycin to levofloxacin to TMP/SMX was found (","exact":"terazosin"},{"setid":"PMC1490169","drugname":"terazosin","startOffset":"152","endOffset":"161","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","prefix":"tion of azithromycin for clinical indications compared with ","suffix":"","exact":"terazosin"},{"setid":"PMC1490169","drugname":"terazosin","startOffset":"714","endOffset":"723","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","prefix":"e azithromycin and levofloxacin groups than the TMP/SMX and ","suffix":" groups; however, the significance of this is unknown but is","exact":"terazosin"},{"setid":"PMC1490169","drugname":"terazosin","startOffset":"839","endOffset":"848","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","prefix":"t is likely to be minimal. Finally, we utilized a negative (","suffix":") and positive (TMP/SMX) control to confer validity to our f","exact":"terazosin"},{"setid":"PMC1490169","drugname":"terazosin","startOffset":"714","endOffset":"723","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","prefix":"e azithromycin and levofloxacin groups than the TMP/SMX and ","suffix":" groups; however, the significance of this is unknown but is","exact":"terazosin"},{"setid":"PMC1490169","drugname":"terazosin","startOffset":"158","endOffset":"167","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"evofloxacin, or trimethoprim/sulfamethoxazole (TMP/SMX)) or ","suffix":" for clinical indications between January 1998 and December ","exact":"terazosin"},{"setid":"PMC1490169","drugname":"terazosin","startOffset":"37","endOffset":"46","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[5]/p[1]","prefix":"The mean change in INR was −0.15 for ","suffix":", 0.51 for azithromycin, 0.85 for levofloxacin, and 1.76 for","exact":"terazosin"},{"setid":"PMC1490169","drugname":"terazosin","startOffset":"206","endOffset":"215","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[5]/p[1]","prefix":"antibiotic groups were all statistically different from the ","suffix":" group. The incidence of supratherapeutic INR was 5% for ter","exact":"terazosin"},{"setid":"PMC1490169","drugname":"terazosin","startOffset":"272","endOffset":"281","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[5]/p[1]","prefix":"sin group. The incidence of supratherapeutic INR was 5% for ","suffix":", 31% for azithromycin, 33% for levofloxacin, and 69% for TM","exact":"terazosin"},{"setid":"PMC1490169","drugname":"terazosin","startOffset":"394","endOffset":"403","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[5]/p[1]","prefix":" for TMP/SMX. The incidence of absolute INR >4.0 was 0% for ","suffix":", 16% for azithromycin, 19% for levofloxacin, and 44% for TM","exact":"terazosin"},{"setid":"PMC1490169","drugname":"terazosin","startOffset":"122","endOffset":"131","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[1]","prefix":"ble warfarin doses and INRs who received a prescription for ","suffix":", azithromycin, levofloxacin, or TMP/SMX for clinical indica","exact":"terazosin"},{"setid":"PMC1490169","drugname":"terazosin","startOffset":"36","endOffset":"45","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"We identified 333 prescriptions for ","suffix":" in 333 patients, 273 prescriptions for azithromycin in 158 ","exact":"terazosin"},{"setid":"PMC1490169","drugname":"terazosin","startOffset":"247","endOffset":"256","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"s for TMP/SMX in 120 patients. Initially 43, 35, 41, and 24 ","suffix":", azithromycin, levofloxacin, and TMP/SMX patients, respecti","exact":"terazosin"},{"setid":"PMC1490169","drugname":"terazosin","startOffset":"530","endOffset":"539","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"all exclusions were made as indicated. Nine patients in the ","suffix":" group had follow-up INRs on or before day 15 and an additio","exact":"terazosin"},{"setid":"PMC1490169","drugname":"terazosin","startOffset":"45","endOffset":"54","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"There were no differences in outcomes in the ","suffix":" data analyzed at day 15 or 30, so the latter was used in al","exact":"terazosin"},{"setid":"PMC1490169","drugname":"terazosin","startOffset":"173","endOffset":"182","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"ll further analysis. The median time to follow-up was 17.5 (","suffix":"), 7 (azithromycin), 6 (levofloxacin), and 6 (TMP/SMX) days.","exact":"terazosin"},{"setid":"PMC1490169","drugname":"terazosin","startOffset":"80","endOffset":"89","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":" both the incidence and degree of warfarin interaction from ","suffix":" to azithromycin to levofloxacin to TMP/SMX was found (","exact":"terazosin"},{"setid":"PMC1490169","drugname":"terazosin","startOffset":"152","endOffset":"161","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","prefix":"tion of azithromycin for clinical indications compared with ","suffix":"","exact":"terazosin"},{"setid":"PMC1490169","drugname":"terazosin","startOffset":"714","endOffset":"723","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","prefix":"e azithromycin and levofloxacin groups than the TMP/SMX and ","suffix":" groups; however, the significance of this is unknown but is","exact":"terazosin"},{"setid":"PMC1490169","drugname":"terazosin","startOffset":"839","endOffset":"848","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","prefix":"t is likely to be minimal. Finally, we utilized a negative (","suffix":") and positive (TMP/SMX) control to confer validity to our f","exact":"terazosin"},{"setid":"PMC1490169","drugname":"terazosin","startOffset":"917","endOffset":"926","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[5]","prefix":"itive (TMP/SMX) control to confer validity to our findings. ","suffix":" is known not to interact with warfarin, while TMP/SMX has a","exact":"Terazosin"}],[{"setid":"PMC90851","drugname":"cholesterol","startOffset":"146","endOffset":"157","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[11]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[11]/p[2]","prefix":"evaluated. Metabolic laboratory parameters, including total ","suffix":", low-density lipoproteins (LDL), triglycerides, glucose, in","exact":"cholesterol"},{"setid":"PMC90851","drugname":"cholesterol","startOffset":"8","endOffset":"19","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[3]","prefix":"Fasting ","suffix":" and LDL levels were significantly reduced in both arms on d","exact":"cholesterol"},{"setid":"PMC90851","drugname":"cholesterol","startOffset":"459","endOffset":"470","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","prefix":"rations in the liver. It was interesting to observe similar ","suffix":"-lowering effects of atorvastatin and simvastatin in the pre","exact":"cholesterol"},{"setid":"PMC90851","drugname":"nelfinavir","startOffset":"664","endOffset":"674","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"e study was performed to determine the interactions between ","suffix":", a protease inhibitor, and two HMG-CoA reductase inhibitors","exact":"nelfinavir"},{"setid":"PMC90851","drugname":"nelfinavir","startOffset":"943","endOffset":"953","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"atin (20 mg once a day) for the first 14 days of the study. ","suffix":" (1,250 mg twice a day) was added on days 15 to 28. Pharmaco","exact":"Nelfinavir"},{"setid":"PMC90851","drugname":"nelfinavir","startOffset":"0","endOffset":"10","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[2]","prefix":"","suffix":" in combination with atorvastatin or simvastatin was well to","exact":"Nelfinavir"},{"setid":"PMC90851","drugname":"nelfinavir","startOffset":"1102","endOffset":"1112","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"med on days 14 and 28. The study drugs were well tolerated. ","suffix":" increased the steady-state area under the plasma concentrat","exact":"Nelfinavir"},{"setid":"PMC90851","drugname":"nelfinavir","startOffset":"388","endOffset":"398","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","prefix":"h Conf. Retrovir. Opportunistic Infect., abstr LB 6, 2000). ","suffix":", like the other protease inhibitors, is an inhibitor of CYP","exact":"Nelfinavir"},{"setid":"PMC90851","drugname":"nelfinavir","startOffset":"525","endOffset":"535","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","prefix":"though it is not as strong a CYP3A4 inhibitor as ritonavir. ","suffix":" is a widely prescribed protease inhibitor. It is therefore ","exact":"Nelfinavir"},{"setid":"PMC90851","drugname":"nelfinavir","startOffset":"633","endOffset":"643","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","prefix":"itor. It is therefore important to study the interaction of ","suffix":" and HMG-CoA reductase inhibitors. Two HMG-CoA reductase inh","exact":"nelfinavir"},{"setid":"PMC90851","drugname":"nelfinavir","startOffset":"124","endOffset":"134","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[2]","prefix":" study to determine the pharmacokinetic interaction between ","suffix":" and atorvastatin or nelfinavir and simvastatin in healthy v","exact":"nelfinavir"},{"setid":"PMC90851","drugname":"nelfinavir","startOffset":"155","endOffset":"165","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[2]","prefix":"okinetic interaction between nelfinavir and atorvastatin or ","suffix":" and simvastatin in healthy volunteers. Thirty-two subjects ","exact":"nelfinavir"},{"setid":"PMC90851","drugname":"nelfinavir","startOffset":"171","endOffset":"181","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[2]","prefix":" In period 2, subjects received simvastatin (20 mg QD) plus ","suffix":" (1,250 mg BID) for an additional 14 days (days 15 to 28). A","exact":"nelfinavir"},{"setid":"PMC90851","drugname":"nelfinavir","startOffset":"171","endOffset":"181","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[2]","prefix":" In period 2, subjects received simvastatin (20 mg QD) plus ","suffix":" (1,250 mg BID) for an additional 14 days (days 15 to 28). A","exact":"nelfinavir"},{"setid":"PMC90851","drugname":"nelfinavir","startOffset":"260","endOffset":"270","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[2]","prefix":" an additional 14 days (days 15 to 28). All simvastatin and ","suffix":" doses were taken with food.","exact":"nelfinavir"},{"setid":"PMC90851","drugname":"nelfinavir","startOffset":"5","endOffset":"15","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[8]/h4[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[8]/h4[1]","prefix":"(ii) ","suffix":" sample collections ","exact":"Nelfinavir"},{"setid":"PMC90851","drugname":"nelfinavir","startOffset":"60","endOffset":"70","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[8]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[8]/p[2]","prefix":"Trough samples (7 ml) were collected prior to initiation of ","suffix":" on day 14 and prior to dosing on days 20 and 25. Serial blo","exact":"nelfinavir"},{"setid":"PMC90851","drugname":"nelfinavir","startOffset":"30","endOffset":"40","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[9]/h4[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[9]/h4[1]","prefix":"Bioanalytical procedures. (i) ","suffix":" and AG1402. ","exact":"Nelfinavir"},{"setid":"PMC90851","drugname":"nelfinavir","startOffset":"18","endOffset":"28","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[9]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[9]/p[2]","prefix":"Concentrations of ","suffix":" and its active metabolite AG1402, previous named M8 (","exact":"nelfinavir"},{"setid":"PMC90851","drugname":"nelfinavir","startOffset":"243","endOffset":"253","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[2]","prefix":". One Caucasian male in treatment group 1 (atorvastatin and ","suffix":") developed a rash, requested withdrawal from the study, and","exact":"nelfinavir"},{"setid":"PMC90851","drugname":"nelfinavir","startOffset":"551","endOffset":"561","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","prefix":"atorvastatin and simvastatin in the presence and absence of ","suffix":" (Table ","exact":"nelfinavir"},{"setid":"PMC90851","drugname":"nelfinavir","startOffset":"563","endOffset":"573","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[2]","prefix":"en days 20 to 25 in period 2. Mean trough concentrations of ","suffix":" on days 15, 20, 25, and 28 were 0 (0), 2.4 (1.9), 3.0 (2.3)","exact":"nelfinavir"},{"setid":"PMC90851","drugname":"nelfinavir","startOffset":"695","endOffset":"705","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[2]","prefix":"and 3.4 (2.0) ng-eq/ml, indicating that the steady state of ","suffix":" was reached between days 20 and 35.","exact":"nelfinavir"},{"setid":"PMC90851","drugname":"nelfinavir","startOffset":"89","endOffset":"99","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[3]","prefix":"ime profiles of atorvastatin in the absence and presence of ","suffix":" are presented in Fig. ","exact":"nelfinavir"},{"setid":"PMC90851","drugname":"nelfinavir","startOffset":"89","endOffset":"99","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[3]","prefix":"ime profiles of atorvastatin in the absence and presence of ","suffix":" are presented in Fig. ","exact":"nelfinavir"},{"setid":"PMC90851","drugname":"nelfinavir","startOffset":"99","endOffset":"109","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/div[1]/div[2]/span[1]","prefix":"files of atorvastatin (ATOR) in the absence and presence of ","suffix":" (NFV). eq., equivalents.","exact":"nelfinavir"},{"setid":"PMC90851","drugname":"nelfinavir","startOffset":"88","endOffset":"98","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[4]","prefix":"time profiles of simvastatin in the absence and presence of ","suffix":" are presented in Fig. ","exact":"nelfinavir"},{"setid":"PMC90851","drugname":"nelfinavir","startOffset":"97","endOffset":"107","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[3]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[3]/div[1]/div[2]/span[1]","prefix":"rofiles of simvastatin (SIM) in the absence and presence of ","suffix":" (NFV). eq., equivalents.","exact":"nelfinavir"},{"setid":"PMC90851","drugname":"nelfinavir","startOffset":"88","endOffset":"98","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[4]","prefix":"time profiles of simvastatin in the absence and presence of ","suffix":" are presented in Fig. ","exact":"nelfinavir"},{"setid":"PMC90851","drugname":"nelfinavir","startOffset":"89","endOffset":"99","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[3]","prefix":"ime profiles of atorvastatin in the absence and presence of ","suffix":" are presented in Fig. ","exact":"nelfinavir"},{"setid":"PMC90851","drugname":"nelfinavir","startOffset":"99","endOffset":"109","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/div[1]/div[2]/span[1]","prefix":"files of atorvastatin (ATOR) in the absence and presence of ","suffix":" (NFV). eq., equivalents.","exact":"nelfinavir"},{"setid":"PMC90851","drugname":"nelfinavir","startOffset":"88","endOffset":"98","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[4]","prefix":"time profiles of simvastatin in the absence and presence of ","suffix":" are presented in Fig. ","exact":"nelfinavir"},{"setid":"PMC90851","drugname":"nelfinavir","startOffset":"97","endOffset":"107","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[3]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[3]/div[1]/div[2]/span[1]","prefix":"rofiles of simvastatin (SIM) in the absence and presence of ","suffix":" (NFV). eq., equivalents.","exact":"nelfinavir"},{"setid":"PMC90851","drugname":"nelfinavir","startOffset":"0","endOffset":"10","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[2]","prefix":"","suffix":" in combination with atorvastatin or simvastatin was well to","exact":"Nelfinavir"},{"setid":"PMC90851","drugname":"nelfinavir","startOffset":"311","endOffset":"321","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[2]","prefix":"onsidered treatment-related adverse events, most related to ","suffix":" treatment. The most frequently reported adverse event was d","exact":"nelfinavir"},{"setid":"PMC90851","drugname":"nelfinavir","startOffset":"472","endOffset":"482","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"ons. In this study, we investigated the interaction between ","suffix":" and two HMG-CoA reductase inhibitors, simvastatin and atorv","exact":"nelfinavir"},{"setid":"PMC90851","drugname":"nelfinavir","startOffset":"70","endOffset":"80","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"s of this study indicate that administration of 1,250 mg of ","suffix":" BID increases the steady-state simvastatin equivalent conce","exact":"nelfinavir"},{"setid":"PMC90851","drugname":"nelfinavir","startOffset":"24","endOffset":"34","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"The interaction between ","suffix":" and simvastatin or atorvastatin is likely due mainly to the","exact":"nelfinavir"},{"setid":"PMC90851","drugname":"nelfinavir","startOffset":"119","endOffset":"129","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"astatin is likely due mainly to the inhibition of CYP3A4 by ","suffix":" since the in vitro and in vivo drug metabolism of these com","exact":"nelfinavir"},{"setid":"PMC90851","drugname":"nelfinavir","startOffset":"241","endOffset":"251","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"hese compounds is well established. Inhibition of CYP3A4 by ","suffix":" could occur at the gastrointestinal wall, which would have ","exact":"nelfinavir"},{"setid":"PMC90851","drugname":"nelfinavir","startOffset":"346","endOffset":"356","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","prefix":"rvastatin and simvastatin caused by the coadministration of ","suffix":" may not reflect the change in drug concentrations in the li","exact":"nelfinavir"},{"setid":"PMC90851","drugname":"nelfinavir","startOffset":"551","endOffset":"561","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","prefix":"atorvastatin and simvastatin in the presence and absence of ","suffix":" (Table ","exact":"nelfinavir"},{"setid":"PMC90851","drugname":"nelfinavir","startOffset":"238","endOffset":"248","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"hronic coadministration of atorvastatin or simvastatin with ","suffix":" in HIV-positive patients. The greater-than-500% increase in","exact":"nelfinavir"},{"setid":"PMC90851","drugname":"nelfinavir","startOffset":"358","endOffset":"368","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"ncrease in the simvastatin concentration in the presence of ","suffix":" was quite extensive and may increase the risk of skeletal m","exact":"nelfinavir"},{"setid":"PMC90851","drugname":"nelfinavir","startOffset":"515","endOffset":"525","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":" is recommended that simvastatin not be coadministered with ","suffix":". Nelfinavir had a more moderate effect on atorvastatin conc","exact":"nelfinavir"},{"setid":"PMC90851","drugname":"nelfinavir","startOffset":"527","endOffset":"537","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"ded that simvastatin not be coadministered with nelfinavir. ","suffix":" had a more moderate effect on atorvastatin concentrations. ","exact":"Nelfinavir"},{"setid":"PMC90851","drugname":"nelfinavir","startOffset":"792","endOffset":"802","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"tion to achieve the desired effect when coadministered with ","suffix":".","exact":"nelfinavir"},{"setid":"PMC90851","drugname":"nelfinavir","startOffset":"34","endOffset":"44","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[7]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[7]","prefix":"In conclusion, a clinical dose of ","suffix":" (1,250 mg BID) increased systemic exposure to simvastatin a","exact":"nelfinavir"},{"setid":"PMC90851","drugname":"nelfinavir","startOffset":"194","endOffset":"204","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[7]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[7]","prefix":"ecommended for long-term coadministration with simvastatin. ","suffix":" also increased systemic exposure to atorvastatin moderately","exact":"Nelfinavir"},{"setid":"PMC90851","drugname":"atorvastatin","startOffset":"736","endOffset":"748","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"a protease inhibitor, and two HMG-CoA reductase inhibitors, ","suffix":" and simvastatin, in healthy volunteers. Thirty-two healthy ","exact":"atorvastatin"},{"setid":"PMC90851","drugname":"atorvastatin","startOffset":"27","endOffset":"39","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/div[1]/div[2]/span[1]","prefix":"(Left) Comparative plot of ","suffix":" AUC","exact":"atorvastatin"},{"setid":"PMC90851","drugname":"atorvastatin","startOffset":"256","endOffset":"268","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","prefix":"been shown to increase the concentration of simvastatin and ","suffix":" (C. Fichtenbaum, J. Gerber, S. Rosenkranz et al., Abstr. 7t","exact":"atorvastatin"},{"setid":"PMC90851","drugname":"atorvastatin","startOffset":"739","endOffset":"751","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","prefix":"wo HMG-CoA reductase inhibitors were chosen for this study. ","suffix":" was studied because it is the most prescribed HMG-CoA reduc","exact":"Atorvastatin"},{"setid":"PMC90851","drugname":"atorvastatin","startOffset":"139","endOffset":"151","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[2]","prefix":"mine the pharmacokinetic interaction between nelfinavir and ","suffix":" or nelfinavir and simvastatin in healthy volunteers. Thirty","exact":"atorvastatin"},{"setid":"PMC90851","drugname":"atorvastatin","startOffset":"39","endOffset":"51","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[7]/h4[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[7]/h4[1]","prefix":"Pharmacokinetic sample collection. (i) ","suffix":" and simvastatin sample collections ","exact":"Atorvastatin"},{"setid":"PMC90851","drugname":"atorvastatin","startOffset":"5","endOffset":"17","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[10]/h4[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[10]/h4[1]","prefix":"(ii) ","suffix":" and simvastatin. ","exact":"Atorvastatin"},{"setid":"PMC90851","drugname":"atorvastatin","startOffset":"33","endOffset":"45","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[10]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[10]/p[2]","prefix":"Plasma samples were analyzed for ","suffix":" equivalent concentrations (as the total of atorvastatin aci","exact":"atorvastatin"},{"setid":"PMC90851","drugname":"atorvastatin","startOffset":"89","endOffset":"101","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[10]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[10]/p[2]","prefix":"for atorvastatin equivalent concentrations (as the total of ","suffix":" acid and its active metabolites) or simvastatin equivalent ","exact":"atorvastatin"},{"setid":"PMC90851","drugname":"atorvastatin","startOffset":"226","endOffset":"238","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[2]","prefix":"nd three females). One Caucasian male in treatment group 1 (","suffix":" and nelfinavir) developed a rash, requested withdrawal from","exact":"atorvastatin"},{"setid":"PMC90851","drugname":"atorvastatin","startOffset":"411","endOffset":"423","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[2]","prefix":"ic analysis. The mean (standard deviation [SD]) ages of the ","suffix":" and simvastatin groups were 31.5 (5.0) and 38.3 (9.7) years","exact":"atorvastatin"},{"setid":"PMC90851","drugname":"atorvastatin","startOffset":"533","endOffset":"545","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[2]","prefix":"9.7) years, respectively. The mean (SD) body weights of the ","suffix":" and simvastatin groups were 74 (12) and 72 (9) kg, respecti","exact":"atorvastatin"},{"setid":"PMC90851","drugname":"atorvastatin","startOffset":"17","endOffset":"29","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[2]","prefix":"Mean (SD) trough ","suffix":" equivalent concentrations on days 1, 5, 10, 14, 20, 25, and","exact":"atorvastatin"},{"setid":"PMC90851","drugname":"atorvastatin","startOffset":"432","endOffset":"444","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[2]","prefix":" ng-eq/ml. These results indicated that the steady state of ","suffix":" and simvastatin was reached on day 5 in period 1 and betwee","exact":"atorvastatin"},{"setid":"PMC90851","drugname":"atorvastatin","startOffset":"45","endOffset":"57","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[3]","prefix":"The mean (SD) concentration-time profiles of ","suffix":" in the absence and presence of nelfinavir are presented in ","exact":"atorvastatin"},{"setid":"PMC90851","drugname":"atorvastatin","startOffset":"48","endOffset":"60","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/div[1]/div[2]/span[1]","prefix":"Mean (SD) plasma concentration-time profiles of ","suffix":" (ATOR) in the absence and presence of nelfinavir (NFV). eq.","exact":"atorvastatin"},{"setid":"PMC90851","drugname":"atorvastatin","startOffset":"30","endOffset":"42","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[2]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[2]/div[1]/div[2]/span[1]","prefix":"Pharmacokinetic parameters of ","suffix":" and simvastatin","exact":"atorvastatin"},{"setid":"PMC90851","drugname":"atorvastatin","startOffset":"31","endOffset":"43","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[2]","prefix":"Nelfinavir in combination with ","suffix":" or simvastatin was well tolerated in this study. There were","exact":"atorvastatin"},{"setid":"PMC90851","drugname":"atorvastatin","startOffset":"537","endOffset":"549","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"navir and two HMG-CoA reductase inhibitors, simvastatin and ","suffix":", because of the potential for drug interaction and the pote","exact":"atorvastatin"},{"setid":"PMC90851","drugname":"atorvastatin","startOffset":"676","endOffset":"688","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"f the coadministration of these drugs. Both simvastatin and ","suffix":" are extensively metabolized by humans, and a number of acti","exact":"atorvastatin"},{"setid":"PMC90851","drugname":"atorvastatin","startOffset":"849","endOffset":"861","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":" The active metabolites account for most of the activity of ","suffix":" and simvastatin. The enzyme inhibition assay used in this s","exact":"atorvastatin"},{"setid":"PMC90851","drugname":"atorvastatin","startOffset":"193","endOffset":"205","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"t concentrations extensively and increases the steady-state ","suffix":" equivalent concentrations moderately. The geometric mean AU","exact":"atorvastatin"},{"setid":"PMC90851","drugname":"atorvastatin","startOffset":"27","endOffset":"39","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/div[1]/div[2]/span[1]","prefix":"(Left) Comparative plot of ","suffix":" AUC","exact":"atorvastatin"},{"setid":"PMC90851","drugname":"atorvastatin","startOffset":"54","endOffset":"66","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"The interaction between nelfinavir and simvastatin or ","suffix":" is likely due mainly to the inhibition of CYP3A4 by nelfina","exact":"atorvastatin"},{"setid":"PMC90851","drugname":"atorvastatin","startOffset":"368","endOffset":"380","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"ve a major effect on the bioavailability of simvastatin and ","suffix":", and/or at the liver, which would have an effect on the bio","exact":"atorvastatin"},{"setid":"PMC90851","drugname":"atorvastatin","startOffset":"493","endOffset":"505","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"the bioavailability and elimination rate of simvastatin and ","suffix":". In addition, a number of in vitro (","exact":"atorvastatin"},{"setid":"PMC90851","drugname":"atorvastatin","startOffset":"283","endOffset":"295","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","prefix":"tion period. The increase in the systemic concentrations of ","suffix":" and simvastatin caused by the coadministration of nelfinavi","exact":"atorvastatin"},{"setid":"PMC90851","drugname":"atorvastatin","startOffset":"491","endOffset":"503","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","prefix":"eresting to observe similar cholesterol-lowering effects of ","suffix":" and simvastatin in the presence and absence of nelfinavir (","exact":"atorvastatin"},{"setid":"PMC90851","drugname":"atorvastatin","startOffset":"205","endOffset":"217","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"are difficult to extrapolate to chronic coadministration of ","suffix":" or simvastatin with nelfinavir in HIV-positive patients. Th","exact":"atorvastatin"},{"setid":"PMC90851","drugname":"atorvastatin","startOffset":"568","endOffset":"580","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"d with nelfinavir. Nelfinavir had a more moderate effect on ","suffix":" concentrations. The recommended doses of atorvastatin are 1","exact":"atorvastatin"},{"setid":"PMC90851","drugname":"atorvastatin","startOffset":"622","endOffset":"634","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"ct on atorvastatin concentrations. The recommended doses of ","suffix":" are 10 to 80 mg/day. Thus, the 10-mg dose of atorvastatin s","exact":"atorvastatin"},{"setid":"PMC90851","drugname":"atorvastatin","startOffset":"680","endOffset":"692","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"f atorvastatin are 10 to 80 mg/day. Thus, the 10-mg dose of ","suffix":" should be started and titrated with caution to achieve the ","exact":"atorvastatin"},{"setid":"PMC90851","drugname":"atorvastatin","startOffset":"241","endOffset":"253","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[7]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[7]","prefix":"simvastatin. Nelfinavir also increased systemic exposure to ","suffix":" moderately and should be coadministered with atorvastatin w","exact":"atorvastatin"},{"setid":"PMC90851","drugname":"atorvastatin","startOffset":"299","endOffset":"311","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[7]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[7]","prefix":"o atorvastatin moderately and should be coadministered with ","suffix":" with caution.","exact":"atorvastatin"},{"setid":"PMC90851","drugname":"atorvastatin","startOffset":"114","endOffset":"126","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/div[2]/p[1]","prefix":"r excellent statistical analysis of the data and the Pfizer ","suffix":" Team for valuable suggestions for the study.","exact":"Atorvastatin"},{"setid":"PMC90851","drugname":"atorvastatin calcium","startOffset":"833","endOffset":"853","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"thy volunteers. Thirty-two healthy subjects received either ","suffix":" (10 mg once a day) or simvastatin (20 mg once a day) for th","exact":"atorvastatin calcium"},{"setid":"PMC90851","drugname":"simvastatin","startOffset":"753","endOffset":"764","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"tor, and two HMG-CoA reductase inhibitors, atorvastatin and ","suffix":", in healthy volunteers. Thirty-two healthy subjects receive","exact":"simvastatin"},{"setid":"PMC90851","drugname":"simvastatin","startOffset":"876","endOffset":"887","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":" received either atorvastatin calcium (10 mg once a day) or ","suffix":" (20 mg once a day) for the first 14 days of the study. Nelf","exact":"simvastatin"},{"setid":"PMC90851","drugname":"simvastatin","startOffset":"170","endOffset":"181","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[2]","prefix":"ction between nelfinavir and atorvastatin or nelfinavir and ","suffix":" in healthy volunteers. Thirty-two subjects were enrolled in","exact":"simvastatin"},{"setid":"PMC90851","drugname":"simvastatin","startOffset":"138","endOffset":"149","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[10]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[10]/p[2]","prefix":"e total of atorvastatin acid and its active metabolites) or ","suffix":" equivalent concentrations (as the total of simvastatin acid","exact":"simvastatin"},{"setid":"PMC90851","drugname":"simvastatin","startOffset":"193","endOffset":"204","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[10]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[10]/p[2]","prefix":") or simvastatin equivalent concentrations (as the total of ","suffix":" acid and its active metabolites) by a validated enzyme inhi","exact":"simvastatin"},{"setid":"PMC90851","drugname":"simvastatin","startOffset":"47","endOffset":"58","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[2]","prefix":"Nelfinavir in combination with atorvastatin or ","suffix":" was well tolerated in this study. There were no serious adv","exact":"simvastatin"},{"setid":"PMC90851","drugname":"simvastatin","startOffset":"221","endOffset":"232","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":" extrapolate to chronic coadministration of atorvastatin or ","suffix":" with nelfinavir in HIV-positive patients. The greater-than-","exact":"simvastatin"},{"setid":"PMC90851","drugname":"simvastatin","startOffset":"91","endOffset":"102","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[2]/div[2]/div[1]/ul[1]/li[2]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[2]/div[2]/div[1]/ul[1]/li[2]/a[1]","prefix":"dies of co-administration of ticagrelor and atorvastatin or ","suffix":" in healthy volunteers.","exact":"simvastatin"},{"setid":"PMC90851","drugname":"simvastatin","startOffset":"47","endOffset":"58","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[2]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[2]/div[1]/div[2]/span[1]","prefix":"Pharmacokinetic parameters of atorvastatin and ","suffix":"","exact":"simvastatin"},{"setid":"PMC90851","drugname":"simvastatin","startOffset":"47","endOffset":"58","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[2]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[2]/div[1]/div[2]/span[1]","prefix":"Pharmacokinetic parameters of atorvastatin and ","suffix":"","exact":"simvastatin"},{"setid":"PMC90851","drugname":"simvastatin","startOffset":"240","endOffset":"251","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","prefix":"s ritonavir has been shown to increase the concentration of ","suffix":" and atorvastatin (C. Fichtenbaum, J. Gerber, S. Rosenkranz ","exact":"simvastatin"},{"setid":"PMC90851","drugname":"simvastatin","startOffset":"831","endOffset":"842","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","prefix":" it is the most prescribed HMG-CoA reductase inhibitor, and ","suffix":" was studied because it is particularly susceptible to CYP3A","exact":"simvastatin"},{"setid":"PMC90851","drugname":"simvastatin","startOffset":"170","endOffset":"181","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[2]/p[2]","prefix":"ction between nelfinavir and atorvastatin or nelfinavir and ","suffix":" in healthy volunteers. Thirty-two subjects were enrolled in","exact":"simvastatin"},{"setid":"PMC90851","drugname":"simvastatin","startOffset":"31","endOffset":"42","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[2]","prefix":"In period 1, subjects received ","suffix":" (Zocor; 20 mg QD) in the morning for the first 14 days of t","exact":"simvastatin"},{"setid":"PMC90851","drugname":"zocor","startOffset":"44","endOffset":"49","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[2]","prefix":"In period 1, subjects received simvastatin (","suffix":"; 20 mg QD) in the morning for the first 14 days of the stud","exact":"Zocor"},{"setid":"PMC90851","drugname":"simvastatin","startOffset":"143","endOffset":"154","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[2]","prefix":" first 14 days of the study. In period 2, subjects received ","suffix":" (20 mg QD) plus nelfinavir (1,250 mg BID) for an additional","exact":"simvastatin"},{"setid":"PMC90851","drugname":"simvastatin","startOffset":"244","endOffset":"255","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[6]/p[2]","prefix":",250 mg BID) for an additional 14 days (days 15 to 28). All ","suffix":" and nelfinavir doses were taken with food.","exact":"simvastatin"},{"setid":"PMC90851","drugname":"simvastatin","startOffset":"56","endOffset":"67","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[7]/h4[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[7]/h4[1]","prefix":"Pharmacokinetic sample collection. (i) Atorvastatin and ","suffix":" sample collections ","exact":"simvastatin"},{"setid":"PMC90851","drugname":"simvastatin","startOffset":"22","endOffset":"33","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[10]/h4[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[10]/h4[1]","prefix":"(ii) Atorvastatin and ","suffix":". ","exact":"simvastatin"},{"setid":"PMC90851","drugname":"simvastatin","startOffset":"138","endOffset":"149","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[10]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[10]/p[2]","prefix":"e total of atorvastatin acid and its active metabolites) or ","suffix":" equivalent concentrations (as the total of simvastatin acid","exact":"simvastatin"},{"setid":"PMC90851","drugname":"simvastatin","startOffset":"428","endOffset":"439","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[2]","prefix":"mean (standard deviation [SD]) ages of the atorvastatin and ","suffix":" groups were 31.5 (5.0) and 38.3 (9.7) years, respectively. ","exact":"simvastatin"},{"setid":"PMC90851","drugname":"simvastatin","startOffset":"550","endOffset":"561","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[2]/p[2]","prefix":"ctively. The mean (SD) body weights of the atorvastatin and ","suffix":" groups were 74 (12) and 72 (9) kg, respectively.","exact":"simvastatin"},{"setid":"PMC90851","drugname":"simvastatin","startOffset":"217","endOffset":"228","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[2]","prefix":".2), and 3.3 (3.3) ng-eq/ml, respectively. Mean (SD) trough ","suffix":" equivalent concentrations on days 1, 5, 10, 14, 20, 25, and","exact":"simvastatin"},{"setid":"PMC90851","drugname":"simvastatin","startOffset":"449","endOffset":"460","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[2]","prefix":"results indicated that the steady state of atorvastatin and ","suffix":" was reached on day 5 in period 1 and between days 20 to 25 ","exact":"simvastatin"},{"setid":"PMC90851","drugname":"simvastatin","startOffset":"45","endOffset":"56","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[4]","prefix":"The mean (SD) concentration-time profiles of ","suffix":" in the absence and presence of nelfinavir are presented in ","exact":"simvastatin"},{"setid":"PMC90851","drugname":"simvastatin","startOffset":"48","endOffset":"59","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[3]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[3]/div[1]/div[2]/span[1]","prefix":"Mean (SD) plasma concentration-time profiles of ","suffix":" (SIM) in the absence and presence of nelfinavir (NFV). eq.,","exact":"simvastatin"},{"setid":"PMC90851","drugname":"simvastatin","startOffset":"47","endOffset":"58","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[2]","prefix":"Nelfinavir in combination with atorvastatin or ","suffix":" was well tolerated in this study. There were no serious adv","exact":"simvastatin"},{"setid":"PMC90851","drugname":"simvastatin","startOffset":"521","endOffset":"532","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"on between nelfinavir and two HMG-CoA reductase inhibitors, ","suffix":" and atorvastatin, because of the potential for drug interac","exact":"simvastatin"},{"setid":"PMC90851","drugname":"simvastatin","startOffset":"660","endOffset":"671","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":" the potential of the coadministration of these drugs. Both ","suffix":" and atorvastatin are extensively metabolized by humans, and","exact":"simvastatin"},{"setid":"PMC90851","drugname":"simvastatin","startOffset":"866","endOffset":"877","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"olites account for most of the activity of atorvastatin and ","suffix":". The enzyme inhibition assay used in this study measured th","exact":"simvastatin"},{"setid":"PMC90851","drugname":"simvastatin","startOffset":"112","endOffset":"123","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"on of 1,250 mg of nelfinavir BID increases the steady-state ","suffix":" equivalent concentrations extensively and increases the ste","exact":"simvastatin"},{"setid":"PMC90851","drugname":"simvastatin","startOffset":"39","endOffset":"50","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"The interaction between nelfinavir and ","suffix":" or atorvastatin is likely due mainly to the inhibition of C","exact":"simvastatin"},{"setid":"PMC90851","drugname":"simvastatin","startOffset":"352","endOffset":"363","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":", which would have a major effect on the bioavailability of ","suffix":" and atorvastatin, and/or at the liver, which would have an ","exact":"simvastatin"},{"setid":"PMC90851","drugname":"simvastatin","startOffset":"477","endOffset":"488","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"ve an effect on the bioavailability and elimination rate of ","suffix":" and atorvastatin. In addition, a number of in vitro (","exact":"simvastatin"},{"setid":"PMC90851","drugname":"simvastatin","startOffset":"300","endOffset":"311","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","prefix":"increase in the systemic concentrations of atorvastatin and ","suffix":" caused by the coadministration of nelfinavir may not reflec","exact":"simvastatin"},{"setid":"PMC90851","drugname":"simvastatin","startOffset":"508","endOffset":"519","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","prefix":"ve similar cholesterol-lowering effects of atorvastatin and ","suffix":" in the presence and absence of nelfinavir (Table ","exact":"simvastatin"},{"setid":"PMC90851","drugname":"simvastatin","startOffset":"221","endOffset":"232","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":" extrapolate to chronic coadministration of atorvastatin or ","suffix":" with nelfinavir in HIV-positive patients. The greater-than-","exact":"simvastatin"},{"setid":"PMC90851","drugname":"simvastatin","startOffset":"313","endOffset":"324","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"IV-positive patients. The greater-than-500% increase in the ","suffix":" concentration in the presence of nelfinavir was quite exten","exact":"simvastatin"},{"setid":"PMC90851","drugname":"simvastatin","startOffset":"476","endOffset":"487","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"f skeletal muscle damage. Therefore, it is recommended that ","suffix":" not be coadministered with nelfinavir. Nelfinavir had a mor","exact":"simvastatin"},{"setid":"PMC90851","drugname":"simvastatin","startOffset":"91","endOffset":"102","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[7]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[7]","prefix":"of nelfinavir (1,250 mg BID) increased systemic exposure to ","suffix":" approximately 500% and is not recommended for long-term coa","exact":"simvastatin"},{"setid":"PMC90851","drugname":"simvastatin","startOffset":"181","endOffset":"192","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[7]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[7]","prefix":" and is not recommended for long-term coadministration with ","suffix":". Nelfinavir also increased systemic exposure to atorvastati","exact":"simvastatin"},{"setid":"PMC90851","drugname":"itraconazole","startOffset":"180","endOffset":"192","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":"uctase inhibitors with CYP3A4 inhibitors/substrates such as ","suffix":" (","exact":"itraconazole"},{"setid":"PMC90851","drugname":"cyclosporine","startOffset":"198","endOffset":"210","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[9]/div[2]/div[11]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[9]/div[2]/div[11]/span[1]","prefix":"tatin and lovastatin in renal transplant patients receiving ","suffix":". ","exact":"cyclosporine"},{"setid":"PMC90851","drugname":"saquinavir","startOffset":"166","endOffset":"176","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","prefix":"itors of CYP3A4. The dual protease inhibitor combination of ","suffix":" plus ritonavir has been shown to increase the concentration","exact":"saquinavir"},{"setid":"PMC90851","drugname":"ritonavir","startOffset":"182","endOffset":"191","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","prefix":" The dual protease inhibitor combination of saquinavir plus ","suffix":" has been shown to increase the concentration of simvastatin","exact":"ritonavir"},{"setid":"PMC90851","drugname":"ritonavir","startOffset":"514","endOffset":"523","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","prefix":" CYP3A4, although it is not as strong a CYP3A4 inhibitor as ","suffix":". Nelfinavir is a widely prescribed protease inhibitor. It i","exact":"ritonavir"},{"setid":"PMC90851","drugname":"retrovir","startOffset":"336","endOffset":"344","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","prefix":"htenbaum, J. Gerber, S. Rosenkranz et al., Abstr. 7th Conf. ","suffix":". Opportunistic Infect., abstr LB 6, 2000). Nelfinavir, like","exact":"Retrovir"},{"setid":"PMC90851","drugname":"insulin","startOffset":"215","endOffset":"222","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[11]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[11]/p[2]","prefix":"ol, low-density lipoproteins (LDL), triglycerides, glucose, ","suffix":", and C-peptide, were determined after an overnight fast on ","exact":"insulin"},{"setid":"PMC90851","drugname":"benadryl","startOffset":"605","endOffset":"613","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[2]","prefix":" 23 and withdrew from the study. Subject 3 was treated with ","suffix":" and prednisone orally plus Kenalog intramuscularly. The ras","exact":"Benadryl"},{"setid":"PMC90851","drugname":"prednisone","startOffset":"618","endOffset":"628","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[2]","prefix":"rew from the study. Subject 3 was treated with Benadryl and ","suffix":" orally plus Kenalog intramuscularly. The rash resolved afte","exact":"prednisone"},{"setid":"PMC90851","drugname":"kenalog","startOffset":"641","endOffset":"648","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[2]","prefix":"ject 3 was treated with Benadryl and prednisone orally plus ","suffix":" intramuscularly. The rash resolved after 13 days. Subject 1","exact":"Kenalog"},{"setid":"PMC90851","drugname":"tylenol","startOffset":"773","endOffset":"780","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[2]","prefix":"erienced a severe migraine headache, which was treated with ","suffix":" and resolved after 2 days. Seven subjects received medicati","exact":"Tylenol"}],[{"setid":"PMC2686068","drugname":"simvastatin","startOffset":"135","endOffset":"146","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":"udy in 12 healthy subjects was performed. Subjects received ","suffix":" 40 mg alone or anacetrapib 150 mg co-administered with simv","exact":"simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":"202","endOffset":"213","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":"atin 40 mg alone or anacetrapib 150 mg co-administered with ","suffix":" 40 mg, once daily. Both treatments were administered follow","exact":"simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":"387","endOffset":"398","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":"sh-out period of at least 14 days. Safety and tolerability, ","suffix":" and simvastatin acid concentrations, and lipoproteins, were","exact":"simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":"61","endOffset":"72","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"oth treatments were well tolerated. The pharmacokinetics of ","suffix":" and simvastatin acid were similar with and without anacetra","exact":"simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":"24","endOffset":"35","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"The pharmacokinetics of ","suffix":" and simvastatin acid were similar with and without anacetra","exact":"simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":"104","endOffset":"115","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","prefix":" effect of anacetrapib on the pharmacokinetic parameters of ","suffix":". When co-administered with simvastatin, anacetrapib appeare","exact":"simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":"130","endOffset":"141","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/ul[1]/li[1]/div[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/ul[1]/li[1]/div[1]","prefix":" effect of anacetrapib on the pharmacokinetic parameters of ","suffix":".","exact":"simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":"143","endOffset":"154","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","prefix":"inetic parameters of simvastatin. When co-administered with ","suffix":", anacetrapib appeared to exhibit incremental LDL-C-lowering","exact":"simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":"286","endOffset":"297","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","prefix":"ue to CETP inhibition. Co-administration of anacetrapib and ","suffix":" was well tolerated.","exact":"simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":"24","endOffset":"35","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","prefix":"CETP inhibition, LDL-C, ","suffix":"","exact":"simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":"104","endOffset":"115","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","prefix":" effect of anacetrapib on the pharmacokinetic parameters of ","suffix":". When co-administered with simvastatin, anacetrapib appeare","exact":"simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":"130","endOffset":"141","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/ul[1]/li[1]/div[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/ul[1]/li[1]/div[1]","prefix":" effect of anacetrapib on the pharmacokinetic parameters of ","suffix":".","exact":"simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":"26","endOffset":"37","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/ul[1]/li[2]/div[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/ul[1]/li[2]/div[1]","prefix":"When co-administered with ","suffix":", anacetrapib appeared to exhibit incremental LDL-C-and apol","exact":"simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":"124","endOffset":"135","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[3]","prefix":" quantify any potential pharmacokinetic interaction between ","suffix":" and anacetrapib, following multiple oral doses of each, whe","exact":"simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":"448","endOffset":"459","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[3]","prefix":". Safety and tolerability of treatment with anacetrapib and ","suffix":" were also assessed.","exact":"simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":"181","endOffset":"192","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","prefix":"ment A, subjects received a once daily oral dose of a 40-mg ","suffix":" tablet (ZOCOR™) for 14 days in the morning. In Treatment B,","exact":"simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":"399","endOffset":"410","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[1]","prefix":"les, co-administered with a once-daily oral dose of a 40-mg ","suffix":" tablet for 14 days in the morning. All doses were administe","exact":"simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":"34","endOffset":"45","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[2]","prefix":"Pharmacokinetic blood samples for ","suffix":" and simvastatin acid were collected on day 14 of Treatments","exact":"simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":"47","endOffset":"58","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","prefix":"The safety and tolerability of anacetrapib and ","suffix":" were assessed throughout the study by physical examinations","exact":"simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":"56","endOffset":"67","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[2]","prefix":"The pharmacokinetic parameters for simvastatin acid and ","suffix":", AUC","exact":"simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":"45","endOffset":"56","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"Anacetrapib administered in combination with ","suffix":" was generally well tolerated. There were no serious clinica","exact":"simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":"24","endOffset":"35","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"The pharmacokinetics of ","suffix":" and simvastatin acid were similar with and without anacetra","exact":"simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":"32","endOffset":"43","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/div[1]/div[2]/span[1]","prefix":"Summary of simvastatin acid and ","suffix":" pharmacokinetic parameters","exact":"simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":"72","endOffset":"83","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[1]/h1[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[1]/h1[1]","prefix":"f a pharmacokinetic and pharmacodynamic interaction between ","suffix":" and anacetrapib, a potent cholesteryl ester transfer protei","exact":"simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":"387","endOffset":"398","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":"sh-out period of at least 14 days. Safety and tolerability, ","suffix":" and simvastatin acid concentrations, and lipoproteins, were","exact":"simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":"403","endOffset":"414","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[2]/p[1]","prefix":" at least 14 days. Safety and tolerability, simvastatin and ","suffix":" acid concentrations, and lipoproteins, were assessed.","exact":"simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":"77","endOffset":"88","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[3]/p[1]","prefix":"ere well tolerated. The pharmacokinetics of simvastatin and ","suffix":" acid were similar with and without anacetrapib administrati","exact":"simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":"286","endOffset":"297","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[4]/p[1]","prefix":"ue to CETP inhibition. Co-administration of anacetrapib and ","suffix":" was well tolerated.","exact":"simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":"448","endOffset":"459","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[3]","prefix":". Safety and tolerability of treatment with anacetrapib and ","suffix":" were also assessed.","exact":"simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":"50","endOffset":"61","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[2]","prefix":"Pharmacokinetic blood samples for simvastatin and ","suffix":" acid were collected on day 14 of Treatments A and B and pre","exact":"simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":"47","endOffset":"58","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","prefix":"The safety and tolerability of anacetrapib and ","suffix":" were assessed throughout the study by physical examinations","exact":"simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":"56","endOffset":"67","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[2]","prefix":"The pharmacokinetic parameters for simvastatin acid and ","suffix":", AUC","exact":"simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":"40","endOffset":"51","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"The pharmacokinetics of simvastatin and ","suffix":" acid were similar with and without anacetrapib administrati","exact":"simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":"32","endOffset":"43","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[2]/div[1]/div[2]/span[1]","prefix":"Summary of simvastatin acid and ","suffix":" pharmacokinetic parameters","exact":"simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":"64","endOffset":"75","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[1]/div[2]/span[1]","prefix":"ma concentration–time profiles for simvastatin acid (A) and ","suffix":" (B). Treatment A (Simvastatin alone) (—•—); Treatment B (Si","exact":"simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":"262","endOffset":"273","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[7]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[7]","prefix":"o B-lowering efficacy. Co-administration of anacetrapib and ","suffix":" was well tolerated.","exact":"simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":"282","endOffset":"293","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[9]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[9]/p[2]","prefix":"ssistance of Rita Chiou and Jin Zhang in outsourcing of the ","suffix":" assay, and the assistance of Josee Cote at the conclusion o","exact":"simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":"74","endOffset":"85","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[11]/div[2]/div[9]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[11]/div[2]/div[9]/span[1]","prefix":"dation of a method for the determination of simvastatin and ","suffix":" acid in human plasma by HPLC with MS/MS detection.  Method ","exact":"simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":"81","endOffset":"92","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[11]/div[2]/div[11]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[11]/div[2]/div[11]/span[1]","prefix":" van Schenck H, Olsson AG. Long-term efficacy and safety of ","suffix":" alone and in combination therapy in treatment of hyperchole","exact":"simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":"91","endOffset":"102","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[11]/div[2]/div[12]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[11]/div[2]/div[12]/span[1]","prefix":" PT. Erythromycin and verapamil considerably increase serum ","suffix":" and simvastatin acid concentrations. ","exact":"simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":"107","endOffset":"118","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[11]/div[2]/div[12]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[11]/div[2]/div[12]/span[1]","prefix":"n and verapamil considerably increase serum simvastatin and ","suffix":" acid concentrations. ","exact":"simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":"111","endOffset":"122","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[11]/div[2]/div[13]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[11]/div[2]/div[13]/span[1]","prefix":"t JA. Concomitant use of cytochrome P450 3A4 inhibitors and ","suffix":". ","exact":"simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":"229","endOffset":"240","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[11]/div[2]/div[14]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[11]/div[2]/div[14]/span[1]","prefix":"ew selective cholesterol absorption inhibitor ezetimibe and ","suffix":". ","exact":"simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":"72","endOffset":"83","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[5]/div[2]/div[1]/div[1]/ul[1]/li[1]/div[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[5]/div[2]/div[1]/div[1]/ul[1]/li[1]/div[1]","prefix":"f a pharmacokinetic and pharmacodynamic interaction between ","suffix":" and anacetrapib, a potent cholesteryl ester transfer protei","exact":"simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":"33","endOffset":"44","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[3]/div[2]/ul[1]/li[3]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[3]/div[2]/ul[1]/li[3]/a[1]","prefix":"Long-term efficacy and safety of ","suffix":" alone and in combination therapy in treatment of hyperchole","exact":"simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":"55","endOffset":"66","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[4]/div[2]/ul[1]/li[1]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[4]/div[2]/ul[1]/li[1]/a[1]","prefix":"Erythromycin and verapamil considerably increase serum ","suffix":" and simvastatin acid concentrations.","exact":"simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":"71","endOffset":"82","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[4]/div[2]/ul[1]/li[1]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[4]/div[2]/ul[1]/li[1]/a[1]","prefix":"n and verapamil considerably increase serum simvastatin and ","suffix":" acid concentrations.","exact":"simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":"33","endOffset":"44","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[6]/div[2]/ul[1]/li[3]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[6]/div[2]/ul[1]/li[3]/a[1]","prefix":"Long-term efficacy and safety of ","suffix":" alone and in combination therapy in treatment of hyperchole","exact":"simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":"74","endOffset":"85","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[3]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[3]/span[1]","prefix":"dation of a method for the determination of simvastatin and ","suffix":" acid in human plasma by HPLC with MS/MS detection.  Method ","exact":"simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":"33","endOffset":"44","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[9]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[9]","prefix":"Long-term efficacy and safety of ","suffix":" alone and in combination therapy in treatment of hyperchole","exact":"simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":"55","endOffset":"66","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[10]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[10]","prefix":"Erythromycin and verapamil considerably increase serum ","suffix":" and simvastatin acid concentrations.","exact":"simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":"71","endOffset":"82","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[10]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[10]","prefix":"n and verapamil considerably increase serum simvastatin and ","suffix":" acid concentrations.","exact":"simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":"94","endOffset":"105","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[1]/div[2]/span[1]","prefix":" for simvastatin acid (A) and simvastatin (B). Treatment A (","suffix":" alone) (—•—); Treatment B (Simvastatin + Anacetrapib) (—○—)","exact":"Simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":"94","endOffset":"105","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[1]/div[2]/span[1]","prefix":" for simvastatin acid (A) and simvastatin (B). Treatment A (","suffix":" alone) (—•—); Treatment B (Simvastatin + Anacetrapib) (—○—)","exact":"Simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":"133","endOffset":"144","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/div[3]/div[1]/div[2]/span[1]","prefix":"in (B). Treatment A (Simvastatin alone) (—•—); Treatment B (","suffix":" + Anacetrapib) (—○—)","exact":"Simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":"174","endOffset":"185","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","prefix":" the effect of anacetrapib on simvastatin pharmacokinetics. ","suffix":" is a lactone that is readily hydrolysed ","exact":"Simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":"7","endOffset":"18","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[11]/div[2]/div[10]/span[1]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[11]/div[2]/div[10]/span[1]/span[1]","prefix":"Zocor (","suffix":") Product Circular.","exact":"Simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":"7","endOffset":"18","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[4]/span[1]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[4]/span[1]/span[1]","prefix":"Zocor (","suffix":") Product Circular.","exact":"Simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":"334","endOffset":"345","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[1]/p[1]","prefix":"aluate the potential for a pharmacokinetic interaction with ","suffix":".","exact":"simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":"24","endOffset":"35","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","prefix":"CETP inhibition, LDL-C, ","suffix":"","exact":"simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":"130","endOffset":"141","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/ul[1]/li[1]/div[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/ul[1]/li[1]/div[1]","prefix":" effect of anacetrapib on the pharmacokinetic parameters of ","suffix":".","exact":"simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":"111","endOffset":"122","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[11]/div[2]/div[13]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[11]/div[2]/div[13]/span[1]","prefix":"t JA. Concomitant use of cytochrome P450 3A4 inhibitors and ","suffix":". ","exact":"simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":"229","endOffset":"240","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[11]/div[2]/div[14]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[11]/div[2]/div[14]/span[1]","prefix":"ew selective cholesterol absorption inhibitor ezetimibe and ","suffix":". ","exact":"simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":"101","endOffset":"112","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[4]/div[2]/ul[1]/li[2]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[4]/div[2]/ul[1]/li[2]/a[1]","prefix":"ew selective cholesterol absorption inhibitor ezetimibe and ","suffix":".","exact":"simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":"101","endOffset":"112","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[6]/div[2]/ul[1]/li[2]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[6]/div[2]/ul[1]/li[2]/a[1]","prefix":"ew selective cholesterol absorption inhibitor ezetimibe and ","suffix":".","exact":"simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":"101","endOffset":"112","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[11]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[11]","prefix":"ew selective cholesterol absorption inhibitor ezetimibe and ","suffix":".","exact":"simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":"334","endOffset":"345","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[1]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/div[1]/p[1]","prefix":"aluate the potential for a pharmacokinetic interaction with ","suffix":".","exact":"simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":"24","endOffset":"35","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[3]/span[1]","prefix":"CETP inhibition, LDL-C, ","suffix":"","exact":"simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":"130","endOffset":"141","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/ul[1]/li[1]/div[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[2]/div[1]/ul[1]/li[1]/div[1]","prefix":" effect of anacetrapib on the pharmacokinetic parameters of ","suffix":".","exact":"simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":"111","endOffset":"122","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[11]/div[2]/div[13]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[11]/div[2]/div[13]/span[1]","prefix":"t JA. Concomitant use of cytochrome P450 3A4 inhibitors and ","suffix":". ","exact":"simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":"229","endOffset":"240","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[11]/div[2]/div[14]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[11]/div[2]/div[14]/span[1]","prefix":"ew selective cholesterol absorption inhibitor ezetimibe and ","suffix":". ","exact":"simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":"101","endOffset":"112","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[4]/div[2]/ul[1]/li[2]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[4]/div[2]/ul[1]/li[2]/a[1]","prefix":"ew selective cholesterol absorption inhibitor ezetimibe and ","suffix":".","exact":"simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":"101","endOffset":"112","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[6]/div[2]/ul[1]/li[2]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[6]/div[2]/ul[1]/li[2]/a[1]","prefix":"ew selective cholesterol absorption inhibitor ezetimibe and ","suffix":".","exact":"simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":"101","endOffset":"112","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[11]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[11]","prefix":"ew selective cholesterol absorption inhibitor ezetimibe and ","suffix":".","exact":"simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":"69","endOffset":"80","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","prefix":" explored primarily the pharmacokinetic interaction between ","suffix":" and anacetrapib, as it relates to the effect of anacetrapib","exact":"simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":"144","endOffset":"155","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","prefix":" anacetrapib, as it relates to the effect of anacetrapib on ","suffix":" pharmacokinetics. Simvastatin is a lactone that is readily ","exact":"simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":"174","endOffset":"185","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[1]","prefix":" the effect of anacetrapib on simvastatin pharmacokinetics. ","suffix":" is a lactone that is readily hydrolysed ","exact":"Simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":"119","endOffset":"130","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","prefix":"meaningful effect of anacetrapib on the pharmacokinetics of ","suffix":" (simvastatin acid or simvastatin). This is not unexpected, ","exact":"simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":"94","endOffset":"105","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[7]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[7]","prefix":"meaningful effect of anacetrapib on the pharmacokinetics of ","suffix":". When co-administered with simvastatin, anacetrapib appeare","exact":"simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":"152","endOffset":"163","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","prefix":"on the pharmacokinetics of simvastatin (simvastatin acid or ","suffix":"). This is not unexpected, given data in the literature show","exact":"simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":"250","endOffset":"261","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[2]","prefix":"given data in the literature showing drug interactions with ","suffix":" were metabolic in nature, as a result of inhibition or indu","exact":"simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":"126","endOffset":"137","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","prefix":"icularly the lipid-altering biomarkers, interaction between ","suffix":" and anacetrapib. Anacetrapib is an investigational CETP inh","exact":"simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":"15","endOffset":"26","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","prefix":"In this study, ","suffix":" alone reduced LDL-C by 36% and Apo B by 29%, whereas in com","exact":"simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":"94","endOffset":"105","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[7]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[7]","prefix":"meaningful effect of anacetrapib on the pharmacokinetics of ","suffix":". When co-administered with simvastatin, anacetrapib appeare","exact":"simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":"133","endOffset":"144","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[7]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[7]","prefix":" pharmacokinetics of simvastatin. When co-administered with ","suffix":", anacetrapib appeared to exhibit incremental LDL-C-and Apo ","exact":"simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":"262","endOffset":"273","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[7]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[7]","prefix":"o B-lowering efficacy. Co-administration of anacetrapib and ","suffix":" was well tolerated.","exact":"simvastatin"},{"setid":"PMC2686068","drugname":"simvastatin","startOffset":"282","endOffset":"293","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[9]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[9]/p[2]","prefix":"ssistance of Rita Chiou and Jin Zhang in outsourcing of the ","suffix":" assay, and the assistance of Josee Cote at the conclusion o","exact":"simvastatin"},{"setid":"PMC2686068","drugname":"cholesterol","startOffset":"328","endOffset":"339","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[1]/div[1]/ul[1]/li[2]/div[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[1]/div[1]/ul[1]/li[2]/div[1]","prefix":"bitor and a statin, and whether the low-density lipoprotein-","suffix":" (LDL-C)-lowering effects are additive with the combination.","exact":"cholesterol"},{"setid":"PMC2686068","drugname":"torcetrapib","startOffset":"79","endOffset":"90","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[1]/div[1]/ul[1]/li[2]/div[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/div[1]/div[1]/ul[1]/li[2]/div[1]","prefix":"blished to date with other investigational CETP inhibitors, ","suffix":" (Pfizer) and dalcetrapib (Roche), have been evaluated in th","exact":"torcetrapib"},{"setid":"PMC2686068","drugname":"midazolam","startOffset":"2","endOffset":"11","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/p[2]","prefix":"A ","suffix":" clinical study in healthy subjects for the assessment of ef","exact":"midazolam"},{"setid":"PMC2686068","drugname":"creatinine","startOffset":"228","endOffset":"238","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","prefix":"s (serum sodium, potassium, chloride, bicarbonate, calcium, ","suffix":", blood urea nitrogen, fasting serum glucose, bilirubin, asp","exact":"creatinine"},{"setid":"PMC2686068","drugname":"urea","startOffset":"246","endOffset":"250","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","prefix":"otassium, chloride, bicarbonate, calcium, creatinine, blood ","suffix":" nitrogen, fasting serum glucose, bilirubin, aspartate amino","exact":"urea"},{"setid":"PMC2686068","drugname":"alanine","startOffset":"323","endOffset":"330","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[1]","prefix":"sting serum glucose, bilirubin, aspartate aminotransferase, ","suffix":" aminotransferase, alkaline phosphatase, albumin; haemoglobi","exact":"alanine"},{"setid":"PMC2686068","drugname":"atorvastatin","startOffset":"372","endOffset":"384","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[3]","prefix":"ith dyslipidaemia, both alone as well as in the presence of ","suffix":" [","exact":"atorvastatin"},{"setid":"PMC2686068","drugname":"atorvastatin","startOffset":"807","endOffset":"819","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","prefix":"with the findings observed with anacetrapib (10–300 mg) and ","suffix":" 20 mg in the Phase 2b study, wherein atorvastatin 20 mg red","exact":"atorvastatin"},{"setid":"PMC2686068","drugname":"atorvastatin","startOffset":"857","endOffset":"869","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","prefix":"0 mg) and atorvastatin 20 mg in the Phase 2b study, wherein ","suffix":" 20 mg reduced LDL-C by approximately 42% and when atorvasta","exact":"atorvastatin"},{"setid":"PMC2686068","drugname":"atorvastatin","startOffset":"920","endOffset":"932","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[4]","prefix":"rvastatin 20 mg reduced LDL-C by approximately 42% and when ","suffix":" 20 mg was given with anacetrapib 150 mg, LDL-C was reduced ","exact":"atorvastatin"},{"setid":"PMC2686068","drugname":"atorvastatin","startOffset":"84","endOffset":"96","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[8]/p[6]","prefix":"ears to have less than additive lipid-altering effects with ","suffix":" [","exact":"atorvastatin"}],[{"setid":"PMC3187007","drugname":"telaprevir","startOffset":"287","endOffset":"297","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"atitis C. This study was conducted to examine the effect of ","suffix":" on atorvastatin and amlodipine pharmacokinetics (PK). This ","exact":"telaprevir"},{"setid":"PMC3187007","drugname":"telaprevir","startOffset":"547","endOffset":"557","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"mlodipine and 20 mg atorvastatin was administered on day 1. ","suffix":" was taken with food as a 750-mg dose every 8 h from day 11 ","exact":"Telaprevir"},{"setid":"PMC3187007","drugname":"telaprevir","startOffset":"783","endOffset":"793","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"lasma samples were collected for determination of the PK of ","suffix":", amlodipine, atorvastatin, ","exact":"telaprevir"},{"setid":"PMC3187007","drugname":"telaprevir","startOffset":"0","endOffset":"10","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","prefix":"","suffix":" is an orally administered inhibitor of the nonstructural 3/","exact":"Telaprevir"},{"setid":"PMC3187007","drugname":"telaprevir","startOffset":"0","endOffset":"10","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","prefix":"","suffix":" inhibits CYP3A-mediated metabolism at therapeutic concentra","exact":"Telaprevir"},{"setid":"PMC3187007","drugname":"telaprevir","startOffset":"217","endOffset":"227","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","prefix":"was designed to evaluate the drug-drug interactions between ","suffix":" and amlodipine and atorvastatin in healthy volunteers.","exact":"telaprevir"},{"setid":"PMC3187007","drugname":"telaprevir","startOffset":"70","endOffset":"80","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[2]","prefix":" phase 1, open-label, single-center, nonrandomized study of ","suffix":" in combination with Caduet tablets containing 5 mg of amlod","exact":"telaprevir"},{"setid":"PMC3187007","drugname":"telaprevir","startOffset":"331","endOffset":"341","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[2]","prefix":"-atorvastatin alone on day 1, followed by a washout period, ","suffix":" at a dose of 750 mg every 8 h (q8h) on days 11 through 26, ","exact":"telaprevir"},{"setid":"PMC3187007","drugname":"telaprevir","startOffset":"0","endOffset":"10","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"","suffix":" is a hepatitis C virus protease inhibitor that is both a su","exact":"Telaprevir"},{"setid":"PMC3187007","drugname":"telaprevir","startOffset":"0","endOffset":"10","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[1]","prefix":"","suffix":" is an orally administered inhibitor of the nonstructural 3/","exact":"Telaprevir"},{"setid":"PMC3187007","drugname":"telaprevir","startOffset":"0","endOffset":"10","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","prefix":"","suffix":" inhibits CYP3A-mediated metabolism at therapeutic concentra","exact":"Telaprevir"},{"setid":"PMC3187007","drugname":"telaprevir","startOffset":"0","endOffset":"10","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[2]","prefix":"","suffix":" (375-mg tablets, Patheon, Mississauga, Ontario, Canada) was","exact":"Telaprevir"},{"setid":"PMC3187007","drugname":"telaprevir","startOffset":"0","endOffset":"10","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[10]/div[2]/div[8]/span[1]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[10]/div[2]/div[8]/span[1]/span[1]","prefix":"","suffix":" for previously untreated chronic hepatitis C virus infectio","exact":"Telaprevir"},{"setid":"PMC3187007","drugname":"telaprevir","startOffset":"0","endOffset":"10","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[10]/div[2]/div[17]/span[1]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[10]/div[2]/div[17]/span[1]/span[1]","prefix":"","suffix":" in combination with peginterferon alfa-2a and ribavirin for","exact":"Telaprevir"},{"setid":"PMC3187007","drugname":"telaprevir","startOffset":"0","endOffset":"10","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[10]/div[2]/div[23]/span[1]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[10]/div[2]/div[23]/span[1]/span[1]","prefix":"","suffix":" for retreatment of HCV infection","exact":"Telaprevir"},{"setid":"PMC3187007","drugname":"telaprevir","startOffset":"0","endOffset":"10","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[2]/div[2]/div[1]/ul[1]/li[5]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[2]/div[2]/div[1]/ul[1]/li[5]/a[1]","prefix":"","suffix":": pharmacokinetics and drug interactions.","exact":"Telaprevir"},{"setid":"PMC3187007","drugname":"telaprevir","startOffset":"0","endOffset":"10","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[1]/div[2]/ul[1]/li[2]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[1]/div[2]/ul[1]/li[2]/a[1]","prefix":"","suffix":" for previously untreated chronic hepatitis C virus infectio","exact":"Telaprevir"},{"setid":"PMC3187007","drugname":"telaprevir","startOffset":"0","endOffset":"10","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[1]/div[2]/ul[1]/li[3]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[1]/div[2]/ul[1]/li[3]/a[1]","prefix":"","suffix":" for retreatment of HCV infection.","exact":"Telaprevir"},{"setid":"PMC3187007","drugname":"telaprevir","startOffset":"0","endOffset":"10","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[9]/div[2]/ul[1]/li[1]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[9]/div[2]/ul[1]/li[1]/a[1]","prefix":"","suffix":" for previously untreated chronic hepatitis C virus infectio","exact":"Telaprevir"},{"setid":"PMC3187007","drugname":"telaprevir","startOffset":"0","endOffset":"10","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[9]/div[2]/ul[1]/li[2]/a[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[6]/div[9]/div[2]/ul[1]/li[2]/a[1]","prefix":"","suffix":" for retreatment of HCV infection.","exact":"Telaprevir"},{"setid":"PMC3187007","drugname":"telaprevir","startOffset":"0","endOffset":"10","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[2]","prefix":"","suffix":" for previously untreated chronic hepatitis C virus infectio","exact":"Telaprevir"},{"setid":"PMC3187007","drugname":"telaprevir","startOffset":"0","endOffset":"10","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[3]/span[1]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[3]/span[1]/span[1]","prefix":"","suffix":" in combination with peginterferon alfa-2a and ribavirin for","exact":"Telaprevir"},{"setid":"PMC3187007","drugname":"telaprevir","startOffset":"0","endOffset":"10","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[4]/div[4]","prefix":"","suffix":" for retreatment of HCV infection.","exact":"Telaprevir"},{"setid":"PMC3187007","drugname":"telaprevir","startOffset":"332","endOffset":"342","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[7]/p[2]","prefix":"dministered alone and when administered in combination with ","suffix":". Clinical chemistry and hematology were assessed predose an","exact":"telaprevir"},{"setid":"PMC3187007","drugname":"telaprevir","startOffset":"100","endOffset":"110","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/div[1]/div[2]/span[1]","prefix":"f amlodipine following oral administration with and without ","suffix":". Error bars represent the standard error of the mean.","exact":"telaprevir"},{"setid":"PMC3187007","drugname":"telaprevir","startOffset":"11","endOffset":"21","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[2]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[2]/div[1]/div[2]/span[1]","prefix":"Effects of ","suffix":" on the PK of amlodipine, atorvastatin, and its metabolite ","exact":"telaprevir"},{"setid":"PMC3187007","drugname":"telaprevir","startOffset":"102","endOffset":"112","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/div[1]/div[1]/div[2]/span[1]","prefix":"atorvastatin following oral administration with and without ","suffix":". Error bars represent the standard error of the mean.","exact":"telaprevir"},{"setid":"PMC3187007","drugname":"telaprevir","startOffset":"102","endOffset":"112","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/div[1]/div[1]/div[2]/span[1]","prefix":"atorvastatin following oral administration with and without ","suffix":". Error bars represent the standard error of the mean.","exact":"telaprevir"},{"setid":"PMC3187007","drugname":"telaprevir","startOffset":"69","endOffset":"79","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[2]","prefix":"steady-state pharmacokinetic parameters were calculated for ","suffix":" on day 17 after coadministration with a single dose of amlo","exact":"telaprevir"},{"setid":"PMC3187007","drugname":"telaprevir","startOffset":"147","endOffset":"157","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[2]","prefix":"he study due to an adverse event (herpes zoster) during the ","suffix":"-alone period. This was considered possibly related to treat","exact":"telaprevir"},{"setid":"PMC3187007","drugname":"telaprevir","startOffset":"428","endOffset":"438","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[2]","prefix":"exception was moderate diarrhea in one volunteer during the ","suffix":"-amlodipine-atorvastatin combination period.","exact":"telaprevir"},{"setid":"PMC3187007","drugname":"telaprevir","startOffset":"547","endOffset":"557","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[3]","prefix":"atorvastatin-alone period, in 2 volunteers [10%] during the ","suffix":"-alone period, and in 1 volunteer [5%] during the telaprevir","exact":"telaprevir"},{"setid":"PMC3187007","drugname":"telaprevir","startOffset":"607","endOffset":"617","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[3]","prefix":"telaprevir-alone period, and in 1 volunteer [5%] during the ","suffix":"-amlodipine-atorvastatin combination period); dizziness (occ","exact":"telaprevir"},{"setid":"PMC3187007","drugname":"telaprevir","startOffset":"716","endOffset":"726","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[3]","prefix":"riod); dizziness (occurred in 2 volunteers [10%] during the ","suffix":"-alone period, and in 3 volunteers [15%] during the telaprev","exact":"telaprevir"},{"setid":"PMC3187007","drugname":"telaprevir","startOffset":"778","endOffset":"788","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[3]","prefix":"laprevir-alone period, and in 3 volunteers [15%] during the ","suffix":"-amlodipine-atorvastatin combination period); diarrhea (occu","exact":"telaprevir"},{"setid":"PMC3187007","drugname":"telaprevir","startOffset":"952","endOffset":"962","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[3]","prefix":"3 periods); nausea (occurred in 1 volunteer [5%] during the ","suffix":"-alone period and in 2 volunteers [11%] during the telaprevi","exact":"telaprevir"},{"setid":"PMC3187007","drugname":"telaprevir","startOffset":"1013","endOffset":"1023","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[3]","prefix":"elaprevir-alone period and in 2 volunteers [11%] during the ","suffix":"-amlodipine-atorvastatin combination period). Rash has been ","exact":"telaprevir"},{"setid":"PMC3187007","drugname":"telaprevir","startOffset":"1108","endOffset":"1118","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[3]","prefix":"combination period). Rash has been previously reported with ","suffix":" administration (","exact":"telaprevir"},{"setid":"PMC3187007","drugname":"telaprevir","startOffset":"36","endOffset":"46","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"Potential drug-drug interactions of ","suffix":" with amlodipine and atorvastatin were investigated in healt","exact":"telaprevir"},{"setid":"PMC3187007","drugname":"telaprevir","startOffset":"196","endOffset":"206","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":" PK of these drugs with and without the coadministration of ","suffix":". A formulation containing a combination of amlodipine and a","exact":"telaprevir"},{"setid":"PMC3187007","drugname":"telaprevir","startOffset":"42","endOffset":"52","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"A clinical drug-drug interaction study of ","suffix":" and midazolam showed that telaprevir increased the AUC of o","exact":"telaprevir"},{"setid":"PMC3187007","drugname":"telaprevir","startOffset":"79","endOffset":"89","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"g interaction study of telaprevir and midazolam showed that ","suffix":" increased the AUC of oral midazolam almost 9-fold (","exact":"telaprevir"},{"setid":"PMC3187007","drugname":"telaprevir","startOffset":"45","endOffset":"55","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"Results from the present study indicate that ","suffix":" significantly inhibited the metabolism of both amlodipine a","exact":"telaprevir"},{"setid":"PMC3187007","drugname":"telaprevir","startOffset":"14","endOffset":"24","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","prefix":"The effect of ","suffix":" on atorvastatin disposition was more pronounced. Atorvastat","exact":"telaprevir"},{"setid":"PMC3187007","drugname":"telaprevir","startOffset":"29","endOffset":"39","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"Upon the coadministration of ","suffix":" with a single dose of amlodipine-atorvastatin, the atorvast","exact":"telaprevir"},{"setid":"PMC3187007","drugname":"telaprevir","startOffset":"25","endOffset":"35","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[6]","prefix":"With coadministration of ","suffix":", the mean (SD) apparent clearance decreased from 685 (272) ","exact":"telaprevir"},{"setid":"PMC3187007","drugname":"telaprevir","startOffset":"10","endOffset":"20","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[8]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[8]","prefix":"The PK of ","suffix":" were evaluated after coadministration at steady state with ","exact":"telaprevir"},{"setid":"PMC3187007","drugname":"telaprevir","startOffset":"42","endOffset":"52","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[9]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[9]","prefix":"The coadministration of multiple doses of ","suffix":" with one dose of amlodipine and atorvastatin administered i","exact":"telaprevir"},{"setid":"PMC3187007","drugname":"telaprevir","startOffset":"491","endOffset":"501","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[9]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[9]","prefix":"ported in other clinical trials after the administration of ","suffix":" alone (","exact":"telaprevir"},{"setid":"PMC3187007","drugname":"telaprevir","startOffset":"51","endOffset":"61","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[10]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[10]","prefix":"In summary, the results of this study suggest that ","suffix":" significantly increased exposure to amlodipine and atorvast","exact":"telaprevir"},{"setid":"PMC3187007","drugname":"amlodipine","startOffset":"105","endOffset":"115","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"hibitor that is both a substrate and an inhibitor of CYP3A. ","suffix":" and atorvastatin are both substrates of CYP3A and are among","exact":"Amlodipine"},{"setid":"PMC3187007","drugname":"amlodipine","startOffset":"318","endOffset":"328","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"ted to examine the effect of telaprevir on atorvastatin and ","suffix":" pharmacokinetics (PK). This was an open-label, single seque","exact":"amlodipine"},{"setid":"PMC3187007","drugname":"amlodipine","startOffset":"486","endOffset":"496","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"healthy male and female volunteers. A coformulation of 5 mg ","suffix":" and 20 mg atorvastatin was administered on day 1. Telaprevi","exact":"amlodipine"},{"setid":"PMC3187007","drugname":"amlodipine","startOffset":"656","endOffset":"666","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"very 8 h from day 11 until day 26, and a single dose of the ","suffix":"-atorvastatin combination was readministered on day 17. Plas","exact":"amlodipine"},{"setid":"PMC3187007","drugname":"amlodipine","startOffset":"795","endOffset":"805","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"s were collected for determination of the PK of telaprevir, ","suffix":", atorvastatin, ","exact":"amlodipine"},{"setid":"PMC3187007","drugname":"amlodipine","startOffset":"0","endOffset":"10","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":"","suffix":" is a dihydropyridine calcium channel antagonist used to tre","exact":"Amlodipine"},{"setid":"PMC3187007","drugname":"amlodipine","startOffset":"232","endOffset":"242","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","prefix":" evaluate the drug-drug interactions between telaprevir and ","suffix":" and atorvastatin in healthy volunteers.","exact":"amlodipine"},{"setid":"PMC3187007","drugname":"amlodipine","startOffset":"135","endOffset":"145","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[2]","prefix":"revir in combination with Caduet tablets containing 5 mg of ","suffix":" and 20 mg of atorvastatin (amlodipine-atorvastatin). Volunt","exact":"amlodipine"},{"setid":"PMC3187007","drugname":"amlodipine","startOffset":"656","endOffset":"666","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"very 8 h from day 11 until day 26, and a single dose of the ","suffix":"-atorvastatin combination was readministered on day 17. Plas","exact":"amlodipine"},{"setid":"PMC3187007","drugname":"amlodipine","startOffset":"135","endOffset":"145","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[2]","prefix":"revir in combination with Caduet tablets containing 5 mg of ","suffix":" and 20 mg of atorvastatin (amlodipine-atorvastatin). Volunt","exact":"amlodipine"},{"setid":"PMC3187007","drugname":"amlodipine","startOffset":"173","endOffset":"183","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[2]","prefix":"ts containing 5 mg of amlodipine and 20 mg of atorvastatin (","suffix":"-atorvastatin). Volunteers received the following treatment:","exact":"amlodipine"},{"setid":"PMC3187007","drugname":"amlodipine","startOffset":"261","endOffset":"271","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[2]","prefix":"lunteers received the following treatment: a single dose of ","suffix":"-atorvastatin alone on day 1, followed by a washout period, ","exact":"amlodipine"},{"setid":"PMC3187007","drugname":"amlodipine","startOffset":"423","endOffset":"433","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[2]","prefix":"very 8 h (q8h) on days 11 through 26, with a single dose of ","suffix":"-atorvastatin on day 17. Outpatient visits occurred at the s","exact":"amlodipine"},{"setid":"PMC3187007","drugname":"amlodipine","startOffset":"242","endOffset":"252","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[7]/p[2]","prefix":") were assessed predose and at 8, 10, and 24 h postdose for ","suffix":"-atorvastatin when administered alone and when administered ","exact":"amlodipine"},{"setid":"PMC3187007","drugname":"amlodipine","startOffset":"135","endOffset":"145","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[2]","prefix":"evir on day 17 after coadministration with a single dose of ","suffix":"-atorvastatin. The mean (SD) ","exact":"amlodipine"},{"setid":"PMC3187007","drugname":"amlodipine","startOffset":"439","endOffset":"449","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[2]","prefix":"as moderate diarrhea in one volunteer during the telaprevir-","suffix":"-atorvastatin combination period.","exact":"amlodipine"},{"setid":"PMC3187007","drugname":"amlodipine","startOffset":"476","endOffset":"486","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[3]","prefix":"ncluded headache (occurred in 5 volunteers [24%] during the ","suffix":"-atorvastatin-alone period, in 2 volunteers [10%] during the","exact":"amlodipine"},{"setid":"PMC3187007","drugname":"amlodipine","startOffset":"618","endOffset":"628","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[3]","prefix":"alone period, and in 1 volunteer [5%] during the telaprevir-","suffix":"-atorvastatin combination period); dizziness (occurred in 2 ","exact":"amlodipine"},{"setid":"PMC3187007","drugname":"amlodipine","startOffset":"789","endOffset":"799","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[3]","prefix":"one period, and in 3 volunteers [15%] during the telaprevir-","suffix":"-atorvastatin combination period); diarrhea (occurred in 1 v","exact":"amlodipine"},{"setid":"PMC3187007","drugname":"amlodipine","startOffset":"1024","endOffset":"1034","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[3]","prefix":"lone period and in 2 volunteers [11%] during the telaprevir-","suffix":"-atorvastatin combination period). Rash has been previously ","exact":"amlodipine"},{"setid":"PMC3187007","drugname":"amlodipine","startOffset":"62","endOffset":"72","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"on the coadministration of telaprevir with a single dose of ","suffix":"-atorvastatin, the atorvastatin AUC","exact":"amlodipine"},{"setid":"PMC3187007","drugname":"amlodipine","startOffset":"97","endOffset":"107","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[8]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[8]","prefix":"fter coadministration at steady state with a single dose of ","suffix":"-atorvastatin. The ","exact":"amlodipine"},{"setid":"PMC3187007","drugname":"amlodipine","startOffset":"29","endOffset":"39","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[10]/div[2]/div[14]/span[1]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[10]/div[2]/div[14]/span[1]/span[1]","prefix":"Clinical pharmacokinetics of ","suffix":"","exact":"amlodipine"},{"setid":"PMC3187007","drugname":"amlodipine","startOffset":"261","endOffset":"271","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[2]","prefix":"lunteers received the following treatment: a single dose of ","suffix":"-atorvastatin alone on day 1, followed by a washout period, ","exact":"amlodipine"},{"setid":"PMC3187007","drugname":"amlodipine","startOffset":"423","endOffset":"433","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[2]","prefix":"very 8 h (q8h) on days 11 through 26, with a single dose of ","suffix":"-atorvastatin on day 17. Outpatient visits occurred at the s","exact":"amlodipine"},{"setid":"PMC3187007","drugname":"amlodipine","startOffset":"0","endOffset":"10","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[3]","prefix":"","suffix":"-atorvastatin (25-mg fixed dose combination tablets containi","exact":"Amlodipine"},{"setid":"PMC3187007","drugname":"amlodipine","startOffset":"78","endOffset":"88","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[3]","prefix":"tatin (25-mg fixed dose combination tablets containing 5 mg ","suffix":" and 20 mg atorvastatin; Pfizer Incorporated, New York, NY) ","exact":"amlodipine"},{"setid":"PMC3187007","drugname":"amlodipine","startOffset":"64","endOffset":"74","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[2]","prefix":"macokinetic evaluations were based on the concentrations of ","suffix":", atorvastatin, ","exact":"amlodipine"},{"setid":"PMC3187007","drugname":"amlodipine","startOffset":"7","endOffset":"17","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[3]","prefix":"Plasma ","suffix":", atorvastatin, ","exact":"amlodipine"},{"setid":"PMC3187007","drugname":"amlodipine","startOffset":"252","endOffset":"262","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[4]","prefix":" (Indianapolis, IN). Analytes and their internal standards (","suffix":"-d4 maleic acid, atorvastatin-d5 sodium salt, ","exact":"amlodipine"},{"setid":"PMC3187007","drugname":"amlodipine","startOffset":"29","endOffset":"39","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[10]/div[2]/div[14]/span[1]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[10]/div[2]/div[14]/span[1]/span[1]","prefix":"Clinical pharmacokinetics of ","suffix":"","exact":"amlodipine"},{"setid":"PMC3187007","drugname":"amlodipine","startOffset":"29","endOffset":"39","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[10]/div[2]/div[14]/span[1]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[10]/div[2]/div[14]/span[1]/span[1]","prefix":"Clinical pharmacokinetics of ","suffix":"","exact":"amlodipine"},{"setid":"PMC3187007","drugname":"amlodipine","startOffset":"242","endOffset":"252","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[7]/p[2]","prefix":") were assessed predose and at 8, 10, and 24 h postdose for ","suffix":"-atorvastatin when administered alone and when administered ","exact":"amlodipine"},{"setid":"PMC3187007","drugname":"amlodipine","startOffset":"16","endOffset":"26","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/p[2]","prefix":"The mean plasma ","suffix":" concentration-time profile is shown in ","exact":"amlodipine"},{"setid":"PMC3187007","drugname":"amlodipine","startOffset":"29","endOffset":"39","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[10]/div[2]/div[14]/span[1]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[10]/div[2]/div[14]/span[1]/span[1]","prefix":"Clinical pharmacokinetics of ","suffix":"","exact":"amlodipine"},{"setid":"PMC3187007","drugname":"amlodipine","startOffset":"42","endOffset":"52","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[1]/div[1]/div[2]/span[1]","prefix":"Mean plasma concentration-time profile of ","suffix":" following oral administration with and without telaprevir. ","exact":"amlodipine"},{"setid":"PMC3187007","drugname":"amlodipine","startOffset":"35","endOffset":"45","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[2]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[2]/div[1]/div[2]/span[1]","prefix":"Effects of telaprevir on the PK of ","suffix":", atorvastatin, and its metabolite ","exact":"amlodipine"},{"setid":"PMC3187007","drugname":"amlodipine","startOffset":"135","endOffset":"145","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[2]","prefix":"evir on day 17 after coadministration with a single dose of ","suffix":"-atorvastatin. The mean (SD) ","exact":"amlodipine"},{"setid":"PMC3187007","drugname":"amlodipine","startOffset":"439","endOffset":"449","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[2]","prefix":"as moderate diarrhea in one volunteer during the telaprevir-","suffix":"-atorvastatin combination period.","exact":"amlodipine"},{"setid":"PMC3187007","drugname":"amlodipine","startOffset":"476","endOffset":"486","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[3]","prefix":"ncluded headache (occurred in 5 volunteers [24%] during the ","suffix":"-atorvastatin-alone period, in 2 volunteers [10%] during the","exact":"amlodipine"},{"setid":"PMC3187007","drugname":"amlodipine","startOffset":"618","endOffset":"628","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[3]","prefix":"alone period, and in 1 volunteer [5%] during the telaprevir-","suffix":"-atorvastatin combination period); dizziness (occurred in 2 ","exact":"amlodipine"},{"setid":"PMC3187007","drugname":"amlodipine","startOffset":"789","endOffset":"799","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[3]","prefix":"one period, and in 3 volunteers [15%] during the telaprevir-","suffix":"-atorvastatin combination period); diarrhea (occurred in 1 v","exact":"amlodipine"},{"setid":"PMC3187007","drugname":"amlodipine","startOffset":"1024","endOffset":"1034","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[3]","prefix":"lone period and in 2 volunteers [11%] during the telaprevir-","suffix":"-atorvastatin combination period). Rash has been previously ","exact":"amlodipine"},{"setid":"PMC3187007","drugname":"amlodipine","startOffset":"52","endOffset":"62","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"Potential drug-drug interactions of telaprevir with ","suffix":" and atorvastatin were investigated in healthy volunteers by","exact":"amlodipine"},{"setid":"PMC3187007","drugname":"amlodipine","startOffset":"250","endOffset":"260","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"on of telaprevir. A formulation containing a combination of ","suffix":" and atorvastatin (Caduet) was used in this study for dosing","exact":"amlodipine"},{"setid":"PMC3187007","drugname":"amlodipine","startOffset":"369","endOffset":"379","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":" for dosing convenience. No significant interaction between ","suffix":" and atorvastatin was expected.","exact":"amlodipine"},{"setid":"PMC3187007","drugname":"amlodipine","startOffset":"103","endOffset":"113","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"t telaprevir significantly inhibited the metabolism of both ","suffix":" and atorvastatin. The bioavailability of amlodipine has bee","exact":"amlodipine"},{"setid":"PMC3187007","drugname":"amlodipine","startOffset":"155","endOffset":"165","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"of both amlodipine and atorvastatin. The bioavailability of ","suffix":" has been reported to be ∼60% (","exact":"amlodipine"},{"setid":"PMC3187007","drugname":"amlodipine","startOffset":"62","endOffset":"72","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"on the coadministration of telaprevir with a single dose of ","suffix":"-atorvastatin, the atorvastatin AUC","exact":"amlodipine"},{"setid":"PMC3187007","drugname":"amlodipine","startOffset":"97","endOffset":"107","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[8]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[8]","prefix":"fter coadministration at steady state with a single dose of ","suffix":"-atorvastatin. The ","exact":"amlodipine"},{"setid":"PMC3187007","drugname":"amlodipine","startOffset":"70","endOffset":"80","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[9]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[9]","prefix":"nistration of multiple doses of telaprevir with one dose of ","suffix":" and atorvastatin administered in 2 periods was well tolerat","exact":"amlodipine"},{"setid":"PMC3187007","drugname":"amlodipine","startOffset":"98","endOffset":"108","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[10]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[10]","prefix":"suggest that telaprevir significantly increased exposure to ","suffix":" and atorvastatin (","exact":"amlodipine"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":"120","endOffset":"132","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":" both a substrate and an inhibitor of CYP3A. Amlodipine and ","suffix":" are both substrates of CYP3A and are among the drugs most f","exact":"atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":"301","endOffset":"313","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":" study was conducted to examine the effect of telaprevir on ","suffix":" and amlodipine pharmacokinetics (PK). This was an open-labe","exact":"atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":"507","endOffset":"519","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"le volunteers. A coformulation of 5 mg amlodipine and 20 mg ","suffix":" was administered on day 1. Telaprevir was taken with food a","exact":"atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":"667","endOffset":"679","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"om day 11 until day 26, and a single dose of the amlodipine-","suffix":" combination was readministered on day 17. Plasma samples we","exact":"atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":"807","endOffset":"819","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"cted for determination of the PK of telaprevir, amlodipine, ","suffix":", ","exact":"atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":"132","endOffset":"144","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":" high blood pressure and angina or coronary artery disease. ","suffix":" is a hydroxymethyl glutaryl coenzyme A (HMG-CoA) reductase ","exact":"Atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":"247","endOffset":"259","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[3]","prefix":"rug-drug interactions between telaprevir and amlodipine and ","suffix":" in healthy volunteers.","exact":"atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":"159","endOffset":"171","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[2]","prefix":"h Caduet tablets containing 5 mg of amlodipine and 20 mg of ","suffix":" (amlodipine-atorvastatin). Volunteers received the followin","exact":"atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":"667","endOffset":"679","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[3]/div[2]/p[1]","prefix":"om day 11 until day 26, and a single dose of the amlodipine-","suffix":" combination was readministered on day 17. Plasma samples we","exact":"atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":"184","endOffset":"196","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[2]","prefix":"ng 5 mg of amlodipine and 20 mg of atorvastatin (amlodipine-","suffix":"). Volunteers received the following treatment: a single dos","exact":"atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":"272","endOffset":"284","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[2]","prefix":"ceived the following treatment: a single dose of amlodipine-","suffix":" alone on day 1, followed by a washout period, telaprevir at","exact":"atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":"434","endOffset":"446","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[2]","prefix":"8h) on days 11 through 26, with a single dose of amlodipine-","suffix":" on day 17. Outpatient visits occurred at the screening visi","exact":"atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":"279","endOffset":"291","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[4]","prefix":"es and their internal standards (amlodipine-d4 maleic acid, ","suffix":"-d5 sodium salt, ","exact":"atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":"253","endOffset":"265","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[7]/p[2]","prefix":"ssed predose and at 8, 10, and 24 h postdose for amlodipine-","suffix":" when administered alone and when administered in combinatio","exact":"atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":"146","endOffset":"158","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[2]","prefix":" 17 after coadministration with a single dose of amlodipine-","suffix":". The mean (SD) ","exact":"atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":"450","endOffset":"462","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[2]","prefix":" diarrhea in one volunteer during the telaprevir-amlodipine-","suffix":" combination period.","exact":"atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":"487","endOffset":"499","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[3]","prefix":"dache (occurred in 5 volunteers [24%] during the amlodipine-","suffix":"-alone period, in 2 volunteers [10%] during the telaprevir-a","exact":"atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":"629","endOffset":"641","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[3]","prefix":"d, and in 1 volunteer [5%] during the telaprevir-amlodipine-","suffix":" combination period); dizziness (occurred in 2 volunteers [1","exact":"atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":"800","endOffset":"812","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[3]","prefix":" and in 3 volunteers [15%] during the telaprevir-amlodipine-","suffix":" combination period); diarrhea (occurred in 1 volunteer [5%]","exact":"atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":"1035","endOffset":"1047","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[3]","prefix":" and in 2 volunteers [11%] during the telaprevir-amlodipine-","suffix":" combination period). Rash has been previously reported with","exact":"atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":"73","endOffset":"85","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"ministration of telaprevir with a single dose of amlodipine-","suffix":", the atorvastatin AUC","exact":"atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":"91","endOffset":"103","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"laprevir with a single dose of amlodipine-atorvastatin, the ","suffix":" AUC","exact":"atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":"108","endOffset":"120","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[8]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[8]","prefix":"nistration at steady state with a single dose of amlodipine-","suffix":". The ","exact":"atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":"272","endOffset":"284","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[2]","prefix":"ceived the following treatment: a single dose of amlodipine-","suffix":" alone on day 1, followed by a washout period, telaprevir at","exact":"atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":"434","endOffset":"446","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[2]","prefix":"8h) on days 11 through 26, with a single dose of amlodipine-","suffix":" on day 17. Outpatient visits occurred at the screening visi","exact":"atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":"11","endOffset":"23","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[3]","prefix":"Amlodipine-","suffix":" (25-mg fixed dose combination tablets containing 5 mg amlod","exact":"atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":"99","endOffset":"111","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[4]/p[3]","prefix":"se combination tablets containing 5 mg amlodipine and 20 mg ","suffix":"; Pfizer Incorporated, New York, NY) was administered orally","exact":"atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":"76","endOffset":"88","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[2]","prefix":"evaluations were based on the concentrations of amlodipine, ","suffix":", ","exact":"atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":"19","endOffset":"31","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[3]","prefix":"Plasma amlodipine, ","suffix":", ","exact":"atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":"19","endOffset":"31","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[3]","prefix":"Plasma amlodipine, ","suffix":", ","exact":"atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":"279","endOffset":"291","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[5]/p[4]","prefix":"es and their internal standards (amlodipine-d4 maleic acid, ","suffix":"-d5 sodium salt, ","exact":"atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":"253","endOffset":"265","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[7]/p[2]","prefix":"ssed predose and at 8, 10, and 24 h postdose for amlodipine-","suffix":" when administered alone and when administered in combinatio","exact":"atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":"47","endOffset":"59","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[2]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[3]/div[2]/div[1]/div[2]/span[1]","prefix":"Effects of telaprevir on the PK of amlodipine, ","suffix":", and its metabolite ","exact":"atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":"16","endOffset":"28","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/p[2]","prefix":"The mean plasma ","suffix":" concentration-time profile obtained is shown in ","exact":"atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":"42","endOffset":"54","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/div[1]/div[1]/div[2]/span[1]","prefix":"Mean plasma concentration-time profile of ","suffix":" following oral administration with and without telaprevir. ","exact":"atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":"42","endOffset":"54","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/div[1]/div[1]/div[2]/span[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[4]/div[1]/div[1]/div[2]/span[1]","prefix":"Mean plasma concentration-time profile of ","suffix":" following oral administration with and without telaprevir. ","exact":"atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":"146","endOffset":"158","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[5]/p[2]","prefix":" 17 after coadministration with a single dose of amlodipine-","suffix":". The mean (SD) ","exact":"atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":"450","endOffset":"462","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[2]","prefix":" diarrhea in one volunteer during the telaprevir-amlodipine-","suffix":" combination period.","exact":"atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":"487","endOffset":"499","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[3]","prefix":"dache (occurred in 5 volunteers [24%] during the amlodipine-","suffix":"-alone period, in 2 volunteers [10%] during the telaprevir-a","exact":"atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":"629","endOffset":"641","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[3]","prefix":"d, and in 1 volunteer [5%] during the telaprevir-amlodipine-","suffix":" combination period); dizziness (occurred in 2 volunteers [1","exact":"atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":"800","endOffset":"812","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[3]","prefix":" and in 3 volunteers [15%] during the telaprevir-amlodipine-","suffix":" combination period); diarrhea (occurred in 1 volunteer [5%]","exact":"atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":"1035","endOffset":"1047","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[6]/div[6]/p[3]","prefix":" and in 2 volunteers [11%] during the telaprevir-amlodipine-","suffix":" combination period). Rash has been previously reported with","exact":"atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":"67","endOffset":"79","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"al drug-drug interactions of telaprevir with amlodipine and ","suffix":" were investigated in healthy volunteers by comparing the PK","exact":"atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":"265","endOffset":"277","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"r. A formulation containing a combination of amlodipine and ","suffix":" (Caduet) was used in this study for dosing convenience. No ","exact":"atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":"384","endOffset":"396","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"venience. No significant interaction between amlodipine and ","suffix":" was expected.","exact":"atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":"118","endOffset":"130","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[3]","prefix":"gnificantly inhibited the metabolism of both amlodipine and ","suffix":". The bioavailability of amlodipine has been reported to be ","exact":"atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":"28","endOffset":"40","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","prefix":"The effect of telaprevir on ","suffix":" disposition was more pronounced. Atorvastatin is given in t","exact":"atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":"74","endOffset":"86","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[4]","prefix":"telaprevir on atorvastatin disposition was more pronounced. ","suffix":" is given in the acid form, and its ","exact":"Atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":"73","endOffset":"85","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"ministration of telaprevir with a single dose of amlodipine-","suffix":", the atorvastatin AUC","exact":"atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":"91","endOffset":"103","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[5]","prefix":"laprevir with a single dose of amlodipine-atorvastatin, the ","suffix":" AUC","exact":"atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":"108","endOffset":"120","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[8]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[8]","prefix":"nistration at steady state with a single dose of amlodipine-","suffix":". The ","exact":"atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":"85","endOffset":"97","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[9]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[9]","prefix":"ultiple doses of telaprevir with one dose of amlodipine and ","suffix":" administered in 2 periods was well tolerated. There were no","exact":"atorvastatin"},{"setid":"PMC3187007","drugname":"atorvastatin","startOffset":"113","endOffset":"125","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[10]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[10]","prefix":"laprevir significantly increased exposure to amlodipine and ","suffix":" (","exact":"atorvastatin"},{"setid":"PMC3187007","drugname":"cholesterol","startOffset":"233","endOffset":"244","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":"coenzyme A (HMG-CoA) reductase inhibitor used to lower high ","suffix":" levels and reduce the risk of heart attack and stroke. Thes","exact":"cholesterol"},{"setid":"PMC3187007","drugname":"caduet","startOffset":"415","endOffset":"421","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":"with CHC and are commercially available as a coformulation (","suffix":"; Pfizer) (","exact":"Caduet"},{"setid":"PMC3187007","drugname":"caduet","startOffset":"101","endOffset":"107","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[2]","prefix":"nter, nonrandomized study of telaprevir in combination with ","suffix":" tablets containing 5 mg of amlodipine and 20 mg of atorvast","exact":"Caduet"},{"setid":"PMC3187007","drugname":"caduet","startOffset":"415","endOffset":"421","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[4]/p[2]","prefix":"with CHC and are commercially available as a coformulation (","suffix":"; Pfizer) (","exact":"Caduet"},{"setid":"PMC3187007","drugname":"caduet","startOffset":"101","endOffset":"107","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[5]/div[3]/p[2]","prefix":"nter, nonrandomized study of telaprevir in combination with ","suffix":" tablets containing 5 mg of amlodipine and 20 mg of atorvast","exact":"Caduet"},{"setid":"PMC3187007","drugname":"caduet","startOffset":"279","endOffset":"285","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[1]","prefix":"on containing a combination of amlodipine and atorvastatin (","suffix":") was used in this study for dosing convenience. No signific","exact":"Caduet"},{"setid":"PMC3187007","drugname":"midazolam","startOffset":"57","endOffset":"66","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":"A clinical drug-drug interaction study of telaprevir and ","suffix":" showed that telaprevir increased the AUC of oral midazolam ","exact":"midazolam"},{"setid":"PMC3187007","drugname":"midazolam","startOffset":"116","endOffset":"125","start":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","end":"/html[1]/body[1]/div[2]/div[1]/div[2]/div[1]/div[2]/div[1]/div[1]/div[3]/div[1]/div[1]/div[7]/p[2]","prefix":" midazolam showed that telaprevir increased the AUC of oral ","suffix":" almost 9-fold (","exact":"midazolam"}]]}